

Definition and validation of targets associated with the metabolic reprogramming of haematological

malignancies

Miriam Guadalupe Contreras Mostazo

ADVERTIMENT. La consulta d'aquesta tesi queda condicionada a l'acceptació de les següents condicions d'ús: La difusió d'aquesta tesi per mitjà del servei TDX (www.tdx.cat) i a través del Dipòsit Digital de la UB (diposit.ub.edu) ha estat autoritzada pels titulars dels drets de propietat intel·lectual únicament per a usos privats emmarcats en activitats d'investigació i docència. No s'autoritza la seva reproducció amb finalitats de lucre ni la seva difusió i posada a disposició des d'un lloc aliè al servei TDX ni al Dipòsit Digital de la UB. No s'autoritza la presentació del seu contingut en una finestra o marc aliè a TDX o al Dipòsit Digital de la UB (framing). Aquesta reserva de drets afecta tant al resum de presentació de la tesi com als seus continguts. En la utilització o cita de parts de la tesi és obligat indicar el nom de la persona autora.

ADVERTENCIA. La consulta de esta tesis queda condicionada a la aceptación de las siguientes condiciones de uso: La difusión de esta tesis por medio del servicio TDR (www.tdx.cat) y a través del Repositorio Digital de la UB (diposit.ub.edu) ha sido autorizada por los titulares de los derechos de propiedad intelectual únicamente para usos privados enmarcados en actividades de investigación y docencia. No se autoriza su reproducción con finalidades de lucro ni su difusión y puesta a disposición desde un sitio ajeno al servicio TDR o al Repositorio Digital de la UB. No se autoriza la presentación de su contenido en una ventana o marco ajeno a TDR o al Repositorio Digital de la UB (framing). Esta reserva de derechos afecta tanto al resumen de presentación de la tesis como a sus contenidos. En la utilización o cita de partes de la tesis es obligado indicar el nombre de la persona autora.

WARNING. On having consulted this thesis you're accepting the following use conditions: Spreading this thesis by the TDX (www.tdx.cat) service and by the UB Digital Repository (diposit.ub.edu) has been authorized by the titular of the intellectual property rights only for private uses placed in investigation and teaching activities. Reproduction with lucrative aims is not authorized nor its spreading and availability from a site foreign to the TDX service or to the UB Digital Repository. Introducing its content in a window or frame foreign to the TDX service or to the UB Digital Repository is not authorized (framing). Those rights affect to the presentation summary of the thesis as well as to its contents. In the using or citation of parts of the thesis it's obliged to indicate the name of the author.





Doktorand:

Miriam Guadalupe Contreras Mostazo

Titel:

Definition and validation of targets associated with the metabolic reprogramming of haematological malignancies

Betreuer:

Prof. Marta Cascante (UB), Dr. Silvia Marín Martínez (UB), Prof. Harald Schwalbe (GUF)

Einleitung und Ziele dieser Arbeit

Krebszellen, einschließlich leukämische Zellen, können auf eine therapeutische Behandlung reagieren, indem sie ihren metabolischen Phänotyp verändern und letztendlich resistent werden, um ihren beschleunigten Proliferationszustand zu erhalten. Dieses Phänomen der Veränderung der zellulären Bioenergetik von Tumoren, und der dadurch verursachten Veränderungen des Zellstoffwechsels und der metabolischen Anpassung ist als "metabolische Reprogrammierung" bekannt und wurde als ein relevantes Kennzeichen von Krebs anerkannt. Dementsprechend gibt es immer mehr Hinweise darauf, dass die metabolische Reprogrammierung einer der Schlüsselmechanismen der Resistenz von Krebszellen ist. Darüber hinaus wurden in den letzten Jahrzehnten mehrere metabolische Studien zur Leukämie und insbesondere zur akuten myeloischen Leukämie (AML) und zur chronisch-myeloischen Leukämie (CML) durchgeführt. Die Forschung zum Verständnis der metabolischen Eigenschaften von AML und CML und die Entdeckung neuer und wirksamer Behandlungsmethoden für Patienten, im Besonderen für AML-Patienten, bleibt jedoch eine Herausforderung für Mediziner. Daher ist das Hauptziel dieser Arbeit die Untersuchung der Anpassungen des Zellstoffwechsels, die im Prozess der Resistenzbildung gegenüber verschiedenen konventionellen therapeutischen Behandlungen bei AML- und CML-Erkrankungen auftreten. Durch die Erforschung dieser neuen metabolischen Anpassungen wollten wir potenzielle metabolische und nicht-metabolische Angriffspunkte aufzeigen, die für eine neuartige Kombination genutzt werden könnten.

Um das Hauptziel dieser Arbeit zu erreichen, wurden die folgenden konkreten Ziele bearbeitet:

1) Charakterisierung des initialen metabolischen Phänotyps von parentalen Zellen bei akuter myeloischer Leukämie (AML).





- 2) Charakterisierung des metabolischen Profils von parentalen Zellen der akuten myeloischen Leukämie (AML) und von Cytarabin- und Doxorubicin-resistenten Zelllinien.
- 3) Definition und Validierung von Targets, die mit der metabolischen Reprogrammierung parentaler und resistenter AML-Zelllinien verbunden sind.
- 4) Generierung einer Imatinib-resistenten CML-Zelllinie KU812 und Charakterisierung des metabolischen Profils von parentalen CML- und Imatinib-resistenten Zellen.
- 5) Definition und Validierung von Targets, die im Zusammenhang mit der metabolischen Reprogrammierung von Imatinib-resistenten CML-Zellen stehen.

Forschungstätigkeiten

Um das erste konkrete Ziel dieser Arbeit zu erreichen, führten wir eine umfassende metabolische Charakterisierung von parentalen AML-Zellen (THP-1 und HL-60 parental, auch THP-1 und HL-60 P genannt) durch, die uns großzügiger Weise von Prof. Jindrich Cinatl (Institut für Medizinische Virologie, Universitätsklinikum Frankfurt, Goethe-Universität Frankfurt, Deutschland) und Prof. Martin Michaelis (Centre for Molecular Processing and School of Biosciences, University of Kent, Canterbury, UK) zur Verfügung gestellt wurden. Unsere Ergebnisse zeigen ein völlig unterschiedliches metabolisches Profil, mit wichtigen Unterschieden zwischen THP-1- und HL-60 P-Zellen hinsichtlich des Verbrauchs von Metaboliten, die Zellen zur Gewinnung von Energie und Vorläuferelementen für die Zellproliferation verwenden. Diese Ergebnisse machen deutlich, wie wichtig es ist, den anfänglichen Phänotyp der Zellen zu untersuchen, um die metabolischen Veränderungen vorherzusehen, die durch die Resistenzbildung in diesen AML-Zelllinien entstehen können.

Um die zweite Zielsetzung zu verwirklichen, wurde eine umfangreiche metabolische Charakterisierung unter normoxischen und hyperoxischen Inkubationsbedingungen von AML-Zellen und ein anschließender Vergleich der resistenten Zellen mit ihren jeweiligen parentalen Gegenstücken durchgeführt. Die AML-Zellen, die von Prof. Jindrich Cinatl und Prof. Martin Michaelis zur Verfügung gestellt wurden, sind parental oder resistent gegen die konventionellen AML-Chemotherapeutika AraC und Dox.

Für die präzise metabolische Charakterisierung wurden verschiedene experimentelle Ansätze verwendet. Zum einen wurden metabolische Messungen unter normoxischen und hypoxischen



Institut für Organische Chemie und Chemische Biologie



Inkubationsbedingungen mit zwei verschiedenen Methoden durchgeführt: 1) mittels Spektrophotometer, das sogenannte Cobas Mira Plus (Horiba ABX), das in der Lage ist, Stoffwechselraten (z.B. Glukose- und Glutaminverbrauch und Laktatproduktion) aus Zellkulturmedien zu messen, indem die Produktion von NAD(P)H in spezifischen Reaktionen für jeden Metabolit bei einer Wellenlänge von 340 nm ermittelt wird; und 2) mittels des Absolute IDQ p180-Kits von Biocrates, welches eine quantitative Analyse von Aminosäuren, biogenen Aminen, Glycerophospholipiden, Sphingolipiden und Acylcarnitinen unter Verwendung einer Flüssigchromatographie-Tandem-Massenspektrometrie- (LC-MS/MS) und Fließinjektions-Massenspektrometrie-Analyse (FIA- MS/MS) ermöglicht. Zum anderen wurden die extrazelluläre Ansäuerungsrate und die Sauerstoffverbrauchsrate unter Normoxie in parentalen und resistenten AML-Zellen, die zuvor unter normoxischen und hypoxischen Inkubationsbedingungen inkubiert worden waren, mit einem Seahorse XF96 Extracellular Flux Analyser gemessen. Schließlich wurden alle hier durchgeführten metabolischen Assays durch die Untersuchung des Proteinexpressionsprofils mittels SILAC-basierter Protein-Massenspektrometrie-Experimente ergänzt, um Änderungen der Metabolitenkonzentrationen direkt mit Änderungen des enzymatischen Repertoires resistenter AML-Zelllinien korrelieren zu können. Zusammenfassend zeigten die Ergebnisse dieser Multi-OMIC-Studie, dass der Erwerb von AraC-Resistenz die Reprogrammierung des Glukosestoffwechsels von THP-1- und HL-60-AML-Zellen, sowohl unter normoxischen, als auch unter hypoxischen Bedingungen durch Erhöhung des glykolytischen Flusses verursacht, während er nicht mit einer Veränderung der mitochondrialen Atmung assoziiert ist. Darüber hinaus beobachteten wir eine mögliche Fehlfunktion des ETC-Komplex I sowie Veränderungen im Glutamin- und Serin-Glycin-1C-Metabolismus in AML-Zellen, die einen aktiveren mitochondrialen Stoffwechsel aufweisen (z.B. THP-1 AraC Zellen).

Hingegen zeigen die Ergebnisse des Erwerbs der Dox-Resistenz Veränderungen im Glukose- und Aminosäuremetabolismus durch Verringerung des glykolytischen Flusses von THP-1- und HL-60-AML-Zellen und die Verringerung des Aminosäureverbrauchs von HL-60 Zellen unter normoxischen Bedingungen. Darüber hinaus hebt die Multi-OMIC-Studie den Polyamin-Stoffwechsel als eine wichtige metabolische Quelle von THP-1 Dox-Zellen unter hypoxischen Bedingungen hervor. Zudem verringert der Erwerb einer Dox-Resistenz dramatisch die mitochondriale Atmungskapazitäz von AML-Zellen unter normoxischen und hypoxischen Bedingungen, welche einen aktiven mitochondrialen Stoffwechsel besitzen. Allerdings ist die





Mehrzahl der mit dem mitochondrialen Metabolismus assoziierten Proteine signifikant hochreguliert. Daher wurden diese metabolischen Veränderungen im mitochondrialen Stoffwechsel und die metabolischen Veränderungen im Zusammenhang mit dem Polyaminstoffwechsel in dieser Arbeit als potenzielle Schwachstellen hervorgehoben, die für die Behandlung von Dox-Chemotherapeutika resistenten AML-Patienten genutzt werden können.

Um das vierte konkrete Ziel dieser Arbeit zu erreichen, generierten wir zunächst aus parentalen KU812 Zellen eine Imatinib-resistente CML-Zellmodelllinie (hier als KU812 ImaR bezeichnet) durch verlängerte Exposition gegenüber subletalen Dosen von Imatinib. Basierend auf den Ergebnissen der metabolischen Charakterisierung von AML-Zellen und mit dem Ziel, das metabolische Profil der parentalen und Imatinib-resistenten CML-Zellen zu charakterisieren, haben wir den gleichen experimentellen Ansatz (eine Multi-OMIC-Studie) für AML-Zellen verfolgt, diesmal jedoch für das hier untersuchte Modell der parentalen und resistenten CML-Zellen. Es ist erwähnenswert, dass diese metabolische Charakterisierung im Vergleich zur metabolischen Charakterisierung von AML-Zellen eine größere Menge und neueste experimentelle Ansätze einschließt, darunter Enzymaktivitäts-Assays, Glutathion, ROS-Messungen und Messungen der mitochondrialen Atmung durch das hochauflösende Respirometer Oroboros. Die Ergebnisse der CML-Multi-OMIC-Studie zeigten, dass der Erwerb einer Imatinib-Resistenz die Neuprogrammierung des Glukosestoffwechsels durch eine Verbesserung des glykolytischen Flusses, des Pentosephosphatwegs und des Glykogenstoffwechsels bewirkt. Diese Veränderungen heben diese Stoffwechselwege als potenzielle metabolische Schwächen der KU812-ImaR-Zellen hervor. Darüber hinaus zeigten unsere Ergebnisse auch eine hohe metabolische Plastizität der KU812 ImaR-Zellen, was die Orchestrierung vieler mit dem Aminosäurestoffwechsel verbundener Stoffwechselwege einschließt. Schließich zeigten die Ergebnisse der Multi-OMIC-Studie mit KU812 ImaR-Zellen eine erhöhte mitochondriale Atmungskapazität, was den mitochondrialen Stoffwechsel dieser Zellen als eine weitere potenzielle Schwachstelle hervorhebt, die zur Überwindung der Imatinib-Resistenz genutzt werden kann.

Die in dieser Arbeit verwendete Multi-OMIC-Studie, die mit Modellen der parentalen und resistenten AML- und CML-Zellen durchgeführt wurde, ist ein zuverlässiger Ansatz zur Identifizierung potenzieller metabolischer und nicht-metabolischer Targets, die für die Behandlung der AML und CML genutzt werden können. Diese Multi-OMIC-Studie hat es uns



Institut für Organische Chemie und Chemische Biologie



ermöglicht, verschiedene Targets vorzuschlagen und/oder zu validieren, die mit Stoffwechselwegen wie Serin-Glycin-1C, Pentosephosphatweg, Glutaminolyse, Glykogenolyse usw. assoziiert sind, und damit die beiden letzten konkreten Zielsetzungen dieser Arbeit zu erreichen, "die Definition und Validierung von Targets, die mit der metabolischen Reprogrammierung von parentalen und resistenten AML-Zellen einerseits, und von parentalen und resistenten CML-Zelllinien andererseits, assoziiert sind".

Abschließend zielt diese Arbeit auf eine umfassende Charakterisierung der metabolischen Profile von parentalen und resistenten AML- und CML-Zellen ab. Die oben genannten Ergebnisse sind Teil dieses Ansatzes und erlauben die Identifizierung potentieller metabolischer und nichtmetabolischer Targets, die in neuartigen Kombinationsbehandlungen zur Verbesserung der Behandlungseffizienz und zur Überwindung von Behandlungsresistenzen genutzt werden könnten. Die Auswahl von Single-Hit-Hemmungen ermöglicht die Zellüberlebensfähigkeit sowohl der parentalen als auch der resistenten AML- und CML-Zellen zu reduzieren. Wenngleich die Nutzung von Medikamenten zu einem neuen Zweck ein vielversprechendes Feld in der Arzneimittelforschung darstellt, und gleichzeitig ein sehr anspruchsvoller Ansatz ist, wurde die Nutzung des Chemotherapeutikums Dox (ein konventionelles AML-Chemotherapeutikum) zur Bekämpfung der Imatibib-Resistenz in KU812-ImaR-Zellen in dieser Doktorarbeit identifiziert.

Definition and validation of targets associated with the metabolic reprogramming of haematological malignancies

Miriam Guadalupe Contreras Mostazo

Doctoral Thesis

2020





Doctoral Program in Biotechnology

Department of Biochemistry and Molecular Biomedicine

Faculty of Biology

Definition and validation of targets associated with the metabolic reprogramming of haematological malignancies

Doctoral Thesis submitted by Miriam Guadalupe Contreras Mostazo to obtain the Ph.D degree from the University of Barcelona and Goethe University of Frankfurt in the frame of dual degree agreement

Prof. Marta Cascante Serratosa Co-supervisor and tutor

Koste Cosconte

Dr. Silvia Marín Martínez Co-supervisor

Miriam Guadalupe Contreras Mostazo Doctoral student, 2020

Prof. Harald Schwalbe Co-supervisor

Prof. Dr. Harald Schwalbe

To Fran, my family, my best friends Patri and Irene and my "Amanitas muscarias" to support me and tolerate all my "peculiar" moments. Without them, these last years could not have been so fantastic.

My sincere thanks to Prof. Marta Cascante, Prof. Harald Schwalbe, Dr. Silvia Marín, Dr. Roldán Cortés, Dr. Frank Schnütgen and Dr. Nina Kurrle for their support, knowledge, and time to make this Ph.D. possible.

My honest gratitude and appreciation to Dr. Marta Casado, Dr. Hubert Serve, Dr. Bernhard Brüne and Dr. Dominik Fuhrmann for giving me the opportunity to work in their labs and for the great advices.

Special thanks to my lab group "BQI" for the continuous help, laughs and moviemaker skills. Also, thanks to Dr. Irene Reyes, to the people of Frankfurt lab and to all my colleagues of the HaemMetabolome project for the continuous help and the great moments that we have lived together.

Finally, but not less important, I would like to express my gratitude to the people of my new lab group (IBIS, Seville) and to Dr. Jose Antonio Pérez Simón for supporting and motivating me this last year of Ph.D. I could not be happier in this new work atmosphere.



INDEX

1	AB	BBREVIA	TIONS
2	IN	TRODU	CTION
	2.1	Cance	er overview
	2.2	Haen	natopoiesis and Leukaemia11
	2.2	2.1	Acute myeloid leukaemia14
		2.2.1.1	Definition, epidemiology and risk factors14
		2.2.1.2	Classification and gene mutations15
		2.2.1.3	Diagnosis
		2.2.1.4	Treatment
	2.2	2.2	Chronic myeloid leukaemia 22
		2.2.2.1	Definition, epidemiology and risk factors
		2.2.2.2	Disease progression and diagnosis22
		2.2.2.3	Treatment
	2.3	Cance	er metabolism and tumour metabolic reprogramming
	2.3	3.1	Glucose metabolism and biosynthetic pathways
		2.3.1.1	Glucose uptake, glycolysis, and pyruvate metabolism
		2.3.1.2	Pentose phosphate pathway 29
		2.3.1.3	Glycogen metabolism
	2.3	3.2	Amino acid metabolism
		2.3.2.1	Glutamine
		2.3.2.2	Glutamate
		2.3.2.3	Aspartate and asparagine35
		2.3.2.4	Arginine, ornithine and urea cycle
		2.3.2.5	Serine, glycine and one-carbon metabolism
		2.3.2.6	Proline
	2.3	3.3	Mitochondrial metabolism
		2.3.3.1	Tricarboxylic acid cycle and oxidative phosphorylation
		2.3.3.2	Glycerol-phosphate shuttle

	2.3.	4 Fatty acid metabolism 44
	2.3.	5 Maintenance of redox homeostasis: ROS mitigation
	2.3.	6 Glutathione: The roles in ROS mitigation and xenobiotic detoxification
	2.3.	7 Hypoxia: its influence in cancer and in leukaemia47
	2.4	Metabolism in leukaemia 49
	2.4.	1 Metabolism of AML cells 49
	2.4.	2 Metabolism of CML cells
	2.4.	3 Metabolism of AML and CML resistant cells
	2.5	Multi-OMIC approach in cancer
	2.5.	1 Proteomics 53
	2.5.	2 Metabolomics 54
3	OBJ	ECTIVES
4	MA	TERIALS AND METHODS
	4.1	Cell culture
	4.2	Generation of the imatinib-resistant KU812 cells
	4.3	Cell characterisation and cell viability assay
	4.4	Cell cycle analysis
	4.5	Intracellular glutathione quantification65
	4.6	Intracellular reactive oxygen species (ROS) levels
	4.7	Measurement of extracellular metabolites 67
	4.8	Metabolites extracellular flux and intracellular content analysis
	4.9	Glycogen content analysis 69
	4.10	Nuclear magnetic resonance (NMR) analysis70
	4.11	Enzymatic activities of CML cell lines71
	4.12	Oxygen consumption rate (OCR) and extracellular acidification rate (ECAR)73
	4.13	Oximetry for KU812 parental and resistant cell lines
	4.14	Western blotting
	4.15	SILAC-based Proteome Analysis80
	4.16	CRISPR/Cas9 technology82
	4.17	Competition cell growth assay and cumulative growth curve
	4.18	Imatinib-resistant BCR-ABL1 kinase domain mutation analysis
5	RES	ULTS

5.1 Resistance mechanism developed by AML cells lines is associated with an important metabolic reprogramming dependent on drug inducer			
5.1.1	In	troduction and scope	
5.1.2	Re	esults	
5.1	.2.1	Metabolic characterisation of THP-1 and HL-60 AML cell lines	
	.2.2 arabin	Resistance validation, cell volume and protein content comparison between he and doxorubicin resistant and parental AML cell lines	
		AML cells resistant to cytarabine and doxorubicin preferentially express ns associated with cellular and metabolic processes	
		2.2 Cytarabine resistance induces an enhancement of glycolysis whereas the of doxorubicin resistance in glycolysis is cell line and oxygen level dependent 105	
c		2.3 Doxorubicin resistance reduces mitochondrial respiration capacity in AML ith high OXPHOS activity, while Cytarabine resistance does not affect nondrial respiration capacity in AML cells	
	5.1.2.2 glutam	4 Development of resistance to both Cytarabine and Doxorubicin impairs ine metabolism	
	5.1.2.2 acid m	.5 Development of resistance to Cytarabine and Doxorubicin alters the amino etabolism of AML cells in a cell line-dependent manner	
	5.1.2.2 Synthe	.6 Development of Cytarabine resistance enhances 1C-metabolism and serine sis pathway in AML cell lines	
a	•	2.7 Development of drug resistance modifies the intracellular content of rnitines in AML cell lines without showing correlation with fatty acid oxidation- dent mitochondrial respiration	
-	5.1.2.2 expres	8.8 Potential metabolic and non-metabolic targets identified by protein sion analysis (SILAC)	
		ing metabolic remodelling associated with BCR-ABL1-independent imatinib hronic myeloid leukaemia (CML) KU812 cells	
5.2.1	In	troduction and scope 139	
5.2.2	Re	esults 140	
5.2	.2.1	Development and characterisation of imatinib-resistant KU812 cell line 140	
we		Development of imatinib-resistance is associated with increased glycolysis as wired glucose to pentose phosphate pathway, glycogen synthesis, and serine- C metabolism	
-	.2.3 vires g	Development of resistance to imatinib enhances glutamine transport and lutamine metabolism	
	.2.4 relate	Development of resistance to imatinib rewires the metabolism of proline and d metabolic precursors	

	5.2.2.5 proline f	Targeting transport and biosynthesis of proline to investigate the essentiality of or the survival of imatinib-resistant cells
	5.2.2.6 proteins	Development of imatinib resistance results in the overexpression of key in ROS and xenobiotics detoxification related pathways
		Development of resistance to imatinib implied a reorganisation of ndrial metabolism and electron transport chain activities to increase ndrial respiration capacity
	5.2.2.8 phospha	Development of resistance to imatinib enhance mitochondrial Glycerol-3- te dehydrogenase expression and branched-chain amino acids metabolism 179
	5.2.2.9 cells	The acquisition of imatinib resistant alters the fatty acid metabolism of KU812 184
	5.2.2.10	The repurposing of Doxorubicin showed to be an effective strategy to
	overcom	e TKI resistance in KU812 cells 186
6	DISCUSSIO	N 191
7	CONCLUSIO	DNS
8	REFERENCE	S
APP	ENDIX 1: Su	pplementary data of results of Chapter 1 251
APP	ENDIX 2: Su	pplementary data of results of Chapter 2 309

1. ABBREVIATIONS

1 ABBREVIATIONS

α-KG	α-ketoglutarate	dCTP	Deoxycytidine triphosphate
1-C	One-carbon	DHEA	Dehydroepiandrosterone
2-DG	2-deoxyglucose	dNTP	Deoxynucleotide triphosphate
2-HG	2-hydroxyglutarate	DRI	Drug resistant index
3-PG	3-phosphoglycerate	Dox	Doxorubicin
AA	Antimycin A	EAA	Essential amino acid
ABC	ATP-binding cassette	ECAR	Extracellular acidification rate
AC	Acylcarnitine	ECM	Extracellular matrix
ALL	Acute lymphoblastic leukaemia	ELISA	Enzyme-linked immunosorbent
AML	Acute myeloid leukaemia	assay	
AP	Accelerated phase	ETC	Electron transport chain
APL	Acute promyelocytic leukaemia	F6P	Fructose-6-phosphate
AraC	Cytarabine	FA	Fatty acid
AraCDP	AraC diphosphate	FACS	Fluorescence-activated cell
AraCMP	AraC monophosphate	sorter	
AraCTP	AraC triphosphate	FAO	Fatty acid oxidation
BCAA	Branched-chain amino acid	FDA	Food and Drug Administration
BM	Bone marrow	FBS	Fetal bovine serum
ВР	Blast phase	G1P	Glucose-1-phosphate
BPTES	Bis-2-[5-phenylacetamido-1,2,4-	3-phosphate	
thiadiazol-2-yl]	ethyl sulfide	GFP	Green fluorescent protein
CAR	Chimeric antigen receptor	GMP	Granulocyte-monocyte
CCCP	Carbonyl cyanide m-	progenitor	
chlorophenylhy	drazone	GO	Gene ontology
CML	Chronic myeloid leukaemia	Gp	Glycerol-3-phosphate
СР	Chronic phase	GSA	Glutamate-y-semialdehyde
CLP	Common lymphoid progenitor	H⁺	Proton
СМР	Common myeloid progenitor		
CR	Complete remission		

DAB 1,4-dideoxy-1,4-imino-d-arabinitol

НВР	Hexosamine biosynthesis	O ₂	Oxygen
pathway		OCR	Oxygen consumption rate
HIF	Hypoxia-inducible factors	OXPHOS	Oxidative phosphorylation
HSC	Hematopoietic stem cell	Р	Parental
HSCT	Hematopoietic stem cell	Pyr	Pyruvate
transplantation		R5P	Ribose-5-phospahte
Нур	Нурохіа	RCS	Reactive chloride species
IC50	Half maximal inhibitory	Ru5P	Ribulose-5-phosphate
concentration		Redox	Reduction-oxidation
ICAT	Isotope-coded affinity tag	ROS	Reactive oxygen species
IMM	Inner mitochondrial membrane	Rot	Rotenone
itraq	isobaric tag for relative and	RNS	Reactive nitrogen species
absolute quantif	ication	RSS	Reactive sulfur species
КО	Knock-out	s-AML	secondary-Acute myeloid
LC-MS-MS	Liquid chromatography-MS	leukaemia	
MALDI-TOF	Matrix-assisted laser	SILAC	Stable isotope labelling with
desorption/ioniz	ation time-of-flight	amino acids in cellular culture	
MDS	Myelodysplastic syndrome	SSP	Serine synthesis pathway
MEPs	Megakaryocyte-erythroid	t-AML	Therapy-related acute myeloid
progenitor		leukaemia	
MPN	Myeloproliferative neoplasm	TCA	Tricarboxylic acid cycle
		TCGA	The Cancer Genome Atlas
MPPs	Multipotent progenitor cells	ТСРА	The Cancer Protein Atlas
MS	Mass spectrometry	TMT	Tandem mass tags
MTORC	Mammalian target of	ТКІ	Tyrosine kinase inhibitor
rapamycin comp	lex	UDP	Uridine diphosphate
NEAA	Non-essential amino acid	VEGF	Vascular endothelial growth
NMR	Nuclear magnetic resonance	factor	
Norm	Normoxia	WBC	White blood cell
NTC	Non-target control	WHO	World Health Organization

PROTEIN/ENZYMES ABBREVIATIONS

6-PGD/PGD	6-phosphogluconate	СОХ	Cytochrome oxidase
dehydrogenase		СРТ	Carnitine palmitoiltransferase
6-PGL	Phosphogluconolactonase	СМРК	Cytidine monophosphate
ACACA	Acetyl-CoA carboxylase alpha	kinase	
ACAT	Acetyl-CoA-acetyltransferase	CS	Citrate synthase
ACC	Acetyl-CoA carboxylase	СТВР	C-Terminal Binding Protein
ACLY	ATP-citrate lyase	CYCS	Cytochrome c
ACO	Aconitase	dCK	Deoxycytidine kinase
ACSS	Acetate acyl-CoA synthetase	DHFR	Dihydrofolate reductase
short-chain fam	ily member	ECHS	Enoyl-CoA hydratase
ADPGK	ADP dependent isoform of	FASN	Fatty acid synthase
glucokinase		FBP	Fructose 1,6-bisphosphatase
AGP	Alpha-1-acid glycoprotein	FDFT1	Squalene synthase
APP	Amyloid Beta Precursor Protein	FH	Fumarate hydratase
ARG	Arginase	FLT3	Fms related tyrosine kinase 3
ASCT	Alanine/serine/cysteine	G6PDH	Glucose-6-phosphate
transporter		dehydrogenase	
transporter ASL	Argininosuccinate lyase	dehydrogenase GAPDH	Glyceraldehyde-3-phosphate
	Argininosuccinate lyase Asparagine synthetase		Glyceraldehyde-3-phosphate
ASL		GAPDH	Glyceraldehyde-3-phosphate 1,4-alpha-glucan-branching
ASL	Asparagine synthetase	GAPDH dehydrogenase	
ASL ASNS ASS1	Asparagine synthetase Argininosuccinate synthetase	GAPDH dehydrogenase GBE	1,4-alpha-glucan-branching
ASL ASNS ASS1 ATG	Asparagine synthetase Argininosuccinate synthetase Autophagy-related protein	GAPDH dehydrogenase GBE GCL	1,4-alpha-glucan-branching Glutamate–cysteine ligase
ASL ASNS ASS1 ATG ATP5	Asparagine synthetase Argininosuccinate synthetase Autophagy-related protein ATP synthase	GAPDH dehydrogenase GBE GCL GDH	1,4-alpha-glucan-branching Glutamate–cysteine ligase Glutamate dehydrogenase Glutamine-fructose-6-
ASL ASNS ASS1 ATG ATP5 BCAT	Asparagine synthetase Argininosuccinate synthetase Autophagy-related protein ATP synthase	GAPDH dehydrogenase GBE GCL GDH GFPT	1,4-alpha-glucan-branching Glutamate–cysteine ligase Glutamate dehydrogenase Glutamine-fructose-6-
ASL ASNS ASS1 ATG ATP5 BCAT Transaminase	Asparagine synthetase Argininosuccinate synthetase Autophagy-related protein ATP synthase Branched Chain Amino Acid	GAPDH dehydrogenase GBE GCL GDH GFPT phosphate amin	1,4-alpha-glucan-branching Glutamate–cysteine ligase Glutamate dehydrogenase Glutamine-fructose-6- otransferase
ASL ASNS ASS1 ATG ATP5 BCAT Transaminase BCKD	Asparagine synthetase Argininosuccinate synthetase Autophagy-related protein ATP synthase Branched Chain Amino Acid	GAPDH dehydrogenase GBE GCL GDH GFPT phosphate amin GK	1,4-alpha-glucan-branching Glutamate–cysteine ligase Glutamate dehydrogenase Glutamine-fructose-6- otransferase Glucokinase
ASL ASNS ASS1 ATG ATP5 BCAT Transaminase BCKD dehydrogenase	Asparagine synthetase Argininosuccinate synthetase Autophagy-related protein ATP synthase Branched Chain Amino Acid Branched-chain keto acid	GAPDH dehydrogenase GBE GCL GDH GFPT phosphate amin GK GLUD	1,4-alpha-glucan-branching Glutamate–cysteine ligase Glutamate dehydrogenase Glutamine-fructose-6- otransferase Glucokinase Glutamate dehydrogenase
ASL ASNS ASS1 ATG ATP5 BCAT Transaminase BCKD dehydrogenase CA	Asparagine synthetase Argininosuccinate synthetase Autophagy-related protein ATP synthase Branched Chain Amino Acid Branched-chain keto acid Carbonic anhydrase	GAPDH dehydrogenase GBE GCL GDH GFPT phosphate amin GK GLUD GLS	1,4-alpha-glucan-branching Glutamate–cysteine ligase Glutamate dehydrogenase Glutamine-fructose-6- otransferase Glucokinase Glutamate dehydrogenase Glutaminase
ASL ASNS ASS1 ATG ATP5 BCAT Transaminase BCKD dehydrogenase CA CA	Asparagine synthetase Argininosuccinate synthetase Autophagy-related protein ATP synthase Branched Chain Amino Acid Branched-chain keto acid Carbonic anhydrase	GAPDH dehydrogenase GBE GCL GDH GFPT phosphate amin GK GLUD GLS GLUT	1,4-alpha-glucan-branching Glutamate–cysteine ligase Glutamate dehydrogenase Glutamine-fructose-6- otransferase Glucokinase Glutamate dehydrogenase Glutaminase Glutaminase
ASL ASNS ASS1 ATG ATP5 BCAT Transaminase BCKD dehydrogenase CA CACT translocase	Asparagine synthetase Argininosuccinate synthetase Autophagy-related protein ATP synthase Branched Chain Amino Acid Branched-chain keto acid Carbonic anhydrase Carnitine acylcarnitine	GAPDH dehydrogenase GBE GCL GDH GFPT phosphate amin GK GLUD GLS GLUT GP/PYG	1,4-alpha-glucan-branching Glutamate–cysteine ligase Glutamate dehydrogenase Glutamine-fructose-6- otransferase Glucokinase Glutamate dehydrogenase Glutaminase Glutaminase Glucose transporter Glycogen phosphorylase
ASL ASNS ASS1 ATG ATP5 BCAT Transaminase BCKD dehydrogenase CA CACT translocase CAT	Asparagine synthetase Argininosuccinate synthetase Autophagy-related protein ATP synthase Branched Chain Amino Acid Branched-chain keto acid Carbonic anhydrase Carnitine acylcarnitine	GAPDH dehydrogenase GBE GCL GDH GFPT phosphate amin GK GLUD GLS GLUT GP/PYG GPD	1,4-alpha-glucan-branching Glutamate–cysteine ligase Glutamate dehydrogenase Glutamine-fructose-6- otransferase Glucokinase Glutamate dehydrogenase Glutaminase Glutaminase Glucose transporter Glycogen phosphorylase

GNPNAT	Glucosamine-6-phosphate	PFK	Phosphofructokinase
N-acetyltransfer	ase	P-gp	P-glycoprotein
GS	Glycogen synthase	PGM	Phosphoglucomutase
GS	Glutamine synthetase	PHGDH	Phosphoglycerate
GSH	Glutathione	dehydrogenase	
GSR	Glutathione reductase	РІЗК	Phosphatidylinositol 3-kinase
GST	Glutathione S-transferase	РК	Pyruvate kinase
GYG	Glycogenin	РКС	Protein kinase C
GYS	Glycogen synthase	РКМ	Pyruvate kinase muscle
НК	Hexokinase	isoenzyme	
HSF	Heat shock transcription factor	PRODH	Proline dehydrogenase
IDH	Isocitrate dehydrogenase	proT	Proline transporter
IGF2BP	Insulin-like growth factor-2	PSAT	Phosphoserine
mRNA-binding p	protein	aminotransferas	e
IRS	Insulin receptor	PSPH	Phosphoserine phosphatase
INSR	Insulin receptor precursor	PYCR	Pyrroline-5-carboxylate
KGDH	α -ketoglutarate dehydrogenase	reductase	
OAT	Ornithine aminotransferase	LDH	Lactate dehydrogenase
OGDH	Oxoglutarate dehydrogenase	MDH	Malate dehydrogenase
P4H	Prolyl 4-hydroxylase	ME	Malic enzyme
P5CDH	Pyrroline-5-carboxylate	MRP	Multidrug-resistance related
dehydrogenase		protein	
P5CS	Pyrroline-5-carboxylate	MTHFD1L	Methylenetetrahydrofolate
synthase		dehydrogenase	1 like
PDC	Pyruvate dehydrogenase	NDPK	Nucleoside diphosphate kinase
complex		NDUF	NADH:Ubiquinone
PDH	Pyruvate dehydrogenase	oxidoreductase	
PDK	Pyruvate dehydrogenase kinase	NOS	Nitric oxide synthase
PDP	Pyruvate dehydrogenase	NOX	NADPH oxidase
phosphatase		NQ01	NAD(P)H quinone
PDPR	Pyruvate dehydrogenase	oxidoreductase	
nhocnhataca rad	ulatory subunit		

phosphatase regulatory subunit

Nrf2	Factor erythroid 2-related factor 2			
RRM2	Ribonucleotide reductase			
regulatory subun	regulatory subunit M2			
SAMHD SAM do	main and HD domain-containing			
protein				
SUCLG	Succinyl-CoA ligase [GDP-forming]			
subunit beta				
SDH	Succinate dehydrogenase			
SFK	Src family kinase			
SHMT	Serine hydromethyltransferase			
SLC	Solute carrier family			
SMO	Spermidine oxidase			
SOAT	Sterol O-acyltransferase			
SUCLA	Succinyl-CoA synthetase			
TALDO	Transaldolase			
THBD	Thrombomodulin			
ткт	Transketolase			
TKTL	Transketolase like			
TOMM20	Translocase of outer mitochondrial			
membrane				
Topo/TOP	Topoisomerase II			
TYMS	Thymidylate synthetase			
UAP	UDP-N- acetylhexosamine			
pyrophosphorylase				

2. INTRODUCTION

2 INTRODUCTION

2.1 Cancer overview

Cancer is a broad term that comprises a collection of diseases in which cellular changes cause the uncontrolled growth and division of abnormal cells. Some cancers result in an abnormal mass of tissue, called solid tumours. However, other cancers (e.g. leukaemia) generally do not form these solid tumours. Cancer is a major public health problem worldwide responsible for an estimated 9.6 million deaths in 2018, hence, 1 in 6 deaths worldwide. In the specific case of leukaemia, the global cancer observatory reported more than 400,000 new cases and 309,006 deaths due to leukaemia in 2018¹.

In the past decades, the understanding of factors that influence the development of cancer has become important. In this line, the influence of the environment, the genetic endowment, and their interactions have been reported to explain the cancer incidence². The World Health Organisation (WHO) established that the transformation of normal cells into tumour cells is the result of the interaction between the genetic conditions and external agents such as physical carcinogens (ultraviolet and ionising radiation), chemical carcinogens (tobacco, food contamination, etc.) and biological carcinogens (infections from virus, bacteria or parasites).

2.2 Haematopoiesis and Leukaemia

Haematopoiesis is a tightly regulated process that gives rise to the different lineages of mature blood cells including lymphocytes, erythrocytes, and monocytes throughout normal life. The origin of the haematopoietic differentiation tree is called the hematopoietic stem cells (HSC)^{3,4}, which are thus responsible for the regeneration of all the cellular components of the haematopoietic system. In particular, HSCs initiate this differentiation by evolving into multipotent progenitor cells (MPPs) which can further generate common lymphoid or myeloid progenitors (CLPs and CMPs, respectively). Next, CLPs and CMPs differentiate into

11

mature blood cells (e.g. red blood cells, megakaryocytes, myeloid cell, and lymphocytes) (**Fig. 2.1**). Moreover, HSCs are regulated by protein niche factors such as cytokines, chemokines, extracellular matrix protein; and by non-protein niche factors including high extracellular concentration of calcium ion and low oxygen (O₂) concentration (hypoxia)⁵. Interestingly, Schofield (1978) first proposed the HSC niche as a possible explanation of the the self-renewal capability of HSCs⁶. In mammals, HSCs are retained in the bone marrow (BM) niche, which is known to be a hypoxic organ. In this hypoxic niche of the BM, hypoxia-inducible factors (HIFs), characterised as stress sensor proteins, play important roles in the cells of the HSC niche, including the HSCs.




Figure 2.1 Haematopoiesis. "The haematopoietic stem cell (HSC) differentiates into common myeloid progenitor (CMP) or common lymphoid progenitor (CLP) cells. CMPs can generate all mature myeloid cells while granulocyte-monocyte progenitors (GMPs) or megakaryocyte-erythroid progenitors (MEPs) produce only myeloid/monocytic and megakaryocytic/erythroid lineage cells, respectively. B and T lymphocytes and lymphoid NK cells differentiate from the common progenitor (CLP)". Taken from http://learnhaem.com/courses/anaemia/lessons/normal-haematopoiesis/topic/haematopoiesis/.

Abnormalities in this system produce many hematological disorders including leukaemia, which is a malignant clonal proliferation of HSCs in the BM that occurs in children and adults. The diagnosis is confirmed by the examination of the BM and peripheral blood⁷ and lymph nodes and spleen.

Leukaemia can be divided into two main groups, myeloid and lymphoid, based on the origin of the cell type affected. Furthermore, each group subdivides into acute or chronic leukaemia depending on how mature the cells are. Therefore, there are four broad subtypes: acute lymphoid, acute myeloid, chronic lymphoid and chronic myeloid leukaemias. In this thesis, only the acute myeloid (AML) and chronic myeloid leukaemia (CML) were specifically addressed.

2.2.1 Acute myeloid leukaemia

2.2.1.1 Definition, epidemiology and risk factors

Acute myeloid leukaemia (AML) is characterised by an aggressive and fast growth of abnormal myeloid blasts in the BM, peripheral blood or extramedullary tissues, leading to BM failure and death. It is a cytogenetically and molecularly⁸ very heterogeneous disease. AML is mainly a disease of older adults and the median age of diagnosis is 67 years⁹.

Furthermore, the American Cancer Society established in 2018 that the principal risk factors are the age of the patient (higher occurrence in older people), the gender (more common in males than in females), lifestyle-related (e.g. smoking), chemical (e.g. benzene, formaldehyde) and radiation exposure, certain chemotherapeutic treatments, blood-disorder predisposition (e.g. myelodysplastic syndrome [MDS]), and genetic syndromes (e.g. anaemia)¹⁰.

2.2.1.2 Classification and gene mutations

AML can be classified into three distinct categories based on clinical ontogeny: i) *de novo* AML, which arises in the absence of an identified exposure or prodromal stem cell disorder, ii) secondary AML (s-AML), which represents a transformation from previous myelodysplastic syndrome (MDS) or myeloproliferative neoplasm (MPN); and iii) therapy-related AML (t-AML), which develops as a late complication in patients with prior exposure to leukemogenic therapies¹¹. In addition, sequencing of AML genomes has been performed in order to study the genetic basis of AML ontogeny. In this regard, many different leukemogenic mutations have been identified. For instance, mutations in proteins necessary for DNA methylation and demethylation (e.g. DNA methyltransferases, DNMTs, or methylcytosine dioxygenase, TET2), in chromatin modification (e.g. polycomb group protein, ASXL1), in genes encoding myeloid transcription factors (e.g. runt-related transcription factor 1, RUNX1 or CCAAT/enhancer-binding protein alpha, CEBPA), or in signal transduction proteins (Fms related tyrosine kinase 3, FLT3)^{11,12}.

2.2.1.3 Diagnosis

The primary diagnosis of AML depends on the morphological identification of leukemic myeloblasts in preparations of peripheral blood and BM¹³. Thereby, a marrow or blood blast count of \geq 20%, including myeloblasts, monoblasts and megakaryoblasts, is a prerequisite for the definitive diagnosis of AML¹⁴. Moreover, other methodologies including immunophenotyping, cytogenetic, and molecular genetic analysis have been incorporated into the diagnosis criteria. Regarding immunophenotyping, Béné *et al.* published a list of markers (e.g. myeloperoxidase, MPO) helpful for establishing the diagnosis of AML¹⁵. In addition, the accomplishment of cytogenetic analysis is mandatory in the evaluation of AML. In this case, the WHO category known as "AML with recurrent genetic abnormalities" was described and includes eight balanced translocations and inversions, and their

variants¹⁶. Furthermore, AML diagnosis should include screening for: a) mutations in NPM1, CEBPA, and RUNX1 genes; b) mutations in FLT3; and c) mutations in TP53 and ASXL1¹⁴.

2.2.1.4 Treatment

Standard treatment

The general approach to AML therapy has not changed substantially in the last decades. It mainly consists of induction of remission and post-remission therapy which contains certain chemotherapies and/or hematopoietic stem cell transplantation (HSCT) ¹⁷. In regard to the induction therapy, for adult patients (<60 years), the "7 + 3" therapy, 7 days standard-dose cytarabine (AraC) and 3 days of anthracycline (e.g. doxorubicin, Dox; or daunorubicin) is recommended¹⁷. However, this chemotherapy is not used for elderly patients (>60 years). Moreover, in terms of post-remission treatment, high-dose of AraC is recommended for adult patients with favourable prognosis, whereas allogenic HSCT is performed in the first remission for patients with adverse prognosis ¹⁷. For elderly patients with favourable risk, consolidation therapy should contain AraC and anthracycline, while nonmyeloablative HSCT should be considered for patients with unfavourable risk. Indeed, for relapsed or refractory AML population, allogeneic HSCT is the selected treatment ¹⁷.

AraC is a pyrimidine nucleoside analogue. As shown in **Fig. 2.2.A**, AraC is transported into cells through a nucleoside transporter, the solute carrier family 29 member 1 (SLC29A1). Next, AraC is phosphorylated to obtain AraC monophosphate (AraCMP) by a deoxycytidine kinase (dCK), and then to AraC diphosphate (AraCDP) by cytidine monophosphate kinase 1 (CMPK1). Finally, AraCDP is converted to AraC triphosphate (AraCTP) by one of several nucleoside diphosphate kinases (NDPKs)¹⁸. Thereafter, AraCTP competes with deoxycytidine triphosphate (dCTP), causing cell death by interfering with DNA synthesis. In fact, AraC is known for its cell-phase-specific cytotoxicity, primarily in the S phase during the DNA synthesis process. However, AraC can occasionally block the progression of cells from G1 phase to the S phase and it can also inhibit DNA polymerases.

Dox, an anthracycline given as the second drug in standard therapy in addition to AraC, is one of the most important anti-cancer chemotherapy drugs used for the treatment of solid tumours and acute leukaemias^{19,20}. Dox enters into the cells through the plasmatic membrane or via the solute carrier family 22 member 16 (SLC22A16)²⁰ (Fig. 2.2.B). Despite the extensive usage for treatment, the molecular mechanisms by which Dox causes cell death are still unclear. A number of mechanisms have been described in the last decades: i) topoisomerase II poisoning, ii) DNA adduct formation, iii) oxidative stress, and iv) ceramide overproduction²¹⁻²⁴ (Fig. 2.2.B). Intercalation of doxorubicin into DNA causing torsional stress and nucleosome destabilisation have been proposed as the basic mechanism of anthracycline, and specifically Dox, causing cell death²¹. However, the oxidative stress mechanism and, more specifically, the role of Dox reduction-oxidation (redox) biology in the cancer cell death has been also recognised²⁵. As depicted in **Fig. 2.2.B**, both the cytochrome P450 enzyme system and the electron transport chain (ETC) complexes carry out the one-electron reduction of dox quinone to dox-semiquinone, leading to NAPDH consumption, redox cycle and generation of superoxide anion radical (i.e. reactive oxygen species [ROS] generation).




Figure 2.2 Schematic representation of AraC and Dox transport and effects on cancer cells. A) Representation of the mechanism of action of AraC chemotherapeutic drug. AraC chemotherapeutic drug causes cell death by DNA synthesis inhibition. **B)** Representation of the mechanism of action of Dox chemotherapeutic drug. Dox treatment causes cell death either by DNA damage via topoisomerase II (TopoII) inhibition, ROS production, or ceramide overproduction. Abbreviations: Cytarabine, AraC; AraCytidine-5'monophosphate, AraCMP; AraCytidine-5'-diphosphate, AraCDP; AraCytidine-5'-triphosphate, AraCTP; cytochrome 450, CYP; deoxycytidine kinase, dCK; electron transport chain, ETC; nucleoside analogue; NDPK; nucleoside diphosphate kinase; NMPK; oxygen, O₂; solute carrier family 29 member 1, SLC29A1; and solute carrier family 22 member 16, SLC22A16.

Mechanism of resistance: AraC and Dox chemotherapeutics

Multiple clinical trials have demonstrated complete remission (CR) rates after the administration of the standard treatment (AraC + Dox) of 60-80% in young adults and 40%-60% in older adults (>65 years old). However, most of patients rapidly relapse resulting in treatment failure^{14,26–28}. Recent studies have underlined drug resistance as a key to this treatment failure. Tumour drug resistance can be divided into: i) primary drug resistance, defined as the absence of drug response; and ii) acquired resistance, characterised by the loss of the previous drug response which results in drug resistance²⁹. Zhang and collaborators reviewed the three main mechanisms of drug resistance in AML²⁹: i) drug

resistance-related protein or enzyme, ii) miRNAs alterations, and iii) autophagy. The first mechanism is formed by proteins or enzymes such as P-glycoprotein (P-gp)³⁰, topoisomerase³¹, protein kinase C (PKC), glutathione S-transferase (GST), or multidrug-resistance related protein (MRP1)³². Thus, P-gp is an organic ion pump with ATP-dependent drug ejection function³³ and its upregulation has been associated with the drug-resistant variant of AML cell lines³⁴. Particularly, it has been shown that PKC could enhance P-gp activity through phosphorylation, thus favouring the acquisition of drug resistance³⁵. Additionally, the amplification of topoisomerase 2 α (TOP2A) has been determined as a mechanism of Dox resistance³⁶. Moreover, GST enzymes, which catalyse the binding of glutathione to chemical drugs³⁷, has been also found to be related to drug resistance in leukaemia^{38,39}. Finally, the inhibition of MRP1, known as a glutathione (GSH) transport pump which mediates the ATP-dependent transmembrane efflux of multiple anticancer drugs as well as other xenobiotics⁴⁰, has been demonstrated to reverse drug resistance by decreasing intracellular ATP⁴¹.

miRNAs alterations constituted the second mechanism of drug resistance. miRNAs are a family of small 18-24 bp noncoding double-stranded RNAs, which are able to suppress protein expression and play an important role in drug resistance⁴². miRNAs may also prove to be relevant in AML, but very few studies have been reported to date. However, a downregulation of miRNA-181a has been reported in AraC resistant AML cells⁴³.

Regarding autophagy (third mechanism of resistance), a process of phagocytosis of the cell's own cytoplasmic proteins and organelles, likewise contributes to the acquisition of AML chemotherapeutics resistance via heat shock transcription factor 1 (HSF1)⁴⁴ or the protooncogene Met⁴⁵. For instance, HSF1 is known to promote drug resistance in leukaemia by upregulating the expression of an autophagy-related protein named autophagy related 7 (ATG7)⁴⁶.

Furthermore, two novel mechanisms of resistance have been described for AraC: overexpression of SAM domain and HD domain-containing protein 1 (SAMHD1) and cytidine deaminase (CDA). SAMHD1 is a deoxynucleotide triphosphate (dNTP) hydrolase responsible

19

of dNTPs cleavage into deoxyribonucleosides and inorganic triphosphate⁴⁷. Importantly, Schneider *et al.* showed its capacity of reducing AraC cytotoxicity in AML cells by hydrolysing AraCTP, thus resulting in a reduction of AraCTP concentration in leukemic cells⁴⁸. On the other hand, the AraC deactivation function of CDA⁴⁹, an enzyme of the pyrimidine salvage pathways, has been also determined and is considered as an AraC resistance factor in AML treated patients⁵⁰.

Novel targets

In the last two years, several novel therapies, mainly small molecules and antibodies, emerged and started to be considered for AML treatment⁵¹. However, exploration of new targets is urgently needed to achieve accurate therapy for AML. Some of the developed treatments are based on FLT3, IDH and nuclear exporter (chromosome region maintenance 1, CRM1) inhibitors (**Table 2.1**); and based on immune therapies. The novel FLT3 inhibitors, G-749 and gilteritinib, acting against both FLT3 ITD and D835 mutations, have been shown to inhibit FLT3 phosphorylation, and thereby increase the ability to overcome midostaurin drug resistance in pre-clinical trials^{52–54}. The IDH1 and IDH2 inhibitors (AG-120 and AG-221, respectively) also showed promising response rates in AML patients⁵⁵. Thus, Food and Drug Administration (FDA) has conceded these inhibitors to be utilised as AML treatment. Moreover, CRM1, a major nuclear exporter protein, plays a role in the export and inactivation of several tumour suppressors, such as p53, p73, FOXO1, RB1, and p21⁵⁶. Interestingly, preclinical studies indicate that treatment of AML cell lines, patient samples and AML xenografts with novel CRM1 inhibitors (Selinexor) induces strong anti-leukemic effects ^{52,56}.

Furthermore, immune therapies have changed the therapeutic landscape of AML. Monoclonal antibodies in AML therapy include antibodies against AML surface antigens such as CD33 (e.g. lintuzumab), antibodies conjugated to toxins in various anti-CD33 (gemtuzumab, ozogamicin, SGN33A, IMGN779) and anti-CD123 (SL-401, SGN-CD123A) formulations, and antibodies conjugated to radioactive particles such as 1311 or 225Ac-

labeled anti-CD33 or anti-CD45 antibodies⁵⁷. In addition, important progress has been made with adoptive cellular therapies using autologous or allogeneic T cells engineered with synthetic chimeric antigen receptors (CARs) redirected against tumour antigens⁵⁸.

Table 2.1 Novel therapies of AML including inhibitors and immune therapies. Treatments based on inhibitors and immune therapies are described. Information obtained from Yang, X. & Wang (2018), and Assi et al. (2018)^{17,57}. Abbreviations: FLT3 Fms-like tyrosine kinase 3; and IDH, isocitrate dehydrogenase.

Type of treatment	Target	Drug
Inhibitor	FLT3	Sorafenib
		Midostaurin
		Quizartinib
		Crenolanib
		Gilteritinib
		Lestaurtinib
		G-749
Inhibitor	IDH1	AG-120
Inhibitor	IDH2	AG-221
Inhibitor	CRM1	Selinexor
Immune therapy	CD33	Lintuzumab
		Gentuzumab ozogamicin
		SGN-33A
		IMGN779
Immune therapy	CD38	Daratumumab
Immune therapy	CD123	SL-401
		SGN-CD123A
Immune therapy	CART-cells	CD33

2.2.2 Chronic myeloid leukaemia

2.2.2.1 Definition, epidemiology and risk factors

Differently from AML which results in an increase of abnormal myeloid blasts, CML is a malignant clonal disorder of HSCs that leads to an aberrant increase of normal myeloid blast, in addition to an increase of erythroid cells and platelets in peripheral blood⁵⁹. In CML, a translocation between chromosomes 9 and 22, known as Philadelphia (Ph) chromosome, is found in 95% of patients⁵⁹ resulting in the formation of BCR-ABL1 fusion gene that disrupts the normal cell regulatory process in the BM. The remaining 5% of patients have diverse translocations involving additional chromosomes but still forming the BCR-ABL1 fusion gene.

Reports from several European CML registries showed an annual incidence of 0.7-1.0 per 100,000 people. Concerning the risk factors, CML is not a hereditary disease and no clear evidence of risk factors are known. However, different studies have manifested that environmental factors, such as radiation, benzene or pesticides, can increase the risk of CML development ^{60,61}.

2.2.2.2 Disease progression and diagnosis

The median age of CML patients diagnosis is 57-60 years ⁶². For diagnosis, the most common sign of CML is an abnormal white blood cell count (more than 5% of blasts in the BM), which can be detected by peripheral blood and bone marrow cell analysis.

Regarding disease progression, CML can be classified into three phases: chronic phase

CP), accelerated phase (AP) and blast phase (BP). Common signs and symptoms of CP-CML is anaemia, splenomegaly, fatigue, weight loss, malaise, etc.⁶³. CP-CML can evolve to AP-

CML, characterised by an increase in the number of leucocytes or white blood cells (WBCs), a more-pronounced splenomegaly and, occasionally, resistance to treatment⁶⁴. Following AP-CML, or in 20% of patients⁶³ immediately after CP-CML, CML can progress to BP-CML, characterised by worsening symptoms, bleeding, fever, infections, resistance to therapy and >20% of WBCs in the BM ^{63,65}. Regarding to the diagnosis, BM aspiration is mandatory for all patients with CML suspicion to confirm the diagnosis, thus providing information that is needed for staging in terms of blast and basophil percentages⁶³. Of note, due to the fact that Ph chromosome is present in more than 90% of CML patients, the diagnosis also relies on the detection of this abnormal chromosome, performed by cytogenetic analysis of BM samples.

2.2.2.3 Treatment

Imatinib, the gold standard CML treatment

The treatment of CML has substantially evolved throughout the years. The use of arsenic was first reported as CML therapy⁶⁶. Next, radiotherapy and chemotherapeutic treatment using busulfan and hydroxyurea remained as standard therapy for long time^{67,68}. However, due to the inefficiency of these treatments, in 1993 the allogeneic stem cell transplantation became the treatment of choice for CML⁶⁹. Moreover, the discovery of the BCR-ABL1 protein in 1986 enabled the development of a new drug with the ability to inhibit the activity of this oncoprotein⁷⁰. This new drug imatinib was approved by the FDA in 2001 and became the standard CML treatment. Imatinib is today the prime example of a success story in cancer research. Imatinib belongs to the first generation of tyrosine kinase inhibitors (TKIs), and acts via competitive inhibition at the ATP-binding site of the BCR-ABL1 protein. Subsequently, Hochhaus *et al.* revealed that the overall survival for CML patients treated with imatinib was 95%⁷¹. However, the best outcomes of imatinib treatment are

determined for patients with CP-CML, because patients with AP-CML or BC-CML poorly respond to imatinib treatment⁷².

Mechanism of resistance to Imatinib

The terms of primary and acquired resistance (explained in **Section 2.2.1.4**) can be also applied for imatinib treatment. In particular, it has been determined that primary resistance occurs in approximately 3% of CP-CML patients and acquired resistance in 20% of CP-CML patients ⁷³.

The molecular mechanisms of imatinib resistance development are heterogeneous. At least there are six well-described mechanism of resistance: 1) lower oral bioavailability⁷⁴, 2) increase of plasma protein binding⁷⁵, 3) overexpression of multidrug resistance genes (e.g. P-gp)⁷⁶, 4) BCR-ABL1 point mutations^{77,78}, and 5) BCR-ABL1 gene amplification⁷⁹. Regarding the first mechanism of resistance, drug efficiency is subject to the gastrointestinal absorption due to the oral administration of imatinib. Moreover, imatinib is known to be 89-96% bound to serum proteins, mainly albumin⁸⁰, but also to alpha-1-acid glycoprotein (AGP)⁸¹, a hepatic acute-phase protein, thus interfering with the imatinib therapeutic effect (mechanism 2). As mechanism 3, drug transporters can play a part in resistance to imatinib either by transporting the drug out of the target cell or by releasing the drug out of cells of the gastrointestinal tract⁸⁰. Proteins of the ATP-binding cassette (ABC) transporter family (e.g. P-gp, also called ATP-binding competitor B1 [ABCB1]), which were already mentioned above (Section 2.2.1.4), have been shown to be responsible for the loss of drug response in many malignancies. In fact, Mahon et al. suggested that overexpression of P-gp as a possible mechanism of imatinib resistance ⁸², and this has been additionally implicated in the lack of cytogenic response with imatinib⁷⁶. Moreover, mechanism 5 comprises point mutations in the ABL tyrosine kinase site, is considered to be one of the principal causes of acquired resistance. To date, more than 50 mutations have been described. Among them, 15 aminoacid substitutions account for more than 85% of the mutations, and the mutations responsible for 66% of reported cases occur at seven sites (G250, Y253, E255, T315, M351,

F359, and H396)⁸⁰. Finally and confirming mechanism 5, cells with higher expression of BCR-ABL1 showed to be much less sensitive to imatinib⁸³. Of note, this mechanism of imatinib resistance was suggested as the most frequent cause of resistance identified in cell lines that were modified to develop resistance⁸². In contrast, in a study of 66 patients with primary or acquired imatinib resistance, only two patients showed BCR-ABL1 genomic amplification⁸⁴. Thus, in practice, imatinib resistance is more likely to be due to point mutations than to BCR-ABL1 overexpression.

Treatment approaches to overcome imatinib resistance

Despite the reported high efficiency of imatinib against Philadelphia chromosome-positive CML, there is an urgent need for additional treatment options for patients who acquired resistance. As a consequence, second-generation TKIs were developed and characterised for their activity against resistant BCR-ABL1 mutations ⁶³.

Several second-generation TKIs have been developed as alternative treatment approaches to inhibit wild-type and mutant forms of BCR-ABL1 (e.g. dasatinib and nilotinib) and have been approved for clinical use in CML patients that are intolerant or resistant to imatinib. Dasatinib is an oral TKI exhibiting a higher in vitro activity than imatinib *in vitro*⁸⁵. Mechanistically, this drug blocks both the activity of BCR-ABL1 and that of the Src family kinases (SFKs)⁸⁶. But in addition, it also inhibits most of the mutated BCR-ABL1 variants, with the exception of the T3151L mutation, and, hence, induces cell death in leukemic cells resistant to imatinib. Due to this success, Dasatinib is therefore nowadays first-line therapy for CP-CML patients^{85,87}. Nilotinib, a structurally related drug to imatinib is 20–50-fold more potent against BCR-ABL1 fusions ⁸⁸ and additionally exhibits high activity against point mutant BCR-ABL1, again with the exception of T3151L mutant. Like dasatinib, nilotinib initially demonstrated the ability to induce hematologic cytogenetic response in patients who failed imatinib treatment⁶³. However, no obvious differences in efficacy between dasatinib and nilotinib have been detected⁸⁹. Up to now, CML patients have a wide CML therapeutic armamentarium, including the mentioned above plus other TKIs (bosutinib,

ponatinib), omacetaxine, and several agents (hydroxyurea, interferon-alpha, busulfan, AraC, etc.)⁶³. Nevertheless, it is important to continue CML research in order to find new strategies to overcome such drug resistance for CML patients in whom therapy still fails and who show signs of drug resistance.

2.3 Cancer metabolism and tumour metabolic reprogramming

Metabolism is the group of all the chemical reactions occurring in a living organism to maintain life. Two types of metabolic reactions are described: catabolism, which comprises the breakdown of molecules to obtain energy; and anabolism, which is described as the synthesis of all compounds that cells require to grow. Metabolic pathways use available nutrients to generate metabolites that can be further utilised as energy sources for important functions such as cell maintenance, biosynthesis processes or to control redox balance in the cell⁹⁰.

The development of cancer depends on genetic alterations that either modify signalling pathways or result in a dysregulation of pathways controlling proliferation processes and metabolism. To explain the tumour's acquired skills during the development of cancer, the commonly known "hallmarks of cancer" were defined. In brief, cancer is characterised by complex phenotypic and molecular changes including uncontrolled and sustained proliferation, which evade growth suppressors, resist cell death, and induce angiogenesis and metastasis ⁹¹.

In contrast to normal cells, cancer cells are also characterised by a hypoxic microenvironment, to which they need to adapt. In this line, different studies have demonstrated that cancer cells coordinate and change different metabolic processes such as glycolysis, glutaminolysis, pentose phosphate pathway (PPP), glycogenolysis, mitochondrial biogenesis, lipid synthesis and fatty acid oxidation (FAO) in order to support cellular biogenesis of macromolecules and energy production (reviewed in [⁹²]). These metabolic changes in tumour cells are commonly known as "metabolic reprogramming",

which is also recognised as a cancer hallmark⁹¹. Furthermore, cancer cells have developed mechanisms that influence these pathways and modify them in order to meet their purposes.

The activation of oncogenes (genes that support cell proliferation and survival) and/or the inactivation of tumour suppressor genes (genes that slow down cell proliferation, promote DNA repair and trigger apoptosis) are examples of the molecular mechanisms developed by cancer cells mentioned above⁹³. Oncogenes comprise transcription factors (e.g. c-MYC), growth factors signalling molecules (e.g. EGFR, RAS, PI3K), serine-threonine protein kinases (e.g. Akt and mTOR), and apoptosis inhibitors such as Bcl-2. On the other hand, tumour suppressor genes are classified into three classes of proteins: i) cell cycle and proliferation inhibitors (e.g. RB, p53, and PTEN), ii) apoptosis inducers (e.g. caspase 8 and p53), and iii) proteins that participate in the DNA repair (e.g. MSH2, MSH6, ATM, and ATR).

2.3.1 Glucose metabolism and biosynthetic pathways

2.3.1.1 Glucose uptake, glycolysis, and pyruvate metabolism

Glucose uptake constitutes the first step of glucose metabolism and is regulated and facilitated by glucose transporters (GLUTs). Based on their sequence similarity, there are 14 GLUT proteins classified into 3 classes (Class I, II and III)⁹⁴. However, GLUT1-4 are the four most studied isoforms. Noteworthily, unlike other members of class I, GLUT4 is sequestered in intracellular compartments, and redistributed to the plasma membrane upon insulin response via the insulin signalling pathway ^{95,96} (**Fig. 2.3**). In addition to glucose, fructose can also be transported into cells and be further utilised in glycolysis by fructose kinase through GLUT5 transporter⁹⁷.




Figure. 2.3 Insulin-regulated GLUT4 translocation. This process occurs through two signaling pathways: one involving the lipid kinase phosphatidylinositol 3-kinase (PI3K) and the other involving proto-oncoprotein c-Cbl. Both pathways take part in GLUT4 translocation from the intracellular GLUT4-containing vesicles to the cell membrane, allowing glucose to enter the cell.

In the context of cancer, the upregulation of GLUT1 transporters has been reported in the majority of cancers ^{98,99}, and correlated with poor cancer prognosis and chemoresistance, for example in AML¹⁰⁰. Moreover, Chen *et al.* revealed that AML cells can compensate low glucose levels by upregulating the gene for the transporter GLUT5. Indeed, they showed that high expression of GLUT5 is associated with poor AML patient prognosis and that the AraC cytotoxic effect *in vitro* was enhanced upon GLUT5 inhibition¹⁰¹.

Cancer cells predominantly produce energy through glycolysis. Glycolysis is the first step in the breakdown of glucose and involves nine reactions catalysed by different enzymes (illustrated in **Fig. 2.4**). From these enzymes, there are three rate-limiting enzymes which are known to control glycolytic flux depending on the conditions: hexokinase (HK), phosphofructokinase (PFK), and pyruvate kinase (PK). Normal cells catabolise glucose through glycolysis to pyruvate, which is transported to the mitochondria. There, pyruvate is oxidatively decarboxylated by pyruvate dehydrogenase complex (PDC), releasing CO₂, producing NADH, and converting pyruvate into acetyl-CoA. Thus, constituting the step between glycolysis and tricarboxylic acid (TCA) cycle. PDC activity is modulated by reversible phosphorylation which is catalysed by pyruvate dehydrogenase kinases (PDKs) and pyruvate dehydrogenase phosphatases (PDPs). Moreover, acetyl-CoA fuels the TCA cycle and the ETC, where oxidative phosphorylation (OXPHOS) occurs and O₂ is the final electron acceptor. On the other hand, cancer cells divergently convert much of the pyruvate into lactate via lactate dehydrogenase (LDH) even in the presence of O_2^{102} . This phenomenon is referred as aerobic glycolysis or Warburg effect¹⁰³. Remarkably, several groups have shown an effective prevention of cancer cell proliferation when knocking down LDHA isoform, thus preventing the pyruvate to lactate conversion^{98,104}.

2.3.1.2 Pentose phosphate pathway

Even tough glycolysis is the central energy-producing pathway, cancer cells also rely on PPP, thus providing an alternative pathway for glucose metabolism. PPP diverts G6P from glycolysis to biosynthesise NADPH, ribose-5-phosphate (R5P) and various glycolytic intermediates¹⁰⁵. Like glycolysis, this pathway takes place in the cytosol. Moreover, PPP is composed of two branches (illustrated in Fig. 2.4): the oxidative branch, which generates NADPH and ribose for subsequent ribonucleotides production, and the nonoxidative branch. The oxidative branch has three irreversible reactions. It starts with the dehydrogenation of G6P to 6-phosphogluconolactone, performed by the enzyme glucose-6-phosphate dehydrogenase (G6PDH). Then, it is hydrolysed by phosphogluconolactonase (6-PGL) into 6-phosphogluconate. In the last reaction 6-phosphogluconate dehydrogenase (6-PGD) catalyses the oxidative decarboxylation of 6-phosphogluconate to ribulose-5phosphate (Ru5P), which is further converted to R5P serving as a nucleotide precursor or being metabolised via the nonoxidative branch to produce fructose-6-phosphate (F6P) and glyceraldehyde-3-phosphate (G3P) by transketolase (TKT) and transaldolase (TALDO) $1^{105,106}$. In the oxidative branch, NADP⁺ acts as electron acceptor, hence, NAPDH is generated. NADPH plays a crucial role in both reductive biosynthesis and in the protection

of cells from ROS, which can cause cell death. The other important molecule, generated in the oxidative and nonoxidative phases, is R5P, which constitutes an important precursor to biomolecules such as DNA, RNA, and ATP.

The role of PPP in cancer cell processes such as proliferation, survival, tumour invasion, angiogenesis, and responses to chemotherapeutics has become of general interestengaging in the recent years. Indeed, overexpression of the main PPP genes has been shown in different cancers types including gastric, colorectal and kidney cancers and leukaemia¹⁰⁷⁻¹⁰⁹. Of note, Jing *et al.* reviewed that the activity of G6PDH, which is the first rate-limiting enzyme in the PPP, directly reflects the flux of oxidative PPP and determines the flux preference between glycolysis and the PPP¹¹⁰. In fact, G6PDH has been suggested as a potential therapeutic target of human cancer due to its role in PPP flux and NADPH production¹⁰⁶.

On the other hand, TKT and TALDO1 are the two major enzymes of the non-oxidative branch. They are able to determine the direction of metabolite flux in PPP due to the reversible metabolic link between the non-oxidative branch of PPP and glycolysis¹⁰⁵. Up to now, one TKT and two transketolase-like genes (TKTL1 and TKTL2) have been identified¹¹¹. Several studies demonstrated that specifically TKTL1 is upregulated in many different cancers including gastric¹¹², colon and urothelial cancer¹⁰⁸ and chronic myeloid leukaemia¹¹³, resulting in an enhanced non-oxidative glucose degradation via the PPP. In contrast, TKT and TKTL2 have not been described to be upregulated in cancer cells¹¹⁴. In agreement, our group and others have previously described the role of TKTL1 in major metabolic reprogramming processes of cancer cells¹¹⁵. Additionally, it has been recently demonstrated that high TKTL1 induces accumulation of R5P, thus facilitating nucleotide and DNA synthesis as well as cell cycle progression¹¹⁶. It is for these reasons that TKTL1 has been suggested as a promising target for new anti-cancer therapies by substrate limitation^{108,117} or DNA synthesis inhibition¹¹⁶.




Figure 2.4 Glycolysis pathway, glycogen metabolism, pentose phosphate pathway and serine synthesis pathway. Schematic representations of the metabolites and enzymes involved in these metabolic processes. Abbreviations: HK, hexokinase; G6PD, glucose-6-phosphate dehydrogenase; 6-PGD, phosphogluconate dehydrogenase; TKT, transketolase; PK, pyruvate kinase; LDH, lactate dehydrogenase; GK, glucokinase; PGK, phosphoglycerate kinase; ENO, enolase; PFKM, phosphofructokinase muscle; PFKP, phosphofructokinase platelet; PSPH, phosphoserine phosphatase; ALDO, aldolase; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; PGAM, phosphoglycerate mutase; PK, pyruvate kinase; PYGL, glycogen phosphorylase L; PYGB, glycogen phosphorylase B; PGM,phosphoglucomutase; NUDT14, nudix hydrolase 14; GYS, glycerol synthetase; UGP2, UDP-glucosa pyrophosphorylase 2; PGLS, 6-phosphogluconolactonase ; RPIA, ribose 5-phosphate isomerase A RPE, ribulose-5-phosphate-3-epimerase; TKTL-1, transketolase like 1; and TALDO 1, transaldolase 1.

2.3.1.3 Glycogen metabolism

Glycogen is a cellular energy source and storage for cells. As illustrated in **Fig. 2.4**, glycogen synthesis is performed in the cytosol starting with the phosphorylation of glucose by glucokinase (GK), in the liver, or by hexokinase, in muscle and other tissues, thus obtaining G6P. In the second step, G6P is converted into glucose-1-phosphate (G1P) by the enzyme

phosphoglucomutase (PGM) and further converted into uridine diphosphate (UDP)-glucose by the reaction with uridine triphosphate (UTP), catalysed by G1P uridylyltransferase. Next, UDP-glucose is converted into glycogenin, which is finally elongated by glycogen synthase (GS) to obtain glycogen. On the other hand, glycogen breakdown requires the coordinated activities of glycogen phosphorylase (GP or PYG) and the bifunctional glycogen debranching enzyme. GP takes care of the cleavage of glucose residues from the glycogen chain, producing G1P¹¹⁸. Moreover, the rates of glycogen synthesis and breakdown depend on the rates of phosphorylation/dephosphorylation of the key enzymes which are controlled, for instance in liver and muscle cells, by hormones such as glucagon, insulin, and epinephrine¹¹⁹. Regarding the regulation of glycogen metabolism, it is mainly regulated by GS and GP, which are the rate-limiting enzymes of glycogen synthesis and degradation, respectively.

Large quantities of glycogen have been described in a variety of cancer entities including breast, kidney, uterus, bladder, ovary, skin and brain cancer^{120–123}. In agreement, cancer genomic data has shown that glycogenic synthase (GYS) enzymes 1 and 2, and 1,4-alpha-glucan-branching (GBE1) enzymes are upregulated in 18% of the AML patients with significantly poor survival outcome¹²⁴.

Taken all the facts mentioned above and due to the fact that some anti-cancer therapies in clinical trials have shown crucial changes in glycogen metabolism within the tumour (reviewed by Jayaraman¹²⁵), glycogen metabolism has been suggested as a novel and potential therapeutic target for cancer treatment. In this line, several GP inhibitors have been developed targeting either the allosteric site binding AMP (e.g. AVE5688, AVE2865, and AVE9423)¹²⁶, the inhibitor sites binding purine nucleotides (e.g. Flavopiridol)¹²⁷, or the catalytic sites binding glucose, G1P and inorganic phosphate (e.g. 1,4-dideoxy-1,4-amino-D-arabinitol, DAB)¹²⁸.

2.3.2 Amino acid metabolism

Amino acids are crucial for the formation of cellular proteins and serves as intermediate molecules in different metabolic processes such as a lipids and nucleic acid biosynthesis. There are twenty defined amino acids, nine of them (histidine, isoleucine, leucine, lysine, methionine, phenylalanine, threonine, tryptophan, and valine) are known as essential amino acids (EEAs), as they need to be supplied by diet due to the fact that humans cannot synthesise them. The rest of amino acids (alanine, aspartate, asparagine, arginine, cysteine, glutamate, glutamine, glycine, proline, serine, and tyrosine) are called non-essential amino acids (NEAAs), as humans can synthesise them. Furthermore, there are many interconnected pathways of NEAA synthesis¹²⁹. For instance, glutamate can be utilised to generate alanine, aspartate, serine or proline. Aspartate is also used to generate asparagine and to generate arginine via the urea cycle. Serine is another example and it is known to serve as a substrate for the glycine generation by donating methyl groups for one-carbon (1C) metabolism and additionally functions as a substrate for the transsulfuration pathway generating cysteine. Contrarily, tyrosine is the only NEAA which is not directly connected to the other NEAAs, but it is synthesised from the essential amino acid (EAA) phenylalanine.

Regarding cancer metabolism, NEAAs support relevant cell processes including biosynthesis of the TCA cycle and NADPH generation and participate in other metabolic pathways such as the urea cycle and one carbon (1-C) metabolism (summarised in **Fig. 2.5**). Consequently, the interest of targeting NEAA metabolism for cancer therapy has gained importance in the last years and, thus, several NEAA-targeted therapies have been already revealed and use for cancer treatment (reviewed in [¹³⁰]).

2.3.2.1 Glutamine

Glutamine is a non-essential amino acid, known to be the most studied in the context of cancer metabolism^{98,131}. It is the most abundant amino acid in human plasma. However, under rapid proliferation or stress conditions, glutamine can become conditionally essential

(i.e. glutamine needs to be obtained through other pathways such as diet). Glutamine can be uptaken via different amino acid transporters, being ASCT2 (alanine/serine/cysteine transporter 2, coded by the SLC1A5 gene) the most known¹³². Then, glutamine is catabolised through a process called glutaminolysis and it is converted into many important metabolites such as glutamate, citrate, pyruvate, lactate, aspartate, alanine and CO₂⁹⁸. Glutamine plays important biological roles within the cell, due to its ability to provide both carbon and nitrogen for many biosynthetic reactions (Fig. 2.5). For example, carbons from glutamine, as α -ketoglutarate (α KG), support the biosynthetic functions of TCA cycle¹³³, while glutamine derived nitrogens are required for the biosynthesis of molecules such as hexosamines, nucleotides, and other NEAAs^{129,134,135}. Furthermore, glutaminolysis is critical for cancer cell proliferation and survival. It has been shown that high concentrations of extracellular glutamine fuel cancer cell growth and survival¹³⁶ and that mitochondrial enzymes relevant to glutamine/glutamate oxidation are also elevated in tumour cells¹³⁷. Additionally, glutaminolysis also helps to regulate redox balance, mTOR signalling, apoptosis, and autophagy⁹⁸. Due to all these facts, numerous approaches targeting glutamine metabolism in cancer have already been proposed and tested^{138,139}. For example, the inhibition of glutamine catabolism by glutaminase (GLS) has gained the major focus of both academic and pharmaceutical cancer metabolism research. GLS can be inhibited by several small molecules, such as bis-2-[5-phenylacetamido-1,2,4-thiadiazol-2-yl] ethyl sulfide (BPTES)¹⁴⁰, CB-839¹⁴¹, and compound 968¹⁴². Of note, CB-839 is currently being tested in multiple phase II trials alone or in combination with other drugs (e.g. everolimus and paclitaxel), showing positive clinical responses in renal cell carcinoma and AML⁹⁸.

On the other hand, glutamine is produced by glutamine synthetase (GS), an enzyme that catalyses the condensation of glutamate and ammonia in an ATP-dependent manner¹⁴³. Despite that the emphasis on glutamine metabolism in cancer has been focused on glutamine catabolism, glutamine synthesis is also crucial because it serves as an essential component in the synthesis of proteins¹⁴⁴. However, cells can overcome glutamine deficiency using asparagine for proliferation and protein synthesis. In addition to the synthesis of protein, glutamine synthesis plays an important role in the transport of EAAs,

balancing pH and detoxifying NH₃ and glutamate¹⁴⁵. Finally, it is worth mentioning that the exposure of hypoxia increases both GS enzymatic activity¹⁴⁶, and GS mRNA and protein levels¹⁴⁷.

2.3.2.2 Glutamate

Glutamate is a nonessential amino acid that can be synthesised through different metabolic pathways. Contrarily to glutamine, glutamate is not an essential amino acid for cancer cells and cannot be found at higher concentrations in human plasma either. In fact, most of the intracellular glutamate is coming from glutamine via GLS^{148} . In addition, glutamate can also be synthesised from branched-chain amino acids (BCAAs) and α KG through transferases (Branched Chain Amino Acid Transaminase 1 and 2, BCAT1/2). Regarding glutamate catabolism, glutamate can be converted to α KG via glutamate dehydrogenase (GDH), or via transaminases.

Furthermore, glutamate plays a relevant role in the biosynthesis of proline, ornithine, aspartate, alanine, and serine, which can be further used for the synthesis of cysteine, glycine, asparagine and arginine^{129,149}, and in the synthesis of glutathione¹⁵⁰ (**Fig. 2.5**). Of note, inhibition of GDH, alone or combined with other treatments, has been shown to inhibit tumour growth in different cancers such as pancreatic and lung cancer^{151,152}.

2.3.2.3 Aspartate and asparagine

Aspartate metabolism is known for its role in the transfer of electrons between the cytosol and the mitochondria through the malate-aspartate shuttle in rapidly proliferating cells (e.g. cancer cells)¹⁵³. Moreover, the transport of aspartate via the aspartate-glutamate carrier has also been described to support cell proliferation and cell redox homeostasis in low-glutamine environments¹⁵⁴. Similar to other amino acid inhibitors, aspartate

aminotransferases inhibitors have been suggested as potential cancer therapeutics, whose inhibition can either decrease or inhibit tumour growth¹⁵¹.

On the other hand, asparagine is required for DNA synthesis in cancer cells. Noteworthy, asparaginase is a good example of a current cancer therapy used against paediatric acute lymphoblastic leukaemia (ALL) that directly targets NEAA metabolism¹⁵⁵. In this therapy, patients are injected with asparaginase preparations resulting in hydrolysis of serum asparagine into aspartic acid and ammonia.

2.3.2.4 Arginine, ornithine and urea cycle

Arginine, an NEAA, and ornithine, a non-protein amino acid, can be trafficked into cells. Arginine can be further converted into ornithine through arginase (ARG1 and ARG2). Both are intermediate metabolites of the urea cycle, a metabolic pathway that converts the toxic ammonia to urea to be excreted via urine (**Fig. 2.5**). Argininosuccinate synthetase 1 (ASS1), responsible for converting aspartate and citrulline into arginosuccinate, and argininosuccinate lyase (ASL), which catalyses the breakdown of arginosuccinate to arginine and fumarate, are relevant urea cycle genes. A study performed by Rabinovich *et al.* revealed that ASS1 and ASL suppression in tumours shows to be beneficial for tumour growth by increasing the availability of aspartate for nucleotide synthesis¹⁵⁶.

Furthermore, arginine is also the precursor of polyamines, small organic cations which are essential for normal cell growth and development in eukaryotes¹⁵⁷. A study performed by Nowotarski *et al.* demonstrated that polyamines are essential for the proliferation and differentiation of the blood cells as the metabolites of L-arginine¹⁵⁸. Interestingly, polyamine catabolism has been associated with carcinogenesis. Specifically, spermidine oxidase (SMO) protein, which is a FAD-dependent enzyme that oxidises spermine to produce spermidine, 3- aminopropanal and H₂O₂, has been determined in colon and lung cancers^{159,160}. Of note, an inhibitor of SMO, known as MDL 72,527, was reported to efficiently inhibit SMO in a valid model for colon carcinogenesis¹⁵⁹.

2.3.2.5 Serine, glycine and one-carbon metabolism

Serine is the third most consumed metabolite by cancer cells after glucose and glutamine¹⁶¹. Like glutamine, serine can be taken by the transporter ASCT2¹³², but it can also synthesised *de novo* through the serine synthesis pathway (SSP) via the glycolytic intermediate 3-phosphoglycerate (3-PG)¹²⁹, as illustrated in **figure 2.4**. Moreover, serine can be converted into glycine via the activity of cytosolic or mitochondrial serine hydromethyltransferases (SHMT1 and SHMT2). This conversion provides 1-C units, which are further utilised by the folate and methionine cycles, metabolic pathways known as 1C-metabolism.

Serine itself is an EAA in cancer cells due to its participation in purine biosynthesis, mitochondrial protein translation, lipid biosynthesis, and glycolysis regulation (**Fig. 2.5**). Certain tumours depend on the environmental serine uptake¹⁶², thus the limitation of serine availability in plasma has been categorised as beneficial for patients with serine-sensitive cancers. Regarding the enzymes associated with serine synthesis and cancer metabolism, PHGDH has been shown to increase in multiple cancers^{163–165} and, consequently, PHGDH inhibitors such as CBR-5884, NCT-502, NCT-503 and indole amines are currently under preclinical studies^{166–168}.

Furthermore, 1-C metabolism has been suggested to benefit cancer survival due to its fundamental role in multiple pathways such as nucleotide synthesis¹⁶⁹, NADPH production¹⁷⁰, redox homeostasis¹⁷⁰ and epigenetic modifications¹⁷¹. For this reason, methotrexate and 5-FU have been used as antifolate chemotherapeutics targeting 1- C metabolism¹⁷².

2.3.2.6 Proline

Proline is a proteogenic amino acid that can be synthesised i) from glutamate by the enzyme pyrroline-5-carboxylate (P5C) synthase (P5CS, so-called ALDH18A1) and P5C reductase

(PYCR) with P5C as the main intermediate or ii) from ornithine via ornithine aminotransferase (OAT) and PYCR (summarised in **Fig. 2.6**). The breakdown of proline back to glutamate occurs strictly in mitochondria and is catalysed by the mitochondrial enzymes proline dehydrogenase (PRODH) and P5C dehydrogenase (P5CDH, so-called ALDH4A1). This proline-P5C cycle is responsible for the transfer of the reducing equivalents from cytosolic NADPH into the mitochondrial respiratory chain when the reductive step occurs outside mitochondria¹⁷³, and it is also involved in other relevant functions such as OXPHOS, pyridine nucleotide levels maintenance, and ROS generation¹⁷⁴.

Besides these functions, proline can be also stored in collagen, the main protein component of the extracellular matrix (ECM), during proline oversupply¹⁷⁵. Therefore, proline can be further released from collagen degradation upon metabolic stress in order to serve as a source of energy, amino acid synthesis, and redox signalling (**Fig. 2.6**).

Furthermore, enzymes associated with proline metabolism including PYCR and PRODH has been linked to cancer cell metabolism. It has been demonstrated that PYCR enzyme generates excess of NADP⁺, which is further utilised by the oxidative branch of PPP, thus supporting nucleotide synthesis and, in turn, activating biomass production ¹⁷⁶. In agreement, Cai *et al.* showed that PYCR1 knockdown/knockout impairs cell proliferation in different cancers such as lymphoma and breast cancer¹⁷⁷. On the other hand, PRODH has been shown to increase and promote metastasis¹⁷⁸ and cell survival under hypoxic conditions¹⁵¹.




Figure 2.5 Functional roles of amino acids in cancer metabolism. Abbreviations: non-essential amino acids, NEAAs; and reactive oxygen species, ROS.




Figure 2.6 Summary of reactions and enzymes involved in proline metabolism. Abbreviations: Arg, arginine; ECM, extracellular matrix; GSA, glutamic semialdehyde; Glu, glutamate; NADP, Nicotinamide adenine dinucleotide phosphate; OAT, ornithine aminotransferase; Orn, ornithine; P4H, prolyl 4-hydroxylase; P5C, delta-1-pyrroline-5-carboxylate; P5CDH, delta-1-pyrroline-5-carboxylate dehydrogenase; P5CS, delta-1-pyrroline-5-carboxylate synthetase; PPP, pentose phosphate pathway; Pro, proline; PRODH, proline dehydrogenase; proT, proline transporter; and PYCR, pyrroline-5-carboxylate reductase.

2.3.3 Mitochondrial metabolism

It is widely accepted that the elevated uptake of glucose and the increase of glycolysis, known as "the Warburg effect", increase bioenergetics and anabolic growth in cancer cells¹⁸⁰. Otto Warburg also suggested that cancer cells maintain these elevated glycolytic rates at the expense of primary mitochondrial defects¹⁸¹. However, it is now well-known that cancer cells are able to orchestrate the reprogramming of glycolysis and mitochondrial metabolism in order to adapt to the tumour microenvironment, which is characterised by hypoxia, pH changes, and metabolite deprivation, thus conferring a high metabolic plasticity

to cancer cells¹⁸². Last but not less important, mitochondria also plays a role in tumour anabolism, redox control, calcium homeostasis, transcriptional regulation and cell death^{182–185}.

2.3.3.1 Tricarboxylic acid cycle and oxidative phosphorylation

TCA cycle is one of the cellular processes of mitochondrial metabolism. In brief, the TCA cycle involves a group of reactions that take place in the mitochondrial matrix and, finally, releases two CO₂ molecules, three NADH, one FADH₂ and one GTP. During this process reducing power is stored via NADH, and FADH₂ electron carriers and further reoxidised in the ETC to obtain ATP (**Fig. 2.7**). From the biochemical point of view, the TCA cycle has been divided into two stages: i) decarboxylative, in which citrate is converted to succinyl-CoA realising two CO₂ molecules, and ii) reductive, including the successive oxidation of succinate to oxaloacetate¹⁸⁶. Moreover, the dual compartmentalisation (cytosolic and mitochondrial) of TCA cycle reactions and metabolites allows cells to respond to metabolic changes and sustain anabolic reactions. Another important characteristic of the TCA cycle is the metabolite interconversion. For instance, citrate can be exported to the cytoplasm and cleaved to obtain acetyl-CoA for fatty acid (FA) synthesis; and other TCA metabolites can indeed provide substrates for amino acid synthesis by transamination or gluconeogenesis.

OXPHOS is the mitochondrial metabolic pathway responsible for ATP synthesis via nutrients oxidation. NADH and FADH₂ are known as electron donors, which transfers the electrons to the final electron acceptor (O₂). As shown in **Fig. 2.7**, these reactions take place in the ETC. Three of the carriers are cytochromes, and two are small mobile electron carriers. The first large carrier is NADH dehydrogenase (complex I), which receives reducing power NADH and then oxidises it to NAD⁺. Complex I transfers its electrons to the small mobile electron carrier known as coenzyme Q or ubiquinone through the NAD dehydrogenase. Next, ubiquinone transfers the electrons to cytochrome c reductase (complex III), which then passes its electrons to cytochrome c, and subsequently to the cytochrome c oxidase (complex IV). Finally, these electrons are transferred to O₂, which is reduced to water. Additionally, these three big electron carriers pump the protons from the matrix into the intermembrane space, generating an important proton gradient, which is further used by the ATP synthase (complex V) to obtain ATP.

Several studies have shown that mutations or dysregulations of multiple enzymes belonging to the TCA cycle and OXPHOS are correlated with disease transformation and progression (reviewed in [¹⁸⁷]). In this line, succinate dehydrogenase (SDH) and fumarate hydratase (FH) inhibitors have been reported even though the development is still in early stages^{188,189}. Mutated-IDH2 inhibitors (e.g. AGI-6780, bromodomain-containing protein 4 (BRD4), or AG-221) have been interestingly highlighted as therapeutic agents for AML^{190–192}.

Regarding OXPHOS metabolism, its role in the understanding of cancer development and cancer drug resistance has gained more interest^{193–195}. Several studies have determined OXPHOS upregulation in diverse cancers such as breast cancer¹⁹⁶, AML¹⁹⁷, and pancreatic ductal adenocarcinoma¹⁹⁸. For instance, OXPHOS inhibitors such as metformin, VLX600, and ME-344 treatment, which are complex I inhibitors, have shown to cause cancer cell death^{199–202}. Complex II inhibitors (lonidamine and vitamin E analog α –tocopheryl succinate) have been evaluated as anti-tumour drugs and showed to be therapeutically effective for some cancers^{203,204}. Moreover, the antiproliferative effect of arsenic trioxide (a complex IV inhibitor) has been determined in human myeloid leukemia²⁰⁵, in addition to other cancer such as prostate and ovarian cancers^{206,207}. Likewise, OXPHOS downregulation has been also associated with poor clinical outcomes in all cancer types and suggested as a key metabolic signature in melanoma and renal cancer²⁰⁸.




Figure 2.7 Biochemical and biosynthetic reactions driving tricarboxylic acid cycle and oxidative phosphorylation. TCA cycle and OXPHOS reactions and derived biosynthetic pathways are illustrated. Abbreviations: α -ketoglutarate, α -KG; electron transport chain, ETC; fatty acid transporter, FATP; glucose transporter, GLUT; oxaloacetate, OAA; and solute carrier family 38 member 1, SLC38A1.

2.3.3.2 Glycerol-phosphate shuttle

The glycerol-3-phosphate (GP) shuttle is a mechanism that transports electrons to the mitochondrial carrier in the OXPHOS pathway. In this shuttle, dihydroxyacetone phosphate (DHAP) is converted to GP by a cytoplasmic glycerol-3-phosphate dehydrogenase 1 (GPD1 or cGPDH), oxidising one molecule of NADH to NAD⁺²⁰⁹. GP can be converted back to DHAP by a mitochondrial glycerol-3-phosphate dehydrogenase 2 (GPD2 or mGPDH), thus transferring 2 electrons and 2 H⁺ onto FAD, forming FADH₂ in the mitochondrial

intermembrane. In the next step, a ubiquinone molecule in the core of the inner membrane collects the two 2 electrons and 2 H⁺, thereby reducing ubiquinone to ubiquinol with concurrent oxidation of FADH₂ to FAD. Finally, ubiquinol transfers electrons to complex III allowing mitochondria to produce ATP independently of complex I and II activities²¹⁰ (**Fig. 2.8**).

There are three main metabolic roles in the GP shuttle: i) the reoxidation of cytosolic NAD in glycolytic cells; ii) the bypassing of complex I during cytosolic NADH oxidation; and iii) the regulation of cytosolic GP as metabolite connecting glycolysis, lipogenesis and OXPHOS²¹⁰. Another important role of the GP shuttle is ROS generation^{211,212}. Moreover, a study carried out by Saheki *et al.* highlighted the metabolic role of GPD2 in glycolysis, gluconeogenesis, glycerol, and lipid metabolism²¹³; and anti-proliferative effects of GPD2 inhibitors have been accordingly reported on thyroid²¹⁴ and pancreatic cancer cells²¹⁵.




Figure 2.8 Diagram of the oxidative phosphorylation and glycerol-3-phosphate shuttle. Abbreviations: flavin adenine dinucleotide, FAD; Glycerol-3-Phosphate Dehydrogenase 1 and 2, GPD1 and 2; nicotinamide adenine dinucleotide, NAD; and coenzyme Q, Q.

2.3.4 Fatty acid metabolism

Fatty acids (FAs) are essential for cell membrane synthesis and energy storage and production. Cells can increase the amount of FAs by "*de novo* lipogenesis" and decrease it by FAO, lipolysis (increase the released of FAs from storage), and re-esterification (decrease of FAs flux towards storage) (**Fig. 2.9**).

FA synthesis starts with the transport of citrate, which is obtained from the TCA cycle or from glutaminolysis by reductive carboxylation. Then, cytosolic citrate via ATP-citrate lyase (ACLY) or acetate acyl-CoA synthetase short-chain family member 2 (ACSS2) generate cytosolic acetyl-CoA. Acetyl-CoA is further carboxylated by acetyl-CoA carboxylase (ACC), thus generating malonyl-CoA. Ultimately, a series of condensation processes catalysed by fatty acid synthase (FASN) produce palmitate using NAPDH, which is further used for FA elongation, desaturation and lipid synthesis²¹⁶ (**Fig. 2.9**).

On the other hand, FAO involves a repeated sequence of four enzyme activities resulting in the release of an acetyl-CoA molecule, one molecule of FADH₂ and NADH. The final product, acetyl-CoA, then enters the TCA cycle and is used to generate ATP. There are three components participating in this transporting system: carnitine palmitoiltransferase 1 (CPT1), the carnitine acylcarnitine translocase (CACT) and CPT2²¹⁷. CPT1 is located in the outer mitochondrial membrane and converts acyl-CoA to acyl-carnitine. Then, CACT, which is located in the IMM, shuttles acylcarnitine into the mitochondrial matrix, where CTP2 reconverts acyl-carnitine to acyl-CoA²¹⁸. Once acyl-CoA is inside the mitochondria, FAO takes place. (**Fig. 2.9**).

Regarding the relation between FA metabolism and cancer, a crucial role of FA metabolism for cancer cell survival, proliferation, differentiation, and metastasis has been reported^{218,219}. The metabolic reprogramming of cancer cells involves an increased FA metabolism due to their high metabolic demand. To this end, both essential lipogenic enzymes (e.g. FASN, ACLY, and ACC), and FAO enzymes (e.g. CPT1) are upregulated in cancer

cells^{216,220}. Of note, CPT1 upregulation has been correlated with poor patient outcomes in AML²²¹

Furthermore, FA metabolism is also related to chemoresistance of cancer cells. To this end, both the FASN inhibition by siRNA and the CPT1A inhibition by etomoxir sensitise breast and ovarian resistant cancer cells to cisplatin^{222,223}, and leukemic cells to AraC²²⁴, respectively.




Figure 2.9 Illustration of fatty acid metabolism. Key enzymes involved in fatty acid metabolism. Abbreviations: acetyl-CoA carboxylase, ACC; ATP citrate lyase, ACLY; acyl-CoA synthetase short-chain family member, ACSS; carnitine acylcarnitine translocase, CACT; carnitine/palmitoyl-transferase (CPT), fatty acid synthase, FASN; fatty acid transporter protein, FATP; nicotinamide adenine dinucleotide , NADH; and tricarboxylic acid cycle, TCA.

2.3.5 Maintenance of redox homeostasis: ROS mitigation

Redox balance changes and redox signalling deregulation are common hallmarks of general cancer progression and resistance to treatment. Reactive species are responsible for the

oxidative stress and can be divided into four groups: ROS, reactive nitrogen species (RNS), reactive sulfur species (RSS) and reactive chloride species (RCS). From them, ROS is the most abundantly reactive species produced. Low concentration of ROS promotes cell proliferation and survival, whereas intermediate concentration promotes a momentary or permanent cell cycle arrest and can induce cell differentiation. On the other hand, high concentrations of ROS produce oxidative DNA damage and subsequent occurrence of mutations²²⁵. Regarding ROS production, cellular enzymes (such as OXPHOS enzymes, NADPH oxidases (NOX), nitric oxide synthases, cyclooxygenases, xanthine oxidase, lipoxygenases and organelles (mitochondria, peroxisomes, endoplasmic reticulum) are the primary sources of ROS in cancer cells (reviewed in ²²⁶). In particular, mitochondria, which consumes approximately 80% of molecular O₂ during OXPHOS, is the one contributing most prominently. Additionally, peroxisomes are also another source of high ROS generation. In this case, superoxide and H₂O₂ are generated by xanthine oxidase.

Excessive ROS production promotes an oxidative imbalance that could harm or kill cancer cells. In consequence, cancer cells develop an immense antioxidant system. They use what is known as the first line of defence against ROS, which includes glutathione peroxidase (GPx), peroxiredoxins, catalases (CATs) and superoxide dismutase enzymes, to transform free radicals into stable and less damaging molecules. Interestingly, decreased levels of SOD, CAT and GPx enzymes have been detected in subtypes of leukaemia including AML and ALL²²⁷. Moreover, other important mechanisms of oxidative stress protection in cancer cells are related to the nuclear factor erythroid 2-related factor 2 (Nrf2), and glutathione.

2.3.6 Glutathione: The roles in ROS mitigation and xenobiotic detoxification

Glutathione is a crucial antioxidant molecule and a detoxifying agent in cells. It also maintains the thiol status of proteins and plays an important role in cellular proliferation and differentiation. There are two forms of glutathione: reduced form (GSH) and oxidised

form (GSSG). Under normal conditions, reduced GSH is the major form in cells²²⁸. However, GSH is reduced under oxidative stress due to its contribution to the H_2O_2 detoxification via GPx enzyme, generating GSSG. Then, GSSG can be recycled to GSH by glutathione reductase (GSR). This mechanism is activated in organelles where H_2O_2 detoxification by CATs is absent (e.g. mitochondria) or overloaded²²⁹.

Lately, studies have targeted the role of GPx and GSR in cell survival and chemotherapeutic resistance^{230–232}. For instance, the increase of GPx4 level was revealed to promote cancer cell survival and resistance to ferroptosis in drug-tolerant cancer cells²³⁰.

Xenobiotic detoxification is another function of GSH. However, the main responsible for this function is the family of enzymes known as GST, which catalyse the conjugation of GSH to a wide range of substrates (e.g. carcinogens, anticancer drugs, metabolites, etc.) and further secrete the conjugates extracellularly²³³. There are three types of GST described: cytosolic, mitochondrial, and nuclear. As mentioned in **Section 2.2.2.4**, GST proteins catalyse the binding of glutathione to AML drugs, thereby reducing the cytotoxic effect of the chemotherapeutic^{37–39}. Indeed, recently developed GST inhibitors have been suggested to overcome therapeutic resistance and it has become a current field of interest²³⁴.

2.3.7 Hypoxia: its influence in cancer and in leukaemia

Hypoxia is defined as the reduced availability of O_2 to cells, tissues or organisms and is known to induce metabolic and proteomic changes²³⁵. Solid tumours, for instance, are often characterised by hypoxic regions, as a consequence of aberrant vascularisation and a poor blood supply²³⁶. Moreover, organs such as thymus, kidney, and BM are characterised by a hypoxia of $\leq 1\%$ of O_2 partial pressure due to their atypical blood vessel networks²³⁷.

Hypoxic stress is mainly regulated by HIFs. The HIF family of transcription factors includes HIF1, HIF2, and HIF3 and all contain an oxygen-sensitive HIF- α subunit, which dimerises with the constitutively expressed HIF1- β subunit^{238,239}. Of the three isoforms, HIF-1 is the most

studied and is frequently overexpressed in tumour cells²⁴⁰. Under normoxic conditions, HIF- α subunits have a very short half-life due to its rapid degradation. However, HIF- α is stabilised under hypoxia. Moreover, HIF regulates transcriptional responses in normal and cancer cells²³⁹. This regulation is mediated by transcriptional activity of HIFs, secretion of signalling molecules, and metabolic rewiring from oxygen-dependent catabolism to glycolysis. Indeed, over 100 genes implicated in numerous cell functions (angiogenesis, erythropoiesis, cell growth and proliferation, invasion/metastasis and metabolic adaptation) are regulated directly and indirectly by HIF, and some of them showed to increase their expression in tumours compared to normal cells^{241,242}.

Tumour cells can adapt to conditions such as nutrition deprivation, and hostile microenvironment, which would typically lead to cell death of normal cells. For instance, tumour cells can overcome proliferation limitations due to stressful microenvironment by stimulating the production of new blood vessels via vascular endothelial growth factor (VEGF)²⁴³. Additionally, the upregulation of genes including VEGF and P-gp by tumour-associated hypoxia has been associated with poor cancer prognosis²⁴⁴ and chemotherapeutic resistance²⁴⁵.

Remarkably, hypoxia is of pathophysiologic importance in solid tumours, but it does not seem to be as crucial in haematological malignancies. As mentioned in **Section 2.2**, haematopoiesis occurs in the stem cell niche, which is characterised by reduced partial pressure of O_2 (p O_2) (<1% of O_2). Upon cell differentiation, hematopoietic cells are constantly facing changes in p O_2 , ranging from maximum 12% O_2 in arterial blood to 1% or lower in tissues far from vessels as they circulate throughout the human body²⁴⁶. Haematological malignancies such as AML and CML are characterised by an intensified blast cell proliferation and it is assumed that this fact is linked with a decrease of O_2 availability by high consumption, thus leading to a hypoxic microenvironment²⁴⁷. Despite some studies suggest no role of real hypoxia in AML due to its usual low O_2 within the BM^{246,248,249}, there are several studies challenging this view. An example is the observations of Jesen *et al.*,

highlighting an increasing level of hypoxia during leukemic progression, similar to the one observed in solid tumour progession²⁵⁰. Moreover, overexpression of HIF-1 α has been reported in several studies targeting subtypes of leukaemia including AML, Acute promyelocytic leukaemia (APL), ALL and CML^{251–253}, and has been additionally selected as a marker of cancer poor prognosis and chemotherapy outcome^{247,254,255}.

2.4 Metabolism in leukaemia

HSCs are responsible for the maintenance of the blood system. Its metabolism is known to be a key player in processes such as proliferation, differentiation or quiescence. Consequently, HSCs are highly dependent on their metabolic flexibility to accomplish these processes and maintain survival in their niche, which is known to be hypoxic²⁵⁶. However, this metabolic adaptation is sufficient to fulfill the low energy demand of HSCs. Another metabolic pathway responsible for the HSCs maintenance is the FAO pathway²⁵⁷. Moreover, HIF1- α also stimulates PDK 2 and 4 activities, thus decreasing pyruvate dehydrogenase (PDH) activities in HSCs and preventing pyruvate contribution to TCA cycle and OXPHOS²⁵⁸. Nevertheless, recent studies have reported that leukemic cells do not only reprogram the metabolism for cell proliferation but also for the acquisition of drug resistance^{194,259–261}.

2.4.1 Metabolism of AML cells

AML cells exhibit a high glucose uptake²⁶² and a high-glycolytic profile, which has been additionally associated with favourable outcomes regarding the diagnosis²⁶³. For instance, serum samples of AML patients and healthy controls were compared and a different glucose metabolic signature was found, where high levels of metabolites including lactate, 2oxoglutarate, pyruvate, 2-hydroxyglutarate (2-HG) and GP were negatively associated with survival²⁶⁴. AML also exhibit activation of the central cellular signalling complex mammalian target of rapamycin complex 1 (mTORC1), known to promote glycolysis and high-glucose flux through the PPP, contributing to glucose supply^{265,266} and emphasising dependence on

PPP for AML cell proliferation and survival. Thus, inhibition of mTORC1 induces a switch towards oxidative metabolism and a glucose-independent survival of AML cells²⁶⁷. Moreover, overexpression of G6PD has been demonstrated to correlate with an adverse AML prognosis²⁶⁷ and, interestingly, *in vitro* and *in vivo* inhibition of G6PD and 6-PDG revealed antileukemic activities and AraC synergies^{259,267}.

The switch from aerobic glycolysis towards mitochondrial respiration has been suggested to interfere with AML cell growth. In fact, Wang *et al.* showed that deletions of the two glycolytic enzymes pyruvate kinase muscle isoenzyme (PKM)2 and LDHA, inhibit leukaemia initiation and maintenance in AML mice models²⁶⁸. However, Škrtić *et al.* revealed that AML cells have higher mitochondrial mass and an increased OCR relative to normal hematopoietic progenitors²⁶⁹. Likewise, a less efficiency of ETC complexes, thus increasing ROS production, has been additionally shown in AML compared to normal cells²⁷⁰. Therefore, targeting the TCA cycle and OXPHOS could potentially impact AML cell proliferation. Noteworthily, CPI-613, which is known to compromise the mitochondrial function by inhibiting PDH and α -ketoglutarate dehydrogenase (KGDH) enzymes, is an example of a chemotherapeutic approach targeting mitochondrial functioning in AML patients²⁷¹.

Furthermore, AML cells are also characterised by alterations in glutamine, arginine and BCAAs metabolism. Glutamine supports redox control by providing glutathione and fuelling the TCA cycle via αKG in AML cells (reviewed in ²⁷²). Interestingly, knockout (KO) or inhibition of GLS by CB-839 inhibitor was determined to reduce OXPHOS, arrest proliferation and induce apoptosis in AML cells²⁷³. Moreover, the dependence of AML cells on arginine and its lack of ASS1 enzyme is well-known²⁷⁴. Regarding to BCAAs, BCAT1 enzyme has been found to be overexpressed in AML cells²⁷⁵ and, additionally, its inhibition by gabapentin (BCAT1 inhibitor) shows to suppress clonal growth of AML cell lines and primary AML cells²⁷⁶.

Lipid metabolism constitutes an additional metabolic pathway highly reprogrammed in leukaemia for energy production. Kreitz *et al.* reviewed that FAs are a crucial requirement

for cell growth, therapeutic resistance and apoptosis induction in AML cells²⁷². Therefore, AML cells depend on high FAO rates and low FAS activity. In fact, the increase of FAO has been associated with AML poor prognosis and chemotherapeutic resistance²⁶⁰. Besides lipid metabolism, diverse studies have pointed to sterol metabolism and the beneficial effect of its inhibition via statins drugs on AML proliferative attenuation^{277–279}.

2.4.2 Metabolism of CML cells

Targeting metabolism of AML cells for cancer therapy has been the subject of diverse studies; however, much less effort has been made for CML cells. To our knowledge, there is a study comparing CD34⁺ CML cells and CD34⁺ normal cells where mitochondrial respiration, glucose oxidation, and anaplerosic reactions were found to be upregulated in CD34⁺ CML cells when compared to CD34⁺ normal cells^{280,281}. Particularly, CD34⁺ CML cells also showed to have an increase in mitochondrial content and mitochondrial membrane potential, thus increasing mitochondrial oxidative functions. Moreover, transcriptome data analysis determined an overall gene overexpression associated with OXPHOS and glycolysis processes in CD34⁺ CML cells²⁸². Finally, CD34⁺ CML cells also enhance the FAO pathway when compared to CD34⁺ normal cells, similarly to AML cells.

2.4.3 Metabolism of AML and CML resistant cells

Resistance of leukemic cells to chemotherapy drugs is acknowledged to be the main obstacle in AML and CML treatment^{29,283}. To date, biomarker predictions by genetic and genomic analyses to identify resistance factors against AML and CML treatments have not been fully established due to the complexity of the information. This problem might be resolved using phenotypic data, such as metabolic profiling²⁸⁴. However, it is equally important to understand the metabolic reprogramming by which AML and CML cells become resistant to chemotherapy drugs (e.g. AraC, Dox, and imatinib).

Some of the general metabolic changes of AML cells treated with AraC chemotherapeutic include the decrease of extracellular acidification and oxygen consumption rates (ECAR and OCR, respectively) (i.e. glycolysis and mitochondrial respiration, respectively)²⁸⁵. Moreover, Farge *et al.* showed by *in vitro* and *in vivo* experiments that residual AML cells resistant to AraC chemotherapeutic drug (i.e. innately resistant to AraC) additionally increase ROS, mitochondrial mass and activity, and mitochondrial respiration²⁶⁰. Interestingly, these cells also showed a high OXPHOS phenotype dependent on an increased TCA cycle activity and FAO, and not on glutamine consumption.

On the other hand, there are no metabolic studies conducted with Dox resistant cells to our knowledge. Nevertheless, Stäubert *et al.* showed that HL-60 cells resistant to daunorubicin, a chemotherapy drug similar to Dox chemotherapeutic drug, are more dependent on glycolysis and FAO, and contrarily less dependent on exogenous glutamine²⁸⁵.

Regarding the imatinib chemotherapy drug, imatinib exposure leads to alterations in glucose uptake, and in the *de novo* nucleic acid and/or FA synthesis of myeloid leukemic cells^{286–288}. Indeed, dose-dependent metabolic changes in the TCA cycle have been additionally revealed. For instance, low doses of imatinib lead to an induction of this cycle, whereas high doses leads to downregulation²⁸⁹. As mentioned in **Section 2.2.1.4**, there are several mechanisms of imatinib resistance including BCR-ABL1 overexpression and BCR-ABL1 mutations in CML cells. Consequently, different metabolic changes are defined depending on these mechanisms of resistance. Therefore, BCR-ABL1-overexpressing CML cells resistant to imatinib enhance glycolysis and non-oxidative PPP¹¹⁷ whereas the accumulation of TCA cycle intermediates, NADH/NAD+ increase, ETC alterations, and low O₂ consumption is determined in BCR-ABL1-mutated CML resistant cells¹⁹⁴. It is worth mentioning that, to date, there has been less exploration of the metabolic rewiring associated with BCR-ABL1-independent imatinib-resistant CML cells. However, Noe et al. showed that TKI resistant CML cells, which are characterised by a positive but not overexpressed or mutated BCR-ABL1 protein, route their metabolism through glycolysis and PPP, and additionally disrupt their mitochondrial metabolism²⁶¹.

2.5 Multi-OMIC approach in cancer

In order to investigate the capabilities acquired during the development of cancer, the investigation of the alterations in the cellular machinery at different levels including genome, epigenome, transcriptome, proteome, and metabolome is required. OMIC technologies are characterised by high-throughput interfaces that facilitate the investigation of these cellular alterations, thus allowing the comprehension of biological systems and uncovering the molecular signatures of cancer cells²⁹⁰. In addition, while the study of a single type of OMICS can provide great knowledge at a unidirectional level, multi-OMIC study enables a deeper understanding and a more complete picture of the complex link between the cancerous genotype and phenotype. One example of a multi-OMIC approach is the one proposed by Yugi *et al.*, in which transcriptomic, proteomics and metabolomics datasets in addition to the newest datasets such as phosphoproteomics, protein-protein interactions, DNA-protein interactions and allosteric regulation, were included²⁹¹.

2.5.1 Proteomics

Proteomics is used to quantify protein abundance in addition to protein modification and interaction. The complexity and dynamic range of the proteome, when compared to the transcriptome, is higher, thus hindering its identification and quantification. Aslam *et al.* reviewed that protein technologies can be divided depending on their applications into: i) protein purification techniques, also called chromatography-based techniques; ii) protein analysis techniques, which comprises protein microarrays, enzyme-linked immunosorbent assay (ELISA), and western blotting; iii) protein characterisation techniques including gelbased approaches and mass spectrometry (MS), iv) protein quantification techniques, which comprise isotope-coded affinity tag (ICAT) labelling, stable isotope labelling with amino acids in cell culture (SILAC), isobaric tag for relative and absolute quantification

(iTRAQ) techniques, and tandem mass tags (TMT); and v) protein structural analysis (e.g. Xray crystallography and nuclear magnetic resonance [NMR] spectrometry).

Liquid chromatography-MS (LC-MS-MS) or matrix-assisted laser desorption/ionisation timeof-flight (MALDI-TOF) characterisation have revolutionised the field of proteomics and are currently the central mass spectrometry techniques used in proteomics²⁹². However, the proteomic field is also moving forward to protein quantification techniques such as SILAC. SILAC is an MS-based approach developed to study regulation of gene expression, cell signalling, and post-translational modifications. In this technique, the proteome of the cells in culture are labelled with "light", "medium" or "heavy" form of amino acids and differentiation is performed via MS^{293,294}. Indeed, one advantage of SILAC, when compared to other labelling strategies such as iTRAQ or TMT, is the direct-handle provision to fundamental cellular processes and proteomes²⁹⁵.

Although proteomics is under continuous development, advance in the understanding of biomedical research such as diagnosis, protein-based biomarkers, and therapeutics has been achieved. The recent development of a new version of The Cancer Protein Atlas (TCPA) called "The Cancer Genome Atlas (TCGA) Pan-cancer Analysis", which provides comprehensive protein-centric analyses that integrate protein expression data and other TCGA data across cancer types, constitutes an example of a valuable resource for cancer research²⁹⁶.

2.5.2 Metabolomics

Metabolomics quantifies small molecules types such as sugars, lipids, amino acids, nucleotides, and steroids from a myriad of sample types including primary cells, cell lines, tissues, biofluids or entire organisms. Metabolite levels reflect metabolic function, and changes of these levels can be used as disease indicative²⁹⁷. In fact, metabolomics is now known to provide biological insights of metabolic pathways and fluxes in diseases²⁹⁸ and has been suggested to be an effective tool in the discovery of biomarkers for cancer

diagnosis and progression²⁹⁰. For instance, the identification of five metabolites (bilirubin, LysoPC(17:0), n-oleoyl threonine, 12- hydroxydodecanoic acid, and tetracosahexaenoic acid) has recently been identified as biomarkers for cervical cancer²⁹⁹.

Metabolomics, when compared to the other OMIC approaches, present several advantages: i) the cell metabolome is the final downstream product of the genome and is the closest to the functional phenotype of the cell or organism studied; ii) cell metabolome is also closer to the environment and more susceptible to external perturbations, thus contributing with additional and valuable information; and iii) metabolomic studies are less costly than the other OMIC studies³⁰⁰. However, there are also challenges regarding metabolite identification such as the enormous diversity regarding the chemical nature and concentration of metabolites. These facts make the identification, quantification, and analysis difficult, thus complicating the reproducibility that must be overcome to improve this OMIC efficiency²⁹⁰.

Metabolomics can be classified into targeted or non-targeted studies. Targeted studies quantitatively measure a selected group of metabolites for metabolic pathways investigation or for biomarkers validation³⁰¹, and require *a priori* knowledge of metabolites of interest and known compounds³⁰². On the other hand, non-targeted studies involve profiling of the metabolome, thus achieving global coverage. This approach is commonly used for studies of biomarker discovery³⁰³. Besides targeted and untargeted metabolomics, tracer-based metabolomics has been widely used. It is considered a special form of targeted metabolomics in which the distribution of ¹³C from a labelled precursor among various metabolic intermediates is determined, helping to define the redistribution of the isotope tracer among metabolic intermediates^{304,305}. Depending on the application and instrumentation, metabolomics can obtain information of small molecules in solid (through solid-state NMR), liquid (through liquid chromatography MS [LC-MS], capillary electrophoresis MS [CE-MS]), or gas phase (e.g. gas chromatography MS [GC-MS]) using spectroscopy (e.g. NMR) and MS (e.g. LC/GC-MS or tandem MS)³⁰⁶.

To sum up, the utilisation of proteins and metabolites through the different OMIC approaches is essential not only to decode the complex phenotype of biological systems but also to identify targets for therapeutic purposes. For this reason, the OMIC approach followed in our study utilised SILAC analysis, as a proteomic technology, and targeted metabolomics.

3. OBJECTIVES

3 OBJECTIVES

Despite the understanding of the metabolic and molecular etiology of both AML and CML haematological malignancies and the development of novel therapeutic strategies, the effective treatment of patients remains a challenge for clinicians. In fact, one of the main obstacles in the treatment of leukaemia is the resistance of leukemic cells to chemotherapeutics and, consequently, research on the mechanism of drug resistance in leukaemia has been accordingly very active. The phenomenon of changes of tumour cellular bioenergetics, where cells experience cell metabolism alterations and metabolic adaptation, is known as "metabolic reprogramming", and it has been recognised as a relevant cancer hallmark. Over the last decades, several metabolic studies targeting leukaemia and specifically AML and CM have been conducted. Indeed, there is an increasing amount of evidence indicating that metabolic reprogramming is one of the key mechanisms of resistance by cancer cells³⁰⁷. Therefore, it is our main objective to investigate the rewiring of cell metabolism occurring in the process of resistance acquisition to different conventional therapeutic treatments in AML and CML diseases. In consequence, by revealing this metabolic rewiring, we plan to highlight potential metabolic and nonmetabolic targets that could be exploited in novel combination treatments to improve treatment efficiency and to overcome resistance to treatment.

In order to achieve the main objective of this thesis, the following specific objectives will be assessed:

- Characterisation of the initial metabolic phenotype of acute myeloid leukaemia (AML) parental cells (Chapter 1).
- Characterisation of the metabolic profile of acute myeloid leukaemia (AML) parental and cytarabine and doxorubicin-resistant cell lines (Chapter 1).

- 3. Definition and validation of targets associated with the metabolic reprogramming of parental and resistant AML cell lines (**Chapter 1**).
- Generation of an imatinib-resistant KU812 CML cell line (Chapter 2) and characterisation of the metabolic profile of CML parental and imatinib-resistant cells (Chapter 2).
- 5. Definition and validation of targets associated with the metabolic reprogramming experienced by imatinib-resistant CML cells (**Chapter 2**).

4. MATERIALS AND METHODS

4 MATERIALS AND METHODS

4.1 Cell culture

AML cell lines (THP-1 and HL-60 parental; cytarabine [AraC] resistant and doxorubicin [Dox] resistant) were generously provided by Prof. Jindrich Cinatl (Institute of Medical Virology, University Hospital Frankfurt, Goethe University Frankfurt, Germany) and Prof. Martin Michaelis (Centre for Molecular Processing and School of Biosciences, University of Kent, Canterbury, UK). The KU812 cell line (CML cell line) was purchased from the American Type Culture Collection (ATCC, Manassas, Virginia, USA). All the cell lines were cultured in RPMI-1640 medium supplemented with 10% fetal bovine serum (FBS), 4mM glutamine and 1% penicillin and streptomycin at 37°C in a humidified incubator with 5% CO2. For hypoxia incubations, cells were kept in a hypoxia chamber so-called SciTive Workstation (Baker Ruskinn, Leeds, UK) at 1% O2 and 5% CO2 during 5 to 7 days. Particularly, AraC and Dox resistant cells were maintained with 8μM of AraC or20pM of Dox, respectively.

4.2 Generation of the imatinib-resistant KU812 cells

To generate imatinib resistant cells, KU812 cells were treated with increasing concentration of imatinib (0.074-1µM). KU812 cells (parental) were also maintained without imatinib at the same passage. Cell viability and proliferation were tested every 24 hours by cell counting using a Scepter TM Handheld Automated Cell Counter (Merck Millipore, Billerica, MA, USA) and the Countess II FL Automated Cell Counter (Thermo Fisher Scientific Inc., Waltham, MA, USA). Furthermore, they were passaged using an increase of 0.017µM imatinib approximately every week. Of note, drug increase was postponed depending on the state of cell viability. When their doubling time in the presence of 1µM imatinib was almost the same as that of the parental cells in the absence of imatinib, cells were considered resistant to imatinib. Acquisition of resistance was also verified every 3 weeks until resistance was obtained. For that, both parental and "imatinib resistant" cells were incubated during 72 hours with the following imatinib concentrations: 0.02, 0.08, 0.2, 0.8, 2, 8, 20, 80 and 200 μ M and cell viability was measured using Cell Titer-Glo[®] Luminescent Cell Viability Assay (Promega, Madison, USA). Imatinib resistant cells (KU812 ImaR) were finally maintained with additional supplementation of 0.2 μ M imatinib. Finally, for KU812 imatinib treated cells, KU812 parental cells were treated with the half maximal inhibitory concentration (IC50, 0.08 μ M) of imatinib during 72 hours before the experiments were performed.

4.3 Cell characterisation and cell viability assay

To assess the characterisation of the cell, cell size was determined using a Scepter TM Handheld Automated Cell Counter (Merck Millipore, Billerica, MA, USA) at different time periods. In addition, protein content differences between the different cell lines (AML and CML parental and resistant cell lines) were further analysed by i) collecting in Eppendorf tubes different number of cells (from 250.000 cells/ml to 2x10⁶ cells/ml), ii) counting cell number of each Eppendorf, and iii) lysing cells and measuring the total protein content in all the conditions by Bicinchoninic acid (BCA) assay (Thermo Fisher Scientific, Waltham, MA USA).

Cell viability was measured using Cell Titer-Glo[®] Luminescent Cell Viability Assay. For the cell viability testing after drug incubation, 16000 cells/well were seeded in 96-well plates using 100µl suspension cell volume. Fresh media (100µl) containing the desired concentration of drug, the combination of drugs under study, or vehicle was added, and cells were incubated 72h. For Hoechst stain assay, cells were washed with PBS before adding 100µl of 0.01% SDS per well. Plates were then stored frozen at -20°C. To analyse the samples, plates were thawed at 37°C until fully liquid and 100µL of 4µg/ml HO33342 in stain solution buffer (1M NaCl, 1mM EDTA, 10mM Tris-HCl pH 7.4) added to each well. Tinfoil-covered plates were placed on a shaker and incubated at 37°C for 1h. Fluorescence was quantified on a FLUOstar OPTIMA Microplate Reader (BMG LABTECH GmbH, Ortenberg, Germany) at 355nm excitation and 460nm emission. For Cell Titer-Glo[®] Luminescent Cell Viability Assay, the same incubation was performed but using 96-well opaque-walled plates and measurements were made according to manufacturer's instructions. Briefly, plates

were removed from the incubator, allowed to equilibrate at room temperature 30 minutes and 100µl of Cell Titer-Glo reagent was added directly to the wells. Content was mixed for 2 minutes on an orbital shaker and plater were allowed to incubate at room temperature for 10 minutes to stabilise the luminescent signal. Luminescence was determined using a Mithras LB 940 reader (Berthold Technologies, DLReady, Germany), which allows the integration of the signals detected in the short-wavelength filter at 485nm and the longwavelength filter at 530nm. Cell viability was assessed and represented as a percentage of viability relative to untreated control cells. IC50 values were calculated using GraphPad Prism 6 software (La Jolla, CA, USA).

4.4 Cell cycle analysis

Cell cycle analysis was performed after 72h imatinib treatment only using CML cells. 1×10^6 cells of KU812 Parental, treated and resistant cells were collected, centrifuged, resuspended in 0.5ml PBS and added dropwise to 4.5ml 70% (v/v) cold ethanol. Samples were stored at -20°C overnight. Then, cells were centrifuged, washed with PBS and resuspended in PBS containing 0.2mg/ml DNAse free RNAse A (Roche, Basel, Switzerland) and incubated for 1h at 37°C shaking. Prior to analysis, 0.05µg/ml propidium iodide (PI) was added. Fluorescence-activated cell sorter (FACS) analysis was accomplished at 488 nm in an Epics XL flow cytometer (Coulter Corporation, Hialeah, GL, USA). Data of 1×10^6 cells were collected and analyses using the software FlowJo® Percentage of cells in G1, S and G2 was determined from the calculated area below the respective gates. Experiments were performed in triplicates and independently repeated twice.

4.5 Intracellular glutathione quantification

Total glutathione content was determined by the glutathione reductase enzymatic method. 5x10⁶ cells of KU812 parental and ImaR cells were lysed with 5% 5-sulfosalicylic acid solution, vortexed and disrupted by two freezing/thawing cycles in liquid nitrogen and 37 °C

water bath. For each sample, 50µl of cell lysate were taken for subsequent protein quantification by BCA assay. Cell extracts were incubated at 4°C for 10min and centrifuged at 10,000g for 10min. For glutathione quantification, a working solution containing 15U/ml of glutathione reductase and 40µg/ml of 5,5'-Dithiobis (2-nitrobenzoic acid) was prepared in assay buffer (100mM K₂HPO₄/KH₂PO₄, 1mM EDTA, pH 7.0). Glutathione standards were prepared from a 50mM oxidised glutathione (GSSG) stock solution. The reaction was initiated by mixing 150µl working solution with 10µl cell extract (diluted 1:5 or 1:10) or 10µl GSSG standard (final concentrations from 0 to 12.5µM). Next, 50µl 0.16mg/ml NADPH solution were added to the samples and the absorbance was recorded at 340nm. Total glutathione concentration was normalised for protein content and cell number.

4.6 Intracellular reactive oxygen species (ROS) levels

400.000 KU812 Parental and ImaR cells were seeded in separated 60cm plates and incubated for 72 hours. Next, approximately 1.5×10^6 cells were collected and washed once with warm PBS. They were further incubated with 5μ M 2'-7'-dichlorodihydrofluorescein diacetate (DCFDA, Invitrogen) in PBS supplemented with 4mM glutamine and 10mM glucose. After 5min at 37° C, cells were centrifuged and supernatant was discarded. Next, cells were resuspended 5μ M DCFDA + PBS + 4mM glutamine + 10mM glucose + PI (20μ g/mI). Finally, the emitted fluorescence was recorded by flow cytometry at 520nm Data for DCF fluorescence intensity using an Epics XL flow cytometer (Coulter Corporation, Hialeah, FL, USA). For negative controls, the same protocol was performed using identical number of cells but without addition of DCFDA and IP. For positive control, the same protocol was followed using identical number of cells but cells were previously incubated with 250µl of 50µM phorbol-12-myristate-13-acetate (PMA) + PBS for 10min at 37° C.

4.7 Measurement of extracellular metabolites

Glucose, lactate, glutamate and glutamine concentrations were determined by spectrophotometry (COBAS Mira Plus, Horiba ABX) from cell culture media by monitoring the production of NAD(P)H in specific reactions for each metabolite at 340nm wavelength ³⁰⁸. Glucose concentration was measured using hexokinase (HK) and glucose-6-phosphate dehydrogenase (G6PD) coupled enzymatic reactions (ABX Pentra Glucose HK CP, HORIBA ABX, Montpellier, France). Lactate concentration was determined by lactate dehydrogenase (LDH) reaction at 37°C by mixing the media samples with 1.55mg/ml NAD+ and 87.7U/ml LDH (Roche) in 0.2M hydrazine 12mM EDTA buffer (pH 9). Glutamate concentration was assessed by its conversion to α -ketoglutarate through glutamate dehydrogenase (GLDH) reaction in the presence of ADP. This reaction was performed at 37°C by adding media sample to a cuvette containing 2.41mM ADP, 3.9mM NAD and 39U/ml of GLDH in 0.5M glycine/0.5M hydrazine buffer, pH 9. Glutamine was determined by its conversion first to glutamate through glutaminase (GLS) reaction and subsequently quantification of glutamate concentration as described above. GLS reaction was performed by adding media sample to a cuvette containing a mixture consisted of 90mU/ml GLS in 111mM acetate buffer, pH 5. Reaction was carried out for 90min at 37°C in agitation.

In order to calculate the consumption/production rate of each metabolite, media samples at the beginning and at the end of the experiment were taken and frozen for subsequent analysis. At the same time points, cell numbers were determined for normalisation. All biochemical assays were carried out under exponential growth conditions. All results are expressed in micromol or nanomol of metabolite consumed or produced per hour and per million cells. Moreover, ratios between the different metabolites were calculated.

4.8 Metabolites extracellular flux and intracellular content analysis

Samples collection

Media samples were used to measure metabolites consumption and production rates measurements. THP-1 and HL-60 parental, AraC and Dox resistant cells; and KU812 Parental and ImaR cells were incubated with RPMI-1640 medium supplemented with 10% FBS, 4mM glutamine and 1% penicillin and streptomycin for 96 hours and media samples were collected at 0h and at specific incubation time points (**Table 4.1**), depending on the cell line and condition.

Cell line	Incubation time points	
	Normoxia	Нурохіа
THP-1 Parent	72h	24h
THP-1 AraC	48h	24h
THP-1 Dox	72h	24h
HL-60 Parental	72h	48h
HL-60 AraC	48h	48h
HL-60 Dox	48h	48h
KU812 Parental	96h	72h
KU812 ImaR	48h	48h

Table 4.1. Incubation times for all the AML and CML cell lines

For metabolites intracellular concentration measurements, cell pellets were used. All the cell lines were incubated for 24 hours and cell pellets were collected, washed 3 times with ice-cold-PBS and snap-freeses using liquid nitrogen until cell pellet preparation.

Samples processing

Right before measuring, cell pellets were thawed at room temperature and resuspended in 70µl of 85:15 EtOH:PBS solution. Cells were disrupted by two

sonication/freezing/defreezing cycles using titanium probe (VibraCell, Sonics & Materials Inc., Tune: 50, Output: 25), liquid N2 and a 95°C heat block. Cell lysates were then centrifuged at 20,000rcf for 5 minutes at 4°C. Supernatants were transferred into new tubes and total protein content was determined by BCA assay. In addition, media samples were defrosted.

The sample preparation and measurements were performed according to the manufacturers' manual of the Biocrates AbsoluteIDQ p180 kit (UM-P180). In detail, internal standards for the LC method were applied to the filter inserts of the 96-well kit plate, which already contained the internal standards (ISTD) for the FIA method. Standards, internal standards, quality controls and media samples (10µl of each) and pellets samples (50µl each) were added onto the filter inserts and dried for 30min under a nitrogen stream. Amino acids and biogenic amines were derivatised for 20min with an excess of 5% phenylisothiocyanate in ethanol/water/pyridine (ratio 1/1/1, v/v/v), and subsequently dried for 45min under a nitrogen stream. Metabolites and internal standards were then extracted with 300µl methanol containing 5mM ammonium acetate by shaking for 30min, and eluted by centrifugation for 5min at room temperature and 500×g. One-half of the eluate was diluted with the kits' running solvent (1/3, v/v) for FIA-MS/MS analysis.

4.9 Glycogen content analysis

For the quantification of the glycogen content, $10x10^6$ millions of KU812 Parental and ImaR cells were collected, centrifuged and washed twice with ice-cold PBS. 400µl of 0.1M NaOH was added and samples were heated to 100°C for 15min for protein denaturation. Samples were sonicated for 5 min 2x3X using a titanium probe (VibraCell, Sonics & Materials Inc., Tune: 50, Output: 30). The pH of the samples was adjusted to pH 6-7 and afterwards 5µl of [U-¹³C-D7]-glucose was added as an internal standard for all of them. Then 200µl of 1,25mg/ml α -amyloglucosidase in 0.4M acetate buffer was added to digest the glycogen and incubated overnight at 37°C under agitation. Both the glucose released from glycogen

and the glucose internal standard were isolated using Dowex 1x8/Dowex-50WX8 ionexchange columns, eluting with water. The eluted samples were then dried overnight under airflow. After drying, the glucose was derivatised (explained below). The GC/MS analysis was carried out under chemical ionisation. Ions were monitored by SIM recording the ion abundance for C1-C6 glucose in the range of 327-334m/z and of [U-¹³C-D7]-glucose in the range of 339-345m/z.

Sample derivatisation

Isolated metabolites were derivatised by first heating to 100° C with 2% (v/v) hydroxylamine hydrochloride in pyridine for 30min and then with acetic anhydride for 60min. Next, samples were evaporated under N₂ gas flow and the final derivative was dissolved with ethyl acetate.

Calibration curve

For calibration curve of the glycogen quantification, the same quantity of the internal standard [U-¹³C-D7]-glucose used for the samples was added to varying quantities of ¹²C-glucose. The calibration solutions were derivatised as explained above. Estimation of glycogen content was performed using the calibration curve and data was normalised by cell number.

4.10 Nuclear magnetic resonance (NMR) analysis

Samples preparation

30x10⁶ millions of KU812 Parental and ImaR cells were plated 24 hours before the experiment in glucose/glutamine-free media and supplemented with 11mM uniformly 13C-labelled glucose for the glucose tracers or 2mM uniformly 13C-labelled glutamine for the glutamine tracers. Cells were harvested, washed with 37°C phosphate buffer saline (PBS) and spun down for 20 seconds at 16000g. PBS was removed, and cells were vortexed for 10 seconds after adding 400µl pre-chilled methanol. 325µl dH2O and 400 µl pre-chilled

chloroform were added to each sample and vortexed for 40 seconds. Cells were placed on ice for 10 minutes and then centrifuged at 5000g for 10min at 4°C in a swingout rotor. 500µl were taken from the upper (polar) layer and then dried using a vacuum dryer for 4h.

NMR measurements

190µl of NMR buffer (100mM phosphate, 100% D2O and 0.5mM TMSP (reference compound), pH 7) was added to each sample (dried cell extracts) and then sonicated for 10min. 190µl of each sample was loaded in the NMR tubes (3mm tubes, Norell, HT version or the new 96-tubes racks). Samples were measured on a 600MHz DRX HD Bruker spectrometer at 25°C, TD: 32K, 512 scans using (zgesgp) pulse program for the 1D measurements. 2D experiments were measured using (hsqcetgpsp.2.cl) pulse program, 298K, TD (1024, 4096) with 14% NUS and 64 scans.

Data analysis and normalisation

Metabolites identification was performed using Chenomx software. Quantification and label incorporation analysis was performed in 'NMRLab'³⁰⁹. Metabolites intensities were normalised to TMSP peak and to million cells. Statistics was performed in GraphPad Prism 6 software using Welch's t-test or Student's t-test.

4.11 Enzymatic activities of CML cell lines

10x 10⁶ cells were collected for each cell line (KU812 Parental and ImaR) and washed with PBS. Pellets were resuspended into 1ml of lysis buffer (20mM TrisHCl, pH 7.5, 1mM dithiothreitol, 1mM EDTA, 0.02% (v/v) Triton X-100, 0.02% (v/v) sodium deoxycholate) supplemented with protease inhibition cocktail (Sigma-Aldrich). Cell lysates were disrupted by sonication using titanium probe (VibraCell, Sonics & Materials Inc., Tune: 50, Output: 25) and immediately centrifuged at 12000×g for 20min at 4 °C. The supernatant was separated and used for the determination of specific enzyme activities by spectrophotometric using a COBAS Mira Plus chemistry analyser. The supernatant was also used to quantify protein content by BCA. All enzymatic activities were determined by monitoring NAD(P)H increment

or decrement at 340nm wavelength. Finally, enzymatic activities were normalised by protein content.

Hexokinase (HK, EC 2.7.1.1)

HK specific activity was determined by coupling HK and G6PD reactions in the following conditions: 3.3mM NADP+ , 14.8mM ATP, 14.8mM MgCl2, 2.8U/ml G6PD and 50mM Tris-HCl, pH 7.6, at 37°C. Reactions were initiated by the addition of glucose up to a final concentration of 10mM.

Glucose-6-phosphate dehydrogenase (G6PD, EC 1.1.1.49.)

G6PD activity was measured by adding samples to a cuvette containing 0.5mM NADP+ in 50mM Tris-HCl, pH 7.6, at 37°C. Reaction was initiated by the addition of G6P up to a final concentration of 2mM.

6-Phosphogluconate dehydrogenase (6-PGD, EC 1.1.1.44.)

G6PD activity was measured by adding samples to a cuvette containing 0.5mM NADP+ in 50mM Tris-HCl, pH 7.6, at 37°C. Reaction was initiated by the addition of G6P up to a final concentration of 2mM.

Transketolase (TKT, EC 2.2.1.1.)

TKT specific activity was determined by adding samples to a cuvette containing 5mM MgCl2, 0.2U/ml triose phosphate isomerase, 0.2mM NADH, 0.1mM thiamine pyrophosphate in 50mM Tris-HCl, pH 7.6, at 37°C. The reaction was initiated by the addition of a substrate mixture prepared by dissolving 50mM R5P in 50mM Tris-HCl, pH 7.6, in the presence of 0.1U/ml ribulose-5-phosphate-3-epimerase and 1.7mU/ml phosphoriboisomerase. The substrate mixture was continuously stirred and held at 37°C for 1h and then kept at -20°C until use.

Pyruvate kinase (PK, EC 2.7.1.40)

PK specific activity was determined by coupling PK and LDH reactions in the following conditions: 0.8mM NADH, 1.6mM ADP, 12.1mM MgCl2, 36.8mM KCl and 5.2U/ml LDH in

20mM KH2PO4/K2HPO4 buffer, pH 7.2, at 37°C. Reactions were initiated by the addition of PEP up to a final concentration of 3.5mM.

Lactate Dehydrogenase (LDH, EC 1.1.1.42)

LDH specific activity was measured by adding sample extracts to a cuvette containing 0.2mM NADH in 100mM KH2PO4/K2HPO4, pH 7.4, at 37°C. Reaction was initiated by the addition of pyruvate up to a final concentration of 0.2mM.

4.12 Oxygen consumption rate (OCR) and extracellular acidification rate (ECAR)

Oxygen consumption rate (OCR) and the extracellular acidification rate (ECAR) were analysed using a Seahorse 96 extracellular flux analyser (Agilent, Waldbronn, Germany). XF96 sensor cartridges (Agilent, Waldbronn, Germany) were hydrated overnight in XF Calibrant Solution (Agilent, Waldbronn, Germany) at 37°C in a non-CO₂ incubator. Stress test reagents (Agilent, Waldbronn, Germany) were re-constituted in appropriate media. A total of 1,5x10⁵ for THP-1, 3x10⁵ for HL-60, and 2x10⁵ for KU812 cells previously incubated under normoxic or hypoxic conditions (also referred as normoxia and hypoxia) in 200µl of KHB Buffer were plated in Seahorse 96-well cell culture plates and equilibrated for 30min before recordings. Oxygen and proton measurements together with were carried out over 110min, following the programmed protocol; hence, basal O₂ consumption rate and basal ECAR were determined under normoxia. In addition, suspension cells for each condition were collected and protein concentration was measured by Lowry protein assay kit (Bio-Rad, Munich, Germany). Data of CML parental and resistant cells were normalised by protein due to fact that protein content was the same in both cell line models. With regard to AML parental and resistant cells, data were normalised by cell number due to the fact that cell protein content varies between cell line models.

Mitostress test

Mitochondrial function was analysed by sequential injections of 2.5µM oligomycin, to block ATP-coupled respiration; 0,2µM carbonyl cyanide m-chlorophenylhydrazone (CCCP) for HL-

60 cell lines and 0.3μM of CCCP for THP-1 and KU812 cell lines, to uncouple the respiratory chain; 0.2μM of CCCP for HL-60 cell lines and 0.3μM of CCCP for THP-1 and KU812 cell lines together with 2mM of Pyruvate, to assure complete maximal respiration; and 1μg/ml antimycin A together with 1μM rotenone, to block mitochondrial respiration. For this test, Krebs Henseleit buffer (111mM NaCl, 4.7mM KCl, 1.25mM CaCl2, 2mM MgSO4, 1.2mM Na2HPO4) supplemented with 10mM L-glucose and 4mM L-glutamine was used. An example of OCR profile is shown in **figure 4.1.A.**

<u>Glycolysis stress test</u>

For the glycolytic stress test, cells were treated with sequential injections of 5mM glucose and another 5mM glucose (10mM in total), to drive the cell to perform glycolysis; 2.5µM oligomycin; and 100mM 2-deoxyglucose (2-DG), to inhibit glycolysis. For this test, Krebs Henseleit buffer (111mM NaCl, 4.7mM KCl, 1.25mM CaCl2, 2mM MgSO4, 1.2mM Na2HPO4) supplemented with 4mM L-glutamine was used. An example of OCR profile is shown in **figure 4.1.B.**

Mito Fuel Flex test

Briefly, the Mito Fuel Flex Test determines the dependency of mitochondrial respiration on three major metabolic substrates, for instance fuel pathways (pyruvate, FAs, and glutamine). The substrate dependency is calculated as one fuel substrate relative to all pathways. For the dependence towards glucose cells were treated with 2mM UK5099, to inhibit the mitochondrial pyruvate transporter, followed by 4mM etomoxir, to block carnitine palmitoyl transferase 1 A together with 3mM BPTES, to antagonise GLS. Finally, 2.5µM oligomycin was used to inhibit total respiration. To determine glutamine dependence, BPTES was added, followed by etomoxir and UK5099. FA dependency was assayed by adding etomoxir, followed by BPTES together with UK5099. For these assays DMEM D5030 supplemented with 10mM L-glucose and 4mM L-glutamine was used. An example of the FA Mito Fuel Flex test is shown in **figure 4.1.C.**




Figure 4.1. Schematic OCR and ECAR profiles of the Glycolysis stress test, Mitostress test and Mito Fuel Flex tests. A) Schematic ECAR profile after glucose 5mM, glucose 5mM (10mM), oligomycin and 2-deoxyglucose (2-DG) sequential injections. ECAR values for basal ECAR, glycolysis and non-glycolytic acidification are illustrated. **B)** Schematic OCR profile after oligomycin, CCCP, CCCP+Pyruvate (Pyr), and rotenone+antimycin A (Rot & AA) sequential injections. OCR rates for basal mitochondrial respiration, ATP production, Maximal respiration and non-mitochondrial respiration are illustrated. **C)** Schematic OCR profile after inhibitors (Etomoxir, BPTES and UK5099) and oligomycin sequential injections. The different Mito Fuel Flex tests are illustrated.

Test calculations

Calculations of parameters coming from the Mitostress test:

- Basal mitochondrial respiration = the subtraction of the non-mitochondrial respiration (OCR value after the infection of rotenone+antimycin A) to the baseline OCR.
- ATP production = the subtraction of the baseline OCR to the OCR rate after the injection of oligomycin.
- Maximal respiration without pyruvate = the subtraction of the non-mitochondrial respiration to the OCR rate after the CCCP injection.

 Maximal respiration with pyruvate = = the subtraction of the non-mitochondrial respiration to the OCR rate after the CCCP+Pyruvate injection.

Calculations of parameters coming from the **Glycolysis stress test**:

- **Basal ECAR** = baseline ECAR without any injections and considering the 4mM of glutamine supplemented in the KHB buffer.

-Total ECAR= the ECAR value after the second injection of 5mM glucose (i.e. 10mM of glucose) and considering the 4mM of glutamine supplemented in the KHB Buffer.

- **Glycolysis rate =** the subtraction of the basal ECAR to the ECAR value after the second injection of 5mM glucose (i.e. 10mM glucose).

- **Crabtree effect** = the subtraction of the baseline OCR to the OCR rate after the second injection of 5mM glucose (i.e. 10mM glucose) divided by the baseline OCR. Next, the fold difference (log₂) of the resulting value was calculated.

Calculations of parameters coming from the Mito Fuel Flex test:

-**Contribution of each substrate to the mitochondrial respiration:** the subtraction of the OCR rate after the target inhibitor injection to the OCR baseline divided by the subtraction of the OCR rate after oligomycin injection to the OCR baseline, and multiply by 100 to obtain the percentage.

-**Contribution of all the inhibitors to the mitochondrial respiration:** the subtraction of the OCR rate after the injection of all the inhibitors to the OCR baseline divided by the subtraction of the OCR rate after oligomycin injection to the OCR baseline, and multiply by 100 to obtain the percentage.

4.13 Oximetry for KU812 parental and resistant cell lines

OXPHOS flux in KU812 Parental, treated (treatment procedure explained above) and ImaR cells was determined using a high-resolution respirometer (Oxygraph-2k, Oroboros

Instruments, Innsbruck, Austria) following the protocol described in (³¹⁰). In brief, 2x10⁶ millions of cells were collected and washed one in phosphate buffered saline (PBS), centrifuge and finally resuspended in MiR05 (3mmol/l MgCl2, 0.5mmol/l EGTA, 20mmol/l taurine, 10mmol/l KH2PO4, 60mmol/l K-lactobionate, 110mmol/l sucrose, 20mmol/l HEPES, and 1g/l bovine serum albumin) for permeabilised-cell approaches and in RPMI-1640 for intact-cell approach. Then, respiratory oxygen consumption was assessed in real time as pmol of O₂ per second per million cells in 2ml Oxygraph chambers. Routine cellular respiration rate was first measured before the addition of any substrate or inhibitor and it was further measured after the addition of substrates and inhibitors of interest following the required protocols for each approach explained as follows:

Cell intact approach

Substrates and inhibitors were sequentially added as follows: 5mM pyruvate, 2.5μ M oligomycin, stepwise titration of CCCP uncoupler in 0.05μ M increment as needed, 0.5μ M rotenone, and 2.5μ M antimycin A. KU812 Parental, treated and ImaR cells were used for this approach.

Complex I activity measurement

Firstly, basal respiration was measured before cells were permeabilised using 15µg digitonin. Then, substrates and inhibitors were sequentially added as follows: 10mM glutamate, 2mM malate, 5mM ADP, 10µM cytochrome c (mitochondrial membrane integrity was verified by the addition of cytochrome c and the changes observed in OCR were always lower than 10%), 5mM pyruvate.

Complex II activity measurement

Basal respiration was first measured and then cells were permeabilised using 15µg digitonin. The following sequential injections were performed: 10mM glycerol-3-phosphate, 5mM ADP and 10mM succinate.

Complex IV activity measurement

Respiration was measured after the addition of 5mM ascorbate plus 0.5mM tetramethylphenylenediamine dihydrochloride (TMPD) and after the addition of 100mM azida, which inhibit complex IV activity. Subtracting the second respiration measurement to the first, complex IV activity was addressed.

Fatty acid approach

Firstly, basal respiration was measured before cells were permeabilised using 15µg digitonin. Then, substrates and inhibitors were sequentially added as follows: 0.04mM palmitoyl-CoA carnitine plus 0.1mM malate, 5mM ADP and 1.9mM malate. This approach was performed using only KU812 Parental and ImaR cells.

Data analysis

Data was analysed using DatLab7 (Oroboros, Austria) software. Oxygen consumption rates (OCRs), expressed as picomoles (pmol) per second (s) per million of cells (Mill). The O_2 flow in these states was corrected by the subtraction of non-mitochondrial respiration, which was obtained after the addition of antimycin A. All data was normalised by cell number.

4.14 Western blotting

Cells were washed with ice-cold PBS and incubated for 30min on ice with RIPA buffer containing 50mM Tris (pH 8.0), 150mM sodium chloride, 1% Triton X-100, 0.5% sodium deoxycholate, 0.1% sodium dodecyl sulphate (SDS), 1% protease inhibitor cocktail and 1% phosphatase inhibitor cocktail (Thermo Fisher Scientific Inc.). Cells were sonicated and centrifuged at 16,000xg for 20min at 4°C. Supernatants were recovered and the protein content was quantified by the BCA kit (Pierce Biotechnology). Equal amounts of protein per sample were size-separated by electrophoresis on 10% SDS polyacrylamide gels and electroblotted onto polyvinylidene fluoride transfer membranes (PVDF) (BioRad

Laboratories, Hercules, CA, USA). 5% skim milk in PBS 0.1% Tween was used for blocking step (1h at RT) and blots were incubated with the corresponding primary antibodies (**Table 4.2**) overnight at 4°C under agitation according to the conditions indicated below. In order to remove the remaining primary antibody, membranes were rinsed with PBS-Tween (0.1%) and further treated with the appropriate secondary antibody (**Table 4.3**) for 1h at room temperature. Afterward, membranes were washed again with PBS-Tween (0.1%) before the analysis. All blots were treated with Immobilon ECL Western Blotting Detection Kit Reagent (EMD Millipore, Billerica, MA, USA) and developed after exposure to an autoradiography film (VWR International, Radnor, PA, USA) in the darkroom. Expression of all the proteins was finally investigated against the Lamin-B or TATABOX housekeeping proteins, as a loading control.

Protein	Brand	Dilution for Western Blot
ALDH18A1/P5CS	Santa Cruz Biotechnology	1:1000
НКІ	Santa Cruz Biotechnology	1:1000
НК ІІ	Santa Cruz Biotechnology	1:1000
НК Ш	Santa Cruz Biotechnology	1:1000
P5CRL/PYCR	Santa Cruz Biotechnology	1:1000
GLUL	Santa Cruz Biotechnology	1:1000
Lamin-B	Santa Cruz Biotechnology	1:10000
PRODH	GeneTex	1:1000
GLS2	GeneTex	1:1000
ΤΑΤΑΒΟΧ	Abcam	1:1000
GLS1	Abcam	1:1000
ТКТ	Sigma-Aldrich	1:1000
SLC6A7/proT	Quimigen	1:500

Table 4.2 Primary antibodies for Western Blotting analysis

Table 4.3 Secondary antibodies for Western Blotting analysis

Protein	Brand	Dilution for Western Blot
Anti-mouse	PO260, Dako	1/10000
Anti-rabbit	NA934V, Amersham Biosciences	1/10000
Anti-goat	Santa Cruz Biotechnology	1/10000

4.15 SILAC-based Proteome Analysis

Stable isotope labelling with amino acids in cellular culture (SILAC)

For SILAC RPMI medium devoid of arginine and lysine (Thermo Fisher, #88365) supplemented with 10% dialysed FBS (Gibco, #26400044), 100U/ml Penicillin, 100µg/ml Streptomycin (Gibco, #15140122) and the respective isotope-labelled amino acids (all from Cambridge Isotopes, Tewksbury, MA) was used. "Light" SILAC medium contained [12C614N4]-L-arginine and [12C614N2]-L-lysine and "heavy" SILAC medium contained [13C615N4]-L-arginine and [13C615N2]-L-lysine.

Both AML and CML cells were grown for at least 5 passages prior sample collection to ensure complete incorporation of the isotopes into proteins.

Sample preparation

Cells were washed with cold 1x PBS and lysed in 0.5% Nonidet P-40 (NP-40) buffer containing 50mM Tris/HCl, pH 7.5, 150mM NaCl, 1mM Na3VO4, 5mM NaF, and protease inhibitors (Complete[™], Mini, EDTA-free Protease Inhibitor Cocktail, Roche). For protein expression profiling, lysates of cells labelled differentially during SILAC were mixed in equimolar ratios and separated by SDS-PAGE using precast Bis-Tris minigels (NuPAGE Novex 4–12%, Life Technologies). After protein visualisation by staining with Coomassie Brilliant Blue (Serva) each gel lane was cut into 23 slices. The separated proteins were reduced with DTT (Sigma-Aldrich) and alkylated with iodoacetamide (Sigma-Aldrich). After overnight in-

gel protein digestion with trypsin (Serva), peptides were extracted from the gel matrix and analysed by liquid chromatography / mass spectrometry (LC/MS).

Liquid chromatography and mass spectrometry

The tryptic peptide mixtures were measured on a quadrupole-Orbitrap hybrid mass spectrometer (Q Exactive HF, Thermo Fisher Scientific) coupled to an Ultimate 3000 HPLC system (Thermo Fisher Scientific). The samples were preconcentrated and desalted on a trap column (20×0.1mm, ReproSil-Pur 120 C18-AQ, 5µm, Dr. Maisch GmbH; packed inhouse) at 5µl·min-1 in loading buffer [2% (vol/vol) ACN, 0.1% FA]. The peptide samples were separated on an analytical column (320×0.075 mm, ReproSil-Pur 120 C18-AQ, 1.9 μ m, Dr. Maisch GmbH; packed in-house) using an 60min linear gradient from 4% to 34% buffer B [95% (vol/vol) ACN, 0.1% FA] versus a decreasing concentration of buffer A (0.1% FA) at a flow rate of 300nl/min. For the analysis of eluting peptides, the mass spectrometer was operated in a data-dependent acquisition mode selecting the 30 most abundant precursor ions (m/z 350-1600 range, charge state 2-6) for higher energy collisional dissociation (HCD) with an isolation width of m/z 1.6 and a stepped normalised collision energy (NCE) setting of 26-30%. Survey spectra and fragment ion spectra were acquired with are solution setting of 70,000 or 15,000 FWHM at m/z 200 in the Orbitrap analyser, respectively. AGC target values and maximum injection times for MS and MS/MS were set to 1×10^6 in 50ms and 1 \times 10⁵ in 60ms, respectively. Fragmented precursor ions were dynamically excluded from selection for 30s.

Data processing

Raw data files from LC-MS/MS measurements were processed using the MaxQuant software (version 1.6.0.1, MPI for Biochemistry)³¹¹. MS/MS spectra were searched against the UniProtKB/Swiss-Prot human database containing 88,993 protein entries (downloaded November 2016) supplemented with 245 frequently observed contaminants with the Andromeda search engine ³¹². Precursor and fragment ion mass tolerances were set to 6 and 20ppm after initial recalibration, respectively. Protein N-terminal acetylation and

methionine oxidation were allowed as variable modifications. Cysteine carbamidomethylation was defined as a fixed modification. Minimal peptide length was set to seven amino acids, with a maximum of two missed cleavages. The false discovery rate (FDR) was set to 1% on both the peptide and the protein level using a forward-and-reverse concatenated decoy database approach. For SILAC quantitation, multiplicity was set to two for double labelling (Lys+0/Arg+0, Lys+8/Arg+10) and at least two ratio counts were required for peptide quantitation. Both the "match between runs" and "re-quantify" options of MaxQuant were enabled.

Subsequent evaluation of MaxQuant output data was conducted with the Perseus software (version 1.6.0.7, MPI for Biochemistry) ³¹³. After removal of hits to the decoy database and potential contaminants, the SILAC ratios were logarithmised and filtered for valid values in each measurement. To assign regulated proteins, ratio thresholds were determined by subjecting the SILAC ratios of the whole population of identified proteins to an outlier analysis based on a FDR < 5% and Benjamini-Hochberg correction for multiple hypothesis testing ³¹⁴. Ratios already reflect the log₂ fold change values. Next, log₂ fold change values were filtered according to a threshold of 0.58 log₂ fold change value (fold difference [FD] of 1.50-fold up) and of -0.58 log₂ fold change value (FD=1.5-fold down) to obtain the significantly up or down regulated proteins, respectively. Finally, log₂ fold change values were integrated and visualised in specific pathways using Pathview Web³¹⁵ and specific biological processes using PANTHER³¹⁶.

4.16 CRISPR/Cas9 technology

Based on the metabolic results, we selected two genes involved in proline metabolism ALDH18A1 [P5CS]; and SLC6A7 [proline transporter, proT]) to be depleted from the CML cell lines KU812 parental and ImaR by CRISPR/Cas9 gene editing. Subsequently, the effect of the depletion regarding imatinib resistance was further evaluated by a competitive cell growth assay and a cumulative growth curve (**Section 4.17**). The CRISPR/Cas9-method, introduced

by Emmanuelle Charpentier and Jennifer Doudna³¹⁷, was used to introduce abrogating point mutations into the ALDH18A1 and SLC6A7 coding regions in both KU812 Parental and ImaR cell lines. Therefore, three different guide RNAs (gRNAs) were designed using the benchling software package (http://benchling.com) targeting different exons of the gene to exclude off target effects. The first step to generate a specific KO is to identify an efficient gRNA that guides the Cas9 protein to its target sequence (**Table 4.4**). This guide RNA has to be complementary to the sequence of the target gene and needs to be in direct proximity to a Protospacer Adjacent Motif (PAM; NGG) sequence. The Benchling software package is a freeware tool that aids in this design. The designed gRNAs were cloned into the LentiCRISPRv2-ΔCas9-EGFP vector (kindly provided by F. Schnuetgen, from the department of Medicine, Hematology/Oncology, Goethe-University Frankfurt).

Using the cell line 293T LentiX (Takara), lentiviral particles were produced for each specific gRNA and transduced into spCas9 expressing CML cell lines (spCas9-Blasticidin; generated in the Serve's lab). Subsequently, Cas9 binds to the expressed gRNA and introduces a DNA double strand break (DSB) at the desired target locus. This DSB is repaired by the endogenous cellular DSB repair pathway "non-homologous end joining" (NHEJ), which is an error-prone process causing small insertions or deletions (indels) leading to the KO of the gene.

The success of the KO cell lines was tested by Western blotting through the detection of the target protein in gRNA treated cells versus cells treated with a gRNA non-target control (NTC).

 Table 4.4 Sequences of the selected gRNAs.

CR NTC1 s	CACCGttccgggctaacaagtcct
CR NTC1 as	AAACaggacttgttagcccggaaC
CR hALDH18A1 E3 s	CACCGtacccctcagtcgtacaca
CR hALDH18A1 E3 as	AAACtgtgtacgactgaggggtaC
CR hALDH18A1 E4 s	CACCGcgcaagcgttgtttgccaa
CR hALDH18A1 E4 as	AAACttggcaaacaacgcttgcgC
CR hALDH18A1 E5 s	CACCGgtaaacatagcctcataca
CR hALDH18A1 E5 as	AAACtgtatgaggctatgtttacC
CR hSLC6A7 E2 s	CACCGtggactttgctgcacaccg
CR hSLC6A7 E2 as	AAACcggtgtgcagcaaagtccaC
CR hSLC6A7 E3 s	CACCGcatgaggaagtagggcacg
CR hSLC6A7 E3 as	AAACcgtgccctacttcctcatgC
CR hSLC6A7 E4 s	CACCGgtctccaaggacggcaacg
CR hSLC6A7 E4 as	AAACcgttgccgtccttggagacC

Golden Gate cloning

Golden Gate cloning describes a one-step cloning method that combines both restriction and ligation reactions in one tube³¹⁸.

Golden Gate reaction mixture	Cycler program:
Vector 150ng	5min 37°C 9cycles
Annealed Oligos 1µl	10min 16°C
10X ligase buffer 2µl	-
T4 DNA ligase 1μl	15min 37°C
BsmBl 1µl	5min 80°C
ddH2O ad 20µl	

Transformation of chemically competent DH5α cells

Chemically competent DH5 α cells were thawed on ice for 15 minutes. Then 20 μ l ligation reaction were added and carefully mixed. After incubation of 20 minutes on ice, a short

heat shock was performed for 1 minute at 42°C in a water bath. The cells were immediately placed on ice and then plated on agar plates containing ampicillin ($100\mu g/ml$) and incubated over night at 37°C.

Plasmid isolation

→ Mini-prep

From an overnight culture, 1.5ml were transferred into reaction tubes and centrifuged (14000xg, 5 min, RT). The supernatant was discarded and the cell pellets were resuspended in 100µl P1 buffer. Then 200µl P2 buffer were added and mixed by inverting the reaction tubes. After addition of 150µl P3 buffer and mixing, the reaction tubes were centrifuged (14000xg, 5 min, RT). The supernatant was transferred to a new reaction tube and mixed with 1ml 100% ethanol. After centrifugation (14000xg, 5 min, RT), the DNA pellet was washed with 150µl 70% ethanol. After centrifugation (14000xg, 1 min, RT), the supernatant was discarded and the pellet shortly dried and resuspended in 50µl ddH2O.

→ Midi-prep

Midi-preps were performed using the "ZyppyTM Plasmid Midiprep"-Kit (Zymo Research) according to the manufacturer's protocol. In short, 50ml of an overnight culture were transferred to a 50ml reaction tube, centrifuged (5000xg, 15 minutes, 4°C) and resuspended in 6ml ddH2O. Then 1ml Lysis Buffer was added and mixed by inverting the tubes. After 5 min incubation time, 3.5ml Neutralisation Buffer were added, mixed and transferred into a combined Zymo-Midi Filter column. After centrifugation (600xg, 5 min, 4°C), the blue Filter was removed and the column placed into a 1.5ml reaction tube. The remaining lysate was removed by another centrifugation step (14000xg, 30sec, RT) and the column was washed with 400µL Endo-Wash Buffer and twice with 400µL Zyppy Wash buffer. The column was transferred onto a new reaction tube, 150µL ddH2O were added, incubated for 1 min and DNA was eluted from the column by centrifugation (14000xg, 1min, RT). DNA concentrations were measured with a NanoDrop spectrometer (Thermo, Wilmington, DE).

➔ Maxi-prep

Maxi-preps were performed using the "NucleoBond PC 500"-Kit (Macherey-Nagel) according to the manufacturer's protocol. In short, 200ml of an overnight culture were transferred to 50ml reaction tubes, centrifuged (5000xg, 15 minutes, 4°C) and resuspended in 12ml P1. Lysis was achieved by addition of 12ml P2 and it was mixed by inverting. Then 12ml P3 were added and the mixture was centrifuged (5000xg, 15 minutes, 4°C). The Filter columns were equilibrated with 6ml N2 and the supernatant transferred onto the columns. After washing with 36ml N3, the column was placed onto a new Reaction tube and DNA was eluted from the column with 15ml N5. Then 11ml isopropanol were added and the mixture was centrifuged (5000xg, 1 min, 4°C). The supernatant was discarded and the DNA pellet shortly dried. DNA was resuspended in 250 μ L ddH2O and DNA concentrations were measured with a NanoDrop spectrometer. All Maxi-Prep plasmids were diluted to a concentration of 1 μ g/ μ l.

DNA sequencing

DNA sequencing was performed by the Seqlab Company (Göttingen, Germany). DNA samples (1µg plasmid or 0.1µg PCR fragments) were prepared with 30pmol oligonucleotide for sequencing in a total volume of 15µL.

Virus production

Virus production was achieved by transfection of Hek293T cells with lentivirus-encoding plasmids (psPax2: Gag-Pol; pMD2.G: VSV.G Env) and PEI ($1\mu g/\mu I$) together with a transfer plasmid carrying the gene that was incorporated into the virus. On the first day, Hek293T cells were seeded onto 15cm dishes at 1.2×10^7 cells. On the second day, the plasmid mix was prepared separately from the PEI mix using DMEM without supplements:

16µg transfer plasmid	ΡΕΙ 1μg/μL 140μl
14µg psPax2	
8μg pMD2.G	
in 1.75ml ØDMEM	in 1.75ml ØDMEM

Both solutions were mixed separately and incubated at RT for 5 min. The solutions were then mixed and incubated at RT for 20 min before addition to the packaging cells dropwise.

On the third day, the medium was changed to new DMEM or RPMI. Two to three days after medium change, the cell supernatant was sterile filtered with a 0,45 μ m sterile filter, transferred to 1.5ml cryotubes and stored at -80°C.

4.17 Competition cell growth assay and cumulative growth curve

Proliferation changes of transduced cells were measured by two different approaches: competition cell growth assay and cumulative growth curve. Both proliferation assays were performed after three days of transduction of KU812 parental and ImaR NTC, ALDH18A1 KO, and SLC6A7 KO cells. Cells were FACS-sorted based on green fluorescent protein (GFP) expression.

For the competition cell growth assay, 70% of GFP positive KU812 cells (KU812 Parental and ImaR NTC, ALDH18A1 KO or SLC6A7 KO cells) were mixed with 30% of untransduced cells (KU812 Parental and ImaR wildtype cells) and seeded in 6-well plates at a density of 1×10⁵ cells per ml in 2.5ml per well in triplicates. GFP percentage was measured every second day over a period of 26 days to test for competitive growth of the respective cells over wildtype cells. After each measurement, fresh media was added to keep the volume constant (2.5ml). At later times, to avoid confluent cultures, parts of the population were discarded, and the remaining cells were diluted with fresh medium.

In order to generate longer growth curves, cumulative growth assays were performed. Therefore, KU812 Parental and ImaR NTC and KO cells were seeded in 12-well plates at a density of 2.5x10⁵ cells/ml in 2ml per well. Every second day, cells were manually counted and reseeded at the initial concentration in fresh medium. The theoretical cumulative growth curve was calculated from the respective dilution factors.

Both proliferation assays were performed once in triplicates. Regarding data analysis of the competition cell growth assay, the GFP expression percentages of KU812 KO cell lines were normalised by the GFP expression of the KU812 NTC cell lines and percentages were plotted using the GraphPad Prism 6 software (La Jolla, CA, USA). Moreover, cumulative growth counting of the different NTC and KO cell lines were also plotted using the GraphPad Prism 6 software (La Jolla, CA, USA).

Flow cytometry

For FACS-sorted by GFP expression and for GFP expression measurements to test cell proliferation, 100-200µl of cell samples plus 4ml of PBS were added into a FACS tube. Samples were centrifuged at 1200rpm for 5min and supernatant was discarded and 100µl of PBS was added. Then, flow cytometry analyses were performed on a BD LSRFortessa[™] Becton Dickinson (Franklin Lakes, USA). Live cells were discriminated from cell debris and dead cells based on physical parameters (forward- and side-0 scatter). Fluorescence background levels were set with untransduced and unstained cells.

4.18 Imatinib-resistant BCR-ABL1 kinase domain mutation analysis

In order to exclude the occurrence of gatekeeper mutations in the production of resistant cells.

Genomic DNA was isolated from 5 x 10^6 cells of the respective cultures by Phenol/Chloroform extraction. Therefore, cells were incubated at 60°C overnight in 400µl PK reaction buffer (50mM Tris/HCl, 5mM EDTA, 150mM NaCl, 0,5% SDS) supplemented

freshly with 100µg/ml Proteinase K. The digested samples were mixed with 400µl Phenol/Chloroform/Isoamylalcohol (25:24:1), carefully mixed by shaking upside down and then centrifuged for 5 min 14.000 rpm. The upper aqueous phase was carefully removed and transferred to a fresh Eppendorf tube. Samples were likewise reextracted using 400µl Chloroform and the aqueous phase was again transferred to a fresh tube. Genomic DNA was precipitated by centrifugation (5min 14,000 rpm) using 1ml ice-cold Ethanol. The DNA pellet was washed using 150µl ice-cold 70% Ethanol and centrifucation (1min, 14,000 rpm) and briefly dried. DNA was dissolved in 0.1mM Tris/HCl pH 8.5 and diluted to a concentration of 200ng/ml.

From these genomic DNA samples exons 4, 5 and 6 of ABL1 were amplified using the following primers (BCR-ABL1 Ex4 s: 5'-AGGCTGTTCCCTGTTTCCTT-3', BCR-ABL1 Ex4 as: 5'-CAGATGCATCGCCTAATGC-3', BCR-ABL1 Ex5 s: 5'-GCTGTCATGGAACCTGTCTG-3', BCR-ABL Ex5 as: ATTCCAACGAGGTTTTGTGC-3', BCL-ABL Ex6 s: GAGCCACGTGTTGAAGTCCT-3', BCR-ABL1 Ex6 as: 5'-AATGTGTTGCCAGCACTGAG-3').

PCR reactions were performed using the following protocol:

5μl DreamTaq buffer 2μl dNTPs (0,2mM each) 2.5μl Sense Primer (10μM) 2.5μl Antisense Primer (10μM) 200ng genomic DNA 0.5μl DreamTaq (2.5 U) to 50μl Water

Moreover, PCRs were performed in a standard PCR cycler using the following protocol: 1 cycle at 98°C for 20 s, 35 cycles of 98°C 20 s, 57°C 30 s, 72°C 1 min and a final elongation step at 72°C for 7 min.

Finally, PCR reactions were separated on an agarose gel and specific amplicons were isolated using the Zymoclean Gel DNA Recovery Kit (Zymoresearch, Freiburg, Germany)

according to the manufacturer's protocol. DNA fragments were Sanger sequenced using the respective sense primers.

5. RESULTS

5 RESULTS

5.1 Resistance mechanism developed by AML cells lines is associated with an important metabolic reprogramming dependent on drug inducer

5.1.1 Introduction and scope

In this chapter, we focus our attention on drug resistance in AML. As mentioned before, the standard treatment for AML involves a combination of cytarabine (AraC) plus anthracycline (e.g. Doxorubicin, Dox)⁸. However, only up to 70% of younger AML patients (aged <65 years), and up to 50% of older AML patients (aged \geq 65 years) achieve complete remission with this treatment³¹⁹ whereas the other 10–40% of patients fail to respond to the standard treatment due to primary refractory disease (e.g. innate resistance) or treatment failure (e.g. acquired resistance). Therefore, new chemotherapeutics able to both overcome innate and acquired resistance in addition to the standard treatment are urgently needed.

As mentioned in the objectives section, we hypothesise that the rewiring of cell metabolism is a crucial part of the process through which AML cells become resistant to AraC and Dox. Thus, the study of the initial metabolic phenotype and the understanding of the metabolic reprogramming after the acquisition of AraC and Dox resistance in two AML cell lines are the main objectives of this chapter. In order to accomplish the second objective "Characterisation of the metabolic profile of AML parental and cytarabine and doxorubicinresistant cell lines", THP-1 and HL-60 cell lines resistant to the chemotherapeutic drugs AraC and Dox were obtained (explained in **section 4.1**). Next, different experimental approaches to elucidate consumption and production rates of metabolites including oxygen, and to determine the intracellular concentrations of these metabolites, were performed to thoroughly characterise the metabolic profile of the THP-1 and HL-60 parental cells, as well as the metabolic reprogramming that underlies the acquisition of resistance to AraC and Dox in both AML cell lines. This metabolic characterisation was performed both under normoxia (21% O_2), as these cell lines were developed under normoxic, and under hypoxic (1% O_2) incubation conditions, as these hypoxic incubation conditions prevail in the physiological environment of AML cell lines within the bone marrow.

All the metabolic assays conducted here were complemented with the study of the protein expression profile via SILAC-based protein mass spectrometry experiments, to be able to correlate changes in metabolite concentrations directly with changes in enzymatic equipment of resistant AML cell lines. Additionally, this protein expression profiling was also used to analyse other metabolic pathways which could not be measured otherwise because of the limited measurability of their metabolites.

Once a comprehensive analysis of the metabolome and proteome was performed, we addressed the second objective of this chapter, which is the "Definition and validation of targets associated with the metabolic reprogramming of parental and resistant AML cell lines". In this line, metabolic and additionally non-metabolic proteins were selected and/or validated as potential therapeutic targets for AraC- and Dox-resistant AML cells.

5.1.2 Results

5.1.2.1 Metabolic characterisation of THP-1 and HL-60 AML cell lines

Prior to characterising of the metabolic reprogramming induced by Ara-C and Dox resistance in THP-1 and HL-60 AML cell lines, we characterised the metabolic profile of the two parental AML cell lines. Therefore, we initially measured glucose consumption, glutamine consumption and lactate production rates in both AML cell lines incubated under both normoxic and hypoxic conditions (also referred as normoxia and hypoxia). Our results showed no differences in the consumption and production rates of the aforementioned metabolites between THP-1 and HL-60 parental cells (from here on named THP-1 P and HL-60 P, respectively) under normoxia (**Fig. 5.1.1.A**). With regard to the hypoxic incubation conditions, only THP-1 P cells displayed a significant increase in glucose consumption and lactate production, and a decrease in glutamine consumption compared to normoxia, thus

suggesting that THP-1 P cells may be more sensitive than HL-60 P cells to the hypoxicmediated effect.

Moreover, the ratio between lactate production and glucose consumption (ratio_{lactate/glucose}) was calculated. The ratio_{lactate/glucose}, which denotes the molecules of lactate generated from each glucose consumed, constitutes an indicator of glycolytic flux. Briefly, when ratio_{lactate/glucose} equals 2 it means that all glucose molecules may have been used for lactate production, exclusively. However, when this ratio is lower than 2, this means that part of glucose carbons has not been converted into lactate but were used for other purposes different to lactate production (e.g. lipid synthesis, or pyruvate for TCA cycle). On the other hand, when this ratio is above 2, this means that the cells produce lactate from other sources different than glucose. **Fig. 5.1.1.B** shows that ratio_{lactate/glucose} was significantly higher for HL-60 P than for THP-1 P cells under normoxia. Moreover, the fact that this ratio was 2.4 \pm 0.1 for HL-60 P but 1.8 \pm 0.1 for THP-1 P indicates that at least HL-60 P cells may have upregulated other pathways apart from glycolysis to fuel lactate production. On the other hand, no differences were obtained for the ratio_{lactate/glucose} between AML parental cells incubated under hypoxic conditions.

Furthermore, the ratio between glucose and glutamine consumptions (ratio_{glucose/glutamine}), indicative of how many molecules of glutamine are consumed per molecule of glucose, was unchanged for both AML parental cells under normoxia (**Fig. 5.1.1.C**). Nevertheless, under hypoxic incubation conditions, both THP-1 P and H-60 P cells increased the ratio_{glucose/glutamine} by 6 and 2 times, respectively. This increase in the ratio_{glucose/glutamine} indicates that both AML parental cell lines decreased glutamine consumption relative to glucose consumption under hypoxia.




Figure 5.1.1 Metabolic differences between THP-1 and HL-60 parental AML cell lines. A) Exchange fluxes for THP-1 parental (P) and HL-60 P under normoxia and under hypoxia (Hyp). Glucose and glutamine consumption, and lactate production rates were determined as described in **Section 4.7**. Data were normalised to cell number and incubation time. **B)** The ratio lactate/glucose was determined by dividing lactate production flux rates by glucose consumption flux rates. **C)** The ratio glucose/glutamine was determined by dividing the glucose consumption flux rate by glutamine consumption flux rates. Data are provided as mean \pm SD of n = 2 and significance was determined by two-tailed independent sample Welch's t-test. Statistically significant between THP-1 P vs. HL-60 P cells under normoxia or under hypoxia, and between THP-1 P or HL-60 under normoxia vs. hypoxia are indicated as p<0.05 (*), p<0.01 (**), and p<0.001 (***).

In order to complement the metabolic profiles of the AML parental cells incubated under normoxic and hypoxic conditions (normoxic or hypoxic-AML cells), ECAR and OCR were determined under normoxia using the XF96 Extracellular Flux Analyser (Seahorse) (**Fig. 5.1.2**). On one hand, ECAR quantifies the total protons produced and excreted by cells which are mainly attributed to lactic acid produced in glycolysis and to the carbonic anhydrase (CA)-mediated hydration of the CO₂ (CO₂ + H₂O --> HCO₃⁻ + H⁺) produced in the TCA cycle. On the other hand, OCR provides information of the mitochondrial respiration, another energy-yielding pathway in cells. Our results show that HL-60 P cells incubated under normoxic conditions (normoxic-HL-60 P cells) displayed higher ECAR values than THP-1 P cells incubated under normoxic conditions (normoxic-THP-1 P cells) (**Fig. 5.1.2.A**). Moreover, normoxic-THP-1 P cells exhibited 11.6 higher OCR values than normoxic-HL-60 P cells. (**Fig. 5.1.2.B**), thus indicating that normoxic-THP-1 P cells exploits more efficiently the mitochondrial respiration capacity for energy production than normoxic-HL-60 P cells. In fact, the elevated OCR of the normoxic-THP-1 P cells is an indicator of higher mitochondrial activity, which is also associated with an increase of CO₂ production from TCA cycle. Thus, the lower ECAR values found in normoxic-THP-1 P cells suggests that these cells should have extra mechanisms (e.g. proton neutralisation) to compensate the high proton production originating from CA-mediated hydration, or that they may reroute the CO₂ to citrate through glutamine-dependent reductive carboxylation.

Regarding AML cells incubated under hypoxic conditions (hypoxic-AML cells), hypoxic-THP-1 P cells) exhibited the same ECAR values than normoxic-THP-1 P cells although lactate production was dramatically increased under hypoxia. On the contrary, ECAR, in HL-60 P cells incubated under hypoxic conditions (hypoxic-HL-60 P cells), decreased although hypoxic-HL-60 P cells showed the same lactate production under normoxic and hypoxic incubation conditions (**Fig. 5.1.2.A**). Thus, these results suggest that glycolysis may not be the only contributor to ECAR value. It is worth mentioning that lactate production measurements were performed under hypoxic incubation conditions but ECAR values were measured in hypoxic-adapted cells under normoxic conditions (reoxygenation conditions). Therefore, even though the aforementioned results still suggest that the changes in the ECAR values are explained by the fact that glycolysis may not be the only contributor to ECAR value. Further experiments measuring ECAR values of hypoxic-AML cells under hypoxic conditions (hypoxic) should be conducted. Furthermore, OCR decreased for hypoxic-THP-1 P cells, but it increased for hypoxic-HL-60 P cells (**Fig. 5.1.2.B**). As OCR increased for hypoxic-

HL-60 cells, a higher proton production (and thus higher ECAR) in hypoxic-adapted cells than normoxic cells would have been expected. Therefore, we hypothesise that the lower ECAR value in hypoxic-HL-60 cells could be due to the neutralisation of proton production occurring inside the hypoxic-HL-60 P cells or to an increase of the CO₂ rerouting to citrate through the glutamine-dependent reductive carboxylation. However, further studies to elucidate this fact would be needed.




Figure 5.1.2 Extracellular acidification (ECAR) and basal mitochondrial oxygen consumption (OCR) rates of THP-1 and HL-60 cell line models. A) ECAR was measured under normoxia in THP-1 and HL-60 Parental (P) cells incubated in KHB buffer with 4mM glutamine and 10mM glucose under normoxic and hypoxic (Hyp) incubation conditions. B) Basal mitochondrial OCR levels measured under normoxia in THP-1 and HL-60 P cells incubated in KHB buffer with 4mM glutamine and 10mM glucose under normoxic and hypoxic (Hyp) incubation conditions. B) Basal mitochondrial OCR levels measured under normoxia in THP-1 and HL-60 P cells incubated in KHB buffer with 4mM glutamine and 10mM glucose under normoxic and hypoxic (Hyp) incubation conditions. The basal mitochondrial OCR was determined by measuring OCR during sequential injections of oligomycin, CCCP, CCCP+Pyruvate, and Rotenone+Antimycin, and was calculated as described in section 4.12. Both ECAR and OCR were measured using a XF96 Extracellular Flux Analyser. Data were normalised by cell number. Data are provided as mean \pm SD of n = 3 and significance was determined by two-tailed independent sample Student's t-test. Statistically significant between THP-1 P vs. HL-60 P cells incubated under normoxic or hypoxic incubation conditions, and between THP-1 or HL-60 P cells incubated under normoxic incubation conditions vs. THP-1 or HL-60 P cells incubated under hypoxic incubation conditions are indicated as p<0.05 (*), p<0.01 (**), and p<0.001 (***).

Since previous results showed metabolic differences between both AML cell lines at the level of mitochondrial metabolism, proton neutralisation, lactate and glutamine synthesis, we decided to perform a more accurate metabolic profiling by analysing the exchange flux rates of all amino acids and of polyamines in both cell lines under normoxia and hypoxia. The full list of exchange flux rates of both AML cell lines under normoxia is provided in **Table 1 from Appendix 1**, while **Figure 5.1.3** depicts the exchange fluxes that were significantly different between THP-1 P and HL-60 P cells. Particularly, higher consumption rates for histidine, isoleucine, leucine, lysine, phenylalanine, threonine, tryptophan, tyrosine, valine and glutamine, and higher production rate for glutamate were determined for THP-1 P when compared to HL-60 P cells. On the other hand, HL-60 P cells exhibited higher production rates of alanine and proline than THP-1 P cells. With regard to the exchange fluxes measured under hypoxia, all the exchange fluxes, with the exception of alanine that was produced more in HL-60 P than in THP-1 P cells, were non-significantly different between both AML cell lines (**Table 2 from Appendix 1**).




Figure 5.1.3 Exchange fluxes of amino acids for THP-1 parental and HL-60 parental AML cell line models under normoxia. Amino acids consumption and production rates in THP-1 parental (P) and HL-60 P cells obtained under normoxia were estimated after measuring the concentration of amino acids using the Absolute p180 Biocrates kit in incubation, as described in **Section 4.8**. Data were normalised to cell number and incubation time. Only exchanges fluxes of amino acids that were significantly different between cells lines were plotted. Data are provided as mean \pm SD of n = 3 of one representative experiment and significance was determined by two-tailed independent sample Student's t-test. Statistically significant differences between THP-1 P and HL-60 P cells are indicated as p<0.05 (*), p<0.01 (**), and p<0.001 (***). Abbreviations: Alanine, Ala; glutamate, Glu; glutamine, Gln; histidine, His; isoleucine, Ile; leucine, Leu; Lysine, Lys; parental, P; phenylalanine, Phe; proline, Pro; threonine, Thr; tryptophan, Trp; tyrosine, Tyr; and valine, Val.

All together, these results suggest that THP-1 P and HL-60 P AML cell lines exhibited completely different metabolic profiles, with important differences in the consumption of metabolites that cells use to obtain energy and precursor units for cell proliferation. Although both cell lines exhibited a similar glycolytic flux under normoxia, THP-1 cells have much higher activity of OXPHOS than HL-60 cells. Moreover, THP-1 cells showed a ratio lactate/glucose lower than 2, indicating that part of pyruvate coming from glucose carbons might enter into TCA cycle. In this line, THP-1 cells also presented higher consumption of amino acids such as isoleucine, leucine, lysine, valine or threonine, among others, whose catabolism produces pyruvate, acetyl-coA or succinyl-coA, thus fuelling the TCA cycle and, thereby, increasing OXPHOS activity. On the other hand, HL-60 cells have increased proline and alanine synthesis, that are processes involved in the redirection of pyruvate and glutamate out of the TCA cycle. This fact together with the lower consumption of other

amino acids could explain the low OXPHOS activity observed in this cell line. Despite these different metabolic profiles, both cell lines proliferate under normoxia with a similar duplication time (49±5.1 and 41±7.4 for THP-1 P and HL-60P, respectively).

5.1.2.2 Resistance validation, cell volume and protein content comparison between cytarabine and doxorubicin resistant and parental AML cell lines

In order to achieve the first objective of this thesis ("to determine the metabolic changes developed by the different AML cell lines after the acquisition of AraC or Dox resistance and compare them to the parental counterparts"), we worked with four resistant AML cell line models generously obtained by Prof. Jindrich Cinatl (Institute of Medical Virology, University Hospital Frankfurt, Goethe University Frankfurt, Germany) and Prof. Martin Michaelis (Centre for Molecular Processing and School of Biosciences, University of Kent, Canterbury, UK): THP-1 resistant to AraC (here named as THP-1 AraC), HL-60 resistant to AraC (HL-60 AraC), THP-1 resistant to Dox (THP-1 Dox), and HL-60 resistant to Dox (HL-60 Dox). Firstly, we confirmed resistance against AraC or Dox by cell viability assay, thus determining the half maximal inhibitory concentrations (IC50) of the different cell models versus the sensitive parental (THP-1 P and HL-60 P) counterparts. All the resistant cell models presented higher IC50 values than their parental counterparts (**Fig. 5.1.4**).




Figure. 5.1.4 Cell viability of THP-1 and HL-60 cells parental or resistant to AraC and Dox after incubation with AraC or Dox. Cells were incubated 72 hours with DMSO (vehicle control) or different concentrations of the corresponding drug (AraC or Dox). Cell viability was determined and the half maximal inhibitory concentration (IC50) was calculated as described in **Section 4.3**. Data are provided as mean ± SD of n=2 and significance was determined by two-tailed independent sample Welch's t-test. Statistically significant differences between the THP-1/HL-60 resistant cells and their parental (P) cell lines are indicated as p<0.05 (*).

Furthertmore, cell volume and protein content of all the AML cells were determined. Whereas development of resistance to AraC did not affect cell volume, both THP-1 and HL-60 cells that developed Dox resistance experienced shrinkage of 34% and 30%, respectively (Fig. 5.1.5.A). Moreover, both THP-1 AraC and Dox cell lines showed a 17% and 33% decrease in protein content compared to THP-1 P cells, respectively (Fig. 5.1.5.B). However, development of resistance to AraC or Dox did not induce any significant change in protein content in HL-60 cells.




Figure 5.1.5 Cell volume and protein content of THP-1 and HL-60 parental and AraC and Dox resistant cells. Cell volume (A) and protein content (B) of THP-1 and HL-60 Parental (P), and AraC and Dox resistant cells determined under normoxia. Cell volume was determined by ScepterTM 2.0 Cell Counter. For protein content, samples from the different cell lines were collected and counted, and protein content of lysates of these samples were measured by BCA assay. Data are provided as mean \pm SD of n = 5 for **panel A** and mean \pm SD of n = 3 for **panel B**. Significance was determined by two-tailed independent sample Student's t-test. Statistically significant differences between resistant and their parental cells are indicated as p≥0.05 (n.s.), p<0.05 (*), and p<0.001 (***).

5.1.2.2.1 AML cells resistant to cytarabine and doxorubicin preferentially express proteins associated with cellular and metabolic processes

Since proteomic analysis, by analysing differentially altered protein concentrations, provides an understanding of the molecular signatures of the disease, we decided to evaluate the effect of AraC and Dox resistance acquisition on the protein profile of THP-1 and HL-60 cells. Therefore, SILAC-based protein mass spectrometry experiments with parental and resistant cells incubated under normoxic and hypoxic conditions were performed.

The results of the protein profiles indicated that from a total of 3461 proteins identified in all THP-1 cell lines under normoxic incubation conditions, 12% were upregulated and 14% downregulated in THP-1 AraC cells; whereas 10% were upregulated and 13%

downregulated in THP-1 Dox cells when compared to THP-1 P cells (**Tables 3-6 from Appendix 1**). On the other hand, differences between the different HL-60 cell lines under normoxic incubation conditions were not as strong as between THP-1 cell lines. From 3486 identified proteins, 11% were upregulated and 9% downregulated in HL-60 AraC cells; and 3% were upregulated and 3% downregulated in HL-60 Dox cells (**Tables 7-10 from Appendix 1**). Unfortunately, the technical replicates of the quantitative proteomic analyses performed for parental and resistant cell lines under hypoxic incubation conditions demonstrated a high variability. So, they could not be statistically evaluated (data not shown). For this reason, we only focussed on the quantitative analysis of the obtained proteomics data of AML cells incubated under normoxic conditions.

Furthermore, differentially regulated proteins under normoxia were clustered into biological processes using the gene ontology classification system so-called PANTHER database system. This analysis of the biological processes revealed that cellular processes (30%), considering any process that is carried out at the cellular level but not necessarily restricted to a single cell, and metabolic processes (21%) were the most altered in the acquisition of the four resistant phenotypes (**Fig. 5.1.6**). Thus, this analysis indicated that reprogramming of metabolism plays a key role in the acquisition of AraC and Dox resistance of THP-1 and HL-60 AML cells.




Figure 5.1.6. Clustering into biological processes, based on the gene ontology classification system, of differentially regulated proteins from the SILAC protein profiles of AraC and Dox resistant vs. parental cells incubated under normoxic conditions. The pie chart shows the biological process enrichment analysis of the regulated proteins. The pie chart shows the distribution of biological processes enrichment into subcategories. On-web analysis was performed using the PANTHER database system as described in Section 4.15. Only biological processes enriched in more than 7.3% appear in the plot. Data are provided as mean ± SD of n=2.

5.1.2.2.2 Cytarabine resistance induces an enhancement of glycolysis whereas the effect of doxorubicin resistance in glycolysis is cell line and oxygen level dependent

Considering that protein expression analysis revealed that metabolic changes plays an important role in the acquisition of AraC and Dox resistance, we further conducted a more complete analysis of the metabolic reprogramming induced by the acquisition of Ara-C and Dox resistance in THP-1 and HL-60 AML cell lines.

Firstly, glucose consumption and lactate production rates of the AML resistant cells were measured under normoxia and hypoxia as described in **Section 4.7**. Under normoxia, both AraC resistant cells increased their glucose consumption when compared to their parental counterparts (**Figs. 5.1.7.A and B**). Regarding the production of extracellular lactate, both AraC resistant cell lines showed a tendency towards an increase of lactate production, although it was only significantly different from its parental counterpart for THP-1 AraC cells. Moreover, the ratio_{lactate/glucose} in the AML cells did not change upon AraC resistance acquisition (**Figs. 5.1.7.C and D**), indicating that the increase of the glucose and lactate rates in AraC resistant cells was of the same order to those of the parental cell lines. On the contrary, Dox resistant cells exhibited lower glucose consumption (THP-1 Dox by 50% and HL-60 Dox by 29%) and lactate production (THP-1 Dox by 75% and HL-60 Dox by 36%) rates relative to their parental cells (**Figs. 5.1.7.A and B**). Furthermore, the ratio_{lactate/glucose} in THP-1 Dox resistant cells was decreased by 51% compared to THP-1 P cells, although this ratio was not affected in the development of Dox resistance in HL-60 cells (**Figs. 5.1.7.C**).

With regard to the extracellular glucose consumption and lactate production under hypoxia, AraC and Dox resistant cells overall exhibited almost the same pattern of changes described under normoxia (**Figs. 5.1.8.A and B**). Contrary to the results under normoxia, both glucose and lactate fluxes were increased in Dox resistant cells under hypoxia. These results suggest that Dox resistant cells may become more glycolytic upon the hypoxic-mediated effect. In parallel to what was observed under normoxia, the ratio_{lactate/glucose} was only affected in THP-1 Dox resistant cells, which showed a decrease of 24% compared to THP-1 P cells (**Figs. 5.1.8.C-D**).




Figure 5.1.7 Effect of AraC and Dox resistance on glucose and lactate exchange fluxes under normoxia. A and B) Exchanges fluxes of THP-1 parental (P) and resistant cells (panel A) and of HL-60 P and resistant cells (panel B). Glucose consumption and lactate production rates were obtained under normoxia as described in Section 4.7. Data were normalised to cell number and incubation time. C and D) Ratio lactate/glucose determined by dividing lactate production rates by glucose consumption flux rates measured under normoxia. Panel C illustrates THP-1 cell lines and panel D, HL-60 cell lines. Data are provided as mean \pm SD of n=2 and significance was determined by two-tailed independent sample Welch's t-test. Statistically significant differences between THP-1/HL-60 resistant cells and their parental (P) cells are indicated as p \ge 0.05 (n.s.), p<0.05 (*), p<0.01 (**), and p<0.001 (***).




Figure 5.1.8 Effect of AraC and Dox resistance on glucose and lactate exchange fluxes under hypoxia. A and B) Exchange fluxes of THP-1 parental (P) and resistant cells (panel A) and of HL-60 P and resistant cells (panel B). Glucose and glutamine consumption, and lactate production rates were obtained under hypoxia as described in Section 4.7. Data were normalised to cell number and incubation time. C and D) Ratio lactate/glucose determined by dividing lactate production rates by glucose consumption flux rates measured under hypoxia. Panel C illustrates THP-1 cell lines and panel D HL-60 cell lines. Data are provided as mean \pm SD of n=2 and significance was determined by two-tailed independent sample Welch's t-test. Statistically significant differences between THP-1/HL-60 resistant cells and their parental (P) cells, are indicated as p \geq 0.05 (n.s.), p<0.05 (*), and p<0.001 (***).

All together, these results suggest that development of resistance to Ara-C induced an increase of glycolytic flux in both cell models both under normoxic and hypoxic conditions. With regard to the development of resistance to Dox, our results show that its effect on the glycolytic flux was dependent on the cell line and on the oxygen conditions to which cells were exposed. Thus, when AML cells were under normoxic conditions, Dox resistant cells decreased glycolytic flux, while under hypoxic conditions the effect depended on the cell line.

We further assessed the total ECAR value under normoxia in all the AML resistant cell lines previously incubated under normoxic or hypoxic conditions (**Fig. 5.1.9**). ECAR values did not increase in any of the AraC resistant cells neither in normoxic nor in hypoxic incubation conditions (**Fig. 5.1.9**). Similar to what was above observed in THP-1 P cells (shown in **section 5.1.2.1**), the fact that THP-1 AraC cells incubated under hypoxic conditions increased lactate production (**Figs. 5.1.7-8**) but non-significant differences were observed regarding the ECAR values suggest that glycolysis is not the only contributor to ECAR value in THP-1 AraC cells. However, as already mentioned in **section 5.1.2.1**, further experiments should be conducted, but this time measuring ECAR values of hypoxic-AML resistant cells under hypoxic conditions (hypoxia), to clarify this suggestion.

Furthermore and considering that CA2 decreased dramatically (10.1-fold down) and that the electroneutral sodium bicarbonate cotransporter (SLC4A7) increased (2.24-fold up), we confirm the relevance of the CA-mediated hydration of the CO₂ as an important contributor to the ECAR values contrary to the generalised assumption that ECAR is a read-out of glycolytic flux. Taking together these results, the fact that no changes were observed in ECAR can be explained by the decrease of CA activity that compensate the increase in glycolytic flux. In addition, the increase in SLC4A7 also must be considered as a key player in the proton efflux balance. On the contrary, CA2 protein expression was increased by 1.92-fold and non-significant differences were observed regarding SLC4A7 protein expression in HL-60 AraC cells when compared to HL-60 P cells (**Fig. 5.1.10**), suggesting that glycolysis and not CA2 is the main contributor to the observed ECAR values in HL-60 AraC cells. Therefore, these results led to the hypothesis that both the decreased contribution of CA2 to the ECAR value and the compensatory mechanisms of intracellular bicarbonate balance may take place in cells highly dependent on mitochondrial respiration (e.g. THP-1 cells).

Regarding the Dox resistant cells, the ECAR value only decreased significantly for HL-60 Dox resistant cells incubated under normoxia (**Figs. 5.1.9.A-B**). Similar to the results observed in HL-60 AraC, the proteomic profiles showed a strong increase of CA2 (9.23-fold up) (**Fig. 5.1.10**), thus again highlighting glycolysis as the main contributor to the observed ECAR values. However, the fact that the protein expression of SLC4A7 protein decreased in these

cells (2.17-fold down) suggests that the enhanced bicarbonate transport could also play a role in the proton balance.




Figure 5.1.9 Extracellular Acidification Rate (ECAR) of THP-1 and HL-60 AraC and Dox resistant, and parental cells incubated under normoxic and hypoxic conditions. ECAR was measured under normoxia using a XF96 Extracellular Flux Analyser in THP-1 and HL-60 parental (P) and resistant cells incubated in KHB Buffer with 4mM glutamine and 10mM glucose under normoxic and hypoxic conditions. Total ECAR value was calculated as explained in Section 4.12., and illustrated in panel A, for THP-1 cell lines incubated under normoxic conditions; panel B, for HL-60 cell lines incubated under normoxic conditions; panel C, for THP-1 cell lines incubated under hypoxic conditions. Data were normalised by cell number. Data are provided as mean \pm SD of n = 3 and significance was determined by two-tailed independent sample Student's t-test. Statistically significant differences THP-1/HL-60 resistant cells and their parental (P) cells are indicated as p \geq 0.05 (n.s.), and p<0.001 (***).




Figure 5.1.10 Protein profile differences of proteins associated with H⁺ production, neutralisation, and bicarbonate buffering in THP-1 AraC, HL-60 AraC and HL-60 Dox resistant cells vs. THP-1 and HL-60 parental cells. The protein expression profile of the carbonic anhydrase 2 (CA2), and the sodium bicarbonate cotransporter (SLC4A7) under normoxia were obtained using SILAC-based proteomic experiments described in section 4.15. Log₂ fold change values were calculated as explained in section 4.15 and represented by green colour= protein upregulation; and red= protein downregulation. Data are provided as mean ± SD of n=2 of one representative experiment.

In order to complement the analysis of the effect of resistance acquisition in glycolysis under normoxia, protein profiles regarding the glycolytic enzymes were analysed (shown in tables 3-10 from Appendix 1). Firstly, non-significant changes were observed in most of the proteins associated with glycolysis between Dox resistant and their respective parental AML cells. With regard to AraC resistant cells, the increase in glucose consumption observed in HL-60 AraC cells was supported by a slight upregulation of the glucose transporter GLUT1 (1.54-fold up) and a high increase on PGM1 (3.39-fold up) and PGM2 (3.06-fold up) (Fig. **5.1.11**). On the other hand, THP-1 AraC cells exhibited a downregulation of several proteins associated with glycolysis (see table 4 from Appendix 1), including hexokinase 1 (HK1), glyceraldehyde-3-phosphate dehydrogenase (GAPDH), and PKM (Fig. 5.1.11), indicating that the observed increase of glucose consumption must be due to mechanisms independent from the overexpression of key glycolytic enzymes (e.g. HK and PKM) or the glucose transporters. In this line, proteins associated with the insulin-dependent glucose uptake via translocation of GLUT4 to the membrane such as insulin-like growth factor-2 mRNA-binding proteins (IGF2BPs) 1, 2 and 3 were upregulated in THP-1 AraC cells compared to THP-1 P cells (1.79, 2.31 and 2.50-fold up, respectively). Moreover, fructose 1,6bisphosphatase (FBP1), which is a key player of gluconeogenesis and a potent negative regulator of glycolysis, was strongly downregulated (3.65-fold down) (Fig. 5.1.11). Of note, it has been reported that the decrease of FBP1 protein expression in glioblastoma cells³²⁰ or the knockdown of FBP1 in HSCs³²¹ substantially increases glucose uptake and extracellular acidification or glycolysis, respectively. Therefore, we hypothesise that THP-1 AraC cells may counteract the downregulation of glycolytic proteins and enhance glycolytic flux via the downregulation of FBP1. However, this hypothesis would require further experimental substantiation.




Figure 5.1.11. Differences in the protein profile of enzymes of the glucose metabolism in THP-1 and HL-60 cells upon AraC resistance. The protein expression profile of proteins associated with glucose uptake and transporters, glycolysis, and glycogen metabolism under normoxia was obtained using SILAC-based proteomic experiments described in **section 4.15**. Log₂ fold change values were calculated as explained in **section 4.15** and represented by green colour= protein upregulation; and red= protein downregulation in THP-1 and HL-60 AraC-resistant cells compared to their parental counterparts. Data are provided as mean ± SD of n = 2. Abbreviations: fructose-biphosphate 1, FBP1; glyceraldehyde-3-phosphate dehydrogenase, GAPDH; glucose transporter, GLUT; hexokinase 1 (HK1); insulin like growth factor 2 mRNA binding protein, IGF2BP; phosphoglucomutase, PGM; and pyruvate kinase, PK.

5.1.2.2.3 Doxorubicin resistance reduces mitochondrial respiration capacity in AML cells with high OXPHOS activity, while Cytarabine resistance does not affect mitochondrial respiration capacity in AML cells

Recent studies have revealed the crucial role of mitochondrial metabolism regarding chemotherapeutic treatment and resistance³²². Therefore, we decided to explore the mitochondrial metabolism of AML resistant cells incubated under normoxia using a

Seahorse XF96 Extracellular Flux Analyser. Briefly, AML parental and resistant cells were incubated in the absence of glucose and sequential injections of oligomycin, CCCP, CCCP+Pyruvate (Pyr), and Rotenone+Antimycin were performed under normoxic conditions in order to measure OCR values and estimate: i) basal mitochondrial respiration, and ii) maximal mitochondrial respiration without and with Pyr.

Figs. 5.1.12.A and B illustrate a significant decrease of basal (87% decrease) and maximal mitochondrial respiration without and with Pyr (83% and 85% decrease, respectively) in THP-1 Dox cells under normoxia compared to their parental counterpart. On the contrary, no differences in basal and maximal mitochondrial respiration were found in HL-60 Dox cells (**Figs. 5.1.12.C and D**). On the other hand, THP-1 AraC resistant cells exhibited the same basal and maximal mitochondrial respiration that THP-1 P cells, while maximal mitochondrial respiration that THP-1 P cells, while maximal mitochondrial respiration that THP-1 P cells, while maximal mitochondrial respiration that THP-1 P cells. While maximal mitochondrial respiration that pyruvate may constitute an important carbon source for mitochondrial respiration in HL-60 AraC cells. In fact and as explained above, basal mitochondrial respiration was much lower in HL-60 P than in THP-1 P cells. Moreover, the basal OCR exhibited by THP-1 Dox cells was of the same level as the observed in all the HL-60 cell lines. This result suggests that HL-60 Dox cells did not decrease the OCR because its metabolism may not be based on mitochondrial respiration.




Figure 5.1.12 Basal and maximal mitochondrial respiration of THP-1 and HL-60 cells resistant to AraC or Dox compared to parental cells incubated and measured under normoxic conditions. Oxygen consumption rate (OCR) was measured under normoxia during sequential injection of oligomycin, CCCP, CCCP + Pyruvate and Rotenone + Antimycin in THP-1 and HL-60 parental and resistant cells incubated under normoxic conditions using a XF96 Extracellular Flux Analyser to illustrate basal mitochondrial respiration of THP-1 cells (panel A) and of HL-60 cells (panel C), maximal mitochondrial respiration without and with pyruvate (Pyr) of THP-1 cells (panel B) and HL-60 cells (panel D). Data were normalised by cell number. Data are provided as mean \pm SD of n = 3 and significance was determined by two-tailed independent sample Student's t-test. Statistically significant differences between THP-1/HL-60 resistant cells and their parental (P) cells are indicated as $p \ge 0.05$ (n.s.), p < 0.05 (*), and p < 0.001 (***).

Since we only observed differences regarding mitochondrial respiration capacity in THP-1 cell lines incubated under normoxic conditions, we also explored the OCR profile of these cells incubated under hypoxic conditions but measure under normoxic conditions (normoxia) (**Figs. 5.1.13.A-B**). Our results showed that the acquisition of resistance to AraC did not affect the mitochondrial respiration capacity of THP-1 cells neither under normoxic nor under hypoxic incubation conditions. However, as observed under normoxic incubation

conditions, THP-1 Dox cells incubated under hypoxic conditions decreased basal (94% decrease) and maximal mitochondrial respiration rates without and with Pyr (85% decrease for both). These results, on one hand, indicate that THP-1 Dox cells previously incubated under hypoxic conditions maintain the low mitochondrial respiration profile produced by the hypoxic adaptation despite the reoxygenation suffered during the OCR measurement process and, on the other hand, confirm our suspicion that the development of Dox resistance induces an important reprogramming of the mitochondrial function in those cell lines which show an active mitochondrial activity.




Figure 5.1.13 Basal and maximal mitochondrial respiration measurements of THP-1 resistant to AraC or Dox compared to THP-1 parental (P) cells incubated under hypoxic conditions. Oxygen consumption rate (OCR) measured under normoxia during sequential injection of oligomycin, CCCP, CCCP + Pyruvate and Rotenone + Antimycin in THP-1 parental and resistant cells previously incubated under hypoxic conditions using a XF96 Extracellular Flux Analyser to illustrate basal mitochondrial respiration (**panel A**), and maximal mitochondrial respiration without and pyruvate (Pyr) (**panel B**). Data were normalised by cell number. Data are provided as mean \pm SD of n = 3 and significance was determined by two-tailed independent sample Student's t-test. Statistically significant differences between THP-1 resistant cells and THP-1P cells are indicated as p≥0.05 (n.s.), p<0.05 (*), and p<0.001 (***).

To better understand the changes in the mitochondrial metabolism upon the acquisition of AraC or Dox resistance, we examined the protein expression profile of proteins associated with the TCA cycle and OXPHOS (**Tables 3-10 from Appendix 1**). Results of THP-1 AraC cells

showed a significant upregulation of PDHA1 (1.59 fold) and PDHB (1.55 fold) and a downregulation of the mitochondrial succinate-CoA ligase [ADP-forming] subunit beta (a subunit of ATP-specific succinyl-CoA synthetase, SUCLA2, 1.60-fold). (Fig. 5.1.14). With regard to the differences in OXPHOS proteins in THP-1 AraC cells, proteins associated with complex I, including NADH:Ubiquinone oxidoreductase (NDUF) subunits A2, A9, A10, A12, B4, B8 and S1, were significantly downregulated; whereas other complex I proteins (e.g. NDUFB5, NDUFB6, and NDUFS6), were upregulated when compared to THP-1 P cells (Fig. 5.1.14), thus suggesting a possible complex I dysfunction (or reorganisation). Moreover, SDHA)which in addition to its role in the TCA cycle is a catalytic subunit of complex II, and the cytochrome oxidase (COX) 5A, 6B1, and 7A2L subunits, which are important for complex IV activity, were also upregulated when compared to THP-1 P cells. Therefore, THP-1 AraC cells seem to counteract the dysfunction of complex I by increasing complex II and complex IV protein expression.

On the other hand, HL-60 AraC cells displayed a downregulation of the mitochondrial aconitate hydratase (ACO2) (1.54-fold down) and an upregulation of mitochondrial succinyl-CoA ligase [GDP-forming] subunit beta (SUCLG2) (2.03-fold up), when compared to HL-60 P cells (**Fig. 5.1.14**). Moreover, the mitochondrial glutamate dehydrogenase (GLUD1) was strongly downregulated (2.65-fold down). All these proteomic changes suggest that TCA cycle activity was decreased in HL-60 AraC cells, while the increase of SUCLG2 could be related to the need of regenerating GTP from GDP. Moreover, a downregulation of proteins associated with complex I (e.g. NDUFA5, NDUFA9, NDUFS2, NDUFS3, and NDUFS8) and complex IV (e.g. COX5B and COX14, COX5B) was observed in HL-60 AraC relative to HL-60 P cells. It is worth mentioning that no changes were observed in complex V (ATPase) proteins in any of the AML cells resistant to AraC (**Fig. 5.1.14**).

Regarding Dox resistant cells, **Fig. 5.1.14** illustrates changes in the TCA cycle and OXPHOS proteins in THP-1 Dox cells. Despite the much lower OCR levels observed in THP-1 Dox relative to THP-1 P cells, THP-1 Dox cells exhibited a general upregulation of proteins associated with TCA cycle, such as citrate synthase (CS), ACO2, oxoglutarate dehydrogenase

(OGDH), SUCLG2 and malate dehydrogenase 2 (MDH2), but also associated with OXPHOS. With regard to OXPHOS, we have observed upregulation of proteins associated with complex I (NDUFA4 and NDUFB6), complex III (cytochrome c, CYCS), and complex IV (COX7C and COX7A2L), although no significant changes were found in proteins associated with complex II and complex V. On the other hand, no changes in proteins associated with TCA cycle and a decrease of two complex I proteins (MT-ND4 and 5) were observed in HL-60 Dox relative to HL-60 P cells.

Taken together, all the results from this section indicate that the development of resistance to AraC may be causing a complex I dysfunction that may be compensated by an enhancement of complex II activity both in THP-1 and in HL-60 cells. Indeed, the total mitochondrial respiration of AraC resistance cells was not affected by the AraC resistance acquisition. Regarding the development of Dox resistance, our results suggest that the acquisition of Dox resistance affects the mitochondrial metabolism especially of cells highly dependent on mitochondrial respiration (i.e. THP-1 cells) (explained in **Section 5.1.2.1**). However, the decrease observed in the mitochondrial respiration of these cells was not accompanied by a decrease in the levels of proteins associated with the TCA cycle and the OXPHOS. In fact, we obtained the opposite result. These results suggest that Dox may be probably affecting the mitochondrial respiration through other processes, thus conditioning the mitochondrial functionality such as the mitochondrial membrane integrity, the mitochondrial dynamic, or the mitochondrial membrane potential. Further studies should be conducted in order to better understand the effect of Dox in the mitochondria of these cells.




Figure 5.1.14 Differences in the protein profile of THP-1 and HL-60 AML resistant vs. their parental cells regarding TCA cycle and the ETC complexes. Protein expression profiling was obtained using SILAC-based protein mass spectrometry experiments described in Section 4.15. Log₂ fold change values were calculated as explained in Section 4.15 and represented by green color= protein upregulation; and red= protein downregulation. Data are provided as mean ± SD of n=3 of one representative experiment. Abbreviations: aconitase, ACO; ATP synthase, ATP5; citrate synthase, CS; cytochrome C oxidase, COX; cytochrome C, CYCS; electron transport chain, ETC; fumarate hydratase, FH; glutamate dehydrogenase, GLUD; isocitrate dehydrogenase, IDH; malate dehydrogenase, MDH; malic enzyme, ME; mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit, MT-ND; NADH:ubiquinone oxidoreductase, NDUF; oxoglutarate dehydrogenase, OGDH; pyruvate carboxylase, PC; pyruvate dehydrogenase, PDH; pyruvate dehydrogenase, PDP; succinate-CoA ligase ADP-forming subunit beta, SUCLA2; succinate-CoA ligase GDP-forming subunit beta, SUCLG2; succinate dehydrogenase, SDH; and tricarboxylic acid, TCA.

5.1.2.2.4 Development of resistance to both Cytarabine and Doxorubicin impairs glutamine metabolism

Once glycolytic flux and mitochondrial metabolism were studied, differences in glutamine metabolism between AML parental and resistant cells were determined. As shown in **figure 5.1.15.A**, AraC resistant THP-1 cells significantly increased glutamine consumption by 91% when compared to THP-1 P cells. Regarding to Dox resistance, glutamine consumption was decreased by 40% in HL-60 Dox cells. Glutamine consumption for THP-1 Dox and HL-60 AraC resistant cells did not differ from the glutamine consumption of their parental cells. Therefore, results under normoxia highlighted a pattern of cell line-dependent changes regarding glutamine consumption. With regard to hypoxia, THP-1 resistant cells displayed higher glutamine consumption than THP-1 P cells, whereas THP-1 Dox and both HL-60 resistant cells consumed the same glutamine than their parental counterparts (**Fig. 5.1.15.B**).

To further analyse the alteration in the glutamine metabolism of AML resistant cells, intracellular content of glutamine was measured by HPLC-MS/MS according to the methodology described in **section 4.8.** Only THP-1 AraC cells showed a significantly higher glutamine content when compared to THP-1 P cells under normoxia (**Fig. 5.1.15.C**), whereas all resistant cells displayed the same glutamine intracellular content when compared to parental cells in hypoxia (**Fig. 5.1.15.D**).




Figure 5.1.15 Effect of AraC and Dox resistance on glutamine metabolism of THP-1 and HL-60 AML cells in normoxic and hypoxic conditions. A and B) Glutamine exchange fluxes of THP-1 and HL-60 parental (P) and AraC or Dox resistant cells under normoxia (panel A) and hypoxia (panel B). Glutamine consumption rates were obtained under normoxia and hypoxia as described in section 4.7. Data were normalised to cell number and incubation time. C and D) Glutamine intracellular content of THP-1 and HL-60 P and AraC or Dox resistant cells under normoxia (panel C) and hypoxia (panel D). Cell pellets were collected to measure the intracellular content of glutamine as described in section 4.8. Data were normalised by the extracted protein. Data are provided as mean \pm SD of n=2 for panels A and B, and as mean \pm SD of n = 3 of one representative experiment for panels C and D. Significance was determined by two-tailed independent sample Student's t-test. Statistically significant differences between THP-1/HL-60 resistant cells and their parental (P) cells are indicated as p≥0.05 (n.s.), p<0.05 (*), p < 0.01 (**), and p < 0.001 (***).

The balance between glutamine anabolism and catabolism depends on the activity of two important enzymes: glutaminase (GLS) and glutamine synthetase (GS). The analysis of the SILAC-based protein mass spectrometry experiments revealed that the protein expression level of GLS was upregulated in both THP-1 AraC (1.51-fold up) and THP-1 Dox cells (3.04-fold up), and the protein expression level of GLUL was also upregulated in THP-1 Dox cells (1.78-fold up) (**Tables 3 and 5 from Appendix 1**). Therefore, the higher glutamine consumption observed in THP-1 AraC but not in THP-1 Dox could be explained by the fact

that the protein expression of GLUL is not upregulated in THP-1 AraC, suggesting that THP-1 AraC compared to THP-1 Dox cells may rely more on external glutamine. With regard to HL-60 resistant cells, no changes were observed in the protein expression of GLS protein while GLUL was downregulated in both resistant cell lines, by a 1.54-fold down for HL-60 AraC and 2.05-fold down for HL-60 Dox. The observed downregulation of GLUL together with the decrease of not only glutamine but also glucose consumption and lactate production suggest that HL-60 Dox cells may slow down its energetic metabolism upon the Dox treatment.

Alltogether, our results reveal that glutamine metabolism was altered in all AML resistant cells, although the changes in protein expression levels did not directly correlate with the glutamine exchange flux. This suggests that there should be other players beyond the expression levels of these two proteins that are taking part in the regulation of the glutamine metabolism. Moreover, the effects on glutamine metabolism were cell line and drug dependent.

5.1.2.2.5 Development of resistance to Cytarabine and Doxorubicin alters the amino acid metabolism of AML cells in a cell line-dependent manner

Since glutamine metabolism was altered in all the AML resistant cells, we decided to explore if the metabolism of the rest of amino acids was also affected upon the acquisition of drug resistance. Therefore, we determined the exchange fluxes and intracellular content of the rest of amino acids and polyamines under normoxia and hypoxia. Results are provided in **tables 11-18 from Appendix 1. Figures 5.1.16 and 5.1.17** illustrate the exchange fluxes and intracellular contents with significant differences between resistant and parental cells under normoxia. We observed that THP-1 AraC cells consumed more asparagine, lysine, methionine, phenylalanine and serine, and produced more glycine and ornithine than THP-1 P cells (**Fig. 5.1.16.A**) whereas HL-60 AraC cells only increased tryptophan consumption when compared to HL-60 P cells (**Fig. 5.1.16.B**) under normoxia. It is worth to note that THP-1 AraC cells also showed a dramatic upregulation of asparagine synthetase (ASNS) (2.3-fold

up) which together with the increased of asparagine consumption is indicative of an increased need of this amino acid by these cells.

Regarding Dox resistant cells, THP-1 Dox cells consumed proline (contrary to the THP-1 P cells that produce it) and consumed less serine than THP-1 P cells (**Fig. 5.1.16.A**) whereas HL-60 Dox cells showed a decrease in the consumption of isoleucine, leucine, methionine and phenylalanine, and a decrease in the production of alanine, glutamate, ornithine and proline when compared to HL-60 P cells (**Fig. 5.1.16.B**). These results highlighted the fact that the metabolic reprogramming which takes place during the acquisition of resistance to a drug is totally dependent on the original metabolic state of the tumour cells.

Regarding the intracellular content of these metabolites, no differences were found between THP-1 resistant and parental cells (**Table 15 from Appendix 1**). On the other hand, results of HL-60 cells revealed that the intracellular content of methionine, phenylalanine, tyrosine and valine was lower in HL-60 AraC relative to HL-60 P cells whereas no differences were observed between HL60 Dox and HL60 P cells (**Fig. 5.1.17**).




Figure 5.1.16 Exchange fluxes of amino acids and polyamines in THP-1 and HL-60 AML cell lines resistant to AraC and Dox compared to parental cells under normoxic conditions. Amino acids consumption and production rates of THP-1 parental (P) versus THP-1 resistant cells (panel A) and of HL-60 P versus resistant cells (panel B) under normoxia were estimated by measuring the concentration of amino acids in incubation media using the Absolute IDQ p180 Biocrates kit, as described in **Section 4.8**. Data were normalised to cell number and incubation time. Only amino acids whose exchange flux was significantly different between cells lines were plotted. Data are provided as mean \pm SD of n = 3 of one representative experiment and significance was determined by two-tailed independent sample Student's t-test. Statistically significant differences between THP-1/HL-60 resistant cells and their parental (P) cells are indicated as p≥0.05 (n.s.), p<0.05 (*), p<0.01 (**), and p<0.001 (***). Abbreviations: alanine, Ala; asparagine, Asn; glutamate, Glu; glycine, Gly; isoleucine, Ile; leucine, Leu; lysine, Lys; methionine, Met; ornithine, Orn; parental, P; phenylalanine, Phe; proline, Pro; serine, Ser; and tryptophan, Trp.




Figure 5.1.17 Intracellular content of amino acids in HL-60 cells resistant to AraC and Dox compared to parental cells under normoxic conditions. Cell pellets were collected to measure the intracellular content of amino acids as described in Section 4.8. Data were normalised by the extracted protein. Only amino acids whose content was significantly different between resistant and parental cell lines were plotted. Data are provided as mean \pm SD of n = 3 of one representative experiment and significance was determined by two-tailed independent sample Student's t-test. Statistically significant differences between HL-60 resistant and P cells are indicated as p \ge 0.05 (n.s.), p<0.05 (*), and p < 0.01 (**). Abbreviations: methionine, Met; parental, P; phenylalanine, Phe; tyrosine, Tyr; and valine, Val.

The observed increase in serine consumption and glycine production in THP-1 AraC cells suggests that 1-C metabolism needed for purine synthesis could be enhanced. In fact, the protein profiling results of THP-1 AraC relative to THP-1 P cells showed an upregulation of 1.5-fold in methylenetetrahydrofolate dehydrogenase 1 like (MTHFD1L), which is the mitochondrial isoform responsible of the synthesis of 1-carbon derivatives of tetrahydrofolate involved in the *de novo* synthesis of purine and thymidylate. Furthermore, the increase of asparagine would also increase the production of aspartate, thus allowing the synthesis of carbamoyl aspartate needed in the pyrimidine synthesis. These results suggest that AraC resistant THP-1 cells may be compensating the toxic effect of AraC chemotherapeutic drug by increasing other processes essential for the DNA synthesis. Nevertheless, this hypothesis would require further investigation.

Beyond the increase of components associated with DNA synthesis, it is noteworthy to mention that the anabolism/catabolism of the other amino acids, whose consumption or

production has been increased (i.e. lysine, ornithine, and phenylalanine), implies a NADPH consumption. Moreover, we observed in the protein profiles (**Table 4 from Appendix 1**) that protein levels of G6PD, PGD, malic enzyme (ME) 1 and IDH1, which play an important role in NADPH synthesis, were significantly downregulated by a 1.85, 2.70, 2.14, and 2.51-fold down, respectively) in THP-1 AraC cells when compared to THP-1 P cells. Only the above mentioned MTHFD1L, that produces NADPH together with the 1-C derivative of tetrahydrofolate, was upregulated. Thus, these results suggest that THP-1 AraC cells may have lower NADPH levels. However, this also requires further validation. On the other hand, none of these effects in DNA components or NADPH balance processes were observed in HL-60 AraC cells. Instead, HL-60 AraC cells downregulated MTHFD1L (1.83-fold down) and upregulated IDH1 (1.67-fold up). Therefore, due to the fact that THP-1 P cells had a more active mitochondrial metabolism when compared to HL-60 P cells, we hypothesise that the metabolic changes induced by AraC in our both AML cell lines were dependent on the mitochondrial activity.

Regarding Dox resistant cells, the decrease in the anabolic/catabolic pathways consuming NADPH (i.e. decrease in ornithine and proline synthesis and in phenylalanine catabolism) was the most remarkable alteration among the affected amino acids metabolic pathways in HL-60 Dox cells. In fact, the protein profile (shown in **table 9 from Appendix 1**) showed a significant upregulation of the IDH1 protein level (1.54-fold up) but not in the others NADPH-producer enzymes. With regard to THP-1 Dox cells, the huge decrease in OCR observed in these cells did not have an effect on the amino acid metabolism, although many of them are TCA cycle intermediates precursors. Curiously, proline was consumed instead of being produced, so that a reduction of proline synthesis from glutamate with a concomitant lower NADPH consumption would be expected. Ultimately, THP-1 Dox cells experienced a decrease in the protein expression levels of PGD (2.35-fold down), ME1 (1.85-fold down) and IDH1 (1.96-fold down), contrary to what was observed in HL60 Dox cells.

Regarding the results of exchange fluxes and intracellular content of amino acids and polyamines under hypoxia, both THP-1 resistant cells exhibited an increase of alanine production, thus indicating that there may be an increase of the production of α -

ketoglutarate for TCA cycle fuelling without release of ammonia to the cytosol (Fig. **5.1.18.A**). In this sense, the intracellular content of alanine was higher in THP-1 resistant when compared to THP-1 P cells (Fig. 5.1.18.B). Moreover, the consumption of isoleucine, lysine and serine was higher in THP-1 AraC cells than in THP-1 P cells. In brief, the catabolism of these amino acids generates acetyl-CoA from isoleucine and lysine, and pyruvate from serine. Thus, these results suggest that THP-1 AraC cells may be fuelling the TCA cycle through the synthesis of acetyl-coA, pyruvate and α -ketoglutarate. In the case of THP-1 Dox cells, a higher ornithine production, and putrescine and spermidine consumptions were observed (Fig. 5.1.18.A), suggesting that ornithine decarboxylase (ODC) may be degraded in THP-1 Dox cells under the effect mediated by hypoxia. In fact, the results of the protein profile highlighted a downregulation of 1.56-fold down in the enzyme NAD(P)H quinone oxidoreductase 1 (NQO1), which binds and stabilises the ODC enzyme³²³. Finally, we observed that phenylalanine intracellular content was higher in THP-1 AraC cells and lower in THP-1 Dox cells when compared to parental cells (Fig 5.1.18.B). Unfortunately, we do not have any plausible explanation for this last result, and specific studies would be needed to properly understand the role of phenylalanine under hypoxia in these resistant cells.

On the other hand, no differences were observed in the exchange fluxes of amino acids and polyamines of HL-60 resistant compared with HL-60 P cells (**Table 14 from Appendix 1**). However, the intracellular levels of arginine, asparagine and lysine were lower in HL-60 AraC cells, and only arginine content was lower in HL-60 Dox cells, both when compared to HL-60 P cells (**Fig. 5.1.18.C**). In this case, specific studies would be also needed to better understand the role that these amino acids play in the metabolism of our HL-60 resistant cells under hypoxia.




Figure 5.1.18 Exchange fluxes and intracellular content of amino acids and polyamines in THP-1 and HL-60 AML cell lines resistant to AraC or Dox compared to parental cells under hypoxic conditions. A) Amino acids consumption and production rates of THP-1 parental (P) versus THP-1 resistant cells in hypoxia estimated after measuring the concentration of amino acids using the Absolute IDQ p180 Biocrates kit in incubation media, as described in **Section 4.8.** Data were normalised to cell number and incubation time. **B and C)** Intracellular content of amino acids and polyamines between THP-1 P and its resistant cells (**panel A**) and between HL-60 P and its resistant cells (**panel B**) in hypoxia. Cell pellets were collected to measure the intracellular content of amino acids as described in **Section 4.8**. Data were normalised by the extracted protein. Only amino acids whose exchange fluxes or intracellular content were significantly different between resistant and their parental cells were plotted. Data are provided as mean \pm SD of n = 3 of one representative experiment and significance was determined by two-tailed independent sample Student's t-test. Statistically significant differences between THP-1/HL-60 resistant cells and their parental (P) cells are indicated as p≥0.05 (n.s.), p<0.05 (*), p<0.01 (**), and p<0.001 (***). Abbreviations: alanine, Ala; arginine, Arg; asparagine, Asn; isoleucine, Ile; lysine, Lys; ornithine, Orn; phenylalanine, Phe; and serine, Ser.

5.1.2.2.6 Development of Cytarabine resistance enhances 1C-metabolism and serine synthesis pathway in AML cell lines

As pointed out above, a significant increase in serine and methionine consumption and glycine production was observed in THP-1 AraC cells. Moreover, an upregulation of MTHFD1L responsible of the synthesis of 1-C derivatives of tetrahydrofolate involved in the *de novo* synthesis of purine and thymidylate was also observed. For this reason, we hypothesised that both the SSP and 1-C metabolisms could be upregulated due to the acquisition of AraC resistance. In order to confirm this hypothesis, the protein expression profile of proteins involved in these pathways was further analysed in THP-1 and HL-60 AraC cells (see **Tables 3-4 from Appendix 1**).

Interestingly, proteins involved in the SSP including phosphoglycerate dehydrogenase (PHGDH) and phosphoserine aminotransferase 1 (PSAT1) were significantly upregulated in THP-1 AraC cells by a of 1.72 and 2.03-fold up, respectively (**Fig. 5.1.19**). Moreover, thymidylate synthetase (TYMS), a protein involved in 1-C metabolism and DNA synthesis, was also upregulated (2.01-fold up). Moreover, other proteins associated with SSP and 1-C metabolisms such as phosphoserine phosphatase (PSPH), SHMT2 and dihydrofolate reductase (DHFR) were slightly upregulated (1.38, 1.37 and 1.39-fold up, respectively) (**data not shown**), although their upregulation was not considered as significant due to the fact that protein expression values were below the threshold selected for SILAC data analysis (FD \geq 1.5) (explained in **Section 4.15**). Regarding HL-60 AraC cells, only TYMS expression was upregulated by a 2.24-fold when compared to HL-60 P cells (**Fig. 5.1.19**).




Figure 5.1.19 Protein profiles of THP-1 AraC and HL-60 AraC compared to their parental counterparts regarding serine synthesis pathway and 1-C metabolism. Protein expression profiling was obtained using SILAC-based protein mass spectrometry experiments described in Section 4.15. Log₂ fold change values were calculated as explained in Section 4.15. Significant proteins changed were represented by green color= protein upregulation. Data are provided as mean ± SD of n=3 of one representative experiment. Abbreviations: dihydrofolate reductase, DHFR; methionine adenosyltransferase, MAT; methylenetetrahydrofolate reductase, PHGDH; phosphoserine aminotransferase 1, PSAT1; phosphoserine phosphatase, PSPH; S-adenosylhomocysteine, SAH; S-adenosylmethionine, SAM; serine hydroxymethyltransferase 2, SHMT; and thymidylate synthetase, TYMS.

According to these results, we next studied if the inhibition of enzymes involved 1-C metabolism could be used as a therapeutic strategy. Therefore, we conducted a cell viability assay after the incubation of AML parental and AraC resistant cells with methotrexate (DHFR inhibitor) and pemetrexed (TYMS and DHFR inhibitor). As shown in **Fig. 5.1.20**, both parental and AraC resistant cells were similarly sensitive to the presence of these inhibitors, indicating that these inhibitors do not have a higher effect in AraC resistant cells. Moreover, it is worth mentioning that IC50 concentrations were indeed inside the concentration range

to be used for AML treatment, especially for THP-1 cells, where the obtained IC50 values were 2500 and 10 times lower than for HL-60 cells for methotrexate and pemetrexed, respectively. Although specific studies should be conducted to confirm this hypothesis, it is possible that the higher effect of methotrexate in THP-1 P and AraC resistant cells might be related to their higher mitochondrial activity.




Figure 5.1.20 Effect of Methotrexate and Pemetrexed on the cell viability of THP-1 and HL-60 AML cells parental and resistant to AraC. Cells were incubated for 72 hours with DMSO (vehicle control) or with increasing concentrations of the corresponding inhibitor. IC50s are on the left side of the figure and were calculated as described in **Section 4.3**. Data are provided as mean ± SD of n=3.

5.1.2.2.7 Development of drug resistance modifies the intracellular content of acylcarnitines in AML cell lines without showing correlation with fatty acid oxidation-dependent mitochondrial respiration

It has been recently described that FA metabolism influences relevant aspects of AML biology including acclimatisation to the microenvironment and response/resistance to chemotherapeutics²⁶⁰. Previous studies have supported the idea that higher intracellular levels of acylcarnitines (ACs) correlate with a more active FAO³²⁴. Therefore, intracellular levels of ACs were examined between AML parental and resistant cells under normoxic and hypoxic conditions in order to study the potential differences regarding FAO (shown in Tables 19-22 from Appendix 1). No differences in the ACs intracellular content were found for THP-1 P and resistant cells under normoxic conditions. However, under hypoxia, THP-1 cells resistant to AraC and Dox showed a lower intracellular content of 25 and 30% of the forty analysed ACs, respectively (Fig. 5.1.21). Regarding HL-60 resistant cell lines under normoxia, HL-60 AraC cells showed a decrease in the intracellular content (28% of the analysed ACs), whereas HL-60 Dox cells increased 20% of the analysed ACs, both compared to HL-60 P cells (Fig. 5.1.22.A). Moreover, both HL-60 resistant cell lines displayed an overall decrease of the intracellular content of the analysed ACs under hypoxia (Fig. 5.1.22.B). Specifically, HL-60 AraC cells exhibited a much bigger reduction of ACs intracellular content (from 28% of the analysed ACs under normoxia to 98% under hypoxia), and HL-60 Dox cells decreased the intracellular content of the ACs that were found to be increased under normoxia (from 20% increased ACs under normoxia to 15% decreased ACs under hypoxia) (Fig. 5.1.22.B). These results indicate a less reliance on FAO of HL-60 Dox cells when compared to HL-60 P cells under normoxia. With regard to hypoxia, all our resistant AML cell lines are less reliant on FAO than their parental counterparts.




Figure 5.1.21 Intracellular content of acylcarnitines in THP-1 AraC and Dox resistant cell lines compared to THP-1 parental cells under hypoxic conditions. Cell pellets were collected to measure the intracellular content of acylcarnitines as described in Section 4.8. Data were normalised by the extracted protein. Data are provided as mean \pm SD of n = 3 of one representative experiment and significance was determined by two-tailed independent sample Student's t-test. Statistically significant differences between THP-1 resistant and parental (P) cells are indicated as p ≥ 0.05 (n.s.), p< 0.05 (*), p< 0.01 (**), and p< 0.001 (***).




Figure 5.1.22 Intracellular content of acylcarnitines in HL-60 AraC and Dox resistant cell lines compared to HL-60 parental cells under normoxic and hypoxic conditions. Cell pellets were collected to measure the intracellular content of acylcarnitines under normoxia (panel A) and hypoxia (panel B). as described in Section 4.8. Data were normalised by the extracted protein. Data are provided as mean \pm SD of n = 3 of one representative experiment and significance was determined by two-tailed independent sample Student's t-test. Only statistically significant differences between HL-60 resistant and parental (P) cells are indicated as p<0,05 (*), p<0.01 (**), and p<0.001 (***).

Next, we decided to investigate the mitochondrial respiration dependency on FAO of AML parental and resistant cells by using the Mito Fuel Flex Test (described in **Section 4.12**). Despite the differences observed in ACs, **Fig. 5.1.23** shows that non-significant differences were observed regarding the mitochondrial respiration dependency on FAO for any of the AML resistant cell lines when compared to their parental ones, neither under normoxic nor in hypoxic incubation conditions.




Figure 5.1.23 Fatty acid contribution to mitochondrial respiration of THP-1 and HL-60 AML cell lines resistant to AraC or Dox relative to their parental (P) counterparts. Oxygen consumption rate (OCR) measured under normoxia during sequential injection of Etomoxir, BPTES + UK5099, and oligomycin in THP-1 and HL-60 parental and resistant cells incubated under both normoxic or hypoxic incubation conditions using a Seahorse XF96 Extracellular Flux Analyser. Cells were first incubated with DMEM media in the presence of glucose and glutamine. Data normalised to protein concentration. Data are provided as mean \pm SD of n = 3 and significance was determined by two-tailed independent sample Student's t-test. Statistically significant differences between THP-1/HL-60 resistant cells and their parental (P) cells are indicated as p \ge 0.05 (n.s.).

Furthermore, protein profiles under normoxia were analysed using the data of the **tables 3-10 from Appendix 1** in order to ensure the correlation between the intracellular levels of ACs and protein levels of proteins related to FAO process. Unfortunately, we could not observe any correlation between the intracellular levels of ACs and protein changes under normoxia. As an example, HL-60 AraC cells showed upregulation of proteins associated with FAO such as the two isoforms of the enzyme acetyl-CoA-acetyltransferase (ACAT1 and 2), although these cells had lower intracellular content of ACs, thus suggesting a less active FAO of HL-60 AraC compared to HL-60 P cells. Therefore, these results together with the results obtained from the Mito Fuel Flex Test lead us to question whether a correlation between ACs intracellular levels and FAO exists.

5.1.2.2.8 Potential metabolic and non-metabolic targets identified by protein expression analysis (SILAC)

We decided to follow the same approach proposed by Ong *et al.* and use the SILAC proteomic data of our AraC and Dox resistant cells under normoxia to identify new putative targets that could be exploited to treat AML disease when AraC and Dox resistance has emerged³²⁵. In fact, we focus our attention on those upregulated proteins that can be further inhibited to reduce the cell viability of AML resistant cells. Therefore, an analysis of which pathways showed the highest number of upregulated proteins, in terms of drugspecific (common for both AraC or Dox resistant AML cells) or cell-line-specific (common for both THP-1 or HL-60 resistant cell lines), was further accomplished using PANTHER database system and selecting the pathway gene ontology.

From the total list of pathways containing the most upregulated proteins in the AML resistant versus parental cells (shown in **tables 23-26 from Appendix 1**), Wnt signaling pathway, an ancient pathway that regulates development and stemness, was the most upregulated regarding the altered AraC resistance-specific pathways (18% of proteins upregulated in THP-1 AraC and 6% in HL-60 AraC cells) (**Table 5.1.1**). Next, p53 pathway was the second most upregulated pathway (19 and 9% of proteins upregulated in THP-1 and HL-60 AraC cells, respectively). It is noteworthy to mention that the only proteins associated with p53 pathway that were upregulated in both AraC resistant cells were the C-Terminal Binding Protein 1 (CTBP1) in regard to Wnt signaling pathway, and cyclin dependent kinase 1 (CDK1) and ribonucleotide reductase regulatory subunit M2 (RRM2) for p53 pathway. However, we could not find any pathway with upregulated proteins that was specific for the acquisition of Dox resistance.

Regarding the cell line-specific pathways with upregulated proteins, we found blood coagulation and *de novo* purine biosynthesis to be specific for THP-1 resistant cell lines (**Table 5.1.1**). In this case, the only common upregulated proteins were the thrombomodulin (THBD) and the Amyloid Beta Precursor Protein (APP), both related with blood coagulation, and non-common upregulated proteins were found for the *de novo* purine biosynthesis pathway.

Finally, cholesterol biosynthesis and androgen/estrogen/progesterone biosynthesis processes emerged to be specific for HL-60 resistant cells. In addition, both HL-60 resistant cell lines showed a common upregulation of squalene synthase (FDFT1) involved in cholesterol biosynthesis process, and the sterol O-acyltransferase 1 (SOAT1) related with the androgen/estrogen/progesterone biosynthesis.

Considering the resultant proteins from the pathway gene ontology PANTHER analysis (**Table 5.1.1**), we chose to study the antiproliferative effect of YM-63501, an inhibitor of FDFT1 (that should be specific for HL-60 resistant cell lines), in all the AML resistant and parental cells. For instance, a reduction of cell viability was found for all the resistant and parental cells by inhibiting the FDFT1 protein (**Fig. 5.1.24**). However, we could not observe the expected selective effect on HL-60 resistant cells, and even THP-1 Dox cells showed the lowest IC50 value among all the cell lines. Unfortunately, we could not perform studies inhibiting the rest of the highlighted proteins (shown in **Table 5.1.1**). Therefore, these studies would be required to validate if their inhibitions could selectively inhibit the proliferation of AML resistant cells.

137

Table 5.1.1 Main drug resistance or cell line -specific pathways upregulated under normoxia. Upregulated proteins with a FD \ge 1.5 (log₂ fold change=0.58) obtained from proteomic profiling (SILAC) data of THP-1 and HL-60 resistant relative to parental cells were analysed using Panther classification systems for pathways selection. Data are provided as mean ± SD of n=2. Abbreviations: Non-detected (N.D.).

	PATHWAYS	COMMON PROTEINS	CELL LINES			
			THP-1 AraC		HL-60 AraC	
			Mean Log2	SD Log2	Mean Log2	SD Log2
			fold change	fold change	fold change	fold change
AraC-resistance specific	Wnt signalling pathway	C-Terminal Binding Protein 1 (CTBP1)	0.83	N.D.	0.83	0.07
	p53 pathway	Cyclin dependent kinase 1 (CDK1)	0.72	0.26	1.02	0.04
		Ribonucleotide reductase regulatory subunit M2 (RRM2)	1.39	0.01	0.70	0.12
THP-1-cell line specific			THP-1 AraC		THP-1 Dox	
			Mean Log2	SD Log2	Mean Log2	SD Log2
			fold change	fold change	fold change	fold change
	Blood coagulation	Amyloid Beta Precursor Protein (APP)	2.15	N.D.	0.94	N.D.
		Thrombomodulin (THBD)	2.69	1.40	0.68	0.39
	de novo purine biosynthesis	Non-common proteins				
HL-60-cell line specific			HL-60 AraC		HL-60 Dox	
			Mean Log2	SD Log2	Mean Log2	SD Log2
			fold change	fold change	fold change	fold change
	Cholesterol biosynthesis	Squalene synthase (FDFT1)	1.36	0.07	0.68	0.02
	Androgen/estrogen/progestorene byosinthesis	Sterol O-acyltransferase 1 (SOAT1)	0.79	N.D.	0.93	N.D.




Figure 5.1.24 Effect of YM-53601 inhibitor on the cell viability of AML parental and resistant cells. Cells were incubated for 72 hours with DMSO (vehicle control) or with increasing concentrations of the inhibitor YM-3601. IC50s were calculated as described in **Section 4.3**. Data are provided as mean ± SD of n=3 and significance was determined by two-tailed independent sample Student's t-test.

5.2 Unveiling metabolic remodelling associated with BCR-ABL1independent imatinib resistance in chronic myeloid leukaemia (CML) KU812 cells

5.2.1 Introduction and scope

Chronic myeloid leukaemia (CML) is a clonal bone marrow stem cell cancer characterised by an increased proliferation of myeloid cells within the bone marrow. This disease progresses typically in three phases, chronic phase, accelerated phase and blast crisis, which behaves like an acute myeloid leukaemia and eventually leads to death of the patient. From all the newly diagnoses of leukaemia in adults, CML accounts for 15% of the cases⁶³. As mentioned above, four TKIs (imatinib, nilotinib, dasatinib and bosutinib) constitute the first line of CML treatment⁶³ in chronic phase and, especially, imatinib has proven to be highly effective. However, up to 25% of CML patients develop TKI resistance during therapy despite initial complete remission³²⁶. Hence, there is an urgent need for additional treatment strategies for patients who acquired resistance. Previous studies have reported the link between metabolic reprogramming and drug resistance acquisition in the BCR-ABL1-dependent CML cells resistant to imatinib^{195,286–288,327}. However, to date, only few studies have investigated the metabolic rewiring associated with BCR-ABL1- independent imatinib resistant CML cells.

This chapter focuses on understanding the metabolic reprogramming of CML cells during acquisition of BCR-ABL1-independent imatinib resistance. To this end, we first generated from KU812 parental cells (here referred as KU812 P) an imatinib-resistant CML cell model line (here referred as KU812 ImaR) by prolonged exposure to sub-lethal doses of imatinib. Next, similarly to **Chapter I**, a multi-OMIC characterisation and comprehensive comparison of the metabolic phenotype of KU812 ImaR cells and KU812 P cells, both under normoxic and hypoxic conditions, was performed in order to achieve the main objectives of this chapter: i) a better knowledge of the metabolic adaptation underlying BCR-ABL1-independent imatinib resistance in CML, and ii) the identification of metabolic

139

vulnerabilities associated with resistance development that can be further validated and exploited for new therapies in CML treatment.

5.2.2 Results

5.2.2.1 Development and characterisation of imatinib-resistant KU812 cell line

In order to investigate the metabolic rewiring underlying BCR-ABL1-independent imatinib resistance in CML, an imatinib-resistant cell line (here referred as KU812 ImaR or TKI-resistant) was developed using KU812 cell line (here referred as KU812 parental or KU812 P), as described in detail in **section 4.2.** The process of developing the KU812 ImaR is illustrated in **figure 5.2.1**.




Figure 5.2.1 Graphical description of the generation of an imatinib-resistant KU812 cell line (KU812 ImaR) under normoxia by exposure to increasing concentrations of imatinib. For details regarding the concentrations used see Materials and Methods (**section 4.2**). Viability was controlled every second day. Acquisition of resistance was verified every 3 weeks until resistance was obtained.

The antiproliferative effect of imatinib resistance was verified as described in **section 4.3** and the IC₅₀ values of imatinib for both KU812 P and KU812 ImaR were determined (**Fig. 5.2.2**). Results showed that KU812 ImaR cells enhanced their tolerance to imatinib by more than two orders of magnitude when compared to KU812 P cells (drug resistance index (DRI)=350). The IC₅₀ values for KU812 P and KU812 ImaR cells were also determined for

dasatinib and nilotinib (TKIs of second generation). Likewise, KU812 ImaR cells showed to be also resistant to these second generation TKIs when compared to the parental counterpart (DRI_{Dasatinib}>8300 and DRI_{Nilotinib}=1280) (**Fig. 5.2.2**).




Figure 5.2.2 Effect of three different clinically relevant tyrosine kinase inhibitors (TKIs) on the viability of KU812 parental and KU812 imatinib-resistant cells. KU812 Parental (P) and Imatinib-resistant (ImaR) cells were incubated 72 hours with DMSO (vehicle control) or increasing concentrations of the corresponding inhibitor. Viability of the cells at each concentration was determined and the half-maximal inhibitory concentrations (IC₅₀) were calculated as described in **section 4.3.** Data are provided as mean±SD of n=3.

In order to exclude the involvement of gatekeeper BCAR-ABL1 mutations during the generation of KU812 ImaR cells, relevant exons of ABL1 were sequenced as described in **section 4.18.** No sequence changes were detected in any of the relevant exons (covering the loci of the known gatekeeper mutations G250, Y253, E255, D276, F311, T315, F317, M351 and F359) (**Fig. 5.2.3**). Moreover, an upregulation of BCR-ABL1 expression as a potential resistance mechanism of the KU812 ImaR cell line could be precluded by SILAC-based protein mass spectrometry as KU812 ImaR cells show a downregulation of BCR-ABL1 expression compared to the parent cell line (4-fold down). All together, these results indicate that a resistant cell line was successfully generated, KU812 ImaR cells show significantly increased IC₅₀ concentrations for to different TKIs and that the resistance

developed was neither associated with a mutation in the kinase domain nor with BCR-ABL1 protein overexpression.




Figure 5.2.3 BCR-ABL1 mutation analysis. The nine indicated mutations account for 60% to 70% of all mutations causing imatinib-resistance ³²⁸. Exon 4, 5 and 6 of ABL1 were amplified as explained in **section 4.18** and Sanger sequenced.

To further characterise KU812 ImaR cells, the growth rate, cell cycle and morphology was assessed and compared to the KU812 P cell line. Although there were no significant differences in the cell proliferation between KU812 ImaR and KU812 P cells under normoxic or hypoxic conditions (**Fig. 5.2.4.A**), both cell lines showed a reduced growth behaviour under hypoxic conditions. With regard to the cell cycle, KU812 ImaR cells showed a small but significant increase in S phase and a corresponding decrease in G0-G1 phase (**Fig. 5.2.4.B**). Moreover, although protein content was equal for KU812 P and KU812 ImaR cells (**Fig. 5.2.4.C**), cell size (cell diameter and cell volume) was increased in KU812 ImaR cells (1.79±0.08pL) compared to KU812 P cells (1.11±0.04pL). Of note, KU812 ImaR underwent a 38±4 % increase in cell volume with respect to KU812 P (**Fig. 5.2.4.D**).




Figure 5.2.4 Characterisation of Parental and ImaR KU812 CML cells. A) Growth curve of KU812 Parental (P) and KU812 ImaR cells under normoxia (Norm) and hypoxia (Hyp). **B)** Cell cycle distribution of KU812 P and KU812 ImaR cells determined by flow cytometry. **C)** Protein content differences between KU812 ImaR relative to parental cells. Cells from the different cell lines were collected and counted, and protein content of these samples was measured by BCA assay. **D)** Cell volume of KU812 P and KU812 ImaR cells under normoxia measured with the ScepterTM Handheld Automated Cell Counter. Data are provided as mean ± SD of n = 2. Significance was determined by two-tailed independent sample Welch's t-test of 2 independent experiments. In **panel A**, the statistically significant differences between KU812 P and KU812 ImaR in hypoxia (**a**), KU812 P under normoxia vs. hypoxia (**b**) or KU812 ImaR under normoxia vs. hypoxia (**c**) are indicated as p<0.05 (a, b or c), p<0.01 (bb, cc or dd), p<0.001 (aaa,bbb or ccc). In **panel B, C and D** the statistical differences between KU812 P and ImaR are indicated as p>0.05 (n.s.), p<0.01 (**), and p<0.001 (***).

Ultimately, to better understand the effect of BCR-ABL1-independent imatinib resistance in CML, we followed SILAC-based protein mass spectrometry experiments to quantify changes in protein expression between KU812 P and ImaR cells under normoxia and hypoxia. From a total of approximately 3,200 identified proteins in the cell lines, 26.6% were upregulated and 26.0% were downregulated in the KU812 ImaR compared to the KU812 P cells under

normoxia (**Tables 1-2 from Appendix 2**). Unfortunately, technical replicates of quantitative proteomic analyses performed for KU812 ImaR and KU812 P under hypoxia demonstrated a high variability and, thus, could not be statistically evaluated (**data not shown**). For this reason, we focussed the quantitative analysis of the obtained proteomics data to normoxia only. From the identified proteins, a total of 850 were upregulated and a total of 831 were downregulated in KU812 ImaR compared to KU812 P cells, respectively (**Tables 1-2 from Appendix 2**). Moreover, clustering of the differentially expressed proteins into biological processes, based on the gene ontology (GO) classification system using PANTHER database system, revealed that the GO terms associated with cellular processes (29%) and metabolic processes showed that the up/down regulated proteins are significantly associated with the GO terms "organic substance metabolic processes" and "cellular metabolic processes". Thus, this analysis indicates that reprogramming of metabolism plays a key role in the acquisition of imatinib resistance of KU812 cells.




Figure 5.2.5. Pathway analysis of differentially expressed proteins identified by SILAC-based proteomics analysis of KU812 ImaR vs. KU812 P under normoxia. The bar chart shows biological processes enrichment analysis, based on the gene ontology classification system, of the up/down regulated proteins using the log₂fold change for the analysis. The pie chart shows the distribution of metabolic processes enrichment into subcategories. On-web analysis was performed using the PANTHER database system as described in **section 4.15.** Only biological processes enriched in more than 1% appear in the plot. Data are provided as mean ± SD of n = 2.

5.2.2.2 Development of imatinib-resistance is associated with increased glycolysis as well as rewired glucose to pentose phosphate pathway, glycogen synthesis, and serine-glycine-1C metabolism

The observation that around 20% of the proteins up/down regulated were associated with metabolic processes prompted us to further analyse the rewiring of the main pathways of central carbon metabolism underlying acquired BCR-ABL1-independent imatinib resistance. Since glycolysis was shown to be affected by BCR-ABL1-mutation-dependent acquisition of imatinib-resistance¹¹⁷ and glucose is together with glutamine one of the two major sources of energy in cancer cells, we aimed to first evaluate if BCR-ABL1-independent resistance acquisition was also accompanied by altered glucose metabolism. Therefore, we measured glucose consumption and lactate production rates in KU812 P and ImaR cells. A proportional enhancement of both glucose consumption and lactate production metabolism.

ImaR cells compared to KU812 P cells both under normoxia (60% higher) and under hypoxia (70% higher) (**Fig. 5.2.6.A**). Moreover, the ratio between lactate production and glucose consumption was the same for both cell lines under normoxia and hypoxia (**Fig. 5.2.6.B**).




Figure 5.2.6 Glucose consumption and lactate production rates of KU812 imatinib-resistant relative to KU812 Parental cells. A) Exchange fluxes of KU812 Parental (P) and imatinib-resistant (ImaR) cells. Glucose and lactate production rates were obtained under normoxia (Norm) and hypoxia (Hyp) (1% O₂) as described in **section 4.7**. Data were normalised to cell number and incubation time. **B)** Ratio lactate/glucose using glucose and lactate flux rates under normoxia and hypoxia. Data are provided as mean ± SD of n=3 and significance was determined by two-tailed independent sample Student's t-test. Statistical differences between KU812 P vs. ImaR cells under normoxia and hypoxia, KU812 P cells under normoxia vs. hypoxia, and KU812 ImaR cells under normoxia vs. hypoxia are indicated as p<0.05 (*), p<0.01 (**), and p<0.001 (***).

We further investigated if the enhanced lactate production observed in KU812 ImaR cells contributes to the ECAR value. Results obtained using the XF96 Extracellular Flux Analyser (Seahorse) showed no significant differences between KU812 P and ImaR cells previously incubated under normoxic and hypoxic conditions regarding the ECAR value under normoxia (**Fig. 5.2.7**). As shown above for THP-1 AraC cells (**Section 5.1.2.2.2**), these results also suggest that the contribution to ECAR of CA mediated TCA-derived CO₂ hydration is lower in KU812 ImaR than in KU812 P cells. Indeed, the downregulation of the CA1 and CA2 protein expressions (13.59 and 15.65- fold down , respectively) together with the

upregulation of SLC4A7 transporter (3.45-fold) again confirmed a decreased contribution of CAs to the ECAR value and a compensatory mechanisms of intracellular bicarbonate balance through extracellular HCO₃⁻ import in KU812 ImaR cells (illustrated in **Fig. 5.2.8**).




Figure 5.2.7 Glycolytic profile of KU812 Imatinib resistant compared to KU812 Parental cells. A) Extracellular acidification rate (ECAR) measured under normoxia using a XF96 Extracellular Flux Analyser during sequential injection of glucose, oligomycin and 2-DG in KU812 Parental (P) and imatinib-resistant (ImaR) cells previously incubated under normoxic (Norm) and hypoxic (Hyp) conditions. Cells were first incubated in the absence of glucose. B) ECAR after glucose addition (Total ECAR) in KU812 P and ImaR previously incubated under normoxic conditions were calculated as explained in **section 4.12** using ECAR values of **panel A**. Data were normalised by protein. Data are provided as mean ± SD of n = 3 and significance was determined by two-tailed independent sample Student's t-test. Statistical differences between KU812 P vs. ImaR cells incubated under normoxic and hypoxic conditions, KU812 P cells incubated under normoxic vs. hypoxic conditions are indicated as p<0.05 (*).

KU812 ImaR cells




Figure 5.2.8 Protein profile differences of protein associated with H+ production and neutralisation, and bicarbonate buffering in KU812 ImaR. vs. KU812 P cells upon imatinib resistance. The protein expression profiling of the carbonic anhydrase (CA) 1 and 2, and the sodium bicarbonate cotransporter (SLC4A7) under normoxia were obtained using SILAC proteomic experiments described in **section 4.15**. Log₂ fold change values were calculated as explained in **section 4.15** and represented by green colour= protein upregulation; and red= protein downregulation. Data are provided as mean ± SD of n=2 of one representative experiment.

In parallel to ECAR measurements, the Crabtree effect was analysed by measuring the OCR changes after glucose addition under normoxia in KU812 P and ImaR cells previously incubated under normoxic and hypoxic conditions, in order to analyse the dependence on glucose as a source of energy. In brief, the Crabtree effect involves the inhibition of the mitochondrial respiration capacity in the presence of a high concentration of glucose. Results showed that the OCR rate decreased dramatically after glucose addition in KU812 P cells incubated under normoxic conditions and measured under normoxia (**Fig. 5.2.9**). On the contrary, the basal OCR in the absence of glucose was maintained after glucose addition in KU812 ImaR cells incubated under normoxic conditions and measured under normoxia,

indicating a total absence of the Crabtree effect. Under hypoxic incubation conditions, the Crabtree effect measured under normoxia was also significantly lower in KU812 ImaR when compared to KU812 P cells. It is well known that cells displaying the Crabtree effect have a reduced need for OXPHOS and higher dependence on glycolysis, thereby having less susceptibility to drugs targeting mitochondria³²⁹. The fact that the acquisition of imatinib resistance results in the loss of Crabtree effect in CML cells highlighted that KU812 ImaR cells may be more dependent on OXPHOS and more sensitive to mitochondrial toxicants, thus opening new avenues to be explored in the treatment of imatinib resistance.




Figure 5.2.9 The Crabtree effect of KU812 Parental versus imatinib-resistant cells incubated under normoxic and hypoxic conditions. OCR rates of both cell lines in both incubation conditions was evaluated under normoxia by adding 10mM of glucose to glucose-deprived media. The Crabtree effect was calculated as described in section 4.12 and the percentage of Δ OCR was represented. Data are provided as mean ± SD of n=3 and significance was determined by two-tailed independent sample Student's t-test. Statistical differences between KU812 P vs. ImaR cells under normoxic and hypoxic incubation conditions, KU812 P cells under normoxic vs. hypoxic incubation conditions, and KU812 ImaR cells under normoxic vs. hypoxic incubation conditions are indicated as p<0.05 (*).

To further analyse differences in glucose metabolism between KU812 P and ImaR cells under normoxia, the protein profile of a subset of proteins related with glucose metabolism was analysed (see data in **tables 1-2 from Appendix 2**). The expression of most of the proteins involved in glycolysis was upregulated in KU812 ImaR cells under normoxia (**Fig. 5.2.10**). However, HK isoforms I and II (HK1 and HK2) and the liver/red blood cell isoform of PK (PKLR) were downregulated. Moreover, the ADP dependent isoform of glucokinase (ADPGK) was strongly upregulated (3.98-fold up). Taking into account that it has been reported that the Km of ADPGK for glucose is similar to HK2 (0.3 mM and 0.4 mM respectively) and higher than HK1 (0.03 mM)³³⁰, it is reasonable to assume that ADPGK plays an important role in the conversion of glucose to glucose-6-P in KU812 ImaR cells. Moreover, it is well known that HK1 and HK2 can bind to the mitochondrial membrane and these mitochondrial-bound hexokinases preferentially use mitochondrial generated-ATP³³¹. These facts lead to the hypothesis that the use of cytosolic ADP to phosphorylate glucose could be an advantage to save mitochondrial ATP for other purposes. Nevertheless, this hypothesis would require further experimental confirmation.

It is also noteworthy to mention the dual role of HK1 and HK2 in binding to mitochondria, protecting cells from apoptosis through the antagonisation of pro-apoptotic BCL2 proteins (e.g. Bak and Bax) at the mitochondrial membrane, and that this additional function cannot be compensated by ADPGK, which is localised in the endoplasmic reticulum. The fact that the protein profile showed an increase in BCL2 protein (4.43-fold up), which is a well-known antiapoptotic protein, lead us to hypothesise that this could be a compensatory mechanism in the loss of apoptosis protection due to the lower HK1 and HK2 protein expression. Moreover, we believe that this BCL2 protein upregulation could result in an increased sensitivity of KU812 ImaR cells towards BCL2 inhibitors. To validate this hypothesis, we treated KU812 P and KU812 ImaR with venetoclax (BCL2 inhibitor). Results showed that venetoclax was effective in reducing cell viability of both KU812 P and ImaR cells at micromolar concentrations without significant differences in the respective obtained IC₅₀ values (**Fig. 5.2.11**).




Figure 5.2.10. Protein profile differences of glucose metabolism and its rewiring in KU812 cells upon imatinib resistance. The protein expression profiling of proteins associated with glucose uptake and transporters, glycolysis, glycerol-3-P shuttle, glycogen metabolism, PPP, serine synthesis and 1-C metabolism under normoxia was obtained using SILAC-based proteomic experiments described in **section 4.15**. Log₂ fold change values were calculated as explained in **section 4.15** and represented by green colour= protein upregulation; and red= protein downregulation in KU812 imatinib-resistant cells compared to KU812 parental cells. Data are provided as mean ± SD of n = 2.




Figure 5.2.11 Effect of venetoclax on the cell viability of KU812 Parental and imatinib-resistant cells. KU812 Parental (P) and imatinib-resistant (ImaR) cells were incubated 72 hours with DMSO (vehicle control) or increasing concentrations of venetoclax. IC_{50} values were calculated as explained in section 4.3. Data are provided as mean ± SD of n=2 and significance was determined by two-tailed independent sample Welch's t-test.

Regarding the expression of glucose transporters, we observed that GLUT3 was downregulated (8.66-fold down) in the protein profile of KU812 ImaR cells and that the expression of GLUT1, 2 and 4 did not show any significant differences between KU812 P and ImaR cells, indicating that the observed increase of glucose consumption must be due to mechanisms independent from the overexpression of the HK enzyme or the canonical glucose transporters. In this regard, protein expression of GLUT5, known for its role in fructose transport and its lower capacity to transport glucose into the cell⁹⁷, was highly upregulated (12.13-fold up). Likewise, proteins associated with the insulin-dependent glucose uptake via translocation of GLUT4 to the membrane such as insulin receptor 2 (IRS2); IGF2BP 1 and 2; and the insulin receptor precursor (INSR) were also upregulated in KU812 ImaR compared to KU812 P cells (4.76, 20.39, 6.08 and 5.04-fold up, respectively). Therefore, KU812 ImaR cells may counteract the downregulation of GLUT3 via GLUT5 and insulin-dependent glucose uptake upregulated upregulation via GLUT4 translocation.

In order to confirm the lower expression of the different HK isoforms as described above, we next performed Western blot analysis to validate these proteomics results. HKI, II and III showed a reduced expression in KU812 ImaR relative to KU812 P cells (Figure 5.2.12.A).

152

Moreover, enzyme activities were determined by enzyme activity assays (described in **section 4.11**) to verify if the changes on protein level regarding the enzymes catalysing the rate-limiting steps of glycolysis affected the respective enzymatic activity. In agreement, HK and PK enzyme activities were significantly reduced in KU812 ImaR compared to KU812 P cells (**Fig. 5.2.12.B**). Thus, enzyme activity results corroborated what was determined in the protein profile.

The fact that the increase of glucose consumption and lactate production in KU812 ImaR cells was proportional, in addition to the observed increase in lactate flux, leads to the hypothesis that other branches of glucose metabolism such as oxidative and non-oxidative PPP, glycogen metabolism, serine-glycine-1C metabolism, glycerol metabolism and pyruvate/lactate transport to mitochondria, could be enhanced.

The protein profile showed that all PPP related proteins are upregulated (**Fig. 5.2.10**), with the exception of TALDO1. Interestingly, G6PD, which is the main enzyme controlling the oxidative branch of PPP, TKT, which is known to control the non-oxidative PPP, and transketolase like 1 (TKTL1), a minority isoenzyme of transketolase, were the most upregulated (2.68, 1.57 and 24.23-fold up, respectively). In order to validate the increase of transketolase and G6PD expression, enzyme activities were measured. In agreement with the observed changes at protein levels, enzyme activities were significantly increased in KU812 ImaR relative to KU812 P cells (**Fig. 5.2.12.B**).

To study if the differences observed in G6PD resulted in an increased sensitivity of resistant cells to G6PD inhibitors, we next incubated KU812 P and ImaR cells with dehydroepiandrosterone (DHEA), an uncompetitive inhibitor of G6PD. Noteworthy, even though the inhibition of the activity of G6PD by DHEA reduced the cell viability of both KU812 P cells ($IC_{50} = 8.1 \mu$ M) and KU812 ImaR cells ($IC_{50} = 11.6 \mu$ M) (**Fig. 5.2.13**), the inhibitory effect of DHEA was not significantly higher in KU812 ImaR relative to KU812 P cells, thus suggesting that this inhibitor may not be a good candidate to target specifically the KU812 ImaR cells.

153




Figure 5.2.12. Correlation of HK protein expression and enzyme activities with imatinib resistance. A) Western blot analysis of differential HK protein expression between KU812 Parental (P) and imatinib-resistant (ImaR) cells under normoxia. B) Hexokinase (HK), pyruvate kinase (PK), glucose-6-phosphate dehydrogenase (G6PD) and transketolase (TKT) + transketolase like 1 (TKTL1) specific enzyme activities measured under normoxia. Data are provided as mean \pm SD of n = 2 and significance was determined by two-tailed independent sample Welch's t-test. Statistically significant differences between KU812 P and ImaR cells are indicated as p<0.05 (*), and p<0.001 (***).




Figure 5.2.13. Effect of the G6PD inhibition on the cell viability of KU812 Parental and imatinib-resistant cells by the dehydroepiandrosterone (DHEA) inhibitor. KU812 Parental (P) and imatinib-resistant (ImaR) cells were incubated 72 hours with DMSO (vehicle control) or different concentrations of DHEA. Data are provided as mean ± SD of n=2 and significance was determined by two-tailed independent sample Welch's t-test. Another pathway, where glucose carbons can be rerouted, is the glycogen metabolism. To explore this possibility, we measured the differences on glycogen content between KU812 P and ImaR cells. Results showed a 2.6-fold increase in glycogen content in KU812 ImaR

relative to KU812 P cells (Fig. 5.2.14.A). Consistently, the protein profile also showed that GYS1 and glycogenin-1 (GYG1), which play a role in glycogen synthesis and maximal glycogen level attainment, were upregulated by a 1.54 and 4.02-fold, respectively, in KU812 ImaR relative to KU812 P cells. In agreement with the glycogen accumulation observed, PGM1, the enzyme which indirectly regulates glycogen and pentose-phosphate synthesis by fine tuning of the glucose-1-P and glucose-6-P balance, was also strongly upregulated (34.15-fold up) in KU812 ImaR cells (Fig. 5.2.10). Besides, glycogen phosphorylase liver (PYGL) and brain (PYGB) isoenzymes, responsible of glycogen degradation and identified as relevant enzymes for the optimal function of PPP³³², were upregulated (17.81 and 1.78-fold up, respectively) in KU812 ImaR cells. All together, these results suggest that an enhanced glycogen synthesis/degradation cycle is necessary to simultaneously sustain glycogen accumulation and to support PPP activity in KU812 ImaR cells. Next, we decided to explore the impact of glycogenolysis inhibitors on KU812 P and ImaR cells by using three different inhibitors (1,4-dideoxy-1,4-imino-d-arabinitol [DAB]; CP-320626; and CP-91149). Figure 5.2.14.B illustrates that glycogenolysis inhibitors reduced cell viability of both parental and ImaR cells. However, we could not observe a higher inhibitory effect in KU812 ImaR relative to KU812 P cells for any of the three inhibitors, suggesting that these inhibitors may not be the best therapeutic approach to overcome imatinib resistance.




Figure 5.2.14 Comparison of glycogen content between KU812 Parental and imatinib-resistant (ImaR) cells (A) and effect of glycogenolysis inhibitors on KU812 Parental and ImaR cell viability (B). A) GC-MS was used to assess the glycogen content of parental (P) and ImaR cells. Measurement of the glycogen content was carried out using $[U^{-13}C-D_7]$ -glucose as recovery standard and internal standard quantification procedures. Glucose from glycogen was corrected by millions of cells. B) Effect of 1,4-dideoxy-1,4-imino-d-arabinitol (DAB), CP-320626, and CP-91149 inhibitors on the cell viability of KU812 P and ImaR cells. Cells were incubated 72 hours with DMSO (vehicle control) or increasing concentrations of the corresponding inhibitor. Data are provided as mean ± SD of n = 2 and significance was determined by two-tailed independent sample Welch's t-test. Statistically significant differences between KU812 P and ImaR cells in **panel A** are indicated as p<0.001 (***).

Finally, we explored the glucose carbons rerouting at the level of 3-carbon molecules. Firstly, we cultured KU812 P and ImaR cells in the presence of uniformly ¹³C labelled [U-¹³C]glucose and subsequently analysed the incorporation of ¹³C into serine and glycine by NMR. **Figure 5.2.15.A** illustrates that ¹³C incorporation from [U-¹³C]-glucose into the C2 position of glycine and C3 position of serine was 3.4 and 2.6-fold increased, respectively, in KU812 ImaR cells when compared to KU812 P cells. Moreover, protein profiling results were analysed in order to examine the changes in key protein levels involved in SSP and 1-C metabolism. In brief, upregulation of PHGDH and PSAT (key players of SSP), and SHMT2, TYMS and MTR (key players of 1-C metabolism) in KU812 ImaR relative to KU812 P cells were observed (**Fig. 5.2.10**). These results indicate that the SSP and 1C-metabolism are also crucial pathways influencing glucose metabolism of KU812 ImaR cells.

Since the above results indicate an enhancement of serine and 1C-metabolism through rerouting carbons from glycolytic intermediates, such as 3-P-glycerate, we hypothesise that KU812 ImaR cells could additionally increase the uptake of serine, glycine, and methionine to fuel these pathways. In order to explore this possibility, we measured the exchange fluxes and intracellular contents of serine, glycine, and methionine by using the Biocrates AbsoluteIDQ p180 Kit (described in **section 4.8**) (data shown in **Tables 3-6 from Appendix 2**). A higher serine and methionine consumption, as well as a higher glycine intracellular content were observed in KU812 ImaR cells under normoxia (**Fig. 5.2.15 B-C**), suggesting a higher flux of those metabolic pathways in KU812 ImaR relative to KU812 P cells. Likewise, serine consumption and glycine intracellular content were also higher in KU812 ImaR under hypoxia. However, we could not determine any significant differences between both cell lines regarding methionine consumption in hypoxia.

Considering these results, which suggest an enhanced SSP and 1-C metabolism in KU812 ImaR relative to KU812 P cells, we determined the cell viability of both parental and ImaR cells after the treatment with several 1-C metabolism inhibitors including methotrexate (DHFR inhibitor), pemetrexed (TYMS and DHFR inhibitor), and SHIN2 (SHMT1 and 2] inhibitor). A reduction of cell viability was found for both cell lines (KU812 P and ImaR) but a selective effect on KU812 ImaR relative to KU812 P cells was not observed (**Fig. 5.2.15 D**), indicating that 1-C metabolism is important for both resistant and non-resistant cells.




Figure 5.2.15 Differences in glycine, serine and methionine metabolism between KU812 Parental and imatinib-resistant cells and the effect of the inhibition of 1-C metabolism. A) ¹³C Glucose label incorporation into glycine and serine metabolites in KU812 imatinib-resistant (ImaR) compared to KU812 parental (P) cells under normoxia, determined by NMR analysis. B and C) Exchange fluxes (B) and intracellular content (C) of serine, glycine, and methionine between KU812 P and ImaR cells measured by HPLC-MS/MS as described in section 4.8. D) Effect of methotrexate, pemetrexed and SHIN2 inhibitors on KU812 P and ImaR cell viability. Cells were incubated 72 hours with DMSO (vehicle control) or increasing concentrations of the respective inhibitor. Data are provided as mean \pm SD of n = 3 of one representative experiment for panel A, B and C, and as mean \pm SD of n=2 for panel D. Significance was determined by two-tailed independent sample Welch's or Student's t-test. Statistically significant differences between KU812 P and ImaR cells are indicated as p≥0.05 (n.s.), p<0.05 (*), p<0.01 (**), and p<0.001 (***).

To further explore the glucose metabolism network at the level of 3-carbon molecules, we analysed the proteomic changes associated with the glycerol metabolism and pyruvate/lactate mitochondrial transporters. Results show that GPD2) the mitochondrial pyruvate carrier MPC1, as well as the monocarboxylate carriers MCT4 (SLC16A3) were upregulated in KU812 ImaR cells (**Fig. 5.2.10**). It is worth mentioning that MCT4 has been described to be localised within the plasmatic and mitochondrial membranes and to be able to import/export lactate/pyruvate between mitochondria and cytosol in symport with a H⁺ ³³³. These changes in pyruvate and monocarboxylate carrier are indicative of an increased flux of pyruvate/lactate into the mitochondria, further suggesting a stronger dependence on pyruvate to support mitochondrial respiration. Moreover, the increase of GPD2 observed in KU812 ImaR cells indicates a stronger dependence on GP shuttle, thus additionally suggesting an altered mitochondrial respiration capacity that will be further explored in **section 5.2.1.2.9**.

5.2.2.3 Development of resistance to imatinib enhances glutamine transport and rewires glutamine metabolism

We next investigated differences associated with the acquisition of imatinib resistance with regard to the transport and metabolism of glutamine, another major energy and carbon source that additionally provides nitrogen to biosynthetic pathways. Therefore, exchange fluxes of glutamine and glutamate under normoxia were determined by using the Biocrates AbsoluteIDQ p180 Kit (described in **section 4.8**). The obtained results showed a higher glutamine consumption and glutamate production in KU812 ImaR when compared to KU812 P cells. (**Fig. 5.2.16 A**).

To elucidate if the increase of glutamine consumption and glutamate production observed in KU812 ImaR cells was due to an increase of the GLS isoenzymes or a decrease in GS (the main enzymes involved in glutaminolysis and glutamine synthesis, respectively), the expression of these proteins were quantified by Western blot analysis and by protein profile (SILAC) analysis. Overall, KU812 ImaR cells showed lower levels of GLS isoenzymes (GLS1

159

and GLS2) in the Western blot results and a slightly downregulation (1.69-fold down) of the total protein concentration (**Table 2 from Appendix 2**). Moreover, no differences were observed regarding GS protein levels. Furthermore, the increased of glutamine consumption observed in KU812 ImaR cells was consistent with the dramatic increase observed at protein level of the two main glutamine transporters SLC38A1 (SNAT1) (15.11-fold up) and SLC38A2 (SNAT2) (5.00-fold up). Other amino acids transporters such as LAT1 were also upregulated (1.73-fold up) in KU812 ImaR cells, indicating that these cells not only have a stronger dependence on glutamine but also on other amino acid metabolic pathways (Fig. 5.2.17). All together, these results demonstrate that the observed changes in the glutamine consumed, and the glutamate produced in KU812 ImaR cells are not due to an increase in glutaminolysis despite the fact that glutamine import is upregulated in KU812 ImaR cells.




Figure 5.2.16 Characterisation of glutamine metabolism in KU812 imatinib-resistant compared to KU812 parental cells. A) Exchanges fluxes of glutamate and glutamine of KU812 Parental (P) and imatinib-resistant (ImaR) cells. Glutamine consumption and glutamate production were obtained under normoxia as described in **section 4.7.** Data were normalised to cell number and incubation time. **B)** Western blotting analysis of total protein fractions related to glutamine metabolism of KU812 P and ImaR cells under normoxia. Data are provided as mean ± SD of n=3 for **panel A** and significance was determined by two-tailed independent sample Student's t-test. Statistically significant differences between KU812 P and ImaR cells are indicated as p<0.05 (*), and p<0.01 (**). Abbreviations: Kidney-type glutaminase 1, KGA-GLS1; glutaminase C, GAC-GLS1; glutaminase 2, GLS2; and glutamine synthetase, GS.

To further investigate the metabolic fate of glutamine in KU812 ImaR cells, the protein profile of enzymes that use glutamine as substrate were analysed using the data from **Tables 1-2 from Appendix 2**. Glutamine-fructose-6-phosphate aminotransferase 1 (GFPT1), the first and rate limiting enzyme in hexosamine biosynthesis pathway (HBP)³³⁴, was one of the enzymes significantly upregulated (5.68-fold up), indicative of the glutamine and glucose rewiring towards HBP in KU812 ImaR cells (**Fig. 5.2.17**). Nevertheless, the other non-rate-limiting enzymes involved in the HBP such as the glucosamine-6-phosphate N-acetyltransferase (GNPNAT1), the PGM3, and the UDP-N- acetylhexosamine pyrophosphorylase 1 (UAP1) were significantly downregulated. In brief, HBP produces uridine diphosphate N-acetylglucosamine (UDP-GlcNAc) from glucose and glutamine and plays an important role in the biosynthesis of glycoproteins³³⁵. Proteomic profiling also unveiled an important increase in another important glutamine consuming enzyme, the ASNS (4.40-fold up), which converts glutamine and aspartate into glutamate and asparagine.

All together, these results prompted us to investigate the exchange fluxes and intracellular content alterations of amino acids upon imatinib resistance generation, specially alterations of proline, an important end product of glutamine metabolism, and its precursors ornithine, aspartate and arginine, due to its close relation with the glutamine metabolism.




Figure 5.2.17 Protein profile of the rewiring of glutamine metabolism in KU812 imatinib-resistant when compared to KU812 parental cells. The protein expression profiling of proteins related to amino acid transporters, glutamine, hexosamine, proline, ornithine, citrulline, arginine and collagen metabolism under normoxia was obtained using SILAC-based proteomic experiments described in **section 4.15**. Log₂ fold change values were calculated as explained in **section 4.15** and represented by green colour = protein upregulation; and red = protein downregulation. Data are provided as mean ± SD of n = 2.

5.2.2.4 Development of resistance to imatinib rewires the metabolism of proline and its related metabolic precursors

To further unveil the metabolic rewiring associated with the acquisition of imatinib resistance, we next investigated differences in proline metabolism and its related precursors including ornithine and glutamate. As shown in **Fig. 5.2.18 A**, KU812 ImaR cells exhibited an enhanced production of proline (13-fold increase) and ornithine (3-fold increase) compared to KU812 P cells. Regarding the intracellular content of these amino acids, we observed that proline and ornithine intracellular contents were sixteen and seven times higher, respectively, in KU812 ImaR compared to KU812 P cells (**Fig. 5.2.18 B**).

Considering that both proline and ornithine can be synthesised from glutamate through glutamate-y-semialdehyde (GSA) synthesis, but ornithine can also be synthesised from other carbon sources such as arginine, we next cultured KU812 P and ImaR cells in the presence of either uniformly ¹³C labelled [U-¹³C]-glucose or [U-¹³C]-glutamine and subsequently analysed the incorporation of ¹³C into glutamate, proline and ornithine metabolites by NMR (data shown in **Tables 7-8 from Appendix 2**). No ¹³C incorporation originating from [U-¹³C]-glucose was observed in proline or in ornithine in both KU812 P and ImaR cells (Fig. 1 from Appendix 2). On the other hand, ¹³C incorporation from [U-¹³C]glutamine in the carbons C3, C4 and C5 of proline was 45, 39 and 33-fold higher, respectively, in KU812 ImaR than in KU812 P cells (Fig. 5.2.18.C), indicating a dramatic increase of proline synthesis from glutamine in KU812 ImaR cells. Likewise, ¹³C incorporation originating from [U-¹³C]-glutamine in the carbons C3 of glutamate was also higher (3.0-fold up) in KU812 ImaR cells. In contrast, ¹³C incorporation originating from [U-¹³C]-glutamine in C2 and C4 of glutamate and in C5 of ornithine were not significantly different in KU812 ImaR when compared to KU812 P cells. The uniformly labelled glutamate coming from [U-¹³C]-glutamine can be transformed into α -ketoglutarate that can be metabolised through the TCA cycle, generating again a new α -ketoglutarate that will have less ¹³C atoms. Thus, the new α -ketoglutarate molecules will have lost the ¹³C in C4 and C5.

Thus, the higher ¹³C label incorporation in C3 than in C4 is indicative of a higher activity of the TCA cycle in KU812 ImaR than in P cells.

To better elucidate the metabolic role of proline in KU812 ImaR cells, the protein profile of proteins associated with proline metabolism and amino acids closely related to proline metabolism was revisited. The rate limiting enzyme of proline and ornithine synthesis, pyrroline-5-carboxylate synthase (P5CS, also called ALDH18A1), was highly upregulated in KU812 ImaR cells (9.91-fold up). This upregulation was accompanied by the downregulation of the enzyme that catalyses the reverse reaction, the delta-1-pyrroline-5-carboxylate dehydrogenase (P5CDH or ALDH4A1) (17.63-fold down) and of the two isoforms of PYCR 1 and 2 (4.70-fold up and 2.04-fold down). (Figs. 5.2.17). Moreover, the downregulation of P5CS and PYCR at protein levels was also validated by Western blot analysis (Fig. 5.2.18.D). In addition, PRODH, which is the enzyme that catalyses the reverse reaction of PYCR, was also analysed by Western blot analysis due to the fact that it was not observed in the protein profiles. Results showed a downregulation of this enzyme in KU812 ImaR when compared to KU812 P cells (Fig. 5.2.18.D). Therefore, we hypothesise that these enzyme changes observed at mitochondrial level could result in a large increase of the mitochondrial P5C pool. It is also worth mentioning that the enzyme responsible for collagen synthesis, prolyl 4-hydroxylase (P4H), was also upregulated (3.63-fold up) in KU812 ImaR compared to KU812 P cells, suggesting that KU812 ImaR cells may be additionally utilising proline for collagen synthesis purpose.




Figure 5.2.18 Glutamine rewiring to proline metabolism in KU812 cells upon imatinib resistance development. A) Exchange flux differences of proline and ornithine between KU812 parental (P) and imatinib-resistant (ImaR) cells were measured under normoxia as described in section 4.8. Data was normalised to cell number and incubation time. B) Intracellular concentrations of proline and ornithine in KU812 Parental and ImaR cells under normoxia. Data was normalised by the extracted protein. C) ¹³C Glutamine label incorporation in different carbons of glutamate, ornithine and proline in KU812 ImaR compared to KU812 Parental cells under normoxia, determined by NMR analysis. D) Western blot analysis of enzymes related to proline metabolism of KU812 Parental and ImaR cells under normoxia, determined by NMR analysis. D Western blot analysis of enzymes related to proline metabolism of KU812 Parental and ImaR cells under normoxia. Data are provided as mean \pm SD of n = 3 of one representative experiment for **panel A, B and C.** Significance was determined by two-tailed independent sample Student's t-test. Statistically significant differences between KU812 P and ImaR cells are indicated as p≥0,05 (n.s.), p<0.05 (*), p<0.01 (**) and p<0.001 (***).

Furthermore, we examined the protein expression of the mitochondrial amino acid transporters by using protein profile analysis (Tables 1-2 from Appendix 2). SLC25A12 and SLC25A13 transporters, which are involved in the exchange of mitochondrial aspartate for cytosolic glutamate across the inner mitochondrial membrane, showed an upregulation in KU812 ImaR compared to KU812 P cells (Fig. 5.2.17). Consistent with the observed increase of ASNS, the upregulation of these transporters in KU812 ImaR cells indicates an enhanced aspartate/glutamate transport, which can be driven by an increased demand of cytosolic aspartate for asparagine synthesis. Moreover, KU812 ImaR cells also exhibited a dramatic upregulation of ASS1 (31.07-fold up), the rate-limiting enzyme of arginine synthesis, which catalyses the synthesis of arginosuccinate from citrulline and aspartate (Fig. 5.2.17). This fact together with the observed upregulation of the SLC25A12 and SLC25A13 transporters suggests an increased requirement of aspartate in the cytosol to serve the need of aspartate-dependent biosynthetic reactions in KU812 ImaR cells. On the other hand, the upregulation of ASS1 observed in KU812 ImaR cells also suggests an enhancement of the pathway producing arginine and fumarate through the sequential reactions of ASS1 and ASL. In brief, arginine generated through this pathway can be utilised for protein synthesis or be converted again to citrulline through nitric oxide synthase (NOS). Moreover, the resulting fumarate can enter the mitochondria to be converted into malate and pyruvate, thereby fuelling the mitochondrial respiration. Therefore, we hypothesise that KU812 ImaR cells utilise the arginine generated to synthesise both proteins or citrulline via NOS, and the fumarate to fuel mitochondrial respiration. It is also worth mentioning that the mitochondrial ME2, which converts malate into pyruvate within the mitochondria, was also upregulated (3.46-fold up) in KU812 ImaR compared to KU812 P cells, thus reinforcing this hypothesis.

Finally, KU812 ImaR cells exhibited a decrease in the expression of the mitochondrial glutamate/H+ symporter (SLC25A22) (1.66-fold down, which is involved in the glutamate transport across the inner mitochondrial membrane providing glutamate to mitochondrial glutamate dehydrogenase for its conversion to α -ketoglutarate and NADPH. It has been

reported that SLC25A22 knockdown results in lack of ETC functioning and NADPH formation³³⁶.

5.2.2.5 Targeting transport and biosynthesis of proline to investigate the essentiality of proline for the survival of imatinib-resistant cells

The results described in the previous section highlighted proline synthesis as a potential metabolic target that could be further exploited to specifically target imatinib-resistant cells. To this end, we used CRISPR/Cas9 technology (described in **section 4.16**) to individually knockout two important proteins of the proline metabolism, the first enzyme in the proline biosynthesis pathway (P5CS/ALDH18A1) and the sodium-dependent proline transporter (proT/SLC6A7). Next, a competitive growth assay was conducted in order to determine the differential effects on cell proliferation between KU812 P and ImaR non-targeted control (NTC) and KO cells. As depicted in **Fig. 5.2.19**, KU812 P and ImaR KO cells including P5CS and proT KOs slightly reduce the cell proliferation when compared to KU812 P and ImaR NTC cells. Moreover, the decrease of cell proliferation induced by these KOs was significantly higher in KU812 ImaR when compared to KU812 P cells. However, we did not observe a decrease of cell proliferation exceeding 65%.

In order to elucidate the effect of P5CS and proT KOs on proline metabolism in KU812 P and ImaR cells, the proline exchange flux was measured by using the Biocrates AbsoluteIDQ p180 Kit (described in **section 4.8**). Consistent with results mentioned above, KU812 ImaR NTC cells produced proline instead of consuming it as observed in KU812 NTC P cells (**Fig. 5.2.19**). However, the differences between both cell models were not as dramatic as the differences observed between KU812 P and KU812 ImaR cells. Moreover, whereas nonsignificant differences were obtained regarding the proT KO, KU812 ImaR cells showed to stop producing proline upon the P5CS KO, indicating a significant effect of P5CS KO in the KU812 ImaR proline metabolism. All together, these results suggest that even though proline metabolism was altered, at least upon P5CS KO, both P5CS and proT KOs will not serve as feasible strategies to overcome TKI resistance.






Figure 5.2.19 Effect of the knockout of proteins involved in proline synthesis and transportation in KU812 Parental vs. imatinib-resistant cells. A) The percentage of GFP in KU812 Parental (P) and KU812 imatinibresistant (ImaR) non-targeted control (NTC) and knockout (KO) cells was measured every second day by flow cytometry as described in **section 4.17. B)** Cell viability of KU812 P and ImaR NTC and KO cells was illustrated by using the percentage of GFP expression. **C)** The exchange flux of proline was measured by HPLC-MS/MS as described in **section 4.8.** Data were normalised by cell number. Data are provided as mean ± SD of n = 2 (**panel A** and **B**) and as mean ± SD of n = 3 (**panel C**) of one representative experiment. Significance was determined by two-tailed independent sample Welch's t-test or Student's t-test and statistical differences between KU812 P and ImaR-NTC vs. KU812 P and ImaR-KO cells, and between KU812 P-KO cells vs. KU812 ImaR-KO cells for **panel A** and **B**, and between KU812 P NTC vs. KU812 ImaR NTC cells, and KU812 ImaR NTC vs. KU812 ImaR-P5CS KO cells for **panel C** are indicated as p<0.05 (*), p<0.01 (**), and p<0.001 (***).

5.2.2.6 Development of imatinib resistance results in the overexpression of key proteins in ROS and xenobiotics detoxification related pathways

Another metabolite directly linked to glutamate (and consequently to glutamine) metabolism and associated with drug resistance is glutathione^{39,230}. Thus, we investigated if glutamine metabolism was rewired to glutathione synthesis in KU812 ImaR cells. Results showed that total glutathione levels as well as ¹³C incorporation (coming from [U-¹³C]-glutamine) into GSH were lower in KU812 ImaR than in KU812 P cells (**Figs. 5.2.20.A-B**). We next analysed the protein profile of proteins associated with *de novo* glutathione synthesis in KU812 ImaR compared to KU812 P cells. Protein levels of glutamate–cysteine ligase (GCL), both the catalytic and regulatory subunits, were reduced in KU812 ImaR (9.04 and 2.62-fold down, respectively) compared to KU812 P cells (**Fig. 5.2.21.A**). Altogether, these results indicate that the *de novo* glutathione synthesis does not contribute to the increase of glutamine consumption observed in KU812 ImaR cells.





Regarding the protein levels of other proteins associated with glutathione metabolism, glutathione peroxidases (GPx1, GPx4 and GPx7) as well as glutathione-S-transferases including (GSTP1, GSTM1, and GSTM3) were strongly upregulated in KU812 ImaR cells (**Fig. 5.2.21.A**). Of note, it has been described that GPx enzymes play an important role in ROS detoxification³³⁷ and GSTs have been also recognised as key players in the detoxification of ROS and xenobiotics such as drugs³³⁸. Moreover, ROS levels were further analysed to verify our hypothesis. Consistently, a decrease of 18% in the ROS levels of KU812 ImaR was determined when compared to KU812 P cells (**Fig 5.2.21.B**). Therefore, these results highlighted an important role of glutathione in the detoxification reactions in KU812 ImaR cells despite the reduced *de novo* synthesis of glutathione described above. In addition, glutathione uptake has been described in different tissues and cells such as brain cells even though the transporters have not been fully elucidated³³⁹. Thus, we hypothesise that KU812 ImaR cells take up glutathione from the cell media (RPMI-1640 contains 3.3 µM of reduced glutathione) in order to accomplish the detoxification reactions mentioned above. Nevertheless, this hypothesis would require further experimental investigation.




Figure 5.2.21 Protein profile of glutathione metabolism and ROS levels differences in KU812 imatinibresistant compared to KU812 Parental cells. A) The protein expression profiling of proteins related to glutathione metabolism in KU812 imatinib-resistant (ImaR) and Parental cells under normoxia was obtained using SILAC-based proteomic experiments described in **section 4.15**. Log2 fold change values (ImaR *vs* Parental) were calculated as explained in **section 4.15** and represented by green colour = protein upregulation; and red = protein downregulation. **B**) Intracellular ROS levels in KU812 Parental and ImaR cells measured under normoxia as explained in **section 4.6**. Data are provided as mean ± SD of n = 2. Significance was determined by two-tailed independent sample Welch's t-test. Statistically significant differences between KU812 Parental and ImaR cells are indicated as p<0.01 (**).

According to the results above, we next studied if the inhibition of ROS scavenging and detoxification processes, by using the inhibitors RSL-3 (GPx4 inhibitor) and Ezatiostat (GSTP1 inhibitor), could be a good strategy to selectively kill the KU812 ImaR cells. Both inhibitors show antiproliferative effects in KU812 P and ImaR cells (**Fig. 5.2.22**). However, we could not find any significant differences between KU812 P and KU812 ImaR cells with regard to IC₅₀ values.




Figure 5.2.22 Effect of RSL-3 and Ezatiostat inhibitors on the cell viability of KU812 parental and imatinibresistant cells. KU812 parental (P) and imatinib-resistant (ImaR) cells were incubated 72 hours with DMSO (vehicle control) or the increasing concentrations of the corresponding inhibitor. Data are provided as mean \pm SD of n=2 and significance was determined by two-tailed independent sample Welch's t-test.

5.2.2.7 Development of resistance to imatinib implied a reorganisation of mitochondrial metabolism and electron transport chain activities to increase mitochondrial respiration capacity

In order to start exploring the mitochondrial metabolism changes upon imatinib resistance in KU812 CML cells incubated under normoxic and hypoxic conditions, a thorough study of the mitochondrial respiration capacity under normoxia using the Seahorse XF96 Extracellular Flux Analyser was performed (described in **section 4.12**). As shown in **Figs. 5.2.23.A-B**, KU812 ImaR cells exhibited higher basal and maximal respiration capacity compared to KU812 P cells, both after normoxic and hypoxic incubation conditions. Indeed, ATP production was also increased upon imatinib resistance acquisition under normoxic incubation conditions (**Figure 5.2.23.C**). With regard to the ATP production capacity of cells incubated under hypoxic conditions, we also observed an increase tendency of ATP production capacity that was not significantly different due to the high variability of the replicates. As mentioned above, KU812 ImaR relative to KU812 P cells increased the cell volume by 38% during the acquisition of imatinib resistance, so it could be that the increase of mitochondrial respiration capacity observed above could be due to the increase of KU812 ImaR cell volume. The translocase of outer mitochondrial membrane 20 (TOMM20) has been shown to correlate with mitochondrial mass and function³⁴⁰ and, interestingly, TOMM20 protein expression was 2.3-fold higher in KU812 ImaR relative to KU812 P cells (**Table 1 from Appendix 2**). For this reason, the mitochondrial respiration capacity results were additionally normalised to the log₂ fold change of the protein TOMM20 (**Fig. 3 from Appendix 2**). Results showed that both the basal and maximal respiration and the ATP production per mitochondrial mass were significantly higher in KU812 ImaR than in KU812 P cells.

We next assessed the contribution of different metabolic sources including glutamine, pyruvate (from glucose or other carbon sources) and FAO to mitochondrial respiration capacity in both cell lines incubated in both normoxic and hypoxic conditions. As depicted in **Fig. 5.2.23.C**, these substrates entailed more than 80 % of the O₂ consumption in KU812 P cells incubated in both normoxic and hypoxic conditions, but they contributed to a much lower extent to O₂ consumption in KU812 ImaR cells (36 % under normoxic incubation conditions and 54 % under hypoxic incubation conditions). Thus, results suggest that KU812 ImaR cells may be utilising other sources rather than pyruvate, glutamine or FAO to perform mitochondrial respiration.




Figure 5.2.23 Characterisation of mitochondrial respiration in KU812 imatinib-resistant vs. KU812 Parental cells. A, B and C) OCR values were measured under normoxia during sequential injection of oligomycin, CCCP, and Rot+Ama in KU812 Parental and imatinib-resistant (ImaR) cells previously incubated under normoxic and hypoxic conditions. Basal and maximal respiration of cells incubated under normoxic (panel A) and hypoxic (panel B) conditions were calculated as described in section 4.12. ATP production-associated respiration of KU812 Parental vs. ImaR cells previously incubated under normoxic and hypoxic conditions (panel C) were calculated as explained in section 4.12. D) Fatty acid, glutamine and glucose/pyruvate contributions to mitochondrial respiration in KU812 Parental and ImaR cells previously incubated under normoxic and hypoxic conditions were determined by measuring OCR under normoxia during sequential injections of Etomoxir, BPTES, UK5099 and Oligomycin inhibitors. For panel A, B and C cells were first incubated with KHB Buffer in the presence of glucose and glutamine. For panel D, cells were first incubated with DMEM media in the presence of glucose and glutamine. Data were normalised by protein. Data are provided as mean ± SD of n=3. Significance was determined by two-tailed independent sample Student's t-test. Statistically significant differences between KU812 P and ImaR cells incubated under normoxic or hypoxic incubation conditions are indicated as p≥0.05 (n.s.), p<0.05 (*), p<0.01(**), and p<0.001(***).

To complete the characterisation of the mitochondrial metabolism, we further looked at the protein profile of proteins involved in the mitochondrial metabolism. Results exhibited higher expression of several proteins of the TCA cycle including CS, ACO2, OGDH, SDH, and MDH in KU812 ImaR compared to KU812 P cells (**Fig. 5.2.24**). Regarding the pyruvate metabolism, the pyruvate carboxylase, which catalyses the conversion of pyruvate to oxaloacetate, was downregulated by a fold of 8.70-fold down KU812 ImaR compared to KU812 P cells, suggesting that pyruvate entrance into TCA cycle occurs via pyruvate PDH. In agreement, even though non-significant differences were found with regard to PDH or PDP in KU812 ImaR cells, we did observe an 2.6-fold increase of the regulatory subunit of pyruvate dehydrogenase phosphatase regulatory subunit (PDPR), which plays a role in PDH activation. Moreover, KU812 ImaR cells also showed a 3.5-fold increase in the NAD-dependent mitochondrial isoform of ME2, suggesting that KU812 ImaR cells can redirect mitochondrial malate to form pyruvate.




Figure 5.2.24 Protein profile differences of KU812 imatinib-resistant when compared to KU812 Parental regarding its mitochondrial metabolism and mitochondrial-complementary metabolic pathways. The protein abundances of proteins related to pyruvate and mitochondrial metabolism under normoxia were obtained using SILAC-based proteomic experiments described in section 4.15. Log₂ fold change values were calculated as explained in section 4.15 and represented by green colour = protein upregulation; and red = protein downregulation. Data are provided as mean ± SD of n=2.

The mitochondrial network is characterised by the final ATP production through the coupled integration of the ETC with oxidative phosphorylation. In our study, we have demonstrated that KU812 cells increased mitochondrial respiration capacity upon the acquisition of imatinib resistance. For that, we next examined the protein profile data (shown in **Tables 1-2 from Appendix 2**) of proteins involved in the ETC function. **Fig. 5.2.24** depicted an overall upregulation of proteins associated with the ETC in KU812 ImaR relative to KU812 P cells. In particular, KU812 ImaR exhibited a higher protein expression of the SDH (complex II), CYCS, and the ATP synthase (ATP5) subunits (complex V) including ATP5C1, ATP5E, ATP5F1, ATP5H, ATP5I, ATP5J2, ATP5J2, ATP5L, and ATP5O, when compared to KU812 P cells. On the other hand, non-significant differences were observed in catalytic protein subunits associated with complex I, III and IV between KU812 P and ImaR cells.

In light of the upregulation of key proteins for ETC function, we next investigated the differences in ETC complex activities associated with imatinib resistance acquisition by using permeabilised cells and measuring OCR using the Oroboros Oxygraph-2k respirometer after the injection of different inhibitors and substrates (approach described in section 4.13). Figure 5.2.25.A showed that complex I activity was significantly lower in KU812 ImaR relative to KU812 P cells when complex I substrates malate and glutamate were only added. Moreover, complex I activity only increased in KU812 ImaR cells until pyruvate was further added. This result suggests that the complex I activity of KU812 ImaR cells turned out to be dependent on pyruvate, unlike in KU812 P cells, whose mitochondria were able to consume O₂ even with only malate as substrate. Regarding the complex II activity, KU812 ImaR cells exhibited the same activity than KU812 P cells when succinate was added as a substrate (Fig. 5.2.25.B). Finally, a lower maximal activity of complex IV was observed in KU812 ImaR cells when compared to KU812 P cells (Fig. 5.2.25.C). However, the OCR measured during the sequential activity of either complexes I+III+IV or complexes II+III+IV, was not significantly different between KU812 P and ImaR cells. These results point out that the available complex IV in KU812 ImaR cells has enough capacity to absorb the electrons

coming from previous complexes and that the control of the ETC relies on the previous steps.




Figure 5.2.25 Activity of the different electron transport chain complexes of KU812 imatinib-resistant vs. KU812 Parental cells. Oxygen consumption rate (OCR) was measured after sequential injections of substrates and inhibitors using a two-channel, high-resolution Oxygraph respirometer under normoxia as indicated in section 4.13. Data were analysed using DatLab7 software. For A (approach to study of complex I activity): 2mM malate + 5mM ADP (M), 10mM glutamate (G), and 5mM pyruvate (P). For B (approach to study complex II activity): 10mM succinate + 5mM ADP (S). For C (approach to study complex IV activity): 5mM Ascorbate + 5mM ADP + 0.5mM tetramethyl-p-phenylendiamine dihydrochloride (TMPD). Data were normalised by cell number. Data are provided as mean \pm SD of n = 3 and significance was determined by two-tailed independent sample Student's t-test. Statistically significant differences between KU812 P and ImaR cells are indicated as $p\geq0.05$ (n.s.), p<0.05 (*), and p<0.01(**). Abbreviations: glutamate, G; malate, M; pyruvate, Pyr; and succinate, S.

Next, we intended to address whether the differences of complex I and IV activities observed in KU812 ImaR when compared to KU812 P cells were due to the imatinib-resistance acquisition or merely to the imatinib treatment. Therefore, complex I, II and IV activities were measured in KU812 P cells treated for 72h with imatinib (from here named KU812 Treated). As shown in **Figs. 5.2.26.A-B**, acute drug exposure to imatinib did not induce complex I pyruvate dependency and neither reduce complex IV activity in KU812 P cells. Moreover, no significant differences were found regarding complex II activity (**Fig. 5.2.26.C**). Thus, we confirmed that the mitochondrial phenotype exhibited in this study by KU812 ImaR cells was due to the imatinib resistance acquisition.




Figure 5.2.26 Activity of the different electron transport chain complexes of KU812 Imatinib-treated vs. KU812 Parental cells. OCR measurements of KU812 Parental and Treated (KU812 Parental cells treated with 80nM imatinib for 72 hours) were determined by Oroboros Oxygraph-2k respirometer under normoxia. OCR were measured after sequential injections of substrates and inhibitors. For A (approach to study complex I activity): 2mM malate + 5mM ADP + 10mM glutamate (M+G), and 5mM pyruvate (P). For B (complex IV activity): 5mM Ascorbate + 5mM ADP + 0.5mM tetramethyl-p-phenylendiamine dihydrochloride (TMPD). For C (approach to study complex II activity): 10mM succinate + 5mM ADP (S). Data were normalised by cell number. Data are provided as mean \pm SD of n = 2 and significance was determined by two-tailed independent sample Welch's t-test. Statistically significant differences between KU812 P and Treated cells are indicated as $p \ge 0.05$ (n.s.).

5.2.2.8 Development of resistance to imatinib enhance mitochondrial Glycerol-3phosphate dehydrogenase expression and branched-chain amino acids metabolism

Since we observed an increase of mitochondrial respiration capacity in KU812 ImaR cells together with the above-mentioned alterations in the mitochondrial metabolism, we further investigated alternative fuelling pathways of mitochondrial respiration. It has been already explained that the GP shuttle plays an important role in bypassing the complex I during cytosolic NADH oxidation²¹⁰. Therefore, we hypothesised that GP shuttle could contribute to the higher mitochondrial respiration capacity observed in KU812 ImaR cells. Differences in the expression profiling of proteins involved in this pathway between KU812 P and ImaR cells were firstly examined. As mentioned in **section 5.2.2.2**, there was a significant upregulation (FD=1.8) of the mitochondrial isoform GPD2 (**Fig. 5.2.10**).

Furthermore, OCR rates were measured by Oroboros Oxygraph-2k respirometer in both permeabilised KU812 P and ImaR cells after the addition of GP. **Fig. 5.2.27.A** shows that there was an increase of mitochondrial respiration when GP was added in KU812 ImaR relative to KU812 P cells, thus confirming a correlation between GPD2 upregulation and its contribution to mitochondrial respiration capacity in KU812 ImaR cells.

Next, we examined if the GPD2-dependent mitochondrial respiration observed in KU812 ImaR cells was due to imatinib resistance acquisition or to imatinib treatment by comparing OCR measurements of KU812 P versus KU812 Treated cells. We observed that KU812 Treated cells were not able to increase mitochondrial respiration after GP addition (**Fig. 5.2.27.B**), thus confirming that the mitochondrial phenotype exhibited by KU812 ImaR cells regarding GP shuttle was due to the acquisition of resistance to imatinib. Nevertheless, when GPD2 was inhibited in both parental and ImaR cells by adding iGP-1 inhibitor³⁴¹, only 60% of decrease of KU812 ImaR and P cells viability was obtained (**Fig. 5.2.27.C**) even though concentrations up to 1mM were added.




Figure 5.2.27 Contribution of glycerol-3-phosphate shuttle to the mitochondrial respiration of KU812 imatinib-treated or KU812 imatinib-resistant vs. KU812 Parental cells. A and B) OCR measurements of KU812 imatinib-resistant (ImaR) vs. KU812 Parental (P) (Panel A), and KU812 Treated (KU812 P cells treated with 80nM imatinib for 72 hours) vs. KU812 P cells (panel B) previously incubated under normoxic conditions determined under normoxia by Oroboros Oxygraph-2k respirometer. OCR were measured after sequential injections of 10mM Gp + 5mM ADP, 10mM succinate + 5mM pyruvate + 2mM malate, 5mM malonic acid, and 0.5 μ M rotenone + 2.5 μ M antimycin. Data were normalised by cell number and recorded parameters were calculated as explained in section 4.13. C) Effect of iGP-1 inhibitor on the cell viability of KU812 P and ImaR cells. Cells were incubated for 72 hours with DMSO (vehicle control) or different concentrations of iGP-1. Data are provided as mean \pm SD of n = 2 and significance was determined by two-tailed independent sample Welch's t-test. Statistically significant differences between KU812 P and Treated cells, and KU812 P and KU812 ImaR are indicated as p≥0.05 (n.s.) and p<0.05 (*).

As BCAAs catabolism has also been described to fuel the TCA cycle, thus contributing to the mitochondrial respiration, we decided to further study their metabolism. First, we determined the exchange fluxes and the intracellular content of isoleucine, leucine, and valine under normoxia and hypoxia. **Figure 5.2.28.A** depicts that there was a higher consumption of BCAAs in KU812 ImaR than in parental cells under normoxia. However, non-significant differences were determined regarding BCAAs exchange fluxes under hypoxia. Moreover, a higher intracellular content of isoleucine and leucine was observed in KU812

ImaR cells under normoxia and hypoxia, while there were no significant differences regarding the intracellular content of valine (**Fig. 5.2.28.B**).

In parallel, the intracellular content of the BCAA degradation products C3, C4 and C5 ACs was determined in KU812 P and ImaR cells under normoxia. As shown in **Fig. 5.2.28.C**, KU812 ImaR cells showed higher intracellular levels of this three ACs when compared to KU812 P cells, indicative of a higher BCAAs catabolism in KU812 ImaR relative to KU812 P cells.




Figure 5.2.28 Exchange fluxes and intracellular content of BCAAs and acylcarnitines in KU812 Parental and imatinib-resistant cells. A and B) Exchange fluxes (A) and intracellular content (B) of isoleucine, leucine and valine in KU812 Parental and imatinib-resistant (ImaR) cells under normoxia (Norm) and hypoxia (Hyp) were measured by HPLC-MS/MS as described in **section 4.8**. C) Intracellular content of C3, C4 and C5 acylcarnitines in KU812 Parental and ImaR cells were measured by HPLC-MS/MS. Data are provided as mean \pm SD of n = 3 of one representative experiment. Significance was determined by two-tailed independent sample Student's t-test. Statistically significant differences between KU812 Parental and ImaR cells are indicated as p \ge 0.05 (*), and p<0.01 (**).

Given that KU812 ImaR cells exhibited a higher consumption of BCAAs under normoxia, we also analysed the protein profile of proteins associated with the transport and catabolism of BCAAs in KU812 ImaR relative to KU812 P cells under normoxia. Consistent with the higher flux of BCAAs observed above, two main BCAA transporters SLC7A5 (also referred as LAT1) and SLC3A2 were significantly upregulated by a FD of 1.73 and 1.84, respectively, in KU812 ImaR cells (Fig. 5.2.29). Moreover, BCAT 1 and 2 and branched-chain keto acid dehydrogenase (BCKD) HA and HB were significantly downregulated in KU812 ImaR cells. It is worth mentioning that the enoyl-CoA hydratase (ECHS1), which is an essential enzyme involved in valine catabolism but not in leucine and isoleucine catabolism³⁴², was significantly upregulated by a FD of 1.9 in KU812 ImaR relative to KU812 P cells. Of note, the end-product of isoleucine and leucine oxidation is acetyl-CoA (metabolic fuel of ETCcomplex I), whereas succinyl-CoA (metabolic fuel of ETC-complex II substrate) is the end product of valine oxidation. Altogether, these results suggest that even though the higher flux of the three BCAAs observed in KU812 ImaR cells, they may be prioritising the oxidation of valine to fuel the TCA cycle through succinyl-CoA, while isoleucine and leucine were accumulated as fuel reserve.






Figure 5.2.29 Protein profile of BCAAs transport and catabolism in KU812 imatinib-resistant vs. KU812 **Parental cells.** The protein expression profiling of proteins related to BCAAs catabolism under normoxia was obtained for KU812 Parental and imatinib-resistant (ImaR) cells using SILAC-based proteomic experiments described in **section 4.15**. Log₂ fold change values (ImaR vs Parental cells) were calculated as explained in **section 4.15** and represented by green colour = protein upregulation; and red = protein downregulation. Data are provided as mean ± SD of n=2.

5.2.2.9 The acquisition of imatinib resistant alters the fatty acid metabolism of KU812 cells

The oxidation of FAs provides Acetyl-CoA to be used in the TCA cycle, and NADH and FADH₂ coenzymes to be used in the ETC, whereas FA synthesis provides building blocks for cellular structures³⁴³. In order to examine FAO and FA synthesis upon the acquisition of imatinib resistance, we firstly analysed the protein profile of proteins involved in these pathways. Secondly, we explored the FAO dependency as another alternative pathway fuelling the mitochondrial respiration of KU812 ImaR relative to KU812 P cells incubated under normoxic conditions by performing a FA Mitofuel test under normoxia using the Seahorse

XF96 Extracellular Flux Analyser (described in **section 4.12**). As depicted in **Figure 5.2.30**, key controlling enzymes involved in FAO (CPT1A; and ACAT1) were significantly upregulated by a 1.76 and 3.61-fold down, respectively, in KU812 ImaR cells. Moreover, mitochondrial respiration capacity of KU812 ImaR was much less dependent on FAO than for KU812 P cells (**Fig. 5.2.31**). Altogether, these results suggest that FAO may not be the cause of the increase of mitochondrial respiration capacity in KU812 ImaR cells observed above. On the other hand, proteins associated with FA synthesis such as the mitochondrial citrate transporter (SLC25A1) and the acetyl-CoA carboxylase alpha (ACACA) proteins were significantly upregulated (2.06 and 3.46-fold up, respectively) in KU812 ImaR compared to KU812 P cells, thereby indicating an alteration of FA synthesis in KU812 cells upon the imatinib resistance acquisition.








Figure 5.2.31 Fatty acid contribution to mitochondrial respiration of KU812 imatinib-resistant vs. KU812 Parental cells. Dependency of mitochondrial respiration to fatty acid oxidation of KU812 Parental (P) and imatinib-resistant (ImaR) cells incubated under normoxic conditions was calculated by measuring under normoxia the OCR value during sequential injections of Etomoxir, BPTES, UK5099 and Oligomycin inhibitors. Cells were first incubated with DMEM in the presence of glucose and glutamine. Data were normalised by protein. The percentage of dependency to fatty acid oxidation was calculated as explained in **section 4.12**. Data are provided as mean ± SD of n=3 and significance was determined by two-tailed independent sample Student's t-test. Statistically significant differences between KU812 P and KU812 ImaR are indicated as p<0.05 (*). Abbreviations: fatty acid oxidation, FAO.

5.2.2.10 The repurposing of Doxorubicin showed to be an effective strategy to overcome TKI resistance in KU812 cells

In **Chapter 1**, we have shown that exposure to Dox significantly reduced the mitochondrial respiration capacity of cells with high mitochondrial activity. Moreover, previous studies also reported that Dox treatment alter the mitochondrial respiration of B-lymphocytes³⁴⁴. The fact that our results unveiled that KU812 ImaR cells exhibit a higher mitochondrial respiration capacity that is less dependent from canonical carbon sources (e.g. amino acids, glutamine and glucose) than KU812 P cells prompted us to hypothesise that Dox treatment could reduce the cell viability of KU812 ImaR stronger than of KU812 P cells. The results obtained when treating KU812 P and ImaR cells with Dox validated our hypothesis. Thus, we obtained a 13-fold lower IC₅₀ value in KU812 ImaR relative to KU812 P cells after Dox treatment (**Fig. 5.2.32**), indicating that Dox treatment could be a suitable treatment approach to overcome imatinib resistance in CML cells.




Figure 5.2.32 Effect of Doxorubicin chemotherapeutic on the cell viability of KU812 Parental and imatinibresistant cells. KU812 Parental (P) and imatinib-resistant (ImaR) cells were incubated 72 hours with DMSO (vehicle control) or different concentrations of Doxorubicin. Data are provided as mean \pm SD of n = 2 and significance was determined by two-tailed independent sample Welch's t-test. Statistically significant differences between KU812 P and KU812 ImaR are indicated as p<0.05 (*).

6. DISCUSSION

6 **DISCUSSION**

Despite the great achievements made during the past decades, resistance to chemotherapeutic drugs continues to be a major problem in leukaemia treatment³⁴⁵. The mechanisms of drug resistance in leukaemia are still not clear. Indeed, many studies have revealed that drug resistance acquisition may be a result of multiple factors. For instance, Zhang et al. reviewed the three common mechanisms of drug resistance in AML cells including drug resistance-related protein and enzymes, miRNAs alterations, and autophagy²⁹. On the other hand, similar and additional mechanisms of resistance have been revealed regarding the acquisition of resistance to imatinib in CML cells (e.g. lower oral bioavailability, increase of plasma protein binding, overexpression of multidrug resistance genes, BCR-ABL1 point mutations, and BCR-ABL1 gene amplification) (reviewed in ³⁴⁶). In the last years, it has emerged that metabolic rewiring may play a relevant role in the development of resistance in leukaemia that can be exploited for the development of new chemotherapeutic drugs.

In this thesis, we have unveiled the importance of the metabolic changes in the process of the acquisition of resistance to common chemotherapeutic drugs in AML and CML. To this end, we have performed a comprehensive metabolic characterisation of AML cells sensitive or resistant to the conventional AML chemotherapeutic drugs, AraC and Dox (**Chapter 1**); and of CML cells sensitive or resistant to TKIs, and particularly to imatinib which is the standard drug of CML treatment (**Chapter 2**). These studies were performed both under normoxic and hypoxic incubation conditions.

Our results revealed that, upon the acquisition of drug resistance, leukaemic cells remodel many of the main metabolic pathways, and that this metabolic rewiring is not unique. Thus, most of the here studied metabolic pathways have shown a reprogramming that is in some cases associated with the chemotherapeutic drug (drug-dependent) while for others depend on the initial metabolic phenotype of the leukemic cells (cell-line dependent).

Leukaemia parental cell lines display different metabolic phenotypes

Glycolysis and mitochondrial respiration are two major energy-yielding pathways. In this thesis, we have demonstrated that AML parental cell lines can display completely opposite metabolic profiles. Although our THP-1 and HL-60 parental AML cell lines exhibited a similar glycolytic phenotype under normoxic and hypoxic conditions, THP-1 P cells presented a greater mitochondrial respiration capacity than HL-60 P cells. And most importantly, this greater mitochondrial respiration capacity seems to be related with a higher consumption and metabolism of some amino acids, especially those that are precursors of TCA cycle intermediates. The observed differences regarding the initial metabolic phenotypes in AML cells provided the answer to the first specific objective of this thesis and, additionally, raised the fact that the metabolic reprogramming derived from the acquisition of AraC and Dox resistance exhibit differences that are dependent on the initial metabolic phenotype of the AML cell line of study (cell-line dependent).

In the case of CML, we have only used a cell line (KU812) so we cannot conclude if there are distinct metabolic profiles among CML cell lines. In any case, our results showed that KU812 P cell model exhibited a similar metabolic profile to the THP-1 cell model at the level of glycolysis and mitochondrial respiration capacity. Moreover, the metabolic alterations observed upon the acquisition of imatinib resistance including the increase of glycolytic flux and mitochondrial respiration capacity were overall similar to the observed changes in THP-1 cells upon the acquisition of AraC resistance.

Reprogramming of metabolism plays a key role in the acquisition of AraC, Dox and imatinib resistance of the studied AML and CML cell models.

Although in literature, there was some evidence of the relevant role of metabolic reprogramming in leukaemia drug resistance acquisition, there were no publications that could demonstrate this conjecture from a systems biology point of view. Therefore, in this thesis we have explored the protein expression levels of our four resistant AML cell lines (**Chapter 1**) and the resistant CML cell line (**Chapter 2**) under normoxic conditions using

SILAC-based protein mass spectrometry experiments. The analysis of the most enriched biological processes has revealed that both cellular processes and metabolic processes were overall the most altered biological processes during the acquisition of AML and CML resistance to common chemotherapeutic drugs. These findings reinforce the idea to carry out the main objective of our thesis "to investigate the rewiring of cell metabolism occurring in the process of resistance acquisition to different conventional therapeutic treatments in AML and CML haematological malignancies" and encouraged us in the subsequent search for similarities and differences in metabolic changes associated with the acquisition of resistance to the different drug studied in the different cell models.

Hereafter, the results obtained and discussed in the context of each cell model are globally examined to highlight the major features observed in terms of metabolic reprogramming that are common for all the resistant cell lines (i.e. due to the drug resistance acquisition), or that are cell line or drug dependent.

Glycolytic flux: The effects of the drug resistance

It is well-known that cancer cells rewire their metabolism to promote cell proliferation and survival. Indeed, one of the common metabolic alterations in the majority of cancers including AML and CML is increased glycolysis^{263,280,282,348,349}. To our knowledge, few metabolic studies have been conducted for AML cells resistant to AraC and Dox chemotherapeutic drugs^{260,285,350}. In the case of CML cells, it has been shown that glycolysis is even more increased in CML cells resistant to imatinib when compared to CML cells non-resistant to imatinib^{117,261}. It is worth noting that these studies were only performed under normoxia. For all these reasons, we decided to carry out two of the specific objectives of this thesis, the characterisation of the metabolic profiles of (1) two different AML cell models and (2) a CML model, under two different oxygen incubation conditions (normoxia and hypoxia).

Our results are unique in that they reveal that AML cells, which are characterised by a very dissimilar initial metabolic phenotype (described in **Chapter 1, section 5.1.2.1**), are both

able to acquire a more glycolytic phenotype upon AraC resistance under both normoxic and hypoxic incubation conditions. With regard to Dox resistance acquisition in AML cells, our results unveiled that the acquisition of Dox resistance correlates with a lower glycolytic phenotype under normoxia. However, the effect of Dox resistance on the glycolytic flux under hypoxia is less evident. Thus, the effect of Dox resistance on the glycolytic flux varies depending on the AML cell line and on the oxygen conditions to which cells were exposed.

Furthermore, the metabolic characterisation of KU812 CML cells resistant to imatinib, showed that the resistant cells increase the glycolytic flux upon the acquisition of imatinib resistance under both normoxic and hypoxic incubation conditions. This metabolic phenotype is similar to the one observed for the AML cells (THP-1 and HL-60) upon the acquisition of AraC resistance, a fact that encourages us to further study possible phenotypic links between the acquisition of AraC and imatinib resistance. Noteworthy, a similar metabolic phenotype has been described for K562 CML cell line resistant to imatinib under normoxia²⁶¹. And, to our knowledge, CML cell's metabolic reprogramming associated with imatinib resistance under hypoxic incubation conditions has not been previously reported in the literature.

The analysis of the protein expression changes upon the acquisition of AraC and imatinib resistance revealed that, even though glycolysis showed to be a metabolic process closely related to the acquisition of AraC and imatinib resistance, the metabolic reprogramming at protein expression level is achieved following a different strategy. In fact, both THP-1 AraC and KU812 ImaR cells showed even a downregulation of some key proteins related to the glycolysis pathway (e.g. GLUTs, HK, PK, etc.). Nevertheless, the data obtained from the protein profile analysis interestingly suggest that both THP-1 AraC and KU812 ImaR cells may be counteracting these observed protein downregulations by upregulating the expression of proteins belonging to alternative pathways associated with glycolysis (as it happens in KU812 ImaR cells) or by dramatically downregulating the FBP protein, the negative regulator of glycolysis³⁵¹ (as it happens in THP-1 AraC cells). In brief, we speculate that the main determinants are the increase of GLUT1 glucose transporter in HL-60 AraC cells, the decrease of FBP1 in THP-1 AraC cells, and the increase of GLUT5 and proteins

associated with the insulin-dependent glucose uptake via translocation of GLUT4 in KU812 ImaR cells.

Pentose phosphate pathway and glycogenolysis: key metabolic features and vulnerabilities of KU812 CML cells resistant to imatinib

PPP has been revealed to play a relevant role in proliferation and redox homeostasis of cancer cells, so it was of our interest to explore since which point this pathway may have a relevant role in drug resistance acquisition. In this thesis, this pathway has been deeply studied in Chapter 2, and only protein expression levels were analised in Chapter 1.

In the case of the here studied CML resistant cell model, we have observed that imatinib resistance development has enhanced both the oxidative and non-oxidative branches of the PPP, concurring with the results reported by Noel *et al.* using K562 imatinib-resistant cells²⁶¹. This fact led to the hypothesis that KU812 ImaR cells may require more R5P, which plays a vital role for nucleotide synthesis, and NADPH, which is essential for fatty acid and proline synthesis, redox homeostasis and ROS scavenging¹⁰⁵. In fact, all these processes are significantly upregulated in KU812 ImaR cells (discussed in more detail below). As an example, the protein profile results of CML resistant vs. parental cells highlighted an overall upregulation in the expression of proteins associated with FA synthesis (shown in **Chapter 2, section 5.2.2.9**). Moreover, our group and others have previously described the role of TKTL1 in major metabolic reprogramming processes of cancer cells¹¹⁵. Interestingly, TKTL1 was one of the most upregulated proteins in the protein profile results. A study performed by Zhao *et al.* (2010) revealed that the inhibition of TKTL1 by oxythiamine enhanced imatinib sensitivity in hematopoietic cells¹¹⁷. Therefore, we propose TKTL1 inhibition as a possible strategy for TKI resistance overcoming.

With regards to AML resistant cells, we have observed a downregulation of proteins of the oxidative PPP in THP-1 AraC cells, whereas non significative changes were observed in the other resistant AML cell lines compared with their parental controls. All together, we can

conclude that the reprogramming of PPP depends on both drug and cell line, and its role in drug resistance should be studied individually attending to specific needs of each cell line.

Furthermore, our results revealed that KU812 ImaR cells ensure an enhanced PPP flux thanks in part to an activation of glycogen synthesis and glycogenolysis, similarly to the results shown in a study performed with T-cells³⁵². These results underlined the inhibition of glycogenolysis as a possible therapeutic strategy to overcome imatinib-resistant in this CML-resistant cell model. The inhibition of glycogenolysis by DAB, CP-320626, or CP-91149 did not substantially affect more the cell viability of KU812 ImaR cells but it decreased the cell viability of both KU812 P and ImaR cells. Thus, the inhibition of glycogenolysis may be a good therapeutic strategy in CML patients whose initial metabolic phenotype is similar to the CML parental and resistant cell models here studied. It is worth noting that no changes in glycogen phosphorylase were observed in any of our AML resistant cell models.

Mitochondrial metabolism: a key metabolic player in the acquisition of resistance to leukemic chemotherapeutic drugs

The metabolic studies conducted throughout this thesis have pointed out the importance of the mitochondrial metabolism in the metabolic reprogramming associated with the drug resistance acquisition in AML and CML leukaemic cells. Mitochondrial metabolism is not only involved in energy production but also in ROS homeostasis regulation, which are essential processes for cancer cell growth and spreading. Our results highlight the importance of knowing the mitochondrial metabolic state of each sensitive/parental AML cell models to understand and anticipate the mechanisms by which these cells will evade/adapt the mitochondrial effects of the specific drugs.

Specifically, in the AML cell models used here, the acquisition of AraC resistance did not induce changes regarding the mitochondrial respiration capacity, opposite to previous studies performed in residual AML cells resistant to AraC (i.e. innately resistant to AraC) that reported an elevation of mitochondrial activity, mitochondrial respiration and a high OXPHOS²⁶⁰. This result has shed light on the metabolic differences between innate and

acquired resistant cell lines to AraC chemotherapeutic drug. Moreover, the protein profile analysis underlined a possible dysfunction of complex I in AraC resistant cells that seemed to be counteracted with an increase in the expression of proteins associated with complex II and IV protein expressions. However, this counteraction was only found in THP-1 AraC cells, thus reinforcing the hypothesis that mitochondrial alterations are more noticeable in cells with a more active mitochondrial metabolism. However, this fact needs experimental substantiation (e.g. measurement of the ETC complex specific activities).

On the other hand, the mitochondrial studies of Dox resistance unveil dramatic alterations in the mitochondrial metabolism of AML cells characterised by a remarkably active mitochondrial respiration capacity (i.e. THP-1 Dox cells). Regarding the protein profile analysis of Dox resistant vs. parental AML cells, our results exhibited an overall upregulation of proteins associated with the TCA cycle and OXPHOS in the THP-1 cell line (mitochondrially more active) but not in the HL-60 cell line (mitochondrially less active). A recent study performed by Wallace et al. unveiled that Dox treatment causes a phenomenon called "induction of the mitochondrial permeability transition" in cardiac cells, which is the mitochondrial ability to develop and maintain electrochemical gradients across the IMM through the opening of mitochondrial permeability transition pores³⁵³. This finding led us to speculate that the same phenomenon may have occurred in THP-1 Dox cells, thus explaining the decrease in mitochondrial respiration capacity observed in this cell line. In this line, we also speculate that THP-1 Dox may have upregulated the entire mitochondrial machinery to compensate for the dramatic effect of Dox treatment on mitochondrial permeability. Regarding HL-60 Dox cells, we hypothesise that the effect of Dox treatment on the mitochondrial permeability is also occurring but, on the contrary, it has not affected the mitochondrial respiration capacity because HL-60 cells themselves have low mitochondrial activity. Nevertheless, this hypothesis needs further experimental validations, for example, measuring mitochondrial membrane potential in both AML parental and Dox-resistant cell models.

The same experimental approaches and analysis conducted in **Chapter 1** were performed for the here studied CML parental and resistant cell models (KU812 P and ImaR cell lines).

Our results highlight the fact that the metabolic phenotype determined for KU812 P cells is similar to the one obtained for THP-1 P cells in that they exhibit a remarkably active mitochondrial metabolism (shown in **Section 5.2.2.7**). This fact together with the above results encouraged us to explore the mitochondria as a potential vulnerability in the here studied CML resistant cell model. As shown in **Section 5.2.2.7**, we did find a striking shift to a more mitochondrial-dependent phenotype in KU812 ImaR cells relative to KU812 P cells both at mitochondrial respiration and protein expression levels and both under normoxic and hypoxic incubations conditions, which is opposite to the mitochondrial metabolism disruptions recently described in another CML cell model (K562 cell line) resistant to imatinib²⁶¹. Considering this finding together with what we observed in the AML study conducted in this thesis (**Chapter 1**), we speculate that the metabolic reprogramming occurring upon the acquisition of imatinib resistance may vary depending on the initial metabolic phenotype of the cell model of study.

Furthermore, in the case of the CML resistant cell we conducted a more thorough study of mitochondrial function, including ETC complex specific activities. Our results showed that despite the mitochondrial respiration capacity was higher in KU812 ImaR relative to KU812 P cells, the specific activity of complexes I and IV were lower in KU812 ImaR than in KU812 P cells. This finding prompted our next question: How did KU812 ImaR cells acquire a more mitochondrial capable phenotype upon imatinib resistance despite the lower specific activities of the ETC complexes?

Interestingly, we proved that KU812 ImaR cells can utilise the GP shuttle as an alternative contributor to mitochondrial respiration. In brief, although NADH oxidation by GP shuttle is energetically less efficient than NADH oxidation by complex I due to the lack of proton pumping activity by GPD2, it still contributes to the OXPHOS for the ATP generation²¹⁰. Therefore, we theorise that KU812 ImaR cells may be counteracting the lower efficiency of complex I and IV activities via GP shuttle and, thereby, contributing to the increased mitochondrial respiration capacity observed in these cells when compared to its parental counterpart. Likewise, the higher flux of BCAAs determined in KU812 ImaR relative to KU812 P cells together with protein profile results of proteins associated with BCAAs transport and

catabolism (shown in **Section 5.2.2.8**) also suggest that KU812 ImaR may be fuelling the TCA cycle via valine but not via isoleucine and leucine, thus additionally contributing to the increased mitochondrial respiration.

The compensation of the extracellular acidification contribution via mitochondrial respiration constitutes a common feature for AraC and Imatinib resistant cells

Acidic extracellular pH is a well-known feature of cancer cells. Cancer cells have successfully controlled proton production and excretion in order to maintain their own cellular activation, increase drug resistance and become more aggressive³⁵⁴. In fact, it has been reported that extracellular acidic pH increases the proliferation and reduces the Dox-induced apoptosis in ALL³⁵⁵.

Despite the fact that the glycolytic production of lactate is considered the major component of extracellular acidification (i.e. extracellular H⁺ production), lately it has been reported that the CO₂ produced during mitochondrial respiration also contributes to the extracellular acidification rate (ECAR)³⁵⁶. Moreover, this CO₂-derived contribution has been described to differ between cell types³⁵⁶. In this thesis, we have demonstrated the importance of the CA enzymes and the SLC4A7 transporter in the contribution to the extracellular acidification associated with CO₂, that appears to be relevant for acidification control both in AML and CML resistant cells. In particular, our results suggest that both THP-1 AraC and KU812 ImaR cells may be compensating the ECAR contribution via mitochondrial respiration through two mechanisms: the decreased contribution of CAs to the ECAR rate and the increased contribution of intracellular bicarbonate balance through extracellular HCO₃ import, both inducing a decrease of intracellular H⁺ levels. However, these common features for THP-1 AraC and KU812 ImaR resistant cells were not found in the HL-60 AraC resistant cells. Due to this, we hypothesise that this proton regulator mechanism is dependent on mitochondrial activity and CO₂ production, being especially relevant in cell models with high mitochondrial respiration capacity. Nevertheless, this hypothesis would require further experimental validation.

The important role of amino acid metabolism in the acquisition of resistance to AML and CML common chemotherapeutic drugs

Cancer cells, including AML and CML cells, require amino acids to fulfil their needs of synthesising proteins for cell proliferation. Besides the role of amino acids in protein synthesis, they are also precursors of metabolic intermediates that replenish glycolysis, TCA cycle, one-carbon metabolism, lipid synthesis and urea cycle, among others. Moreover, in their catabolism and anabolism, there are many redox reactions that participate in the NADH and NADPH homeostasis. In this thesis, we have focused on the role of amino acids metabolism in the resistant leukaemic cells and how this fulfils other metabolic roles (e.g. nucleic acid biosynthesis and NADH redox maintenance) that take part in the metabolic reprogramming associated with chemotherapeutic drug resistance including AraC, Dox and imatinib.

Glutamine and glutamate metabolism: key metabolic players, especially in KU812 ImaR cells

Glutamine is by far the main amino acid consumed by tumour cells. Its metabolism is determinant for tumour growth and survival¹³⁶. The importance of glutamine in tumor survival lies in its participation in many synthetic pathways. As depicted in **figure 6.1**, glutamine serves as substrate for different metabolic reactions (e.g. HBP and transaminases reactions), which are independent of glutaminolysis. Moreover, glutamine can also be converted to glutamate via glutaminolysis. Glutamine-derived glutamate is involved in different transaminase reactions but, most importantly, is well-known for its contribution to the anaplerotic and non-anaplerotic reactions. In light of this complexity of glutamine metabolism, the alterations of glutamine metabolism upon AML and CML chemotherapeutic drug resistance were explored throughout this thesis. With regard to AML cells, our results indicate that glutamine consumption was enhanced upon the acquisition of AraC resistance in AML cells whereas a decrease of the total glutamine consumed was associated with the acquisition of Dox resistance (i.e. drug-dependent metabolic changes). However, these differences in glutamine metabolism showed to be dependent on the mitochondrial-respiration phenotype (i.e. cell line-dependent metabolic

changes) and on the oxygen conditions in which AML cells were incubated. Moreover, as THP-1 cells exhibited a metabolic phenotype with a highly active mitochondrial respiration capacity, we thus theorise that THP-1 cells may have a higher dependency on glutamine to fuel the TCA cycle and obtain TCA cycle intermediates for energetic purposes. All these findings, first, underline the importance of studying the metabolic reprogramming of distinct cell models upon the acquisition of drug resistance; and second and more importantly, highlight the glutaminase reaction as a possible vulnerability of AML cells resistant to AraC, especially of THP-1 AraC cells. In this regard, we propose that the inhibition of the glutaminase reaction, for instance via its inhibition with GLS inhibitor BPTES³⁵⁷ or CB-839⁹⁸, could reduce the viability of AML cells resistant to AraC. However, further validation studies are needed.

On the other hand, the analysis of the glutamine consumption and glutamate production profiles revealed a more active glutamine metabolism in the CML cell model used in our thesis upon the acquisition of imatinib resistance despite the downregulation determined for the protein expression of the key enzyme in the glutaminolysis process, GLS. This result was partially attenuated by the upregulation of the specific glutamine transporters (SNAT1-2) in addition to other amino acids transporters (e.g. LAT1). These findings suggest that KU812 ImaR cells may be using glutamine through reactions and processes that are independent of glutaminolysis. In this regard, our protein profile results showed an upregulation of proteins associated with the HBP, which has a crucial role in many cancer processes including signalling, metabolism, gene regulation and epithelial-mesenchymal transition³³⁵. Glutamine transaminase reactions are also independent of glutaminolysis and, more importantly, are key players in the synthesis of DNA and RNA (shown in **Fig. 6.1**).

As aforementioned, glutamine participates in metabolic reactions that are dependent on glutaminolysis. Therefore, we explored the metabolic fates of glutamine-derived glutamate to elucidate the increased glutamine consumption observed in the CML resistant cells. Considering the protein profile results, the glutamate-dependent transamination reactions did not explain the increase on glutamine consumption. Moreover, our data showed that glutamine-derived glutamate contributes in a lower extent to the mitochondrial respiration

of KU812 ImaR cells (**Chapter 2, section 5.2.2.7**). This finding together with the downregulation of the glutamate/H⁺ symporter SLC25A22 observed in KU812 ImaR cells, whose knockdown has been reported to result in a lack of ETC functioning in astrocytes³³⁶, suggest that glutamine-derived glutamate should contribute to metabolic pathways other than TCA cycle anaplerosis in the CML resistant cell model used in this thesis. Accordingly, these results showed that glutamine-derived glutamate is rewired to other non-anaplerotic reactions such as synthesis of proline, ornithine, arginine, citrulline and collagen in KU812 ImaR cells (**depicted schematically in Fig. 6.1.B** and further discussed below).

The contribution of glutamine-derived glutamate in proline synthesis was the most significant alteration in the here studied CML resistant cells. KU812 ImaR cells exhibited both a substantial increase of proline synthesis (13-fold up) and a significant upregulation of the proteins involved in the proline synthesis. Proline synthesis has been shown to fuel protein production for cell proliferation¹⁷⁴. Indeed, other studies have demonstrated that the knockdown of proline synthesis enzymes significantly reduces cell proliferation in different tumour cells including lymphoma, lung, breast, melanoma and prostate cancer cells¹⁷⁶. Thus, we hypothesised that proline metabolism, and particularly its synthesis, could constitute a vulnerability for CML cells resistant to TKIs. However, the inhibition of proline synthesis via P5CS or proT knockouts alone was not sufficient to overcome imatinib resistance in the KU812 ImaR cells.

Related with the observed glutamine rewiring to non-anaplerotic reactions, our results have accordingly unveiled an upregulation of the enzyme ASS1 in KU812 ImaR cells. This result together with the higher intracellular content of ornithine (shown in **Chapter 2, section 5.2.2.4**) led us to hypothesise that KU812 ImaR cells may be in part rewiring the glutamine-derived ornithine and the aspartate to the urea cycle to obtain arginine and fumarate. These two metabolites would be further used to synthesise proteins and to replenish the TCA cycle, respectively. It is worth mentioning that ASS1 has been additionally described as a metabolic regulator in colorectal cancer and its inhibition has been suggested as a novel therapeutic approach³⁵⁸. Therefore, we propose ASS1 inhibition as a suitable therapeutic approach to revert TKI resistance, and particularly imatinib resistance, in CML resistant cells.

Another non-anaplerotic reaction in which the glutamine-derived glutamate participates is the synthesis of glutathione, which is the main redox buffer in a cell³⁵⁹. However, there was no correlation between the observed increase of glutamine consumption and transport in KU812 ImaR cells, and the increase of the *de novo* glutathione synthesis. Besides, we did find a significant upregulation of glutathione peroxidases (GPX1, GPX4 and GPX7) and glutathione-S-transferases including (GSTP1, GSTM1, and GSTM3), which are involved in the processes of ROS scavenging and xenobiotic detoxification^{337,338} (Chapter 2, section **5.2.2.6**). In this line, previous studies revealed that GSTP1 is a drug-resistance associated protein in leukaemia³⁶⁰, and that GPX4 may represent a therapeutic strategy to prevent acquired drug resistance in cancer cells²³⁰. Interestingly, our data highlighted GSTP and GPX4 enzymes as potential targets to counteract TKI resistance, due to their upregulation at protein expression levels. The inhibitory effect of Ezatiostat (a GSTP1 inhibitor), and RSL-3 (a GPX4 inhibitor) on the cell viability of both KU812 P and ImaR cells was not sufficient to overcome TKI resistance. However, they did decrease the cell viability of both KU812 P and ImaR cells and, more importantly, IC₅₀ values were within the pharmacological concentration range³⁶¹. Therefore, we speculate that these inhibitors could be a suitable alternative or combinatory choice for the treatment of CML patients.




Figure 6.1 Schematic representation of the role of glutamine and glutamine-derived glutamate in different metabolic pathways. Glutamine has its own specific functions (panel A) but it can also be converted to glutamate to exert other functions (panel B). **A)** Glutamine can be converted into UDP-GlcNac through the hexosamine biosynthetic pathway (HBP) and, thereby, contribute to the functioning of different cancer cell processes. Moreover, glutamine can be used in different transamination reactions, thus contributing to the synthesis of either asparagine or purine and pyrimidine (essential metabolites for DNA and RNA synthesis). **B)** Glutamine-derived glutamate can be used in transamination reaction or in anaplerotic and non-anaplerotic reactions as indicated. Regarding the anaplerotic and non-anaplerotic reactions, the first contribute to the TCA cycle replenishment whereas the non-anaplerotic reactions have as a result the synthesis of crucial metabolites that have key roles in the indicated metabolic processes. Abbreviations: guanosine monophosphate, GMP; uridine monophosphate, UMP; and tricarboxylic acids, TCA.

<u>The link between serine-glycine-1C metabolism and DNA synthesis: a phenotypic</u> commonality of THP-1 AraC and KU812 ImaR cells under normoxic conditions

After glutamine, serine is the second most-consumed amino acid by tumour cells. Serine metabolism, including its synthesis and catabolism, plays an important role in the transfer of 1-C units to the tetrahydrofolate, in a metabolic pathway known as the serine-glycine-1C metabolism. The importance of this metabolic pathway was brought to light in some of the here studied resistant cell models, which is an indicator that serine-glycine-1C metabolism may be relevant in the process of drug-resistant acquisition in leukaemic cells.

As shown in Chapter 1, section 5.1.2.2.5, THP-1 and HL-60 AraC resistant cells displayed a different pattern of changes regarding the amino acids associated with the serine-glycine-1C metabolism (cell-line dependent phenotype) under normoxic and hypoxic incubation conditions. More specifically, serine and glycine consumption/production profiles together with the protein profile results highlighted that THP-1 AraC cells under normoxia metabolised serine to obtain glycine and 1-C units, which would be further used for purine synthesis (thereby DNA synthesis). Likewise, the protein profile results regarding the CML resistant model under normoxia also underlined a possible need for DNA synthesis (shown in **Chapter 2**, section 5.2.2.2). As it has been described that the decrease of DNA synthesis can be an AraC dose-dependent effect on normal human peripheral blood cells³⁶², and that imatinib treatment decreases DNA synthesis by inhibiting the cell-cycle progression of Tcells³⁶³, we hypothesise that both THP-1 AraC and KU812 ImaR cells may have enhanced metabolic pathways associated with DNA synthesis to counteract the detrimental effect of the AraC and Imatinib treatments. In this line, we decided to validate if the inhibition of enzymes associated with 1-C metabolism, thus in part DNA synthesis, had an effect on the cell viability of KU812 and THP-1 parental and, especially, on the resistant cells. Even though a more detrimental effect regarding the resistant cells was not observed, our results exhibited a cell viability disadvantage for both parental and resistant cells when cells were treated with these inhibitors. In addition, IC₅₀ values were also within the pharmacological concentration range observed in the treatment of other leukaemia such as childhood leukaemia³⁶⁴, thus we speculate that these inhibitors, similar to Ezatiostat and RSL-3 inhibitors in CML cells, could be a suitable alternative choice for AML and CML patients treatment.

<u>Amino acids alterations of AraC and Dox resistant cells under hypoxic incubation conditions:</u> <u>a cell-line dependent pattern of changes</u>

The here exhibited metabolic reprogramming by AML and CML cells resistant to conventional chemotherapeutic drugs under normoxia has been crucial to better understand how these cells can evade/adapt to drug treatments. However, BM, which is the primary niche of leukaemic cells, is known to be a hypoxic organ. In fact, it has been reported that a hypoxic niche, characterized by a low content of oxygen and drug, plays an important role in the emergence of drug resistance by cell damage elusion³⁶⁵. Therefore, we considered that a better knowledge of the amino acid metabolism not only under normoxia but also under hypoxia could be crucial to better understand the metabolic alterations occurring upon drug resistance acquisition in order to better design a therapeutic strategy to kill these resistant leukaemic cells.

As shown in **Chapter 1, section 5.1.2.2.5**), the amino acid fluxes alterations associated with the acquisition of drug resistance under hypoxia were only observed in THP-1 resistant cells (cell-line dependent). As mentioned above, the metabolic phenotype of these cells is characterised by a highly active mitochondrial respiration capacity that also results in higher consumption of several amino acids. Therefore, we speculate that THP-1 resistant cells under hypoxia may have altered the amino acid metabolism to adapt to the reduction of the oxygen levels, and thereby, to the lower possibility to respire.

Regarding the THP-1 Dox cells, polyamine consumption seems to be crucial when THP-1 Dox are under the hypoxic-stress effect. A previous study has shown that the upregulation of the polyamine system promotes the survival of cancer cells, including glioblastoma, prostate and colon cancer cells, during hypoxic stress³⁶⁶. Therefore, we propose polyamine metabolism as a possible metabolic target to be inhibited and, thereby, to overcome Dox resistance in AML patients. Interestingly, a recent study has shown that MLD72.527, an inhibitor of polyamine catabolism, re-sensitises THP-1 cells that are infected with the

human cytomegalovirus (HCMV) and that are resistant to Dox chemotherapeutic drug³⁶⁷. Thus, we propose that the combination of the doxorubicin and MDL72.527 as an initial treatment in AML patients could avoid the acquisition of Dox resistance in these patients. However, this would need further experimental substantiation.

Finally, even though the amino acid fluxes were not altered in HL-60 resistant cells under hypoxic incubation conditions, the intracellular content of arginine and asparagine did decrease. Nevertheless, further experimental substantiation needs to be performed to better understand the role of amino acid alterations in HL-60 resistant cells under hypoxia.

Metabolic and non-metabolic drug-targets underlined via a comprehensive multi-OMIC approach

The last specific objectives of this thesis are "the definition and validation of targets associated with the metabolic reprogramming of the resistant AML and CML cells". In this regard, the multi-OMIC approach conducted for the AML (**Chapter 1**) and CML (**Chapter 2**) cells in this thesis uncovers both potential weaknesses of metabolic pathways and metabolic and non-metabolic drug-target candidates that could be exploited for leukaemia treatment. As depicted in **figure 6.2**, some of these drug-target candidates were validated and others were proposed for further validation.

Our validation results unveiled that the single-hit inhibition approach by either using specific protein inhibitors of the selected targets or, in the case of proline metabolism, using CRISPR/Cas9 technology, is not a good strategy to efficiently overcome AraC, Dox and imatinib resistance in AML and CML cells. In this regard, we hypothesise that AML and CML resistant cells may be circumventing the inhibition of individual metabolic pathways due to their high metabolically plasticity here described. However, we demonstrated that the majority of these single-hit inhibitions reduce the cell viability of both parental and resistant AML and CML cells with an appropriate concentration range regarding the therapeutic index (i.e. measurement of the relative safety of a drug). In fact, we suggest that inhibitors such as methotrexate or pemetrexed could be potential inhibitors for the treatment of

leukemic cells with high mitochondrial capacity. For all these reasons, we propose that both the single use of the inhibitors their combination with AraC, Dox or imatinib chemotherapeutic drugs could constitute an effective strategy to treat AML and CML patients who initially were resistant or non-resistant to these chemotherapeutic drugs.

Remarkably, in this thesis we have found that the acquisition of Dox resistance negatively alters the mitochondrial metabolism of cells with an active mitochondrial respiration capacity (e.g. THP-1 and KU812 cells). This study has allowed us to propose Dox as a new drug in the treatment of tumours with high mitochondrial activity. In this regard, a very novel proposal which is the repurposing of Dox chemotherapeutic drug (a conventional AML chemotherapeutic drug) to counteract the imatinib resistance in the KU812 ImaR cells has emerged in this thesis. Interestingly, Dox treatment decreased the cell viability of KU812 ImaR cells significantly more than KU812 P cells.

To sum up, the results from the here conducted multi-OMIC study support the conclusion that the resistance mechanisms developed by AML and CML cells lines are associated with an important metabolic reprogramming. Moreover, this study also unveils different metabolic commonalities between both AML and CML parental cells in addition to commonalities in the metabolic reprogramming of AML and CML cells upon the acquisition of chemotherapeutic drug resistance. These metabolic commonalities allow us to associate the effect that drugs have in AML parental and/or resistant cells with the effect that may have in CML parental and/or resistant cells, and vice versa. Finally, the results of this multi-OMIC study pave the way to propose novel and promising therapeutic opportunities for the improvement of AML and CML treatment.




Figure 6.2. Schematic representation of the highlighted drug-targets and metabolic pathways for AML and/or CML treatment. The illustration depicts both the proposed and the validated drug-targets and metabolic pathways that arose from the multi-OMIC approach performed in AML and CML parental and resistant cells. Abbreviations: Amyloid beta precursor protein, APP; cytarabine, AraC; argininosuccinate synthase, ASS1; cyclin dependent kinase 1, CDK1; c-terminal binding protein 1, CTBP1; dehydroepiandrosterone, DHEA; dihydrofolate reductase, DHFR; doxorubicin, Dox; squalene synthase, FDFT1; glutaminase, GLS; glycerol-3-phosphate, GP; glutathione peroxidase 4, GPX4; glutathione s-transferase pi 1, GSTP1; glycerol-3-phosphate dehydrogenase, GPD2; glycogen phosphorylase , PYG; imatinib-resistant, ImaR; pyrroline-5-carboxylate synthase, P5CS; ribonucleotide reductase regulatory subunit M2, RRM2; serine hydroxymethyltransferase, SHMT; sodium-dependent proline transporter, proT; sterol O-acyltransferase 1, SOAT1; thrombomodulin, THBD; transketolase like 1, TKTL1; and thymidylate synthetase, TYMS.

7. CONCLUSIONS

7 CONCLUSIONS

1. The multi-OMIC study conducted for the AML and CML parental and resistant cell models used in this thesis is a reliable approach to identify potential metabolic and non-metabolic targets that can be exploited for AML and CML treatment. The use of this approach has allowed us (1) to find metabolic commonalities in the metabolic reprogramming of AML and CML resistant cells and (2) to propose and/or validate different targets associated with metabolic pathways including serine-glycine-1C, PPP, glutaminolysis, glycogenolysis, among others. Indeed, we found that the single-hit inhibitions reduce the cell viability of both parental and resistant AML and CML cells.

2. The initial metabolic phenotype of AML cells influences the metabolic reprogramming derived from the acquisition of AraC and Dox resistance, which highlights the importance of investigating the initial phenotype of cells to anticipate the metabolic changes that may arise due to the acquisition of resistance.

3. The acquisition of AraC resistance causes the reprogramming of the glucose metabolism of THP-1 and HL-60 AML cells under both normoxic and hypoxic conditions by increasing the glycolytic flux whereas it is not associated with an alteration in the mitochondrial respiration capacity. Nevertheless, we observed a possible disfunction of ETC complex I as well as alterations in glutamine and serine-glycine-1C metabolism in AML cells that display a more active mitochondrial metabolism (i.e. THP-1 AraC cells). These metabolic alterations constitute promising vulnerabilities in AML cells resistant to AraC with these mitochondrial features.

4. The acquisition of Dox resistance causes alterations in the glucose and amino acid metabolism by decreasing the glycolytic flux of THP-1 and HL-60 AML cells as well as the amino acid consumptions of HL-60 AML cells under normoxic conditions. Moreover, we identified the polyamine metabolism as an important metabolic source of THP-1 Dox cells

under hypoxic conditions. On the other hand, the acquisition of Dox resistance dramatically decreases the mitochondrial respiration capacity of AML cells with an active mitochondrial metabolism under normoxic and hypoxic conditions whereas it significantly upregulates the majority of the proteins associated with the mitochondrial metabolism. These metabolic alterations in the mitochondrial metabolism together with the metabolic changes related to the polyamine metabolism constitute potential metabolic vulnerabilities that can be exploited for the treatment of AML patients resistant to Dox chemotherapeutic drugs.

5. The acquisition of imatinib resistance causes the reprograming of glucose metabolism by enhancing the glycolytic flux, PPP, and glycogen metabolism. These changes highlight these metabolic pathways as potential metabolic weaknesses of KU812 ImaR cells. Moreover, the high metabolic plasticity exhibited by KU812 ImaR cells includes the orchestration of many metabolic routes associated with the amino acid metabolism. The enhancement of glutamine, proline, glutathione, serine-glycine-1C metabolism, among others, provides KU812 ImaR cells with high metabolic flexibility that can be used not only for energetic purposes but also to accomplish crucial metabolic processes such as ROS scavenging, xenobiotic detoxification, DNA synthesis or NADPH/NADP balance. Finally, KU812 ImaR cells display enhanced mitochondrial respiration capacity. This metabolic feature underlines mitochondrial metabolism as another potential vulnerability that can be exploited to overcome imatinib resistance. Consequently, we propose the repurposing of Dox treatment as a promising therapy to overcome imatinib resistance in KU812 ImaR cells.

8. REFERENCES

8 **REFERENCES**

- Bray, F. *et al.* Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA. Cancer J. Clin.* 68, 394–424 (2018).
- 2. Bansal, R. *Cancer and the Environment*. *IEEE Microwave Magazine* **10**, (National Academies Press, 2002).
- 3. Ng, A. P. & Alexander, W. S. Haematopoietic stem cells: past, present and future. *Cell Death Discov.* **3**, 17002 (2017).
- 4. Bonnet, D. Haematopoietic stem cells. J. Pathol. 197, 430–440 (2002).
- Morikawa, T. & Takubo, K. Hypoxia regulates the hematopoietic stem cell niche. *Pflügers* Arch. - Eur. J. Physiol. 468, 13–22 (2016).
- Schofield, R. The relationship between the spleen colony-forming cell and the haemopoietic stem cell. *Blood Cells* 4, 7–25 (1978).
- 7. Davis, A. S., Viera, A. J. & Mead, M. D. Leukemia: An overview for primary care. *Am. Fam. Physician* **89**, 731–738 (2014).
- Döhner, H., Weisdorf, D. J. & Bloomfield, C. D. Acute Myeloid Leukemia. *N. Engl. J. Med.* 373, 1136–1152 (2015).
- Noone AM, Howlader N, Krapcho M, Miller D, Brest A, Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis DR, Chen HS, Feuer EJ, C. K. SEER Cancer Statistics Review, 1975- 2015, National Cancer Institute. 430–439 (2018).
- Bray, F. *et al.* Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA. Cancer J. Clin.* 68, 394–424 (2018).
- Lindsley, R. C. *et al.* Acute myeloid leukemia ontogeny is defined by distinct somatic mutations. *Blood* 125, 1367–1376 (2015).
- 12. Walter, M. J. What came first: MDS or AML? *Blood* **125**, 1357–1358 (2015).
- 13. Lowenberg, B., Downing, J. R. & Burnett, A. Acute Myeloid Leukemia. N. Engl. J. Med. 341,

1051-1062 (1999).

- 14. Dohner, H. *et al.* Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. *Blood* **129**, 424–448 (2017).
- Béné, M. C. *et al.* Immunophenotyping of acute leukemia and lymphoproliferative disorders: a consensus proposal of the European LeukemiaNet Work Package 10. *Leukemia* 25, 567–574 (2011).
- Arber, D. A. *et al.* The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. *Blood* 127, 2391–405 (2016).
- 17. Yang, X. & Wang, J. Precision therapy for acute myeloid leukemia. *J. Hematol. Oncol.* **11**, 1–11 (2018).
- Li, Z. *et al.* Exploring the antitumor mechanism of high-dose cytarabine through the metabolic perturbations of ribonucleotide and deoxyribonucleotide in human promyelocytic Leukemia HL-60 Cells. *Molecules* 22, (2017).
- Cortés-Funes, H. & Coronado, C. Role of anthracyclines in the era of targeted therapy. *Cardiovasc. Toxicol.* 7, 56–60 (2007).
- Thorn, C. F. *et al.* Doxorubicin pathways: pharmacodynamics and adverse effects.
 Pharmacogenet. Genomics 21, 440–6 (2011).
- 21. Yang, F., Teves, S. S., Kemp, C. J. & Henikoff, S. Doxorubicin, DNA torsion, and chromatin dynamics. *Biochim. Biophys. Acta Rev. Cancer* **1845**, 84–89 (2014).
- Gewirtz, D. A. A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. *Biochem. Pharmacol.* 57, 727–741 (1999).
- Minotti, G., Menna, P., Salvatorelli, E., Cairo, G. & Gianni, L. Anthracyclines: Molecular Advances and Pharmacologic Developments in Antitumor Activity and Cardiotoxicity. *Pharmacol. Rev.* 56, 185–229 (2004).
- 24. Senchenkov, A., Litvak, D. A. & Cabot, M. C. Targeting ceramide metabolism A strategy for overcoming drug resistance. *J. Natl. Cancer Inst.* **93**, 347–357 (2001).

- Zhu, H. *et al.* Doxorubicin Redox Biology: Redox Cycling, Topoisomerase Inhibition, and Oxidative Stress. *React. Oxyg. species (Apex, N.C.)* 1, 189–198 (2016).
- Kumar, C. C. Genetic abnormalities and challenges in the treatment of acute myeloid Leukemia. *Genes and Cancer* 2, 95–107 (2011).
- Döhner, H. *et al.* Diagnosis and management of acute myeloid leukemia in adults: Recommendations from an international expert panel, on behalf of the European LeukemiaNet. *Blood* 115, 453–474 (2010).
- 28. Bryan, J. C. & Jabbour, E. J. Management of Relapsed/Refractory Acute Myeloid Leukemia in the Elderly: Current Strategies and Developments. *Drugs and Aging* **32**, 623–637 (2015).
- Zhang, J., Gu, Y. & Chen, B. Mechanisms of drug resistance in acute myeloid leukemia.
 Onco. Targets. Ther. 12, 1937–1945 (2019).
- Hofmann, J. Protein Kinase C Isozymes as Potential Targets for Anticancer Therapy. *Curr. Cancer Drug Targets* 4, 125–146 (2004).
- 31. Burgess, D. J. *et al.* Topoisomerase levels determine chemotherapy response in vitro and in vivo. *Proc. Natl. Acad. Sci.* **105**, 9053–9058 (2008).
- 32. Cole, S. *et al.* Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. *Science (80-.).* **258**, 1650–1654 (1992).
- Germann, U. A. P-glycoprotein—A mediator of multidrug resistance in tumour cells. *Eur. J. Cancer* 32, 927–944 (1996).
- Messingerova, L. *et al.* Acute myeloid leukemia cells MOLM-13 and SKM-1 established for resistance by azacytidine are crossresistant to P-glycoprotein substrates. *Toxicol. Vitr.* 29, 1405–1415 (2015).
- 35. Hofmann, J. Protein Kinase C Isozymes as Potential Targets for Anticancer Therapy. *Curr. Cancer Drug Targets* **4**, 125–146 (2004).
- Burgess, D. J. *et al.* Topoisomerase levels determine chemotherapy response in vitro and in vivo. *Proc. Natl. Acad. Sci. U. S. A.* **105**, 9053–9058 (2008).
- 37. Hatem, E., El Banna, N. & Huang, M. E. Multifaceted Roles of Glutathione and Glutathione-

Based Systems in Carcinogenesis and Anticancer Drug Resistance. *Antioxidants Redox Signal.* **27**, 1217–1234 (2017).

- Mossallam, G. I., Abdel Hamid, T. M. & Samra, M. A. Glutathione S-transferase GSTM1 and GSTT1 polymorphisms in adult acute myeloid leukemia; its impact on toxicity and response to chemotherapy. *J. Egypt. Natl. Canc. Inst.* 18, 264–273 (2006).
- Weich, N. *et al.* GSTM1 and GSTP1, but not GSTT1 genetic polymorphisms are associated with chronic myeloid leukemia risk and treatment response. *Cancer Epidemiol.* 44, 16–21 (2016).
- 40. Slot, A. J., Molinski, S. V. & Cole, S. P. C. Mammalian multidrug-resistance proteins (MRPs). *Essays Biochem.* **50**, 179–207 (2011).
- Ji, Q. & Qiu, L. Mechanism study of PEGylated polyester and β-cyclodextrin integrated micelles on drug resistance reversal in MRP1-overexpressed HL60/ADR cells. *Colloids Surfaces B Biointerfaces* 144, 203–213 (2016).
- Gabra, M. M. & Salmena, L. microRNAs and Acute Myeloid Leukemia Chemoresistance: A Mechanistic Overview. *Front. Oncol.* 7, 255 (2017).
- Bai, H., Cao, Z., Deng, C., Zhou, L. & Wang, C. miR-181a sensitizes resistant leukaemia HL-60/Ara-C cells to Ara-C by inducing apoptosis. *J. Cancer Res. Clin. Oncol.* 138, 595–602 (2012).
- Vydra, N., Toma, A., Glowala-Kosinska, M., Gogler-Piglowska, A. & Widlak, W.
 Overexpression of heat shock transcription factor 1 enhances the resistance of melanoma cells to doxorubicin and paclitaxel. *BMC Cancer* 13, 504 (2013).
- Lin, C. I. *et al.* Autophagy induction with RAD001 enhances chemosensitivity and radiosensitivity through met inhibition in papillary thyroid cancer. *Mol. Cancer Res.* 8, 1217–1226 (2010).
- Vydra, N., Toma, A., Glowala-Kosinska, M., Gogler-Piglowska, A. & Widlak, W.
 Overexpression of heat shock transcription factor 1 enhances the resistance of melanoma cells to doxorubicin and paclitaxel. *BMC Cancer* 13, 1 (2013).
- 47. Franzolin, E. *et al.* The deoxynucleotide triphosphohydrolase SAMHD1 is a major regulator

of DNA precursor pools in mammalian cells. Proc. Natl. Acad. Sci. 110, 14272–14277 (2013).

- 48. Schneider, C. *et al.* SAMHD1 is a biomarker for cytarabine response and a therapeutic target in acute myeloid leukemia. *Nat. Med.* **23**, 250–255 (2017).
- 49. Ohta, T. *et al.* Impact of cytidine deaminase activity on intrinsic resistance to cytarabine in carcinoma cells. *Oncol. Rep.* **12**, 1115–20 (2004).
- 50. Fanciullino, R. *et al.* CDA as a predictive marker for life-threatening toxicities in patients with AML treated with cytarabine. *Blood Adv.* **2**, 462–469 (2018).
- 51. Briot, T., Roger, E., Thépot, S. & Lagarce, F. Advances in treatment formulations for acute myeloid leukemia. *Drug Discov. Today* **23**, 1936–1949 (2018).
- Saultz, J. N. & Garzon, R. Acute Myeloid Leukemia: A Concise Review. J. Clin. Med. 5, 1–17 (2016).
- 53. H.K., L. *et al.* G-749, a novel FLT3 kinase inhibitor, can overcome drug resistance for the treatment of acute myeloid leukemia. *Blood* **123**, 2209–2219 (2014).
- Altman, J. K. *et al.* Antileukemic Activity and Tolerability of ASP2215 80mg and Greater in FLT3 Mutation-Positive Subjects with Relapsed or Refractory Acute Myeloid Leukemia: Results from a Phase 1/2, Open-Label, Dose-Escalation/Dose-Response Study. *Blood* 126, 321 LP 321 (2015).
- 55. Hansen, E. *et al.* AG-120, an Oral, Selective, First-in-Class, Potent Inhibitor of Mutant IDH1, Reduces Intracellular 2HG and Induces Cellular Differentiation in TF-1 R132H Cells and Primary Human IDH1 Mutant AML Patient Samples Treated Ex Vivo; *Blood* **124**, 3734 LP – 3734 (2014).
- 56. Kojima, K. *et al.* Prognostic impact and targeting of CRM1 in acute myeloid leukemia. *Blood* **121**, 4166–74 (2013).
- Assi, R., Kantarjian, H., Ravandi, F. & Daver, N. Immune therapies in acute myeloid leukemia: a focus on monoclonal antibodies and immune checkpoint inhibitors. *Curr. Opin. Hematol.* 25, 136–145 (2018).
- 58. Tasian, S. K. Acute myeloid leukemia chimeric antigen receptor T-cell immunotherapy: how far up the road have we traveled? *Ther. Adv. Hematol.* **9**, 135–148 (2018).

- 59. Sawyers, C. L. Chronic myeloid leukemia. *N. Engl. J. Med.* **340**, 1330–40 (1999).
- 60. Preston, D. L. *et al.* Cancer Incidence in Atomic Bomb Survivors. Part III: Leukemia, Lymphoma and Multiple Myeloma, 1950-1987. *Radiat. Res.* **137**, S68 (1994).
- 61. Vlaanderen, J., Lan, Q., Kromhout, H., Rothman, N. & Vermeulen, R. Occupational benzene exposure and the risk of chronic myeloid leukemia: A meta-analysis of cohort studies incorporating study quality dimensions. *Am. J. Ind. Med.* **55**, 779–785 (2012).
- 62. Höglund, M., Sandin, F. & Simonsson, B. Epidemiology of chronic myeloid leukaemia: an update. *Ann. Hematol.* **94**, 241–247 (2015).
- 63. Jabbour, E. & Kantarjian, H. Chronic myeloid leukemia: 2020 update on diagnosis, therapy and monitoring. *Am. J. Hematol.* **95**, 691–709 (2020).
- Furtado, V. F. *et al.* Accelerated phase chronic myeloid leukemia: Evaluation of clinical criteria as predictors of survival, major cytogenetic response and progression to blast phase. *Rev. Bras. Hematol. Hemoter.* **37**, 341–347 (2015).
- 65. Robert S Negrin, MD, Charles A Schiffer, M. Treatment of chronic myeloid leukemia in blast crisis. *Haematologica* **93**, 1765–1769 (2019).
- 66. Lissauer, H. Zwei Falle von Leucaemie. *Berl Klin Wochenshrift* **2**, 403–404 (1865).
- 67. Galton, D. A. G. MYLERAN IN CHRONIC MYELOID LEUKÆMIA RESULTS OF TREATMENT. *Lancet* **261**, 208–213 (1953).
- 68. Rushing, D., Goldman, A., Gibbs, G., Howe, R. & Kennedy, B. J. Hydroxyurea versus busulfan in the treatment of chronic myelogenous leukemia. *Am. J. Clin. Oncol.* **5**, 307–314 (1982).
- 69. Clift, R. A., Appelbaum, F. R. & Thomas, E. D. Treatment of chronic myeloid leukemia by marrow transplantation. *Blood* **82**, 1954–196 (1993).
- 70. Druker, B. J. & Lydon, N. B. Lessons learned from the development of an Abl tyrosine kinase inhibitor for chronic myelogenous leukemia. *J. Clin. Invest.* **105**, 3–7 (2000).
- Hochhaus, A. *et al.* Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. *Leukemia* 23, 1054–1061 (2009).
- 72. Hjorth-Hansen, H. et al. European LeukemiaNet recommendations for the management of

chronic myeloid leukemia: 2013. *Blood* **122**, 872–884 (2013).

- 73. Gora-Tybor, J. & Robak, T. Targeted drugs in chronic myeloid leukemia. *Curr. Med. Chem.*15, 3036–3051 (2008).
- 74. Le Coutre, P. *et al.* Pharmacokinetics and cellular uptake of imatinib and its main metabolite CGP74588. *Cancer Chemother. Pharmacol.* **53**, 313–323 (2004).
- Gambacorti-Passerini, C. Role of alpha1 Acid Glycoprotein in the In Vivo Resistance of Human BCR-ABL+ Leukemic Cells to the Abl Inhibitor STI571. J. Natl. Cancer Inst. 92, 1641– 1650 (2000).
- Illmer, T. *et al.* P-glycoprotein-mediated drug efflux is a resistance mechanism of chronic myelogenous leukemia cells to treatment with imatinib mesylate. *Leukemia* 18, 401–408 (2004).
- Branford, S. & Hughes, T. Detection of BCR-ABL mutations and resistance to imatinib mesylate. *Methods Mol. Med.* **125**, 93–106 (2006).
- 78. Jabbour, E. *et al.* Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate. *Leukemia* **20**, 1767–1773 (2006).
- Gorre, M. E. *et al.* Linking clinical Resistance to STI-571 Cancer Therapy Caused by Gene Mutation or BCR-ABL Amplification. *Adv. Sci.* 293, 876–880 (2001).
- Apperley, J. F. Part I: mechanisms of resistance to imatinib in chronic myeloid leukaemia.
 Lancet. Oncol. 8, 1018–29 (2007).
- Gambacorti-Passerini, C. B. *et al.* Differences between in vivo and in vitro sensitivity to imatinib of Bcr/Abl+ cells obtained from leukemic patients. *Blood Cells, Mol. Dis.* 28, 361– 372 (2002).
- Mahon, F. X. *et al.* Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance. *Blood* 96, 1070–9 (2000).
- Barnes, D. J. *et al.* Bcr-Abl expression levels determine the rate of development of resistance to imatinib mesylate in chronic myeloid leukemia. *Cancer Res.* 65, 8912–8919 (2005).

- Hochhaus, A. *et al.* Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. *Leukemia* 16, 2190–2196 (2002).
- Kantarjian, H. *et al.* Dasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia. *N. Engl. J. Med.* 362, 2260–2270 (2010).
- Chan, W. Y., Lau, P. M., Yeung, K. W. & Kong, S. K. The second generation tyrosine kinase inhibitor dasatinib induced eryptosis in human erythrocytes—An in vitro study. *Toxicol. Lett.* 295, 10–21 (2018).
- 87. Fujisawa, S. *et al.* Efficacy and safety of dasatinib versus imatinib in Japanese patients with newly diagnosed chronic-phase chronic myeloid leukemia (CML-CP): Subset analysis of the DASISION trial with 2-year follow-up. *Int. J. Hematol.* **99**, 141–153 (2014).
- Breccia, M. & Alimena, G. Nilotinib: A second-generation tyrosine kinase inhibitor for chronic myeloid leukemia. *Leuk. Res.* 34, 129–134 (2010).
- 89. Wei, G., Rafiyath, S. & Liu, D. First-line treatment for chronic myeloid leukemia: Dasatinib, nilotinib, or imatinib. *J. Hematol. Oncol.* **3**, 47 (2010).
- 90. Vazquez, A. et al. Cancer metabolism at a glance. J. Cell Sci. 129, 3367–3373 (2016).
- 91. Hanahan, D. & Weinberg, R. A. Hallmarks of cancer: The next generation. *Cell* 144, 646–674 (2011).
- 92. Phan, L. M., Yeung, S.-C. J. & Lee, M.-H. Cancer metabolic reprogramming: importance, main features, and potentials for precise targeted anti-cancer therapies. *Cancer Biol. Med.* 11, 1–19 (2014).
- Tarrado-Castellarnau, M., de Atauri, P. & Cascante, M. Oncogenic regulation of tumor metabolic reprogramming. *Oncotarget* 7, 62726–62753 (2016).
- 94. Mueckler, M. *et al.* Sequence and structure of a human glucose transporter. *Science* 229, 941–5 (1985).
- 95. Holman, G. D. & Sandoval, I. V. Moving the insulin-regulated glucose transporter GLUT4 into and out of storage. *Trends Cell Biol.* **11**, 173–179 (2001).
- 96. Bryant, N. J., Govers, R. & James, D. E. Regulated transport of the glucose transporter

GLUT4. Nat. Rev. Mol. Cell Biol. 3, 267–277 (2002).

- 97. Shepherd, P. R., Gibbs, E. M., Wesslau, C., Gould, G. W. & Kahn, B. B. Human small intestine facilitative fructose/glucose transporter (GLUT5) is also present in insulin-responsive tissues and brain. Investigation of biochemical characteristics and translocation. *Diabetes* 41, 1360–5 (1992).
- Counihan, J. L., Grossman, E. A. & Nomura, D. K. Cancer Metabolism: Current Understanding and Therapies. *Chem. Rev.* **118**, 6893–6923 (2018).
- Wilson, W. R. & Hay, M. P. Targeting hypoxia in cancer therapy. *Nat. Rev. Cancer* 11, 393–410 (2011).
- Song, K. *et al.* HIF-1α and GLUT1 Gene Expression is Associated with Chemoresistance of Acute Myeloid Leukemia. *Asian Pacific J. Cancer Prev.* **15**, 1823–1829 (2014).
- 101. Chen, W.-L. *et al.* Enhanced Fructose Utilization Mediated by SLC2A5 Is a Unique Metabolic Feature of Acute Myeloid Leukemia with Therapeutic Potential. *Cancer Cell* **30**, 779–791 (2016).
- Bunney, P. E., Zink, A. N., Holm, A. A., Billington, C. J., & Kotz, C. M. Targeting Metabolism for Cancer Therapy. *Physiol. Behav.* 176, 139–148 (2017).
- 103. Warburg, O. & Minami, S. Versuche an Überlebendem Carcinom-gewebe. *Klin. Wochenschr.* 2, 776–777 (1923).
- Shim, H. *et al.* c-Myc transactivation of LDH-A: Implications for tumor metabolism and growth (oncogenelactate dehydrogenasehypoxiatumorigenicity). *Natl. Institutes Heal.* 94, 6658–6663 (1997).
- 105. Patra, K. C. & Hay, N. The pentose phosphate pathway and cancer. *Trends Biochem. Sci.* **39**, 347–354 (2014).
- 106. Cho, E. S., Cha, Y. H., Kim, H. S., Kim, N. H. & Yook, J. I. The pentose phosphate pathway as a potential target for cancer therapy. *Biomol. Ther.* **26**, 29–38 (2018).
- 107. Kekec, Y. *et al.* Antioxidant enzyme levels in cases with gastrointesinal cancer. *Eur. J. Intern. Med.* 20, 403–406 (2009).

- 108. Langbein, S. *et al.* Expression of transketolase TKTL1 predicts colon and urothelial cancer patient survival: Warburg effect reinterpreted. *Br. J. Cancer* **94**, 578–585 (2006).
- 109. Xu, S. N., Wang, T. S., Li, X. & Wang, Y. P. SIRT2 activates G6PD to enhance NADPH production and promote leukaemia cell proliferation. *Sci. Rep.* **6**, 1–13 (2016).
- 110. Jiang, P., Du, W. & Wu, M. Regulation of the pentose phosphate pathway in cancer. *Protein Cell* **5**, 592–602 (2014).
- Coy, J. F. *et al.* Molecular cloning of tissue-specific transcripts of a transketolase-related gene: Implications for the evolution of new vertebrate genes. *Genomics* **32**, 309–316 (1996).
- 112. Staiger, W. I. *et al.* Expression of the mutated transketolase TKTL1, a molecular marker in gastric cancer. *Oncol. Rep.* **16**, 657–61 (2006).
- Philipp, M. *et al.* Expression of transketolase-like gene 1 (TKTL1) depends on disease phase in patients with chronic myeloid leukaemia (CML). *J. Cancer Res. Clin. Oncol.* 140, 411–417 (2014).
- 114. Coy, J. F., Dressler, D., Wilde, J. & Schubert, P. Mutations in the transketolase-like gene TKTL1: Clinical implications for neurodegenerative diseases, diabetes and cancer. *Clin. Lab.* 51, 257–273 (2005).
- Diaz-Moralli, S. *et al.* A key role for transketolase-like 1 in tumor metabolic reprogramming.
 Oncotarget 7, 51875–51897 (2016).
- 116. Li, Y. *et al.* APC/CCDH1 synchronizes ribose-5-phosphate levels and DNA synthesis to cell cycle progression. *Nat. Commun.* **10**, 2502 (2019).
- 117. Zhao, F. *et al.* Imatinib resistance associated with BCR-ABL upregulation is dependent on
 HIF-1alpha-induced metabolic reprograming. *Oncogene* 29, 2962–72 (2010).
- Zois, C. E. & Harris, A. L. Glycogen metabolism has a key role in the cancer microenvironment and provides new targets for cancer therapy. *J. Mol. Med.* 94, 137–154 (2016).
- 119. Berg, J. M., Tymoczko, J. L. & Stryer, L. Glycogen Breakdown and Synthesis Are Reciprocally Regulated. *Biochemistry* 2002 (2002).

- 120. Rousset, M., Zweibaum, A. & Fogh, J. Presence of glycogen and growth-related variations in
 58 cultured human tumor cell lines of various tissue origins. *Cancer Res.* 41, 1165–70 (1981).
- 121. Rousset, M., Chevalier, G., Rousset, J. P., Dussaulx, E. & Zweibaum, A. Presence and cell growth-related variations of glycogen in human colorectal adenocarcinoma cell lines in culture. *Cancer Res.* **39**, 531–4 (1979).
- 122. Rousset, M. *et al.* Kinetics of glycogen levels in asynchronous and synchronous cultures of a human colon carcinoma cell line, HT 29. *Front. Gastrointest. Res.* **4**, 73–9 (1979).
- Rousset, M., Robine-Leon, S., Dussaulx, E., Chevalier, G. & Zweibaum, A. Glycogen storage in foetal and malignant epithelial cells of the human colon. *Front. Gastrointest. Res.* 4, 80–5 (1979).
- 124. Bhanot, H. *et al.* Pathological glycogenesis through glycogen synthase 1 and suppression of excessive AMP kinase activity in myeloid leukemia cells. *Leukemia* **29**, 1555–1563 (2015).
- 125. Jayaraman, A. Characterization of endothelial cell metabolism under different microenvironmental challenges : exploring therapeutic implications of targeting glycogen degradation Characterization of endothelial cell metabolism under different microenvironmental challen. (2016).
- Anderka, O. *et al.* Thermodynamic Characterization of Allosteric Glycogen Phosphorylase Inhibitors. *Biochemistry* 47, 4683–4691 (2008).
- 127. Oikonomakos, N. G. *et al.* Flavopiridol Inhibits Glycogen Phosphorylase by Binding at the Inhibitor Site. *J. Biol. Chem.* **275**, 34566–34573 (2000).
- Andersen, B., Rassov, A., Westergaard, N. & Lundgren, K. Inhibition of glycogenolysis in primary rat hepatocytes by 1,4-dideoxy-1,4-imino-D-arabinitol. *Biochem. J.* 342, 545–550 (1999).
- 129. Choi, B.-H. & Coloff, J. L. The Diverse Functions of Non-Essential Amino Acids in Cancer. *Cancers (Basel).* **11**, 675 (2019).
- Lukey, M. J., Katt, W. P. & Cerione, R. A. Targeting amino acid metabolism for cancer therapy. *Drug Discov. Today* 22, 796–804 (2017).

- Altman, B. J., Stine, Z. E. & Dang, C. V. From Krebs to clinic: glutamine metabolism to cancer therapy. *Nat. Rev. Cancer* 16, 619 (2016).
- 132. Bhutia, Y. D., Babu, E., Ramachandran, S. & Ganapathy, V. Amino acid transporters in cancer and their relevance to 'glutamine addiction': Novel Targets for the design of a new class of anticancer drugs. *Cancer Res.* **75**, 1782–1788 (2015).
- Hosios, A. M. *et al.* Amino Acids Rather than Glucose Account for the Majority of Cell Mass in Proliferating Mammalian Cells. *Dev. Cell* 36, 540–9 (2016).
- 134. Meng, M., Chen, S., Lao, T., Liang, D. & Sang, N. Nitrogen anabolism underlies the importance of glutaminolysis in proliferating cells. *Cell Cycle* **9**, 3921–3932 (2010).
- 135. Ma, Z. & Vosseller, K. O-GlcNAc in cancer biology. Amino Acids 45, 719–733 (2013).
- 136. Dang, C. V. Glutaminolysis: Supplying carbon or nitrogen or both for cancer cells? *Cell Cycle*9, 3884–3886 (2010).
- 137. Friday, E., Oliver, R., Welbourne, T. & Turturro, F. Glutaminolysis and glycolysis regulation by troglitazone in breast cancer cells: Relationship to mitochondrial membrane potential. *J. Cell. Physiol.* 226, 511–519 (2011).
- Jin, L., Alesi, G. N. & Kang, S. Glutaminolysis as a target for cancer therapy. *Oncogene* 35, 3619–25 (2016).
- Matés, J. M., Di Paola, F. J., Campos-Sandoval, J. A., Mazurek, S. & Márquez, J. Therapeutic targeting of glutaminolysis as an essential strategy to combat cancer. *Semin. Cell Dev. Biol.* 98, 34–43 (2020).
- 140. Robinson, M. M. *et al.* Novel mechanism of inhibition of rat kidney-type glutaminase by bis2-(5-phenylacetamido-1,2,4-thiadiazol-2-yl)ethyl sulfide (BPTES). *Biochem. J.* 406, 407–414 (2007).
- 141. Gross, M. I. *et al.* Antitumor activity of the glutaminase inhibitor CB-839 in triple-negative breast cancer. *Mol. Cancer Ther.* **13**, 890–901 (2014).
- 142. Wang, J. *et al.* Targeting mitochondrial glutaminase activity inhibits oncogenic transformation. *Cancer Cell* **18**, 207–19 (2010).

- Clancy, K. P. *et al.* Localization of the L-Glutamine Synthetase Gene to Chromosome 1q23.
 Genomics 38, 418–420 (1996).
- 144. Jepson, M. M., Bates, P. C., Broadbent, P., Pell, J. M. & Millward, D. J. Relationship between glutamine concentration and protein synthesis in rat skeletal muscle. *Am. J. Physiol. Metab.* 255, E166–E172 (1988).
- 145. Bott, A. J., Maimouni, S. & Zong, W.-X. The Pleiotropic Effects of Glutamine Metabolism in Cancer. *Cancers (Basel).* **11**, 1–16 (2019).
- Vats, P. *et al.* Changes in the activity levels of glutamine synthetase, glutaminase and glycogen synthetase in rats subjected to hypoxic stress. *Int. J. Biometeorol.* 42, 205–209 (1999).
- 147. Kobayashi, S. & Millhorn, D. E. Hypoxia regulates glutamate metabolism and membrane transport in rat PC12 cells. *J. Neurochem.* **76**, 1935–1948 (2001).
- Krebs, H. A. Metabolism of amino-acids: The synthesis of glutamine from glutamic acid and ammonia, and the enzymic hydrolysis of glutamine in animal tissues. *Biochem. J.* 29, 1951–69 (1935).
- 149. Jones, M. E. Conversion of Glutamate to Ornithine and Proline: Pyrroline-5-Carboxylate, a
 Possible Modulator of Arginine Requirements. *J. Nutr.* **115**, 509–515 (1985).
- 150. Meister, A. & Anderson, M. E. Glutathione. Annu. Rev. Biochem. 52, 711–760 (1983).
- 151. Son, J. *et al.* Glutamine supports pancreatic cancer growth through a KRAS-regulated metabolic pathway. *Nature* **496**, 101 (2013).
- 152. Jin, L. *et al.* The PLAG1-GDH1 Axis Promotes Anoikis Resistance and Tumor Metastasis through CamKK2-AMPK Signaling in LKB1-Deficient Lung Cancer. *Mol. Cell* 69, 87-99.e7 (2018).
- Birsoy, K. *et al.* An Essential Role of the Mitochondrial Electron Transport Chain in Cell
 Proliferation Is to Enable Aspartate Synthesis. *Cell* 162, 540–51 (2015).
- Alkan, H. F. *et al.* Cytosolic Aspartate Availability Determines Cell Survival When Glutamine Is Limiting. *Cell Metab.* 28, 706-720.e6 (2018).

- 155. Knott, S. R. V *et al.* Asparagine bioavailability governs metastasis in a model of breast cancer. *Nature* **554**, 378–381 (2018).
- 156. Rabinovich, S. *et al.* Diversion of aspartate in ASS1-deficient tumours fosters de novo pyrimidine synthesis. *Nature* **527**, 379–383 (2015).
- Gerner, E. W. & Meyskens, F. L. Polyamines and cancer: old molecules, new understanding. *Nat. Rev. Cancer* 4, 781–92 (2004).
- 158. Nowotarski, S. L., Woster, P. M. & Casero, R. A. Polyamines and cancer: implications for chemotherapy and chemoprevention. *Expert Rev. Mol. Med.* **15**, e3 (2013).
- 159. Goodwin, A. C. *et al.* Polyamine catabolism contributes to enterotoxigenic Bacteroides fragilis-induced colon tumorigenesis. *Proc. Natl. Acad. Sci.* **108**, 15354–15359 (2011).
- 160. Babbar, N. & Casero, R. A. Tumor Necrosis Factor- Increases Reactive Oxygen Species by Inducing Spermine Oxidase in Human Lung Epithelial Cells: A Potential Mechanism for Inflammation-Induced Carcinogenesis. *Cancer Res.* 66, 11125–11130 (2006).
- 161. Dolfi, S. C. *et al.* The metabolic demands of cancer cells are coupled to their size and protein synthesis rates. *Cancer Metab.* **1**, 20 (2013).
- 162. Maddocks, O. D. K. *et al.* Modulating the therapeutic response of tumours to dietary serine and glycine starvation. *Nature* **544**, 372–376 (2017).
- Locasale, J. W. *et al.* Phosphoglycerate dehydrogenase diverts glycolytic flux and contributes to oncogenesis. *Nat. Genet.* 43, 869–74 (2011).
- 164. Possemato, R. *et al.* Functional genomics reveal that the serine synthesis pathway is essential in breast cancer. *Nature* **476**, 346–350 (2011).
- 165. Nowotarski, S. L., Woster, P. M. & Casero, R. A. Polyamines and cancer: implications for chemotherapy and chemoprevention. *Expert Rev. Mol. Med.* **15**, e3 (2013).
- Mullarky, E. *et al.* Identification of a small molecule inhibitor of 3-phosphoglycerate dehydrogenase to target serine biosynthesis in cancers. *Proc. Natl. Acad. Sci. U. S. A.* **113**, 1778–1783 (2016).
- 167. Pacold, M. E. et al. A PHGDH inhibitor reveals coordination of serine synthesis and 1-carbon

unit fate HHS Public Access Author manuscript. Nat Chem Biol 12, 452–458 (2016).

- Mullarky, E. *et al.* Inhibition of 3-phosphoglycerate dehydrogenase (PHGDH) by indole amides abrogates de novo serine synthesis in cancer cells. *Bioorg. Med. Chem. Lett.* 29, 2503–2510 (2019).
- 169. Tong, X., Zhao, F. & Thompson, C. B. The molecular determinants of de novo nucleotide biosynthesis in cancer cells. *Curr. Opin. Genet. Dev.* **19**, 32–37 (2009).
- 170. Fan, J. *et al.* Quantitative flux analysis reveals folate-dependent NADPH production. *Nature* 510, 298–302 (2014).
- 171. Mentch, S. J. & Locasale, J. W. One-carbon metabolism and epigenetics: understanding the specificity. *Ann. N. Y. Acad. Sci.* **1363**, 91–8 (2016).
- 172. Newman, A. C. & Maddocks, O. D. K. One-carbon metabolism in cancer. *Br. J. Cancer* **116**, 1499–1504 (2017).
- 173. Hagedorn, C. H. & Phang, J. M. Catalytic transfer of hydride ions from NADPH to oxygen by the interconversions of proline and Δ1-pyrroline-5-carboxylate. *Arch. Biochem. Biophys.*248, 166–174 (1986).
- 174. Tanner, J. J., Fendt, S. M. & Becker, D. F. The Proline Cycle As a Potential Cancer Therapy Target. *Biochemistry* **57**, 3433–3444 (2018).
- 175. Phang, J. M., Liu, W., Hancock, C. N. & Fischer, J. W. Proline metabolism and cancer: Emerging links to glutamine and collagen. *Curr. Opin. Clin. Nutr. Metab. Care* 18, 71–77 (2015).
- Liu, W., Hancock, C. N., Fischer, J. W., Harman, M. & Phang, J. M. Proline biosynthesis augments tumor cell growth and aerobic glycolysis: Involvement of pyridine nucleotides. *Sci. Rep.* 5, 1–13 (2015).
- 177. Cai, F. *et al.* Pyrroline-5-carboxylate reductase 1 promotes proliferation and inhibits apoptosis in non-small cell lung cancer. *Oncol. Lett.* **15**, 731–740 (2018).
- 178. Elia, I. *et al.* Proline metabolism supports metastasis formation and could be inhibited to selectively target metastasizing cancer cells. *Nat. Commun.* **8**, 1–11 (2017).

- Liu, W. *et al.* Proline oxidase promotes tumor cell survival in hypoxic tumor microenvironments. *Cancer Res.* 72, 3677–86 (2012).
- Danhier, P. *et al.* Cancer metabolism in space and time: Beyond the Warburg effect.
 Biochim. Biophys. Acta Bioenerg. 1858, 556–572 (2017).
- 181. Warburg, O. On the Origin of Cancer Cells. *Science (80-.).* **123**, 309 LP 314 (1956).
- Porporato, P. E., Filigheddu, N., Pedro, J. M. B. S., Kroemer, G. & Galluzzi, L. Mitochondrial metabolism and cancer. *Cell Res.* 28, 265–280 (2018).
- 183. Collins, Y. et al. Mitochondrial redox signalling at a glance. J. Cell Sci. 125, 1837 (2012).
- 184. Rizzuto, R., De Stefani, D., Raffaello, A. & Mammucari, C. Mitochondria as sensors and regulators of calcium signalling. *Nat. Rev. Mol. Cell Biol.* **13**, 566 (2012).
- 185. Parsons, M. J. & Green, D. R. Mitochondria in cell death. *Essays Biochem.* 47, 99–114 (2010).
- Cardaci, S. & Ciriolo, M. R. TCA Cycle Defects and Cancer: When Metabolism Tunes Redox State. *Int. J. Cell Biol.* 2012, 1–9 (2012).
- 187. Lunt, S. Y. & Vander Heiden, M. G. Aerobic glycolysis: meeting the metabolic requirements of cell proliferation. *Annu. Rev. Cell Dev. Biol.* **27**, 441–64 (2011).
- Kitazawa, S. *et al.* Succinate dehydrogenase B-deficient cancer cells are highly sensitive to bromodomain and extra-terminal inhibitors. *Oncotarget* 8, 28922–28938 (2017).
- 189. Takeuchi, T., Schumacker, P. T. & Kozmin, S. A. Identification of fumarate hydratase inhibitors with nutrient-dependent cytotoxicity. *J. Am. Chem. Soc.* **137**, 564–567 (2015).
- Yen, K. *et al.* AG-221, a First-in-Class Therapy Targeting Acute Myeloid Leukemia Harboring Oncogenic IDH2 Mutations. *Cancer Discov.* 7, 478–493 (2017).
- Wang, F. *et al.* Targeted Inhibition of Mutant IDH2 in Leukemia Cells Induces Cellular Differentiation. *Science (80-.).* **340**, 622–626 (2013).
- 192. Chen, C. *et al.* Cancer-associated IDH2 mutants drive an acute myeloid leukemia that is susceptible to Brd4 inhibition. *Genes Dev.* **27**, 1974–1985 (2013).
- 193. Viale, A., Corti, D. & Draetta, G. F. Tumors and mitochondrial respiration: a neglected

connection. Cancer Res. 75, 3685–3686 (2015).

- 194. Kluza, J. *et al.* Exploiting Mitochondrial Dysfunction for Effective Elimination of Imatinib-Resistant Leukemic Cells. *PLoS One* **6**, e21924 (2011).
- Damaraju, V. L., Kuzma, M., Cass, C. E., Putman, C. T. & Sawyer, M. B. Multitargeted kinase inhibitors imatinib, sorafenib and sunitinib perturb energy metabolism and cause cytotoxicity to cultured C2C12 skeletal muscle derived myotubes. *Biochem. Pharmacol.* 155, 162–171 (2018).
- 196. Whitaker-Menezes, D. *et al.* Hyperactivation of oxidative mitochondrial metabolism in epithelial cancer cells in situ. *Cell Cycle* **10**, 4047–4064 (2011).
- 197. Lagadinou, D. *et al.* BCL-2 inhibition targets oxidative phosphorilation and selectively eradicates quiscent human leukemia stem cells. *Cell Stem Cell* **127**, 358–366 (2012).
- 198. Wylie, B. J. *et al.* Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial function. *Nature* **514**, 628–632 (2014).
- 199. Birsoy, K. *et al.* Metabolic determinants of cancer cell sensitivity to glucose limitation and biguanides. *Nature* **508**, 108–12 (2014).
- 200. Scotland, S. *et al.* Mitochondrial energetic and AKT status mediate metabolic effects and apoptosis of metformin in human leukemic cells. *Leukemia* **27**, 2129–2138 (2013).
- 201. Zhang, X. *et al.* Induction of mitochondrial dysfunction as a strategy for targeting tumour cells in metabolically compromised microenvironments. *Nat. Commun.* **5**, 3295 (2014).
- Lim, S. C., Carey, K. T. & McKenzie, M. Anti-cancer analogues ME-143 and ME-344 exert toxicity by directly inhibiting mitochondrial NADH: Ubiquinone oxidoreductase (Complex I). *Am. J. Cancer Res.* 5, 689–701 (2015).
- 203. Guo, L. *et al.* Inhibition of mitochondrial complex II by the anticancer agent lonidamine. *J. Biol. Chem.* 291, 42–57 (2016).
- 204. Swettenham, E., Witting, P. K., Salvatore, B. A. & Neuzil, J. α-tocopheryl succinate selectively induces apoptosis in neuroblastoma cells: Potential therapy of malignancies of the nervous system? *J. Neurochem.* 94, 1448–1456 (2005).

- 205. Perkins, C., Kim, C. N., Fang, G. & Bhalla, K. N. Arsenic induces apoptosis of multidrugresistant human myeloid leukemia cells that express Bcr-Abl or overexpress MDR , MRP , Bcl-2 , or Bcl-x L. 95, 1014–1023 (2019).
- 206. Maeda, H. *et al.* Tumor growth inhibition by arsenic trioxide (As2O3) in the orthotopic metastasis model of androgen-independent prostate cancer. *Cancer Res.* 61, 5432–5440 (2001).
- 207. Bornstein, J., Sagi, S., Haj, A., Harroch, J. & Fares, F. Arsenic Trioxide inhibits the growth of human ovarian carcinoma cell line. *Gynecol. Oncol.* **99**, 726–729 (2005).
- Gaude, E. & Frezza, C. Tissue-specific and convergent metabolic transformation of cancer correlates with metastatic potential and patient survival. *Nat. Commun.* 7, 1–9 (2016).
- 209. Ansell, R., Granath, K., Hohmann, S., Thevelein, J. M. & Adler, L. The two isoenzymes for yeast NAD + -dependent glycerol 3-phosphate dehydrogenase encoded by GPD1 and GPD2 have distinct roles in osmoadaptation and redox regulation. *EMBO J.* 16, 2179–2187 (1997).
- Mráček, T., Drahota, Z. & Houštěk, J. The function and the role of the mitochondrial glycerol-3-phosphate dehydrogenase in mammalian tissues. *Biochim. Biophys. Acta -Bioenerg.* 1827, 401–410 (2013).
- 211. Sekhar, B. S., Kurup, C. K. R. & Ramasarma, T. Generation of hydrogen peroxide by brown adipose tissue mitochondria. *J. Bioenerg. Biomembr.* **19**, 397–407 (1987).
- Drahota, Z. *et al.* Glycerophosphate-dependent hydrogen peroxide production by brown adipose tissue mitochondria and its activation by ferricyanide. *J. Bioenerg. Biomembr.* 34, 105–113 (2002).
- Saheki, T. *et al.* Effects of supplementation on food intake, body weight and hepatic metabolites in the citrin/mitochondrial glycerol-3-phosphate dehydrogenase double-knockout mouse model of human citrin deficiency. *Mol. Genet. Metab.* 107, 322–329 (2012).
- 214. Thakur, S. *et al.* Metformin Targets Mitochondrial Glycerophosphate Dehydrogenase to Control Rate of Oxidative Phosphorylation and Growth of Thyroid Cancer In Vitro and In Vivo. *Clin. Cancer Res.* 24, 4030–4043 (2018).

- 215. Singh, G. Mitochondrial FAD-linked glycerol-3-phosphate dehydrogenase: A target for cancer therapeutics. *Pharmaceuticals* **7**, 192–206 (2014).
- 216. Kuo, C. Y. & Ann, D. K. When fats commit crimes: Fatty acid metabolism, cancer stemness and therapeutic resistance. *Cancer Commun.* **38**, 1–12 (2018).
- 217. Carracedo, A., Cantley, L. C. & Pandolfi, P. P. Cancer metabolism: fatty acid oxidation in the limelight. *Nat. Rev. Cancer* **13**, 227–32 (2013).
- Ma, Y. *et al.* Fatty acid oxidation: An emerging facet of metabolic transformation in cancer.
 Cancer Lett. 435, 92–100 (2018).
- Yu, X. H., Ren, X. H., Liang, X. H. & Tang, Y. L. Roles of fatty acid metabolism in tumourigenesis: Beyond providing nutrition (Review). *Mol. Med. Rep.* 18, 5307–5316 (2018).
- 220. Zaugg, K. *et al.* Carnitine palmitoyltransferase 1C promotes cell survival and tumor growth under conditions of metabolic stress. *Genes Dev.* **25**, 1041–51 (2011).
- 221. Shi, J. *et al.* High Expression of CPT1A Predicts Adverse Outcomes: A Potential Therapeutic Target for Acute Myeloid Leukemia. *EBioMedicine* **14**, 55–64 (2016).
- 222. Al-Bahlani, S. *et al.* Fatty acid synthase regulates the chemosensitivity of breast cancer cells to cisplatin-induced apoptosis. *Apoptosis* **22**, 865–876 (2017).
- 223. Bauerschlag, D. O. *et al.* Fatty acid synthase overexpression: Target for therapy and reversal of chemoresistance in ovarian cancer. *J. Transl. Med.* **13**, 1–12 (2015).
- 224. Samudio, I. *et al.* Pharmacologic inhibition of fatty acid oxidation sensitizes human leukemia cells to apoptosis induction. *J. Clin. Invest.* **120**, 142–156 (2010).
- 225. del Río, L. A., Sandalio, L. M., Palma, J. M., Bueno, P. & Corpas, F. J. Metabolism of oxygen radicals in peroxisomes and cellular implications. *Free Radic. Biol. Med.* **13**, 557–580 (1992).
- 226. Purohit, V., Simeone, D. M. & Lyssiotis, C. A. Metabolic Regulation of Redox Balance in Cancer. *Cancers (Basel).* **11**, 955 (2019).
- 227. Rasool, M. *et al.* Assessment of circulating biochemical markers and antioxidative status in acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML) patients. *Saudi J.*

Biol. Sci. 22, 106–111 (2015).

- 228. Wu, G., Fang, Y.-Z., Yang, S., Lupton, J. R. & Turner, N. D. Glutathione Metabolism and Its Implications for Health. *J. Nutr.* **134**, 489–492 (2004).
- 229. Garcia-Ruiz, C. & Fernandez-Checa, J. C. Mitochondrial glutathione: Hepatocellular survivaldeath switch. *J. Gastroenterol. Hepatol.* **21**, 3–6 (2006).
- Hangauer, M. J. *et al.* Drug-tolerant persister cancer cells are vulnerable to GPX4 inhibition.
 Nature 551, 247–250 (2017).
- Short, S. P. & Williams, C. S. Selenoproteins in Tumorigenesis and Cancer Progression. *Adv. Cancer Res.* 136, 49–83 (2017).
- 232. Zhu, Z. *et al.* Glutathione reductase mediates drug resistance in glioblastoma cells by regulating redox homeostasis. *J. Neurochem.* **144**, 93–104 (2018).
- Zhang, H., Jay Forman, H. & Choi, J. γ-Glutamyl Transpeptidase in Glutathione Biosynthesis.
 in *Methods in Enzymology* **401**, 468–483 (2005).
- Allocati, N., Masulli, M., Di Ilio, C. & Federici, L. Glutathione transferases: substrates, inihibitors and pro-drugs in cancer and neurodegenerative diseases. *Oncogenesis* 7, 8 (2018).
- Al Tameemi, W., Dale, T. P., Al-Jumaily, R. M. K. & Forsyth, N. R. Hypoxia-Modified Cancer Cell Metabolism. *Front. Cell Dev. Biol.* 7, 1–15 (2019).
- 236. Pouysségur, J., Dayan, F. & Mazure, N. M. Hypoxia signalling in cancer and approaches to enforce tumour regression. *Nature* **441**, 437–443 (2006).
- 237. Simon, M. C. & Keith, B. The role of oxygen availability in embryonic development and stem cell function. *Nat. Rev. Mol. Cell Biol.* **9**, 285–296 (2008).
- Wang, G. L., Jiang, B. H., Rue, E. A. & Semenza, G. L. Hypoxia-inducible factor 1 is a basichelix-loop-helix-PAS heterodimer regulated by cellular O2 tension. *Proc. Natl. Acad. Sci. U. S. A.* 92, 5510–4 (1995).
- 239. Petrova, V., Annicchiarico-Petruzzelli, M., Melino, G. & Amelio, I. The hypoxic tumour microenvironment. *Oncogenesis* **7**, 10 (2018).

- 240. Weidemann, A. & Johnson, R. S. Biology of HIF-1α. *Cell Death Differ*. **15**, 621–627 (2008).
- 241. Goda, N. & Kanai, M. Hypoxia-inducible factors and their roles in energy metabolism. *Int. J. Hematol.* **95**, 457–463 (2012).
- 242. Al Tameemi, W., Dale, T. P., Al-Jumaily, R. M. K. & Forsyth, N. R. Hypoxia-Modified Cancer Cell Metabolism. *Front. Cell Dev. Biol.* **7**, 1–15 (2019).
- Seo, B. R., DelNero, P. & Fischbach, C. In vitro models of tumor vessels and matrix:
 Engineering approaches to investigate transport limitations and drug delivery in cancer.
 Adv. Drug Deliv. Rev. 69–70, 205–216 (2014).
- 244. Vaupel, P. Hypoxia and Aggressive Tumor Phenotype: Implications for Therapy and Prognosis. *Oncologist* **13**, 21–26 (2008).
- 245. Trédan, O., Galmarini, C. M., Patel, K. & Tannock, I. F. Drug resistance and the solid tumor microenvironment. *J. Natl. Cancer Inst.* **99**, 1441–1454 (2007).
- 246. Rieger, C. T. & Fiegl, M. Microenvironmental oxygen partial pressure in acute myeloid leukemia: Is there really a role for hypoxia? *Exp. Hematol.* **44**, 578–582 (2016).
- 247. Deynoux, M., Sunter, N., Hérault, O. & Mazurier, F. Hypoxia and hypoxia-inducible factors in leukemias. *Front. Oncol.* **6**, 1–9 (2016).
- Fiegl, M. *et al.* Physiological hypoxia promotes lipid raft and PI3K-dependent activation of MAPK 42/44 in leukemia cells. *Leukemia* 24, 1364–7 (2010).
- 249. Drolle, H. *et al.* Hypoxia regulates proliferation of acute myeloid leukemia and sensitivity against chemotherapy. *Leuk. Res.* **39**, 779–785 (2015).
- 250. Jensen, P. O. *et al.* Increased cellular hypoxia and reduced proliferation of both normal and leukaemic cells during progression of acute myeloid leukaemia in rats. *Cell Prolif.* 33, 381–395 (2000).
- 251. Forristal, C. E. *et al.* Hypoxia inducible factor (HIF)-2α accelerates disease progression in mouse models of leukemia and lymphoma but is not a poor prognosis factor in human AML. *Leukemia* 29, 2075–2085 (2015).
- 252. Coltella, N. et al. HIF factors cooperate with PML-RARα to promote acute promyelocytic

leukemia progression and relapse. EMBO Mol. Med. 6, 640-50 (2014).

- 253. Zhang, H., Li, H., Xi, H. S. & Li, S. HIF1α is required for survival maintenance of chronic myeloid leukemia stem cells. *Blood* **119**, 2595–2607 (2012).
- 254. Deeb, G. *et al.* Hypoxia-inducible factor-1α protein expression is associated with poor survival in normal karyotype adult acute myeloid leukemia. *Leuk. Res.* **35**, 579–584 (2011).
- 255. Zhe, N. *et al.* Heme oxygenase-1 plays a crucial role in chemoresistance in acute myeloid leukemia. *Hematology* **20**, 384–391 (2015).
- Ito, K. & Suda, T. Metabolic requirements for the maintenance of self-renewing stem cells.
 Nat. Rev. Mol. Cell Biol. 15, 243–256 (2014).
- 257. Ito, K. *et al.* A PML-PPAR-δ pathway for fatty acid oxidation regulates hematopoietic stem cell maintenance. *Nat. Med.* 18, 1350–1358 (2012).
- 258. Takubo, K. *et al.* Regulation of glycolysis by Pdk functions as a metabolic checkpoint for cell cycle quiescence in hematopoietic stem cells. *Cell Stem Cell* **12**, 49–61 (2013).
- Bhanot, H. *et al.* Acute myeloid leukemia cells require 6-phosphogluconate dehydrogenase for cell growth and NADPH-dependent metabolic reprogramming. *Oncotarget* 8, 67639– 67650 (2017).
- Farge, T. *et al.* Chemotherapy-Resistant Human Acute Myeloid Leukemia Cells Are Not Enriched for Leukemic Stem Cells but Require Oxidative Metabolism. *Cancer Discov.* 7, 716– 735 (2017).
- Noel, B. M. *et al.* Multiomic Profiling of Tyrosine Kinase Inhibitor-Resistant K562 Cells Suggests Metabolic Reprogramming To Promote Cell Survival. *J. Proteome Res.* 18, 1842– 1856 (2019).
- Cunningham, I. & Kohno, B. 18 FDG-PET/CT: 21st century approach to leukemic tumors in 124 cases. *Am. J. Hematol.* **91**, 379–384 (2016).
- Herst, P. M., Howman, R. A., Neeson, P. J., Berridge, M. V. & Ritchie, D. S. The level of glycolytic metabolism in acute myeloid leukemia blasts at diagnosis is prognostic for clinical outcome. *J. Leukoc. Biol.* 89, 51–55 (2011).

- 264. Chen, W.-L. *et al.* A distinct glucose metabolism signature of acute myeloid leukemia with prognostic value. *Blood* **124**, 1645–1654 (2014).
- 265. Xu, Q., Simpson, S.-E., Scialla, T. J., Bagg, A. & Carroll, M. Survival of acute myeloid leukemia cells requires PI3 kinase activation. *Blood* **102**, 972–980 (2003).
- 266. Tamburini, J. *et al.* Protein synthesis is resistant to rapamycin and constitutes a promising therapeutic target in acute myeloid leukemia. *Blood* **114**, 1618–1627 (2009).
- 267. Poulain, L. *et al.* High mTORC1 activity drives glycolysis addiction and sensitivity to G6PD inhibition in acute myeloid leukemia cells. *Leukemia* **31**, 2326–2335 (2017).
- Wang, Y.-H. *et al.* Cell-state-specific metabolic dependency in hematopoiesis and leukemogenesis. *Cell* **158**, 1309–1323 (2014).
- 269. Skrtić, M. *et al.* Inhibition of mitochondrial translation as a therapeutic strategy for human acute myeloid leukemia. *Cancer Cell* **20**, 674–88 (2011).
- Sriskanthadevan, S. *et al.* AML cells have low spare reserve capacity in their respiratory chain that renders them susceptible to oxidative metabolic stress. *Blood* 125, 2120–2130 (2015).
- Pardee, T. S. *et al.* A phase I study of the first-in-class mitochondrial metabolism inhibitor
 CPI-613 in patients with advanced hematologic malignancies. Subcategory: *Clin Cancer Res* 20, 5255–5264 (2013).
- 272. Kreitz et al. Metabolic Plasticity of Acute Myeloid Leukemia. Cells 8, 805 (2019).
- Parlati, F. *et al.* Antitumor Activity Of The Glutaminase Inhibitor CB-839 In Hematological Malignances. *Blood* 122, 4226–4226 (2013).
- 274. Miraki-Moud, F. *et al.* Arginine deprivation using pegylated arginine deiminase has activity against primary acute myeloid leukemia cells in vivo. *Blood* **125**, 4060–4068 (2015).
- 275. Raffel, S. *et al.* BCAT1 restricts αKG levels in AML stem cells leading to IDHmut-like DNA hypermethylation. *Nature* **551**, 384 (2017).
- 276. Hattori, A. *et al.* Cancer progression by reprogrammed BCAA metabolism in myeloid leukaemia. *Nature* **545**, 500–504 (2017).

- 277. Stirewalt, D. L., Appelbaum, F. R., Willman, C. L., Zager, R. A. & Banker, D. E. Mevastatin can increase toxicity in primary AMLs exposed to standard therapeutic agents, but statin efficacy is not simply associated with ras hotspot mutations or overexpression. *Leuk. Res.*27, 133–45 (2003).
- 278. Lishner, M., Bar-Sef, A., Elis, A. & Fabian, I. Effect of Simvastatin Alone and in Combination With Cytosine Arabinoside on the Proliferation of Myeloid Leukemia Cell Lines. *J. Investig. Med.* 49, 319–324 (2001).
- Holstein, S. A. & Hohl, R. J. Interaction of cytosine arabinoside and lovastatin in human leukemia cells. *Leuk. Res.* 25, 651–660 (2001).
- 280. Kuntz, E. M. An Investigation of Metabolic Vulnerabilities in Chronic Myeloid Leukaemic Stem Cells. (2017).
- 281. Kuntz, E. M. *et al.* Targeting mitochondrial oxidative phosphorylation eradicates therapyresistant chronic myeloid leukemia stem cells. *Nat. Med.* **23**, 1234–1240 (2017).
- 282. Giustacchini, A. *et al.* Single-cell transcriptomics uncovers distinct molecular signatures of stem cells in chronic myeloid leukemia. *Nat. Med.* **23**, 692–702 (2017).
- 283. Patel, A. B., O'Hare, T. & Deininger, M. W. Mechanisms of Resistance to ABL Kinase Inhibition in Chronic Myeloid Leukemia and the Development of Next Generation ABL Kinase Inhibitors. *Hematol. Oncol. Clin. North Am.* **31**, 589–612 (2017).
- Ward, P. S. & Thompson, C. B. Metabolic reprogramming: a cancer hallmark even warburg did not anticipate. *Cancer Cell* 21, 297–308 (2012).
- Stäubert, C. *et al.* Rewired metabolism in drug-resistant leukemia cells: A metabolic switch hallmarked by reduced dependence on exogenous glutamine. *J. Biol. Chem.* 290, 8348– 8359 (2015).
- Boren, J. *et al.* Gleevec (STI571) Influences Metabolic Enzyme Activities and Glucose Carbon
 Flow toward Nucleic Acid and Fatty Acid Synthesis in Myeloid Tumor Cells. *J. Biol. Chem.* 276, 37747–37753 (2001).
- 287. Gottschalk, S. *et al.* Imatinib (STI571) -Mediated Changes in Glucose Metabolism in Human Leukemia BCR-ABL-Positive Cells Imatinib (STI571) -Mediated Changes in Glucose

Metabolism in. 10, 6661–6668 (2004).

- 288. Breccia, M. & Alimena, G. The metabolic consequences of imatinib mesylate: Changes on glucose, lypidic and bone metabolism. *Leuk. Res.* **33**, 871–5 (2009).
- 289. Poliaková, M., Aebersold, D. M., Zimmer, Y. & Medová, M. The relevance of tyrosine kinase inhibitors for global metabolic pathways in cancer. *Mol. Cancer* **17**, 27 (2018).
- Chakraborty, S., Hosen, M. I., Ahmed, M. & Shekhar, H. U. Onco-Multi-OMICS Approach: A New Frontier in Cancer Research. *Biomed Res. Int.* 2018, 1–14 (2018).
- Yugi, K., Kubota, H., Hatano, A. & Kuroda, S. Trans-Omics: How To Reconstruct Biochemical Networks Across Multiple 'Omic' Layers. *Trends Biotechnol.* 34, 276–290 (2016).
- 292. Aslam, B., Basit, M., Nisar, M. A., Khurshid, M. & Rasool, M. H. Proteomics: Technologies and their applications. *J. Chromatogr. Sci.* **55**, 182–196 (2017).
- 293. Ong, S.-E. & Mann, M. Stable Isotope Labeling by Amino Acids in Cell Culture for Quantitative Proteomics. in *Journal of Chemical Information and Modeling* 53, 37–52 (2007).
- Jakobsen, L., Schrøder, J. M., Larsen, K. M., Lundberg, E. & Andersen, J. S. Centrosome Isolation and Analysis by Mass Spectrometry-Based Proteomics. in *Methods in Enzymology* 525, 371–393 (Elsevier Inc., 2013).
- 295. Terzi, F. & Cambridge, S. An Overview of Advanced SILAC-Labeling Strategies for Quantitative Proteomics. in *Methods in Enzymology* **585**, 29–47 (2017).
- 296. Chen, M.-J. M. *et al.* TCPA v3.0: An Integrative Platform to Explore the Pan-Cancer Analysis of Functional Proteomic Data. *Mol. Cell. Proteomics* **18**, S15–S25 (2019).
- 297. Hasin, Y., Seldin, M. & Lusis, A. Multi-omics approaches to disease. *Genome Biol.* 18, 1–15 (2017).
- 298. Gowda, G. A. N. & Djukovic, D. Overview of mass spectrometry-based metabolomics: opportunities and challenges. *Methods Mol. Biol.* **1198**, 3–12 (2014).
- 299. Yang, K. *et al.* A Comprehensive Analysis of Metabolomics and Transcriptomics in Cervical Cancer. *Sci. Rep.* **7**, 1–11 (2017).

- 300. Coene, K. L. M. *et al.* Next-generation metabolic screening: targeted and untargeted metabolomics for the diagnosis of inborn errors of metabolism in individual patients. *J. Inherit. Metab. Dis.* **41**, 337–353 (2018).
- Roberts, L. D., Souza, A. L., Gerszten, R. E. & Clish, C. B. Targeted Metabolomics. *Curr. Protoc. Mol. Biol.* 98, 30.2.1-30.2.24 (2012).
- Zhang, X., Zhu, X., Wang, C., Zhang, H. & Cai, Z. Non-targeted and targeted metabolomics approaches to diagnosing lung cancer and predicting patient prognosis. *Oncotarget* 7, 63437–63448 (2016).
- Vinayavekhin, N. & Saghatelian, A. Untargeted Metabolomics. in *Current Protocols in Molecular Biology* 90, 1–24 (John Wiley & Sons, Inc., 2010).
- 304. Lee, W.-N. P. & Go, V. L. W. Nutrient-gene interaction: tracer-based metabolomics. J. Nutr.
 135, 3027S-3032S (2005).
- 305. Paul Lee, W.-N., Wahjudi, P. N., Xu, J. & Go, V. L. Tracer-based metabolomics: Concepts and practices. *Clin. Biochem.* **43**, 1269–1277 (2010).
- Misra, B. B., Langefeld, C. D., Olivier, M. & Cox, L. A. Integrated Omics: Tools, Advances, and Future Approaches. J. Mol. Endocrinol. 62, R21–R45 (2018).
- 307. DeBerardinis, R. J. & Chandel, N. S. Fundamentals of cancer metabolism. *Sci. Adv.* **2**, e1600200 (2016).
- De Atauri, P. *et al.* Carbon metabolism and the sign of control coefficients in metabolic adaptations underlying K-ras transformation. *Biochim. Biophys. Acta - Bioenerg.* 1807, 746– 754 (2011).
- Christian, L. & Ulrich, G. MetaboLab-advanced NMR data processing and analysis for metabolomics. *BMC Bioinformatics* 12, 366 (2011).
- 310. Pesta, D. & Gnaiger, E. *Mitochondrial Bioenergetics*. **810**, (Humana Press, 2012).
- 311. Cox, J. & Mann, M. MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification. *Nat. Biotechnol.* 26, 1367–72 (2008).

- 312. Cox, J. *et al.* Andromeda: A peptide search engine integrated into the MaxQuant environment. *J. Proteome Res.* **10**, 1794–1805 (2011).
- 313. Tyanova, S. *et al.* The Perseus computational platform for comprehensive analysis of (prote)omics data. *Nat. Methods* **13**, 731–740 (2016).
- 314. Cox, J. & Mann, M. MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification. *Nat. Biotechnol.* 26, 1367–72 (2008).
- Luo, W., Pant, G., Bhavnasi, Y. K., Blanchard, S. G. & Brouwer, C. Pathview Web: User friendly pathway visualization and data integration. *Nucleic Acids Res.* 45, W501–W508 (2017).
- 316. Mi, H. *et al.* Protocol Update for large-scale genome and gene function analysis with the PANTHER classification system (v.14.0). *Nat. Protoc.* **14**, 703–721 (2019).
- 317. Jinek, M. *et al.* A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. *Science* **337**, 816–21 (2012).
- 318. Engler, C., Kandzia, R. & Marillonnet, S. A One Pot, One Step, Precision Cloning Method with High Throughput Capability. *PLoS One* **3**, e3647 (2008).
- Network, N. C. C. NCCN Clinical Practice Guidelines in Oncology: Acute Myeloid Leukemia. National Comprehensive Cancer 1, 2019 (2019).
- 320. Son, B. *et al.* Decreased FBP1 expression rewires metabolic processes affecting aggressiveness of glioblastoma. *Oncogene* **39**, 36–49 (2020).
- 321. Guo, B., Huang, X., Lee, M. R., Lee, S. A. & Broxmeyer, H. E. Antagonism of PPAR-γ signaling expands human hematopoietic stem and progenitor cells by enhancing glycolysis. *Nat. Med.* 24, 360–367 (2018).
- Panina, S. B., Baran, N., Brasil da Costa, F. H., Konopleva, M. & Kirienko, N. V. A mechanism for increased sensitivity of acute myeloid leukemia to mitotoxic drugs. *Cell Death Dis.* 10, (2019).
- 323. Asher, G., Bercovich, Z., Tsvetkov, P., Shaul, Y. & Kahana, C. 20S Proteasomal Degradation of Ornithine Decarboxylase Is Regulated by NQO1. *Mol. Cell* **17**, 645–655 (2005).

- 324. Marín de Mas, I. *et al.* Model-driven discovery of long-chain fatty acid metabolic reprogramming in heterogeneous prostate cancer cells. *PLoS Comput. Biol.* 14, e1005914 (2018).
- 325. Ong, S. E. *et al.* Identifying the proteins to which small-molecule probes and drugs bind in cells. *Proc. Natl. Acad. Sci. U. S. A.* **106**, 4617–4622 (2009).
- 326. Flis, S. & Chojnacki, T. Chronic myelogenous leukemia, a still unsolved problem: pitfalls and new therapeutic possibilities. *Drug Des. Devel. Ther.* **13**, 825–843 (2019).
- 327. Will, Y. *et al.* Effect of the multitargeted tyrosine kinase inhibitors imatinib, dasatinib, sunitinib, and sorafenib on mitochondrial function in isolated rat heart mitochondria and H9c2 cells. *Toxicol. Sci.* **106**, 153–161 (2008).
- Jones, D. *et al.* Laboratory practice guidelines for detecting and reporting BCR-ABL drug resistance mutations in chronic myelogenous leukemia and acute lymphoblastic leukemia.
 J. Mol. Diagnostics 11, 4–11 (2009).
- 329. Kenakin, T. P. Pharmacology. in *Pharmacology in Drug Discovery and Development* 1–20 (Elsevier, 2017).
- 330. Richter, S. *et al.* Expression and role in glycolysis of human ADP-dependent glucokinase.
 Mol. Cell. Biochem. 364, 131–45 (2012).
- Schindler, A. & Foley, E. Hexokinase 1 blocks apoptotic signals at the mitochondria. *Cell. Signal.* 25, 2685–2692 (2013).
- 332. Favaro, E. *et al.* Glucose utilization via glycogen phosphorylase sustains proliferation and prevents premature senescence in cancer cells. *Cell Metab.* **16**, 751–764 (2012).
- Hussien, R. & Brooks, G. A. Mitochondrial and plasma membrane lactate transporter and lactate dehydrogenase isoform expression in breast cancer cell lines. *Physiol. Genomics* 43, 255–64 (2011).
- 334. Chiaradonna, F., Ricciardiello, F. & Palorini, R. The Nutrient-Sensing Hexosamine
 Biosynthetic Pathway as the Hub of Cancer Metabolic Rewiring. *Cells* 7, 53 (2018).
- 335. Akella, N. M., Ciraku, L. & Reginato, M. J. Fueling the fire: emerging role of the hexosamine biosynthetic pathway in cancer. *BMC Biol.* **17**, 52 (2019).

- Goubert, E. *et al.* Inhibition of the Mitochondrial Glutamate Carrier SLC25A22 in Astrocytes
 Leads to Intracellular Glutamate Accumulation. *Front. Cell. Neurosci.* 11, 1–15 (2017).
- Espinosa-Diez, C. et al. Antioxidant responses and cellular adjustments to oxidative stress. *Redox Biol.* 6, 183–197 (2015).
- 338. Tew, K. D. *et al.* The role of glutathione S-transferase P in signaling pathways and S-glutathionylation in cancer. *Free Radic. Biol. Med.* **51**, 299–313 (2011).
- Bachhawat, A. K., Thakur, A., Kaur, J. & Zulkifli, M. Glutathione transporters. *Biochim. Biophys. Acta Gen. Subj.* 1830, 3154–3164 (2013).
- 340. Whitaker-Menezes, D. *et al.* Hyperactivation of oxidative mitochondrial metabolism in epithelial cancer cells in situ. *Cell Cycle* **10**, 4047–4064 (2011).
- Orr, A. L. *et al.* Novel Inhibitors of Mitochondrial sn-Glycerol 3-phosphate Dehydrogenase.
 PLoS One 9, e89938 (2014).
- 342. Ferdinandusse, S. *et al.* Clinical and biochemical characterization of four patients with mutations in ECHS1. *Orphanet J. Rare Dis.* **10**, 79 (2015).
- 343. Maher, M., Diesch, J., Casquero, R. & Buschbeck, M. Epigenetic-Transcriptional Regulation of Fatty Acid Metabolism and Its Alterations in Leukaemia. *Front. Genet.* **9**, 1–9 (2018).
- Aryal, B. & Rao, V. A. Deficiency in Cardiolipin Reduces Doxorubicin-Induced Oxidative Stress and Mitochondrial Damage in Human B-Lymphocytes. *PLoS One* **11**, e0158376 (2016).
- 345. Ross, D. Novel mechanisms of drug resistance in leukemia. Leukemia 14, 467–473 (2000).
- Apperley, J. F. Part II: Management of resistance to imatinib in chronic myeloid leukaemia. Lancet Oncol. 8, 1116–1128 (2007).
- 347. Zaal, E. A. & Berkers, C. R. The Influence of Metabolism on Drug Response in Cancer. *Front.* Oncol. 8, 1–15 (2018).
- 348. Jia, D. *et al.* Elucidating cancer metabolic plasticity by coupling gene regulation with metabolic pathways. *Proc. Natl. Acad. Sci. U. S. A.* **116**, 3909–3918 (2019).
- 349. Chen, W. L. et al. A distinct glucose metabolism signature of acute myeloid leukemia with

prognostic value. Blood 124, 1645–1654 (2014).

- 350. Henkenius, K. *et al.* Maintenance of cellular respiration indicates drug resistance in acute myeloid leukemia. *Leuk. Res.* **62**, 56–63 (2017).
- Zhang, B. *et al.* FBP1, A Tumor Suppressor and Negative Regulator of Glycolysis, was Epigenetically Silenced in Pancreatic Cancer. *Curr. Signal Transduct. Ther.* 9, 156–163 (2015).
- 352. Olivas, J. & Horng, T. Sugar fuels T-cell memory. *Nat. Cell Biol.* **20**, 2–3 (2018).
- Wallace, K. B., Sardão, V. A. & Oliveira, P. J. Mitochondrial Determinants of Doxorubicin-Induced Cardiomyopathy. *Circ. Res.* 126, 926–941 (2020).
- 354. Kato, Y. *et al.* Acidic extracellular microenvironment and cancer. *Cancer Cell Int.* 13, 89 (2013).
- 355. Bohloli, M., Atashi, A., Soleimani, M., Kaviani, S. & Anbarlou, A. Investigating Effects of Acidic pH on Proliferation, Invasion and Drug-Induced Apoptosis in Lymphoblastic Leukemia. *Cancer Microenviron.* **9**, 119–126 (2016).
- 356. Mookerjee, S. A., Goncalves, R. L. S., Gerencser, A. A., Nicholls, D. G. & Brand, M. D. The contributions of respiration and glycolysis to extracellular acid production. *Biochim. Biophys. Acta Bioenerg.* 1847, 171–181 (2015).
- 357. Seltzer, M. J. *et al.* Inhibition of glutaminase preferentially slows growth of glioma cells with mutant IDH1. *Cancer Res.* **70**, 8981–7 (2010).
- 358. Bateman, L. A. *et al.* Argininosuccinate Synthase 1 is a Metabolic Regulator of Colorectal Cancer Pathogenicity. *ACS Chem. Biol.* **12**, 905–911 (2017).
- 359. Schafer, F. Q. & Buettner, G. R. Redox environment of the cell as viewed through the redox state of the glutathione disulfide/glutathione couple. *Free Radic. Biol. Med.* **30**, 1191–1212 (2001).
- 360. Zeng, D.-F. *et al.* Analysis of drug resistance-associated proteins expressions of patients with the recurrent of acute leukemia via protein microarray technology. *Eur. Rev. Med. Pharmacol. Sci.* **18**, 537–43 (2014).

- Raza, A. *et al.* A phase 2 randomized multicenter study of 2 extended dosing schedules of oral ezatiostat in low to intermediate-1 risk myelodysplastic syndrome. *Cancer* **118**, 2138– 2147 (2012).
- 362. Vilpo, J. A., Veromaa, T. & Eerola, E. Effect of cytosine arabinoside on the human immunosystem: metabolism and cytotoxicity studied with mitogen-stimulated normal blood lymphocytes in vitro. *Int. J. Immunopharmacol.* **10**, 593–600 (1988).
- 363. Dietz, A. B. *et al.* Imatinib mesylate inhibits T-cell proliferation in vitro and delayed-type hypersensitivity in vivo. *Blood* **104**, 1094–1099 (2004).
- 364. Norris, R. E. & Adamson, P. C. Clinical potency of methotrexate, aminopterin, talotrexin and pemetrexed in childhood leukemias. *Cancer Chemother. Pharmacol.* **65**, 1125–1130 (2010).
- 365. Pérez-Velázquez, J., Gevertz, J. L., Karolak, A. & Rejniak, K. A. Microenvironmental Niches and Sanctuaries: A Route to Acquired Resistance. *Adv. Exp. Med. Biol.* **936**, 149–164 (2016).
- 366. Svensson, K. J. *et al.* Hypoxia-Mediated Induction of the Polyamine System Provides Opportunities for Tumor Growth Inhibition by Combined Targeting of Vascular Endothelial Growth Factor and Ornithine Decarboxylase. *Cancer Res.* **68**, 9291–9301 (2008).
- Fedorova, N. E. *et al.* Inhibitor of polyamine catabolism MDL72.527 restores the sensitivity to doxorubicin of monocytic leukemia Thp-1 cells infected with human cytomegalovirus.
 Biochimie 158, 82–89 (2019).

APPENDIX 1

EXTRACELLULAR FLUXES NORMOXIA								
	Kpc (nmol*millioncell-1*h-1)							
	THP-1 P							
Amino acids								
	Mean	SD	Mean	SD	pvalue			
Ala	2.29	1.23	7.60	1.28	0.007			
Arg	D	D	D	D	D			
Asn	-0.84	0.53	0.41	0.90	0.105			
Asp	0.21	0.49	0.26	0.27	0.883			
Cit	-0.03	0.04	-0.02	0.01	0.658			
Gln	-24.37	1.06	-12.51	1.42	0.002			
Glu	11.29	1.48	3.76	0.85	0.005			
Gly	0.87	1.71	0.33	0.43	0.626			
His	-0.57	0.13	-0.17	0.20	0.044			
lle	-2.91	0.79	-0.80	0.12	0.010			
Leu	-3.97	0.63	-1.69	0.12	0.004			
Lys	-2.36	0.33	-1.10	0.08	0.003			
Met	-0.83	0.17	-0.55	0.06	0.049			
Orn	1.27	0.61	2.22	0.20	0.063			
Phe	-0.93	0.14	-0.53	0.05	0.010			
Pro	0.21	0.39	2.35	0.37	0.002			
Ser	-3.91	0.82	-2.73	0.31	0.078			
Thr	-1.32	0.46	-0.13	0.26	0.017			
Trp	-0.35	0.08	-0.13	0.00	0.009			
Tyr	-1.09	0.21	-0.30	0.20	0.009			
Val	-2.16	0.51	-0.97	0.14	0.017			
			Polyamines					
Putrescine	1E-03	7E-04	6E-04	3E-04	0.365			
Spermidine	3E-04	2E-04	1E-04	5E-05	0.214			
Spermine	D	D	D	D	D			

APPENDIX 1: Supplementary data of results of Chapter 1

 Table 1. Extracellular fluxes result of THP-1 and HL-60 Parental cell lines under normoxia. Non-detected amino acids or polyamines or amino acids and polyamines whose replicates were not reproducible are named as discarded (D).

EXTRACELLULAR FLUXES HYPOXIA					
		Kpc (nmc	ol*millioncell-1*h-1	L)	
	THP-1 P	arental	HL-60 P	arental	pvalue
			Amino acids		
	Mean	SD	Mean	SD	pvalue
Ala	-1.36	1.27	10.99	4.55	0.011
Arg	D	D	D	D	D
Asn	-0.29	2.64	0.35	0.32	0.698
Asp	-0.14	2.51	0.18	0.98	0.848
Cit	D	D	0.05	0.07	D
Gln	-3.59	10.99	-13.89	8.46	0.268
Glu	0.36	5.33	8.24	3.94	0.109
Gly	3.33	1.95	4.35	2.71	0.623
His	-0.72	0.64	0.47	0.81	0.116
lle	-0.64	0.20	0.10	0.71	0.156
Leu	-2.41	0.85	-0.28	1.62	0.115
Lys	-2.41	0.90	-0.42	0.85	0.049
Met	-0.70	0.79	-0.33	0.20	0.474
Orn	2.31	0.05	3.13	1.98	0.617
Phe	-0.46	0.42	-0.04	0.11	0.168
Pro	0.76	0.45	2.23	1.05	0.091
Ser	-3.76	2.42	-5.20	1.98	0.471
Thr	0.63	2.73	0.49	0.65	0.935
Trp	0.17	0.22	-0.02	0.10	0.247
Tyr	-0.51	0.41	-0.20	0.10	0.277
Val	-1.90	1.98	-0.25	1.23	0.289
			Poliamines		
Putrescine	6E-03	1E-03	3E-03	2E-03	0.077
Spermidine	5E-03	8E-04	4E-03	2E-03	0.401
Spermine	D	D	D	D	0.675

 Table 2. Extracellular fluxes result of THP-1 and HL-60 Parental cell lines under hypoxia. Non-detected amino

 acids or polyamines or amino acids and polyamines whose replicates were not reproducible are named as

 discarded (D).

UPREGULATED PROTEINS IN TH	HP-1 AraC VS THP-1	 >	
Protein names	Gene names	Mean Log ₂ fold change	SD Log ₂ fold change
Thrombomodulin	THBD	2.69	1.40
Deoxyribonuclease-2-alpha	DNASE2	2.43	0.71
Protein FAM173B	FAM173B	2.38	0.78
Flavin reductase (NADPH)	BLVRB	2.30	0.13
Unconventional myosin-X	MYO10	2.26	N.D.
Amyloid beta A4 protein	APP	2.15	N.D.
Apoptosis regulator Bcl-2	BCL2	2.11	0.26
Heat shock protein beta-1	HSPB1	2.09	0.28
Kynureninase	KYNU	2.06	0.28
Eukaryotic translation initiation factor 3 subunit C ADP-ribosylation factor GTPase-activating protein 1	EIF3C;EIF3CL	2.03	1.16
Serine/arginine repetitive matrix protein 2	ARFGAP1 SRRM2	1.99	N.D. 1.24
Acyl-CoA synthetase family member 2, mitochondrial	ACSF2	1.95	N.D.
Protein AATF	AATF	1.94	N.D.
Protein VPRBP	VPRBP	1.87	1.47
Protein NDRG1	NDRG1	1.75	N.D.
U4/U6.U5 tri-snRNP-associated protein 1	SART1	1.74	0.07
Interferon regulatory factor 2-binding protein 1	IRF2BP1	1.74	N.D.
D-tyrosyl-tRNA(Tyr) deacylase 1	DTD1	1.73	N.D.
N-acetylserotonin O-methyltransferase-like protein	ASMTL	1.63	0.39
Alpha/beta hydrolase domain-containing protein 14B	ABHD14B	1.63	0.15
TBC1 domain family member 1	TBC1D1	1.62	N.D.
Eukaryotic translation initiation factor 4B	EIF4B	1.61	0.35
Protein Red	IK ANO6	1.61	0.87
Anoctamin-6 Bromodomain adjacent to zinc finger domain protein 1A	BAZ1A	1.60 1.57	0.08
Very low-density lipoprotein receptor	VLDLR	1.55	0.02
Gametocyte-specific factor 1	GTSF1	1.55	0.56
Leukosialin (CD43)	SPN	1.53	0.17
Serine/threonine-protein kinase WNK1	WNK1	1.53	0.21
Mitochondrial import inner membrane translocase subunit TIM14	DNAJC19	1.51	0.10
Ubiquitin-conjugating enzyme E2 T	UBE2T	1.48	0.24
Ornithine aminotransferase, mitochondrial	OAT	1.45	0.03
Telomere-associated protein RIF1	RIF1	1.45	0.33
Protein O-GlcNAcase	MGEA5	1.44	0.23
Matrin-3	MATR3	1.43	0.70
Nuclear export mediator factor NEMF	NEMF	1.43	0.19
Mycophenolic acid acyl-glucuronide esterase, mitochondrial	ABHD10	1.42	0.20
Vesicle transport through interaction with t-SNAREs homolog 1B Fascin	VTI1B FSCN1	1.41	0.07
Cyclin-dependent kinases regulatory subunit 1	CKS1B	1.39	0.06
Ribonucleoside-diphosphate reductase subunit M2	RRM2	1.39	0.00
Protein disulfide-isomerase A5	PDIA5	1.39	0.45
mRNA-decapping enzyme 1A	DCP1A	1.37	N.D.
Coiled-coil domain-containing protein 58	CCDC58	1.36	N.D.
Ras GTPase-activating-like protein IQGAP3	IQGAP3	1.35	N.D.
U8 snoRNA-decapping enzyme	NUDT16	1.34	N.D.
ER degradation-enhancing alpha-mannosidase-like protein 1	EDEM1	1.33	N.D.
Insulin-like growth factor 2 mRNA-binding protein 3	IGF2BP3	1.32	0.39
UPF0562 protein C7orf55	C7orf55	1.32	N.D.
MARCKS-related protein	MARCKSL1	1.32	N.D.
DNL-type zinc finger protein	DNLZ	1.32	0.11
Nischarin Tripartite motif-containing protein 65	NISCH	1.31	0.00
CGG triplet repeat-binding protein 1	TRIM65 CGGBP1	1.31	N.D. N.D.
Charged multivesicular body protein 1	CHMP1B	1.31	N.D.
Pterin-4-alpha-carbinolamine dehydratase	PCBD1	1.30	0.59
Collagen type IV alpha-3-binding protein	COL4A3BP	1.29	N.D.
Proteasome subunit beta type-5	PSMB5	1.28	N.D.
Regulatory-associated protein of mTOR	RPTOR	1.28	N.D.
Metaxin-2	MTX2	1.28	0.23
Ubiquitin-conjugating enzyme E2 G1	UBE2G1	1.28	0.01
Gamma-aminobutyric acid receptor-associated protein-like 2	GABARAPL2	1.27	0.17
Arf-GAP with coiled-coil, ANK repeat and PH domain-containing protein 2	ACAP2	1.25	0.49
Melanoma-associated antigen D2	MAGED2	1.24	0.57
Phosphatidylglycerophosphatase and protein-tyrosine phosphatase 1	PTPMT1	1.23	N.D.
Protein FAM162A	FAM162A SUMF2	1.23	N.D.
Sulfatase-modifying factor 2 Tyrosine-protein phosphatase non-receptor type 23	PTPN23	1.23	N.D. N.D.
Succinate-semialdehyde dehydrogenase, mitochondrial	ALDH5A1	1.22	0.50
Insulin-like growth factor 2 mRNA-binding protein 2	IGF2BP2	1.21	0.22
Asparagine synthetase [glutamine-hydrolyzing]	ASNS	1.20	0.11
5-3 exoribonuclease 1	XRN1	1.20	N.D.
E2/E3 hybrid ubiquitin-protein ligase UBE2O	UBE2O	1.20	0.13
1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase beta-3	PLCB3	1.20	N.D.
GTP cyclohydrolase 1 feedback regulatory protein	GCHFR	1.18	N.D.
NTF2-related export protein 2	NXT2	1.18	0.28
CAP-Gly domain-containing linker protein 1	CLIP1	1.17	0.40
Protein C10	C12orf57	1.17	N.D.
Branched-chain-amino-acid aminotransferase, mitochondrial	BCAT2	1.17	0.21

Aldehyde dehydrogenase, mitochondrial	ALDH2	1,17	0,09
Uncharacterized protein KIAA0930	KIAA0930	1,17	0,67
Ubiquitin carboxyl-terminal hydrolase 4	USP4	1,16	N.D.
Sodium bicarbonate cotransporter 3	SLC4A7	1,16	0,39
G2/mitotic-specific cyclin-B1	CCNB1	1,16	0,14
PERQ amino acid-rich with GYF domain-containing protein 2	GIGYF2	1,15	N.D.
WW domain-binding protein 11	WBP11	1,14	1,98
NADH dehydrogenase [ubiquinone] iron-sulfur protein 6, mitochondrial	NDUFS6	1,14	0,00
Kinetochore protein Spc24	SPC24	1,13	N.D.
Annexin A4	ANXA4	1,13	0,16
Endoplasmic reticulum mannosyl-oligosaccharide 1,2-alpha-mannosidase	MAN1B1	1,13	1,72
Lymphocyte antigen 75	LY75	1,12	0,05
60S ribosomal export protein NMD3	NMD3	1,12	N.D.
Coiled-coil domain-containing protein 124	CCDC124	1,11	0,00
Copper homeostasis protein cutC homolog	CUTC	1,11	N.D.
3-hydroxyisobutyryl-CoA hydrolase, mitochondrial	HIBCH	1,10	0,18
Ras-related protein Rab-31	RAB31	1,10	0,06
DCC-interacting protein 13-alpha	APPL1		
		1,10	0,05
Single-stranded DNA-binding protein, mitochondrial	SSBP1	1,09	0,00
Fragile X mental retardation syndrome-related protein 1	FXR1	1,09	1,48
DNA mismatch repair protein Mlh1	MLH1	1,08	N.D.
AT-rich interactive domain-containing protein 1A	ARID1A	1,08	0,48
Reactive oxygen species modulator 1	ROM01	1,07	0,08
E3 ubiquitin-protein ligase CBL	CBL	1,07	0,25
LanC-like protein 1	LANCL1	1,07	0,05
Probable leucinetRNA ligase, mitochondrial	LARS2	1,07	0,48
Importin subunit alpha-5	KPNA1	1,06	0,51
Putative ATP-dependent RNA helicase DHX30	DHX30	1,06	0,26
Peptidase M20 domain-containing protein 2	PM20D2	1,05	0,08
Bromodomain-containing protein 4	BRD4	1,05	N.D.
Splicing factor, arginine/serine-rich 15	SCAF4	1,05	N.D.
KH domain-containing, RNA-binding, signal transduction-associated protein 1	KHDRBS1	1,04	0,76
Kinetochore protein Spc25	SPC25	1,04	0,94
CD166 antigen	ALCAM	1,04	0,28
Cytochrome c oxidase protein 20 homolog	COX20	1,03	N.D.
CKLF-like MARVEL transmembrane domain-containing protein 6	CMTM6	1,03	0,23
THUMP domain-containing protein 3	THUMPD3	1,03	0,59
Alpha-adducin	ADD1	1,03	0,23
E1A-binding protein p400	EP400	1,03	1,19
Ubiquitin carboxyl-terminal hydrolase 11	USP11	1,02	0,46
Phosphoserine aminotransferase	PSAT1	1,02	0,17
HIG1 domain family member 1A, mitochondrial	HIGD1A	1,02	0,06
Replication protein A 14 kDa subunit	RPA3	1,02	0,10
Ubiquitin carboxyl-terminal hydrolase 19	USP19	1,02	0,40
Mitochondrial import inner membrane translocase subunit TIM16	PAM16	1,01	N.D.
Replication protein A 70 kDa DNA-binding subunit	RPA1	1,01	0,38
Gem-associated protein 5	GEMIN5	1,01	0,60
·			
Sorcin	SRI	1,01	N.D.
Thymidylate synthase	TYMS	1,01	0,01
Microtubule-associated protein 4	MAP4	1,00	0,31
Replication protein A 32 kDa subunit	RPA2	1,00	0,54
Plasminogen activator inhibitor 1 RNA-binding protein	SERBP1	1,00	0,58
Oxygen-dependent coproporphyrinogen-III oxidase, mitochondrial	CPOX	0,99	0,07
Glutathione S-transferase Mu 1 and 4	GSTM1;GSTM4	0,99	0,07
High affinity immunoglobulin epsilon receptor subunit gamma	FCER1G	0,99	0,18
Ubiquitin-conjugating enzyme E2 C	UBE2C	0,99	0,81
Metaxin-1	MTX1	0,99	0,10
Girdin	CCDC88A	0,99	N.D.
Pre-rRNA-processing protein TSR1 homolog	TSR1	0,99	0,13
Spectrin alpha chain, non-erythrocytic 1	SPTAN1	0,98	0,13
Condensin complex subunit 2	NCAPH	0,98	0,18
Myocyte-specific enhancer factor 2D	MEF2D	0,98	0,32
ADP-ribosylation factor-related protein 1	ARFRP1	0,98	N.D.
Protein timeless homolog	TIMELESS	0,98	N.D.
Guanidinoacetate N-methyltransferase	GAMT	0,97	N.D.
WD repeat and FYVE domain-containing protein 1	WDFY1	0,97	0,06
Latrophilin-2	LPHN2	0,97	0,73
Neurotrypsin	PRSS12	0,97	N.D.
Protein CDV3 homolog	CDV3	0,97	0,41
Transferrin receptor protein 1	TFRC	0,97	0,01
Enoyl-CoA delta isomerase 1, mitochondrial	ECI1	0,97	0,22
Transcription initiation factor TFIID subunit 9	TAF9B;TAF9	0,97	N.D.
5-demethoxyubiquinone hydroxylase, mitochondrial	COQ7	0,96	N.D.
Calcium-binding mitochondrial carrier protein Aralar2	SLC25A13	0,96	0,12
Ubiquitin carboxyl-terminal hydrolase 10	USP10	0,96	0,43
Epidermal growth factor receptor substrate 15	EPS15	0,95	0,26
	ECSIT	0,95	N.D.
	ECSII	0,95	
Evolutionarily conserved signaling intermediate in Toll pathway, mitochondrial	FROOT	0.04	
DNA repair protein complementing XP-G cells	ERCC5	0,94	1,14
	ERCC5 FNBP1	0,94 0,94	1,14 0,50

RNA-binding protein 12	RBM12	0,94	0,29
NADH dehydrogenase [ubiquinone] 1 alpha subcomplex assembly factor 3	NDUFAF3	0,94	0,52
Reticulocalbin-2	RCN2	0,93	N.D.
Plexin-A1	PLXNA1	0,93	0,50
Protein-tyrosine kinase 2-beta	PTK2B	0,93	0,10
Spectrin beta chain, non-erythrocytic 1	SPTBN1	0,93	0,02
Alpha-endosulfine	ENSA	0,93	N.D.
SWI/SNF complex subunit SMARCC1	SMARCC1	0,93	0,24
HEAT repeat-containing protein 1	HEATR1	0,93	0,12
CD2-associated protein	CD2AP	0,92	N.D.
DNA polymerase epsilon catalytic subunit A	POLE	0,92	0,07
Complex I assembly factor TIMMDC1, mitochondrial	TIMMDC1	0,92	0,16
Cyclin-dependent kinase 2	CDK2	0,92	0,06
E3 ubiquitin-protein ligase UHRF1	UHRF1		
		0,92	0,17
Biorientation of chromosomes in cell division protein 1-like 1	BOD1L1	0,91	N.D.
Mediator of RNA polymerase II transcription subunit 20	MED20	0,91	0,47
WD repeat and HMG-box DNA-binding protein 1	WDHD1	0,91	0,32
DNA mismatch repair protein Msh6	MSH6	0,91	0,00
FAST kinase domain-containing protein 3	FASTKD3	0,91	0,56
Nucleolar protein 56	NOP56	0,90	N.D.
Serpin H1	SERPINH1	0,90	0,02
Endoglin	ENG	0,90	N.D.
Band 4.1-like protein 3;Band 4.1-like protein 3, N-terminally processed	EPB41L3	0,90	0,02
Calcium-binding mitochondrial carrier protein Aralar1	SLC25A12	0,89	0,26
Small integral membrane protein 20	SMIM20	0,89	N.D.
Importin-8	IPO8	0,89	0,00
·	IMPDH2		
Inosine-5-monophosphate dehydrogenase 2		0,89	0,23
Dihydropteridine reductase	QDPR	0,89	0,04
Serine/threonine-protein phosphatase 6 regulatory subunit 1	PPP6R1	0,88	1,36
39S ribosomal protein L12, mitochondrial	MRPL12	0,88	0,30
NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 5, mitochondrial	NDUFB5	0,88	N.D.
DNA replication complex GINS protein PSF3	GINS3	0,88	0,10
Protein jagunal homolog 1	JAGN1	0,87	0,92
Mitotic spindle assembly checkpoint protein MAD2A	MAD2L1	0,87	0,08
PEST proteolytic signal-containing nuclear protein	PCNP	0,87	0,11
Coiled-coil-helix-coiled-coil-helix domain-containing protein 2	CHCHD2;CHCHD2P9	0,87	N.D.
Pterin-4-alpha-carbinolamine dehydratase 2	PCBD2	0,87	N.D.
Putative E3 ubiquitin-protein ligase UBR7	UBR7	0,86	N.D.
	NUTF2		
Nuclear transport factor 2		0,86	0,14
Hypoxanthine-guanine phosphoribosyltransferase	HPRT1	0,86	0,09
Glucosamine 6-phosphate N-acetyltransferase	GNPNAT1	0,86	0,08
Mitochondrial 10-formyltetrahydrofolate dehydrogenase	ALDH1L2	0,85	0,04
Tubulintyrosine ligase-like protein 12	TTLL12	0,85	0,19
Protein SCAF11	SCAF11	0,85	N.D.
Cytoplasmic FMR1-interacting protein 2	CYFIP2	0,85	0,48
Serine/arginine repetitive matrix protein 1	SRRM1	0,85	0,04
Lysine-specific demethylase 3B	KDM3B	0,84	1,04
Mitochondrial import inner membrane translocase subunit Tim23 and 23B	TIMM23;TIMM23B	0,84	N.D.
Insulin-like growth factor 2 mRNA-binding protein 1	IGF2BP1	0,84	0,05
Ubiquitin-like modifier-activating enzyme 5	UBA5	0,84	0,49
Hematopoietic lineage cell-specific protein	HCLS1	0,84	0,23
EKC/KEOPS complex subunit LAGE3	LAGE3		
		0,83	N.D.
Fanconi anemia group D2 protein	FANCD2	0,83	N.D.
Shootin-1	KIAA1598	0,83	N.D.
	EIF4H	0,83	0,24
Eukaryotic translation initiation factor 4H			
DNA replication licensing factor MCM6	MCM6	0,83	0,02
DNA replication licensing factor MCM6 C-terminal-binding protein 1	MCM6 CTBP1	0,83	N.D.
DNA replication licensing factor MCM6 C-terminal-binding protein 1 Zinc finger CCCH domain-containing protein 15	MCM6 CTBP1 ZC3H15	0,83 0,83	N.D. 0,25
DNA replication licensing factor MCM6 C-terminal-binding protein 1 Zinc finger CCCH domain-containing protein 15 RILP-like protein 2	MCM6 CTBP1 ZC3H15 RILPL2	0,83 0,83 0,83	N.D. 0,25 N.D.
DNA replication licensing factor MCM6 C-terminal-binding protein 1 Zinc finger CCCH domain-containing protein 15	MCM6 CTBP1 ZC3H15	0,83 0,83	N.D. 0,25
DNA replication licensing factor MCM6 C-terminal-binding protein 1 Zinc finger CCCH domain-containing protein 15 RILP-like protein 2	MCM6 CTBP1 ZC3H15 RILPL2	0,83 0,83 0,83	N.D. 0,25 N.D.
DNA replication licensing factor MCM6 C-terminal-binding protein 1 Zinc finger CCCH domain-containing protein 15 RILP-like protein 2 Glutathione peroxidase 1	MCM6 CTBP1 ZC3H15 RILPL2 GPX1	0,83 0,83 0,83 0,83	N.D. 0,25 N.D. 0,08
DNA replication licensing factor MCM6 C-terminal-binding protein 1 Zinc finger CCCH domain-containing protein 15 RILP-like protein 2 Glutathione peroxidase 1 Arylsulfatase B	MCM6 CTBP1 ZC3H15 RILPL2 GPX1 ARSB	0,83 0,83 0,83 0,83 0,83 0,82	N.D. 0,25 N.D. 0,08 0,27
DNA replication licensing factor MCM6 C-terminal-binding protein 1 Zinc finger CCCH domain-containing protein 15 RILP-like protein 2 Glutathione peroxidase 1 Arylsulfatase B ATP-binding cassette sub-family F member 1	MCM6 CTBP1 ZC3H15 RILPL2 GPX1 ARSB ABCF1	0,83 0,83 0,83 0,83 0,82 0,82	N.D. 0,25 N.D. 0,08 0,27 0,02
DNA replication licensing factor MCM6 C-terminal-binding protein 1 Zinc finger CCCH domain-containing protein 15 RILP-like protein 2 Glutathione peroxidase 1 Arylsulfatase B ATP-binding cassette sub-family F member 1 Plasma membrane calcium-transporting ATPase 4	MCM6 CTBP1 ZC3H15 RILPL2 GPX1 ARSB ABCF1 ATP2B4	0,83 0,83 0,83 0,83 0,82 0,82 0,82	N.D. 0,25 N.D. 0,08 0,27 0,02 N.D.
DNA replication licensing factor MCM6 C-terminal-binding protein 1 Zinc finger CCCH domain-containing protein 15 RILP-like protein 2 Glutathione peroxidase 1 Arylsulfatase B ATP-binding cassette sub-family F member 1 Plasma membrane calcium-transporting ATPase 4 General transcription factor 3C polypeptide 5 Protein PRRC2A	MCM6 CTBP1 ZC3H15 RILPL2 GPX1 ARSB ABCF1 ATP284 GTF3C5 PRRC2A	0,83 0,83 0,83 0,82 0,82 0,82 0,82 0,82 0,82	N.D. 0,25 N.D. 0,08 0,27 0,02 N.D. N.D. N.D. 0,00
DNA replication licensing factor MCM6 C-terminal-binding protein 1 Zinc finger CCCH domain-containing protein 15 RILP-like protein 2 Glutathione peroxidase 1 Arylsulfatase B ATP-binding cassette sub-family F member 1 Plasma membrane calcium-transporting ATPase 4 General transcription factor 3C polypeptide 5 Protein PRRC2A E3 SUMO-protein ligase RanBP2	MCM6 CTBP1 ZC3H15 RILPL2 GPX1 ARSB ABCF1 ATP2B4 GTF3C5 PRRC2A RANBP2	0,83 0,83 0,83 0,82 0,82 0,82 0,82 0,82 0,82 0,82 0,82	N.D. 0,25 N.D. 0,08 0,27 0,02 N.D. N.D. 0,00 0,13
DNA replication licensing factor MCM6 C-terminal-binding protein 1 Zinc finger CCCH domain-containing protein 15 RILP-like protein 2 Glutathione peroxidase 1 Arylsulfatase B ATP-binding cassette sub-family F member 1 Plasma membrane calcium-transporting ATPase 4 General transcription factor 3C polypeptide 5 Protein PRRC2A E3 SUMO-protein ligase RanBP2 Ribosomal L1 domain-containing protein 1	MCM6 CTBP1 ZC3H15 RILPL2 GPX1 ARSB ABCF1 ATP2B4 GTF3C5 PRRC2A RANBP2 RSL1D1	0,83 0,83 0,83 0,82 0,82 0,82 0,82 0,82 0,82 0,82 0,81	N.D. 0,25 N.D. 0,08 0,27 0,02 N.D. N.D. 0,00 0,13 0,12
DNA replication licensing factor MCM6 C-terminal-binding protein 1 Zinc finger CCCH domain-containing protein 15 RILP-like protein 2 Glutathione peroxidase 1 Arylsulfatase 8 ATP-binding cassette sub-family F member 1 Plasma membrane calcium-transporting ATPase 4 General transcription factor 3C polypeptide 5 Protein PRRC2A E3 SUMO-protein ligase RanBP2 Ribosomal L1 domain-containing protein 1 Mitochondrial import inner membrane translocase subunit Tim17-B	MCM6 CTBP1 ZC3H15 RILPL2 GPX1 ARSB ABCF1 ATP2B4 GTF3C5 PRRC2A RANBP2 RSL1D1 TIMM17B	0,83 0,83 0,83 0,82 0,82 0,82 0,82 0,82 0,82 0,82 0,82	N.D. 0,25 N.D. 0,08 0,27 0,02 N.D. N.D. 0,00 0,13 0,12 N.D.
DNA replication licensing factor MCM6 C-terminal-binding protein 1 Zinc finger CCCH domain-containing protein 15 RILP-like protein 2 Glutathione peroxidase 1 Arylsulfatase 8 ATP-binding cassette sub-family F member 1 Plasma membrane calcium-transporting ATPase 4 General transcription factor 3C polypeptide 5 Protein PRRC2A E3 SUMO-protein ligase RanBP2 Ribosomal L1 domain-containing protein 1 Mitochondrial import inner membrane translocase subunit Tim17-B G patch domain and KOW motifs-containing protein	MCM6 CTBP1 ZC3H15 RILPL2 GPX1 ARSB ABCF1 ATP2B4 GTF3C5 PRRC2A RANBP2 RSLID1 TIMM17B GPKOW	0,83 0,83 0,83 0,82 0,82 0,82 0,82 0,82 0,82 0,82 0,81 0,81 0,81	N.D. 0,25 N.D. 0,08 0,27 0,02 N.D. N.D. 0,00 0,13 0,12 N.D. N.D.
DNA replication licensing factor MCM6 C-terminal-binding protein 1 Zinc finger CCCH domain-containing protein 15 RILP-like protein 2 Glutathione peroxidase 1 Arylsulfatase B ATP-binding cassette sub-family F member 1 Plasma membrane calcium-transporting ATPase 4 General transcription factor 3C polypeptide 5 Protein PRRC2A E3 SUMO-protein ligase RanBP2 Ribosomal L1 domain-containing protein 1 Mitochondrial import inner membrane translocase subunit Tim17-B G patch domain and KOW motifs-containing protein	MCM6 CTBP1 ZC3H15 RILPL2 GPX1 ARS8 ABCF1 ATP284 GTF3C5 PRRC2A RANBP2 RSL1D1 TIMM17B GPKOW LYRM4	0,83 0,83 0,83 0,82 0,82 0,82 0,82 0,82 0,82 0,82 0,81 0,81 0,81 0,81	N.D. 0,25 N.D. 0,08 0,27 0,02 N.D. N.D. 0,00 0,13 0,12 N.D. N.D. N.D.
DNA replication licensing factor MCM6 C-terminal-binding protein 1 Zinc finger CCCH domain-containing protein 15 RILP-like protein 2 Glutathione peroxidase 1 Arylsulfatase B ATP-binding cassette sub-family F member 1 Plasma membrane calcium-transporting ATPase 4 General transcription factor 3C polypeptide 5 Protein PRRC2A E3 SUMO-protein ligase RanBP2 Ribosomal L1 domain-containing protein 1 Mitochondrial import inner membrane translocase subunit Tim17-B G patch domain and KOW motifs-containing protein LYR motifs-containing protein 4 Glycine cleavage system H protein, mitochondrial	MCM6 CTBP1 ZC3H15 RILPL2 GPX1 ARSB ABCF1 ATP2B4 GTF3C5 PRRC2A RANBP2 RSL1D1 TIMM17B GPKOW LYRM4 GCSH	0,83 0,83 0,83 0,82 0,82 0,82 0,82 0,82 0,82 0,82 0,81 0,81 0,81 0,81 0,81 0,81 0,81	N.D. 0,25 N.D. 0,08 0,27 0,02 N.D. N.D. 0,00 0,13 0,12 N.D. N.D. N.D. N.D.
DNA replication licensing factor MCM6 C-terminal-binding protein 1 Zinc finger CCCH domain-containing protein 15 RILP-like protein 2 Glutathione peroxidase 1 Arylsulfatase 8 ATP-binding cassette sub-family F member 1 Plasma membrane calcium-transporting ATPase 4 General transcription factor 3C polypeptide 5 Protein PRRC2A E3 SUMO-protein ligase RanBP2 Ribosomal L1 domain-containing protein 1 Mitochondrial import inner membrane translocase subunit Tim17-B G patch domain and KOW motifs-containing protein LYR motif-containing protein 4 Glycine cleavage system H protein, mitochondrial Rab3 GTPase-activating protein catalytic subunit	MCM6 CTBP1 ZC3H15 RILPL2 GPX1 ARSB ABCF1 ATP2B4 GTF3C5 PRRC2A RANBP2 RSL1D1 TIMM17B GPKOW LYRM4 GCSH RAB3GAP1	0,83 0,83 0,83 0,82 0,82 0,82 0,82 0,82 0,82 0,82 0,82	N.D. 0,25 N.D. 0,27 0,02 N.D. N.D. 0,13 0,12 N.D. N.D. N.D. N.D. N.D. 0,04
DNA replication licensing factor MCM6 C-terminal-binding protein 1 Zinc finger CCCH domain-containing protein 15 RILP-like protein 2 Glutathione peroxidase 1 Arylsulfatase 8 ATP-binding cassette sub-family F member 1 Plasma membrane calcium-transporting ATPase 4 General transcription factor 3C polypeptide 5 Protein PRRC2A E3 SUMO-protein ligase RanBP2 Ribosomal L1 domain-containing protein 1 Mitochondrial import inner membrane translocase subunit Tim17-B G patch domain and KOW motifs-containing protein LYR motif-containing protein 4 Glycine cleavage system H protein, mitochondrial Rab3 GTPase-activating protein catalytic subunit HIG1 domain family member 2A, mitochondrial	MCM6 CTBP1 ZC3H15 RILPL2 GPX1 ARSB ABCF1 ATP2B4 GTF3C5 PRRC2A RANBP2 RSLID1 TIMM17B GPKOW LYRM4 GCSH RAB3GAP1 HIGD2A	0,83 0,83 0,83 0,82 0,82 0,82 0,82 0,82 0,82 0,82 0,82	N.D. 0,25 N.D. 0,08 0,27 0,02 N.D. N.D. 0,00 0,13 0,12 N.D. N.D. N.D. N.D. N.D. 0,04 0,12
DNA replication licensing factor MCM6 C-terminal-binding protein 1 Zinc finger CCH domain-containing protein 15 RiLP-like protein 2 Glutathione peroxidase 1 Arylsulfatase B ATP-binding cassette sub-family F member 1 Plasma membrane calcium-transporting ATPase 4 General transcription factor 3C polypeptide 5 Protein PRRC2A E3 SUMO-protein ligase RanBP2 Ribosomal L1 domain-containing protein 1 Mitochondrial import inner membrane translocase subunit Tim17-B G patch domain and KOW motifs-containing protein LYR motif-containing protein 4 Glycine cleavage system H protein, mitochondrial Rab3 GTPase-activating protein catalytic subunit HIG1 domain family member 2A, mitochondrial Uncharacterized protein C18orf8	MCM6 CTBP1 ZC3H15 RILPL2 GPX1 ARSB ABCF1 ATP284 GTF3C5 PRRC2A RANBP2 RSL1D1 TIMM17B GPKOW LYRM4 GCSH RAB3GAP1 HIGD2A C18orf8	0,83 0,83 0,83 0,82 0,82 0,82 0,82 0,82 0,82 0,82 0,81 0,81 0,81 0,81 0,81 0,81 0,81 0,81	N.D. 0,25 N.D. 0,08 0,27 0,02 N.D. 0,00 0,13 0,12 N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D
DNA replication licensing factor MCM6 C-terminal-binding protein 1 Zinc finger CCCH domain-containing protein 15 RILP-like protein 2 Glutathione peroxidase 1 Arylsulfatase B ATP-binding cassette sub-family F member 1 Plasma membrane calcium-transporting ATPase 4 General transcription factor 3C polypeptide 5 Protein PRRC2A E3 SUMO-protein ligase RanBP2 Ribosomal L1 domain-containing protein 1 Mitochondrial import inner membrane translocase subunit Tim17-B G patch domain and KOW motifs-containing protein LYR motif-containing protein 4 Gilycine cleavage system H protein ratolordrial Rab3 GTPase-activating protein catalytic subunit HIG1 domain family member 2A, mitochondrial UNCharacterized protein C18orf8 DNA replication complex GINS protein SLD5	MCM6 CTBP1 ZC3H15 RILPL2 GPX1 ARSB ABCF1 ATP2B4 GTF3C5 PRRC2A RANBP2 RSLID1 TIMM17B GPKOW LYRM4 GCSH RAB3GAP1 HIGD2A	0,83 0,83 0,83 0,82 0,82 0,82 0,82 0,82 0,82 0,82 0,82	N.D. 0,25 N.D. 0,08 0,27 0,02 N.D. N.D. 0,00 0,13 0,12 N.D. N.D. N.D. N.D. N.D. 0,04 0,12
DNA replication licensing factor MCM6 C-terminal-binding protein 1 Zinc finger CCCH domain-containing protein 15 RILP-like protein 2 Glutathione peroxidase 1 Arylsulfatase B ATP-binding cassette sub-family F member 1 Plasma membrane calcium-transporting ATPase 4 General transcription factor 3C polypeptide 5 Protein PRRC2A E3 SUMO-protein ligase RanBP2 Ribosomal L1 domain-containing protein 1 Mitochondrial import inner membrane translocase subunit Tim17-B G patch domain and KOW motifs-containing protein LYR motif-containing protein 4 Glycine cleavage system H protein, mitochondrial Rab3 GTPase-activating protein calalytic subunit HIG1 domain family member 2A, mitochondrial Uncharacterized protein C18orf8	MCM6 CTBP1 ZC3H15 RILPL2 GPX1 ARSB ABCF1 ATP284 GTF3C5 PRRC2A RANBP2 RSL1D1 TIMM17B GPKOW LYRM4 GCSH RAB3GAP1 HIGD2A C18orf8	0,83 0,83 0,83 0,82 0,82 0,82 0,82 0,82 0,82 0,82 0,81 0,81 0,81 0,81 0,81 0,81 0,81 0,81	N.D. 0,25 N.D. 0,08 0,27 0,02 N.D. 0,00 0,13 0,12 N.D. N.D. N.D. N.D. N.D. N.D. N.D.
DNA replication licensing factor MCM6 C-terminal-binding protein 1 Zinc finger CCCH domain-containing protein 15 RILP-like protein 2 Glutathione peroxidase 1 Arylsulfatase B ATP-binding cassette sub-family F member 1 Plasma membrane calcium-transporting ATPase 4 General transcription factor 3C polypeptide 5 Protein PRRC2A E3 SUMO-protein ligase RanBP2 Ribosomal L1 domain-containing protein 1 Mitochondrial import inner membrane translocase subunit Tim17-B G patch domain and KOW motifs-containing protein LYR motif-containing protein 4 Gilycine cleavage system H protein, mitochondrial Rab3 GTPase-activating protein catalytic subunit HIG1 domain family member 2A, mitochondrial Uncharacterized protein C18orf8 DNA replication complex GINS protein SLD5	MCM6 CTBP1 ZC3H15 RILPL2 GPX1 ARSB ABCF1 ATP2B4 GTF3C5 PRRC2A RANBP2 RSL1D1 TIMM17B GPKOW LYRM4 GCSH RAB3GAP1 HIGD2A C18orf8 GINS4	0,83 0,83 0,83 0,82 0,82 0,82 0,82 0,82 0,82 0,82 0,81 0,81 0,81 0,81 0,81 0,81 0,81 0,80 0,79 0,79 0,79	N.D. 0,25 N.D. 0,27 0,02 N.D. 0,00 0,13 0,12 N.D. N.D.
DNA replication licensing factor MCM6 C-terminal-binding protein 1 Zinc finger CCCH domain-containing protein 15 RILP-like protein 2 Glutathione peroxidase 1 Arylsulfatase B ATP-binding cassette sub-family F member 1 Plasma membrane calcium-transporting ATPase 4 General transcription factor 3C polypeptide 5 Protein PRRC2A E3 SUMO-protein ligase RanBP2 Ribosomal L1 domain-containing protein 1 Mitochondrial import inner membrane translocase subunit Tim17-B G patch domain and KOW motifs-containing protein LYR motif-containing protein 4 Glycine Cleavage system H protein, mitochondrial Rab3 GTPase-activating protein catalytic subunit HIG1 domain family member 2A, mitochondrial Uncharacterized protein ClBosf8 DNA replication complex GINS protein SLD5 DNA-directed RNA polymerase, mitochondrial	MCM6 CTBP1 ZC3H15 RILPL2 GPX1 ARSB ABCF1 ATP2B4 GTF3C5 PRRC2A RANBP2 RSL1D1 TIMM17B GFKOW LYRM4 GCSH RAB3GAP1 HIGD2A C18orf8 GINS4 POLRMT	0,83 0,83 0,83 0,82 0,82 0,82 0,82 0,82 0,82 0,82 0,82	N.D. 0,25 N.D. 0,08 0,27 0,02 N.D. N.D. 0,13 0,13 0,13 N.D. N.D. N.D. N.D. 0,04 0,12 N.D. 0,04 0,12 N.D.
DNA replication licensing factor MCM6 C-terminal-binding protein 1 Zinc finger CCCH domain-containing protein 15 RILP-like protein 2 Glutathione peroxidase 1 Arylsulfatase B ATP-binding cassette sub-family F member 1 Plasma membrane calcium-transporting ATPase 4 General transcription factor 3C polypeptide 5 Protein PRRC2A E 3 SUMO-protein ligase RanBP2 Ribosomal L1 domain-containing protein 1 Mitochondrial import inner membrane translocase subunit Tim17-B G patch domain and KOW motifs-containing protein LYR motif-containing protein 4 Glycine cleavage system H protein, mitochondrial Rab3 GTPase-activating protein catalytic subunit HIG1 domain family member 2A, mitochondrial DNA replication complex GINS protein SLD5 DNA-directed RNA polymerase, mitochondrial Bone morphogenetic protein 8A;Bone morphogenetic protein 88	MCM6 CTBP1 ZC3H15 RILPL2 GPX1 ARSB ABCF1 ATP2B4 GTF3C5 PRRC2A RANBP2 RSL1D1 TIMM17B GPKOW LYRM4 GCSH RAB3GAP1 HIGD2A C18orf8 GINS4 POLRMT BMP8A;BMP8B	0,83 0,83 0,83 0,82 0,82 0,82 0,82 0,82 0,82 0,82 0,81 0,81 0,81 0,81 0,81 0,81 0,81 0,81	N.D. 0,25 N.D. 0,08 0,27 0,02 N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D

E3 ubiquitin-protein ligase HERC2	HERC2	0,78	0,09
Probable ATP-dependent RNA helicase DDX20	DDX20	0,78	N.D.
Succinate dehydrogenase [ubiquinone] flavoprotein subunit, mitochondrial D-3-phosphoglycerate dehydrogenase	SDHA PHGDH	0,78	0,05
	NOC2L	0,78	0,05
Nucleolar complex protein 2 homolog Lysine-specific demethylase 4A	KDM4A	0,78 0,78	0,49 N.D.
Queuine tRNA-ribosyltransferase subunit QTRTD1	QTRTD1	0,78	0,24
Glia maturation factor beta	GMFB	0,77	N.D.
Trans-2-enoyl-CoA reductase, mitochondrial	MECR	0,77	N.D.
Receptor-type tyrosine-protein phosphatase F	PTPRF	0,77	0,79
Extended synaptotagmin-2	ESYT2	0,77	0,25
Zinc finger CCCH domain-containing protein 4	ZC3H4	0,77	N.D.
Glucoside xylosyltransferase 1	GXYLT1	0,77	0,35
Protein Niban	FAM129A	0,77	0,03
N(G),N(G)-dimethylarginine dimethylaminohydrolase 2	DDAH2	0,76	0,32
Phosphoenolpyruvate carboxykinase [GTP], mitochondrial	PCK2	0,76	0,12
Calponin-2	CNN2	0,76	0,72
DNA replication licensing factor MCM3	MCM3	0,76	0,16
RNA pseudouridylate synthase domain-containing protein 2	RPUSD2	0,76	0,53
Protein IWS1 homolog	IWS1	0,76	0,02
Dehydrogenase/reductase SDR family member 7	DHRS7	0,76	N.D.
Kinesin-like protein KIF2A	KIF2A	0,76	1,46
Retinoblastoma-binding protein 5	RBBP5	0,75	0,04
Kinase D-interacting substrate of 220 kDa	KIDINS220	0,75	N.D.
Nuclease-sensitive element-binding protein 1	YBX1	0,75	0,14
Cat eye syndrome critical region protein 5	CECR5	0,75	0,23
FK506-binding protein 15	FKBP15	0,75	0,75
Mitochondrial chaperone BCS1	BCS1L	0,75	N.D.
Guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-10	GNG10	0,75	0,56
GA-binding protein alpha chain	GABPA	0,75	N.D.
Citron Rho-interacting kinase	CIT	0,75	0,47
AT-rich interactive domain-containing protein 3A	ARID3A	0,74	0,04
Cyclin-dependent kinase 4 inhibitor C	CDKN2C	0,74	N.D.
Cystatin-A;Cystatin-A, N-terminally processed	CSTA	0,74	0,04
Pumilio domain-containing protein KIAA0020	KIAA0020	0,73	0,10
Regulator of nonsense transcripts 1	UPF1	0,73	0,21
Sterol O-acyltransferase 1	SOAT1	0,73	0,08
POU domain, class 2, transcription factor 1, 3 and 2	POU2F1;POU2F3;POU2F2	0,73	N.D.
Succinate dehydrogenase assembly factor 2, mitochondrial	SDHAF2	0,73	0,03
RalBP1-associated Eps domain-containing protein 1	REPS1	0,73	N.D.
GMP synthase [glutamine-hydrolyzing]	GMPS	0,73	0,12
Phosphatidylinositol 3,4,5-trisphosphate 5-phosphatase 2	INPPL1	0,73	0,16
Cyclin-dependent kinase 1	CDK1	0,72	0,26
DNA replication licensing factor MCM2	MCM2	0,72	0,01
FH1/FH2 domain-containing protein 1	FHOD1	0,72	N.D.
Inositol 1,4,5-trisphosphate receptor type 1	ITPR1	0,72	0,03
YEATS domain-containing protein 4	YEATS4	0,72	N.D.
Programmed cell death protein 4	PDCD4	0,72	0,08
Small ubiquitin-related modifier 1;Small ubiquitin-related modifier	SUM01	0,72	0,03
Uncharacterized protein C19orf43	C19orf43	0,72	0,60
PHD finger protein 3	PHF3	0,72	N.D.
Protein BRICK1	BRK1	0,71	0,09
ADP-ribosylation factor-like protein 8A	ARL8A	0,71	N.D.
Sulfhydryl oxidase 2	QSOX2	0,71	0,94
Retinoid-inducible serine carboxypeptidase	SCPEP1	0,71	0,09
2,5-phosphodiesterase 12	PDE12	0,71	0,05
39S ribosomal protein L54, mitochondrial	MRPL54 GSTP1	0,71	N.D.
		0,70	0,00
Glutathione S-transferase P		0,70	0,14 0,07
Glutathione S-transferase P tRNA (cytosine(34)-C(5))-methyltransferase	NSUN2		
Glutathione S-transferase P tRNA (cytosine(34)-C(5))-methyltransferase Integrin alpha-L	NSUN2 ITGAL	0,70	
Glutathione S-transferase P tRNA (cytosine(34)-C(5))-methyltransferase Integrin alpha-L U2 snRNP-associated SURP motif-containing protein	NSUN2 ITGAL U2SURP	0,70 0,70	0,73
Glutathione S-transferase P tRNA (cytosine(34)-C(5))-methyltransferase Integrin alpha-L U2 snRNP-associated SURP motif-containing protein F-box-like/WD repeat-containing protein TBL1XR1	NSUN2 ITGAL U2SURP TBL1XR1	0,70 0,70 0,70	0,73 0,08
Glutathione S-transferase P tRNA (cytosine(34)-C(5))-methyltransferase Integrin alpha-L U2 snRNP-associated SURP motif-containing protein F-box-like/WD repeat-containing protein TBL1XR1 Plasminogen receptor (KT)	NSUN2 ITGAL U2SURP TBL1XR1 PLGRKT	0,70 0,70 0,70 0,70	0,73 0,08 N.D.
Glutathione S-transferase P tRNA (cytosine(34)-C(5))-methyltransferase Integrin alpha-L U2 snRNP-associated SURP motif-containing protein F-box-like/WD repeat-containing protein TBL1XR1 Plasminogen receptor (KT) NEDD8-activating enzyme E1 catalytic subunit	NSUN2 ITGAL U2SURP TBL1XR1 PLGRKT UBA3	0,70 0,70 0,70 0,70 0,70 0,70	0,73 0,08 N.D. 0,24
Glutathione S-transferase P tRNA (cytosine(34)-C(5))-methyltransferase Integrin alpha-L U2 snRNP-associated SURP motif-containing protein F-box-like/WD repeat-containing protein TBL1XR1 Plasminogen receptor (KT) NEDD8-activating enzyme E1 catalytic subunit Eukaryotic translation initiation factor 2D	NSUN2 ITGAL UZSURP TBL1XR1 PLGRKT UBA3 EIF2D	0,70 0,70 0,70 0,70 0,70 0,70	0,73 0,08 N.D. 0,24 N.D.
Glutathione S-transferase P tRNA (cytosine(34)-C(5))-methyltransferase Integrin alpha-L U2 snRNP-associated SURP motif-containing protein F-box-like/WD repeat-containing protein TBL1XR1 Plasminogen receptor (KT) NEDD8-activating enzyme E1 catalytic subunit Eukaryotic translation initiation factor 2D Probable helicase senataxin	NSUN2 ITGAL UZSURP TBLIXR1 PLGRKT UBA3 EIF2D SETX	0,70 0,70 0,70 0,70 0,70 0,70 0,69	0,73 0,08 N.D. 0,24 N.D. N.D.
Glutathione S-transferase P tRNA (cytosine(34)-C(5))-methyltransferase Integrin alpha-L U2 snRNP-associated SURP motif-containing protein F-box-like/WD repeat-containing protein TBL1XR1 Plasminogen receptor (KT) NEDD8-activating enzyme E1 catalytic subunit Eukaryotic translation initiation factor 2D Probable helicase senataxin COP9 signalosome complex subunit 7b	NSUN2 ITGAL U2SURP TBL1XR1 PLGRKT UBA3 EIF2D SETX COPS7B	0,70 0,70 0,70 0,70 0,70 0,70 0,69 0,69	0,73 0,08 N.D. 0,24 N.D. N.D. N.D.
Glutathione S-transferase P tRNA (cytosine(34)-C(5))-methyltransferase Integrin alpha-L U2 snRNP-associated SURP motif-containing protein F-box-like/WD repeat-containing protein TBL1XR1 Plasminogen receptor (KT) NEDD8-activating enzyme E1 catalytic subunit Eukaryotic translation initiation factor 2D Probable helicase senataxin COP9 signalosome complex subunit 7b Pachytene checkpoint protein 2 homolog	NSUN2 ITGAL U2SURP TBL1XR1 PLGRKT UBA3 EIF2D SETX COP57B TRIP13	0,70 0,70 0,70 0,70 0,70 0,70 0,69 0,69 0,69	0,73 0,08 N.D. 0,24 N.D. N.D. N.D. 0,07
Glutathione S-transferase P tRNA (cytosine(34)-C(5))-methyltransferase Integrin alpha-L U2 snRNP-associated SURP motif-containing protein F-box-like/WD repeat-containing protein TBL1XR1 Plasminogen receptor (KT) NEDD8-activating enzyme E1 catalytic subunit Eukaryotic translation initiation factor 2D Probable helicase senataxin COP9 signalosome complex subunit 7b Pachytene checkpoint protein 2 homolog N-terminal kinase-like protein	NSUN2 ITGAL UZSURP TBL1XR1 PLGRKT UBA3 EIF2D SETX COPS7B TRIP13 SCYL1	0,70 0,70 0,70 0,70 0,70 0,69 0,69 0,69 0,69	0,73 0,08 N.D. 0,24 N.D. N.D. N.D. 0,07 1,33
Glutathione S-transferase P tRNA (cytosine(34)-C(5))-methyltransferase Integrin alpha-L U2 snRNP-associated SURP motif-containing protein F-box-like/WD repeat-containing protein TBL1XR1 Plasminogen receptor (KT) NEDD8-activating enzyme E1 catalytic subunit Eukaryotic translation initiation factor 2D Probable helicase senataxin COP9 signalosome complex subunit 7b Pachytene checkpoint protein 2 homolog N-terminal kinase-like protein Cellular nucleic acid-binding protein	NSUN2 ITGAL U2SURP TBL1XR1 PLGRKT UBA3 EIF2D SETX COP57B TRIP13 SCYL1 CNBP	0,70 0,70 0,70 0,70 0,70 0,70 0,69 0,69 0,69 0,69	0,73 0,08 N.D. 0,24 N.D. N.D. N.D. 0,07 1,33 0,15
Glutathione S-transferase P tRNA (cytosine(34)-C(5))-methyltransferase Integrin alpha-L U2 snRNP-associated SURP motif-containing protein F-box-like/WD repeat-containing protein TBL1XR1 Plasminogen receptor (KT) NEDD8-activating enzyme E1 catalytic subunit Eukaryotic translation initiation factor 2D Probable helicase senataxin COP9 signalosome complex subunit 7b Pachytene checkpoint protein 2 homolog N-terminal kinase-like protein Cellular nucleic acid-binding protein	NSUN2 ITGAL U2SURP TBL1XR1 PLGRKT UBA3 EIF2D SETX COPS7B TRIP13 SCYL1 CNBP TRADD	0,70 0,70 0,70 0,70 0,70 0,70 0,69 0,69 0,69 0,69 0,69	0,73 0,08 N.D. 0,24 N.D. N.D. 0,07 1,33 0,15 N.D.
Glutathione S-transferase P tRNA (cytosine(34)-C(5))-methyltransferase Integrin alpha-L U2 snRNP-associated SURP motif-containing protein F-box-like/WD repeat-containing protein TBL1XR1 Plasminogen receptor (KT) NEDD8-activating enzyme E1 catalytic subunit Eukaryotic translation initiation factor 2D Probable helicase senataxin COP9 signalosome complex subunit 7b Pachytene checkpoint protein 2 homolog N-terminal kinase-like protein Cellular nucleic acid-binding protein UPF0609 protein C4orf27	NSUN2 ITGAL U2SURP TBL1XR1 PLGRKT UBA3 EIF2D SETX COP57B TRIP13 SCYL1 CNBP TRADD C4orf27	0,70 0,70 0,70 0,70 0,70 0,69 0,69 0,69 0,69 0,69 0,69 0,69 0,6	0,73 0,08 N.D. 0,24 N.D. N.D. 0,07 1,33 0,15 N.D. 0,13
Glutathione S-transferase P tRNA (cytosine(34)-C(5))-methyltransferase Integrin alpha-L U2 snRNP-associated SURP motif-containing protein F-box-like/WD repeat-containing protein TBL1XR1 Plasminogen receptor (KT) NEDD8-activating enzyme E1 catalytic subunit Eukaryotic translation initiation factor 2D Probable helicase senataxin COP9 signalosome complex subunit 7b Pachytene checkpoint protein 2 homolog N-terminal kinase-like protein Cellular nucleic acid-binding protein Tumor necrosis factor receptor type 1-associated DEATH domain protein UPF0609 protein C4orf27 Nucleosome-remodeling factor subunit BPTF	NSUN2 ITGAL U2SURP TBL1XR1 PLGRKT UBA3 EIF2D SETX COP57B TRIP13 SCYL1 CNBP TRADD C4orf27 BPTF	0,70 0,70 0,70 0,70 0,70 0,69 0,69 0,69 0,69 0,69 0,69 0,69 0,6	0,73 0,08 N.D. 0,24 N.D. N.D. 0,07 1,33 0,15 N.D. 0,13 N.D.
Glutathione S-transferase P tRNA (cytosine(34)-C(5))-methyltransferase Integrin alpha-L U2 snRNP-associated SURP motif-containing protein F-box-like/WD repeat-containing protein TBL1XR1 Plasminogen receptor (KT) NEDD8-activating enzyme E1 catalytic subunit Eukaryotic translation initiation factor 2D Probable helicase senataxin COP9 signalosome complex subunit 7b Pachytene checkpoint protein 2 homolog N-terminal kinase-like protein Cellular nucleic acid-binding protein Tumor necrosis factor receptor type 1-associated DEATH domain protein UPF0609 protein C4orf27 Nucleosome-remodeling factor subunit BPTF U6 snRNA-associated Sm-like protein LSm7	NSUN2 ITGAL U2SURP TBL1XR1 PLGRKT UBA3 EIF2D SETX COP57B TRIP13 SCYL1 CNBP TRADD C4orf27 BPTF LSM7	0,70 0,70 0,70 0,70 0,70 0,70 0,69 0,69 0,69 0,69 0,69 0,69 0,69 0,6	0,73 0,08 N.D. 0,24 N.D. N.D. 0,07 1,33 0,15 N.D. 0,13 N.D. 0,13
Glutathione S-transferase P tRNA (cytosine(34)-C(5))-methyltransferase Integrin alpha-L U2 snRNP-associated SURP motif-containing protein F-box-like/WD repeat-containing protein TBL1XR1 Plasminogen receptor (KT) NEDD8-activating enzyme E1 catalytic subunit Eukaryotic translation initiation factor 2D Probable helicase senataxin COP9 signalosome complex subunit 7b Pachytene checkpoint protein 2 homolog N-terminal kinase-like protein Cellular nucleic acid-binding protein Tumor necrosis factor receptor type 1-associated DEATH domain protein UPF0609 protein C4orf27 Nucleosome-remodeling factor subunit BPTF U6 snRNA-associated Sm-like protein LSm7 PAX3- and PAX7-binding protein 1	NSUN2 ITGAL U2SURP TBL1XR1 PLGRKT UBA3 EIF2D SETX COPS7B TRIP13 SCYL1 CNBP TRADD C4orf27 BPTF LSM7 PAXBP1	0,70 0,70 0,70 0,70 0,70 0,69 0,69 0,69 0,69 0,69 0,69 0,69 0,6	0,73 0,08 N.D. 0,24 N.D. N.D. 0,07 1,33 0,15 N.D. 0,13 N.D. 0,77 N.D.
Glutathione S-transferase P tRNA (cytosine(34)-C(5))-methyltransferase Integrin alpha-L U2 snRNP-associated SURP motif-containing protein F-box-like/WD repeat-containing protein TBL1XR1 Plasminogen receptor (KT) NEDD8-activating enzyme E1 catalytic subunit Eukaryotic translation initiation factor 2D Probable helicase senataxin COP9 signalosome complex subunit 7b Pachytene checkpoint protein 2 homolog N-terminal kinase-like protein Cellular nucleic acid-binding protein Tumor necrosis factor receptor type 1-associated DEATH domain protein UPF0609 protein C4orf27 Nucleosome-remodeling factor subunit BPTF U6 snRNA-associated Sm-like protein 1 Cell cycle progression protein 1	NSUN2 ITGAL U2SURP TBL1XR1 PLGRKT UBA3 EIF2D SETX COPS7B TRIP13 SCYL1 CNBP TRADD C4orf27 BPTF LSM7 PAXBP1 CCPG1	0,70 0,70 0,70 0,70 0,70 0,69 0,69 0,69 0,69 0,69 0,69 0,69 0,6	0,73 0,08 N.D. 0,24 N.D. N.D. N.D. 0,07 1,33 0,15 N.D. 0,13 N.D. 0,77 N.D. 0,77 N.D.
Glutathione S-transferase P tRNA (cytosine(34)-C(5))-methyltransferase Integrin alpha-L U2 snRNP-associated SURP motif-containing protein F-box-like/WD repeat-containing protein TBL1XR1 Plasminogen receptor (KT) NEDD8-activating enzyme E1 catalytic subunit Eukaryotic translation initiation factor 2D Probable helicase senataxin COP9 signalosome complex subunit 7b Pachytene checkpoint protein 2 homolog N-terminal kinase-like protein Cellular nucleic acid-binding protein Tumor necrosis factor receptor type 1-associated DEATH domain protein UPF0609 protein C4orf27 Nucleosome-remodeling factor subunit BPTF U6 snRNA-associated Sm-like protein 1 Cell cycle progression protein 1 Protein phosphatase 1 regulatory subunit 27	NSUN2 ITGAL U2SURP TBL1XR1 PLGRKT UBA3 EIF2D SETX COP57B TRIP13 SCYL1 CNBP TRADD C4orf27 BPTF LSM7 PAXBP1 CCP61 PPP1R27	0,70 0,70 0,70 0,70 0,70 0,69 0,69 0,69 0,69 0,69 0,69 0,68 0,68 0,68 0,68 0,68 0,68	0,73 0,08 N.D. 0,24 N.D. N.D. N.D. 0,07 1,33 0,15 N.D. 0,13 N.D. 0,13 N.D. 0,77 N.D. 0,06
Glutathione S-transferase P tRNA (cytosine(34)-C(5))-methyltransferase Integrin alpha-L U2 snRNP-associated SURP motif-containing protein F-box-like/WD repeat-containing protein TBL1XR1 Plasminogen receptor (KT) NEDD8-activating enzyme E1 catalytic subunit Eukaryotic translation initiation factor 2D Probable helicase senataxin COP9 signalosome complex subunit 7b Pachytene checkpoint protein 2 homolog N-terminal kinase-like protein Cellular nucleic acid-binding protein Tumor necrosis factor receptor type 1-associated DEATH domain protein UPF0609 protein C4orf27 Nucleosome-remodeling factor subunit BPTF U6 snRNA-associated Sm-like protein 1 Cell cycle progression protein 1	NSUN2 ITGAL U2SURP TBL1XR1 PLGRKT UBA3 EIF2D SETX COPS7B TRIP13 SCYL1 CNBP TRADD C4orf27 BPTF LSM7 PAXBP1 CCPG1	0,70 0,70 0,70 0,70 0,70 0,69 0,69 0,69 0,69 0,69 0,69 0,69 0,6	0,73 0,08 N.D. 0,24 N.D. N.D. N.D. 0,07 1,33 0,15 N.D. 0,13 N.D. 0,13 N.D. 0,77 N.D.

Obg-like ATPase 1	OLA1	0,68	0,11
Phosphatidylinositide phosphatase SAC1	SACM1L	0,68	0,30
Rho GTPase-activating protein 4	ARHGAP4	0,68	0,07
Polypyrimidine tract-binding protein 3	PTBP3	0,67	N.D.
Tubulin beta-4A chain	TUBB4A	0,67	0,14
DNA replication licensing factor MCM4	MCM4	0,67	0,18
Echinoderm microtubule-associated protein-like 4	EML4	0,67	0,49
Calcium uniporter protein, mitochondrial	MCU	0,67	0,06
Phospholipid hydroperoxide glutathione peroxidase, mitochondrial	GPX4	0,67	0,35
Cytochrome c oxidase assembly factor 6 homolog	COA6	0,67	N.D.
CCA tRNA nucleotidyltransferase 1, mitochondrial	TRNT1	0,67	0,06
Prostaglandin E synthase 2; Prostaglandin E synthase 2 truncated form	PTGES2	0,67	0,19
Elongation factor G, mitochondrial	GFM1	0,67	0,08
Pyruvate dehydrogenase E1 component subunit alpha, somatic form, mitochondrial	PDHA1	0,67	0,04
AP-1 complex subunit sigma-1A	AP1S1	0,67	N.D.
TBC1 domain family member 15	TBC1D15	0,67	N.D.
Nuclear pore complex protein Nup50	NUP50	0,67	0,10
Pre-mRNA-splicing factor ATP-dependent RNA helicase PRP16	DHX38	0,67	0,44
DnaJ homolog subfamily B member 1	DNAJB1	0,66	0,03
Ras GTPase-activating protein-binding protein 1	G3BP1	0,66	0,33
Cleavage and polyadenylation specificity factor subunit 4	CPSF4	0,66	N.D.
Lysophospholipase-like protein 1	LYPLAL1	0,66	0,54
	UBE2Z	0,66	0,54 N.D.
Ubiquitin-conjugating enzyme E2 Z			
Tetraspanin-14	TSPAN14	0,66	N.D.
DNA replication licensing factor MCM5	MCM5	0,66	0,13
Crooked neck-like protein 1	CRNKL1	0,66	0,34
Cleavage and polyadenylation specificity factor subunit 2	CPSF2	0,65	0,22
Aflatoxin B1 aldehyde reductase member 2	AKR7A2	0,65	0,06
Cleavage stimulation factor subunit 2	CSTF2	0,65	N.D.
Cytochrome c oxidase subunit 5A, mitochondrial	COX5A	0,65	0,06
Mortality factor 4-like protein 1	MORF4L1	0,65	N.D.
Peptidyl-prolyl cis-trans isomerase FKBP3	FKBP3	0,64	N.D.
Ubiquitin-like protein 5	UBL5	0,64	0,32
Cytochrome c oxidase subunit 6B1	COX6B1	0,64	0,18
Protein QIL1	QIL1	0,64	0,15
Ubiquitin-conjugating enzyme E2 A	UBE2A	0,64	0,37
Ubiquitin carboxyl-terminal hydrolase 47	USP47	0,64	0,21
Eukaryotic translation initiation factor 5B	EIF5B	0,64	0,01
Pyruvate dehydrogenase E1 component subunit beta, mitochondrial	PDHB	0,64	0,15
Seizure 6-like protein 2	SEZ6L2	0,64	0,37
Golgi membrane protein 1	GOLM1	0,63	0,13
Ubiquitin carboxyl-terminal hydrolase 48	USP48	0,63	N.D.
GRIP and coiled-coil domain-containing protein 2	GCC2	0,63	1,09
TGF-beta-activated kinase 1 and MAP3K7-binding protein 1	TAB1	0,63	N.D.
SerinetRNA ligase, mitochondrial	SARS2	0,63	0,22
GTP-binding protein 1	GTPBP1	0,63	0,07
Activator of 90 kDa heat shock protein ATPase homolog 1	AHSA1	0,63	0,15
D-beta-hydroxybutyrate dehydrogenase, mitochondrial	BDH1	0,63	0,17
Poly(ADP-ribose) glycohydrolase ARH3	ADPRHL2	0,63	N.D.
Transcriptional repressor protein YY1	YY1	0,63	N.D.
NEDD8-activating enzyme E1 regulatory subunit	NAE1	0,62	0,02
Casein kinase II subunit alpha	CSNK2A1	0,62	0,07
Zyxin	ZYX	0,62	0,17
Glutaryl-CoA dehydrogenase, mitochondrial	GCDH	0,62	0,02
DnaJ homolog subfamily C member 13	DNAJC13	0,62	0,11
Aminoacylase-1	ACY1	0,62	0,28
High mobility group protein B3	HMGB3	0,62	0,33
Tubulin beta-6 chain	TUBB6	0,62	0,33
Transcription elongation factor A protein 1	TCEA1	0,62	0,14
Tyrosyl-DNA phosphodiesterase 1	TDP1	0,62	0,36
Serine/threonine-protein kinase tousled-like 1	TLK1	0,61	0,57 N.D.
Uridine 5-monophosphate synthas	UMPS		
		0,61	0,15
DCN1-like protein 1	DCUN1D1	0,61	0,08
Selenocysteine-specific elongation factor	EEFSEC	0,61	N.D.
Cutochromo covidaço cubunit 74 veleted aveteia mitechandulat	COX7A2L	0,61	0,05
Cytochrome c oxidase subunit 7A-related protein, mitochondrial	NAD) (4 71 2	0,61	N.D.
Mpv17-like protein 2	MPV17L2		0,18
Mpv17-like protein 2 Serpin B8	SERPINB8	0,61	0.00
Mpv17-like protein 2 Serpin B8 Beta-glucuronidase	SERPINB8 GUSB	0,61 0,61	0,29
Mpv17-like protein 2 Serpin B8 Beta-glucuronidase Sjoegren syndrome/scleroderma autoantigen 1	SERPINB8 GUSB SSSCA1	0,61 0,61 0,61	0,57
Mpv17-like protein 2 Serpin B8 Beta-glucuronidase Sjoegren syndrome/Scleroderma autoantigen 1 Replication factor C subunit 4	SERPINB8 GUSB SSSCA1 RFC4	0,61 0,61 0,61 0,61	0,57 0,13
Mpv17-like protein 2 Serpin B8 Beta-glucuronidase Sjoegren syndrome/scleroderma autoantigen 1 Replication factor C subunit 4 ATP-binding cassette sub-family F member 3	SERPINB8 GUSB SSSCA1 RFC4 ABCF3	0,61 0,61 0,61 0,61 0,61	0,57 0,13 0,23
Mpv17-like protein 2 Serpin B8 Beta-glucuronidase Sjoegren syndrome/scleroderma autoantigen 1 Replication factor C subunit 4 ATP-binding cassette sub-family F member 3 Protein FAM195A	SERPINB8 GUSB SSSCA1 RFC4 ABCF3 FAM195A	0,61 0,61 0,61 0,61 0,61 0,61	0,57 0,13 0,23 N.D.
Mpv17-like protein 2 Serpin B8 Beta-glucuronidase Sjoegren syndrome/scleroderma autoantigen 1 Replication factor C subunit 4 ATP-binding cassette sub-family F member 3 Protein FAM195A DNA replication licensing factor MCM7	SERPINB8 GUSB SSSCA1 RFC4 ABCF3 FAM195A MCM7	0,61 0,61 0,61 0,61 0,61 0,61 0,61	0,57 0,13 0,23 N.D. 0,18
Mpv17-like protein 2 Serpin B8 Beta-glucuronidase Sjoegren syndrome/Scleroderma autoantigen 1 Replication factor C subunit 4 ATP-binding cassette sub-family F member 3 Protein FAM195A DNA replication licensing factor MCM7 ATP-dependent RNA helicase DDX50	SERPINB8 GUSB SSSCA1 RFC4 ABCF3 FAM195A	0,61 0,61 0,61 0,61 0,61 0,61	0,57 0,13 0,23 N.D.
Mpv17-like protein 2 Serpin B8 Beta-glucuronidase Sjoegren syndrome/scleroderma autoantigen 1 Replication factor C subunit 4 ATP-binding cassette sub-family F member 3 Protein FAM195A DNA replication licensing factor MCM7	SERPINB8 GUSB SSSCA1 RFC4 ABCF3 FAM195A MCM7	0,61 0,61 0,61 0,61 0,61 0,61 0,61	0,57 0,13 0,23 N.D. 0,18
Mpv17-like protein 2 Serpin B8 Beta-glucuronidase Sjoegren syndrome/Scleroderma autoantigen 1 Replication factor C subunit 4 ATP-binding cassette sub-family F member 3 Protein FAM195A DNA replication licensing factor MCM7 ATP-dependent RNA helicase DDX50	SERPINB8 GUSB SSSCA1 RFC4 ABCF3 FAM195A MCM7 DDX50	0,61 0,61 0,61 0,61 0,61 0,61 0,61 0,61	0,57 0,13 0,23 N.D. 0,18 0,03
Mpv17-like protein 2 Serpin B8 Beta-glucuronidase Sjoegren syndrome/scleroderma autoantigen 1 Replication factor C subunit 4 ATP-binding cassette sub-family F member 3 Protein FAM195A DNA replication licensing factor MCM7 ATP-dependent RNA helicase DDX50 NudC domain-containing protein 2	SERPINB8 GUSB SSSCA1 RFC4 ABCF3 FAM195A MCM7 DDX50 NUDCD2	0,61 0,61 0,61 0,61 0,61 0,61 0,61 0,61	0,57 0,13 0,23 N.D. 0,18 0,03 0,24
Mpv17-like protein 2 Serpin B8 Beta-glucuronidase Sjoegren syndrome/scleroderma autoantigen 1 Replication factor C subunit 4 ATP-binding cassette sub-family F member 3 Protein FAM195A DNA replication licensing factor MCM7 ATP-dependent RNA helicase DDX50 NudC domain-containing protein 2 Large neutral amino acids transporter small subunit 1	SERPINB8 GUS8 SSSCA1 RFC4 ABCF3 FAM195A MCM7 DDX50 NUDCD2 SLC7A5	$\begin{array}{c} 0,61\\ 0,61\\ 0,61\\ 0,61\\ 0,61\\ 0,61\\ 0,61\\ 0,61\\ 0,61\\ 0,61\\ 0,61\\ \end{array}$	0,57 0,13 0,23 N.D. 0,18 0,03 0,24 0,02
Mpv17-like protein 2 Serpin B8 Beta-glucuronidase Sjoegren syndrome/scleroderma autoantigen 1 Replication factor C subunit 4 ATP-binding cassette sub-family F member 3 Protein FAM195A DNA replication licensing factor MCM7 ATP-dependent RNA helicase DDX50 NudC domain-containing protein 2 Large neutral amino acids transporter small subunit 1 1,2-dihydroxy-3-keto-5-methylthiopentene dioxygenase	SERPINB8 GUS8 SSSCA1 RFC4 ABCF3 FAM195A MCM7 DDX50 NUDCD2 SLC7A5 AD11	$\begin{array}{c} 0,61\\ 0,61\\ 0,61\\ 0,61\\ 0,61\\ 0,61\\ 0,61\\ 0,61\\ 0,61\\ 0,61\\ 0,61\\ 0,61\\ 0,60\\ \end{array}$	0,57 0,13 0,23 N.D. 0,18 0,03 0,24 0,02 0,04
Mpv17-like protein 2 Serpin B8 Beta-glucuronidase Sjoegren syndrome/scleroderma autoantigen 1 Replication factor C subunit 4 ATP-binding cassette sub-family F member 3 Protein FAM195A DNA replication licensing factor MCM7 ATP-dependent RNA helicase DDX50 NudC domain-containing protein 2 Large neutral amino acids transporter small subunit 1 1,2-dihydroxy-3-keto-5-methylthiopentene dioxygenase Rab-like protein 6	SERPINB8 GUS8 SSSCA1 RFC4 ABCF3 FAM195A MCM7 DDX50 NUDCD2 SLC7A5 AD11 RABL6	$\begin{array}{c} 0,61\\ 0,61\\ 0,61\\ 0,61\\ 0,61\\ 0,61\\ 0,61\\ 0,61\\ 0,61\\ 0,61\\ 0,61\\ 0,60\\ 0,60\\ \end{array}$	0,57 0,13 0,23 N.D. 0,18 0,03 0,24 0,02 0,04 0,19

Helicase SKI2W	SKIV2L	0,60	1,04
Oxysterol-binding protein 1	OSBP	0,60	0,09
Glutaminase kidney isoform, mitochondrial	GLS	0,60	1,17
General transcription factor 3C polypeptide 3	GTF3C3	0,60	0,42
39S ribosomal protein L51, mitochondrial	MRPL51	0,60	0,69
Pyruvate dehydrogenase phosphatase regulatory subunit, mitochondrial	PDPR	0,60	1,06
tRNA (guanine(26)-N(2))-dimethyltransferase	TRMT1	0,60	0,20
Alpha-globin transcription factor CP2	TFCP2	0,60	0,23
Condensin-2 complex subunit D3	NCAPD3	0,60	0,07
Small ubiquitin-related modifier 2	SUMO2	0,60	0,32
Mitochondrial import inner membrane translocase subunit Tim8 B	TIMM8B	0,60	0,37
Complement component 1 Q subcomponent-binding protein, mitochondrial	C1QBP	0,59	0,15
Ran-specific GTPase-activating protein	RANBP1	0,59	0,05
Prostaglandin reductase 1	PTGR1	0,59	N.D.
Monofunctional C1-tetrahydrofolate synthase, mitochondrial	MTHFD1L	0,59	0,07
WD repeat-containing protein 3	WDR3	0,59	0,23
Glutamine-dependent NAD(+) synthetase	NADSYN1	0,59	N.D.
CDKN2A-interacting protein	CDKN2AIP	0,59	N.D.
Clathrin interactor 1	CLINT1	0,59	0,28
Importin subunit alpha-7	KPNA6	0,59	N.D.
NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 6	NDUFB6	0,59	N.D.
39S ribosomal protein L40, mitochondrial	MRPL40	0,59	N.D.
Replication factor C subunit 2	RFC2	0,59	0,12
L-xylulose reductase	DCXR	0,59	0,02

Table 3. Upregulated proteins in THP-1 AraC compared to THP-1 P cells under normoxia. Proteomic profiling (SILAC) data were used. Significantly upregulated proteins were calculated using the fold difference threshold of 1.5 (log₂ fold change=0.58). Mean±SD for n=2 replicates. Non-detected (N.D.) means less than 2 replicates detected for one protein measured.

DOWNREGULATED PROTEINS IN		D	
Protein names	Gene names	Mean Log ₂ fold change	SD Log ₂ fold change
Arachidonate 5-lipoxygenase-activating protein	ALOX5AP	-5.07	N.D.
Apolipoprotein B-100;Apolipoprotein B-48	APOB	-5.07	N.D.
Deoxycytidine kinase	DCK	-4.36	N.D.
Desmoplakin	DSP	-4.15	0.77
Thymidine phosphorylase	TYMP	-4.08	0.14
Hexokinase-1	HK1	-3.66	N.D.
Carbonyl reductase [NADPH] 1	CBR1	-3.63	0.51
Glycogenin-1	GYG1	-3.56	0.31
Carbonic anhydrase 2	CA2	-3.33	0.65
Keratinocyte proline-rich protein	KPRP	-3.20	1.17
Conserved oligomeric Golgi complex subunit 8 Junction plakoglobin	COG8	-3.11	N.D. 0.90
Vacuolar protein sorting-associated protein 11 homolog	JUP VPS11	-3.08 -3.01	0.90 N.D.
Phospholipase D3	PLD3	-2.99	0.06
Creatine kinase B-type	СКВ	-2.95	0.16
Septin-11	40787	-2.90	0.27
Succinyl-CoA:3-ketoacid coenzyme A transferase 1, mitochondrial	OXCT1	-2.68	0.38
Acetyl-CoA acetyltransferase, cytosolic	ACAT2	-2.59	0.37
Cathepsin G	CTSG	-2.59	0.16
Protein furry homolog	FRY	-2.59	0.64
Engulfment and cell motility protein 1	ELMO1	-2.55	N.D.
Galectin-3	LGALS3	-2.54	N.D.
Receptor expression-enhancing protein 5	REEP5	-2.49	N.D.
Dihydropyrimidine dehydrogenase [NADP(+)]	DPYD	-2.36	0.81
Myeloid cell nuclear differentiation antigen	MNDA TRONI	-2.35	1.04
Two pore calcium channel protein 1 Acylglycerol kinase, mitochondrial	TPCN1 AGK	-2.33 -2.33	N.D. N.D.
Acyigiycerol kinase, mitochondrial Prelamin-A/C;Lamin-A/C	LMNA	-2.33	0.03
Lysozyme C	LYZ	-2.29	0.03
Tripartite motif-containing protein 72	TRIM72	-2.16	N.D.
Unconventional myosin-Ig	MY01G	-2.15	0.02
Isoamyl acetate-hydrolyzing esterase 1 homolog	IAH1	-2.12	0.47
NAD(P)H dehydrogenase [quinone] 1	NQ01	-2.11	0.09
Junctional adhesion molecule A	F11R	-2.11	0.08
Neurochondrin	NCDN	-2.10	N.D.
RNA-binding motif protein	RBMX	-2.04	0.45
Long-chain-fatty-acidCoA ligase 3	ACSL3	-2.00	0.06
Histone H1.2	HIST1H1C	-1.95	1.87
Annexin A1	ANXA1	-1.92	0.32
Ribonuclease T2 Cathepsin L1	RNASET2 CTSL	-1.91 -1.88	0.44 0.26
Fructose-1,6-bisphosphatase 1	FBP1	-1.87	0.28 N.D.
Ribosome production factor 2 homolog	RPF2	-1.86	2.21
Vimentin	VIM	-1.84	0.12
Cytochrome b-245 heavy chain	СУВВ	-1.83	0.47
Glutathione S-transferase Mu 3	GSTM3	-1.81	0.63
Exocyst complex component 1	EXOC1	-1.80	N.D.
Type-1 angiotensin II receptor-associated protein	AGTRAP	-1.78	0.51
BTB/POZ domain-containing protein KCTD12	KCTD12	-1.76	N.D.
Transformer-2 protein homolog alpha	TRA2A	-1.75	0.49
Gamma-glutamylaminecyclotransferase	GGACT	-1.73	0.23
Antigen peptide transporter 1	TAP1	-1.72	0.02
Glutaredoxin-1	GLRX	-1.70	0.30
Carboxypeptidase M	CPM	-1.69	0.28
Tubulin alpha-4A chain Plectin	TUBA4A PLEC	-1.66	0.02
Plectin V-type proton ATPase 116 kDa subunit a isoform 3	TCIRG1	-1.66	0.09 N.D.
Arf-GAP with SH3 domain	ASAP1	-1.64	N.D.
5-nucleotidase domain-containing protein 1	NT5DC1	-1.62	0.16
Methionine aminopeptidase 2	METAP2	-1.62	0.73
Heterogeneous nuclear ribonucleoproteins C1/C2	HNRNPC	-1.62	0.55
RNA-binding protein Raly	RALY	-1.60	0.40
Antigen peptide transporter 2	TAP2	-1.59	0.02
Fumarylacetoacetase	FAH	-1.59	0.01
Polypeptide N-acetylgalactosaminyltransferase 2	GALNT2	-1.58	0.07
Heat shock 70 kDa protein 1B and A	HSPA1B;HSPA1A	-1.56	0.16
Ras-related protein Rab-44	RAB44	-1.56	N.D.
ADP-ribosylation factor-like protein 3	ARL3	-1.56	0.26
Exosome complex exonuclease RRP44 Importin subunit alpha-4	DIS3	-1.56	0.60
Importin subunit alpha-4 Rap guanine nucleotide exchange factor 6	KPNA3 RAPGEF6	-1.55 -1.54	0.26 N.D.
Suppressor of G2 allele of SKP1 homolog	SUGT1	-1.54	0.14
Conserved oligomeric Golgi complex subunit 2	COG2	-1.54	N.D.
DIS3-like exonuclease 2	DIS3L2	-1.53	N.D.
Dipeptidyl peptidase 2	DPP7	-1.52	0.35
Neutrophil cytosol factor 4	NCF4	-1.51	N.D.
Macrosialin	CD68	-1.50	N.D.
Granulins	GRN	-1.50	N.D.
N-acetylgalactosamine-6-sulfatase	GALNS	-1.49	0.48
C-type mannose receptor 2	MRC2	-1.49	0.20

CD70 antigen			
	CD70	-1,48	0,71
Chromatin target of PRMT1 protein	СНТОР	-1,48	0,09
Synaptic vesicle membrane protein VAT-1 homolog	VAT1	-1,47	0,14
TYRO protein tyrosine kinase-binding protein	TYROBP	-1,47	0,14 N.D.
Unconventional myosin-Ic	MYO1C	-1,46	N.D.
Formin-like protein 1	FMNL1	-1,45	0,10
CTP synthase 2	CTPS2	-1,44	0,18
Pyruvate kinase PKM	PKM	-1,44	0,03
Tapasin	TAPBP	-1,44	0,21
6-phosphogluconate dehydrogenase, decarboxylating	PGD	-1,44	0,04
Bifunctional coenzyme A synthase	COASY	-1,43	0,09
Annexin A6	ANXA6	-1,43	0,03
PHD finger protein 6	PHF6	-1,43	N.D.
Protein S100-P	S100P	-1,42	0,17
Hydroxymethylglutaryl-CoA lyase, mitochondrial	HMGCL	-1,42	N.D.
Chitinase-3-like protein 1	CHI3L1	-1,42	0,44
DNA topoisomerase 2-alpha	TOP2A	-1,42	0,37
Acidic fibroblast growth factor intracellular-binding protein	FIBP	-1,41	N.D.
DNA-directed RNA polymerase III subunit RPC2	POLR3B	-1,41	N.D.
Lysosome-associated membrane glycoprotein 1	LAMP1	-1,41	0,67
NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 10, mitochondrial	NDUFA10	-1,41	0,35
Zinc finger ZZ-type and EF-hand domain-containing protein 1	ZZEF1	-1,40	N.D.
ATP-binding cassette sub-family B member 10, mitochondrial	ABCB10	-1,39	0,07
Nuclear receptor coactivator 5	NCOA5	-1,39	N.D.
Protein kinase C beta type	PRKCB	-1,37	0,03
60S ribosomal protein L7-like 1	RPL7L1	-1,37	N.D.
Sortilin-related receptor	SORL1	-1,36	0,44
Synaptophysin-like protein 1	SYPL1	-1,36	0,44 N.D.
60S ribosomal protein L26-like 1	RPL26L1	-1,35	N.D.
RNA-binding protein FUS	FUS	-1,35	0,76
1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase beta-2	PLCB2	-1,34	N.D.
Choline/ethanolaminephosphotransferase 1	CEPT1	-1,33	0,21
Isocitrate dehydrogenase [NADP] cytoplasmic	IDH1	-1,33	0,04
DNA topoisomerase 2-beta	TOP2B	-1,32	0,36
Ras GTPase-activating protein 3	RASA3	-1,31	N.D.
			-
Toll-interacting protein	TOLLIP	-1,31	0,00
U1 small nuclear ribonucleoprotein C	SNRPC	-1,30	0,50
Exportin-4	XPO4	-1,30	0,31
Interleukin-1 receptor-associated kinase 3	IRAK3	-1,30	0,42
Stomatin-like protein 2, mitochondrial	STOML2	-1,29	0,38
Titin	TTN	-1,29	1,89
Plastin-2	LCP1	-1,29	0,07
Myotubularin-related protein 6	MTMR6	-1,28	N.D.
N-acylethanolamine-hydrolyzing acid amidase	NAAA	-1,28	0,03
Transcriptional activator protein Pur-alpha	PURA	-1,28	0,29
V-type proton ATPase subunit d 1	ATP6V0D1	-1,28	0,33
Neutrophil elastase	ELANE	-1,27	0,20
ADP/ATP translocase 1	SLC25A4	-1,27	N.D.
Dual specificity protein phosphatase 23	DUSP23	-1,26	N.D.
NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 12	NDUFA12	-1,25	0,21
Gelsolin	GSN	-1,25	0,06
BRO1 domain-containing protein BROX	BROX	-1,24	0,02
Glutamatecysteine ligase regulatory subunit	GCLM	-1,24	N.D.
	ICAM3	-1,23	1,42
Intercellular adhesion molecule 3			
Intercellular adhesion molecule 3 Nicotinate phosphoribosyltransferase	NAPRT	-1,22	0,03
Nicotinate phosphoribosyltransferase			
Nicotinate phosphoribosyltransferase Lysosomal alpha-glucosidase	NAPRT GAA	-1,22	0,24
Nicotinate phosphoribosyltransferase Lysosomal alpha-glucosidase Glutamatecysteine ligase catalytic subunit	NAPRT GAA GCLC	-1,22 -1,22	0,24 0,65
Nicotinate phosphoribosyltransferase Lysosomal alpha-glucosidase Glutamatecysteine ligase catalytic subunit NADH-ubiquinone oxidoreductase 75 kDa subunit, mitochondrial	NAPRT GAA GCLC NDUFS1	-1,22 -1,22 -1,22	0,24 0,65 0,03
Nicotinate phosphoribosyltransferase Lysosomal alpha-glucosidase Glutamatecysteine ligase catalytic subunit NADH-ubiquinone oxidoreductase 75 kDa subunit, mitochondrial Torsin-1A	NAPRT GAA GCLC NDUFS1 TOR1A	-1,22 -1,22 -1,22 -1,21	0,24 0,65 0,03 0,75
Nicotinate phosphoribosyltransferase Lysosomal alpha-glucosidase Glutamatecysteine ligase catalytic subunit NADH-ubiquinone oxidoreductase 75 kDa subunit, mitochondrial Torsin-1A Serine/arginine-rich splicing factor 10	NAPRT GAA GCLC NDUFS1 TOR1A SRSF10	-1,22 -1,22 -1,22 -1,21 -1,21	0,24 0,65 0,03 0,75 0,24
Nicotinate phosphoribosyltransferase Lysosomal alpha-glucosidase Glutamatecysteine ligase catalytic subunit NADH-ubiquinone oxidoreductase 75 kDa subunit, mitochondrial Torsin-1A Serine/arginine-rich splicing factor 10 Cathepsin D;Cathepsin D light chain;Cathepsin D heavy chain	NAPRT GAA GCLC NDUFS1 TOR1A SRSF10 CTSD	-1,22 -1,22 -1,22 -1,21	0,24 0,65 0,03 0,75
Nicotinate phosphoribosyltransferase Lysosomal alpha-glucosidase Glutamatecysteine ligase catalytic subunit NADH-ubiquinone oxidoreductase 75 kDa subunit, mitochondrial Torsin-1A Serine/arginine-rich splicing factor 10	NAPRT GAA GCLC NDUFS1 TOR1A SRSF10	-1,22 -1,22 -1,22 -1,21 -1,21	0,24 0,65 0,03 0,75 0,24
Nicotinate phosphoribosyltransferase Lysosomal alpha-glucosidase Glutamatecysteine ligase catalytic subunit NADH-ubiquinone oxidoreductase 75 kDa subunit, mitochondrial Torsin-1A Serine/arginine-rich splicing factor 10 Cathepsin D;Cathepsin D light chain;Cathepsin D heavy chain Deoxyhypusine hydroxylase	NAPRT GAA GCLC NDUFS1 TOR1A SRSF10 CTSD	-1,22 -1,22 -1,22 -1,21 -1,21 -1,21 -1,20 -1,19	0,24 0,65 0,03 0,75 0,24 0,06 0,07
Nicotinate phosphoribosyltransferase Lysosomal alpha-glucosidase Glutamatecysteine ligase catalytic subunit NADH-ubiquinone oxidoreductase 75 kDa subunit, mitochondrial Torsin-1A Serine/arginine-rich splicing factor 10 Cathepsin D;Cathepsin D light chain;Cathepsin D heavy chain Deoxyhypusine hydroxylase Peptidyl-prolyl cis-trans isomerase B	NAPRT GAA GCLC NDUFS1 TOR1A SRSF10 CTSD DOHH PPIB	-1,22 -1,22 -1,22 -1,21 -1,21 -1,21 -1,20 -1,19 -1,19	0,24 0,65 0,03 0,75 0,24 0,06 0,07 0,09
Nicotinate phosphoribosyltransferase Lysosomal alpha-glucosidase Glutamatecysteine ligase catalytic subunit NADH-ubiquinone oxidoreductase 75 kDa subunit, mitochondrial Torsin-1A Serine/arginine-rich splicing factor 10 Cathepsin D;Cathepsin D light chain;Cathepsin D heavy chain Deoxyhypusine hydroxylase Peptidyl-prolyl cis-trans isomerase B HLA class I histocompatibility antigen, A-24 and 23 alpha chain	NAPRT GAA GCLC NDUFS1 TOR1A SRSF10 CTSD DOHH PPIB HLA-A	-1,22 -1,22 -1,22 -1,21 -1,21 -1,21 -1,20 -1,19 -1,19 -1,18	0,24 0,65 0,03 0,75 0,24 0,06 0,07 0,09 0,05
Nicotinate phosphoribosyltransferase Lysosomal alpha-glucosidase Glutamatecysteine ligase catalytic subunit NADH-ubiquinone oxidoreductase 75 kDa subunit, mitochondrial Torsin-1A Serine/arginine-rich splicing factor 10 Cathepsin D;Cathepsin D light chain;Cathepsin D heavy chain Deoxyhypusine hydroxylase Peptidyl-prolyl cis-trans isomerase B HLA class I histocompatibility antigen, A-24 and 23 alpha chain Prenylcysteine oxidase-like	NAPRT GAA GCLC NDUFS1 TOR1A SRSF10 CTSD DOHH PPIB HLA-A PCYOX1L	-1,22 -1,22 -1,22 -1,21 -1,21 -1,21 -1,20 -1,19 -1,19 -1,18 -1,17	0,24 0,65 0,03 0,75 0,24 0,06 0,07 0,09 0,05 0,03
Nicotinate phosphoribosyltransferase Lysosomal alpha-glucosidase Glutamatecysteine ligase catalytic subunit NADH-ubiquinone oxidoreductase 75 kDa subunit, mitochondrial Torsin-1A Serine/arginine-rich splicing factor 10 Cathepsin D;Cathepsin D light chain;Cathepsin D heavy chain Deoxyhypusine hydroxylase Peptidyl-prolyl cis-trans isomerase B HLA class I histocompatibility antigen, A-24 and 23 alpha chain Prenylcysteine oxidase-like Core histone macro-H2A.1	NAPRT GAA GCLC NDUFS1 TOR1A SRSF10 CTSD DOHH PPIB HLA-A PCVOX1L H2AFY	-1,22 -1,22 -1,22 -1,21 -1,21 -1,20 -1,19 -1,19 -1,18 -1,17 -1,17	0,24 0,65 0,03 0,75 0,24 0,06 0,07 0,09 0,05 0,03 0,79
Nicotinate phosphoribosyltransferase Lysosomal alpha-glucosidase Glutamatecysteine ligase catalytic subunit NADH-ubiquinone oxidoreductase 75 kDa subunit, mitochondrial Torsin-1A Serine/arginine-rich splicing factor 10 Cathepsin D;Cathepsin D light chain;Cathepsin D heavy chain Deoxyhypusine hydroxylase Peptidyl-prolyl cis-trans isomerase B HLA class I histocompatibility antigen, A-24 and 23 alpha chain Prenylcysteine oxidase-like Core histone macro-HZA.1 Sulfide:quinone oxidoreductase, mitochondrial	NAPRT GAA GCLC NDUFS1 TOR1A SRSF10 CTSD DOHH PPIB HLA-A PCVOX1L H2AFY SQRDL	-1,22 -1,22 -1,22 -1,21 -1,21 -1,20 -1,19 -1,19 -1,18 -1,17 -1,17 -1,17	0,24 0,65 0,03 0,75 0,24 0,06 0,07 0,09 0,05 0,03 0,79 0,07
Nicotinate phosphoribosyltransferase Lysosomal alpha-glucosidase Glutamatecysteine ligase catalytic subunit NADH-ubiquinone oxidoreductase 75 kDa subunit, mitochondrial Torsin-1A Serine/arginine-rich splicing factor 10 Cathepsin D;Cathepsin D light chain;Cathepsin D heavy chain Deoxyhypusine hydroxylase Peptidyl-prolyl cis-trans isomerase B HLA class I histocompatibility antigen, A-24 and 23 alpha chain Prenylcysteine oxidase-like Core histone macro-H2A.1 Sulfide:quinone oxidoreductase, mitochondrial Thiosulfate sulfurtransferase	NAPRT GAA GCLC NDUFS1 TOR1A SRSF10 CTSD DOHH PPIB HLA-A PCYOX1L H2AFY SQRDL TST	-1,22 -1,22 -1,22 -1,21 -1,21 -1,20 -1,19 -1,19 -1,18 -1,17 -1,17 -1,17 -1,17	0,24 0,65 0,03 0,75 0,24 0,06 0,07 0,09 0,05 0,03 0,79 0,07 N.D.
Nicotinate phosphoribosyltransferase Lysosomal alpha-glucosidase Glutamatecysteine ligase catalytic subunit NADH-ubiquinone oxidoreductase 75 kDa subunit, mitochondrial Torsin-1A Serine/arginine-rich splicing factor 10 Cathepsin D;Cathepsin D light chain;Cathepsin D heavy chain Deoxyhypusine hydroxylase Peptidyl-prolyl cis-trans isomerase B HLA class I histocompatibility antigen, A-24 and 23 alpha chain Prenylcysteine oxidase-like Core histone macro-H2A.1 Sulfide:quinone oxidoreductase, mitochondrial Thiosulfate sulfurtransferase NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 4	NAPRT GAA GCLC NDUFS1 TOR1A SRSF10 CTSD DOHH PPIB HLA-A PCVOX1L H2AFY SQRDL	-1,22 -1,22 -1,22 -1,21 -1,21 -1,20 -1,19 -1,19 -1,18 -1,17 -1,17 -1,17	0,24 0,65 0,03 0,75 0,24 0,06 0,07 0,09 0,05 0,03 0,79 0,07
Nicotinate phosphoribosyltransferase Lysosomal alpha-glucosidase Glutamatecysteine ligase catalytic subunit NADH-ubiquinone oxidoreductase 75 kDa subunit, mitochondrial Torsin-1A Serine/arginine-rich splicing factor 10 Cathepsin D;Cathepsin D light chain;Cathepsin D heavy chain Deoxyhypusine hydroxylase Peptidyl-prolyl cis-trans isomerase B HLA class I histocompatibility antigen, A-24 and 23 alpha chain Prenylcysteine oxidase-like Core histone macro-H2A.1 Sulfide:quinone oxidoreductase, mitochondrial Thiosulfate sulfurtransferase	NAPRT GAA GCLC NDUFS1 TOR1A SRSF10 CTSD DOHH PPIB HLA-A PCYOX1L H2AFY SQRDL TST	-1,22 -1,22 -1,22 -1,21 -1,21 -1,20 -1,19 -1,19 -1,18 -1,17 -1,17 -1,17 -1,17	0,24 0,65 0,03 0,75 0,24 0,06 0,07 0,09 0,05 0,03 0,79 0,07 N.D.
Nicotinate phosphoribosyltransferase Lysosomal alpha-glucosidase Glutamatecysteine ligase catalytic subunit NADH-ubiquinone oxidoreductase 75 kDa subunit, mitochondrial Torsin-1A Serine/arginine-rich splicing factor 10 Cathepsin D;Cathepsin D light chain;Cathepsin D heavy chain Deoxyhypusine hydroxylase Peptidyl-prolyl cis-trans isomerase B HLA class I histocompatibility antigen, A-24 and 23 alpha chain Prenylcysteine oxidase-like Core histone macro-H2A.1 Sulfide:quinone oxidoreductase, mitochondrial Thiosulfate sulfurtransferase NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 4 Calpain-2 catalytic subunit	NAPRT GAA GCLC NDUFS1 TOR1A SRSF10 CTSD DOHH PPIB HLA-A PCYOX1L HZAFY SQRDL TST NDUFB4 CAPN2	$\begin{array}{c} -1,22\\ -1,22\\ -1,22\\ -1,21\\ -1,21\\ -1,20\\ -1,19\\ -1,19\\ -1,19\\ -1,18\\ -1,17\\ -1,17\\ -1,17\\ -1,17\\ -1,17\\ -1,16\\ -1,16\\ \end{array}$	0,24 0,65 0,03 0,75 0,24 0,06 0,07 0,09 0,05 0,03 0,79 0,07 N.D. 0,25 0,12
Nicotinate phosphoribosyltransferase Lysosomal alpha-glucosidase Glutamatecysteine ligase catalytic subunit NADH-ubiquinone oxidoreductase 75 kDa subunit, mitochondrial Torsin-1A Serine/arginine-rich splicing factor 10 Cathepsin D;Cathepsin D light chain;Cathepsin D heavy chain Deoxyhypusine hydroxylase Peptidyl-prolyl cis-trans isomerase B HLA class I histocompatibility antigen, A-24 and 23 alpha chain Prenylcysteine oxidase-like Core histone macro-HZA.1 Sulfide:quinone oxidoreductase, mitochondrial Thiosulfate sulfurtransferase NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 4 Calpain-2 catalytic subunit Methylcrotonoyl-CoA carboxylase subunit alpha, mitochondrial	NAPRT GAA GCLC NDUFS1 TOR1A SRSF10 CTSD DOHH PPIB HLA-A PCYOX1L H2AFY SQRDL TST NDUFB4 CAPN2 MCCC1	$\begin{array}{c} -1,22\\ -1,22\\ -1,22\\ -1,21\\ -1,21\\ -1,20\\ -1,19\\ -1,19\\ -1,19\\ -1,18\\ -1,17\\ -1,17\\ -1,17\\ -1,17\\ -1,17\\ -1,16\\ -1,16\\ -1,16\\ \end{array}$	0,24 0,65 0,03 0,75 0,24 0,06 0,07 0,09 0,05 0,03 0,79 0,07 N.D. 0,07 N.D. 0,22 0,21
Nicotinate phosphoribosyltransferase Lysosomal alpha-glucosidase Glutamatecysteine ligase catalytic subunit NADH-ubiquinone oxidoreductase 75 kDa subunit, mitochondrial Torsin-1A Serine/arginine-rich splicing factor 10 Cathepsin D;Cathepsin D light chain;Cathepsin D heavy chain Deoxyhypusine hydroxylase Peptidyl-prolyl cis-trans isomerase B HLA class I histocompatibility antigen, A-24 and 23 alpha chain Prenylcysteine oxidase-like Core histone macro-H2A.1 Sulfide:quinone oxidoreductase, mitochondrial Thiosulfate sulfurtransferase NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 4 Calpain-2 catalytic subunit Methylcrotonoyl-CoA carboxylase subunit alpha, mitochondrial Far upstream element-binding protein 1	NAPRT GAA GCLC NDUFS1 TOR1A SRSF10 CTSD DOHH PPIB HLA-A PCYOX1L H2AFY SQRDL TST NDUFB4 CAPN2 MCCC1 FUBP1	-1,22 -1,22 -1,22 -1,21 -1,21 -1,21 -1,20 -1,19 -1,19 -1,19 -1,18 -1,17 -1,17 -1,17 -1,17 -1,17 -1,16 -1,16 -1,15	0,24 0,65 0,03 0,72 0,24 0,06 0,07 0,09 0,05 0,03 0,79 0,07 N.D. 0,25 0,21 0,14
Nicotinate phosphoribosyltransferase Lysosomal alpha-glucosidase Glutamatecysteine ligase catalytic subunit NADH-ubiquinone oxidoreductase 75 kDa subunit, mitochondrial Torsin-1A Serine/arginine-rich splicing factor 10 Cathepsin D;Cathepsin D light chain;Cathepsin D heavy chain Deoxyhypusine hydroxylase Peptidyl-prolyl cis-trans isomerase B HLA class I histocompatibility antigen, A-24 and 23 alpha chain Prenylcysteine oxidase-like Core histone marco-H2A.1 Sulfide:quinone oxidoreductase, mitochondrial Thiosulfate sulfurtransferase NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 4 Calpain-2 catalytic subunit Methylcrotonoyl-CoA carboxylase subunit alpha, mitochondrial Far upstream element-binding protein 1 Unconventional myosin-XVIIIa	NAPRT GAA GCLC NDUFS1 TOR1A SRSF10 CTSD DOHH PPIB HLA-A PCYOX1L H2AFY SQRDL TST NDUFB4 CAPN2 MCCC1 FUBP1 MYO18A	$\begin{array}{c} -1,22\\ -1,22\\ -1,22\\ -1,21\\ -1,21\\ -1,21\\ -1,20\\ -1,19\\ -1,19\\ -1,18\\ -1,17\\ -1,18\\ -1,17\\ -1,17\\ -1,17\\ -1,17\\ -1,16\\ -1,16\\ -1,16\\ -1,15\\ -1,14\\ \end{array}$	0,24 0,65 0,03 0,75 0,24 0,06 0,07 0,09 0,05 0,03 0,79 0,05 0,03 0,79 0,05 0,03 0,79 0,25 0,12 0,21 0,21
Nicotinate phosphoribosyltransferase Lysosomal alpha-glucosidase Glutamatecysteine ligase catalytic subunit NADH-ubiquinone oxidoreductase 75 kDa subunit, mitochondrial Torsin-1A Serine/arginine-rich splicing factor 10 Cathepsin D;Cathepsin D light chain;Cathepsin D heavy chain Deoxyhypusine hydroxylase Peptidyl-prolyl cis-trans isomerase B HLA class I histocompatibility antigen, A-24 and 23 alpha chain Prenylcysteine oxidase-like Core histone macro-H2A.1 Sulfide:quinone oxidoreductase, mitochondrial Thiosulfate sulfurtransferase NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 4 Calpain-2 catalytic subunit Methylcrotonoyl-CoA carboxylase subunit alpha, mitochondrial Far upstream element-binding protein 1 Unconventional myosin-XVIIIa Heme-binding protein 2	NAPRT GAA GCLC NDUFS1 TOR1A SRSF10 CTSD DOHH PPIB HLA-A PCYOX1L H2AFY SQRDL TST NDUFB4 CAPN2 MCCC1 FUBP1 MYO18A HEBP2	$\begin{array}{c} -1,22\\ -1,22\\ -1,22\\ -1,21\\ -1,21\\ -1,20\\ -1,19\\ -1,19\\ -1,19\\ -1,18\\ -1,17\\ -1,17\\ -1,17\\ -1,17\\ -1,16\\ -1,16\\ -1,16\\ -1,16\\ -1,16\\ -1,14\\ -1,14\\ \end{array}$	0,24 0,65 0,03 0,75 0,24 0,06 0,07 0,09 0,05 0,03 0,07 0,07 N.D. 0,25 0,12 0,21 0,14 0,27 0,26
Nicotinate phosphoribosyltransferase Lysosomal alpha-glucosidase Glutamatecysteine ligase catalytic subunit NADH-ubiquinone oxidoreductase 75 kDa subunit, mitochondrial Torsin-1A Serine/arginine-rich splicing factor 10 Cathepsin D;Cathepsin D light chain;Cathepsin D heavy chain Deoxyhypusine hydroxylase Peptidyl-prolyl cis-trans isomerase B HLA class I histocompatibility antigen, A-24 and 23 alpha chain Prenylcysteine oxidase-like Core histone macro-HZA.1 Sulfide:quinone oxidoreductase, mitochondrial Thiosulfate sulfurtransferase NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 4 Calpain-2 catalytic subunit Methylcrotonoyl-CoA carboxylase subunit alpha, mitochondrial Far upstream element-binding protein 1 Unconventional myosin-XVIIIa Heme-binding protein 2 Tyrosine-protein kinase Lyn	NAPRT GAA GCLC NDUFS1 TOR1A SRSF10 CTSD DOHH PPIB HLA-A PCYOX1L HZAFY SQRDL TST NDUFB4 CAPN2 MCCC1 FUBP1 MYO18A HEBP2 LYN	$\begin{array}{c} -1,22\\ -1,22\\ -1,22\\ -1,21\\ -1,21\\ -1,20\\ -1,19\\ -1,19\\ -1,19\\ -1,18\\ -1,17\\ -1,17\\ -1,17\\ -1,17\\ -1,17\\ -1,16\\ -1,16\\ -1,16\\ -1,16\\ -1,15\\ -1,14\\ -1,13\\ \end{array}$	0,24 0,65 0,03 0,75 0,24 0,06 0,07 0,09 0,05 0,03 0,79 0,07 N.D. 2,25 0,12 0,21 0,21 0,21 0,24 0,27 0,26 N.D.
Nicotinate phosphoribosyltransferase Lysosomal alpha-glucosidase Glutamatecysteine ligase catalytic subunit NADH-ubiquinone oxidoreductase 75 kDa subunit, mitochondrial Torsin-1A Serine/arginine-rich splicing factor 10 Cathepsin D;Cathepsin D light chain;Cathepsin D heavy chain Deoxyhypusine hydroxylase Peptidyl-prolyl cis-trans isomerase B HLA class I histocompatibility antigen, A-24 and 23 alpha chain Prenylcysteine oxidase-like Core histone macro-H2A.1 Sulfide:quinone oxidoreductase, mitochondrial Thiosulfate sulfurtransferase NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 4 Calpain-2 catalytic subunit Methylcrotonoyl-CoA carboxylase subunit alpha, mitochondrial Far upstream element-binding protein 1 Unconventional myosin-XVIIIa Heme-binding protein 2	NAPRT GAA GCLC NDUFS1 TOR1A SRSF10 CTSD DOHH PPIB HLA-A PCYOX1L H2AFY SQRDL TST NDUFB4 CAPN2 MCCC1 FUBP1 MYO18A HEBP2	$\begin{array}{c} -1,22\\ -1,22\\ -1,22\\ -1,21\\ -1,21\\ -1,20\\ -1,19\\ -1,19\\ -1,19\\ -1,18\\ -1,17\\ -1,17\\ -1,17\\ -1,17\\ -1,16\\ -1,16\\ -1,16\\ -1,16\\ -1,16\\ -1,14\\ -1,14\\ \end{array}$	0,24 0,65 0,03 0,75 0,24 0,06 0,07 0,09 0,05 0,03 0,07 0,07 N.D. 0,25 0,12 0,21 0,14 0,27 0,26
Nicotinate phosphoribosyltransferase Lysosomal alpha-glucosidase Glutamatecysteine ligase catalytic subunit NADH-ubiquinone oxidoreductase 75 kba subunit, mitochondrial Torsin-1A Serine/arginine-rich splicing factor 10 Cathepsin D,Cathepsin D light chain;Cathepsin D heavy chain Deoxyhypusine hydroxylase Peptidyl-prolyl cis-trans isomerase B HLA class I histocompatibility antigen, A-24 and 23 alpha chain Prenylcysteine oxidase-like Core histone macro-HZA.1 Sulfide:quinone oxidoreductase, mitochondrial Thiosulfate sulfurtransferase NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 4 Calpain-2 catalytic subunit Methylcrotonoyl-CoA carboxylase subunit alpha, mitochondrial Far upstream element-binding protein 1 Unconventional myosin-XVIIIa Heme-binding protein 2 Tyrosine-protein Kinase Lyn	NAPRT GAA GCLC NDUFS1 TOR1A SRSF10 CTSD DOHH PPIB HLA-A PCYOX1L HZAFY SQRDL TST NDUFB4 CAPN2 MCCC1 FUBP1 MYO18A HEBP2 LYN	$\begin{array}{c} -1,22\\ -1,22\\ -1,22\\ -1,21\\ -1,21\\ -1,20\\ -1,19\\ -1,19\\ -1,19\\ -1,18\\ -1,17\\ -1,17\\ -1,17\\ -1,17\\ -1,17\\ -1,16\\ -1,16\\ -1,16\\ -1,16\\ -1,15\\ -1,14\\ -1,13\\ \end{array}$	0,24 0,65 0,03 0,75 0,24 0,06 0,07 0,09 0,05 0,03 0,79 0,07 N.D. 0,25 0,12 0,21 0,21 0,21 0,27 0,26 N.D.
Nicotinate phosphoribosyltransferase Lysosomal alpha-glucosidase Glutamatecysteine ligase catalytic subunit NADH-ubiquinone oxidoreductase 75 kDa subunit, mitochondrial Torsin-1A Serine/arginine-rich splicing factor 10 Cathepsin D;Cathepsin D light chain;Cathepsin D heavy chain Deoxyhypusine hydroxylase Peptidyl-prolyl cis-trans isomerase B HLA class I histocompatibility antigen, A-24 and 23 alpha chain Prenylcysteine oxidase-like Core histone macro-H2A.1 Sulfide:quinone oxidoreductase, mitochondrial Thiosulfate sulfurtransferase NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 4 Calpain-2 catalytic subunit Methylcrotonoyl-CoA carboxylase subunit alpha, mitochondrial Far upstream element-binding protein 1 Unconventional myosin-XVIIIa Heme-binding protein 2 Tyrosine-protein kinase Lyn NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 7 Phosphomevalonate kinase	NAPRT GAA GCLC NDUFS1 TOR1A SRSF10 CTSD DOHH PPIB HLA-A PCYOX1L H2AFY SQRDL TST NDUFB4 CAPN2 MCCC1 FUBP1 MYO18A HEBP2 LYN NDUFA7	$\begin{array}{c} -1,22\\ -1,22\\ -1,22\\ -1,21\\ -1,21\\ -1,20\\ -1,19\\ -1,19\\ -1,19\\ -1,19\\ -1,18\\ -1,17\\ -1,17\\ -1,17\\ -1,17\\ -1,17\\ -1,16\\ -1,16\\ -1,16\\ -1,16\\ -1,16\\ -1,16\\ -1,16\\ -1,14\\ -1,14\\ -1,13\\ -1,13\\ \end{array}$	0,24 0,65 0,03 0,75 0,24 0,06 0,07 0,09 0,05 0,03 0,79 0,07 N.D. 0,25 0,12 0,21 0,21 0,21 0,22 0,22 0,22 N.D. N.D. N.D. 0,26
Nicotinate phosphoribosyltransferase Lysosomal alpha-glucosidase Glutamatecysteine ligase catalytic subunit NADH-ubiquinone oxidoreductase 75 kDa subunit, mitochondrial Torsin-1A Serine/arginine-rich splicing factor 10 Cathepsin D;Cathepsin D light chain;Cathepsin D heavy chain Deoxyhypusine hydroxylase Peptidyl-prolyl cis-trans isomerase B HLA class I histocompatibility antigen, A-24 and 23 alpha chain Prenylcysteine oxidase-like Core histone macro-H2A.1 Sulfide:quinone oxidoreductase, mitochondrial Thiosulfate sulfurtransferase NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 4 Calpain-2 catalytic subunit alpha, mitochondrial Far upstream element-binding protein 1 Unconventional myosin-XVIIIa Heme-binding protein 2 Tyrosine-protein kinase Lyn NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 7	NAPRT GAA GCLC NDUFS1 TOR1A SRSF10 CTSD DOHH PPIB HLA-A PCYOX1L H2AFY SQRDL TST NDUFB4 CAPN2 MCCC1 FUBP1 MYO18A HEBP2 LYN NDUFA7 PMVK	$\begin{array}{c} -1,22\\ -1,22\\ -1,22\\ -1,21\\ -1,21\\ -1,20\\ -1,19\\ -1,19\\ -1,18\\ -1,17\\ -1,17\\ -1,17\\ -1,17\\ -1,17\\ -1,17\\ -1,16\\ -1,16\\ -1,16\\ -1,16\\ -1,15\\ -1,14\\ -1,13\\ -1,13\\ -1,13\\ -1,13\\ \end{array}$	0,24 0,65 0,03 0,75 0,24 0,06 0,07 0,09 0,05 0,03 0,79 0,07 N.D. 0,25 0,12 0,21 0,21 0,21 0,21 0,27 0,26 N.D. N.D.

High affinity cationic amino acid transporter 1	SLC7A1	-1,12	0,40
Serine/arginine-rich splicing factor 3	SRSF3	-1,11	0,58
Zinc finger CCCH-type antiviral protein 1-like	ZC3HAV1L	-1,11	0,66
HEAT repeat-containing protein 5B	HEATR5B	-1,11	N.D.
Protein diaphanous homolog 3	DIAPH3	-1,10	0,10
Protein LYRIC	MTDH	-1,10	0,68
NADH dehydrogenase [ubiquinone] flavoprotein 1, mitochondrial	NDUFV1		
		-1,10	0,31
Laminin subunit gamma-1	LAMC1	-1,10	N.D.
LEM domain-containing protein 2	LEMD2	-1,10	N.D.
Caspase recruitment domain-containing protein 9	CARD9	-1,10	0,16
NADP-dependent malic enzyme	ME1	-1,10	N.D.
Mast cell-expressed membrane protein 1	MCEMP1	-1,09	N.D.
Vesicle-fusing ATPase	NSF	-1,09	0,14
Phosphatidylinositol 4-kinase type 2-alpha	PI4K2A	-1,08	0,19
Ubiquitin-like modifier-activating enzyme 7	UBA7	-1,08	0,01
Aminopeptidase N	ANPEP	-1,08	0,39
Translationally-controlled tumor protein	TPT1	-1,07	0,19
Protein-L-isoaspartate(D-aspartate) O-methyltransferase	PCMT1		
		-1,07	0,08
Trifunctional enzyme subunit beta, mitochondrial;3-ketoacyl-CoA thiolase	HADHB	-1,07	0,15
6-phosphogluconolactonase	H6PD	-1,06	0,44
Voltage-gated potassium channel subunit beta-2	KCNAB2	-1,06	0,11
28S ribosomal protein S24, mitochondrial	MRPS24	-1,06	N.D.
Erythrocyte band 7 integral membrane protein	STOM	-1,05	N.D.
Gamma-glutamyl hydrolase	GGH	-1,05	0,11
Ras-related protein Rap-2c;Ras-related protein Rap-2a	RAP2C;RAP2A	-1,04	0,41
Cullin-1	CUL1	-1,03	0,40
Sequestosome-1	SQSTM1	-1,03	0,30
Adenosine 3-phospho 5-phosphosulfate transporter 1	SLC35B2	-1,03	0,05
E3 ubiquitin-protein ligase TRIP12	TRIP12	-1,02	0,05
Metallo-beta-lactamase domain-containing protein 2	MBLAC2	-1,02	N.D.
Enoyl-CoA hydratase 2	HSD17B4	-1,02	0,11
Beta-2-microglobulin;Beta-2-microglobulin form pl 5.3	B2M	-1,02	0,08
Arylamine N-acetyltransferase 1	NAT1	-1,02	0,09
Nucleobindin-1	NUCB1	-1,01	0,09
Abhydrolase domain-containing protein 16A	ABHD16A	-1,01	N.D.
Protein disulfide-isomerase A3	PDIA3	-1,01	0,00
Syntaxin-4	STX4	-1,00	N.D.
Protein EVI2B	EVI2B	-1,00	N.D.
Axin interactor, dorsalization-associated protein	AIDA	-1,00	N.D.
Epididymis-specific alpha-mannosidase	MAN2B2	-1,00	N.D.
Protein S100-A6	S100A6	-1,00	0,07
Ubiquitin-fold modifier 1	UFM1	-1,00	0,12
Translocating chain-associated membrane protein 1	TRAM1	-0,99	0,24
Tyrosine-protein phosphatase non-receptor type substrate 1	SIRPA	-0,99	N.D.
DnaJ homolog subfamily C member 3	DNAJC3	-0,99	0,09
Protein phosphatase 1 regulatory subunit 7	PPP1R7	-0,99	0,05
Ovarian cancer-associated gene 2 protein	OVCA2	-0,99	0,07
HLA class I histocompatibility antigen, A-2 and 74 alpha chain	HLA-A	-0,99	0,03
TBC1 domain family member 24	TBC1D24	-0,99	N.D.
HLA class I histocompatibility antigen, B-57 and 58 alpha chain	HLA-B	-0,99	0,00
Peroxiredoxin-2	PRDX2	-0,99	0,20
BET1-like protein	BET1L	-0,98	0,20 N.D.
·			-
AP-3 complex subunit beta-1	AP3B1	-0,98	0,16
Fatty aldehyde dehydrogenase	ALDH3A2	-0,97	0,67
Major facilitator superfamily domain-containing protein 10	MFSD10	-0,97	0,10
MOB kinase activator 3A	MOB3A	-0,97	0,54
Protein transport protein Sec16A	SEC16A	-0,96	0,07
Myeloid-associated differentiation marker	MYADM	-0,96	0,29
Multidrug resistance-associated protein 4	ABCC4	-0,95	0,32
Protein CutA	CUTA	-0,95	N.D.
Protein disulfide-isomerase A6	PDIA6	-0,95	0,07
Fatty acid-binding protein, epidermal	FABP5	-0,94	0,25
Pirin	PIR	-0,94	N.D.
Caspase-8	CASP8	-0,94	0,20
BRISC complex subunit Abro1	FAM175B	-0,94	0,20
	HLA-C		
HLA class I histocompatibility antigen, Cw-7 alpha chain		-0,94	0,01
Cytoplasmic aconitate hydratase	ACO1	-0,94	0,07
Forkhead box protein K1	FOXK1	-0,93	0,20
LanC-like protein 2	LANCL2	-0,93	1,16
Vacuolar protein sorting-associated protein 16 homolog	VPS16	-0,92	0,06
Trafficking protein particle complex subunit 1	TRAPPC1	-0,92	N.D.
FAD-AMP lyase (cyclizing)	DAK	-0,92	0,15
Diacylglycerol kinase zeta	DGKZ	-0,92	1,57
Calcineurin B homologous protein 1	CHP1	-0,91	N.D.
UPF0160 protein MYG1, mitochondrial	C12orf10	-0,91	0,39
DNA ligase 4	LIG4	-0,91	0,39 N.D.
-			
Integrin alpha-5	ITGA5	-0,91	0,13
Departicular and the transmission of the second		-0,90	0,63
Peptidyl-prolyl cis-trans isomerase FKBP8	FKBP8		
Peptidyl-prolyl cis-trans isomerase FKBP8 Guanine nucleotide-binding protein-like 1 Heterogeneous nuclear ribonucleoproteins A2/B1	GNL1 HNRNPA2B1	-0,90	0,09 0,01

Protein kinase C alpha type	PRKCA	-0,90	N.D.
Vacuolar protein sorting-associated protein 33A	VPS33A	-0,90	N.D.
YTH domain-containing family protein 3	YTHDF3	-0,89	N.D.
Glucose-6-phosphate 1-dehydrogenase	G6PD	-0,89	0,07
Heat shock protein 105 kDa	HSPH1	-0,89	0,06
40S ribosomal protein S24	RPS24	-0,88	1,09
60S ribosomal protein L13	RPL13	-0,88	0,20
CDP-diacylglycerolinositol 3-phosphatidyltransferase	CDIPT	-0,88	0,09
Heterogeneous nuclear ribonucleoprotein F	HNRNPF	-0,87	0,06
Protein unc-13 homolog D	UNC13D	-0,87	0,15
Sister chromatid cohesion protein PDS5 homolog B	PDS5B SAR1B	-0,87	0,22
GTP-binding protein SAR1b	LAMP2	-0,87	0,10
Lysosome-associated membrane glycoprotein 2 Flotillin-2		-0,87	0,04
	FLOT2	-0,87	0,54
60S ribosomal protein L24	RPL24	-0,87	0,27
Lysosome membrane protein 2	SCARB2 CBX3	-0,87	0,15
Chromobox protein homolog 3		-0,86	0,16
Astrocytic phosphoprotein PEA-15	PEA15 ABCD3	-0,86	0,02
ATP-binding cassette sub-family D member 3		-0,86	0,01
COP9 signalosome complex subunit 7a	COPS7A	-0,86	N.D.
Lysophospholipid acyltransferase 7	MBOAT7	-0,86	0,03
Bcl-2-associated transcription factor 1	BCLAF1	-0,85	0,03
Apoptosis regulator BAX	BAX	-0,85	0,09
Histone H3.1;Histone H3.1t	HIST1H3A;HIST3H3;H3F3C	-0,85	0,25
Glycogen debranching enzyme	AGL	-0,85	0,20
WW domain-binding protein 2	WBP2	-0,85	0,05
Non-secretory ribonuclease	RNASE2	-0,85	N.D.
Secretory carrier-associated membrane protein 2	SCAMP2	-0,85	0,01
Delta(24)-sterol reductase	DHCR24	-0,85	0,31
Microsomal glutathione S-transferase 1	MGST1	-0,85	0,89
Eukaryotic peptide chain release factor GTP-binding subunit ERF3B	GSPT2	-0,85	N.D.
ATP-dependent RNA helicase A	DHX9	-0,84	0,26
Calnexin	CANX	-0,84	0,16
Transmembrane protein 165	TMEM165	-0,84	0,02
Glycine amidinotransferase, mitochondrial	GATM	-0,84	N.D.
Synaptobrevin homolog YKT6	YKT6	-0,84	0,60
ADP-sugar pyrophosphatase	NUDT5	-0,83	0,19
Dedicator of cytokinesis protein 10	DOCK10	-0,83	0,21
Annexin A2;Putative annexin A2-like protein	ANXA2;ANXA2P2	-0,83	0,10
Ubiquitin carboxyl-terminal hydrolase isozyme L3	UCHL3	-0,83	N.D.
Iron-responsive element-binding protein 2	IREB2	-0,83	N.D.
EH domain-containing protein 1	EHD1	-0,83	0,08
Calcium-binding mitochondrial carrier protein SCaMC-1	SLC25A24	-0,83	0,04
Peroxisomal acyl-coenzyme A oxidase 1	ACOX1	-0,83	0,31
V-type proton ATPase 116 kDa subunit a isoform 2	ATP6V0A2	-0,82	0,72
Protein disulfide-isomerase	P4HB	-0,82	0,06
Nucleophosmin	NPM1	-0,82	0,24
Vacuolar protein-sorting-associated protein 36	VPS36	-0,82	N.D.
NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 2	NDUFA2	-0,81	0,24
Gamma-aminobutyric acid receptor-associated protein	GABARAP;GABARAPL1	-0,81	0,04
UDP-N-acetylhexosamine pyrophosphorylase-like protein 1	UAP1L1	-0,81	0,09
WASH complex subunit strumpellin	KIAA0196	-0,81	0,14
1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase eta-1	PLCH1	-0,81	0,53
5(3)-deoxyribonucleotidase, cytosolic type	NT5C	-0,81	N.D.
Serine/arginine-rich splicing factor 1	SRSF1	-0,81	0,28
GPI transamidase component PIG-T	PIGT	-0,81	0,52
Lysosomal Pro-X carboxypeptidase	PRCP	-0,81	0,09
Golgi-associated plant pathogenesis-related protein 1	GLIPR2	-0,80	0,25
POTE ankyrin domain family member J	POTEJ	-0,80	N.D.
Integrin alpha-M	ITGAM	-0,80	0,58
Inhibitor of nuclear factor kappa-B kinase subunit beta	IKBKB	-0,80	0,18
40S ribosomal protein S27-like	RPS27L	-0,80	0,41
Heterogeneous nuclear ribonucleoprotein K	HNRNPK	-0,80	0,15
Long chain 3-hydroxyacyl-CoA dehydrogenase	HADHA	-0,80	0,04
Probable ATP-dependent RNA helicase DDX47	DDX47	-0,80	0,63
Serine-protein kinase ATM	ATM	-0,79	0,70
General transcription factor 3C polypeptide 2	GTF3C2	-0,79	N.D.
40S ribosomal protein S11	RPS11	-0,79	0,57
Cytochrome b-245 light chain	СҮВА	-0,79	0,05
LIM and SH3 domain protein 1	LASP1	-0,79	0,26
EMILIN-2	EMILIN2	-0,79	N.D.
tRNA (guanine-N(7)-)-methyltransferase	METTL1	-0,79	N.D.
Zinc transporter SLC39A7	SLC39A7	-0,79	0,23
UDP-N-acetylglucosamine pyrophosphorylase	UAP1	-0,78	0,00
Heterogeneous nuclear ribonucleoprotein U-like protein 2	HNRNPUL2	-0,78	0,05
Dolichyl-phosphate beta-glucosyltransferase	ALG5	-0,78	1,14
Equilibrative nucleoside transporter 1	SLC29A1	-0,78	0,49
Biliverdin reductase A	BLVRA	-0,78	0,08
			1 0.45
60S ribosomal protein L4	RPL4	-0,78	0,15

U4/U6 small nuclear ribonucleoprotein Prp3			
04/00 smail nuclear ribonucleoprotein Prps	PRPF3	-0,77	0,34
Protein transport protein Sec24A	SEC24A	-0,77	N.D.
Staphylococcal nuclease domain-containing protein 1	SND1	-0,77	0,11
S-formylglutathione hydrolase	ESD	-0,76	0,04
2,3-cyclic-nucleotide 3-phosphodiesterase	CNP	-0,76	0,27
Pericentrin	PCNT	-0,76	N.D.
WASH complex subunit 7	KIAA1033	-0,76	0,23
Protein unc-45 homolog A	UNC45A	-0,76	0,14
N-acetylglucosamine-6-sulfatase	GNS	-0,76	0,64
Trafficking protein particle complex subunit 2-like protein	TRAPPC2L	-0,75	N.D.
GPI transamidase component PIG-S	PIGS	-0,75	0,12
Septin-7	39326	-0,75	0,03
Neutral amino acid transporter A	SLC1A4	-0,74	0,20
Leukocyte immunoglobulin-like receptor subfamily B member 4	LILRB4	-0,74	N.D.
60S ribosomal protein L23a	RPL23A	-0,74	0,16
Histone deacetylase complex subunit SAP18 Golgin subfamily A member 2	SAP18	-0,74	0,04
Mitotic spindle assembly checkpoint protein MAD1	GOLGA2 MAD1L1	-0,74	0,09
Reticulon-4	RTN4	-0,74 -0,74	N.D. 0,11
B-cell receptor-associated protein 29	BCAP29	-0,74	0,11
	PPIL3		0,15 N.D.
Peptidyl-prolyl cis-trans isomerase-like 3 Lanosterol synthase	LSS	-0,74	0,03
	POLR1B	-0,73	
DNA-directed RNA polymerase I subunit RPA2	CFD	-0,73	0,67 N.D.
Complement factor D TBC1 domain family member 13	TBC1D13	-0,73 -0,73	0,32
BAG family molecular chaperone regulator 1	BAG1		
Peroxiredoxin-4	PRDX4	-0,73 -0,73	N.D. 0,38
DAZ-associated protein 1	DAZAP1	-0,72	0,58
Triple functional domain protein	TRIO	-0,72	0,08 N.D.
Alpha-actinin-4	ACTN4	-0,72	0,02
28S ribosomal protein S18b, mitochondrial	MRPS18B	-0,72	0,02 N.D.
Mitochondrial fission factor	MFF	-0,72	N.D.
DnaJ homolog subfamily C member 7	DNAJC7	-0,72	0,21
Adenylyl cyclase-associated protein 1	CAP1	-0,71	0,03
Serine/threonine-protein phosphatase 2B catalytic subunit alpha isoform	PPP3CA	-0,71	0,23
CCR4-NOT transcription complex subunit 11	CNOT11	-0,71	N.D.
Endoplasmic reticulum resident protein 44	ERP44	-0,71	0,03
60S acidic ribosomal protein P2	RPLP2	-0,71	0,01
ATP-dependent RNA helicase DDX3X	DDX3X	-0,71	0,17
Isochorismatase domain-containing protein 2, mitochondrial	ISOC2	-0,71	0,20
myloid beta A4 precursor protein-binding family B member 1-interacting protein	APBB1IP	-0,70	0,01
Protein S100-A8;Protein S100-A8, N-terminally processed	\$100A8	-0,70	0,08
Erlin-2	ERLIN2	-0,70	0,10
DnaJ homolog subfamily C member 5	DNAJC5	-0,70	0,08
Rab GDP dissociation inhibitor beta	GDI2	-0,70	0,02
Alpha-1,3/1,6-mannosyltransferase ALG2	ALG2	-0,70	N.D.
Very-long-chain enoyl-CoA reductase	TECR	-0,70	0,05
Stromal cell-derived factor 2-like protein 1	SDF2L1	-0,70	0,02
2-5A-dependent ribonuclease	RNASEL	-0,70	N.D.
Golgi SNAP receptor complex member 1	GOSR1	-0,69	0,08
Methylmalonyl-CoA mutase, mitochondrial	MUT	-0,69	0,03
AMP deaminase 2	AMPD2	-0,69	N.D.
cAMP-dependent protein kinase catalytic subunit alpha	PRKACA	-0,69	N.D.
Glutathione synthetase	GSS	-0,69	0,15
60S ribosomal protein L32	RPL32	-0,69	0,27
Protein syndesmos	NUDT16L1	-0,69	0,02
Deoxyribose-phosphate aldolase	DERA	-0,69	0,17
Catalase	CAT	-0,69	0,11
Leucine-rich repeat flightless-interacting protein 1	LRRFIP1	-0,69	0,03
Tripeptidyl-peptidase 2	TPP2	-0,68	0,01
NADH-ubiquinone oxidoreductase chain 4	MT-ND4	-0,68	0,06
HBS1-like protein	HBS1L	-0,68	0,07
Succinyl-CoA ligase [ADP-forming] subunit beta, mitochondrial	SUCLA2	-0,68	N.D.
	HDGFRP2	-0,68	0,49
Hepatoma-derived growth factor-related protein 2	AARSD1	-0,68	0,28
Alanyl-tRNA editing protein Aarsd1		-0,68	0,06
Alanyl-tRNA editing protein Aarsd1 NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 9	NDUFB9		0,03
Alanyl-tRNA editing protein Aarsd1 NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 9 Tyrosine-protein phosphatase non-receptor type 6	PTPN6	-0,68	
Alanyl-tRNA editing protein Aarsd1 NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 9 Tyrosine-protein phosphatase non-receptor type 6 Signal transducer and activator of transcription 1-alpha/beta	PTPN6 STAT1	-0,68 -0,68	0,01
Alanyl-tRNA editing protein Aarsd1 NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 9 Tyrosine-protein phosphatase non-receptor type 6 Signal transducer and activator of transcription 1-alpha/beta Chloride intracellular channel protein 1	PTPN6 STAT1 CLIC1	-0,68 -0,68 -0,67	0,01 0,07
Alanyl-tRNA editing protein Aarsd1 NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 9 Tyrosine-protein phosphatase non-receptor type 6 Signal transducer and activator of transcription 1-alpha/beta Chloride intracellular channel protein 1 Sarcoplasmic/endoplasmic reticulum calcium ATPase 2	PTPN6 STAT1 CLIC1 ATP2A2	-0,68 -0,68 -0,67 -0,67	0,01 0,07 0,15
Alanyl-tRNA editing protein Aarsd1 NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 9 Tyrosine-protein phosphatase non-receptor type 6 Signal transducer and activator of transcription 1-alpha/beta Chloride intracellular channel protein 1 Sarcoplasmic/endoplasmic reticulum calcium ATPase 2 E3 ubiquitin-protein ligase RNF213	PTPN6 STAT1 CLIC1 ATP2A2 RNF213	-0,68 -0,68 -0,67 -0,67 -0,67	0,01 0,07 0,15 0,02
Alanyl-tRNA editing protein Aarsd1 NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 9 Tyrosine-protein phosphatase non-receptor type 6 Signal transducer and activator of transcription 1-alpha/beta Chloride intracellular channel protein 1 Sarcoplasmic/endoplasmic reticulum calcium ATPase 2 E 3 ubiquitin-protein ligase RNF213 NADH dehydrogenase [ubiquinone] iron-sulfur protein 5	PTPN6 STAT1 CLIC1 ATP2A2 RNF213 NDUFS5	-0,68 -0,68 -0,67 -0,67 -0,67 -0,67	0,01 0,07 0,15 0,02 0,15
Alanyl-tRNA editing protein Aarsd1 NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 9 Tyrosine-protein phosphatase non-receptor type 6 Signal transducer and activator of transcription 1-alpha/beta Chloride intracellular channel protein 1 Sarcoplasmic/endoplasmic reticulum calcium ATPase 2 E3 ubiquitin-protein ligase RNF213 NADH dehydrogenase [ubiquinone] iron-sulfur protein 5 Gamma-soluble NSF attachment protein	PTPN6 STAT1 CLIC1 ATP2A2 RNF213 NDUFS5 NAPG	-0,68 -0,68 -0,67 -0,67 -0,67 -0,67 -0,67	0,01 0,07 0,15 0,02 0,15 N.D.
Alanyl-tRNA editing protein Aarsd1 NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 9 Tyrosine-protein phosphatase non-receptor type 6 Signal transducer and activator of transcription 1-alpha/beta Chloride intracellular channel protein 1 Sarcoplasmic/endoplasmic reticulum calcium ATPase 2 E3 ubiquitin-protein ligase RNF213 NADH dehydrogenase [ubiquinone] iron-sulfur protein 5 Gamma-soluble NSF attachment protein Very long-chain specific acyl-CoA dehydrogenase, mitochondrial	PTPN6 STAT1 CLIC1 ATP2A2 RNF213 NDUF55 NAPG ACADVL	-0,68 -0,68 -0,67 -0,67 -0,67 -0,67 -0,67 -0,67	0,01 0,07 0,15 0,02 0,15 N.D. 0,00
Alanyl-tRNA editing protein Aarsd1 NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 9 Tyrosine-protein phosphatase non-receptor type 6 Signal transducer and activator of transcription 1-alpha/beta Chloride intracellular channel protein 1 Sarcoplasmic/endoplasmic reticulum calcium ATPase 2 E3 ubiquitin-protein ligase RNF213 NADH dehydrogenase [ubiquinone] iron-sulfur protein 5 Gamma-soluble NSF attachment protein Very long-chain specific acyl-CoA dehydrogenase, mitochondrial Tyrosine-protein kinase SYK	PTPN6 STAT1 CLIC1 ATP2A2 RNF213 NDUFS5 NAPG ACADVL SYK	-0,68 -0,68 -0,67 -0,67 -0,67 -0,67 -0,67 -0,67 -0,66	0,01 0,07 0,15 0,02 0,15 N.D. 0,00 0,06
Alanyl-tRNA editing protein Aarsd1 NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 9 Tyrosine-protein phosphatase non-receptor type 6 Signal transducer and activator of transcription 1-alpha/beta Chloride intracellular channel protein 1 Sarcoplasmic/endoplasmic reticulum calcium ATPase 2 E3 ubiquitin-protein ligase RNF213 NADH dehydrogenase [ubiquinone] iron-sulfur protein 5 Gamma-soluble NSF attachment protein Very long-chain specific acyl-CoA dehydrogenase SVK 2,4-dienoyl-CoA reductase, mitochondrial	PTPN6 STAT1 CLIC1 ATP2A2 RNF213 NDUFS5 NAPG ACADVL SYK DECR1	-0,68 -0,67 -0,67 -0,67 -0,67 -0,67 -0,67 -0,67 -0,66 -0,66	0,01 0,07 0,15 0,02 0,15 N.D. 0,00 0,06 0,08
Alanyl-tRNA editing protein Aarsd1 NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 9 Tyrosine-protein phosphatase non-receptor type 6 Signal transducer and activator of transcription 1-alpha/beta Chloride intracellular channel protein 1 Sarcoplasmic/endoplasmic reticulum calcium ATPase 2 E3 ubiquitin-protein ligase RNF213 NADH dehydrogenase [ubiquinone] iron-sulfur protein 5 Gamma-soluble NSF attachment protein Very long-chain specific acyl-CoA dehydrogenase, mitochondrial Tyrosine-protein kinase SYK 2,4-dienoyl-CoA reductase, mitochondrial Ethanolamine-phosphate cytidylyltransferase	PTPN6 STAT1 CLIC1 ATP2A2 RNF213 NDUFS5 NAPG ACADVL SYK DECR1 PCYT2	-0,68 -0,67 -0,67 -0,67 -0,67 -0,67 -0,67 -0,67 -0,66 -0,66 -0,66	0,01 0,07 0,15 0,02 0,15 N.D. 0,00 0,06 0,08 0,11
Alanyl-tRNA editing protein Aarsd1 NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 9 Tyrosine-protein phosphatase non-receptor type 6 Signal transducer and activator of transcription 1-alpha/beta Chloride intracellular channel protein 1 Sarcoplasmic/endoplasmic reticulum calcium ATPase 2 E3 ubiquitin-protein ligase RNF213 NADH dehydrogenase [ubiquinone] iron-sulfur protein 5 Gamma-soluble NSF attachment protein Very long-chain specific acyl-CoA dehydrogenase SVK 2,4-dienoyl-CoA reductase, mitochondrial	PTPN6 STAT1 CLIC1 ATP2A2 RNF213 NDUFS5 NAPG ACADVL SYK DECR1	-0,68 -0,67 -0,67 -0,67 -0,67 -0,67 -0,67 -0,67 -0,66 -0,66	0,01 0,07 0,15 0,02 0,15 N.D. 0,00 0,06 0,08

Mitochondrial carrier homolog 1	MTCH1	-0,66	N.D.
Leucine-rich repeat-containing protein 57	LRRC57	-0,66	N.D.
Ubiquitin conjugation factor E4 A	UBE4A	-0,65	0,43
40S ribosomal protein S13	RPS13	-0,65	0,07
Putative RNA-binding protein 15 Lamin-B1	RBM15	-0,65	N.D.
Transmembrane 9 superfamily member 2	LMNB1 TM9SF2	-0,65	0,15 0,13
Chromosome alignment-maintaining phosphoprotein 1	CHAMP1	-0,65	0,13
DnaJ homolog subfamily C member 17	DNAJC17	-0,65	0,00 N.D.
60S ribosomal protein L34	RPL34	-0,64	0,26
Liver carboxylesterase 1	CES1	-0,64	0,16
Signal transducer and activator of transcription 3	STAT3	-0,64	0,15
Vacuolar protein sorting-associated protein 52 homolog	VPS52	-0,64	N.D.
60S ribosomal protein L21	RPL21	-0,64	0,06
Glyceraldehyde-3-phosphate dehydrogenase	GAPDH	-0,64	0,19
Protein canopy homolog 2	CNPY2	-0,64	0,14
60S ribosomal protein L13a	RPL13A	-0,64	0,16
Annexin A11	ANXA11	-0,64	0,13
PDZ and LIM domain protein 1	PDLIM1	-0,64	N.D.
Proteasome activator complex subunit 4	PSME4	-0,63	0,40
Vesicle transport protein GOT1B	GOLT1B	-0,63	0,05
Protein S100-A9	S100A9	-0,63	0,11
Probable ATP-dependent RNA helicase DDX27	DDX27	-0,63	1,27
DnaJ homolog subfamily B member 11	DNAJB11	-0,63	0,87
60S ribosomal protein L18	RPL18	-0,63	0,07
SH3 domain-containing kinase-binding protein 1	SH3KBP1	-0,63	0,01
Ubiquitin-related modifier 1	URM1	-0,63	N.D.
Nuclear cap-binding protein subunit 1	NCBP1	-0,63	0,01
Neurofibromin;Neurofibromin truncated	NF1	-0,62	N.D.
Decaprenyl-diphosphate synthase subunit 2	PDSS2	-0,62	N.D.
NADH dehydrogenase [ubiquinone] flavoprotein 2, mitochondrial	NDUFV2	-0,62	0,01
Kynurenineoxoglutarate transaminase 3	CCBL2	-0,62	0,16
Clathrin heavy chain 2	CLTCL1	-0,62	0,11
SRSF protein kinase 1	SRPK1	-0,62	0,62
Serine/threonine-protein kinase N1	PKN1	-0,62	0,19
Egl nine homolog 1	EGLN1	-0,62	0,26
Antigen KI-67	MKI67	-0,62	N.D.
Small integral membrane protein 7	SMIM7	-0,62	N.D.
5-nucleotidase domain-containing protein 3	NT5DC3	-0,62	N.D.
SPRY domain-containing protein 4	SPRYD4	-0,62	N.D.
Cysteine and glycine-rich protein 1	CSRP1	-0,61	0,11
Non-specific lipid-transfer protein	SCP2	-0,61	0,13
Homer protein homolog 3	HOMER3	-0,61	N.D.
General transcription factor IIF subunit 1	GTF2F1	-0,61	0,53
40S ribosomal protein S25	RPS25	-0,61	0,15
Transformer-2 protein homolog beta	TRA2B	-0,61	0,22
Serine/threonine-protein kinase 10	STK10	-0,61	0,24
General transcription factor IIF subunit 2 Manganese-transporting ATPase 13A1	GTF2F2 ATP13A1	-0,61 -0,61	0,57 0,08
COMM domain-containing protein 1	COMMD1	-0,61	0,08 N.D.
Commition Containing protein 1 Carnitine O-palmitoyltransferase 1, liver isoform	COMMD1 CPT1A	-0,61	0,28
60S ribosomal protein L29	RPL29	-0,61	0,28
5-oxoprolinase	OPLAH	-0,61	0,00 N.D.
Ras-related protein Rab-4A	RAB4A	-0,60	0,62
Endoplasmin	HSP90B1	-0,60	0,02
Vacuolar protein sorting-associated protein 18 homolog	VPS18	-0,60	0,34
Elongation of very long chain fatty acids protein 5	ELOVL5	-0,60	0,13
Thyroid receptor-interacting protein 11	TRIP11	-0,60	0,38
Proteasome subunit beta type-9	PSMB9	-0,60	0,07
E3 ubiquitin-protein ligase MYCBP2	MYCBP2	-0,60	0,11
NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 7	NDUFB7	-0,60	N.D.
Tyrosine-protein phosphatase non-receptor type 1	PTPN1	-0,60	0,44
Signal transducer and activator of transcription 6	STAT6	-0,60	0,42
Ras-related C3 botulinum toxin substrate 1	RAC1;RAC3	-0,60	0,29
Enhancer of rudimentary homolog	ERH	-0,60	0,02
ERO1-like protein alpha	ERO1L	-0,59	0,00
60S ribosomal protein L7a	RPL7A	-0,59	0,50
Platelet-activating factor acetylhydrolase IB subunit alpha	PAFAH1B1	-0,59	0,27
Protein SON	SON	-0,59	0,27
Lamin-B receptor	LBR	-0,59	0,26

Table 4. Downregulated proteins in THP-1 AraC compared to THP-1 P cells under normoxia. Proteomic profiling (SILAC) data were used. Significantly downregulated proteins were calculated using the fold difference threshold of 0.7 (log₂ fold change=-0.58). Mean±SD for n=2 replicates. Non-detected (N.D.) means less than 2 replicates detected for one protein measured.

UPREGULATED PROTEINS IN THP-1 Do	x VS. THP-1 P		
Protein names	Gene names	Mean Log ₂ fold change	SD Log ₂ fold change
Succinate-semialdehyde dehydrogenase, mitochondrial	ALDH5A1	2.40	0.21
Serine/arginine repetitive matrix protein 2	SRRM2	2.23	0.91
Reticulocalbin-2	RCN2	1.98	0.15
Eukaryotic translation initiation factor 3 subunit C	EIF3C;EIF3CL	1.92	0.71
NFX1-type zinc finger-containing protein 1	ZNFX1	1.91	N.D.
DNL-type zinc finger protein	DNLZ	1.84	0.01
Sepiapterin reductase	SPR	1.81	0.19
1,4-alpha-glucan-branching enzyme	GBE1	1.76	0.07
Sorcin	SRI	1.74	N.D.
Protein VPRBP	VPRBP	1.72	0.60
Calcium-binding mitochondrial carrier protein Aralar2	SLC25A13	1.70	0.03
Eukaryotic translation initiation factor 4B	EIF4B	1.68	0.08
5-demethoxyubiquinone hydroxylase, mitochondrial	COQ7	1.63	N.D.
AP-1 complex subunit sigma-1A	AP1S1	1.61	N.D.
Pterin-4-alpha-carbinolamine dehydratase 2 Glutaminase kidney isoform, mitochondrial	PCBD2 GLS	1.61	0.16 0.29
Coiled-coil domain-containing protein 124	CCDC124	1.59	0.23
	TSR1	1.59	
Pre-rRNA-processing protein TSR1 homolog U4/U6.U5 tri-snRNP-associated protein 1	SART1	1.53	0.33
3-hydroxyisobutyryl-CoA hydrolase, mitochondrial	HIBCH	1.53	0.12
Protein NDRG1	NDRG1	1.55	0.12 N.D.
	SLC25A12	1.49	0.05
Calcium-binding mitochondrial carrier protein Aralar1 Isochorismatase domain-containing protein 1	ISOC1	1.49	0.05
Matrin-3	MATR3	1.46	0.52
Branched-chain-amino-acid aminotransferase, mitochondrial	BCAT2	1.45	0.12
Fumarylacetoacetate hydrolase domain-containing protein 2A and B	FAHD2A;FAHD2B	1.44	N.D.
Mammalian ependymin-related protein 1	EPDR1	1.44	0.23
Spectrin beta chain, non-erythrocytic 1	SPTBN1	1.40	0.19
2-methoxy-6-polyprenyl-1,4-benzoquinol methylase, mitochondrial	COQ5	1.39	N.D.
Sodium-coupled neutral amino acid transporter 2	SLC38A2	1.38	0.20
1-acyl-sn-glycerol-3-phosphate acyltransferase epsilon	AGPAT5	1.36	0.28
Protein FAM173B	FAM173B	1.36	0.46
Calcium uniporter protein, mitochondrial	MCU	1.35	0.10
Glucosamine 6-phosphate N-acetyltransferase	GNPNAT1	1.34	0.09
Spectrin alpha chain, non-erythrocytic 1	SPTAN1	1.34	0.28
Macrophage migration inhibitory factor	MIF	1.34	0.13
Putative hydroxypyruvate isomerase	HYI	1.32	N.D.
Dehydrogenase/reductase SDR family member 7	DHRS7	1.29	N.D.
UPF0562 protein C7orf55	C7orf55	1.28	N.D.
UDP-N-acetylglucosaminedolichyl-phosphate N-acetylglucosaminephosphotransferase	DPAGT1	1.28	0.33
Peptidyl-prolyl cis-trans isomerase FKBP4	FKBP4	1.27	0.06
General transcription factor II-I	GTF2I	1.26	0.01
Heat shock protein beta-1	HSPB1	1.23	0.09
Protein disulfide-isomerase A5	PDIA5	1.23	0.16
Protein AATF	AATF	1.23	1.08
Proteasome subunit beta type-5	PSMB5	1.23	N.D.
Pterin-4-alpha-carbinolamine dehydratase	PCBD1	1.22	0.21
Protein SMG5	SMG5	1.22	0.89
Aldehyde dehydrogenase X, mitochondrial	ALDH1B1	1.22	N.D.
Alpha/beta hydrolase domain-containing protein 14B	ABHD14B	1.20	0.18
Zinc finger protein 622	ZNF622	1.20	1.25
Peroxisomal membrane protein PMP34	SLC25A17	1.20	0.42
Probable Xaa-Pro aminopeptidase 3	XPNPEP3	1.19	N.D.
Probable leucinetRNA ligase, mitochondrial	LARS2	1.19	0.24
PDZ and LIM domain protein 1	PDLIM1	1.19	N.D.
Ferritin light chain	FTL	1.18	0.10
Flavin reductase (NADPH)	BLVRB PRPF4B	1.18	0.13
Serine/threonine-protein kinase PRP4 homolog		1.17	
3-hydroxyisobutyrate dehydrogenase, mitochondrial Vitamin K epoxide reductase complex subunit 1-like protein 1	HIBADH VKORC1L1	1.17	0.13
Zinc finger CCCH-type antiviral protein 1-like	ZC3HAV1L	1.16	0.27
Insulin-like growth factor 2 mRNA-binding protein 1	IGF2BP1	1.15	0.03
Serpin B10	SERPINB10	1.15	0.02
Calumenin	CALU	1.15	0.15
Lipopolysaccharide-responsive and beige-like anchor protein	LRBA	1.15	0.44
Complement component 1 Q subcomponent-binding protein, mitochondrial	C1QBP	1.12	0.06
Isovaleryl-CoA dehydrogenase, mitochondrial	IVD	1.12	0.10
D-beta-hydroxybutyrate dehydrogenase, mitochondrial	BDH1	1.12	0.10
Metaxin-2	MTX2	1.11	0.16
Membrane-associated progesterone receptor component 1	PGRMC1	1.09	0.25
Acyl-coenzyme A thioesterase 13	ACOT13	1.08	0.27
Mitochondrial import inner membrane translocase subunit Tim8 A	TIMM8A	1.08	0.09
Ubiquitin-conjugating enzyme E2 G	UBE2G1	1.07	0.02
Survival motor neuron protein	SMN1	1.07	0.15
Iron-sulfur cluster assembly 2 homolog, mitochondrial	ISCA2	1.06	N.D.
Glutathione S-transferase Mu 1;Glutathione S-transferase Mu 4	GSTM1;GSTM4	1.05	0.11
Transferrin receptor protein 1; Transferrin receptor protein 1, serum form	TFRC	1.05	0.13
Ribose-5-phosphate isomerase	RPIA	1.05	0.28
Isochorismatase domain-containing protein 2, mitochondrial	ISOC2	1.05	0.37
	RDH13	1.04	0.18

Mycophenolic acid acyl-glucuronide esterase, mitochondrial	ABHD10	1,04	0,04
Tripartite motif-containing protein 72	TRIM72	1,04	N.D.
Histidine triad nucleotide-binding protein 1	HINT1	1,03	0,03
Cytochrome c oxidase subunit 1	MT-CO1	1,03	0,17
Aconitate hydratase, mitochondrial Putative helicase MOV-10	ACO2 MOV10	1,03	0,01 0,02
Sulfatase-modifying factor 2	SUMF2	1,02	0,02 N.D.
Tetraspanin-14	TSPAN14	1,02	N.D.
DNA-directed RNA polymerase III subunit RPC1	POLR3A	1,01	0,53
Aspartate aminotransferase, mitochondrial	GOT2	1,01	0,10
Aminopeptidase N	ANPEP	1,01	0,40
Transmembrane protein 70, mitochondrial	TMEM70	1,00	0,06
Microtubule-associated protein 4	MAP4	1,00	0,05
Elongation of very long chain fatty acids protein 1	ELOVL1	1,00	0,10
Histidine triad nucleotide-binding protein 2, mitochondrial	HINT2	1,00	0,12
Cat eye syndrome critical region protein 5	CECR5	0,99	0,10
Protein CDV3 homolog	CDV3	0,97	0,16
Single-stranded DNA-binding protein, mitochondrial	SSBP1	0,97	0,06
Spermine synthase	SMS	0,96	0,02
Aldose reductase	AKR1B1	0,95	0,10
Annexin A1	ANXA1	0,95	0,13
Scavenger receptor class B member 1	SCARB1	0,95	0,05
Gem-associated protein 5	GEMIN5	0,95	0,09
Protein FAM136A	FAM136A	0,95	N.D.
Cytochrome c oxidase subunit 2 Probable ATP-dependent RNA belicase DDX49	MT-CO2	0,95	0,03
Probable ATP-dependent RNA helicase DDX49 Amyloid beta A4 protein fragment 50	DDX49 APP	0,94	0,47
Amyloid beta A4 protein fragment 50 Evolutionarily conserved signaling intermediate in Toll pathway, mitochondrial	ECSIT	0,94	N.D. 0,27
Enoyl-CoA hydratase/3,2-trans-enoyl-CoA isomerase	EHHADH	0,94	0,27
Glycine cleavage system H protein, mitochondrial	GCSH	0,94	0,08 N.D.
Rho GTPase-activating protein 15	ARHGAP15	0,94	0,08
Apoptosis-inducing factor 1, mitochondrial	AIFM1	0,93	0,05
Dihydropteridine reductase	QDPR	0,92	0,21
Vacuolar protein sorting-associated protein 13A	VPS13A	0,92	0,13
Lipoamide acyltransferase component of branched-chain alpha-keto acid dehydrogenase complex, m.	DBT	0,92	0,36
Glucose-6-phosphate isomerase	GPI	0,92	0,09
Nuclear export mediator factor NEMF	NEMF	0,92	0,55
Ribonuclease UK114	HRSP12	0,91	0,02
Pseudouridylate synthase 7 homolog	PUS7	0,91	0,10
Asparagine synthetase [glutamine-hydrolyzing]	ASNS	0,91	0,10
Nuclear pore complex protein Nup50	NUP50	0,91	0,19
Phosphoribosylformylglycinamidine synthase	PFAS	0,91	0,23
Cytochrome c	CYCS	0,91	0,02
Nicotinamide phosphoribosyltransferase	NAMPT	0,91	0,07
2-oxoisovalerate dehydrogenase subunit alpha, mitochondrial	BCKDHA	0,91	0,03
Transmembrane protein 14C	TMEM14C	0,90	0,42
Tubulintyrosine ligase-like protein 12	TTLL12	0,90	0,06
Peptidase M20 domain-containing protein 2	PM20D2	0,90	0,12
CD166 antigen Telomere-associated protein RIF1	ALCAM RIF1	0,90	0,38 0,23
Serglycin	SRGN	0,90	1,41
Stress-70 protein, mitochondrial	HSPA9	0,90	0,08
Cytochrome c oxidase subunit 3	MT-CO3	0,90	0,08
Mitochondrial fission 1 protein	FIS1	0,89	0,05 N.D.
Ferritin heavy chain	FTH1	0,89	0,09
DNA mismatch repair protein Mlh1	MLH1	0,89	0,03
N-terminal kinase-like protein	SCYL1	0,88	1,05
Transportin-2	TNPO2	0,88	0,10
CAP-Gly domain-containing linker protein 1	CLIP1	0,88	0,04
N-alpha-acetyltransferase 20	NAA20	0,88	0,30
Succinyl-CoA ligase [GDP-forming] subunit beta, mitochondrial	SUCLG2	0,88	0,06
Glutathione peroxidase 7	GPX7	0,88	0,15
Nuclear receptor 2C2-associated protein	NR2C2AP	0,88	0,14
Transducin beta-like protein 2	TBL2	0,88	0,07
NudC domain-containing protein 3	NUDCD3	0,88	0,24
Dol-P-Man:Man(5)GlcNAc(2)-PP-Dol alpha-1,3-mannosyltransferase	ALG3	0,87	0,27
Regulator of nonsense transcripts 1	UPF1	0,87	0,20
Titin	TTN	0,87	0,48
	INTS7	0,87	N.D.
Integrator complex subunit 7		0,87	0,16
Integrator complex subunit 7 CAD protein	CAD		0,23
Integrator complex subunit 7 CAD protein Gamma-glutamyl hydrolase	GGH	0,86	
Integrator complex subunit 7 CAD protein Gamma-glutamyl hydrolase Prohibitin	GGH PHB	0,86	0,07
Integrator complex subunit 7 CAD protein Gamma-glutamyl hydrolase Prohibitin Fatty acid-binding protein, epidermal	GGH PHB FABP5	0,86 0,86	0,05
Integrator complex subunit 7 CAD protein Gamma-glutamyl hydrolase Prohibitin Fatty acid-binding protein, epidermal NudC domain-containing protein 1	GGH PHB FABP5 NUDCD1	0,86 0,86 0,86	0,05 0,08
Integrator complex subunit 7 CAD protein Gamma-glutamyl hydrolase Prohibitin Fatty acid-binding protein, epidermal NudC domain-containing protein 1 Mitochondrial import inner membrane translocase subunit TIM14	GGH PHB FABP5 NUDCD1 DNAJC19	0,86 0,86 0,86 0,85	0,05 0,08 0,18
Integrator complex subunit 7 CAD protein Gamma-glutamyl hydrolase Prohibitin Fatty acid-binding protein, epidermal NudC domain-containing protein 1 Mitochondrial import inner membrane translocase subunit TIM14 Eukaryotic translation initiation factor 4H	GGH PHB FABP5 NUDCD1 DNAJC19 EIF4H	0,86 0,86 0,85 0,85	0,05 0,08 0,18 0,19
Integrator complex subunit 7 CAD protein Gamma-glutamyl hydrolase Prohibitin Fatty acid-binding protein, epidermal NudC domain-containing protein 1 Mitochondrial import inner membrane translocase subunit TIM14 Eukaryotic translation initiation factor 4H Mannosyl-oligosaccharide glucosidase	GGH PHB FABP5 NUDCD1 DNAJC19 EIF4H MOGS	0,86 0,86 0,86 0,85 0,85 0,85	0,05 0,08 0,18 0,19 0,02
Integrator complex subunit 7 CAD protein Gamma-glutamyl hydrolase Prohibitin Fatty acid-binding protein, epidermal NudC domain-containing protein 1 Mitochondrial import inner membrane translocase subunit TIM14 Eukaryotic translation initiation factor 4H	GGH PHB FABP5 NUDCD1 DNAJC19 EIF4H	0,86 0,86 0,85 0,85	0,05 0,08 0,18 0,19

Receptor expression-enhancing protein 5	REEP5	0,84	N.D.
Zinc phosphodiesterase ELAC protein 2	ELAC2	0,84	0,55
Intraflagellar transport protein 27 homolog	IFT27	0,84	0,09
Glutathione S-transferase P	GSTP1	0,84	0,09
Glutamine synthetase Azurocidin	GLUL AZU1	0,83 0,83	0,18 0,08
Prohibitin-2	PHB2	0,83	0,08
Mannose-1-phosphate guaryltransferase beta	GMPPB	0,83	1,13
Deoxyhypusine synthase	DHPS	0,82	0,11
Forkhead box protein K1	FOXK1	0,82	0,17
Aminoacylase-1	ACY1	0,82	0,37
Mitochondrial chaperone BCS1	BCS1L	0,82	0,21
Vesicle transport through interaction with t-SNAREs homolog 1B	VTI1B	0,82	0,51
Cytochrome c oxidase subunit 7A2, mitochondrial	COX7A2	0,82	0,07
Lymphocyte antigen 75	LY75	0,82	0,23
DNA-directed RNA polymerase III subunit RPC2	POLR3B	0,82	1,21
Treacle protein	TCOF1	0,82	0,15
Protein FAM162A	FAM162A	0,81	0,07
SPRY domain-containing protein 4	SPRYD4	0,81	N.D.
ATP-binding cassette sub-family B member 7, mitochondrial	ABCB7	0,81	0,35
Coatomer subunit gamma-2	COPG2	0,81	0,53
ADP/ATP translocase 1	SLC25A4	0,81	N.D.
Zinc finger protein 638	ZNF638 RAD50	0,81	0,19
DNA repair protein RAD50 Electron transfer flavoprotein subunit alpha, mitochondrial	ETFA	0,80 0,80	0,06
NADPHcytochrome P450 reductase	POR	0,80	0,00
Acyl-coenzyme A thioesterase 1;Acyl-coenzyme A thioesterase 2, mitochondrial	ACOT1;ACOT2	0,80	0,14
Glutamine-dependent NAD(+) synthetase	NADSYN1	0,80	0,04 N.D.
Peptidyl-tRNA hydrolase 2, mitochondrial	PTRH2	0,80	0,11
TyrosinetRNA ligase, mitochondrial	YARS2	0,80	0,30
Probable ATP-dependent RNA helicase DDX27	DDX27	0,80	1,42
Microsomal glutathione S-transferase 1	MGST1	0,80	0,29
Eukaryotic translation initiation factor 5B	EIF5B	0,79	0,16
Mitochondrial import inner membrane translocase subunit Tim13	TIMM13	0,79	0,05
Pre-mRNA-splicing factor 38B	PRPF38B	0,79	0,09
Zinc finger CCCH domain-containing protein 15	ZC3H15	0,79	0,29
Glutaryl-CoA dehydrogenase, mitochondrial	GCDH	0,79	0,17
Mitochondrial import inner membrane translocase subunit Tim17-B	TIMM17B	0,78	0,28
Mitochondrial import inner membrane translocase subunit TIM44	TIMM44	0,78	0,02
Elongation factor Ts, mitochondrial	TSFM	0,78	0,37
Serine/threonine-protein kinase tousled-like 1	TLK1	0,78	0,42
pre-mRNA 3 end processing protein WDR33	WDR33	0,78	0,26
Heat shock 70 kDa protein 4L	HSPA4L	0,77	0,17
MICOS complex subunit MIC60	IMMT	0,77	0,02
Thioredoxin domain-containing protein 5 High mobility group protein B2	TXNDC5 HMGB2	0,77 0,77	0,11 0,20
ATP-binding cassette sub-family F member 1	ABCF1	0,77	0,20
Putative E3 ubiquitin-protein ligase UBR7	UBR7	0,76	0,24 N.D.
BET1 homolog	BET1	0,76	0,31
Transmembrane protein 261	TMEM261	0,76	0,15
Cell growth-regulating nucleolar protein	LYAR	0,76	0,09
Cell cycle progression protein 1	CCPG1	0,76	0,30
Electron transfer flavoprotein subunit beta	ETFB	0,76	0,20
Ras-related protein Rab-5B	RAB5B	0,76	0,05
Thioredoxin-like protein 4B	TXNL4B	0,76	N.D.
Ribose-phosphate pyrophosphokinase 1	PRPS1	0,76	0,07
Annexin A4	ANXA4	0,75	0,02
Fatty aldehyde dehydrogenase	ALDH3A2	0,75	0,31
Phosphatidylinositol 4-kinase alpha	PI4KA	0,75	1,20
NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 6	NDUFB6	0,75	0,19
Voltage-dependent anion-selective channel protein 3	VDAC3	0,75	0,02
Sorting and assembly machinery component 50 homolog	SAMM50	0,75	0,23
ELAV-like protein 1	ELAVL1	0,75	0,16
Tyrosyl-DNA phosphodiesterase 1 Superoxide dismutase [Cu-Zn]	TDP1 SOD1	0,75 0,75	0,46
Ornithine aminotransferase, mitochondrial	OAT	0,75	0,02 0,02
Squamous cell carcinoma antigen recognized by T-cells 3	SART3	0,74	0,62
2,4-dienoyl-CoA reductase, mitochondrial	DECR1	0,74	0,06
Hsc70-interacting protein;Putative protein FAM10A4;Putative protein FAM10A5	ST13;ST13P4;ST13P5	0,74	0,06
Pyridoxine-5-phosphate oxidase	PNPO	0,74	N.D.
Malate dehydrogenase, mitochondrial	MDH2	0,74	0,07
E3 ubiquitin-protein ligase HUWE1	HUWE1	0,74	0,24
Phosphatidylglycerophosphatase and protein-tyrosine phosphatase 1	PTPMT1	0,73	0,24
Collagen type IV alpha-3-binding protein	COL4A3BP	0,73	0,27
Ubiquinone biosynthesis protein COQ9, mitochondrial	COQ9	0,73	0,43
Syntaxin-16	STX16	0,73	0,51
DnaJ homolog subfamily B member 1	DNAJB1	0,72	0,02
Heterogeneous nuclear ribonucleoprotein A/B	HNRNPAB	0,72	0,05
		0 7 2	
Coiled-coil domain-containing protein 58 NADH-ubiquinone oxidoreductase chain 5	CCDC58 MT-ND5	0,72 0,72	N.D. 0,14

Sigma non-opioid intracellular receptor 1	SIGMAR1	0,72	0,32
Metaxin-1	MTX1	0,72	0,45
RNA pseudouridylate synthase domain-containing protein 2	RPUSD2	0,72	0,07
Phosphatidylethanolamine-binding protein 1;Hippocampal cholinergic neurostimulating peptide	PEBP1	0,71	0,05
Beta-lactamase-like protein 2	LACTB2	0,71	0,03
E2/E3 hybrid ubiquitin-protein ligase UBE20	UBE2O	0,71	0,06
Nuclease-sensitive element-binding protein 1	YBX1	0,71	0,70
28S ribosomal protein S25, mitochondrial	MRPS25	0,71	0,35
Cell cycle and apoptosis regulator protein 2	CCAR2	0,71	0,05
Protein NipSnap homolog 2	GBAS	0,71	0,08
Citrate synthase, mitochondrial	CS	0,71	0,05
Nuclear pore complex protein Nup214	NUP214	0,71	0,28
	SURF4		
Surfeit locus protein 4		0,71	0,09
Latrophilin-2	LPHN2	0,71	0,57
High mobility group protein B3	HMGB3	0,70	0,13
Translin	TSN	0,70	0,06
Serine/threonine-protein kinase TAO3	TAOK3	0,70	0,08
WD repeat and HMG-box DNA-binding protein 1	WDHD1	0,70	0,05
Epidermal growth factor receptor substrate 15	EPS15	0,70	0,12
Monocarboxylate transporter 1	SLC16A1	0,70	0,08
Replication protein A 32 kDa subunit	RPA2	0,70	0,08
Oxygen-dependent coproporphyrinogen-III oxidase, mitochondrial	CPOX	0,70	0,04
Isocitrate dehydrogenase [NAD] subunit gamma, mitochondrial	IDH3G	0,69	1,06
DnaJ homolog subfamily A member 3, mitochondrial	DNAJA3	0,69	0,04
Grancalcin	GCA	0,69	0,14
Thyroid hormone receptor-associated protein 3	THRAP3	0,69	0,05
CGG triplet repeat-binding protein 1	CGGBP1	0,69	N.D.
Acylphosphatase-2	ACYP2	0,69	0,21
Activator of 90 kDa heat shock protein ATPase homolog 1	AHSA1	0,69	0,01
Methylcrotonoyl-CoA carboxylase beta chain, mitochondrial	MCCC2	0,69	0,19
DNA replication licensing factor MCM2	MCM2	0,69	0,16
Signal recognition particle receptor subunit beta	SRPRB	0,68	0,15
Thrombomodulin	THBD	0,68	0,39
DNA-directed RNA polymerase I subunit RPA1	POLR1A	0,68	0,29
Arf-GAP with coiled-coil, ANK repeat and PH domain-containing protein 2	ACAP2	0,68	0,39
	-		
KDEL motif-containing protein 2	KDELC2	0,68	0,11
DNA mismatch repair protein Msh6	MSH6	0,68	0,04
Peptidyl-prolyl cis-trans isomerase H	PPIH	0,68	0,07
Proteasome assembly chaperone 3	PSMG3	0,68	0,14
AFG3-like protein 2	AFG3L2	0,68	0,10
Serine/threonine-protein phosphatase PGAM5, mitochondrial	PGAM5	0,68	0,18
Protein LSM14 homolog A	LSM14A	0,68	0,06
Protein phosphatase 1 regulatory subunit 14B	PPP1R14B	0,67	N.D.
Ras-related protein Ral-A	RALA	0,67	N.D.
Crk-like protein	CRKL	0,67	0,26
Nucleoside diphosphate kinase A	NME1	0,67	0,04
Queuine tRNA-ribosyltransferase subunit QTRTD1	QTRTD1	0,66	0,23
Cytochrome c oxidase subunit NDUFA4	NDUFA4	0,66	0,11
Nucleolar protein 58	NOP58	0,66	0,03
2-oxoglutarate dehydrogenase, mitochondrial	OGDH	0,66	0,05
	PITPNB		
Phosphatidylinositol transfer protein beta isoform		0,66	0,01
Apolipoprotein O	APOO	0,65	0,17
Protein Red	IK	0,65	0,25
Double-strand break repair protein MRE11A	MRE11A	0,65	0,14
Proteasome assembly chaperone 4	PSMG4	0,65	0,21
Golgi reassembly-stacking protein 2	GORASP2	0,65	0,20
Cytosolic non-specific dipeptidase	CNDP2	0,64	0,12
Carnitine O-palmitoyltransferase 2, mitochondrial			
	CPT2	0,64	0,09
Bifunctional UDP-N-acetylglucosamine 2-epimerase/N-acetylmannosamine kinase	GNE	0,64	0,28
Small integral membrane protein 20	SMIM20	0,64	0,04
Voltage-dependent anion-selective channel protein 1	VDAC1	0,64	0,08
Prostaglandin E synthase 2; Prostaglandin E synthase 2 truncated form	PTGES2	0,64	0,17
Transmembrane emp24 domain-containing protein 4	TMED4	0,64	0,12
Cytochrome c oxidase subunit 7C, mitochondrial	COX7C	0,64	0,15
Ras-related protein Rab-21			
	RAB21	0,63	0,23
NudC domain-containing protein 2	NUDCD2	0,63	0,01
DnaJ homolog subfamily C member 11	DNAJC11	0,63	0,08
E3 SUMO-protein ligase RanBP2	RANBP2	0,63	0,11
Heat shock protein 75 kDa, mitochondrial	TRAP1	0,63	0,15
Ribose-phosphate pyrophosphokinase 2	PRPS2	0,63	0,05
Glutamatecysteine ligase catalytic subunit	GCLC	0,63	0,29
Probable ATP-dependent RNA helicase DDX20	DDX20	0,63	1,12
NADH-ubiquinone oxidoreductase chain 4	MT-ND4	0,63	0,13
Apoptosis regulator Bcl-2	BCL2	0,63	0,19
Dihydrolipoyl dehydrogenase, mitochondrial	DLD	0,63	0,08
NEDD8 ultimate buster 1	NUB1	0,63	N.D.
	SRRM1	0,62	0,09
	SIGNIT	0,02	
Serine/arginine repetitive matrix protein 1	NITEC		
5(3)-deoxyribonucleotidase, cytosolic type	NT5C	0,62	N.D.
	NT5C MTFP1 ZC3H4	0,62	N.D. N.D. 0,74

Protein FAM195A	FAM195A	0,62	N.D.
GDP-mannose 4,6 dehydratase	GMDS	0,62	0,70
Myeloperoxidase; Myeloperoxidase	MPO	0,62	0,35
Acid ceramidase	ASAH1	0,62	0,05
Glyoxalase domain-containing protein 4	GLOD4	0,62	0,10
Proliferating cell nuclear antigen	PCNA	0,62	0,05
Acyl-CoA synthetase family member 2, mitochondrial	ACSF2	0,62	0,20
Lon protease homolog, mitochondrial	LONP1	0,62	0,06
tRNA (adenine(58)-N(1))-methyltransferase catalytic subunit TRMT61A	TRMT61A	0,62	0,52
Ras-related protein Ral-B	RALB	0,61	0,07
UBX domain-containing protein 7	UBXN7	0,61	0,08
Replication protein A 70 kDa DNA-binding subunit	RPA1	0,61	0,12
Protein DEK	DEK	0,61	0,38
3-mercaptopyruvate sulfurtransferase	MPST	0,61	0,05
B-cell receptor-associated protein 31	BCAP31	0,61	0,12
Focadhesin	FOCAD	0,61	0,06
DNA replication licensing factor MCM5	MCM5	0,61	0,04
DNA replication licensing factor MCM4	MCM4	0,61	0,02
NAD(P) transhydrogenase, mitochondrial	NNT	0,61	0,06
Selenide, water dikinase 2	SEPHS2	0,61	0,23
Peptidyl-prolyl cis-trans isomerase-like 4	PPIL4	0,61	0,59
Mitochondrial ribonuclease P protein 1	TRMT10C	0,60	0,21
Poly(A)-specific ribonuclease PARN	PARN	0,60	0,33
NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 7	NDUFB7	0,60	N.D.
Eukaryotic translation initiation factor 5A-1;Eukaryotic translation initiation factor 5A-1-like	EIF5A;EIF5AL1	0,60	0,11
Hydroxyacyl-coenzyme A dehydrogenase, mitochondrial	HADH	0,60	0,05
DNA replication licensing factor MCM3	MCM3	0,60	0,03
Protein Hikeshi	C11orf73	0,59	0,11
DnaJ homolog subfamily C member 10	DNAJC10	0,59	0,24
Heat shock protein HSP 90-alpha	HSP90AA1	0,59	0,16
Glycogen debranching enzyme;4-alpha-glucanotransferase;Amylo-alpha-1,6-glucosidase	AGL	0,59	0,11
Exportin-7	XPO7	0,59	0,12
Heterogeneous nuclear ribonucleoprotein U	HNRNPU	0,59	0,30
OCIA domain-containing protein 1	OCIAD1	0,59	0,10
Ribosome maturation protein SBDS	SBDS	0,59	0,18
Deoxyguanosine kinase, mitochondrial	DGUOK	0,59	N.D.
Putative pre-mRNA-splicing factor ATP-dependent RNA helicase DHX16	DHX16	0,59	0,24
Putative transferase CAF17, mitochondrial	IBA57	0,59	0,29
NHP2-like protein 1	NHP2L1	0,59	0,14
Ubiquinol-cytochrome-c reductase complex assembly factor 1	UQCC1	0,59	N.D.
Synaptophysin-like protein 1	SYPL1	0,59	N.D.

Table 5. Upregulated proteins in THP-1 Dox compared to THP-1 P cells under normoxia. Proteomic profiling (SILAC) data were used. Significantly upregulated proteins were calculated using the fold difference threshold of 1.5 (log₂ fold change=0.58). Mean±SD for n=2 replicates. Non-detected (N.D.) means less than 2 replicates detected for one protein measured.

DOWNREGULATED P	PROTEINS IN THP-1 Dox VS. THP-1 P		
Protein names	Gene names	Mean Log ₂ fold change	SD Log ₂ fold chang
Annexin A6	ANXA6	-4.05	0.07
Insulin-like growth factor 2 mRNA-binding protein 3	IGF2BP3	-3.46	N.D.
Leukosialin	SPN	-3.00	2.42
Cathepsin G	CTSG	-2.87	0.44
Angiotensinogen	AGT	-2.78	N.D.
Keratinocyte proline-rich protein	KPRP	-2.67	0.60
Gelsolin	GSN	-2.65	0.43
Vimentin	VIM	-2.63	0.05
HLA class II histocompatibility antigen,	HLA-DRB1	-2.57	0.22
HLA class II histocompatibility antigen	HLA-DRA	-2.44	0.27
TYRO protein tyrosine kinase-binding protein	TYROBP	-2.42	N.D.
Lysozyme C	LYZ	-2.33	0.19
Protein S100-P	S100P	-2.27	0.02
Arachidonate 5-lipoxygenase-activating protein	ALOX5AP	-2.17	N.D.
Prelamin-A/C;Lamin-A/C			
	LMNA	-2.13	0.07
Apolipoprotein C-II	APOC2	-2.11	0.60
Protein S100-A4	S100A4	-2.10	0.09
Fructose-1,6-bisphosphatase 1	FBP1	-2.06	N.D.
EMILIN-2	EMILIN2	-2.04	N.D.
1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase beta-2	PLCB2	-2.01	0.46
Cystatin-C	CST3	-2.00	0.20
Plectin	PLEC	-1.99	0.14
Putative RNA-binding protein 15	RBM15		
		-1.95	N.D.
Unconventional myosin-XVIIIa	MYO18A	-1.95	0.30
Protein-methionine sulfoxide oxidase MICAL1	MICAL1	-1.94	0.04
Caspase recruitment domain-containing protein 9	CARD9	-1.92	0.97
Creatine kinase B-type	СКВ	-1.92	0.39
Platelet endothelial cell adhesion molecule	PECAM1	-1.90	0.46
Lysosomal alpha-glucosidase; 76 kDa lysosomal alpha-glucosidase	GAA	-1.88	0.03
Junction plakoglobin	JUP	-1.81	0.89
Inactive ubiquitin thioesterase FAM105A	FAM105A	-1.81	0.10
Integrin alpha-M	ITGAM	-1.79	0.45
Formin-like protein 1	FMNL1	-1.78	0.29
Granulins	GRN	-1.78	N.D.
Lactoylglutathione lyase	GLO1	-1.73	0.14
IgG receptor FcRn large subunit p51	FCGRT	-1.73	0.27
Conserved oligomeric Golgi complex subunit 8	COG8	-1.69	N.D.
CapZ-interacting protein	RCSD1	-1.69	0.19
	PLD3	-1.65	0.17
Phospholipase D3			
DNA-binding protein SATB1	SATB1	-1.64	0.39
Plasma membrane calcium-transporting ATPase 4	ATP2B4	-1.64	N.D.
Glutathione S-transferase Mu 3	GSTM3	-1.63	1.21
ADP-ribosylation factor-like protein 3	ARL3	-1.62	0.21
Galectin-9	LGALS9	-1.62	0.40
HLA class I histocompatibility antigen	HLA-C	-1.58	N.D.
Protein unc-13 homolog D	UNC13D	-1.58	0.11
Interferon-induced 35 kDa protein	IF135	-1.56	0.34
	VPS11	-1.56	N.D.
Vacuolar protein sorting-associated protein 11 homolog			
Desmoplakin	DSP	-1.55	0.07
Septin-9	40057	-1.54	N.D.
Volume-regulated anion channel subunit LRRC8C	LRRC8C	-1.54	0.23
C-type lectin domain family 11 member A	CLEC11A	-1.53	0.64
Unconventional myosin-VI	MYO6	-1.51	0.48
Protein S100-A10	S100A10	-1.50	0.75
Two pore calcium channel protein 1	TPCN1	-1.50	N.D.
Sperm-associated antigen 5	SPAG5	-1.50	N.D.
	NAPRT	-1.49	0.42
Nicotinate phosphoribosyltransferase			
DNA topoisomerase 2-alpha	TOP2A	-1.49	0.34
Glutaredoxin-1	GLRX	-1.47	0.14
Iron-responsive element-binding protein 2	IREB2	-1.47	N.D.
CD70 antigen	CD70	-1.45	N.D.
Macrosialin	CD68	-1.43	N.D.
Filamin-A	FINA	-1.42	0.12
E3 ubiquitin-protein ligase RNF213	RNF213	-1.41	0.11
Egl nine homolog 1	EGLN1	-1.40	N.D.
Acetyl-CoA acetyltransferase, cytosolic	ACAT2	-1.39	0.04
Neurochondrin	NCDN	-1.39	N.D.
Tyrosine-protein kinase HCK	HCK	-1.37	0.58
Annexin A2;Putative annexin A2-like protein	ANXA2;ANXA2P2	-1.36	0.06
Acylglycerol kinase, mitochondrial	AGK	-1.36	0.17
Hydroxymethylglutaryl-CoA synthase, cytoplasmic	HMGCS1	-1.35	0.42
Tropomyosin alpha-4 chain	TPM4	-1.35	1.13
Thymidine kinase, cytosolic			
	TK1	-1.35	0.12
Thymidylate synthase	TYMS	-1.35	0.09
CCR4-NOT transcription complex subunit 11	CNOT11	-1.34	N.D.
	GBF1	-1.33	N.D.
Golgi-specific brefeldin A-resistance guanine nucleotide exchange factor 1			
Golgi-specific brefeldin A-resistance guanine nucleotide exchange factor 1 Copine-8	CPNE8	-1.33	0.27
	CPNE8 SYNE3	-1.33 -1.32	0.27 N.D.
Copine-8			

Ribosome production factor 2 homolog	RPF2	-1,30	0,59
Galectin-1	LGALS1	-1,29	0,09
P-selectin glycoprotein ligand 1	SELPLG	-1,29	0,58
Astrocytic phosphoprotein PEA-15	PEA15	-1,29	0,23
Antigen KI-67	MKI67	-1,28	0,09
Protein phosphatase 1 regulatory subunit 27	PPP1R27	-1,27	0,09
Plexin-B2	PLXNB2	-1,27	0,16
	SUN2		0,05
SUN domain-containing protein 2		-1,26	
Schlafen family member 11	SLFN11	-1,26	0,13
DNA topoisomerase 2-beta	TOP2B	-1,25	0,14
Wiskott-Aldrich syndrome protein	WAS	-1,25	0,27
Fermitin family homolog 3	FERMT3	-1,25	0,19
Myeloid cell nuclear differentiation antigen	MNDA	-1,25	0,22
KIF1-binding protein	KIAA1279	-1,25	0,19
0.			
Calpain-2 catalytic subunit	CAPN2	-1,24	0,31
6-phosphogluconate dehydrogenase, decarboxylating	PGD	-1,23	0,13
Ubiquitin-conjugating enzyme E2 T	UBE2T	-1,23	N.D.
Pericentrin	PCNT	-1,22	0,46
DNA ligase 4	LIG4	-1,22	N.D.
	KCTD12		N.D.
BTB/POZ domain-containing protein KCTD12		-1,21	
SH3 domain-binding glutamic acid-rich-like protein 3	SH3BGRL3	-1,21	0,10
Chloride intracellular channel protein 4	CLIC4	-1,19	0,04
Adenylate kinase isoenzyme 1	AK1	-1,19	0,15
Ubiquitin-like modifier-activating enzyme 7	UBA7	-1,19	0,36
Fatty acid desaturase 1	FADS1	-1,19	N.D.
Pyruvate kinase PKM	PKM	-1,19	0,07
Protein kinase C beta type	PRKCB	-1,18	0,18
Thymidine phosphorylase	ТҮМР	-1,18	0,20
5-oxoprolinase	OPLAH	-1,17	N.D.
BET1-like protein	BET1L	-1,17	0,12
MMS19 nucleotide excision repair protein homolog	MMS19	-1,17	0,25
Golgi phosphoprotein 3	GOLPH3	-1,15	0,24
Probable methyltransferase TARBP1	TARBP1	-1,15	0,08
Protein furry homolog	FRY	-1,15	0,54
WD repeat- and FYVE domain-containing protein 4	WDFY4	-1,14	0,17
Tapasin	ТАРВР	-1,14	0,36
Carboxypeptidase M	СРМ	-1,14	0,12
	DHCR24		
Delta(24)-sterol reductase		-1,13	0,17
Centromere protein F	CENPF	-1,13	0,15
Leukocyte immunoglobulin-like receptor subfamily B member 4	LILRB4	-1,13	1,52
Vesicle-associated membrane protein 3	VAMP3	-1,13	0,23
NmrA-like family domain-containing protein 1	NMRAL1	-1,13	N.D.
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform	PIK3CD	-1,12	0,15
	IRF8	-1,12	0,33
Interferon regulatory factor 8			
Polymerase delta-interacting protein 3	POLDIP3	-1,12	0,20
Macrophage-capping protein	CAPG	-1,12	0,04
F-actin-capping protein subunit alpha-2	CAPZA2	-1,12	0,12
Long-chain-fatty-acidCoA ligase 3	ACSL3	-1,11	0,07
Differentially expressed in FDCP 6 homolog	DEF6	-1,11	0,34
	NUDT5	-1,11	0,23
ADP-sugar pyrophosphatase			
Dihydrofolate reductase	DHFR	-1,10	0,30
BAG family molecular chaperone regulator 1	BAG1	-1,10	N.D.
Synaptic vesicle membrane protein VAT-1 homolog	VAT1	-1,10	0,05
Translocator protein	TSPO	-1,10	0,09
Piezo-type mechanosensitive ion channel component 1	PIEZO1	-1,10	0,11
Dihydropyrimidinase-related protein 2	DPYSL2	-1,09	0,16
Alpha-N-acetylgalactosaminidase	NAGA	-1,09	0,10
Phosphatidylinositol 3,4,5-trisphosphate-dependent Rac exchanger 1 protein	PREX1	-1,09	0,51
Tensin-3	TNS3	-1,08	N.D.
Aminopeptidase B	RNPEP	-1,08	0,09
Neutrophil cytosol factor 4	NCF4	-1,08	N.D.
Bifunctional coenzyme A synthase	COASY	-1,08	0,04
WD repeat and FYVE domain-containing protein 1	WDFY1	-1,08	0,05
Major vault protein	MVP	-1,08	0,03
			-
DNA repair protein complementing XP-G cells	ERCC5	-1,08	N.D.
Guanine nucleotide exchange factor MSS4	RABIF	-1,07	0,53
Sortilin-related receptor	SORL1	-1,07	0,01
Beta-2-microglobulin;Beta-2-microglobulin form pl 5.3	B2M	-1,07	0,04
Coiled-coil domain-containing protein 88B	CCDC88B	-1,07	0,19
Toll-like receptor 2	TLR2	-1,07	0,13
			0,15
40S ribosomal protein S4, Y isoform 1	RPS4Y1	-1,06	
Tyrosine-protein phosphatase non-receptor type 6	PTPN6	-1,06	0,08
Cathepsin L1	CTSL	-1,06	0,05
Ethylmalonyl-CoA decarboxylase	ECHDC1	-1,05	0,25
Carbonyl reductase [NADPH] 1	CBR1	-1,05	0,05
Sorting nexin-4	SNX4	-1,05	N.D.
5			
Suppressor of G2 allele of SKP1 homolog	SUGT1	-1,05	0,03
SH3 domain-binding protein 1	SH3BP1	-1,05	0,62
Protein diaphanous homolog 3	DIAPH3	-1,05	0,22
N-myc-interactor	NMI	-1,05	0,34

Serpin B8	SERPINB8	-1.05	0.08
Interferon regulatory factor 5	IRF5	-1.04	0.25
Geranylgeranyl pyrophosphate synthase	GGPS1	-1.04	0.29
Dedicator of cytokinesis protein 10	DOCK10	-1.04	0.25
Ribonuclease inhibitor	RNH1	-1.04	0.07
Dual specificity protein phosphatase 23	DUSP23	-1.03	0.15
Axin interactor, dorsalization-associated protein	AIDA	-1.03	0.27
Transmembrane 9 superfamily member 2	TM9SF2	-1.03	0.27
Cytohesin-3;Cytohesin-1	CYTH3;CYTH1	-1.03	N.D.
Serine/arginine-rich splicing factor 10	SRSF10	-1.02	0.77
Cytochrome b-245 heavy chain	CYBB	-1.02	0.29
Acidic fibroblast growth factor intracellular-binding protein	FIBP	-1.01	N.D.
Diacylglycerol kinase zeta	DGKZ	-1.01	0.25
Vesicle-fusing ATPase	NSF	-1.01	0.15
Tudor domain-containing protein 7	TDRD7	-1.01	0.58
2-5A-dependent ribonuclease	RNASEL	-1.01	0.31
Syntaxin-12	STX12	-1.00	0.46
WAS/WASL-interacting protein family member 1	WIPF1	-1.00	0.16
Fatty acid desaturase 2	FADS2	-1.00	0.12
E3 ubiquitin-protein ligase TRIP12	TRIP12	-1.00	0.32
Pyrroline-5-carboxylate reductase 2	PYCR2	-0.99	0.05
Protein unc-93 homolog B1	UNC93B1	-0.99	0.12
Tubulin alpha-4A chain	TUBA4A	-0.98	0.12
Tyrosine-protein kinase SYK	SYK	-0.98	0.05
Utrophin	UTRN	-0.98	0.02
Vasodilator-stimulated phosphoprotein	VASP	-0.98	0.28
Tetratricopeptide repeat protein 37	TTC37	-0.98	0.22
Dimethyladenosine transferase 1, mitochondrial	TFB1M	-0.98	0.35
SHC SH2 domain-binding protein 1	SHCBP1	-0.97	0.24
Peptidyl-prolyl cis-trans isomerase FKBP8	FKBP8	-0.97	0.31
Isocitrate dehydrogenase [NADP] cytoplasmic	IDH1	-0.97	0.06
Filamin-B	FLNB	-0.97	0.22
Lysophosphatidylcholine acyltransferase 2	LPCAT2	-0.97	0.12
Signal-induced proliferation-associated protein 1	SIPA1	-0.96	0.48
Golgi SNAP receptor complex member 1	GOSR1	-0.96	0.38
Mitotic-spindle organizing protein 1	MZT1	-0.96	N.D.
Inositol 1,4,5-trisphosphate receptor type 3	ITPR3	-0.96	1.81
DIS3-like exonuclease 2	DIS3L2	-0.95	N.D.
Integrin beta-2	ITGB2	-0.95	0.21
Nicotinate-nucleotide pyrophosphorylase [carboxylating]	QPRT	-0.95	0.18
Nucleoside diphosphate kinase 3	NME3	-0.95	N.D.
Leucine-rich repeat-containing protein 57	LRRC57	-0.95	0.21
Nuclear RNA export factor 1	NXF1	-0.94	0.12
Serine/threonine-protein phosphatase 6 regulatory ankyrin repeat subunit B	ANKRD44	-0.94	0.03
Phosphoacetylglucosamine mutase	PGM3	-0.94	0.13
Ras-related protein Rab-44	RAB44	-0.93	N.D.
General transcription factor 3C polypeptide 2	GTF3C2	-0.93	N.D.
Fanconi anemia group I protein	FANCI	-0.93	0.36
Zyxin	ZYX	-0.93	0.25
ATP-binding cassette sub-family B member 10, mitochondrial	ABCB10	-0.93	0.23
Ethanolamine-phosphate cytidylyltransferase	PCYT2	-0.93	0.15
Serine/threonine-protein kinase mTOR	MTOR	-0.93	0.40
Retinoblastoma-associated protein	RB1	-0.93	0.58
Exosome complex exonuclease RRP44	DIS3	-0.93	0.16
HBS1-like protein	HBS1L	-0.92	0.13
tRNA (uracil-5-)-methyltransferase homolog A	TRMT2A	-0.92	0.43
Lymphocyte cytosolic protein 2	LCP2	-0.92	0.05
Heterogeneous nuclear ribonucleoprotein F	HNRNPF	-0.92	0.23
LIM and SH3 domain protein 1	LASP1	-0.92	0.22
Ras GTPase-activating protein 3	RASA3	-0.92	0.41
Diphosphomevalonate decarboxylase	MVD	-0.92	0.22
Mothers against decapentaplegic homolog 2,3 and 9	SMAD2;SMAD3;SMAD9	-0.92	0.35
Calpain small subunit 1	CAPNS1	-0.91	0.14
·			
WD repeat-containing protein 26	WDR26	-0.91	0.02
Synaptosomal-associated protein 23	SNAP23	-0.91	0.21
Protein FAM49B	FAM49B	-0.91	0.02
Nuclear receptor coactivator 5	NCOA5	-0.91	N.D.
1,2-dihydroxy-3-keto-5-methylthiopentene dioxygenase	ADI1	-0.91	0.75
Tyrosine-protein phosphatase non-receptor type 7	PTPN7	-0.90	0.38
X-ray repair cross-complementing protein 5	XRCC5	-0.90	0.09
Deoxynucleoside triphosphate triphosphohydrolase SAMHD1	SAMHD1	-0.90	0.08
Importin-9	IPO9	-0.89	0.38
Parafibromin	CDC73	-0.89	0.13
NADP-dependent malic enzyme	ME1	-0.89	0.08
Mitochondrial import inner membrane translocase subunit Tim17-A	TIMM17A	-0.89	N.D.
Tumor necrosis factor alpha-induced protein 2	TNFAIP2	-0.89	N.D.
Translationally-controlled tumor protein	TPT1	-0.88	0.13
Peroxisomal acyl-coenzyme A oxidase 3	ACOX3	-0.88	0.35
Argininosuccinate synthase	ASS1	-0.88	0.05
Growth factor receptor-bound protein 2	GRB2	-0.88	0.10
Phosphatidylinositol 4-kinase type 2-alpha	PI4K2A	-0.88	0.46
Protein PAXX	C9orf142	-0.88	0.19
Junctional adhesion molecule A	F11R	-0.87	0.08
Protein unc-45 homolog A	UNC45A	-0.87	0.16
rioteni une 45 nomolog A	0110407	0.07	0.10

Serpin B8	SERPINB8	-1,05	0,08
Interferon regulatory factor 5	IRF5	-1,04	0,25
Geranylgeranyl pyrophosphate synthase	GGPS1	-1,04	0,29
Dedicator of cytokinesis protein 10	DOCK10	-1,04	0,25
Ribonuclease inhibitor	RNH1	-1,04	0,07
Dual specificity protein phosphatase 23	DUSP23	-1,03	0,15
Axin interactor, dorsalization-associated protein	AIDA	-1,03	0,27
Transmembrane 9 superfamily member 2	TM9SF2	-1,03	0,27
Cytohesin-3;Cytohesin-1	CYTH3;CYTH1	-1,03	N.D.
Serine/arginine-rich splicing factor 10	SRSF10	-1,02	0,77
Cytochrome b-245 heavy chain	CYBB	-1,02	0,29
Acidic fibroblast growth factor intracellular-binding protein	FIBP	-1,01	N.D.
Diacylglycerol kinase zeta	DGKZ	-1,01	0,25
Vesicle-fusing ATPase	NSF	-1,01	0,15
Tudor domain-containing protein 7	TDRD7	-1,01	0,58
2-5A-dependent ribonuclease	RNASEL	-1,01	0,31
Syntaxin-12	STX12	-1,00	0,46
WAS/WASL-interacting protein family member 1	WIPF1	-1,00	0,16
Fatty acid desaturase 2	FADS2	-1,00	0,12
E3 ubiquitin-protein ligase TRIP12	TRIP12	-1,00	0,32
Pyrroline-5-carboxylate reductase 2	PYCR2	-0,99	0,05
Protein unc-93 homolog B1	UNC93B1	-0,99	0,12
Tubulin alpha-4A chain	TUBA4A	-0,98	0,27
Tyrosine-protein kinase SYK	SYK	-0,98	0,05
Utrophin	UTRN	-0,98	0,02
Vasodilator-stimulated phosphoprotein	VASP	-0,98	0,28
Tetratricopeptide repeat protein 37	TTC37	-0,98	0,22
Dimethyladenosine transferase 1, mitochondrial	TFB1M	-0,98	0,35
SHC SH2 domain-binding protein 1	SHCBP1	-0,97	0,24
Peptidyl-prolyl cis-trans isomerase FKBP8	FKBP8	-0,97	0,31
Isocitrate dehydrogenase [NADP] cytoplasmic	IDH1	-0,97	0,06
Filamin-B	FLNB	-0,97	0,08
Lysophosphatidylcholine acyltransferase 2	LPCAT2	-0,97	0,12
Signal-induced proliferation-associated protein 1	SIPA1	-0,96	0,48
Golgi SNAP receptor complex member 1	GOSR1	-0,96	0,38
Mitotic-spindle organizing protein 1	MZT1	-0,96	N.D.
Inositol 1,4,5-trisphosphate receptor type 3	ITPR3	-0,96	1,81
DIS3-like exonuclease 2	DIS3L2	-0,95	N.D.
Integrin beta-2	ITGB2	-0,95	0,21
Nicotinate-nucleotide pyrophosphorylase [carboxylating]	QPRT	-0,95	0,18
Nucleoside diphosphate kinase 3	NME3	-0,95	N.D.
Leucine-rich repeat-containing protein 57	LRRC57	-0,95	0,21
Nuclear RNA export factor 1	NXF1	-0,94	0,12
Serine/threonine-protein phosphatase 6 regulatory ankyrin repeat subunit B	ANKRD44	-0,94	0,03
Phosphoacetylglucosamine mutase	PGM3	-0,94	0,13
Ras-related protein Rab-44	RAB44	-0,93	N.D.
General transcription factor 3C polypeptide 2	GTF3C2	-0,93	N.D.
Fanconi anemia group I protein	FANCI	-0,93	0,36
Zyxin	ZYX	-0,93	0,25
ATP-binding cassette sub-family B member 10, mitochondrial	ABCB10	-0,93	0,23
Ethanolamine-phosphate cytidylyltransferase	PCYT2	-0,93	0,15
Serine/threonine-protein kinase mTOR	MTOR	-0,93	0,40
Retinoblastoma-associated protein	RB1	-0,93	0,58
Exosome complex exonuclease RRP44	DIS3	-0,93	0,16
HBS1-like protein	HBS1L	-0,92	0,13
tRNA (uracil-5-)-methyltransferase homolog A	TRMT2A	-0,92	0,43
	LCP2		
Lymphocyte cytosolic protein 2		-0,92	0,05
Heterogeneous nuclear ribonucleoprotein F	HNRNPF	-0,92	0,23
LIM and SH3 domain protein 1	LASP1	-0,92	0,22
Ras GTPase-activating protein 3	RASA3	-0,92	0,41
Diphosphomevalonate decarboxylase	MVD	-0,92	0,22
Mothers against decapentaplegic homolog 2,3 and 9	SMAD2;SMAD3;SMAD9	-0,92	0,35
Calpain small subunit 1	CAPNS1	-0,91	0,14
WD repeat-containing protein 26	WDR26	-0,91	0,02
Synaptosomal-associated protein 23	SNAP23	-0,91	0,21
Protein FAM49B	FAM49B	-0,91	0,21
Nuclear receptor coactivator 5	NCOA5	-0,91	N.D.
1,2-dihydroxy-3-keto-5-methylthiopentene dioxygenase	ADI1	-0,91	0,75
Tyrosine-protein phosphatase non-receptor type 7	PTPN7	-0,90	0,38
X-ray repair cross-complementing protein 5	XRCC5	-0,90	0,09
Deoxynucleoside triphosphate triphosphohydrolase SAMHD1	SAMHD1	-0,90	0,08
Importin-9	IPO9	-0,89	0,38
Parafibromin	CDC73	-0,89	0,13
NADP-dependent malic enzyme	ME1	-0,89	0,08
Mitochondrial import inner membrane translocase subunit Tim17-A	TIMM17A	-0,89	N.D.
Tumor necrosis factor alpha-induced protein 2	TNFAIP2	-0,89	N.D.
Translationally-controlled tumor protein	TPT1	-0,88	0,13
	ACOX3	-0,88	0,35
Peroxisomal acyl-coenzyme A oxidase 3	ACOAS		0.05
Peroxisomal acyl-coenzyme A oxidase 3 Argininosuccinate synthase	ASS1	-0,88	0,05
		-0,88 -0,88	0,05
Argininosuccinate synthase Growth factor receptor-bound protein 2	ASS1 GRB2	-0,88	0,10
Argininosuccinate synthase Growth factor receptor-bound protein 2 Phosphatidylinositol 4-kinase type 2-alpha	ASS1 GRB2 PI4K2A	-0,88 -0,88	0,10 0,46
Argininosuccinate synthase Growth factor receptor-bound protein 2 Phosphatidylinositol 4-kinase type 2-alpha Protein PAXX	ASS1 GRB2 PI4K2A C9orf142	-0,88 -0,88 -0,88	0,10 0,46 0,19
Argininosuccinate synthase Growth factor receptor-bound protein 2 Phosphatidylinositol 4-kinase type 2-alpha	ASS1 GRB2 PI4K2A	-0,88 -0,88	0,10 0,46

	ANK repeat and PH domain-containing protein 1	ASAP1	-0,87	N.D.
	HLA class I histocompatibility antigen	HLA-C	-0,87	0,18
	Lanosterol 14-alpha demethylase	CYP51A1	-0,86	0,45
	Copine-1	CPNE1	-0,86	0,15
	C-type mannose receptor 2	MRC2	-0,86	0,22
	Cysteine and glycine-rich protein 1	CSRP1	-0,85	0,18
	Protein Niban	FAM129A	-0,85	0,20
	Serine/threonine-protein kinase Nek7	NEK7	-0,85	0,48
	Histone H1.2	HIST1H1C		
			-0,85	0,85
	Golgi membrane protein 1	GOLM1	-0,84	0,10
	Lysosomal alpha-mannosidase	MAN2B1	-0,84	0,08
		VAV1	-0,84	0,14
	Proto-oncogene vav			
	UDP-N-acetylglucosaminepeptide N-acetylglucosaminyltransferase	OGT	-0,84	0,18
	Chromodomain-helicase-DNA-binding protein 1-like	CHD1L	-0,84	0,17
	Ubiquitin carboxyl-terminal hydrolase isozyme L5	UCHL5	-0,84	0,06
	Unconventional myosin-Ig; Minor histocompatibility antigen HA-2	MY01G	-0,84	0,15
	Protein disulfide-isomerase A3	PDIA3	-0,84	0,09
	Ubiquitin-conjugating enzyme E2 A	UBE2A	-0,83	0,06
		TRAPPC8		0,54
	Trafficking protein particle complex subunit 8		-0,83	
	Chitinase-3-like protein 1	CHI3L1	-0,83	0,18
	Transmembrane protein 165	TMEM165	-0,83	0,20
	Isopentenyl-diphosphate Delta-isomerase 1	IDI1	-0,82	0,01
	Fructose-2,6-bisphosphatase TIGAR	TIGAR	-0,82	0,09
	Polypeptide N-acetylgalactosaminyltransferase 2	GALNT2	-0,82	0,03
	Eukaryotic translation initiation factor 4 gamma 3	EIF4G3	-0,81	N.D.
	-			
	Protein S100-A11	S100A11	-0,81	0,08
	Leucine-rich repeat flightless-interacting protein 1	LRRFIP1	-0,81	0,05
	Rho guanine nucleotide exchange factor 7	ARHGEF7	-0,81	0,17
	-			
	Minor histocompatibility protein HA-1	HMHA1	-0,81	0,03
A	rf-GAP with Rho-GAP domain, ANK repeat and PH domain-containing protein 1	ARAP1	-0,81	0,19
	RNA polymerase-associated protein CTR9 homolog	CTR9	-0,81	0,13
	Exocyst complex component 1	EXOC1	-0,81	N.D.
	AP-1 complex subunit sigma-2	AP1S2	-0,80	0,30
	Triple functional domain protein	TRIO	-0,80	N.D.
	mRNA-capping enzyme;Polynucleotide 5-triphosphatase	RNGTT	-0,80	0,15
	PCI domain-containing protein 2	PCID2	-0,80	0,11
	Mast cell-expressed membrane protein 1	MCEMP1	-0,80	N.D.
	Activated RNA polymerase II transcriptional coactivator p15	SUB1	-0,80	0,04
		PREB		N.D.
	Prolactin regulatory element-binding protein		-0,80	
	Uncharacterized protein KIAA2013	KIAA2013	-0,80	0,50
	Ribonucleoside-diphosphate reductase large subunit	RRM1	-0,80	0,03
	Shootin-1	KIAA1598	-0,79	N.D.
	Coactosin-like protein	COTL1	-0,79	0,11
	X-ray repair cross-complementing protein 6	XRCC6	-0,79	0,05
	Putative 60S ribosomal protein L39-like 5	RPL39P5;RPL39	-0,79	0,13
	E3 ubiquitin-protein ligase UHRF1	UHRF1	-0,79	0,14
	Serine/threonine-protein kinase N1	PKN1	-0,79	0,22
	HLA class I histocompatibility antigen, A-24 and 23 alpha chain	HLA-A	-0,79	0,09
	Double-strand-break repair protein rad21 homolog	RAD21	-0,79	0,19
	Pyridoxal kinase	PDXK	-0,78	N.D.
	Alpha-actinin-4	ACTN4	-0,78	0,01
	Prenylcysteine oxidase-like	PCYOX1L	-0,78	0,21
		GNG10	-0,78	0,37
	Guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-10			
	Ras-related protein Rab-18	RAB18	-0,78	0,23
	Ubiquitin-like protein 5	UBL5	-0,77	0,07
	Uridine-cytidine kinase 2	UCK2	-0,77	0,12
	Ubiquitin-associated domain-containing protein 2	UBAC2	-0,77	0,14
	Chloride intracellular channel protein 1	CLIC1	-0,77	0,03
	PHD finger protein 6	PHF6	-0,77	N.D.
	Dipeptidyl peptidase 2	DPP7	-0,77	0,22
	N(G),N(G)-dimethylarginine dimethylaminohydrolase 2	DDAH2	-0,77	0,16
	Protein EVI2B	EVI2B	-0,77	N.D.
	GDP-L-fucose synthase	TSTA3	-0,77	0,09
	Sorting nexin-3	SNX3	-0,76	0,03
	5			
	HLA class I histocompatibility antigen, B-58 and 57 alpha chain	HLA-B	-0,76	0,07
	Phosphatidylinositol 3,4,5-trisphosphate 5-phosphatase 1	INPP5D	-0,76	0,02
	Ubiquitin carboxyl-terminal hydrolase 8	USP8	-0,76	0,32
	Neudesin	NENF	-0,76	0,52 N.D.
	Calcium/calmodulin-dependent protein kinase type II subunit delta	CAMK2D	-0,76	0,72
	DnaJ homolog subfamily C member 7	DNAJC7	-0,76	0,08
	Golgin subfamily A member 2	GOLGA2	-0,76	0,06
	Signal transducer and activator of transcription 5B and A	STAT5B;STAT5A	-0,76	0,18
	Importin subunit alpha-4	KPNA3	-0,75	0,08
	ER degradation-enhancing alpha-mannosidase-like protein 1	EDEM1	-0,75	0,12
	Leucine-rich repeat-containing protein 40	LRRC40	-0,75	0,07
		CKAP4	-0,75	N.D.
	Cytoskeleton-associated protein 4			0.50
		STOM	-0,74	0,56
	Erythrocyte band 7 integral membrane protein		-0,74	
	Erythrocyte band 7 integral membrane protein CD97 antigen	CD97	-0,74	0,27
	Erythrocyte band 7 integral membrane protein			
	Erythrocyte band 7 integral membrane protein CD97 antigen	CD97	-0,74	0,27
	Erythrocyte band 7 integral membrane protein CD97 antigen Tumor necrosis factor alpha-induced protein 8-like protein 2 Zinc finger ZZ-type and EF-hand domain-containing protein 1	CD97 TNFAIP8L2 ZZEF1	-0,74 -0,74 -0,74	0,27 0,93 N.D.
	Erythrocyte band 7 integral membrane protein CO97 antigen Tumor necrosis factor alpha-induced protein 8-like protein 2 Zinc finger ZZ-type and EF-hand domain-containing protein 1 BRO1 domain-containing protein BROX	CD97 TNFAIP8L2 ZZEF1 BROX	-0,74 -0,74 -0,74 -0,74	0,27 0,93 N.D. 0,13
	Erythrocyte band 7 integral membrane protein CD97 antigen Tumor necrosis factor alpha-induced protein 8-like protein 2 Zinc finger ZZ-type and EF-hand domain-containing protein 1 BRO1 domain-containing protein BROX Endophilin-B1	CD97 TNFAIP8L2 ZZEF1 BROX SH3GLB1	-0,74 -0,74 -0,74 -0,74 -0,74	0,27 0,93 N.D. 0,13 0,04
	Erythrocyte band 7 integral membrane protein CO97 antigen Tumor necrosis factor alpha-induced protein 8-like protein 2 Zinc finger ZZ-type and EF-hand domain-containing protein 1 BRO1 domain-containing protein BROX	CD97 TNFAIP8L2 ZZEF1 BROX	-0,74 -0,74 -0,74 -0,74	0,27 0,93 N.D. 0,13
	Erythrocyte band 7 integral membrane protein CD97 antigen Tumor necrosis factor alpha-induced protein 8-like protein 2 Zinc finger ZZ-type and EF-hand domain-containing protein 1 BRO1 domain-containing protein BROX Endophilin-B1 V-type proton ATPase 116 kDa subunit a isoform 3	CD97 TNFAIP8L2 ZZEF1 BROX SH3GLB1 TCIRG1	-0,74 -0,74 -0,74 -0,74 -0,74 -0,74	0,27 0,93 N.D. 0,13 0,04 N.D.
	Erythrocyte band 7 integral membrane protein CD97 antigen Tumor necrosis factor alpha-induced protein 8-like protein 2 Zinc finger ZZ-type and EF-hand domain-containing protein 1 BRO1 domain-containing protein BROX Endophilin-B1	CD97 TNFAIP8L2 ZZEF1 BROX SH3GLB1	-0,74 -0,74 -0,74 -0,74 -0,74	0,27 0,93 N.D. 0,13 0,04

AT departer if NACIPUP instants in ADDR: 6.032 6.032 6.032 Stanty Cash Instants in Soluti Spin-S ADDR: 6.032 6.032 Stanty Cash Instants in Soluti Spin-S MM2D 6.03 6.032 Predmain Craiting proton BDR1 6.02 6.03 Stant Tropped protons - BDR1 6.02 6.03 Add and Information - BDR1 6.02 6.03 Add and Information - BDR1 6.03 6.03 Add and Information - BDR1 6.03 6.03 Add and Information - BDR1 6.03 6.03 BDR1 BDR1 6.03 6.03 6.03 BDR1 BDR1 6.04 6.05 6.05 BDR1 BDR1 6.04 6.05 6.05 BDR2 BDR2 BDR2 6.04				
Meta storager, restarts fram.ADRICLQ.72Q.73Q.73Q.73Scoraft, Co.73G.74Q.75Q.75Q.75Metors specific enhance (ranker)G.74Q.72Q.74Provise specific enhance (ranker)G.74Q.72Q.74Provise specific enhance (ranker)G.74Q.74Q.72Q.74Provise specific enhance (ranker)G.74Q.74Q.74Q.74Q.74Provise specific enhance (ranker)G.74Q	ATP-dependent (S)-NAD(P)H-hydrate dehydratase	CARKD	-0,73	0,34
Succin/Col-3 excession/excessi				
Image of the stand is a part				
Weepersonalise memore facts 20MEED-0.020.13Off come contrains proteinCOM-0.020.03Weepersonalise proteinCOM-0.020.03Weepersonalise proteinCOM-0.020.03Synalis matcains proteinSYNAT-0.020.03Synalis matcains proteinNAMANI-0.020.03Anness ALNAMANI-0.020.03Memore matcains complex bolding proteinMCMP-0.710.03Memore matcains complex bolding proteinMCMP-0.720.03Memore mat				
Lif domain containing protein 1 Life 1 0.02 0.11 Off-Nog D(Phs 1 GPM 2 0.01 0.02 0.01 Neuroblact of entrotypins 1 STAT 0.02 0.02 0.02 Signal tension accounts of entrotypins 1 STAT 0.02	Importin subunit alpha-1	KPNA2	-0,73	0,12
Lif domain containing protein 1 Life 1 0.02 0.11 Off-Nog D(Phs 1 GPM 2 0.01 0.02 0.01 Neuroblact of entrotypins 1 STAT 0.02 0.02 0.02 Signal tension accounts of entrotypins 1 STAT 0.02	Myocyte-specific enhancer factor 2D	MFF2D	-0.73	0.13
GM 1000 CT 2010 0.410 0.72 0.42 Neurobiast press ALVA ANAX 0.72 0.42 Septime press and press ALVA 192 A 0.72 0.20 Septime press and press ALVA 192 A 0.72 0.20 Number 2010 AND 2010 0.72 0.20 Number 2010 Number 2010 0.72 0.20 Number 2010 Number 2010 0.72 0.20 Number 2010 MCD 2010 0.72 0.21 0				
Hunobias differentiation associate grants MNMK AMAK 6.0.2 6.0.3 Signal Frankation associate grants MNMK MPM 6.0.7 6.0.3 Signal Frankation associate grants MNMK MPM 6.0.7 6.0.3 Signal Frankation associate grants MNMK MPM 6.0.7 6.0.3 Molitorizame antistance complexenting grants MCMM 6.0.7 6.0.3 Molitorizame maintenance complexenting grants MCMM 6.0.7 6.0.3 Molitorizame maintenance complexenting grants MCMM 6.0.7 6.0.3 MORIC Canvel, CM sep for Engrey control MCMM 6.0.7 6.0.3 MCM complexenting grants MCMM 6.0.3 6.0.3 MCM complexenting monts MCMM 6.0.3 6.0.3 MCM complexenting montshantering monts MCMM <td< td=""><td></td><td></td><td></td><td></td></td<>				
Trapsipid parts 2 1992 6.27 6.08 Signal fundamini and scheding protein ASAM1 6.77 6.09 Main AT ASAM1 6.77 6.09 Main AT ASAM1 6.77 6.09 Main Atom AT ASAM1 6.77 6.03 Main Atom AT ASAM1 6.77 6.03 Main Atom Atom Atom Atom Atom Atom Atom Atom	GPN-loop GTPase 1	GPN1	-0,72	0,44
Trapsipid parts 2 1992 6.27 6.08 Signal fundamini and scheding protein ASAM1 6.77 6.09 Main AT ASAM1 6.77 6.09 Main AT ASAM1 6.77 6.09 Main Atom AT ASAM1 6.77 6.03 Main Atom AT ASAM1 6.77 6.03 Main Atom Atom Atom Atom Atom Atom Atom Atom	Neuroblast differentiation-associated protein AHNAK	AHNAK	-0.72	0.28
Signal bandker med shoring of theorem (1990) State 6.072 6.092 Amene Atla AMANAI 6.072 6.092 Twollin-1 AMANAI 6.072 6.013 Main charmen banding strein AMANAI 6.021 6.013 Main charmen banding strein ACID 6.013 6.013 Main charmen banding strein ACID 6.013 6.013 Main charmen banding strein ACID 6.013 6.013 Main charmen banding strein MAIS 6.01 6.013 Main charmen strein strein MAIS 6.01 6.01 Main charmen strein strein MAIS 6.01 6.01 Main charmen strein strein MAIS 6.01 6.01 Main charmen strein strein strein MAIS 6.01 6.01 Main charmen strein st				
Anceni A13 ANXA13 O,72 0.01 Mini-chromosen antineur complex holding protein MCPU 0.01 0.01 Mini-chromosen antineur complex holding protein MCPU 0.01 0.01 Adveyd (cybar=ascoards protein) MCR 0.01 0.02 0.02 MCR Enclosing protein (Sing protein) MCR 0.02 0.02 0.02 MCR Enclosing protein (Sing protein) MCR 0.02 0.02 0.02 MCR Enclosing protein (Sing protein) MCR 0.02 0.02 0.02 MCR Enclosing protein (Sing protein) MCR 0.02 0.02 0.02 MCR Enclosing protein (Sing protein) MCR 0.02 0.02 0.02 MCR Enclosing protein (Sing protein) MCR 0.02 0.02 0.02 MCR Enclosing protein (Sing protein) MCR 0.02 0.03 0.03 MCR Enclosing protein (Sing protein) MCR 0.03 0.03 0.03 MCR Enclosing protei				
Twofile.1 Twofile.3 TWH 0.01 0.01 Mini-Stremscome maintenine complex-building protein MCMP 0.01 0.03 Manual complex-building protein TCA 0.03 0.03 Manual complex-building protein TCA 0.03 0.03 Manual complex-building protein TCA 0.03 0.03 Manual complex-building protein MCMP 0.07 0.08 Manual complex-building protein MCMP 0.03 0.03 Manual complex-building protein MCMP 0.03 0.03	Signal transducer and activator of transcription 3	STAT3	-0,72	0,02
Twofile.1 Twofile.3 TWH 0.01 0.01 Mini-Stremscome maintenine complex-building protein MCMP 0.01 0.03 Manual complex-building protein TCA 0.03 0.03 Manual complex-building protein TCA 0.03 0.03 Manual complex-building protein TCA 0.03 0.03 Manual complex-building protein MCMP 0.07 0.08 Manual complex-building protein MCMP 0.03 0.03 Manual complex-building protein MCMP 0.03 0.03	Annexin A11	ANXA11	-0.72	0.09
Add bases ACTNL 0.71 0.03 Missi downsom mainsmuss compositing protein Gennes studial complex component 3 GM1 0.71 0.33 Missi downsom mainsmuss complex binding protein 3 GM1 0.71 0.33 MORE family (W special Charge protein 3 GM1 0.71 0.33 MORE family (W special Charge protein 3 MORC1 0.70 0.80 Wales-studial Ages MARES 0.80 0.80 Wales-studial Ages MARES 0.80 0.80 Wales-studial Ages MARES 0.80				
Min-dramosome automic component 3 Adamyk optase associated protein 1 Pode synchronic component 3 Pode synchronicomponent 3 Pode synchronic component 3 Pode synchronic componen				
Gennetubulic components ¹ CVBCCP3 0.071 0.032 Northyle cybes associated protein 1 GAB 0.71 0.02 Northyle cybes associated protein 3 NORTBALL 0.70 0.80 NortBall 0.70 NortBall 0.70 0.80 NortBall NortBall 0.70 0.80 NortBall NortBall 0.70 0.70 NortBall 0.70 0.70 0.70 NortBall	Alpha-actinin-1	ACTN1	-0,71	0,03
Gennetubulic components ¹ CVBCCP3 0.071 0.032 Northyle cybes associated protein 1 GAB 0.71 0.02 Northyle cybes associated protein 3 NORTBALL 0.70 0.80 NortBall 0.70 NortBall 0.70 0.80 NortBall NortBall 0.70 0.80 NortBall NortBall 0.70 0.70 NortBall 0.70 0.70 0.70 NortBall	Mini-chromosome maintenance complex-hinding protein	MCMBP	-0 71	0.15
Adenyi (robine-associated protein 1) CAT Q-71 Q-72 Q-72 <thq-72< th=""> Q-72 Q-72</thq-72<>				
MODILE NUDITAL 0.70 0.89 MODEL 0.70 0.80 0.70 0.80 Fancois integroup D2 protein FANCD2 0.70 0.80 Rine paintine decode schape fator 2 ANIEST2 0.70 0.80 Bisto complex schape schape fator 2 ANIEST2 0.70 0.80 Bisto complex schape s				
MORE (anit) (CV-type intr. Integr protein 3 a francoil anew group 2 protein 4 francoil anew group 2 protein 12 francoil anew group 2 protein 13 francoil anew group anew group 2 protein 13 francoil anew group 2 prote	Adenylyl cyclase-associated protein 1	CAP1	-0,71	0,12
MORE (anit) (CV-type intr. Integr protein 3 a francoil anew group 2 protein 4 francoil anew group 2 protein 12 francoil anew group 2 protein 13 francoil anew group anew group 2 protein 13 francoil anew group 2 prote	Protein syndesmos	NUDT16L1	-0.70	0.09
Bancal membra group D2 protein FAACD2 0.70 0.80 Bible painte nucleoting exchange factor 2 AMRGF2 0.70 0.70 0.70 TARfreeze exchange factor 2 VARS 0.70 0.70 0.70 0.70 Bible Complex subunit Arra1 FAAL378 0.60 0.80 0.80 0.80 Discourse rest MA domain-containing protein A FAAL378 0.60 0.9				
Bits Description Description <thdescription< th=""> <thde< td=""><td></td><td></td><td></td><td></td></thde<></thdescription<>				
Wate Wate Wate Out Dut TRA-intercing protein with Handmannet mainer protein A TRA -0.70 0.76 BIRSC complex suburit Abrai FAM1758 0.68 0.05 Dolichy-interpainer MAX BR311 0.69 0.68 Dolichy-interpainer MAX BR311 0.69 0.30 Regulation of nuclear pre-mRAX for aniso-containing protein 1A BR301A1 0.89 0.31 Regulation of nuclear pre-mRAX for aniso-containing protein 1A BR301A1 0.69 0.09 Bite S-syntrophin Sintra 0.69 0.69 0.09 Galenia-3 GaleX153 0.69 0.09 0.69 Galenia-3 GaleX153 0.69 0.09 0.09 Galenia-3 GaleX153 0.69 0.09	Fanconi anemia group D2 protein	FANCD2	-0,70	0,80
Wate Wate Wate Out Dut TRA-intercing protein with Handmannet mainer protein A TRA -0.70 0.76 BIRSC complex suburit Abrai FAM1758 0.68 0.05 Dolichy-interpainer MAX BR311 0.69 0.68 Dolichy-interpainer MAX BR311 0.69 0.30 Regulation of nuclear pre-mRAX for aniso-containing protein 1A BR301A1 0.89 0.31 Regulation of nuclear pre-mRAX for aniso-containing protein 1A BR301A1 0.69 0.09 Bite S-syntrophin Sintra 0.69 0.69 0.09 Galenia-3 GaleX153 0.69 0.09 0.69 Galenia-3 GaleX153 0.69 0.09 0.09 Galenia-3 GaleX153 0.69 0.09	Rho guanine nucleotide exchange factor 2	ARHGEF2	-0,70	0,08
TRAE-interacting protein with FMA domain containing protein A TFA 0.02 0.03 BRSC complex subound Abors FRM1758 0.09 0.05 Dolichy-phosphale betty blacks/transferate RR31 0.09 0.05 Regulation of nuclear pre-mRMA domain containing protein 1A RR31 0.09 0.011 Regulation of nuclear pre-mRMA domain containing protein 1A RR31 0.09 0.031 Responsibility and the subound Abors CLIG111 0.09 0.031 Responsibility and the subound Abors SITER 0.09 0.031 Responsibility and the subound Abors SITER 0.09 0.031 Responsibility and the subound Abors SITER 0.090 0.090 Gearms - Evaluation Aborsolog IS SITER 0.090 0.090 0.090 Proteins maket bubbin Aborsolog IS MSTORT 0.090		VAPS		
BRIE FAM T3B 0.66 0.26 D010hy/shp2bate beta-glucosyntransferse ALGS 0.67 0.01 Begulation of nuclear pre-MAX domain-ordinating protein 1A BRBDIA 0.66 0.03 Begulation of nuclear pre-MAX domain-ordinating protein 1A BRBDIA 0.66 0.03 Lanoscier of nuclear pre-MAX domain-ordinating protein 1A BRBDIA 0.66 0.03 Receptor hype transing protein babbitase C PTPRC 0.69 0.03 Receptor hype transing protein habbitase C PTPRC 0.69 0.03 Tubling prima - 2 chain TUBG(PZ) 0.69 0.03 Tubling prima - 2 chain TUBG(PZ) 0.69 0.03 Protein misch homolog 1 MST01 0.66 0.03 Protein misch homolog 1 PP1817 0.68 0.03 Protein misch homolog 1 PP1817 0.68 0.03 Tardickaprotein partie charge 3, social beta hybe 3 PP2817 0.68 0.02 Tardickaprotein partie charge 3, social beta hybe 3 PP2817 0.68 0.02 Tardickaprotein partie charge 4	-			
0005:nbosma protein 131 RP31 0.05 Begulation of nuclear pre-mRNA domain-containing protein 1A RP801A 0.05 Regulation of nuclear pre-mRNA domain-containing protein 1A RP801A 0.06 0.15 Noncollege gulation of nuclear pre-mRNA domain-containing protein 1A RP801A 0.06 0.10 Noncollege gulation of nuclear pre-mRNA domain-containing protein 1A SR801A 0.06 0.03 Receptor-type trysine-spretein phosphates C PP1R0 0.06 0.09 0.03 Calama-back contoxy trysine RCNA33 0.09 0.03 0.06 0.03 0.03 0.03 0.02 0.03 0.02 0.03 0.02 0.02 0.02 0.02 0.02 0.02	TRAF-interacting protein with FHA domain-containing protein A	TIFA	-0,70	0,46
0005:nbosma protein 131 RP31 0.05 Begulation of nuclear pre-mRNA domain-containing protein 1A RP801A 0.05 Regulation of nuclear pre-mRNA domain-containing protein 1A RP801A 0.06 0.15 Noncollege gulation of nuclear pre-mRNA domain-containing protein 1A RP801A 0.06 0.10 Noncollege gulation of nuclear pre-mRNA domain-containing protein 1A SR801A 0.06 0.03 Receptor-type trysine-spretein phosphates C PP1R0 0.06 0.09 0.03 Calama-back contoxy trysine RCNA33 0.09 0.03 0.06 0.03 0.03 0.03 0.02 0.03 0.02 0.03 0.02 0.02 0.02 0.02 0.02 0.02	BRISC complex subunit Abro1	FAM175B	-0,69	0,26
Dolichy ib posphate bin-glucosyltransferase 1 ALGS 0.09 0.11 Regulation of nuclear per MNA domain-containing protein 1A RPBDIA 0.06 0.03 Landsteel synthase LSS 0.06 0.01 Begulation synthase LSS 0.06 0.02 Receptor Synch works SN181 0.06 0.02 Gamma Hubbin complex component 2 TUBGL?10822 0.02 0.02 Tubing per MAL Synch Sy				
Regulation of nuclear pre-mRN4 domain-containing protein 1A Decodings guidatory interfaces RPR01A 9.0.9 0.30 Neocolings guidatory interfaces USS 0.0.9 0.0.0 Beat-3-particle STR1 0.0.9 0.0.0 Receptor-type trysine protein (hosphatase C PTPRC 0.0.9 0.0.0 Gamma-bubin complex component 2 TUBIC/12 0.0.6 0.0.0 Trubuin gentma-2 chain trubuin mode BRH05 0.0.0 0.0.0 Rectar trubuin gentma-2 chain TUBIC/12 0.0.6 0.0.0 Protessone subulin to trubuin BHO BRH05 BRH06 0.0.0 Protessone subulin to trubuin BHO BRH06 0.0.0 0.0.0 Protessone subulin to the type 9 0.0.6 0.0.6 0.0.6 Vinnf/Vr339/like protein V739 0.0.6 0.0.6 Section protein trubuin to the type 9 0.0.6 0.0.6 0.0.6 Vinnf/Vr339/like protein SPC20 0.0.6 0.0.6 Section to the type 9 0.0.6 0.0.6 0.0.6 Sectin to the type 1 SPC20 <t< td=""><td></td><td></td><td></td><td></td></t<>				
Proceinger galacosyltranset CCIGATT 0.69 0.15 Lansterd synthes LSS 0.69 0.01 Receptorype tyroline protein phosphatas C PTRC 0.69 0.02 Gamma tubulin complex component 2 TUBGC2 0.69 0.01 Gamma tubulin complex component 2 TUBGC2 0.69 0.09 Galectin 3 LGALS3 0.69 0.02 Mition gamma t- chain garotin finds RHOG 0.69 0.02 Protein matas homolog 1 MStol 1 0.68 0.09 Protein matas homolog 1 MStol 1 0.68 0.01 Protein matas homolog 1 MStol 1 0.68 0.04 Vamo (V23) Exportion VS39 0.68 N.D. Vamo (V23) Exportion VS39 0.68 0.04 Vamo (V23) Exportion Stature 1 Stature 2 0.68 N.D. Stature 2 Stature 2 0.68 0.04 0.48 Retinal cod motopoin-sensitive complex bubicators as bubicator 2 0.67 0.02 0.68 0.01				
Processing registronyintance COLGAT1 0.69 0.15 Lanotter's prote price 0.55 0.69 0.10 Retract-syntrophin SYTB1 0.69 0.02 Gamma-tubulin complex component 2 TUBGC72 0.69 0.09 Gamma-tubulin complex component 2 TUBGC72 0.69 0.09 Galectin 3 LGAL33 0.66 0.09 Galectin 3 LGAL33 0.66 0.09 Mithor synthes AND 0.68 0.09 Protesting synthes that 60 0.09 0.02 0.09 Protesting synthes that 60 0.09 0.02 0.02 Protesting synthes that 60 0.08 0.04 0.08 0.04 Vamo/Var35 Hile protein YS39 0.08 N.D. 0.68 0.04 Synthin Synthin Synthin Synthin 0.68 0.04 0.04 Retinal of motopic synthin 51 Synthin Synthin 0.68 0.06 0.07 Retinal of motopic synthin 51 Synthin 51 <	Regulation of nuclear pre-mRNA domain-containing protein 1A	RPRD1A	-0,69	0,30
Lanciterol synthasie LS 0.60 0.03 Receptor-type tyrosine-protein phosphatase C PTPRC 0.60 0.03 Receptor-type tyrosine-protein phosphatase C PTPRC 0.60 0.03 Garmas-Lubilin gamma-2 chain TUBGCP 0.60 0.03 Tubulin gamma-1 chain, Tubulin gamma-2 chain TUBGCP 0.60 0.03 Receptor-type tyrosine-protein RMO RHOG 0.60 0.03 Protein misch homolg 1 MST01 0.60 0.03 Protein misch homolg 1 MST01 0.60 0.02 Protein misch homolg 1 MST01 0.60 0.02 Protein phosphatase 1 regulatory subunt 1 MST01 0.60 0.02 Mane(MySS) Hile protein SMIN 0.60 0.02 Mane(MySS) Hile protein SMIN 0.60 0.02 Mane(MySS) Hile protein SMIN 0.60 0.02 Mane(MySS) Hile protein MST01 0.60 0.02 Mane(MySSS) Hile protein MST01 0.60 0.02 Mane MySSS SMI		COLGALT1		0.15
Bets-i-syntrophin SNTB1 0.69 0.32 Receptor-loper types protein protein state or component 2 TUBG(T)(BG(C2) 0.69 0.01 Tubbling arman - 1 chain arguets in tubblin complex component 2 TUBG(T)(BG(C2) 0.69 0.01 Scherting Throthing arman - 1 chain arguets in tubblin complex component 2 TUBG(T)(BG(C2) 0.69 0.03 Dis-related (TP-binding protein RhoG RHOG 0.69 0.03 Protein missate homolog 1 MSTD1 0.69 0.02 Protein missate homolog 1 MSTD1 0.69 0.02 Protein missate inclusion 1 TRAPCI 0.68 0.02 Protein missate inclusion 1 TRAPCI 0.68 0.06 Saratin SGG(D) 0.68 N.D. Retinal rad incloppinis-entitice complex subunit 1 TRAPCI 0.68 0.04 Retinal rad inclospinis-entitice complex subunit 1 RHOB 0.66 0.02 Retinal rad inclospinis-entitice complex subunit 1 RHOB 0.66 0.02 Retinal rad inclospinis-entitice complex subunit 2 RHOB 0.67 0.02				
Receptor-type tyrosine-protein phosphatase C PTPC 0.69 0.91 Samma-tubulin gamma-2 chain TUBCCP2 0.69 0.91 Tubulin gamma-1 chain, Tubulin gamma-2 chain TUBCCP2 0.69 0.92 Bit cetta-3 TUBCCP2 0.69 0.93 Protein phosphatase 1 regulatory subunit 7 PPRI/7 0.66 0.02 Protein phosphatase 1 regulatory subunit 7 PPRI/7 0.66 0.02 Protein phosphatase 1 regulatory subunit 7 PPRI/7 0.66 0.02 Protein phosphatase 1 regulatory subunit 1 TBAPCritic works 0.68 0.05 Tafficking protein particle complex subunit felts PPER/7 0.68 0.68 Sparin SGG20 0.68 0.04 0.04 Cyclin-dependent kinases regulatory subunit 1 GSB36 0.05 0.068 0.04 Cyclin-dependent kinases regulatory subunit 1 GSB36 0.068 0.04 Cyclin-dependent kinases regulatory subunit 2 GSB choosing protein file 0.04 0.07 0.02 Cyclin-dependent kinases regulatory subunit 2 GSB36				
damms subulin complex component 2 TUBGCP2 -0.69 0.01 Tubbing arms 1 chain (Subing protein RhoG ILGALS3 -0.69 0.03 Bhoristed (FP) chaining protein RhoG RHOG -0.69 0.03 Protein misato homoig 1 MST01 -0.69 0.03 Protein phosphates 1 regulatory subunit 7 MPP (FP) -0.68 0.02 Protessme Subunit bet Hype 9 PMB9 -0.68 0.05 Tubbing protein subunit bet Hype 9 PMB99 -0.68 0.06 Spartin Spartin SPG20 -0.68 0.06 Resnal rod rhodposin-servite complex subunit 1 TRAPCC1 -0.68 0.06 Spartin SPG20 -0.68 0.06 -0.02 Protein glucantes regulatory subunit 1 CASIB -0.68 0.02 Resnal rod rhodpsin-servite complex subunit 1 CASIB -0.68 0.02 Protein glucantes regulatory subunit 1 CASIB -0.67 0.02 Protein glucantes regulatory subunit 1 CASIB -0.67 0.02 Protein glucantes regulatory subunit 1	Beta-1-syntrophin	SNTB1	-0,69	0,32
damms subulin complex component 2 TUBGCP2 -0.69 0.01 Tubbing arms 1 chain (Subing protein RhoG ILGALS3 -0.69 0.03 Bhoristed (FP) chaining protein RhoG RHOG -0.69 0.03 Protein misato homoig 1 MST01 -0.69 0.03 Protein phosphates 1 regulatory subunit 7 MPP (FP) -0.68 0.02 Protessme Subunit bet Hype 9 PMB9 -0.68 0.05 Tubbing protein subunit bet Hype 9 PMB99 -0.68 0.06 Spartin Spartin SPG20 -0.68 0.06 Resnal rod rhodposin-servite complex subunit 1 TRAPCC1 -0.68 0.06 Spartin SPG20 -0.68 0.06 -0.02 Protein glucantes regulatory subunit 1 CASIB -0.68 0.02 Resnal rod rhodpsin-servite complex subunit 1 CASIB -0.68 0.02 Protein glucantes regulatory subunit 1 CASIB -0.67 0.02 Protein glucantes regulatory subunit 1 CASIB -0.67 0.02 Protein glucantes regulatory subunit 1	Receptor-type tyrosine-protein phosphatase C	PTPRC	-0.69	0.09
Tubbin gamma-1 chain (Tubin gamma-2 chain Geletich 3) TUBG1/TUBG2 0.69 0.99 Retine all control of the state of the s				
Galetin 3 LGALS3 0.69 N.D. Bhor-dated Tribinding protein RhoG HKIGG 0.69 0.03 Protein misato homolog 1 MKIG1 0.69 0.03 ATD-citrate synthase ACLY 0.69 0.03 Protesome shunh tbeta type 3 ACLY 0.69 0.02 YamG/Vra33-like protein YF33 0.68 0.05 YamG/Vra33-like protein YF33 0.68 0.68 Spartin SPC20 0.68 0.66 Spartin SPC20 0.68 0.66 Spartin SPC20 0.68 0.66 Spartin SPC20 0.68 0.03 Child-dependert, Minases regulatory subunit 1 CK18 0.66 0.03 Ribosomal Protein Jhandrease RAB27A 0.68 0.03 Ribosomal Protein Jhandrease CMP 0.67 0.03 Ribosomal Protein Jhandrease CMP 0.67 0.03 Ribosomal Protein Jhandrease CMP 0.67 0.02 Systephosphotesextreas				
Bho-cated GT-binding protein RhoG BHOG 0.69 0.09 Protein phosphatise 1 regulatory subunit 7 PPDER 0.69 0.33 ATP-otta synthase ACUY 0.69 0.02 ATP-ottasione subunit beta type-9 PSMB9 0.68 0.05 Yumin (YV33) like protein YPS33 0.68 N.D. Trafficial protein particle complex subunit 1 TRAPPC1 0.69 0.68 Synth Sprith SPC0 0.68 N.D. Retinal rod rhodopsis-sensitive CMM 3-Spcit(c phosphodiesterase subunit delta PDE60 0.68 N.D. Ras-relate protein faba-27A RABATT 0.68 0.071 Ras-relate protein faba-27A RABATT 0.681 0.072 Ras-relate protein faba-27A RABATT 0.681 0.071 Rabinal RO-motiphatiserase GPP 0.671 0.33 Ribional RN-protein photiphatiserase GPP 0.671 0.33 Ribional RN-protein faba synthase GPC7 0.33 0.661 0.662 Ribional RN-protein faba synthase GPC7	Tubulin gamma-1 chain;Tubulin gamma-2 chain	TUBG1;TUBG2	-0,69	0,09
Bho-cated GT-binding protein RhoG BHOG 0.69 0.09 Protein phosphatise 1 regulatory subunit 7 PPDER 0.69 0.33 ATP-otta synthase ACUY 0.69 0.02 ATP-ottasione subunit beta type-9 PSMB9 0.68 0.05 Yumin (YV33) like protein YPS33 0.68 N.D. Trafficial protein particle complex subunit 1 TRAPPC1 0.69 0.68 Synth Sprith SPC0 0.68 N.D. Retinal rod rhodopsis-sensitive CMM 3-Spcit(c phosphodiesterase subunit delta PDE60 0.68 N.D. Ras-relate protein faba-27A RABATT 0.68 0.071 Ras-relate protein faba-27A RABATT 0.681 0.072 Ras-relate protein faba-27A RABATT 0.681 0.071 Rabinal RO-motiphatiserase GPP 0.671 0.33 Ribional RN-protein photiphatiserase GPP 0.671 0.33 Ribional RN-protein faba synthase GPC7 0.33 0.661 0.662 Ribional RN-protein faba synthase GPC7	Galectin-3	LGALS3	-0.69	N.D.
Protein misab homolog 1 MST01 -0.69 0.39 ATP-citrate synthase ACLY -0.69 0.02 Vam6/Vp33-like protein VPS39 -0.68 0.05 Vam6/Vp33-like protein VPS39 -0.68 0.68 Spartin SPC20 -0.68 0.66 Spartin SPC20 -0.68 0.66 Coll-dependent kinases regulatory subunit 1 SPC20 -0.68 0.66 Coll-dependent kinases regulatory subunit 1 CSLS -0.68 0.04 Reinal rod rhodopsin-sensitive CMM subases regulatory subunit 1 CSLS -0.68 0.04 Reinal rod rhodopsin-sensitive CMM subases regulatory subunit 1 CSLS -0.68 0.03 Ribosonal Protein 7 homolog A RBP3A -0.68 0.03 Ribosonal RNA-processing protein 7 homolog A RBP7A -0.67 0.03 Ribosonal Protein rhomolog A RBP7A -0.67 0.02 Action Compose helices subunit 2 FLOT2 -0.67 0.02 Action Compose helices subunit 2 RBP7A -0.67 0.02 <		PHOG		
Protein phosphases 1 regulatory subunit 7 PPP1R7 0.69 0.09 APP-Citrle synthase ACV 0.69 0.05 Vam6/V539-like protein VVS39 0.68 N.D. Trafficting protein particle complex subunit 1 TRAPPC1 0.68 0.68 Spartin SPG2D 0.68 0.68 0.66 Cyclin dependent tinases regulatory subunit 1 FRAPPC1 0.68 0.68 0.01 Resinal rod rhodopin-sensitive GMP 3-5-ryclic phosphodiestrase subunit delta PPDE5D 0.68 0.03 Resinal rod rhodopin-sensitive GMP 3-5-ryclic phosphodiestrase CMP 0.68 0.03 Resinal rod rhodopin-sensitive GMP 3-5-ryclic phosphodiestrase CMP 0.67 N.D. Resinal rod rhodopin-sensitive GMP 3-5-ryclic phosphodiestrase CMP 0.67 N.D. Resinal rod rod rodopin-sensitive GMP 3-5-ryclic phosphodiestrase CMP 0.67 N.D. Resinal rod rodopin-sensitive GMP 3-5-ryclic phosphodiestrase CMP 0.67 0.02 Alpha-1-fineary 1 CAR 0.67 0.02 0.62 0.02 Alpha-				
ATP-citrate synthesic ACV 0.69 0.02 Vares/Vps3-Hige protein VPS39 0.68 0.05 Vares/Vps3-Hige protein VPS39 0.68 0.66 Spartin Spartin Spartin 0.68 0.66 Spartin Spartin Spartin 0.68 0.66 Spartin Spartin Spartin 0.68 0.02 Restrated protein Rarse regulatory subunit 1 Spartin 0.68 0.021 Restrated protein Rarse regulatory subunit 1 CPC 0.68 0.021 Restrated protein Rarse regulatory subunit 1 CPC 0.68 0.021 Restrated protein Rarse regulatory subunit 1 CPC 0.67 0.02 Restrated protein Rarse regulatory subunit 1 CPC 0.67 0.02 Restrated protein Rarse regulatory subunit 1 CPC 0.67 0.02 Restrated protein Rarse regulatory subunit 2 Restrate 0.67 0.02 Restrate regulatory regulatoregulatory regul		MST01	-0,69	0,13
Protessome subunit beta type-9 PPMB9 0.68 0.05 VamS(Nr)391kie protein Systin Visition Visition 0.68 N.D. Retinal rod rhodopsin-sensitive GMP 3.5-cyclic phosphodiesterase subunit deta GB ribosomal protein 137a PDE60 0.68 0.48 Retinal rod rhodopsin-sensitive GMP 3.5-cyclic phosphodiesterase subunit deta GB ribosomal protein 137a RBA27A 0.68 0.01 Retinal rod rhodopsin-sensitive GMP 3.5-cyclic phosphodiesterase GVP 0.67 0.68 0.01 Ribosomal protein 7 homolog A RB77A 0.68 0.07 Ribosomal RNA-processing protein 7 homolog A RB77A 0.67 0.32 Farreely (prophosphat synthse Footing transcription phosphat synthse FDDF 0.67 0.32 THIH basil transcription factor complex helicase XPD subunit Calponin-2 ECN2 0.67 0.22 Calponin-2 CNR2 0.66 0.03 0.06 0.03 Athin-1-6-manosyl-glycoprotein 24 CARAB 0.66 0.02 0.02 0.07 0.22 Calponin-2 CNR2 0.67 0.22 0.66 0.13 <t< td=""><td>Protein phosphatase 1 regulatory subunit 7</td><td>PPP1R7</td><td>-0,69</td><td>0,19</td></t<>	Protein phosphatase 1 regulatory subunit 7	PPP1R7	-0,69	0,19
Protessome subunit beta type-9 PPMB9 0.68 0.05 VamS(Nr)391kie protein Systin Visition Visition 0.68 N.D. Retinal rod rhodopsin-sensitive GMP 3.5-cyclic phosphodiesterase subunit deta GB ribosomal protein 137a PDE60 0.68 0.48 Retinal rod rhodopsin-sensitive GMP 3.5-cyclic phosphodiesterase subunit deta GB ribosomal protein 137a RBA27A 0.68 0.01 Retinal rod rhodopsin-sensitive GMP 3.5-cyclic phosphodiesterase GVP 0.67 0.68 0.01 Ribosomal protein 7 homolog A RB77A 0.68 0.07 Ribosomal RNA-processing protein 7 homolog A RB77A 0.67 0.32 Farreely (prophosphat synthse Footing transcription phosphat synthse FDDF 0.67 0.32 THIH basil transcription factor complex helicase XPD subunit Calponin-2 ECN2 0.67 0.22 Calponin-2 CNR2 0.66 0.03 0.06 0.03 Athin-1-6-manosyl-glycoprotein 24 CARAB 0.66 0.02 0.02 0.07 0.22 Calponin-2 CNR2 0.67 0.22 0.66 0.13 <t< td=""><td>ATP-citrate synthese</td><td>ΔΟΙΥ</td><td>-0.69</td><td>0.02</td></t<>	ATP-citrate synthese	ΔΟΙΥ	-0.69	0.02
Vame(/vp33-nike protein VP339 0.68 N.D. ITREFicieng protein particle complex bulunt 1 TRRMPC1 0.68 0.66 Spartin Spartin Spartin 0.68 0.66 Betinal rod rhodopsin-sensitive (Shopshodiseterase subunt delta PPGED 0.68 0.01 Cipii dependent insess regulatory subunt 1 CKSTB 0.68 0.21 Res-related protein Rab-27A RAB27A 0.68 0.01 Protein glutamate O-methylrinard erase RAB27A 0.67 0.27 Ribosomal RNA- processing protein 7 homolog A RBP7A 0.67 0.21 Scheen Complex Heliase XPD subunt Elstorz 0.67 0.22 Chilm 2 Chilm 2 0.67 0.22 Alpha 1-Gmanoly divgorphetic Poten Scheen Complex Heliase XPD subunt Elstorz 0.67 0.22 Chilm 2 Chilm 2 0.67 0.02 0.01 0.06 0.02 Alpha 3-dmal gamma-adaptin-binding protein P34 Chalcase St2W 0.66 0.02 0.03 Chalpasatin CAST 0.66 0.02				
Trafficking protein particle complex subunit 1 TRAPPC1 -0.68 0.68 Retinal rod rhodopsin sensitive CMP 3.5-cplic phosphodiestrese subunit delts PDE60 -0.68 N.D. Retinal rod rhodopsin sensitive CMP 3.5-cplic phosphodiestrese subunit delts PDE60 -0.68 0.04 SG ribossmal protein 137 RB737A -0.68 0.01 Rus-related protein Rab-27A RA027A -0.68 0.03 Ribossmal RNA-processing protein 7 homolog A RB77A -0.67 N.D. 2.5-cplic nucleids 2-phosphodiestress CNP -0.67 0.23 Flotlin 2 FLOTZ -0.67 0.22 Apha-1_6-mannosyl-glycoprotein 2-beta-Nacetylglucosaminytransferase MGA12 -0.67 0.22 TFIH basi transcription adaptitiv hinding protein p34 AAGAB -0.66 0.02 Apha-1_6-mannosyl-glycoprotein 3 ACTR3 -0.66 0.02<				
Spartin SPG20 -0.68 0.48 Retinal rod rhotopis-sensitive CGM 35-cyclic phosphodiesterase subunit delta PDEED -0.68 0.04 Betinal rod rhotopis-sensitive CGM 35-cyclic phosphodiesterase subunit 1 CG31B -0.68 0.01 Ras-related protein Ray-2/A RAB27/A -0.68 0.021 Ras-related protein Ray-2/A RAB27/A -0.68 0.031 Robissemial RNA-processing protein 71 homolog A RBP7/A -0.67 0.032 Spartin -0.68 0.077 RND. -0.67 0.032 Spartin -0.67 0.021 -0.67 0.022 -0.67 0.022 Spartin -0.67 0.022 -0.67 0.022 -0.67 0.022 Alpha-Si-Gmanoy-leycoprothyphate synthase FDPS -0.67 0.022 -0.67 0.022 Alpha-Si-Gmanoy-leycoprothyphate Synthase FDPS -0.67 0.022 -0.67 0.022 Protein flightiess-1 homolog FUI -0.66 0.012 -0.66 0.012 Holicares S02W SVIV2L	Vam6/Vps39-like protein	VPS39	-0,68	N.D.
Spartin Spactin Spacton 4.0.8 0.48 Betinal rod rhotopisnesmitter (CM) 35-optic phosphodiesterase subunit delta PPEED 4.0.8 0.0.4 SG ribosomal protein 137a R137A 4.0.8 0.0.1 Ras-related protein Rab-27A RAB27A 0.0.68 0.0.1 Ras-related protein Rab-27A RAB27A 0.0.68 0.0.3 Robisomal RNA-processing protein Thomolog A RRP7A 0.0.67 0.0.3 Spartin Option Protein Spartin Thomolog A RRP7A 0.0.67 0.0.3 Lapha-L-Ensinoxyl-propriorbalter Systemase GNA 0.0.67 0.0.27 Firstemax/prophosphate synthase FDPS -0.67 0.0.23 Alpha-L-Ensinoxyl-prophosphate synthase FDPS -0.67 0.0.22 Calponin-2 CNN2 -0.67 0.0.22 Protein flighters-1 homolog ERC2 -0.67 0.0.20 Heilares SN2W SWIV2L -0.66 0.114 Adhr-Ensited protein 3 ACR183 -0.66 0.124 Adhr-Brastin CAST -0.66 </td <td>Trafficking protein particle complex subunit 1</td> <td>TRAPPC1</td> <td>-0.68</td> <td>0.66</td>	Trafficking protein particle complex subunit 1	TRAPPC1	-0.68	0.66
Petinal rod rhodopsin-sensitive GMP 35-golic phosphodiserses subunit delta PDEGD 4.08 N.D. 065 ribossma protein 137a RP137A 4.08 0.04 070 ribossma protein 137a RP137A 4.08 0.021 Ras-related protein Rab-27A RA027A 4.068 0.031 Ribossma RNA-processing protein 7 homolog A RRF7A 4.067 0.33 Ribossma RNA-processing protein 7 homolog A RRF7A 4.067 0.022 Apha-1,6-mannosyl-glycoprotein 2-beta-Nacetylglucosaminytransferase MGAT2 4.067 0.021 Apha-1,6-mannosyl-glycoprotein 2-beta-Nacetylglucosaminytransferase MGAT2 4.067 0.022 Apha-1,6-mannosyl-glycoprotein 2-beta-Nacetylglucosaminytransferase MGAT2 4.066 0.021 Apha-1,6-mannosyl-glycoprotein 2-beta-Nacetylglucosaminytransferase MGAT4 4.066 </td <td></td> <td></td> <td></td> <td></td>				
605 ribosomal protein L37a RPL37A 0.68 0.04 Cyclin-dependent kinase regulatory subunit 1 CKS1B 0.688 0.21 Ras-related protein Rab-27A RAB27A 0.68 0.07 Protein-glutamate 0-methyltransferase ARM71A 0.67 N.0. Ribosomal KN-processing protein 7 homolog A RNP7A 0.67 0.33 Attorneous Complex high prophosphate synthase FD07 0.67 0.27 Farresvi psycholesterase GD07 0.67 0.27 Alpha-1.5-manosri-glycoprosphate synthase FD07 0.67 0.22 Alpha-1.5-manosri-glycoprosphate synthase FD07 0.67 0.22 Alpha-1.5-manosri-glycoprosphate synthase FD07 0.67 0.22 Alpha-1.5-manosri-glycoprosphate synthase FD07 0.67 0.21 Alpha-1.5-manosri-glycoprosphate synthase FB07 0.67 0.22 Alpha-1.5-manosri-glycoprosphate synthase FB07 0.67 0.02 Alpha-1.5-manosri-glycoprosphate synthase FB07 0.67 0.010 Heitcase SN2W SKN/2L<				
Cyclin-dependent kinase regulatory subunit 1 CK318 -0.68 0.21 Ras-related protein Rab-Z7A RAB27A RAB27A 0.67 0.03 Ribosomal RM-processing protein 7 homolog A RRP7A 0.67 N.0. 2.3-cyclic-nucledie 3-phosphodiesterase CNP 0.67 0.33 Flostilin-2 FL01 0.67 0.22 Alpha-1,6-mannosyl-glycoprotein 2-beta-Nacetylglucosaminyltransferase MGA7 0.67 0.02 TFIHI basal transcription factor complex helicase XPD subunit ERC2 0.67 0.02 Alpha-1,6-mannosyl-glycoprotein 2-beta-Nacetylglucosaminyltransferase MGA7 0.66 0.60 TFIHI basal transcription factor complex helicase XPD subunit ERC2 0.67 0.10 Helicase S02W SKIV2L 0.66 0.60 0.12 Alpha-and gamma-adaptin-binding protein p34 AGA8A 0.66 0.02 MW domain-binding protein 1 CAST 0.66 0.02 MW domain-binding protein 2 WBP2 0.66 0.02 MW domain-binding protein 1A CC201A 0.65 0.013	Retinal rod rhodopsin-sensitive cGMP 3,5-cyclic phosphodiesterase subunit delta	PDE6D	-0,68	N.D.
Ras-related protein Rab-27A RAB27A 0.68 0.07 Protein-glutame 0-methyltransferase ARMT1 0.69 0.03 Ribosomal NN-processing protein 7 homolog A RNP7A 0.67 0.03 2.3-cyclie-nucleotide 3-phosphodiesterase NP 0.67 0.33 Alpha-1.5-manos/-glycoprotein 2-beta-N-acelyglucosaminyltransferase FIDT2 0.67 0.22 Alpha-1.5-manos/-glycoprotein 2-beta-N-acelyglucosaminyltransferase MGAT2 0.67 0.22 Alpha-1.5-manos/-glycoprotein 2-beta-N-acelyglucosaminyltransferase MGAT2 0.67 0.10 Protein flightless-1 homolog FLII 0.67 0.10 Protein flightless-1 homolog FLII 0.67 0.10 Helicase SN2W SKIV2L 0.66 0.60 Actin-related protein 3 ACTR3 0.66 0.02 Actin-related protein 3 ACTR3 0.66 0.02 Maspardin CSPG1 0.66 0.02 Maspardin SPG21 0.66 0.02 Maspardin CSPG1 0.65 0.13 <td>60S ribosomal protein L37a</td> <td>RPL37A</td> <td>-0,68</td> <td>0,04</td>	60S ribosomal protein L37a	RPL37A	-0,68	0,04
Ras-related protein Rab-27A RAB27A 0.68 0.07 Protein-glutame 0-methyltransferase ARMT1 0.69 0.03 Ribosomal NN-processing protein 7 homolog A RNP7A 0.67 0.03 2.3-cyclie-nucleotide 3-phosphodiesterase NP 0.67 0.33 Alpha-1.5-manos/-glycoprotein 2-beta-N-acelyglucosaminyltransferase FIDT2 0.67 0.22 Alpha-1.5-manos/-glycoprotein 2-beta-N-acelyglucosaminyltransferase MGAT2 0.67 0.22 Alpha-1.5-manos/-glycoprotein 2-beta-N-acelyglucosaminyltransferase MGAT2 0.67 0.10 Protein flightless-1 homolog FLII 0.67 0.10 Protein flightless-1 homolog FLII 0.67 0.10 Helicase SN2W SKIV2L 0.66 0.60 Actin-related protein 3 ACTR3 0.66 0.02 Actin-related protein 3 ACTR3 0.66 0.02 Maspardin CSPG1 0.66 0.02 Maspardin SPG21 0.66 0.02 Maspardin CSPG1 0.65 0.13 <td>Cyclin-dependent kinases regulatory subunit 1</td> <td>CKS1B</td> <td>-0.68</td> <td>0.21</td>	Cyclin-dependent kinases regulatory subunit 1	CKS1B	-0.68	0.21
Protein-glutamate O-methyltransferase ARMT1 -0.68 0.03 Ribosoma RN-brocessing protein 7 homolog A RRP7A -0.67 N.B. 12,3-cyclic-nucleotide 3-phosphodiesterase CNP -0.67 0.33 Farenedy prophosphate synthase FLDTZ -0.67 0.027 Alpha-1,6-mannosyl-glycoprotein 2-beta-N-acetylglucosaminytransferase MGATZ -0.67 0.02 Alpha-1,6-mannosyl-glycoprotein 2-beta-N-acetylglucosaminytransferase MGATZ -0.67 0.02 Calponin-2 CNN2 -0.67 0.02 0.00 Protein fightees: 1-homolog Full -0.66 0.02 0.00 Alpha- and gamma-adaptin-binding protein p34 AG6B -0.66 0.12 Fascin CAST -0.66 0.12 Actin-related protein 3 ACTR3 -0.66 0.02 MW domain-binding protein 2 WBP2 -0.66 0.02 WW domain-binding protein 1A CC2DIA -0.65 0.013 Glide-col and C domain-containing protein 1A CC2DIA -0.65 0.031 Glide-col and				
Ribosomal RNA-processing protein 7 homolog A RBP7A 0.672 N.D. 2,3-cyclic-nucleotide 3-phosphodiesterase CNP -0.672 0.33 Farnesyl pyrophosphate synthase FID172 -0.67 0.027 Apipa-1,5-manosyl-gkycoprotein 2-beta-Acetylglucosaminytransferase MGAT2 -0.67 0.022 Apipa-1,5-manosyl-gkycoprotein 2-beta-Acetylglucosaminytransferase MGAT2 -0.67 0.02 Calponin-2 CNN2 -0.67 0.02 0.01 Meliase SN2W SkiV2L -0.66 0.01 -0.66 0.01 Helicase SN2W SkiV2L -0.66 0.01 -0.66 0.01 Adin-related protein 3 ACTR3 -0.66 0.02 -0.66 0.02 Calpastatin CAST -0.66 0.02 -0.66 0.02 -0.66 0.02 -0.66 0.02 -0.66 0.02 -0.66 0.02 -0.66 0.02 -0.66 0.02 -0.66 0.02 -0.66 0.02 -0.66 0.02 -0.66 0.02 -0.66 <td< td=""><td></td><td></td><td></td><td></td></td<>				
2,3-cyclic-nucleotide 3-phosphodesterase CNP 0.67 0.33 Hotillin-2 FLOT2 0.67 0.27 Farnesyl prophosphate synthase FDPS 0.67 0.02 Alpha-1.6-mannosyl-glycoprotein 2-beta-N-acetylgucosaminytransferase MGAT2 0.67 0.32 THIH basil transcripting helicase SVD subunit ERCC2 0.67 0.30 Calponin-2 CNN2 0.66 0.60 Helicase SXI2W SKIV2L 0.66 0.60 Alpha- and gamma-adaptin-binding protein p34 AAGAB 0.66 0.12 Actin-related protein 3 CATR3 0.66 0.05 Calpastain CAST 0.66 0.01 WW domain-binding protein 2 WBP2 0.66 0.02 WW domain-binding protein 1A CCDIIA 0.65 0.03 Gos rubosomal protein 1A CODIA 0.65 0.03 Gos rubosomal protein 1A CCDIA 0.65 0.04 Coiled-coil and C2 domain-containing protein 1A RCBA 0.65 0.01 Coiled-coil and C2 domai	Protein-glutamate O-methyltransferase	ARMT1	-0,68	0,03
2,3-cyclic-nucleotide 3-phosphodesterase CNP 0.67 0.33 Hotillin-2 FLOT2 0.67 0.27 Farnesyl prophosphate synthase FDPS 0.67 0.02 Alpha-1.6-mannosyl-glycoprotein 2-beta-N-acetylgucosaminytransferase MGAT2 0.67 0.32 THIH basil transcripting helicase SVD subunit ERCC2 0.67 0.30 Calponin-2 CNN2 0.66 0.60 Helicase SXI2W SKIV2L 0.66 0.60 Alpha- and gamma-adaptin-binding protein p34 AAGAB 0.66 0.12 Actin-related protein 3 CATR3 0.66 0.05 Calpastain CAST 0.66 0.01 WW domain-binding protein 2 WBP2 0.66 0.02 WW domain-binding protein 1A CCDIIA 0.65 0.03 Gos rubosomal protein 1A CODIA 0.65 0.03 Gos rubosomal protein 1A CCDIA 0.65 0.04 Coiled-coil and C2 domain-containing protein 1A RCBA 0.65 0.01 Coiled-coil and C2 domai	Ribosomal RNA-processing protein 7 homolog A	RRP7A	-0,67	N.D.
Hotilin-2 FLOT2 0.67 0.27 Alpha-1,6-mannosyl-gtvorphosphate synthase FDPS 0.67 0.02 Alpha-1,6-mannosyl-gtvorphosphate synthase FDPS 0.67 0.02 TFIIH basal transcription factor complex helicase XPD subunit ERCC2 0.67 0.02 Calponin-2 CMO 0.67 0.02 Protein flightless-1 homolog FUI 0.67 0.00 Helicase SN2W SKIV2L 0.66 0.012 Alpha-and gamma-adaptin-binding protein p34 AAGAB 0.66 0.12 Actina 666 0.05 0.66 0.02 MW domain-binding protein 2 WBP2 0.66 0.02 WW domain-binding protein 1A CAST 0.66 0.02 Colled-coll and C domain-containing protein 1A CC2DIA 0.65 0.013 Synembryn-A RICBA 0.65 0.015 Gold coll and C domain-containing protein 1A CC2DIA 0.65 0.014 Colled-coll and C domain-containing protein 1A CC2DIA 0.65 0.014 <tr< td=""><td>2 3-cvclic-nucleotide 3-nhosnhodiesterase</td><td>CNP</td><td>-0.67</td><td>0.33</td></tr<>	2 3-cvclic-nucleotide 3-nhosnhodiesterase	CNP	-0.67	0.33
Farresyl pyrophosphate synthase FDPS -0.67 0.02 Alpha-1,6-manosyl-glycoprotein 2-beta-N-acthylglucosaminytansferase MGAT2 -0.67 0.38 TRIH basal transcription factor complex helicase XPD subunit ERCC2 -0.67 0.10 Protein fightless-1 homolog FILI -0.667 0.10 Helicase SRI2W SRIV2L -0.666 0.60 Alpha- and gamma-adaptin-binding protein p34 AAGAB -0.666 0.012 Actin-related protein 3 CAST -0.666 0.02 WW domain-binding protein 13 CAST -0.666 0.02 WW domain-binding protein 14 CST -0.666 N.D. WW domain-binding protein 14 SPC21 -0.666 N.D. Colled-coil and C2 domain-containing protein 1A CC201A -0.65 0.031 Colled-coil and C2 domain-containing protein 14 RPL4 -0.65 0.041 Colled-coil and C2 domain-containing protein 14 RPL4 -0.65 0.041 Colled-coil and C2 domain-containing protein 14 RPL4 -0.65 0.041 Cod5 ribos				
Alpha-1.6-mannos/l-glycogratein 2-beta-N-acetylglucosaminyltransferase MGAT2 -0.67 0.38 TFIH basal transcription factor complex helicase XPD subunit ERCC2 -0.67 0.10 Protein flightless-1 homolog FLI -0.67 0.10 Protein flightless-1 homolog FLI -0.67 0.10 Alpha- and gamma-adaptin-binding protein p34 AAGAB -0.66 0.04 Actin-related protein 3 ACTR3 -0.66 0.01 Calpositin CAST -0.66 0.02 WW domain-binding protein 2 WBP2 -0.66 0.02 WW domain-binding protein 1A CC2DIA -0.65 0.03 Maspardin SPG21 -0.66 N.D. WW domain-binding protein 1A CC2DIA -0.65 0.02 Coiled-coil and C2 domain-containing protein 1A CC2DIA -0.65 0.03 Symembryn-A RICSA -0.65 0.04 Pre-mRNA-splicing factor SYF1 XAB2 -0.65 0.01 Condensin-2 complex subunit 62 ACTR2 -0.65 0.02				
TFIIH basal transcription factor complex helicase XPD subunit ERCC2 -0.67 0.10 Calponin-2 CNN2 -0.67 0.10 Protein flightess-1 homolog FLII -0.66 0.00 Alpha- and gamma-adaptin-binding protein p34 AAGAB -0.66 0.10 Fascin FSCN1 -0.66 0.12 Actin-related protein 3 CAST -0.66 0.05 WW domain-binding protein 2 WBP2 -0.66 0.013 Maspardin CAST -0.66 0.02 WW domain-binding protein 1 CAST -0.66 0.03 Maspardin SPG21 -0.66 0.03 Maspardin SPG21 -0.65 0.03 Synembryn-A RICBA -0.65 0.04 Pre-mRNA-splicing factor SY11 XAB2 -0.65 0.04 Condensi-2 complex subunit 62 ACTR2 -0.65 0.07 Pettidyl-prolyl cis trans isomerase FKBP5 FKBP5 -0.65 0.07 Condensi-2 complex subunit 62 NCAF62 -0.65 <t< td=""><td>Farnesyl pyrophosphate synthase</td><td>FDPS</td><td>-0,67</td><td>0,02</td></t<>	Farnesyl pyrophosphate synthase	FDPS	-0,67	0,02
TFIIH basal transcription factor complex helicase XPD subunit ERCC2 -0.67 0.10 Calponin-2 CNN2 -0.67 0.10 Protein flightess-1 homolog FLII -0.66 0.00 Alpha- and gamma-adaptin-binding protein p34 AAGAB -0.66 0.10 Fascin FSCN1 -0.66 0.12 Actin-related protein 3 CAST -0.66 0.05 WW domain-binding protein 2 WBP2 -0.66 0.013 Maspardin CAST -0.66 0.02 WW domain-binding protein 1 CAST -0.66 0.03 Maspardin SPG21 -0.66 0.03 Maspardin SPG21 -0.65 0.03 Synembryn-A RICBA -0.65 0.04 Pre-mRNA-splicing factor SY11 XAB2 -0.65 0.04 Condensi-2 complex subunit 62 ACTR2 -0.65 0.07 Pettidyl-prolyl cis trans isomerase FKBP5 FKBP5 -0.65 0.07 Condensi-2 complex subunit 62 NCAF62 -0.65 <t< td=""><td>Alpha-1,6-mannosyl-glycoprotein 2-beta-N-acetylglucosaminyltransferase</td><td>MGAT2</td><td>-0,67</td><td>0,38</td></t<>	Alpha-1,6-mannosyl-glycoprotein 2-beta-N-acetylglucosaminyltransferase	MGAT2	-0,67	0,38
Calponin-2 CNN2 -0.67 0.10 Protein flightless-1 homolog FLI -0.67 0.10 Helicase SKI2W SKIV2L -0.66 0.00 Alpha- and gamma-adaptin-binding protein p34 AAGAB -0.66 0.14 Fascin FSCN1 -0.66 0.012 Actin-related protein 3 ACTR3 -0.66 0.012 WW domain-binding protein 2 WBP2 -0.66 0.013 WW domain-binding protein 1 CAST -0.66 0.02 WBP2S -0.66 0.02 0.02 0.02 0.02 UPF0553 protein C90r64 C90r64 -0.66 N.D. 0.05 0.13 GOS ribosomal protein 1A CC2D1A -0.65 0.13 0.65 0.14 CDied-coil and C2 domain-containing protein 1A CC2D1A -0.65 0.04 CDied-soil and C2 domain-containing protein 1A CRCBA -0.65 0.15 GOS ribosomal protein 1A CRCBA -0.65 0.12 Condensin-2 complex subunit C2 ACTR2 -0.		FRCC2		
Protein flightless-1 homolog FLI 0,67 0,10 Helicase SU2W SKIV2L 0,66 0,60 Alpha- and gamma-adaptito-binding protein p34 AAGAB 0,66 0,14 Fascin FSCN1 0,66 0,012 Actin-related protein 3 ACTR3 0,66 0,012 Calpastatin CAST 0,66 0,012 WW domain-binding protein 2 WBP2 0,66 0,012 WW domain-binding protein 1A CAST 0,66 0,02 UPF0553 protein C9orf64 C9orf64 0,66 N.D. Colled-coil and C2 domain-containing protein 1A CC2D1A 0,65 0,13 G0S ribosomal protein L4 RPL4 0,65 0,04 Pre-mRNA-splicing factor SY11 XAB2 0,65 0,14 Condensin-2 complex subunit G2 NCAP62 0,65 0,12 Condensin-2 complex subunit G2 NCAP62 0,65 0,12 Condensin-2 complex subunit G2 NCAP62 0,65 0,15 Basic leucine zipper and W2 domain-containing protein 1				
Helicase Ski2W SkiV2L 0,66 0,60 Alpha- and gamma-adaptin-binding protein p34 AAGAB 0,66 0,12 Actin-related protein 3 ACTR3 0,66 0,05 Calpastatin CAST 0,66 0,13 WW domain-binding protein 2 WBP2 0,66 0,013 Maspardin SPG21 0,66 0,02 UPF0555 protein C9orf64 C201A 0,65 0,03 Synembryn-A RICBA 0,65 0,14 Colled-coil and C2 domain-containing protein 1A CC2D1A 0,65 0,15 605 ribosomal protein 14 RPL4 0,65 0,14 CD99 antigen C099 0,65 0,14 CD99 antigen C099 0,65 0,12 Condensin-2 complex subunit 2 ARPC2 0,65 0,15		CNN2	-0,67	0,10
Alpha- and gamma-adaptin-binding protein p34 AAGAB -0,66 0,14 Fascin FSCN1 -0,66 0,12 Actin-related protein 3 ACTR3 -0,66 0,05 Calpastatin CAST -0,66 N.D. WW domain-binding protein 2 WBP2 -0,66 0,02 WPF053S protein C50rf64 CSorf64 -0,66 N.D. Coiled-coil and C2 domain-containing protein 1A CC2D1A -0,65 0,13 Synembryn-A RICSA -0,65 0,14 CD99 antigen CD99 -0,65 0,14 CD99 antigen CD99 -0,65 0,14 CD99 antigen CD99 -0,65 0,12 Condensin-2 complex subunit 2 ACTR2 -0,65 0,07 Petidyl-prolyl cist-trains isomerase FKBP5 FKBP5 -0,65 0,12 Condensin-2 complex subunit 62 NCAPG2 -0,65 0,02 Basic leucine: zipper and W2 domain-containing protein 1 BZW1 -0,64 0,15 Goff H transamidase component PIG-T PIGT	Protein flightless-1 homolog	FLII	-0,67	0,10
Alpha- and gamma-adaptin-binding protein p34 AAGAB -0,66 0,14 Fascin FSCN1 -0,66 0,12 Actin-related protein 3 ACTR3 -0,66 0,05 Calpastatin CAST -0,66 N.D. WW domain-binding protein 2 WBP2 -0,66 0,02 WPF053S protein C50rf64 CSorf64 -0,66 N.D. Coiled-coil and C2 domain-containing protein 1A CC2D1A -0,65 0,13 Synembryn-A RICSA -0,65 0,14 CD99 antigen CD99 -0,65 0,14 CD99 antigen CD99 -0,65 0,14 CD99 antigen CD99 -0,65 0,12 Condensin-2 complex subunit 2 ACTR2 -0,65 0,07 Petidyl-prolyl cist-trains isomerase FKBP5 FKBP5 -0,65 0,12 Condensin-2 complex subunit 62 NCAPG2 -0,65 0,02 Basic leucine: zipper and W2 domain-containing protein 1 BZW1 -0,64 0,15 Goff H transamidase component PIG-T PIGT	Helicase SKI2W	SKIV2I	-0.66	0,60
Fascin FSCN1 -0,66 0,12 Actin-related protein 3 ACTR3 -0,66 0,05 Calpastain CAST -0,66 0,13 WW domain-binding protein 2 WBP2 -0,66 0,13 Maspardin SPG21 -0,66 0,02 UPF0553 protein C9orf64 C9orf64 -0,66 0,02 Coiled-coil and C2 domain-containing protein 1A CC2D1A -0,65 0,33 Synembryn-A RICBA -0,65 0,14 C0959 antigen CD99 -0,65 0,14 CD9 antigen CD99 -0,65 0,12 Condensin-2 complex subunit 2 ARPC2 -0,64 0,15				
Actin-related protein 3 ACTR3 -0,66 0.05 Calpastatin CAST -0,66 N.D. WW domain-binding protein 2 WPP2 -0,66 0,03 Maspardin SPG21 -0,66 0,02 UPP05S3 protein C90r64 C90r64 -0,66 N.D. Coiled-coil and C2 domain-containing protein 1A CC2D1A -0,65 0,33 Synembryn-A RIC8A -0,65 0,04 Pre-mRNA-splicing factor SYF1 XAB2 -0,65 0,014 CD99 antigen CD99 -0,65 0,017 Peptidyl-prolyl (st-trans isomerase FKBP5 FKBP5 -0,65 0,012 Condensin-2 complex subunit C3 NCAP62 -0,65 0,012 Condensin-2 complex subunit C3 ARPC2 -0,65 0,012 Actin-related protein 2/3 complex subunit 1 BZW1 -0,64 0,115 GPI transamidase component PIG-T PIGT -0,64 0,15 GPI transamidase component PIG-T PIGT -0,64 0,25 ZoS proteasome non-ATPase regulatory subunit 5<				
Calpastatin CAST -0,66 N.D. WW domain-binding protein 2 WBP2 -0,66 0,13 Maspardin SPG21 -0,66 0,02 UPF0553 protein C9orf64 C9orf64 -0,66 N.D. Coiled-coil and C2 domain-containing protein 1A CC2D1A -0,65 0,33 Symembryn-A RICBA -0,65 0,015 605 ribosomal protein 14 RPL4 -0,65 0,014 CD99 antigen CD99 -0,65 0,14 CD9 antigen CD99 -0,65 0,015 Actin-related protein 2 ACTR2 -0,65 0,012 CD9 antigen CD99 -0,65 0,012 Condensin-2 complex subunit G2 NCAPG2 -0,65 0,02 Basic leucine zipper and W2 domain-containing protein 1 BZW1 -0,64 0,15 GPI transamidase component PIG-T PIGT -0,64 0,15 GPI transamidase component PIG-T PIGT -0,64 0,15 SDS protensome non-TPAreseregulatory subunit 5 PISMD5 -0	Fascin	FSCN1	-0,66	0,12
Calpastatin CAST -0,66 N.D. WW domain-binding protein 2 WBP2 -0,66 0,13 Maspardin SPG21 -0,66 0,02 UPF0553 protein C9orf64 C9orf64 -0,66 N.D. Coiled-coil and C2 domain-containing protein 1A CC2D1A -0,65 0,33 Symembryn-A RICBA -0,65 0,015 605 ribosomal protein 14 RPL4 -0,65 0,014 CD99 antigen CD99 -0,65 0,14 CD9 antigen CD99 -0,65 0,015 Actin-related protein 2 ACTR2 -0,65 0,012 CD9 antigen CD99 -0,65 0,012 Condensin-2 complex subunit G2 NCAPG2 -0,65 0,02 Basic leucine zipper and W2 domain-containing protein 1 BZW1 -0,64 0,15 GPI transamidase component PIG-T PIGT -0,64 0,15 GPI transamidase component PIG-T PIGT -0,64 0,15 SDS protensome non-TPAreseregulatory subunit 5 PISMD5 -0	Actin-related protein 3	ACTR3	-0,66	0,05
WW domain-binding protein 2 WBP2 -0,66 0,13 Maspardin SPG21 -0,66 0,02 UPF0553 protein C9orf64 C9orf64 -0,66 N.D. Coiled-coil and C2 domain-containing protein 1A CC2D1A -0,65 0,33 Synembryn-A RIC8A -0,65 0,15 605 ribosomal protein 14 RPL4 -0,65 0,14 CD99 antigen CD99 -0,65 0,12 CD99 antigen CD99 -0,65 0,12 Condensin-2 complex subunit 62 NCAP62 -0,65 0,12 Condensin-2 complex subunit 62 NCAP62 -0,65 0,12 Condensin-2 complex subunit 62 NCAP62 -0,65 0,15 Actin-related protein 2/3 complex subunit 1 BZW1 -0,64 0,15 Encyl-CoA hydratase 2 HSD17B4 -0,64 0,15 GPI transamidase component PIG-T PIGT -0,64 0,15 GPI transamidase component PIG-T PIGT -0,64 0,25 265 proteasome non-ATPase regulatory subunit 5				
Maspardin SPG21 -0,66 0,02 UPF05S3 protein C9orf64 C9orf64 -0,66 N.D. Coiled-coil and C2 domain-containing protein 1A CC2D1A -0,65 0,33 Synembryn-A RICBA -0,65 0,04 Pre-mRNA-splicing factor SYF1 XAB2 -0,65 0,04 CD99 antigen CD99 -0,65 N.D. Actin-related protein 2 ACTR2 -0,65 0,12 Condensin-2 complex subunit 62 NCAPG2 -0,65 0,12 Condensin-2 complex subunit 2 ARPC2 -0,65 0,12 Condensin-2 complex subunit 2 ARPC2 -0,65 0,02 Basic leucine zipper and W2 domain-containing protein 1 BZW1 -0,64 0,15 GPI transmidase component PIG-T PIGT -0,64 0,15 MAD(P)H dehydrogenase [quitore] 1 NQ01 -0,64 0,25 265 proteasome non-ATPase regulatory subunit 5 PSMD5 -0,64 0,25 605 ribosomal protein 136a-like NP136AL -0,64 0,53 RNA-bindi	· ·			
UPF0553 protein C9orf64 C9orf64 -0,66 N.D. Coiled-coil and C2 domain-containing protein 1A CC2D1A -0,65 0,33 Synembryn-A RIC8A -0,65 0,04 G05 ribosomal protein 14 RPL4 -0,65 0,04 Pre-mRNA-splicing factor SYF1 XAB2 -0,65 0,04 CD99 antigen CD99 -0,65 0,07 Actin-related protein 2 ACTR2 -0,65 0,12 Condensin-2 complex subunit 62 NCAP62 -0,65 0,12 Condensin-2 complex subunit 62 NCAP62 -0,65 0,15 Actin-related protein 2/3 complex subunit 2 RRPC2 -0,65 0,12 Basic leucine 2ipper and W2 domain- containing protein 1 BZW1 -0,64 0,15 GPI transamidase component PIG-T PIGT -0,64 0,15 NAD(P)H dehydrogenase [quinone] 1 NQO1 -0,64 0,25 GS ribosomal protein 137 ZNF217 -0,64 0,25 GS ribosomal protein NOB1 NOB1 -0,64 0,25 GS ribo				
Colled-coll and C2 domain-containing protein 1ACC2D1A-0,650,33Synembryn-ARIC8A-0,650,1560S ribosomal protein L4RPL4-0,650,04Pre-mRNA-splicing factor SYF1XAB2-0,650,04CD99 antigenCD99-0,650,07Actin-related protein 2ACTR2-0,650,07Peptidyl-prolyl cis-trans isomerase FKBP5FKBP5-0,650,15Condensin-2 complex subunit G2NCAPG2-0,650,12Condensin-2 complex subunit 2ARPC2-0,650,02Basic leucine zipper and W2 domain-containing protein 1BZW1-0,640,15GPI transamidase component PIG-TPIGT-0,640,15GPI transamidase component PIG-TPIGT-0,640,2526S proteasome non-ATPase regulatory subunit 5PSMD5-0,640,2526S ribosomal protein 136a-likeRPL36AL-0,640,11Charter capping protein NOB1NOB1-0,640,11Charter capping protein subunit alpha-1CAPZA1-0,640,11Caide-coil and C2 domain-containing protein 3CCCD1B-0,630,28Coiled-coil and C2 domain-containing protein 18 <t< td=""><td>Maspardin</td><td></td><td>-0,66</td><td>0,02</td></t<>	Maspardin		-0,66	0,02
Coiled-coil and C2 domain-containing protein 1A CC2D1A -0,65 0,33 Synembryn-A RIC8A -0,65 0,15 60S ribosomal protein L4 RPL4 -0,65 0,04 Pre-mRNA-splicing factor SYF1 XAB2 -0,65 0,014 CD99 antigen CD99 -0,65 0,07 Actin-related protein 2 ACTR2 -0,65 0,07 Peptidyl-prolyl cis-trans isomerase FKBP5 FKBP5 -0,65 0,12 Condensin-2 complex subunit 62 NCAPG2 -0,65 0,02 Basic leucine zipper and W2 domain-containing protein 1 BZW1 -0,64 0,15 GPI transamidase component PIG-T PIGT -0,64 0,15 GPI transamidase component PIG-T PIGT -0,64 0,25 GS proteasome non-ATPase regulatory subunit 5 PSMD5 -0,64 0,25 GS ribosomal protein L36a-like RPL36AL -0,64 0,25 GS ribosomal protein NOB1 NOB1 -0,64 0,25 GPI transamidase component PIG-T PSMD5 -0,64 0,25	UPF0553 protein C9orf64	C9orf64	-0,66	N.D.
Synembryn-A RIC8A -0,65 0,15 605 ribosomal protein L4 RPL4 -0,65 0,04 Pre-mRNA-splicing factor SYF1 XAB2 -0,65 0,15 CD99 antigen CD99 -0,65 0,07 Actin-related protein 2 ACTR2 -0,65 0,12 Condensin-2 complex subunit G2 NCAPG2 -0,65 0,12 Condensin-2 complex subunit G2 NCAPG2 -0,65 0,12 Actin-related protein 2/3 complex subunit 2 ARPC2 -0,65 0,12 Basic leucine zipper and W2 domain-containing protein 1 BZW1 -0,64 0,15 GPI transamidase component PIG-T PIGT -0,64 0,15 GPI transamidase component PIG-T NQ01 -0,64 0,15 Cinfinger protein 217 ZINF217 -0,64 0,25 Z65 proteasome non-ATPase regulatory subunit 5 PSMD5 -0,64 0,22 G05 ribosomal protein N081 -0,64 0,64 0,11 Cheptidyl-prolyl cis-trans isomerase B PPIB -0,64 0,11	· · ·	CC2D1A		
605 ribosomal protein L4 RPL4 -0,65 0,04 Pre-mRNA-splicing factor SYF1 XAB2 -0,65 0,14 CD99 antigen CD99 -0,65 N.0 Actin-related protein 2 ACTR2 -0,65 0,12 Condensin-2 complex subunit 62 NCAP62 -0,65 0,12 Condensin-2 complex subunit 62 NCAP62 -0,65 0,02 Basic leucine zipper and W2 domain-containing protein 1 BZW1 -0,64 0,15 Enoyl-CoA hydratase 2 HSD17B4 -0,64 0,15 GP1 transamidase component PIG-T PIGT -0,64 0,15 XAB2 O,65 0,64 0,15 Cofe protein 217 ZNF217 -0,64 0,25 C65 PSMD5 -0,64 0,22 GOS ribosomal protein L36-like RPL36AL -0,64 0,22 GOS ribosomal protein NOB1 NOB1 -0,64 0,22 GOS ribosomal protein NOB1 NOB1 -0,64 0,22 GOS ribosomal protein NOB1 NOB1 -0,64 0				
Pre-mRNA-splicing factor SYF1 XAB2 -0,65 0,14 CD99 antigen CD99 -0,65 N.D. Actin-related protein 2 ACTR2 -0,65 0,07 Peptidyl-prolyl (st-trans isomerase FKBP5 FKBP5 -0,65 0,12 Condensin-2 complex subunit G2 NCAPG2 -0,65 0,15 Actin-related protein 2/3 complex subunit 2 ARPC2 -0,65 0,15 Basic leucine zipper and W2 domain-containing protein 1 BZW1 -0,64 0,15 Enoyl-CoA hydratase 2 HSD17B4 -0,64 0,15 GPI transamidase component PIG-T PIGT -0,64 0,15 NAD(P)H dehydrogenase [quinne] 1 NQO1 -0,64 0,25 Z6S proteasome non-ATPase regulatory subunit 5 PSMD5 -0,64 0,22 GOS ribosomal protein 136-like RP136AL -0,64 0,15 GP retains protein NOB1 NOB1 -0,64 0,12 Cold-GoS ribosomal protein NOB1 NOB1 -0,64 0,53 GP retain-crapping protein NOB1 NOB1 -0,64 0,11				
CD99 antigen CD99 -0,65 N.D. Actin-related protein 2 ACTR2 -0,65 0,07 Peptidyl-prolyl cis-trans isomerase FKBPS FKBPS -0,65 0,12 Condensin-2 complex subunit G2 NCAPG2 -0,65 0,15 Actin-related protein 2/3 complex subunit 2 ARPC2 -0,65 0,02 Basic leucine zipper and W2 domain-containing protein 1 BZW1 -0,64 0,15 GPI transamidase component PIG-T PIGT -0,64 0,15 GPI transamidase component PIG-T PIGT -0,64 0,15 Coldy Sribosomal protein 217 ZNF217 -0,64 0,25 Zinc finger protein 217 ZNF217 -0,64 0,25 Zinc finger protein 136a-like RPI36AL -0,64 0,25 GDS ribosomal protein L36a-like RPI36AL -0,64 0,25 GPI transarioing protein NOB1 NOB1 -0,64 0,25 GDS ribosomal protein L36a-like RPI36AL -0,64 0,53 RNA-binding protein NOB1 NOB1 -0,64 0,11		RPL4	-0,65	0,04
CD99 antigen CD99 -0,65 N.D. Actin-related protein 2 ACTR2 -0,65 0,07 Peptidyl-prolyl cis-trans isomerase FKBPS FKBPS -0,65 0,12 Condensin-2 complex subunit G2 NCAPG2 -0,65 0,15 Actin-related protein 2/3 complex subunit 2 ARPC2 -0,65 0,02 Basic leucine zipper and W2 domain-containing protein 1 BZW1 -0,64 0,15 GPI transamidase component PIG-T PIGT -0,64 0,15 GPI transamidase component PIG-T PIGT -0,64 0,15 Coldy Sribosomal protein 217 ZNF217 -0,64 0,25 Zinc finger protein 217 ZNF217 -0,64 0,25 Zinc finger protein 136a-like RPI36AL -0,64 0,25 GDS ribosomal protein L36a-like RPI36AL -0,64 0,25 GPI transarioing protein NOB1 NOB1 -0,64 0,25 GDS ribosomal protein L36a-like RPI36AL -0,64 0,53 RNA-binding protein NOB1 NOB1 -0,64 0,11	Pre-mRNA-splicing factor SYF1	XAB2	-0,65	0,14
Actin-related protein 2 ACTR2 -0,65 0,07 Peptidyl-prolyl cis-trans isomerase FKBP5 FKBP5 -0,65 0,12 Condensin-2 complex subunit G2 NCAPG2 -0,65 0,02 Actin-related protein 2/3 complex subunit 2 ARPC2 -0,65 0,02 Basic leucine zipper and W2 domain-containing protein 1 BZW1 -0,64 0,15 GPI transamidase component PIG-T PIGT -0,64 0,15 GPI transamidase component PIG-T PIGT -0,64 0,15 XAD(P)H dehydrogenase [quinone] 1 NQO1 -0,64 0,15 Zinc finger protein 217 ZINF217 -0,64 0,25 Z65 proteasome non-ATPase regulatory subunit 5 PSMD5 -0,64 0,22 GOS ribosomal protein 136a-like RPL36AL -0,64 0,22 GOS ribosomal protein NOB1 NOB1 -0,64 0,11 Pretidyl-prolyl cis-trans isomerase B PPIB -0,64 0,11 Qinc finger CCHC domain-containing protein 3 CCCHC3 -0,64 0,11 Zinc finger CCHC domain-containing protein 3				
Peptidyl-prolyl cis-trans isomerase FKBP5 FKBP5 -0,65 0,12 Condensin-2 complex subunit G2 NCAPG2 -0,65 0,15 Actin-related protein 2/3 complex subunit 2 ARPC2 -0,65 0,015 Basic leucine zipper and W2 domain-containing protein 1 BZW1 -0,64 0,15 Enoyl-CoA hydratase 2 HSD17B4 -0,64 0,15 GP1 transamidase component PIG-T PIGT -0,64 0,15 NAD(P)H dehydrogenase [quinone] 1 NQO1 -0,64 0,15 Zinc finger protein 217 ZNF217 -0,64 0,22 G65 tribosomal protein 136-like RPL36AL -0,64 0,22 G65 tribosomal protein 136-like RPL36AL -0,64 0,22 G65 tribosomal protein NOB1 NOB1 -0,64 0,22 G65 tribosomal protein NOB1 NOB1 -0,64 0,10 F+actin-capping protein NOB1 NOB1 -0,64 0,11 Qinc finger CCHC domain-containing protein 3 ZCCHC3 -0,64 0,11 Zinc finger CCHC domain-containing protein 3 ZCCHC3 <	-			
Condensin-2 complex subunit G2 NCAPG2 -0,65 0,15 Actin-related protein 2/3 complex subunit 2 ARPC2 -0,65 0,02 Basic leucine zipper and W2 domain-containing protein 1 BZW1 -0,64 0,15 Enoyl-CoA hydratase 2 HSD1784 -0,64 0,15 GPI transamidase component PIG-T PIGT -0,64 0,15 NAD(P)H dehydrogenase [quinone] 1 NQ01 -0,64 0,15 Zinc finger protein 217 ZNF217 -0,64 0,22 G5 proteasome non-ATPase regulatory subunit 5 PSMD5 -0,64 0,22 G05 ribosomal protein 136-like RP136AL -0,64 0,22 G05 ribosomal protein NOB1 -0,64 0,64 0,53 ARPC2 OB1 -0,64 0,10 Peptidyl-prolyl cis-trans isomerase B PPIB -0,64 0,11 Zinc finger CCHC domain-containing protein 3 ZCCHC3 -0,64 0,01 Zinc finger CCHC domain-containing protein 3 ZCCHC3 -0,64 0,01 GPI reactin-comptining protein 3 ZCCHC3 -0,64				
Actin-related protein 2/3 complex subunit 2 ARPC2 -0,65 0,02 Basic leucine zipper and W2 domain-containing protein 1 BZW1 -0,64 0,15 Enoyl-CoA hydratase 2 HSD17B4 -0,64 0,15 GPI transamidase component PIG-T PIGT -0,64 0,11 NAD(P)H dehydrogenase [quinone] 1 NQ01 -0,64 0,25 Z6S proteasome non-ATPase regulatory subunit 5 PSMD5 -0,64 0,25 GOS ribosomal protein L36a-like RPL36AL -0,64 0,25 GS ribosomal protein NOB1 NOB1 -0,64 0,25 GG reduction in NOB1 NOB1 -0,64 0,25 GG reduction in Subunit alpha-1 CAPZA1 -0,64 0,25 Petidyl-prolyl cis-trans isomerase B PPIB -0,64 0,10 Petidyl-prolyl cis-trans isomerase B PPIB -0,64 0,11 Zinc finger CCHC domain-containing protein 3 ZCCHC3 -0,64 0,11 GD reduct-coil and C2 domain-containing protein 3 CCCD1B -0,63 0,28 Kinesin-like protein KIFC1 KIFC1 </td <td></td> <td>FKBP5</td> <td>-0,65</td> <td>0,12</td>		FKBP5	-0,65	0,12
Actin-related protein 2/3 complex subunit 2 ARPC2 -0,65 0,02 Basic leucine zipper and W2 domain-containing protein 1 BZW1 -0,64 0,15 Enoyl-CoA hydratase 2 HSD17B4 -0,64 0,15 GPI transamidase component PIG-T PIGT -0,64 0,11 NAD(P)H dehydrogenase [quinone] 1 NQ01 -0,64 0,25 Z6S proteasome non-ATPase regulatory subunit 5 PSMD5 -0,64 0,25 GOS ribosomal protein L36a-like RPL36AL -0,64 0,25 GS ribosomal protein NOB1 NOB1 -0,64 0,25 GG reduction in NOB1 NOB1 -0,64 0,25 GG reduction in Subunit alpha-1 CAPZA1 -0,64 0,25 Petidyl-prolyl cis-trans isomerase B PPIB -0,64 0,10 Petidyl-prolyl cis-trans isomerase B PPIB -0,64 0,11 Zinc finger CCHC domain-containing protein 3 ZCCHC3 -0,64 0,11 GD reduct-coil and C2 domain-containing protein 3 CCCD1B -0,63 0,28 Kinesin-like protein KIFC1 KIFC1 </td <td>Condensin-2 complex subunit G2</td> <td>NCAPG2</td> <td>-0,65</td> <td>0,15</td>	Condensin-2 complex subunit G2	NCAPG2	-0,65	0,15
Basic leucine zipper and W2 domain-containing protein 1 BZW1 -0,64 0,15 Enoyl-CoA hydratase 2 HSD17B4 -0,64 0,15 GPI transmidase component PIG-T PIGT -0,64 0,15 NAD(P)H dehydrogenase [quinone] 1 NQ01 -0,64 0,11 Zinc finger protein 217 ZNF217 -0,64 0,22 265 proteasome non-ATPase regulatory subunit 5 PSMD5 -0,64 0,22 605 ribosomal protein 136a-like RPL36AL -0,64 0,22 ARNA-binding protein NOB1 NOB1 -0,64 0,54 Pretidy-prolyl cis-trans isomerase B PPIB -0,64 0,11 Zinc finger CCHC domain-containing protein 3 ZCCHC3 -0,64 0,11 Zinc finger CCHC domain-containing protein 3 CCCD1B -0,64 0,11 Coiled-coil and C2 domain-containing protein 3B CCCD1B -0,63 0,28 Kinesin-like protein KIFC1 KIFC1 -0,63 0,29				
Enoyl-CoA hydratase 2 HSD17B4 -0,64 0,15 GP1 transamidase component PIG-T PIGT -0,64 0,15 NAD(P)H dehydrogenase [quinone] 1 NQO1 -0,64 0,15 Zinc finger protein 217 ZNF217 -0,64 0,25 GOS ribosomal protein 136-like RPI36AL -0,64 0,22 GOS ribosomal protein 136-like RPI36AL -0,64 0,53 RNA-binding protein NOB1 NOB1 -0,64 0,53 F-actin-capping protein subunit alpha-1 CAPZA1 -0,64 0,10 Peptidyl-prolyl cis-trans isomerase B PPIB -0,64 0,11 Zinc finger CCHC domain-containing protein 3 ZCCHC33 -0,64 0,11 Zinc finger CCHC domain-containing protein 3 CC2D1B -0,63 0,28 Kinesin-like protein KIFC1 KIFC1 -0,63 0,29				
GPI transanidase component PIG-T PIGT -0,64 0,15 NAD(P)H dehydrogenase [quinone] 1 NQO1 -0,64 0,11 Zinc finger protein 217 ZNF217 -0,64 0,22 Z6S proteasome non-ATPase regulatory subuit 5 PSMD5 -0,64 0,22 GOS ribosomal protein L36a-like RPI36AL -0,64 0,53 RNA-binding protein NOB1 NOB1 -0,64 0,10 Pettidyl-prolyl cis-trans isomerase B PPIB -0,64 0,11 Zinc finger CCHC domain-containing protein 3 ZCCHC3 -0,64 0,11 Coiled-coil and C2 domain-containing protein 1B CC2D1B -0,63 0,22 Kinesin-like protein KIFC1 KIFC1 -0,63 0,29				
GPI transamidase component PIG-T PIGT -0,64 0,15 NAD(P)H dehydrogenase [quinone] 1 NQ01 -0,64 0,11 Zinc finger protein 217 ZNF217 -0,64 0,25 265 proteasome non-ATPase regulatory subuit 5 PSMD5 -0,64 0,22 605 ribosomal protein 136a-like RPI36AL -0,64 0,53 RNA-binding protein NOB1 NOB1 -0,64 0,10 Petidyl-prolyl cis-trans isomerase B PPIB -0,64 0,10 Zinc finger CCHC domain-containing protein 3 ZCCHC3 -0,64 0,08 Coiled-coil and C2 domain-containing protein 1B CC2D1B -0,63 0,28 Kinesin-like protein KIFC1 KIFC1 -0,63 0,29	Enoyl-CoA hydratase 2	HSD17B4	-0,64	0,15
NAD(P)H dehydrogenase [quinone] 1 NQ01 -0,64 0,11 Zinc finger protein 217 ZNF217 -0,64 0,25 265 proteasome non-ATPase regulatory subunit 5 PSMD5 -0,64 0,25 605 ribosomal protein L36a-like RPL36AL -0,64 0,23 RNA-binding protein NOB1 NOB1 -0,64 0,10 F-actin-capping protein subunit alpha-1 CAPZA1 -0,64 0,11 Petidyl-prolyl cis-trans isomerase B PPIB -0,64 0,11 Zinc finger CCHC domain-containing protein 3 ZCCHC3 -0,63 0,28 Coiled-coil and C2 domain-containing protein 1B CC2D1B -0,63 0,28 Kinesin-like protein KIFC1 KIFC1 -0,63 0,29	GPI transamidase component PIG-T			
Zinc finger protein 217 ZNF217 -0,64 0,25 265 proteasome non-ATPase regulatory subunit 5 PSMD5 -0,64 0,22 605 ribosomal protein L36a-like RPL36AL -0,64 0,22 MA-binding protein NOB1 NOB1 -0,64 0,54 F-actin-capping protein subunit alpha-1 CAPZA1 -0,64 0,10 Petptidyl-prolyl cis-trans isomerase B PPIB -0,64 0,11 Zinc finger CCHC domain-containing protein 3 ZCCCHC3 -0,63 0,28 Coiled-coil and C2 domain-containing protein 1B CC2D1B -0,63 0,29 Kinesin-like protein KIFC1 KIFC1 -0,63 0,29				
265 proteasome non-ATPase regulatory subunit 5 PSMD5 -0,64 0,22 605 ribosomal protein L36a-like RPL36AL -0,64 0,53 RNA-binding protein NOB1 NOB1 -0,64 0,10 F-actin-capping protein subunit alpha-1 CAPZA1 -0,64 0,11 Peptidyl-prolyl cis-trans isomerase B PPIB -0,64 0,01 Zinc finger CCHC domain-containing protein 3 ZCCHC3 -0,64 0,08 Coiled-coil and C2 domain-containing protein 1B CC2D1B -0,63 0,28 Kinesin-like protein KIFC1 KIFC1 -0,63 0,29				
60S ribosomal protein L36a-likeRPL36AL-0,640,53RNA-binding protein NOB1NOB1-0,64N.D.F-actin-capping protein subunit alpha-1CAP2A1-0,640,10Peptidyl-prolyl cis-trans isomerase BPPIB-0,640,08Zinc finger CCHC domain-containing protein 3ZCCHC3-0,640,08Coiled-coil and C2 domain-containing protein 1BCC2D1B-0,630,28Kinesin-like protein KIFC1KIFC1-0,630,29	Zinc finger protein 217	ZNF217	-0,64	0,25
60S ribosomal protein L36a-likeRPL36AL-0,640,53RNA-binding protein NOB1NOB1-0,64N.D.F-actin-capping protein subunit alpha-1CAP2A1-0,640,10Peptidyl-prolyl cis-trans isomerase BPPIB-0,640,08Zinc finger CCHC domain-containing protein 3ZCCHC3-0,640,08Coiled-coil and C2 domain-containing protein 1BCC2D1B-0,630,28Kinesin-like protein KIFC1KIFC1-0,630,29	26S proteasome non-ATPase regulatory subunit 5	PSMD5	-0,64	0,22
RNA-binding protein NOB1-0,64N.D.F-actin-capping protein subunit alpha-1CAPZA1-0,640,10Peptidyl-prolyl cis-trans isomerase BPPIB-0,640,11Zinc finger CCHC domain-containing protein 3ZCCHC3-0,640,08Coiled-coil and C2 domain-containing protein 1BCC2D1B-0,630,28Kinesin-like protein KIFC1KIFC1-0,630,29				
F-actin-capping protein subunit alpha-1 CAPZA1 -0,64 0,10 Peptidyl-protyl cis-trans isomerase B PPIB -0,64 0,11 Zinc finger CCHC domain-containing protein 3 ZCCHC3 -0,64 0,08 Coiled-coil and C2 domain-containing protein 1B CC2D1B -0,63 0,28 Kinesin-like protein KIFC1 KIFC1 -0,63 0,29				
Peptidyl-prolyl cis-trans isomerase B PPIB -0,64 0,11 Zinc finger CCHC domain-containing protein 3 ZCCHC3 -0,64 0,08 Coiled-coil and C2 domain-containing protein 1B CC2D1B -0,63 0,28 Kinesin-like protein KIFC1 KIFC1 -0,63 0,29		NOB1	-0,64	N.D.
Peptidyl-prolyl cis-trans isomerase B PPIB -0,64 0,11 Zinc finger CCHC domain-containing protein 3 ZCCHC3 -0,64 0,08 Coiled-coil and C2 domain-containing protein 1B CC2D1B -0,63 0,28 Kinesin-like protein KIFC1 KIFC1 -0,63 0,29	F-actin-capping protein subunit alpha-1	CAPZA1	-0,64	0,10
Zinc finger CCHC domain-containing protein 3 ZCCHC3 -0,64 0,08 Coiled-coil and C2 domain-containing protein 1B CC2D1B -0,63 0,28 Kinesin-like protein KIFC1 KIFC1 -0,63 0,29				
Coiled-coil and C2 domain-containing protein 1B CC2D1B -0,63 0,28 Kinesin-like protein KIFC1 KIFC1 -0,63 0,29				
Kinesin-like protein KIFC1 KIFC1 -0,63 0,29				
	Kinesin-like protein KIFC1	KIFC1	-0,63	0,29

ER degradation-enhancing alpha-mannosidase-like protein 3	EDEM3	-0,63	0,61
Proteasome activator complex subunit 3	PSME3	-0,63	0,05
Plexin-A1	PLXNA1	-0,63	0,22
Dual specificity protein phosphatase 3	DUSP3	-0,62	0,07
Phosphomevalonate kinase	PMVK	-0,62	0,05
Heterogeneous nuclear ribonucleoprotein U-like protein 2	HNRNPUL2	-0,62	0,21
60S ribosomal protein L35a	RPL35A	-0,62	0,11
Transformer-2 protein homolog alpha	TRA2A	-0,62	0,77
Plastin-2	LCP1	-0,62	0,05
Inositol 1,4,5-trisphosphate receptor type 1	ITPR1	-0,62	0,16
Heat shock 70 kDa protein 14	HSPA14	-0,62	0,89
40S ribosomal protein S24	RPS24	-0,62	0,42
Antigen peptide transporter 1	TAP1	-0,62	0,13
Torsin-1A-interacting protein 1	TOR1AIP1	-0,62	0,11
Heterogeneous nuclear ribonucleoproteins C1/C2	HNRNPC	-0,62	0,35
Decaprenyl-diphosphate synthase subunit 2	PDSS2	-0,62	0,14
E3 ubiquitin-protein ligase MYCBP2	MYCBP2	-0,62	0,21
DENN domain-containing protein 3	DENND3	-0,61	0,19
Transgelin-2	TAGLN2	-0,61	0,13
Interferon regulatory factor 2-binding protein 2	IRF2BP2	-0,61	0,10
Atlastin-3	ATL3	-0,61	0,09
Leucine-rich repeat and calponin homology domain-containing protein 4	LRCH4	-0,61	N.D.
Ubiquitin-protein ligase E3C	UBE3C	-0,61	N.D.
FH1/FH2 domain-containing protein 1	FHOD1	-0,61	N.D.
Myotubularin-related protein 14	MTMR14	-0,61	0,44
Wings apart-like protein homolog	WAPAL	-0,61	N.D.
Heterochromatin protein 1-binding protein 3	HP1BP3	-0,61	0,17
Probable global transcription activator SNF2L2	SMARCA2	-0,61	0,37
Tyrosine-protein kinase CSK	CSK	-0,61	0,11
Mitogen-activated protein kinase 3	МАРКЗ	-0,61	0,16
Actin-related protein 2/3 complex subunit 5	ARPC5	-0,60	N.D.
Syntaxin-binding protein 2	STXBP2	-0,60	0,08
U1 small nuclear ribonucleoprotein C	SNRPC	-0,60	0,09
E3 ubiquitin-protein ligase RBX1	RBX1	-0,60	0,42
Protein-L-isoaspartate(D-aspartate) O-methyltransferase	PCMT1	-0,60	0,06
Charged multivesicular body protein 4a	CHMP4A	-0,60	0,04
Fructose-bisphosphate aldolase C	ALDOC	-0,59	0,55
Homer protein homolog 3	HOMER3	-0,59	0,11
60S ribosomal protein L3	RPL3	-0,59	0,20
60S acidic ribosomal protein P2	RPLP2	-0,59	0,18
GlutaminetRNA ligase	QARS	-0,59	0.07
Nardilysin	NRD1	-0,59	0,20
Calcineurin B homologous protein 1	CHP1	-0,59	N.D.

Table 6. Downregulated proteins in THP-1 Dox compared to THP-1 P cells under normoxia. Proteomic profiling (SILAC) data were used. Significantly downregulated proteins were calculated using the fold difference threshold of 0.7 (log₂ fold change=-0.58). Mean±SD for n=2 replicates. Non-detected (N.D.) means less than 2 replicates detected for one protein measured.

	AraC VS. HL-60 P		1
Protein names	Gene names	Mean Log ₂ fold change	
N-acetylserotonin O-methyltransferase-like protein	ASMTL	3.71	0.02
Vimentin	VIM	3.10	0.12
Annexin A1	ANXA1	2.73	0.03
Hydroxymethylglutaryl-CoA synthase, cytoplasmic	HMGCS1	2.55	0.01
Histone H1.5 Neutrophil defensin 3	HIST1H1B DEFA3;DEFA1	2.53	N.D. 0.04
Alpha-2-macroglobulin receptor-associated protein	LRPAP1	2.34	0.04
Fatty acid desaturase 2	FADS2	2.18	0.03
UDP-N-acetylhexosamine pyrophosphorylase	UAP1	2.10	0.09
Neuroblast differentiation-associated protein AHNAK	AHNAK	2.13	0.12
Zinc finger CCCH-type antiviral protein 1-like	ZC3HAV1L	2.10	0.06
Sepiapterin reductase	SPR	2.02	0.13
RNA polymerase II-associated protein 1	RPAP1	1.93	0.23
Dynein assembly factor 5, axonemal	DNAAF5	1.92	0.67
Fatty acid desaturase 1	FADS1	1.91	0.38
Tumor suppressor p53-binding protein 1	TP53BP1	1.89	0.07
Coiled-coil-helix domain-containing protein 2, mitochondrial	CHCHD2;CHCHD2P9	1.88	0.05
5-nucleotidase domain-containing protein 1	NT5DC1	1.87	0.00
Dihydropteridine reductase	QDPR	1.85	0.03
Protein FAM198B	FAM198B	1.84	0.42
Azurocidin	AZU1	1.79	1.93
Histone H2AX	H2AFX;HIST1H2AA	1.78	0.05
Transmembrane protein 33	TMEM33	1.77	0.02
Cytosol aminopeptidase	LAP3	1.76	0.03
Phosphoglucomutase-1	PGM1	1.76	0.21
Transforming acidic coiled-coil-containing protein 3	TACC3	1.74	0.13
7-dehydrocholesterol reductase	DHCR7	1.72	0.11
Omega-amidase NIT2	NIT2	1.72	0.08
Transmembrane protein 128	TMEM128	1.70	0.14
Hematopoietic lineage cell-specific protein	HCLS1	1.68	0.04
Cytoplasmic FMR1-interacting protein 1 Very long-chain acyl-CoA synthetase	CYFIP1 SLC27A2	1.67	0.13
Histone RNA hairpin-binding protein	SLC27A2	1.67	0.03 N.D.
DNA topoisomerase 2-alpha	TOP2A	1.66	N.D.
Tricarboxylate transport protein, mitochondrial	SLC25A1	1.65	0.06
FAD-AMP lyase (cyclizing)	DAK	1.65	0.08
Huntingtin	HTT	1.64	0.03
Ras-related protein Rab-18	RAB18	1.63	0.05
Phosphoglucomutase-2	PGM2	1.61	0.02
Gelsolin	GSN	1.60	0.09
Thymidine kinase, cytosolic	TK1	1.60	0.13
Alpha-adducin	ADD1	1.58	0.12
Transferrin receptor protein 1	TFRC	1.57	0.13
WD repeat-containing protein 1	WDR1	1.55	0.03
Procollagen-lysine,2-oxoglutarate 5-dioxygenase 1	PLOD1	1.54	0.96
C-type lectin domain family 11 member A	CLEC11A	1.54	0.23
Epididymis-specific alpha-mannosidase	MAN2B2	1.53	0.08
Replication factor C subunit 1	RFC1	1.52	0.58
2,4-dienoyl-CoA reductase, mitochondrial	DECR1	1.52	0.11
Bone marrow proteoglycan; Eosinophil granule major basic protein	PRG2	1.52	0.16
Carbonyl reductase [NADPH] 1	CBR1	1.51	0.08
Deoxyuridine 5-triphosphate nucleotidohydrolase, mitochondrial	DUT	1.51	0.03
Helicase-like transcription factor	HLTF	1.51	N.D.
Acetyl-CoA acetyltransferase, cytosolic	ACAT2	1.50	0.03
Nck-associated protein 1-like	NCKAP1L	1.49	0.07
Cytochrome c oxidase copper chaperone	COX17	1.49	N.D.
Small integral membrane protein 20	SMIM20	1.46	N.D.
Cystatin-A; Cystatin-A, N-terminally processed	CSTA BCSD1	1.45	0.03
CapZ-interacting protein	RCSD1	1.44	N.D.
Kinetochore protein Nuf2	NUF2	1.42	N.D.
Zinc transporter ZIP14	SLC39A14	1.41	N.D.
Mevalonate kinase	MVK ARCC1	1.40	N.D.
Multidrug resistance-associated protein 1 Ubiquitin-conjugating enzyme E2 K	ABCC1 UBE2K	1.39	0.33
Oxygen-dependent coproporphyrinogen-III oxidase, mitochondrial	CPOX	1.38	0.08
Giyoxylate reductase/hydroxypyruvate reductase	GRHPR	1.37	0.02
Protein disulfide-isomerase A5	PDIA5	1.37	0.09
Protein IMPACT	IMPACT	1.37	0.07
Squalene synthase	FDFT1	1.36	0.07
Transformer-2 protein homolog alpha	TRA2A	1.36	N.D.
Sjoegren syndrome/scleroderma autoantigen 1	SSSCA1	1.36	0.07
Heterogeneous nuclear ribonucleoprotein U-like protein 2	HNRNPUL2	1.35	0.08
Ubiquitin carboxyl-terminal hydrolase 8	USP8	1.35	0.00
Niemann-Pick C1 protein	NPC1	1.35	0.19
1,4-alpha-glucan-branching enzyme	GBE1	1.34	0.13
Aminoacylase-1	ACY1	1.34	0.13
DnaJ homolog subfamily C member 17	DNAJC17	1.34	0.05
Ubiquitin-like protein 5	UBL5	1.33	0.11
Serine/threonine-protein kinase N1	PKN1	1.33	0.12

Protein FAM98B NEDD8-activating enzyme E1 catalytic subunit	FAM98B UBA3	1,29 1,27	0,12 0,04
OCIA domain-containing protein 1	OCIAD1	1,27	0,04
Cold-inducible RNA-binding protein	CIRBP	1,27	0,05
UDP-glucose 6-dehydrogenase	UGDH	1,27	0,12
UDP-N-acetylglucosaminepeptide N-acetylglucosaminyltransferase	OGT	1,26	0,16
DnaJ homolog subfamily C member 13	DNAJC13	1,25	0,16
Phosphatidylinositol 3,4,5-trisphosphate 5-phosphatase 2	INPPL1	1,25	0,03
LETM1 and EF-hand domain-containing protein 1, mitochondrial	LETM1	1,25	0,12
Derlin-3	DERL3	1,23	0,07
Sulfide:quinone oxidoreductase, mitochondrial Golgin subfamily B member 1	SQRDL GOLGB1	1,23	0,24 0,08
Importin subunit alpha-1	KPNA2	1,23	0,08
Heterogeneous nuclear ribonucleoprotein A3	HNRNPA3	1,22	0,01
Heterogeneous nuclear ribonucleoprotein D-like	HNRNPDL	1,21	0,20
DDB1- and CUL4-associated factor 16	DCAF16	1,20	0,04
RuvB-like 2	RUVBL2	1,19	0,05
Uridine 5-monophosphate synthase	UMPS	1,18	0,05
NEDD8-activating enzyme E1 regulatory subunit	NAE1	1,17	0,05
Heterogeneous nuclear ribonucleoproteins A2/B1	HNRNPA2B1	1,17	0,01
Kinetochore protein Spc24	SPC24	1,17	0,06
CGG triplet repeat-binding protein 1	CGGBP1	1,16	N.D.
Thymidylate synthase Cysteine and histidine-rich domain-containing protein 1	TYMS CHORDC1	1,16	0,03
Isopentenyl-diphosphate Delta-isomerase 1	IDI1	1,15	0,01
Protein furry homolog-like	FRYL	1,13	0,00
Alpha-mannosidase 2C1	MAN2C1	1,15	0,23 N.D.
Dipeptidyl peptidase 3	DPP3	1,11	0,07
Intraflagellar transport protein 25 homolog	HSPB11	1,11	N.D.
Serglycin	SRGN	1,11	N.D.
Equilibrative nucleoside transporter 2	SLC29A2	1,11	0,26
Serine/threonine-protein phosphatase 4 regulatory subunit 3B	SMEK2	1,11	N.D.
Constitutive coactivator of peroxisome proliferator-activated receptor gamma	FAM120B	1,10	N.D.
Leupaxin	LPXN	1,10	N.D.
Alpha-mannosidase 2	MAN2A1	1,09	0,26
Beta-glucuronidase	GUSB	1,09	0,17
Fascin	FSCN1	1,09	0,01
Histone chaperone ASF1B	ASF1B	1,09	N.D.
Oxysterol-binding protein-related protein 9	OSBPL9 CMAS	1,08 1,08	N.D.
N-acylneuraminate cytidylyltransferase Centromere protein F	CENPF	1,08	N.D. N.D.
Heterogeneous nuclear ribonucleoprotein H3	HNRNPH3	1,00	0,12
Acetyl-CoA acetyltransferase, mitochondrial	ACAT1	1,06	0,04
Eukaryotic translation initiation factor 2A	EIF2A	1,05	0,12
Peroxisomal acyl-coenzyme A oxidase 3	ACOX3	1,05	0,29
Serine/arginine-rich splicing factor 9	SRSF9	1,05	0,09
Ubiquitin-conjugating enzyme E2 S	UBE2S	1,04	N.D.
Tetratricopeptide repeat protein 9C	TTC9C	1,03	0,06
Cyclin-dependent kinase 1	CDK1	1,02	0,04
Radixin	RDX	1,02	0,26
Protein phosphatase 1 regulatory subunit 12A	PPP1R12A	1,02	N.D.
Succinyl-CoA ligase [GDP-forming] subunit beta, mitochondrial	SUCLG2	1,02	0,02
Retinoid-inducible serine carboxypeptidase Apoptosis regulator Bcl-2	SCPEP1 BCL2	1,02	0,07 0,08
Probable dolichyl pyrophosphate alpha-1,3-glucosyltransferase	ALG8	1,02	0,08
Transmembrane protein 126A	TMEM126A	1,01	0,08
Glutamatecysteine ligase regulatory subunit	GCLM	1,00	0,05 N.D.
Signal recognition particle 14 kDa protein	SRP14	1,00	0,12
Protein disulfide-isomerase A3	PDIA3	0,99	0,01
Vacuolar protein sorting-associated protein 51 homolog	VPS51	0,99	0,49
Vinculin	VCL	0,99	0,05
Porphobilinogen deaminase	HMBS	0,99	0,09
Sorbitol dehydrogenase	SORD	0,99	0,08
V-type proton ATPase subunit C 1	ATP6V1C1	0,99	0,11
Transmembrane protein 189	TMEM189	0,99	N.D.
Translation initiation factor eIF-2B subunit beta	EIF2B2	0,99	0,01
Farnesyl pyrophosphate synthase	FDPS	0,98	0,01
Trans-3-hydroxy-L-proline dehydratase Ribonuclease P protein subunit p40	L3HYPDH RPP40	0,98	N.D. N.D.
Ribonuclease UK114	HRSP12	0,98	0,12
Coiled-coil domain-containing protein 58	CCDC58	0,97	0,12
Girdin	CCDC88A	0,96	0,16
Protein FAM162A	FAM162A	0,95	0,09
Heterogeneous nuclear ribonucleoprotein A0	HNRNPAO	0,95	0,03
Biorientation of chromosomes in cell division protein 1-like 1	BOD1L1	0,95	0,02
Cob(I)yrinic acid a,c-diamide adenosyltransferase, mitochondrial	MMAB	0,95	0,19
Serine-protein kinase ATM	ATM	0,95	0,04
Transformer-2 protein homolog beta	TRA2B	0,95	0,06
E3 ubiquitin-protein ligase CHIP Carbonic anhydrase 2	STUB1 CA2	0,95 0,94	0,11 0,07

Protein S100-A4	\$100A4	0,94	0,17
Cystatin-F	CST7	0,94	0,18
GPI ethanolamine phosphate transferase 2	PIGG	0,94	0,08
cAMP-dependent protein kinase catalytic subunit beta	PRKACB	0,94	0,14
Lymphokine-activated killer T-cell-originated protein kinase	PBK	0,94	N.D.
AH receptor-interacting protein	AIP	0,94	0,05
Transcription termination factor 2	TTF2	0,93	0,07
Delta(3,5)-Delta(2,4)-dienoyl-CoA isomerase, mitochondrial	ECH1	0,93	0,09
182 kDa tankyrase-1-binding protein	TNKS1BP1	0,93	0,03
Heterogeneous nuclear ribonucleoproteins C1/C2	HNRNPC	0,93	0,09
RNA pseudouridylate synthase domain-containing protein 2	RPUSD2	0,92	0,41
Beta-2-microglobulin;Beta-2-microglobulin form pl 5.3	B2M	0,92	0,02
Xaa-Pro dipeptidase	PEPD	0,92	0,02
Peptidyl-prolyl cis-trans isomerase FKBP2	FKBP2	0,92	0,03
Translation initiation factor eIF-2B subunit delta	EIF2B4	0,92	0,05
Sister chromatid cohesion protein PDS5 homolog A	PDS5A	0,92	0,02
Ena/VASP-like protein	EVL	0,92	0,22
Signal recognition particle 9 kDa protein	SRP9	0,91	0,03
Prolyl 4-hydroxylase subunit alpha-1	P4HA1	0,91	0,09
Receptor-type tyrosine-protein phosphatase C	PTPRC	0,91	0,10
FH1/FH2 domain-containing protein 1	FHOD1	0,90	0,58
ELAV-like protein 1	ELAVL1	0,90	0,09
Zinc finger HIT domain-containing protein 2	ZNHIT2	0,89	N.D.
Receptor-type tyrosine-protein phosphatase alpha	PTPRA	0,89	N.D.
Apoptotic chromatin condensation inducer in the nucleus	ACIN1	0,89	0,07
N-acetyltransferase 14	NAT14	0,88	0,26
Acyl-CoA desaturase	SCD	0,88	0,03
V-type proton ATPase catalytic subunit A	ATP6V1A	0,88	0,04
Prolyl 3-hydroxylase 1	LEPRE1	0,88	0,07
Mitochondrial import inner membrane translocase subunit Tim8 B	TIMM8B	0,87	0,07
Interferon-inducible double-stranded RNA-dependent protein kinase activator A	PRKRA	0,87	N.D.
Mycophenolic acid acyl-glucuronide esterase, mitochondrial			
, , , , , , , , , , , , , , , , , , , ,	ABHD10	0,87	0,09
DNA polymerase alpha subunit B	POLA2	0,87	N.D.
V-type proton ATPase subunit B, brain isoform	ATP6V1B2	0,87	0,22
Armadillo repeat-containing protein 8	ARMC8	0,87	0,14
Protein TFG	TFG	0,86	0,08
Small integral membrane protein 12	SMIM12	0,86	0,18
Glycogen [starch] synthase, muscle	GYS1	0,86	0,09
Proteasome subunit beta type-5	PSMB5	0,86	0,06
WD repeat-containing protein 74	WDR74	0,85	N.D.
Cofilin-1	CFL1	0,85	0,03
Protein phosphatase methylesterase 1	PPME1	0,85	0,10
Chromosome-associated kinesin KIF4A	KIF4A	0,85	0,10
Oligoribonuclease, mitochondrial	REXO2	0,85	0,12
ADP-ribosylation factor-like protein 6-interacting protein 1	ARL6IP1	0,84	0,04
Calpain small subunit 1	CAPNS1	0,84	0,04
Phosphoinositide 3-kinase regulatory subunit 4	PIK3R4	0,84	0,11
Heterogeneous nuclear ribonucleoprotein A1	HNRNPA1;HNRNPA1L2	0,83	0,11
	FANCI		
Fanconi anemia group I protein		0,83	0,17
Ubiquitin thioesterase OTUB1	OTUB1	0,83	0,06
Cartilage-associated protein	CRTAP	0,83	0,18
FACT complex subunit SSRP1	SSRP1	0,83	0,04
C-terminal-binding protein 1	CTBP1	0,83	0,07
Acyl-CoA dehydrogenase family member 9, mitochondrial	ACAD9	0,83	0,16
Protein CMSS1	CMSS1	0,82	0,03
Ethanolamine-phosphate cytidylyltransferase	PCYT2	0,82	0.05
	-	•	.,
Chromosome transmission fidelity protein 8 homolog	CHTF8	0,81	0,07
Phosphatidylinositol-binding clathrin assembly protein	PICALM	0,81	N.D.
Serine/arginine-rich splicing factor 10	SRSF10	0,81	0,26
Intron-binding protein aquarius	AQR	0,80	0,09
	C14orf1	0,80	N.D.
Probable ergosterol biosynthetic protein 28		0,80	0,06
	ATOX1	0,80	0,06
Probable ergosterol biosynthetic protein 28 Copper transport protein ATOX1	ATOX1		0,00
Probable ergosterol biosynthetic protein 28 Copper transport protein ATOX1 Proteasomal ATPase-associated factor 1	ATOX1 PAAF1		
Probable ergosterol biosynthetic protein 28 Copper transport protein ATOX1 Proteasomal ATPase-associated factor 1 PRA1 family protein 3	ATOX1 PAAF1 ARL6IP5	0,80	
Probable ergosterol biosynthetic protein 28 Copper transport protein ATOX1 Proteasomal ATPase-associated factor 1 PRAI family protein 3 ATP-binding cassette sub-family D member 2	ATOX1 PAAF1 ARL6IP5 ABCD2	0,80 0,80	N.D.
Probable ergosterol biosynthetic protein 28 Copper transport protein ATOX1 Proteasomal ATPase-associated factor 1 PRA1 family protein 3 ATP-binding cassette sub-family D member 2 Lysophospholipid acyltransferase 5	ATOX1 PAAF1 ARL6IP5 ABCD2 LPCAT3	0,80 0,80 0,80	N.D. 0,06
Probable ergosterol biosynthetic protein 28 Copper transport protein ATOX1 Proteasomal ATPase-associated factor 1 PRA1 family protein 3 ATP-binding cassette sub-family D member 2 Lysophospholipid acyltransferase 5 Ribonuclease P protein subunit p14	ATOX1 PAAF1 ARL6IP5 ABCD2 LPCAT3 RPP14	0,80 0,80 0,80 0,79	N.D. 0,06 0,12
Probable ergosterol biosynthetic protein 28 Copper transport protein ATOX1 Proteasomal ATPase-associated factor 1 PRA1 family protein 3 ATP-binding cassette sub-family D member 2 Lysophospholipid acyltransferase 5 Ribonuclease P protein subunit p14 Sterol O-acyltransferase 1	ATOX1 PAAF1 ARL6IP5 ABCD2 LPCAT3	0,80 0,80 0,80 0,79 0,79	N.D. 0,06 0,12 N.D.
Probable ergosterol biosynthetic protein 28 Copper transport protein ATOX1 Proteasomal ATPase-associated factor 1 PRA1 family protein 3 ATP-binding cassette sub-family D member 2 Lysophospholipid acyltransferase 5 Ribonuclease P protein subunit p14	ATOX1 PAAF1 ARL6IP5 ABCD2 LPCAT3 RPP14	0,80 0,80 0,80 0,79	N.D. 0,06 0,12
Probable ergosterol biosynthetic protein 28 Copper transport protein ATOX1 Proteasomal ATPase-associated factor 1 PRA1 family protein 3 ATP-binding cassette sub-family D member 2 Lysophospholipid acyltransferase 5 Ribonuclease P protein subunit p14 Sterol O-acyltransferase 1	ATOX1 PAAF1 ARL6IP5 ABCD2 LPCAT3 RPP14 SOAT1	0,80 0,80 0,80 0,79 0,79	N.D. 0,06 0,12 N.D.
Probable ergosterol biosynthetic protein 28 Copper transport protein ATOX1 Proteasomal ATPase-associated factor 1 PRA1 family protein 3 ATP-binding cassette sub-family D member 2 Lysophospholipid acyltransferase 5 Ribonuclease P protein subunit p14 Sterol O-acyltransferase 1 Ubiquitin conjugation factor E4 A Destrin	ATOX1 PAAF1 ARL6IP5 ABCD2 LPCAT3 RPP14 SOAT1 UBE4A DSTN	0,80 0,80 0,80 0,79 0,79 0,79 0,79	N.D. 0,06 0,12 N.D. 0,12 0,02
Probable ergosterol biosynthetic protein 28 Copper transport protein ATOX1 Proteasomal ATPase-associated factor 1 PRA1 family protein 3 ATP-binding cassette sub-family D member 2 Lysophospholipid acyltransferase 5 Ribonuclease P protein subunit p14 Sterol O-acyltransferase 1 Ubiquitin conjugation factor E4 A Destrin Ras-related protein Rab-88	ATOX1 PAAF1 ARL6IP5 ABCD2 LPCAT3 RPP14 SOAT1 UBE4A DSTN RAB8B	0,80 0,80 0,79 0,79 0,79 0,79 0,79 0,79	N.D. 0,06 0,12 N.D. 0,12 0,02 0,26
Probable ergosterol biosynthetic protein 28 Copper transport protein ATOX1 Proteasomal ATPase-associated factor 1 PRA1 family protein 3 ATP-binding cassette sub-family D member 2 Lysophospholipid acyltransferase 5 Ribonuclease P protein subunit p14 Sterol O-acyltransferase 1 Ubiquitin conjugation factor E4 A Destrin Ras-related protein Rab-8B Cullin-4A	ATOX1 PAAF1 ARL6IP5 ABCD2 LPCAT3 RPP14 SOAT1 UBE4A DSTN RAB8B CUL4A	0,80 0,80 0,79 0,79 0,79 0,79 0,79 0,79 0,79	N.D. 0,06 0,12 N.D. 0,12 0,02 0,26 0,10
Probable ergosterol biosynthetic protein 28 Copper transport protein ATOX1 Proteasomal ATPase-associated factor 1 PRA1 family protein 3 ATP-binding cassette sub-family D member 2 Lysophospholipid acyltransferase 5 Ribonuclease P protein subunit p14 Sterol O-acyltransferase 1 Ubiquitin conjugation factor E4 A Destrin Ras-related protein Rab-8B Cullin-4A V-type proton ATPase subunit H	ATOX1 PAAF1 ARL6IP5 ABCD2 LPCAT3 RPP14 SOAT1 UBE4A DSTN RAB8B CUL4A ATP6V1H	0,80 0,80 0,80 0,79 0,79 0,79 0,79 0,79 0,79 0,78 0,78	N.D. 0,06 0,12 N.D. 0,12 0,02 0,26 0,10 0,09
Probable ergosterol biosynthetic protein 28 Copper transport protein ATOX1 Proteasomal ATPase-associated factor 1 PRA1 family protein 3 ATP-binding cassette sub-family D member 2 Lysophospholipid acyltransferase 5 Ribonuclease P protein subunit p14 Sterol O-acyltransferase 1 Ubiquitin conjugation factor E4 A Destrin Ras-related protein Rab-8B Cullin-4A V-type proton ATPase subunit H Gamma-glutamyl hydrolase	ATOX1 PAAF1 ARL6IP5 ABCD2 LPCAT3 RPP14 SOAT1 UBE4A DSTN RAB8B CUL4A ATP6V1H GGH	0,80 0,80 0,79 0,79 0,79 0,79 0,79 0,79 0,79 0,7	N.D. 0,06 0,12 N.D. 0,02 0,26 0,10 0,09 0,09
Probable ergosterol biosynthetic protein 28 Copper transport protein ATOX1 Proteasomal ATPase-associated factor 1 PRA1 family protein 3 ATP-binding cassette sub-family D member 2 Lysophospholipid acyltransferase 5 Ribonuclease P protein subunit p14 Sterol O-acyltransferase 1 Ubiquitin conjugation factor E4 A Destrin Ras-related protein Rab-88 Cullin-4A V-type proton ATPase subunit H Gamma-glutamyl hydrolase Transmembrane 9 superfamily member 1	ATOX1 PAAF1 ARL6IP5 ABCD2 LPCAT3 RPP14 SOAT1 UBE4A DSTN RAB8B CUL4A ATP6V1H GGH TM9SF1	0,80 0,80 0,79 0,79 0,79 0,79 0,79 0,79 0,78 0,78 0,78	N.D. 0,06 0,12 N.D. 0,12 0,02 0,26 0,10 0,09 0,09 0,04
Probable ergosterol biosynthetic protein 28 Copper transport protein ATOX1 Proteasomal ATPase-associated factor 1 PRA1 family protein 3 ATP-binding cassette sub-family D member 2 Lysophospholipid acyltransferase 5 Ribonuclease P protein subunit p14 Sterol O-acyltransferase 1 Ubiquitin conjugation factor E4 A Destrin Ras-related protein Rab-88 Cullin-4A V-type proton ATPase subunit H Gamma-glutamyl hydrolase Transmerbrane 9 superfamily member 1 Pre-mRNA-splicing factor 38A	ATOX1 PAAF1 ARL6IP5 ABCD2 LPCAT3 RPP14 SOAT1 UBE4A DSTN RAB8B CUL4A ATP6V1H GGH	0,80 0,80 0,79 0,79 0,79 0,79 0,79 0,79 0,79 0,7	N.D. 0,06 0,12 N.D. 0,02 0,26 0,10 0,09 0,09
Probable ergosterol biosynthetic protein 28 Copper transport protein ATOX1 Proteasomal ATPase-associated factor 1 PRA1 family protein 3 ATP-binding cassette sub-family D member 2 Lysophospholipid acyltransferase 5 Ribonuclease P protein subunit p14 Sterol O-acyltransferase 1 Ubiquitin conjugation factor E4 A Destrin Ras-related protein Rab-88 Cullin-4A V-type proton ATPase subunit H Gamma-glutamyl hydrolase Transmembrane 9 superfamily member 1 Pre-mRNA-splicing factor 38A Anaphase-promoting complex subunit 4	ATOX1 PAAF1 ARL6IP5 ABCD2 LPCAT3 RPP14 SOAT1 UBE4A DSTN RAB8B CUL4A ATP6V1H GGH TM9SF1	0,80 0,80 0,79 0,79 0,79 0,79 0,79 0,79 0,78 0,78 0,78	N.D. 0,06 0,12 N.D. 0,02 0,26 0,10 0,09 0,09 0,44
Probable ergosterol biosynthetic protein 28 Copper transport protein ATOX1 Proteasomal ATPase-associated factor 1 PRA1 family protein 3 ATP-binding cassette sub-family D member 2 Lysophospholipid acyltransferase 5 Ribonuclease P protein subunit p14 Sterol O-acyltransferase 1 Ubiquitin conjugation factor E4 A Destrin Ras-related protein Rab-88 Cullin-4A V-type proton ATPase subunit H Gamma-glutamyl hydrolase Transmembrane 9 superfamily member 1 Pre-mRNA-splicing factor 38A	ATOX1 PAAF1 ARL6IP5 ABCD2 LPCAT3 RPP14 SOAT1 UBE4A DSTN RAB8B CUL4A ATP6V1H GGH TM9SF1 PRPF38A	0,80 0,80 0,79 0,79 0,79 0,79 0,79 0,79 0,78 0,78 0,78 0,78 0,78	N.D. 0,06 0,12 N.D. 0,12 0,02 0,26 0,10 0,09 0,09 0,09 0,44 0,22
Probable ergosterol biosynthetic protein 28 Copper transport protein ATOX1 Proteasomal ATPase-associated factor 1 PRA1 family protein 3 ATP-binding cassette sub-family D member 2 Lysophospholipid acyltransferase 5 Ribonuclease P protein subunit p14 Sterol O-acyltransferase 1 Ubliquitin conjugation factor E4 A Destrin Ras-related protein Rab-8B Cullin-4A V-type proton ATPase subunit H Gamma-glutamyl hydrolase Transmembrane 9 superfamily member 1 Pre-mRNA-splicing factor 38A Anaphase-promoting complex subunit 4	ATOX1 PAAF1 ARL6IP5 ABCD2 LPCAT3 RPP14 SOAT1 UBE4A DSTN RAB8B CUL4A ATP6V1H GGH TM9SF1 PRPF38A ANAPC4	0,80 0,80 0,79 0,79 0,79 0,79 0,79 0,79 0,78 0,78 0,78 0,78 0,78 0,78	N.D. 0,06 0,12 N.D. 0,02 0,26 0,10 0,09 0,09 0,44 0,22 N.D.

Pyruvate kinase PKM	PKM	0.77	0.03
Mammalian ependymin-related protein 1	EPDR1	0.77	0.16
DNA-(apurinic or apyrimidinic site) lyase, mitochondrial	APEX1	0.76	0.03
Lysosomal protective protein	CTSA	0.76	0.10
HD domain-containing protein 2	HDDC2	0.76	0.02
Mitochondrial import inner membrane translocase subunit Tim13	TIMM13	0.76	0.21
Thymocyte nuclear protein 1	THYN1	0.76	0.04
COMM domain-containing protein 4	COMMD4	0.75	0.17
V-type proton ATPase subunit E 1	ATP6V1E1	0.75	0.04
DNA replication complex GINS protein PSF2	GINS2	0.75	0.23
GrpE protein homolog 1, mitochondrial	GRPEL1	0.75	0.03
Cyclin-G-associated kinase	GAK	0.75	0.16
RNA-binding protein 3	RBM3	0.75	0.10
ATP-dependent zinc metalloprotease YME1L1	YME1L1	0.75	N.D.
F-actin-capping protein subunit alpha-2	CAPZA2	0.74	0.09
2-deoxynucleoside 5-phosphate N-hydrolase 1	DNPH1	0.74	0.13
Polypeptide N-acetylgalactosaminyltransferase 2	GALNT2	0.74	0.27
Dolichyl-diphosphooligosaccharideprotein glycosyltransferase 48 kDa subunit	DDOST	0.74	0.27
Isocitrate dehydrogenase [NADP] cytoplasmic	IDH1	0.74	0.02
			-
Spermine synthase	SMS	0.74	0.05
Protein tyrosine phosphatase receptor type C-associated protein	PTPRCAP	0.73	N.D.
L-aminoadipate-semialdehyde dehydrogenase-phosphopantetheinyl transferase	AASDHPPT	0.73	0.08
Glucoamylase	MGAM	0.73	0.18
Epidermal growth factor receptor substrate 15-like 1	EPS15L1	0.72	0.33
Mediator of RNA polymerase II transcription subunit 12	MED12	0.72	0.02
Ras-related protein Rab-27A	RAB27A	0.72	0.07
Bromodomain-containing protein 3	BRD3	0.72	0.29
Diphosphomevalonate decarboxylase	MVD	0.72	N.D.
Beta-hexosaminidase subunit beta	HEXB	0.72	0.18
Sterol-4-alpha-carboxylate 3-dehydrogenase, decarboxylating	NSDHL	0.72	0.09
Ras-related protein Rab-4B	RAB4B	0.72	0.10
Death domain-associated protein 6	DAXX	0.72	N.D.
DNA replication licensing factor MCM2	MCM2	0.72	0.03
Mitochondrial import receptor subunit TOM34	TOMM34	0.72	0.24
PCI domain-containing protein 2	PCID2	0.71	0.11
Calpain-1 catalytic subunit	CAPN1	0.71	0.03
Dolichyl-diphosphooligosaccharideprotein glycosyltransferase subunit 1	RPN1	0.71	0.01
Histidine triad nucleotide-binding protein 2, mitochondrial	HINT2	0.71	0.12
ATP-citrate synthase	ACLY	0.71	0.02
N6-adenosine-methyltransferase 70 kDa subunit	METTL3	0.71	N.D.
GH3 domain-containing protein	GHDC	0.71	0.08
PEST proteolytic signal-containing nuclear protein	PCNP	0.71	0.04
Complex I assembly factor TIMMDC1, mitochondrial	TIMMDC1	0.71	0.20
Uridine-cytidine kinase 2	UCK2	0.71	0.13
Transcriptional repressor p66-alpha	GATAD2A	0.70	N.D.
Nardilysin	NRD1	0.70	0.04
Ribonucleoside-diphosphate reductase subunit M2	RRM2	0.70	0.12
DNA replication complex GINS protein PSF3	GINS3	0.70	0.12
Serine/arginine-rich splicing factor 7	SRSF7	0.70	0.06
	EEFSEC	0.70	0.00
Selenocysteine-specific elongation factor	PNO1	0.70	0.03
RNA-binding protein PNO1			
Queuine tRNA-ribosyltransferase	QTRT1	0.70	0.15
Caseinolytic peptidase B protein homolog	CLPB	0.70	0.10
UDP-N-acetylglucosaminedolichyl-phosphate N-acetylglucosaminephosphotransferase	DPAGT1	0.70	0.07
Target of EGR1 protein 1	TOE1	0.69	0.14
Beta-arrestin-1	ARRB1	0.69	0.01
Cyclin-dependent kinases regulatory subunit 1	CKS1B	0.69	N.D.
Amyloid beta A4 precursor protein-binding family B member 1-interacting protein	APBB1IP	0.69	0.05
Cathepsin G	CTSG	0.69	0.02
Delta-1-pyrroline-5-carboxylate synthase	ALDH18A1/P5CS	0.69	0.04
Protein CDV3 homolog	CDV3	0.69	0.09
Translation factor GUF1, mitochondrial	GUF1	0.68	N.D.
DNA topoisomerase 2-beta	TOP2B	0.68	0.32
Recombining binding protein suppressor of hairless	RBPJ	0.68	0.23
Trafficking protein particle complex subunit 4	TRAPPC4	0.68	0.18
Calcium-binding mitochondrial carrier protein Aralar1	SLC25A12	0.68	0.04
DNA dC->dU-editing enzyme APOBEC-3C	APOBEC3C	0.68	0.10
Mediator of RNA polymerase II transcription subunit 28	MED28	0.68	N.D.
DNA replication licensing factor MCM7	MCM7	0.68	0.03
Anaphase-promoting complex subunit 2	ANAPC2	0.68	0.17
U3 small nucleolar RNA-associated protein 18 homolog	UTP18	0.68	N.D.
Ras-related protein Rab-32	RAB32	0.68	0.15
RNA-binding protein Raly	RALY	0.68	0.12
Leucine-rich repeat-containing protein 57	LRRC57	0.68	0.12
Histone deacetylase complex subunit SAP18	SAP18	0.68	0.20
DnaJ homolog subfamily C member 10	DNAJC10	0.67	0.08
Pachytene checkpoint protein 2 homolog	TRIP13	0.67	0.18
UPF0160 protein MYG1, mitochondrial	C12orf10	0.67	0.07
· · · · · · · · · · · · · · · · · · ·			
ATPase ASNA1	ASNA1	0.67	0.09
Ubiquitin-conjugating enzyme E2 A	UBE2A	0.66	0.07

		-	-
Pyrroline-5-carboxylate reductase 3	PYCRL	0,66	0,07
COMM domain-containing protein 8	COMMD8	0,66	N.D.
GMP reductase 2	GMPR2	0,66	0,20
Nodal modulator 1	NOM01	0,66	0,05
Histone-binding protein RBBP7	RBBP7	0,66	0,07
Cellular nucleic acid-binding protein	CNBP	0,66	0,03
Polyadenylate-binding protein 2	PABPN1	0,66	0,05
Ribonuclease P protein subunit p30	RPP30	0,66	0,31
Periodic tryptophan protein 2 homolog	PWP2	0,65	0,01
Nodal modulator 2 and 3	NOMO2;NOMO3	0,65	0,02
Zinc finger protein ZPR1	ZPR1	0,65	0,02
DNA replication licensing factor MCM6			
	MCM6	0,65	0,03
Ubiquitin-like-conjugating enzyme ATG3	ATG3	0,65	0,07
Torsin-1A-interacting protein 2	TOR1AIP2	0,65	0,35
Brefeldin A-inhibited guanine nucleotide-exchange protein 1	ARFGEF1	0,65	0,32
Beta-hexosaminidase subunit alpha	HEXA	0,65	0,07
All-trans-retinol 13,14-reductase	RETSAT	0,65	0,12
Translation initiation factor eIF-2B subunit gamma	EIF2B3	0,65	0,14
m7GpppX diphosphatase	DCPS	0,65	0,04
Acetyl-CoA carboxylase 1;Biotin carboxylase	ACACA	0,64	0,19
Echinoderm microtubule-associated protein-like 3	EML3	0,64	0,03
•			
Protein dopey-2	DOPEY2	0,64	0,18
Endoplasmic reticulum-Golgi intermediate compartment protein 2	ERGIC2	0,64	0,03
Bifunctional polynucleotide phosphatase/kinase	PNKP	0,64	N.D.
Golgi-associated PDZ and coiled-coil motif-containing protein	GOPC	0,63	N.D.
Fatty acid synthase; [Acyl-carrier-protein] S-acetyltransferase	FASN	0,63	0,01
B-cell receptor-associated protein 29	BCAP29	0,63	N.D.
Ubiquitin-protein ligase E3A	UBE3A	0,63	0,04
Flap endonuclease 1	FEN1	0,63	0,02
Heat shock 70 kDa protein 1-like	HSPA1L	0,63	0,00
DNA replication licensing factor MCM4	MCM4	0,63	0,02
Glutaminyl-peptide cyclotransferase-like protein	QPCTL	0,63	0,11
	MCM5		
DNA replication licensing factor MCM5		0,63	0,03
V-type proton ATPase subunit G 1	ATP6V1G1	0,62	0,23
Major facilitator superfamily domain-containing protein 10	MFSD10	0,62	0,14
Syntaxin-binding protein 2	STXBP2	0,62	0,07
Cytosolic non-specific dipeptidase	CNDP2	0,62	0,02
E3 ubiquitin-protein ligase BRE1A	RNF20	0,62	0,04
Glycosaminoglycan xylosylkinase	FAM20B	0,62	N.D.
Solute carrier family 2, facilitated glucose transporter member 1	SLC2A1	0,62	0,06
SPRY domain-containing protein 4	SPRYD4	0,62	0,09
CUGBP Elav-like family member 2	CELF2	0,62	0,15
SH3 domain-binding glutamic acid-rich-like protein 3	SH3BGRL3		
		0,61	0,06
F-box only protein 22	FBXO22	0,61	N.D.
Eukaryotic translation initiation factor 1b	EIF1B	0,61	N.D.
Kinesin-like protein KIFC1	KIFC1	0,61	N.D.
Caspase recruitment domain-containing protein 9	CARD9	0,61	0,04
Histone acetyltransferase type B catalytic subunit	HAT1	0,61	0,02
Condensin-2 complex subunit D3	NCAPD3	0,61	0,12
Lanosterol synthase	LSS	0,61	0,10
Leukocyte elastase inhibitor	SERPINB1	0,61	0,04
Antigen KI-67	MKI67	0,61	0,15
Serine/threonine-protein phosphatase 4 catalytic subunit	PPP4C	0,61	0,10
	EPHX1		
Epoxide hydrolase 1		0,61	0,11
Calcium-binding mitochondrial carrier protein Aralar2	SLC25A13	0,61	0,10
3(2),5-bisphosphate nucleotidase 1	BPNT1	0,60	0,05
Protein arginine N-methyltransferase 6	PRMT6	0,60	N.D.
Protein transport protein Sec61 subunit gamma	SEC61G	0,60	0,17
Mannose-1-phosphate guanyltransferase alpha	GMPPA	0,60	0,06
Translation initiation factor eIF-2B subunit epsilon	EIF2B5	0,60	0,03
E3 ubiquitin-protein ligase RNF123	RNF123	0,59	N.D.
tRNA (uracil-5-)-methyltransferase homolog A	TRMT2A	0,59	0,15
Ribonuclease H2 subunit C	RNASEH2C	0,55	0,04
HEAT repeat-containing protein 3	HEATR3	0,55	
			0,20
Serine protease HTRA2, mitochondrial	HTRA2	0,59	0,14
Putative glutathione-specific gamma-glutamylcyclotransferase 2	CHAC2	0,59	N.D.
RNA-binding protein with serine-rich domain 1	RNPS1	0,59	N.D.
Heterogeneous nuclear ribonucleoprotein U	HNRNPU	0,59	0,01
DCN1-like protein 5	DCUN1D5	0,59	0,20
	DAD1	0,59	0,05

Table 7. Upregulated proteins in HL-60 AraC compared to HL-60 P cells under normoxia. Proteomic profiling (SILAC) data were used. Significantly upregulated proteins were calculated using the fold difference threshold of 1.5 (log₂ fold change=0.58). Mean±SD for n=2 replicates. Non-detected (N.D.) means less than 2 replicates detected for one protein measured.

	60 AraC VS. HL-60		
Protein names	Gene names	Mean Log ₂ fold change	SD Log ₂ fold char
HLA class I histocompatibility antigen, B-57 alpha chain	HLA-B	-4.09	N.D.
Ankyrin repeat domain-containing protein 22	ANKRD22	-4.06	N.D.
Basigin	BSG	-3.22	0.41
Proteasome subunit beta type-8	PSMB8	-3.04	0.11
Argininosuccinate synthase	ASS1	-2.99	0.10
Cation-dependent mannose-6-phosphate receptor	M6PR	-2.44	0.64
Chloride channel CLIC-like protein 1	CLCC1	-1.88	0.11
Very-long-chain 3-oxoacyl-CoA reductase	HSD17B12	-1.80	0.05
DNA-directed RNA polymerase, mitochondrial	POLRMT	-1.67	0.17
Tapasin	TAPBP	-1.59	N.D.
Beta-mannosidase	MANBA	-1.59	1.07
Stromal interaction molecule 1	STIM1	-1.58	N.D.
Phosphoenolpyruvate carboxykinase [GTP], mitochondrial	PCK2	-1.57	0.08
Serpin B8	SERPINB8	-1.56	0.14
Nuclear pore complex protein Nup98-Nup96	NUP98	-1.53	N.D.
Heat shock 70 kDa protein 1B;Heat shock 70 kDa protein 1A	HSPA1B;HSPA1A	-1.50	0.05
Microsomal glutathione S-transferase 2	MGST2	-1.49	0.02
Switch-associated protein 70	SWAP70	-1.46	0.07
Galectin-9	LGALS9	-1.44	0.00
Ferritin light chain	FTL	-1.43	0.05
Cat eye syndrome critical region protein 5	CECR5	-1.43	0.17
Glutamate dehydrogenase 1, mitochondrial	GLUD1;GLUD2	-1.41	0.13
Integrin beta-1	ITGB1	-1.40	0.27
Leucyl-cystinyl aminopeptidase	LNPEP	-1.38	0.20
Lamin-B2	LMNB2	-1.35	0.20
LIM domain and actin-binding protein 1	LIVINB2	-1.33	N.D.
Myeloid-associated differentiation marker	MYADM	-1.33	0.08
Drebrin	DBN1		
		-1.30	0.43
Protein jagged-1	JAG1	-1.29	N.D.
Synaptophysin-like protein 1	SYPL1	-1.28	N.D.
Estradiol 17-beta-dehydrogenase 11	HSD17B11	-1.26	0.02
Nuclear pore complex protein Nup160	NUP160	-1.26	0.19
Proteasome maturation protein	POMP	-1.24	0.03
Golgi apparatus protein 1	GLG1	-1.23	0.70
Mitochondrial carrier homolog 2	MTCH2	-1.23	0.14
CD81 antigen	CD81	-1.23	0.26
2-methoxy-6-polyprenyl-1,4-benzoquinol methylase, mitochondrial	COQ5	-1.22	0.07
Transmembrane protein 41B	TMEM41B	-1.21	N.D.
NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 4	NDUFB4	-1.21	N.D.
Leukocyte-associated immunoglobulin-like receptor 1	LAIR1	-1.21	0.75
Protein FAM107B	FAM107B	-1.18	0.09
Apoptosis inhibitor 5	API5	-1.18	0.12
Voltage-dependent anion-selective channel protein 2	VDAC2	-1.16	0.01
Manganese-transporting ATPase 13A1	ATP13A1	-1.15	0.55
Ras-related protein Rab-4A	RAB4A	-1.14	N.D.
High affinity cationic amino acid transporter 1	SLC7A1	-1.13	0.35
Uncharacterized protein NCBP2-AS2	NCBP2-AS2	-1.13	N.D.
Thromboxane-A synthase	TBXAS1	-1.13	0.38
Importin-7	IPO7	-1.12	0.02
Prosaposin	PSAP	-1.11	0.07
Phosphatidylglycerophosphatase and protein-tyrosine phosphatase 1	PTPMT1	-1.11	0.19
60S ribosomal protein L7-like 1	RPL7L1	-1.10	0.10
Histone H1.2	HIST1H1C	-1.10	N.D.
Ras-related protein Rab-3D	RAB3D	-1.10	N.D.
Transaldolase	TALDO1	-1.10	0.03
N-acetyltransferase 10	NAT10	-1.09	0.03
Lysosome-associated membrane glycoprotein 2	LAMP2	-1.05	0.21
MICOS complex subunit MIC19	CHCHD3	-1.08	0.12
Rho-related GTP-binding protein RhoG	RHOG	-1.08	0.12
	UNG	-1.07	0.08 N.D.
Uracil-DNA glycosylase L-lactate dehydrogenase A chain			
	LDHA	-1.05	0.03
CysteinetRNA ligase, cytoplasmic	CARS	-1.04	0.15
Receptor-type tyrosine-protein phosphatase epsilon	PTPRE	-1.04	N.D.
Succinyl-CoA ligase [ADP-forming] subunit beta, mitochondrial	SUCLA2	-1.03	0.32
Arf-GAP with coiled-coil, ANK repeat and PH domain-containing protein 1	ACAP1	-1.03	N.D.
UPF0317 protein C14orf159, mitochondrial	C14orf159	-1.03	0.25
Cytochrome c oxidase subunit 5B, mitochondrial	COX5B	-1.02	0.23
Protein MAK16 homolog	MAK16	-1.01	N.D.
Arf-GAP with Rho-GAP domain	ARAP1	-1.01	N.D.
	MGST3	-1.00	0.17
Microsomal glutathione S-transferase 3	AGA	-1.00	0.04
		-1.00	0.06
Microsomal glutathione S-transferase 3	GRAMD4		0.05
Microsomal glutathione S-transferase 3 N(4)-(beta-N-acetylglucosaminyl)-L-asparaginase	GRAMD4 APIP	-0.99	
Microsomal glutathione S-transferase 3 N(4)-{beta-N-acetylglucosaminyl)-L-asparaginase GRAM domain-containing protein 4		-0.99 -0.99	0.11
Microsomal glutathione S-transferase 3 N(4)-(beta-N-acetylglucosaminyi)-L-asparaginase GRAM domain-containing protein 4 Methylthioribulose-1-phosphate dehydratase Ribonuclease inhibitor	APIP RNH1	-0.99	
Microsomal glutathione S-transferase 3 N(4)-{beta-N-acety/glucosaminyl}-L-asparaginase GRAM domain-containing protein 4 Methylthioribulose-1-phosphate dehydratase Ribonuclease inhibitor Alpha-N-acety/galactosaminidase	APIP RNH1 NAGA	-0.99 -0.99	N.D.
Microsomal glutathione S-transferase 3 N(4)-(beta-N-acetylglucosaminyi)-Lasparaginase GRAM domain-containing protein 4 Methylthioribulose-1-phosphate dehydratase Ribonuclease inhibitor Alpha-N-acetylgalactosaminidase MICOS complex subunit MIC60	APIP RNH1 NAGA IMMT	-0.99 -0.99 -0.98	N.D. 0.01
Microsomal glutathione S-transferase 3 N(4)-{beta-N-acety[glucosaminy])-Lasparaginase GRAM domain-containing protein 4 Methylthioribulose-1-phosphate dehydratase Ribonuclease inhibitor Alpha-N-acety[galactosaminidase MICOS complex subunit MIC60 Erlin-1	APIP RNH1 NAGA IMMT ERLIN1	-0.99 -0.99 -0.98 -0.98	N.D. 0.01 0.18
Microsomal glutathione S-transferase 3 N(4)-(beta-N-acetylglucosaminyi)-Lasparaginase GRAM domain-containing protein 4 Methylthioribulose-1-phosphate dehydratase Ribonuclease inhibitor Alpha-N-acetylgalactosaminidase MICOS complex subunit MIC60	APIP RNH1 NAGA IMMT	-0.99 -0.99 -0.98	N.D. 0.01

Heat shock 70 kDa protein 4L	HSPA4L	-0,97	0,06
Glutaredoxin-1	GLRX	-0,97	0,08
NADH-ubiquinone oxidoreductase chain 4	MT-ND4	-0,97	0,04
Pyruvate dehydrogenase protein X component, mitochondrial	PDHX	-0,97	0,16
ADP-ribosylation factor-like protein 8A	ARL8A	-0,97	N.D.
39S ribosomal protein L30, mitochondrial	MRPL30	-0,96	N.D.
Multifunctional protein ADE2	PAICS	-0,96	0,05
Eukaryotic translation initiation factor 4E	EIF4E	-0,96	0,04
General transcription factor IIH subunit 2-like protein	GTF2H2C;GTF2H2	-0,96	N.D.
Voltage-dependent anion-selective channel protein 1	VDAC1	-0,96	0,05
Amidophosphoribosyltransferase	PPAT	-0,96	0,03
Sorting and assembly machinery component 50 homolog	SAMM50	-0,96	0,07
Retinol dehydrogenase 14	RDH14	-0,95	0,23
Grancalcin	GCA	-0,95	0,14
Ubiquitin-like modifier-activating enzyme 6	UBA6	-0,94	0,10
Nucleolar protein 58	NOP58	-0,94	0,16
Tumor susceptibility gene 101 protein	TSG101	-0,94	0,14
RNA-binding protein 12B	RBM12B	-0,93	0,12
Caspase-6	CASP6	-0,93	N.D.
Histone H1x	H1FX	-0,93	N.D.
Translocator protein	TSPO	-0,93	0,06
		-	,
Lon protease homolog, mitochondrial	LONP1	-0,92	0,01
LEM domain-containing protein 2	LEMD2	-0,92	N.D.
Protein CEBPZOS	CEBPZOS	-0,92	N.D.
SH3 domain-binding protein 1	SH3BP1	-0,92	0,06
Protein SDE2 homolog	SDE2	-0,91	N.D.
PITH domain-containing protein 1	PITHD1	-0,91	0,07
Coactosin-like protein	COTL1	-0,91	0,01
SUN domain-containing protein 2	SUN2	-0,90	N.D.
Junctional adhesion molecule A	F11R	-0,90	0,66
N-alpha-acetyltransferase 15, NatA auxiliary subunit	NAA15	-0,90	0,05
Cytochrome c oxidase subunit 2	MT-CO2	-0,90	0,02
Nucleosome assembly protein 1-like 4	NAP1L4	-0,89	0,07
Pericentriolar material 1 protein	PCM1	-0,89	0,26
Thymosin beta-4;Hematopoietic system regulatory peptide	TMSB4X	-0,89	0,04
Inorganic pyrophosphatase 2, mitochondrial	PPA2	-0,89	0,04
Type-1 angiotensin II receptor-associated protein	AGTRAP	-0,89	0,05
Peptidyl-prolyl cis-trans isomerase-like 3	PPIL3	-0,89	N.D.
Calcineurin subunit B type 1	PPP3R1	-0,89	0,14
	PPP3CA	-0,89	0,14
Serine/threonine-protein phosphatase 2B catalytic subunit alpha isoform		-	
ATPase family AAA domain-containing protein 3B	ATAD3B	-0,89	0,17
39S ribosomal protein L23, mitochondrial	MRPL23	-0,88	0,13
Programmed cell death protein 4	PDCD4	-0,88	0,10
Nucleoprotein TPR	TPR	-0,88	0,04
E3 ubiquitin/ISG15 ligase TRIM25	TRIM25	-0,88	0,05
Lamin-B1	LMNB1	-0,88	0,02
Sodium/potassium-transporting ATPase subunit beta-3	ATP1B3	-0,87	0,28
Nucleolar protein 56	NOP56	-0,87	0,13
Synembryn-A	RIC8A	-0,87	0,19
Lysosome-associated membrane glycoprotein 1	LAMP1	-0,87	0,29
CDGSH iron-sulfur domain-containing protein 2	CISD2	-0,87	0,09
Nuclear pore complex protein Nup107	NUP107	-0,87	0,15
Rho GTPase-activating protein 1	ARHGAP1	-0,87	0,03
Monofunctional C1-tetrahydrofolate synthase, mitochondrial	MTHFD1L	-0,87	0,18
Dol-P-Man:Man(7)GlcNAc(2)-PP-Dol alpha-1,6-mannosyltransferase	ALG12	-0,87	N.D.
Mitotic spindle assembly checkpoint protein MAD1	MAD1L1	-0,87	0,14
Choline/ethanolaminephosphotransferase 1	CEPT1	-0,86	0,05
Protein S100-A8; Protein S100-A8, N-terminally processed	S100A8	-0,86	0,23
Nuclear pore membrane glycoprotein 210	NUP210	-0,86	0,03
CAAX prenyl protease 1 homolog	ZMPSTE24	-0,86	0,14
Voltage-dependent anion-selective channel protein 3	VDAC3	-0,86	0,10
Small ubiquitin-related modifier 1;Small ubiquitin-related modifier	SUM01	-0,85	0,10
Galectin-1	LGALS1	-0,85	0,05
ATPase family AAA domain-containing protein 3A	ATAD3A	-0,85	0,00
Vacuolar protein sorting-associated protein 45	VPS45	-0,85	0,02
Hydroxyacyl-coenzyme A dehydrogenase, mitochondrial		-	
Hydroxyacyi-coenzyme A denydrogenase, mitochondriai Nicastrin	HADH	-0,84	0,04
	NCSTN	-0,84	0,01
Lysocardiolipin acyltransferase 1	LCLAT1	-0,83	0,10
General vesicular transport factor p115	USO1	-0,83	0,04
Protein FAN	NSMAF	-0,83	N.D.
Battenin	CLN3	-0,82	N.D.
Myotubularin-related protein 5	SBF1	-0,82	N.D.
Isochorismatase domain-containing protein 2, mitochondrial	ISOC2	-0,82	N.D.
Enolase-phosphatase E1	ENOPH1	-0,81	0,15
Plasma membrane calcium-transporting ATPase 4	ATP2B4	-0,81	0,10
Probable rRNA-processing protein EBP2	EBNA1BP2	-0,81	0,46
Neutral amino acid transporter A	SLC1A4	-0,81	0,14
	FBL	-0,81	0,03
rRNA 2-O-methyltransferase fibrillarin	TDL		
rRNA 2-O-methyltransferase fibrillarin Rap1 GTPase-GDP dissociation stimulator 1	RAP1GDS1	-0,81	0,17

Leucine-rich repeat flightless-interacting protein 1	LRRFIP1	-0,81	0,01
	ABCB7		0,01
ATP-binding cassette sub-family B member 7, mitochondrial		-0,81	
Mitochondrial-processing peptidase subunit alpha	PMPCA	-0,80	0,01
Double-strand-break repair protein rad21 homolog	RAD21	-0,80	0,09
Sn1-specific diacylglycerol lipase beta	DAGLB	-0,80	0,25
Carboxypeptidase D	CPD	-0,80	0,23
TraB domain-containing protein	TRABD	-0,80	0,01
60S ribosomal export protein NMD3	NMD3	-0,80	0,31
Nucleoporin NUP53	NUP35	-0,79	N.D.
· · · · · · · · · · · · · · · · · · ·			
Protein SON	SON	-0,79	0,07
Methionine aminopeptidase 1	METAP1	-0,79	0,02
Unconventional myosin-Ig	MYO1G	-0,79	0,06
· -			
Ferritin heavy chain; Ferritin heavy chain, N-terminally processed	FTH1	-0,79	0,04
Nuclear pore complex protein Nup155	NUP155	-0,79	0,04
Plastin-2	LCP1	-0,79	0,02
Ubiquinol-cytochrome-c reductase complex assembly factor 2			
	UQCC2	-0,79	N.D.
Importin subunit alpha-4	KPNA3	-0,78	0,05
39S ribosomal protein L38, mitochondrial	MRPL38	-0,78	0,18
Mitotic spindle assembly checkpoint protein MAD2A	MAD2L1	-0,78	0,35
RNA exonuclease 4	REXO4	-0,77	N.D.
Inositol 1,4,5-trisphosphate receptor type 1	ITPR1	-0,77	0,12
Egl nine homolog 1	EGLN1	-0,77	N.D.
Unconventional myosin-XVIIIa	MYO18A	-0,77	0,03
Mitochondrial-processing peptidase subunit beta	PMPCB	-0,77	0,22
NADH dehydrogenase [ubiquinone] iron-sulfur protein 2, mitochondrial	NDUFS2	-0,76	0,09
Protein FAM136A	FAM136A	-0,76	0,10
N-alpha-acetyltransferase 10	NAA10	-0,76	0,05
Core histone macro-H2A.1	H2AFY	-0,76	0,00
Brain acid soluble protein 1	BASP1	-0,75	0,06
Transmembrane protein 205	TMEM205	-0,75	0,05
Mitochondrial import inner membrane translocase subunit TIM14	DNAJC19	-0,75	0,10
Exportin-4	XPO4		
·		-0,74	0,05
Sister chromatid cohesion protein PDS5 homolog B	PDS5B	-0,74	0,03
Histidine triad nucleotide-binding protein 3	HINT3	-0,74	N.D.
	ACSL1	-0,74	0,16
Long-chain-fatty-acidCoA ligase 1			
39S ribosomal protein L14, mitochondrial	MRPL14	-0,73	0,12
Cyclin-dependent kinase 13	CDK13	-0,73	N.D.
	NDUFS3		
NADH dehydrogenase [ubiquinone] iron-sulfur protein 3, mitochondrial		-0,73	0,05
Choline transporter-like protein 1	SLC44A1	-0,72	N.D.
Tumor necrosis factor receptor type 1-associated DEATH domain protein	TRADD	-0,72	N.D.
F-box-like/WD repeat-containing protein TBL1XR1	TBL1XR1	-0,72	0,10
Protein lunapark	LNP	-0,72	0,00
Chloride intracellular channel protein 4	CLIC4	-0,72	0,05
CCAAT/enhancer-binding protein zeta	CEBPZ	-0,72	0,01
Docking protein 3	DOK3	-0,71	0,37
Vacuole membrane protein 1	VMP1	-0,71	N.D.
Medium-chain specific acyl-CoA dehydrogenase, mitochondrial	ACADM	-0,71	0,06
DnaJ homolog subfamily C member 3	DNAJC3		
		-0,71	0,05
Syntaxin-12	STX12	-0,71	0,09
Toll-interacting protein	TOLLIP	-0,71	0,15
Ubiquitin-associated domain-containing protein 2	UBAC2	-0,71	0,02
		-	-
NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 9	NDUFB9	-0,71	N.D.
Translocation protein SEC62	SEC62	-0,71	0,06
Cytochrome c oxidase assembly protein COX14	COX14	-0,70	0,26
Ubiquitin carboxyl-terminal hydrolase 48	USP48	-0,70	0,38
Polycomb protein EED	EED	-0,70	0,16
Pre-B-cell leukemia transcription factor-interacting protein 1	PBXIP1	-0,70	0,18
39S ribosomal protein L28, mitochondrial	MRPL28	-0,70	0,09
NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 5	NDUFA5	-0,70	0,09
UBX domain-containing protein 7	UBXN7	-0,70	0,17
Protein scribble homolog	SCRIB	-0,70	0,19
		,	
Cytochrome b-245 light chain	CYBA	-0,70	0,09
Large neutral amino acids transporter small subunit 1	SLC7A5	-0,69	0,05
Protein kinase C iota type	PRKCI	-0,69	0,03
Acid ceramidase;Acid ceramidase subunit alpha;Acid ceramidase subunit beta			0,06
· · ·	ASAH1	-0,69	
GTP-binding protein 10	GTPBP10	-0,69	0,38
39S ribosomal protein L43, mitochondrial	MRPL43	-0,69	0,18
Protein arginine N-methyltransferase 3	PRMT3	-0,69	0,66
AlaninetRNA ligase, mitochondrial	AARS2	-0,68	0,10
Transmembrane protein 192	TMEM192	-0,68	0,06
Nucleolar pre-ribosomal-associated protein 1	URB1	-0,68	0,09
		-	
39S ribosomal protein L47, mitochondrial	MRPL47	-0,68	0,07
Ras-related protein Rab-24	RAB24	-0,67	N.D.
BCL2/adenovirus E1B 19 kDa protein-interacting protein 2;Caytaxin	BNIP2;ATCAY	-0,67	0,16
	SERPINB10	-0,67	0,07
Serpin B10		-0,66	0,06
	MRPL45		
Serpin B10 395 ribosomal protein L45, mitochondrial		-0.66	0,17
Serpin B10 395 ribosomal protein L45, mitochondrial Cathepsin B	CTSB	-0,66	0,17
Serpin B10 395 ribosomal protein L45, mitochondrial Cathepsin B Fatty aldehyde dehydrogenase	CTSB ALDH3A2	-0,66	0,05
Serpin B10 395 ribosomal protein L45, mitochondrial Cathepsin B	CTSB	-	

			_
Macrophage-capping protein	CAPG	-0,66	0,04
S-formylglutathione hydrolase	ESD	-0,65	0,03
Myeloperoxidas	MPO	-0,65	0,02
TyrosinetRNA ligase, mitochondrial	YARS2	-0,65	0,06
Probable phospholipid-transporting ATPase IF	ATP11B	-0,65	0,38
NADH dehydrogenase [ubiquinone] iron-sulfur protein 8, mitochondrial	NDUFS8	-0,65	0,10
Ribosome production factor 2 homolog	RPF2	-0,65	0,10
Protein SDA1 homolog	SDAD1	-0,65	0,31
Centriolin	CNTRL	-0,65	N.D.
Nucleoporin Nup37	NUP37	-0,65	0,34
Nuclear pore complex protein Nup133	NUP133	-0,65	0,17
Diacylglycerol kinase zeta	DGKZ	-0,65	0,43
Retinol dehydrogenase 13	RDH13	-0,65	0,22
Protein CCSMST1	CCSMST1	-0,65	0,22
Diphosphoinositol polyphosphate phosphohydrolase 1	NUDT3	-0,65	0,25
Oligosaccharyltransferase complex subunit OSTC	OSTC	-0,64	0,05
	MRPL16		0,15
395 ribosomal protein L16, mitochondrial Zinc finger CCHC domain-containing protein 8		-0,64	
	ZCCHC8	-0,64	0,07
Nucleoside diphosphate-linked moiety X motif 19, mitochondrial	NUDT19	-0,64	0,45
39S ribosomal protein L15, mitochondrial	MRPL15	-0,64	0,10
15 kDa selenoprotein	42248	-0,64	0,00
39S ribosomal protein L50, mitochondrial	MRPL50	-0,64	0,21
39S ribosomal protein L41, mitochondrial	MRPL41	-0,64	0,06
39S ribosomal protein L49, mitochondrial	MRPL49	-0,64	0,08
Nucleobindin-2;Nesfatin-1	NUCB2	-0,64	0,15
H/ACA ribonucleoprotein complex subunit 1	GAR1	-0,64	0,11
Histone H1.4;Histone H1.3	HIST1H1E;HIST1H1D	-0,64	0,12
Endoplasmic reticulum aminopeptidase 2	ERAP2	-0,64	N.D.
Transmembrane 9 superfamily member 2	TM9SF2	-0,63	0,07
Pleckstrin	PLEK	-0,63	0,10
ADP-ribosylation factor-like protein 8B	ARL8B	-0,63	0,04
IsoleucinetRNA ligase, cytoplasmic	IARS	-0,63	0,03
Protein lin-7 homolog A	LIN7A	-0,63	N.D.
Mitochondrial import inner membrane translocase subunit TIM16	PAM16	-0,63	0,05
RNA-binding protein 33	RBM33	-0,63	N.D.
Glutamine synthetase	GLUL	-0,63	0,10
Nucleolar protein 9	NOP9	-0,62	0,10
	IPO5	-0,62	
Importin-5	MT-CYB		0,05 N.D.
Cytochrome b		-0,62	
Alpha-1,6-mannosyl-glycoprotein 2-beta-N-acetylglucosaminyltransferase	MGAT2	-0,62	0,91
Aconitate hydratase, mitochondrial	ACO2	-0,62	0,07
Eukaryotic translation initiation factor 4 gamma 2	EIF4G2	-0,62	0,08
Translationally-controlled tumor protein	TPT1	-0,62	0,03
Mitochondrial fission process protein 1	MTFP1	-0,62	0,13
Multidrug resistance-associated protein 4	ABCC4	-0,61	0,18
NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 9, mitochondrial	NDUFA9	-0,61	0,04
Ras GTPase-activating protein-binding protein 2	G3BP2	-0,61	0,19
39S ribosomal protein L24, mitochondrial	MRPL24	-0,61	N.D.
39S ribosomal protein L1, mitochondrial	MRPL1	-0,61	0,18
39S ribosomal protein L4, mitochondrial	MRPL4	-0,61	0,03
Ras-related protein Rab-7b	RAB7B	-0,61	0,15
Protein VPRBP	VPRBP	-0,61	N.D.
39S ribosomal protein L19, mitochondrial	MRPL19	-0,61	0,05
39S ribosomal protein L27, mitochondrial	MRPL27	-0,61	0,07
Uncharacterized protein C2orf47, mitochondrial	C2orf47	-0,61	0,28
Presenilins-associated rhomboid-like protein, mitochondrial;P-beta	PARL	-0,61	0,10
39S ribosomal protein L22, mitochondrial	MRPL22	-0,60	0,23
Structural maintenance of chromosomes protein 3	SMC3	-0,60	0,07
THUMP domain-containing protein 1	THUMPD1	-0,60	0,06
DnaJ homolog subfamily C member 11	DNAJC11	-0,60	0,08
Pentatricopeptide repeat domain-containing protein 3, mitochondrial	PTCD3	-0,60	0,09
Transmembrane protein 11, mitochondrial	TMEM11	-0,60	0,28
ATP synthase mitochondrial F1 complex assembly factor 2	ATPAF2	-0,60	0,28 N.D.
SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily A	SMARCAD1	-0,60	0,24
Tyrosine-protein phosphatase non-receptor type 7	PTPN7		
		-0,60	0,23
Dolichyl-phosphate beta-glucosyltransferase	ALG5	-0,60	0,06
39S ribosomal protein L17, mitochondrial	MRPL17	-0,60	0,03
Platelet-activating factor acetylhydrolase IB subunit gamma	PAFAH1B3	-0,60	0,04
ADD site substant for the CTD state in CTD			
ADP-ribosylation factor GTPase-activating protein 2 Monocarboxylate transporter 1	ARFGAP2 SLC16A1	-0,60 -0,60	0,27 0,07

E3 SUMO-protein ligase RanBP2	RANBP2	-0,60	0,05
Ragulator complex protein LAMTOR3	LAMTOR3	-0,60	0,06
39S ribosomal protein L33, mitochondrial	MRPL33	-0,60	0,17
NHL repeat-containing protein 2	NHLRC2	-0,59	0,05
Glucosamine-6-phosphate isomerase 1	GNPDA1	-0,59	0,03
Very long-chain specific acyl-CoA dehydrogenase, mitochondrial	ACADVL	-0,59	0,03
39S ribosomal protein L9, mitochondrial	MRPL9	-0,59	0,14
Protein transport protein Sec31A	SEC31A	-0,59	0,07
Unhealthy ribosome biogenesis protein 2 homolog	URB2	-0,59	N.D.
Transcription factor ETV6	ETV6	-0,59	0,25
Trifunctional enzyme subunit beta, mitochondrial;3-ketoacyl-CoA thiolase	HADHB	-0,59	0,04
Neurolysin, mitochondrial	NLN	-0,59	0,13
HIV Tat-specific factor 1	HTATSF1	-0,59	0,04

Table 8. Downregulated proteins in HL-60 AraC compared to HL-60 P cells under normoxia. Proteomic profiling (SILAC) data were used. Significantly downregulated proteins were calculated using the fold difference threshold of 0.7 (log₂ fold change=-0.58). Mean±SD for n=2 replicates. Non-detected (N.D.) means less than 2 replicates detected for one protein measured.

	Dox VS. HL-60 P		1
Protein names	Gene names	Mean Log ₂ fold change	
Carbonic anhydrase 2	CA2	3.21	0.05
Neutrophil defensin 3 and 1	DEFA3;DEFA1	2.98	0.11
Arachidonate 5-lipoxygenase-activating protein	ALOX5AP	1.91	N.D.
Vimentin	VIM	1.60	0.13
Cathepsin B	CTSB	1.47	0.41
Constitutive coactivator of peroxisome proliferator-activated receptor gamma	FAM120B	1.39	N.D.
CapZ-interacting protein	RCSD1	1.38	N.D.
Target of Myb protein 1	TOM1	1.29	N.D.
Kinetochore protein Nuf2	NUF2	1.22	N.D.
F-box only protein 22	FBXO22	1.17	N.D.
Transcriptional activator protein Pur-beta	PURB	1.11	N.D.
Heat shock 70 kDa protein 14	HSPA14	1.07	N.D.
Alpha-adducin	ADD1	1.03	0.11
Beta-glucuronidase	GUSB	1.02	0.10
Brefeldin A-inhibited guanine nucleotide-exchange protein 1	ARFGEF1	1.01	0.32
C-type mannose receptor 2	MRC2	1.00	0.09
Procollagen-lysine,2-oxoglutarate 5-dioxygenase 1	PLOD1	0.98	0.31
MORC family CW-type zinc finger protein 2	MORC2	0.97	N.D.
Sterol O-acyltransferase 1	SOAT1	0.93	N.D.
Gamma-tubulin complex component 3	TUBGCP3	0.93	N.D.
UDP-N-acetylglucosaminepeptide N-acetylglucosaminyltransferase	OGT 5100AR	0.92	0.06
Protein S100-A8;Protein S100-A8, N-terminally processed	S100A8	0.92	0.01
ATP-dependent zinc metalloprotease YME1L1	YME1L1		N.D.
Integrin beta-2 Endoplasmic reticulum aminopeptidase 2	ITGB2 ERAP2	0.90	0.16 N.D.
Histone H1.5	HIST1H1B		N.D.
Granulins	GRN	0.89	0.11
	TST		
Thiosulfate sulfurtransferase Ubiquilin-1	UBQLN1	0.87	0.19
Cathepsin D	CTSD		0.02
RAS guanyl-releasing protein 2	RASGRP2	0.84	0.02
Delta(3,5)-Delta(2,4)-dienoyl-CoA isomerase, mitochondrial	ECH1	0.85	0.24
SPRY domain-containing protein 4	SPRYD4	0.81	0.19
Ubiquitin-like protein ISG15	ISG15	0.79	0.15
Beta-hexosaminidase subunit beta	HEXB	0.78	0.38
Mannosyl-oligosaccharide 1,2-alpha-mannosidase IB	MAN1A2	0.77	N.D.
Rapamycin-insensitive companion of mTOR	RICTOR	0.77	N.D.
Vacuolar protein sorting-associated protein 51 homolog	VPS51	0.77	0.48
N6-adenosine-methyltransferase 70 kDa subunit	METTL3	0.75	N.D.
LEM domain-containing protein 2	LEMD2	0.75	N.D.
All-trans-retinol 13,14-reductase	RETSAT	0.75	0.18
Melanoma-associated antigen D2	MAGED2	0.72	N.D.
RNA polymerase II-associated protein 1	RPAP1	0.71	0.12
Tetratricopeptide repeat protein 39C	TTC39C	0.70	0.45
Pyrroline-5-carboxylate reductase 1, mitochondrial	PYCR1	0.70	0.05
Vacuolar ATPase assembly integral membrane protein VMA21	VMA21	0.70	N.D.
Uncharacterized protein KIAA0930	KIAA0930	0.70	N.D.
Protein dopey-2	DOPEY2	0.69	0.21
AP-2 complex subunit alpha-2	AP2A2	0.69	0.18
Proteasome activator complex subunit 1	PSME1	0.69	0.04
C-type lectin domain family 11 member A	CLEC11A	0.69	0.26
Putative phospholipase B-like 2	PLBD2	0.69	0.22
Squalene synthase	FDFT1	0.68	0.02
Proteasome activator complex subunit 2	PSME2	0.68	0.07
Disco-interacting protein 2 homolog B	DIP2B	0.68	0.03
Tyrosine-protein phosphatase non-receptor type 9	PTPN9	0.67	0.27
Receptor-type tyrosine-protein phosphatase C	PTPRC	0.67	0.01
Serglycin	SRGN	0.67	N.D.
Dynein assembly factor 5, axonemal	DNAAF5	0.67	0.02
WASH complex subunit CCDC53	CCDC53	0.66	N.D.
Leukocyte-associated immunoglobulin-like receptor 1	LAIR1	0.66	0.00
Leucine-rich repeat-containing protein 57	LRRC57	0.66	0.20
Fumarylacetoacetate hydrolase domain-containing protein 2A and B	FAHD2A;FAHD2B	0.66	N.D.
HLA class I histocompatibility antigen, B-58 alpha chain	HLA-B	0.65	0.11
Conserved oligomeric Golgi complex subunit 7	COG7	0.65	0.46
Protein diaphanous homolog 2	DIAPH2	0.65	0.07
Calumenin	CALU	0.65	0.33
Structural maintenance of chromosomes protein 5	SMC5	0.64	N.D.
Transmembrane protein 189	TMEM189	0.64	N.D.
Metallo-beta-lactamase domain-containing protein 2	MBLAC2	0.64	N.D.

N-acetyltransferase 14	NAT14	0,64	0.06
Protein FAM210A	FAM210A	0,63	N.D.
Translational activator GCN1	GCN1L1	0,63	0,16
Cysteine and glycine-rich protein 1	CSRP1	0,63	0,04
Isocitrate dehydrogenase [NADP] cytoplasmic	IDH1	0,62	0,12
Coatomer subunit gamma-2	COPG2	0,62	0,09
Maestro heat-like repeat-containing protein family member 1	MROH1	0,62	N.D.
Coronin-1B	CORO1B	0,61	0,15
Cytochrome b-245 light chain	CYBA	0,61	0,21
WASH complex subunit strumpellin	KIAA0196	0,61	0,24
Beta-hexosaminidase subunit alpha	HEXA	0,61	0,11
Dolichol-phosphate mannosyltransferase subunit 1	DPM1	0,61	0,03
Peptidyl-prolyl cis-trans isomerase FKBP8	FKBP8	0,60	0,15
Fatty acid desaturase 2	FADS2	0,60	0,03
Molybdate-anion transporter	MFSD5	0,60	N.D.
Golgi SNAP receptor complex member 2	GOSR2	0,60	N.D.
Golgi apparatus protein 1	GLG1	0,60	0,06
Coiled-coil-helix-coiled-coil-helix domain-containing protein 2	CHCHD2;CHCHD2P9	0,59	0,05
Very long-chain specific acyl-CoA dehydrogenase, mitochondrial	ACADVL	0,59	0,03
DnaJ homolog subfamily C member 10	DNAJC10	0,59	0,08
Fatty acid desaturase 1	FADS1	0,59	0,14
RELT-like protein 1	RELL1	0,59	N.D.

Table 9. Upregulated proteins in HL-60 Dox compared to HL-60 P cells under normoxia. Proteomic profiling (SILAC) data were used. Significantly upregulated proteins were calculated using the fold difference threshold of 1.5 (log₂ fold change=0.58). Mean±SD for n=2 replicates. Non-detected (N.D.) means less than 2 replicates detected for one protein measured.

DOWNREGULATED PROTEINS IN HL-6	0 Dox VS. I	HL-60 P	
Protein names	Gene names	Mean Log ₂ fold change	SD Log ₂ fold change
DNA topoisomerase 2-beta	TOP2B	-1.35	0.65
V-type proton ATPase 116 kDa subunit a isoform 1	ATP6V0A1	-1.33	N.D.
Probable cysteinetRNA ligase, mitochondrial	CARS2	-1.29	N.D.
RNA polymerase-associated protein LEO1	LEO1	-1.28	N.D.
Kinesin-like protein KIF15	KIF15	-1.27	0.03
Bridging integrator 2	BIN2	-1.26	0.48
Cathepsin G	CTSG	-1.24	0.10
Sodium bicarbonate cotransporter 3	SLC4A7	-1.12	0.06
Succinate-semialdehyde dehydrogenase, mitochondrial	ALDH5A1	-1.09	0.30
Leucine zipper transcription factor-like protein 1 DNA topoisomerase 2-alpha	LZTFL1 TOP2A	-1.07 -1.07	0.23 N.D.
Reticulon-4	RTN4	-1.07	0.02
CCA tRNA nucleotidyltransferase 1, mitochondrial	TRNT1	-1.07	0.25
MAP kinase-activated protein kinase 3	МАРКАРКЗ	-1.03	0.34
Glutamine synthetase	GLUL	-1.03	0.07
Glycerol-3-phosphate dehydrogenase 1-like protein	GPD1L	-1.02	0.08
Ras-related protein Rab-3D	RAB3D	-1.01	N.D.
Microtubule-associated protein 4	MAP4	-0.97	0.06
Cytochrome b561 domain-containing protein 2	CYB561D2	-0.96	0.05
Coiled-coil domain-containing protein 12	CCDC12	-0.94	0.38
Phosphatidylinositide phosphatase SAC1	SACM1L	-0.93	0.09
Inosine-5-monophosphate dehydrogenase 2	IMPDH2	-0.91	0.05
Ubiquitin-conjugating enzyme E2 T	UBE2T	-0.90	N.D.
Centriolin	CNTRL	-0.86	N.D.
Programmed cell death 6-interacting protein	PDCD6IP	-0.86	0.03
Cytochrome b	MT-CYB	-0.86	N.D.
Protein VPRBP	VPRBP	-0.85	N.D.
Erythrocyte band 7 integral membrane protein	STOM	-0.85	0.02
tRNA-splicing endonuclease subunit Sen34	TSEN34	-0.84	N.D.
Dolichyl-diphosphooligosaccharideprotein glycosyltransferase subunit STT3B	STT3B	-0.84	0.06
Twinfilin-2	TWF2	-0.84	0.04
Protein RFT1 homolog	RFT1	-0.82	0.10
Peptide-N(4)-(N-acetyl-beta-glucosaminyl)asparagine amidase	NGLY1	-0.82	0.15
Myosin-14	MYH14	-0.82	0.07
NADH-ubiquinone oxidoreductase chain 5	MT-ND5	-0.82	0.19
Beta-arrestin-1	ARRB1	-0.79	0.20
Serine/threonine-protein kinase OSR1	OXSR1	-0.79	0.03
Bone marrow proteoglycan; Eosinophil granule major basic protein	PRG2	-0.78	0.08
Aminopeptidase N	ANPEP	-0.78	0.04
Protein kinase C delta type	PRKCD	-0.77	0.19
NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 9	NDUFB9	-0.76	N.D.
NADH-ubiquinone oxidoreductase chain 4	MT-ND4	-0.76	0.06
Myosin-9	MYH9	-0.75	0.02
Antigen KI-67	MKI67	-0.75	0.12
Scaffold attachment factor B2	SAFB2	-0.74	0.10
Guanine nucleotide-binding protein-like 3	GNL3	-0.73	0.06
Mannose-1-phosphate guanyltransferase beta Azurocidin	GMPPB AZU1	-0.73 -0.73	0.21
Filamin-B	FLNB	-0.73	0.80
Acylamino-acid-releasing enzyme	APEH	-0.72	0.28
Guanine nucleotide-binding protein G(i) subunit alpha-2	GNAI2	-0.72	0.08
Protein jagged-1	JAG1	-0.71	N.D.
Serine/threonine-protein kinase tousled-like 1	TLK1	-0.71	N.D.
Inositol 1,4,5-trisphosphate receptor type 1	ITPR1	-0.71	0.12
NEDD8 ultimate buster 1	NUB1	-0.71	N.D.
Voltage-dependent anion-selective channel protein 3	VDAC3	-0.71	0.09
Serine/threonine-protein phosphatase 2A 56 kDa regulatory subunit alpha isoform		-0.71	N.D.
THUMP domain-containing protein 3	THUMPD3	-0.70	0.56
Magnesium transporter protein 1	MAGT1	-0.70	0.09
Transketolase	ТКТ	-0.69	0.02
Cytoplasmic dynein 1 light intermediate chain 1	DYNC1LI1	-0.68	0.14
Cytochrome c oxidase copper chaperone	COX17	-0.68	N.D.
NADH-ubiquinone oxidoreductase 75 kDa subunit, mitochondrial	NDUFS1	-0.67	N.D.
Nucleoside diphosphate-linked moiety X motif 19, mitochondrial	NUDT19	-0.67	0.67
NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 11	NDUFA11	-0.66	N.D.
SWI/SNF complex subunit SMARCC1	SMARCC1	-0.65	0.03
AT-rich interactive domain-containing protein 3A	ARID3A	-0.65	0.14
Golgin subfamily A member 4	GOLGA4	-0.65	0.11
ADP-ribosylation factor-like protein 8B	ARL8B	-0.64	0.04
Protein CCSMST1	CCSMST1	-0.64	0.33

Beta-galactosidase	GLB1	-0,64	0,13
AspartatetRNA ligase, mitochondrial	DARS2	-0,63	0,08
Voltage-dependent anion-selective channel protein 2	VDAC2	-0,63	0,08
Ubiquitin carboxyl-terminal hydrolase 48	USP48	-0,63	0,38
Ras-related protein Rab-7b	RAB7B	-0,63	0,11
DNA fragmentation factor subunit alpha	DFFA	-0,63	0,19
PX domain-containing protein kinase-like protein	PXK	-0,63	0,10
Cytoplasmic FMR1-interacting protein 2	CYFIP2	-0,63	0,09
HIG1 domain family member 1A, mitochondrial	HIGD1A	-0,63	N.D.
Nuclear pore membrane glycoprotein 210	NUP210	-0,63	0,01
Pre-mRNA-processing factor 40 homolog A	PRPF40A	-0,63	0,02
Recombining binding protein suppressor of hairless	RBPJ	-0,63	0,21
Pyruvate dehydrogenase E1 component subunit beta, mitochondrial	PDHB	-0,63	0,05
Cystatin-A	CSTA	-0,62	0,19
Very long-chain acyl-CoA synthetase	SLC27A2	-0,62	0,05
Tubulin alpha-4A chain	TUBA4A	-0,62	0,16
Guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-10	GNG10	-0,62	N.D.
Peptidyl-prolyl cis-trans isomerase FKBP5	FKBP5	-0,61	0,02
Serpin B10	SERPINB10	-0,61	0,05
Cytochrome c oxidase assembly factor 7	COA7	-0,61	0,12
Guanine nucleotide-binding protein subunit beta-4	GNB4	-0,61	0,32
Transmembrane protein 50A	TMEM50A	-0,60	0,09
WD repeat-containing protein 18	WDR18	-0,60	N.D.
NADH dehydrogenase [ubiquinone] 1 subunit C2	NDUFC2	-0,59	0,11
DCC-interacting protein 13-alpha	APPL1	-0,59	0,10

Table 10. Downregulated proteins in HL-60 Dox compared to HL-60 P cells under normoxia. Proteomic profiling (SILAC) data were used. Significantly downregulated proteins were calculated using the fold difference threshold of 0.7 (log₂ fold change=-0.58). Mean±SD for n=2 replicates. Non-detected (N.D.) means less than 2 replicates detected for one protein measured.

		EX	TRACELLULA	AR FLUXES NOR	RMOXIA			
	THF	P-1 P		-1 AraC	тнр	-1 Dox	nyaluo	
	Mean	SD	крс (nmoi*m Mean	illioncell-1*h-1) SD	Mean	SD	pvalue (AraC vs. P)	pvalue (Dox vs. P)
	Weall	30		mino acids	Weall	30	(Arac vs. P)	(DOX VS. P)
Ala	2.29	1.23	3.95	1.17	3.50	0.42	0.230	0.184
Arg	D	D	D	, D	D	D	D	D
Asn	-0.84	0.53	-2.62	0.91	-1.14	0.27	0.042	0.441
Asp	0.21	0.49	1.52	1.44	0.42	0.78	0.251	0.716
Cit	-0.03	0.04	-0.07	0.17	0.01	0.01	0.705	0.218
Gin	-24.37	6.09	-10.14	7.75	-20.64	1.28	0.136	0.952
Glu	11.29	4.51	13.31	6.12	10.67	1.97	0.363	0.554
Gly	-0.12	0.13	8.35	1.35	0.01	0.58	0.013	0.481
His	-0.57	0.13	-0.31	0.77	-0.65	0.23	0.622	0.629
Ile	-2.91	0.79	-3.05	0.72	-2.14	0.25	0.825	0.225
Leu	-3.97	0.63	-5.41	1.33	-3.57	0.24	0.194	0.389
Lys	-2.36	0.33	-3.66	0.32	-2.82	0.17	0.008	0.123
Met	-0.83	0.17	-1.61	0.08	-0.78	0.04	0.006	0.627
Orn	1.27	0.61	4.62	1.29	1.27	0.32	0.029	0.992
Phe	-0.93	0.14	-1.53	0.22	-1.00	0.06	0.023	0.473
Pro	0.21	0.39	1.80	1.70	-0.63	0.12	0.191	0.023
Ser	-4.34	0.47	-8.44	0.52	-2.58	0.18	0.001	0.003
Thr	-1.32	0.46	-2.44	0.60	-1.42	0.09	0.069	0.762
Trp	-0.35	0.08	-0.52	0.15	-0.37	0.02	0.170	0.717
Tyr	-1.09	0.21	-0.93	0.18	-0.83	0.11	0.356	0.147
Val	-2.16	0.51	-3.25	0.80	-2.01	0.13	0.130	0.663
			F	olyamines				
Putrescine	1E-03	7E-04	1E-03	1E-03	7E-05	3E-05	0.642	0.147
Spermidine	3E-04	2E-04	4E-04	4E-04	5E-05	5E-05	0.733	0.119
Spermine	D	D	D	D	D	D	D	D

Table 11. Extracellular fluxes result of THP-1 cell line under normoxia. Non-detected amino acids or

polyamines or amino acids and polyamines whose replicates were not reproducible are named as discarded (D).

		ΕX	TRACELLULA	AR FLUXES NOF	RMOXIA		·	-
	HL-60 P		-	i0 AraC	HL-60 Dox		nyaluo	
	Mean	SD	Kpc (nmol*mi Mean	llioncell-1*h-1) SD	Mean	SD	pvalue	pvalue
	wear	30		mino acids	Weall	30	(AraC vs. P)	(Dox vs. P)
Ala	7.60	1.28	10.04	4.41	2.44	0.22	0.442	0.017
Arg	D	D	D	D	D	D	D	D
Asn	0.41	0.90	-1.39	3.19	-0.47	0.39	0.433	0.226
Asp	0.26	0.27	-0.25	0.53	-0.05	0.23	0.236	0.216
Cit	-0.02	0.01	0.08	0.12	0.00	0.07	0.296	0.687
Gln	-12.51	1.42	-16.88	14.71	-8.26	1.17	0.658	0.017
Glu	3.76	0.85	3.98	1.27	1.23	1.02	0.818	0.032
Gly	0.33	0.43	0.93	1.45	0.86	0.08	0.556	0.164
His	-0.17	0.20	0.06	0.53	0.04	0.12	0.530	0.194
lle	-0.80	0.12	-2.37	1.69	-0.53	0.04	0.183	0.021
Leu	-1.69	0.12	-2.38	0.38	-1.18	0.02	0.214	0.018
Lys	-1.10	0.08	-2.26	1.83	-1.16	0.24	0.387	0.736
Met	-0.55	0.06	-0.96	0.64	-0.39	0.02	0.385	0.028
Orn	2.22	0.20	2.11	1.04	0.80	0.48	0.877	0.022
Phe	-0.53	0.05	-1.06	0.77	-0.30	0.02	0.357	0.008
Pro	2.35	0.37	2.11	1.31	1.19	0.27	0.781	0.014
Ser	-2.73	0.31	-4.40	3.39	-2.49	0.08	0.484	0.319
Thr	-0.13	0.26	-1.13	1.30	-0.24	0.20	0.310	0.564
Trp	-0.13	0.00	-0.23	0.02	-0.11	0.03	0.009	0.292
Tyr	-0.30	0.20	-1.26	0.81	-0.12	0.12	0.169	0.262
Val	-0.97	0.14	-1.50	0.86	-0.73	0.03	0.395	0.098
			P	olyamines			•	
Putrescine	6E-04	4E-04	-5E-04	8E-04	1E-03	2E-04	0.020	0.010
Spermidine	1E-04	5E-05	2E-04	2E-04	1E-04	7E-05	0.696	0.727
Spermine	D	D	D	D	D	D	D	D

 Table 12. Extracellular fluxes result of HL-60 cell line under normoxia. Non-detected amino acids or polyamines or amino acids and polyamines whose replicates were not reproducible are named as discarded (D).

		l	EXTRACELLUI	AR FLUXES HY	ΡΟΧΙΑ			
	THF	P-1 P		-1 AraC	THP-1 Dox			
				llioncell-1*h-1)			pvalue	pvalue
	Mean	SD	Mean	SD	Mean	SD	(AraC vs. P)	(Dox vs. P)
-			А	mino acids				-
Ala	-2.04	0.64	3.10	0.13	2.44	0.29	0.001	0.033
Arg	D	D	D	D	D	D	D	D
Asn	-0.29	2.64	-1.14	1.49	1.37	1.30	0.659	0.401
Asp	-0.14	2.51	-0.23	1.24	2.65	1.41	0.959	0.188
Cit	-0.10	0.03	-0.03	0.11	0.05	0.15	0.423	0.224
Gin	-3.59	10.99	-8.31	8.85	-15.06	14.83	0.595	0.347
Glu	0.36	5.33	5.81	1.09	8.58	3.41	0.215	0.099
Gly	3.33	1.95	1.42	1.27	0.29	0.49	0.239	0.106
His	-0.72	0.64	-0.76	0.37	-0.84	0.80	0.919	0.843
lle	-0.64	0.20	-1.83	0.08	-0.45	0.25	0.004	0.464
Leu	-2.41	0.85	-3.96	0.38	-1.10	1.59	0.070	0.295
Lys	-2.41	0.90	-5.95	0.80	-0.65	1.46	0.007	0.165
Met	-0.70	0.79	-1.08	0.53	-0.16	0.54	0.530	0.393
Orn	2.31	0.05	0.01	1.91	4.18	0.20	0.096	0.002
Phe	-0.46	0.42	-1.03	0.42	-0.49	0.22	0.172	0.907
Pro	1.02	0.08	0.70	0.66	0.34	0.65	0.490	0.208
Ser	-2.37	0.10	-9.58	0.52	-1.83	0.15	0.001	0.300
Thr	0.63	2.73	-2.01	0.22	0.73	0.20	0.236	0.952
Trp	0.17	0.22	-0.21	0.10	0.04	0.15	0.076	0.443
Tyr	-0.51	0.41	0.47	0.63	-0.44	0.34	0.099	0.828
Val	-1.90	1.98	-3.13	0.04	-0.74	2.23	0.392	0.540
		·	P	olyamines				
Putrescine	6E-03	1E-03	9E-03	2E-03	-2E-03	1E-04	0.075	0.008
Spermidine	5E-03	8E-04	4E-03	1E-03	-6E-05	2E-04	0.273	0.006
Spermine	1E-03	9E-04	3E-03	8E-04	6E-05	5E-05	0.089	0.107

 Table 13. Extracellular fluxes result of THP-1 cell line under hypoxia. Non-detected amino acids or polyamines or amino acids and polyamines whose replicates were not reproducible are named as discarded (D).

		E	XTRACELLUI	AR FLUXES HY	ΡΟΧΙΑ		<u> </u>	
	HL-	60 P		60 AraC	HL-60 Dox			
			• •	illioncell-1*h-1)			pvalue	pvalue
	Mean	SD	Mean	SD	Mean	SD	(AraC vs. P)	(Dox vs. P)
				mino acids				
Ala	10.99	4.55	9.61	2.91	8.15	1.17	0.684	0.394
Arg	D	D	D	D	D	D	D	D
Asn	0.35	0.32	0.39	0.66	0.23	0.72	0.930	0.807
Asp	0.18	0.98	0.42	1.13	0.43	0.55	0.795	0.721
Cit	0.05	0.07	0.02	0.10	0.01	0.11	0.644	0.572
Gln	-13.89	8.46	-6.08	4.19	-15.64	4.42	0.250	0.772
Glu	8.24	3.94	5.46	3.85	4.68	1.01	0.433	0.255
Gly	4.35	2.71	0.75	1.24	3.11	0.54	0.134	0.512
His	0.47	0.81	-0.07	0.34	0.32	0.36	0.371	0.783
lle	0.10	0.71	-0.38	0.69	0.08	0.26	0.452	0.969
Leu	-0.28	1.62	-1.01	1.25	-0.46	0.31	0.572	0.866
Lys	-0.42	0.85	-1.69	0.41	-1.79	0.84	0.104	0.116
Met	-0.33	0.20	-0.46	0.45	-0.30	0.21	0.680	0.877
Orn	3.13	1.98	1.85	0.57	2.10	0.81	0.381	0.471
Phe	-0.04	0.11	-0.25	0.04	-0.07	0.11	0.062	0.691
Pro	2.23	1.05	1.16	0.92	3.21	0.46	0.255	0.241
Ser	-5.20	1.98	-3.38	0.41	-4.00	0.35	0.250	0.404
Thr	0.49	0.65	-0.32	0.65	0.32	0.03	0.310	0.564
Trp	-0.02	0.10	-0.22	0.11	0.01	0.01	0.080	0.681
Tyr	-0.20	0.10	-0.27	0.34	0.17	0.35	0.752	0.204
Val	-0.25	1.23	-0.33	0.99	-0.67	0.29	0.935	0.621
		-		Polyamines				
Putrescine	3E-03	2E-03	8E-04	1E-03	6E-03	1E-03	0.189	0.077
Spermidine	4E-03	2E-03	2E-03	4E-04	6E-03	3E-04	0.318	0.311
Spermine	2E-03	8E-04	1E-04	1E-04	7E-04	2E-04	0.065	0.154

 Table 14. Extracellular fluxes result of HL-60 cell line under hypoxia. Non-detected amino acids or polyamines or amino acids and polyamines whose replicates were not reproducible are named as discarded (D).

		INT	RACELLULAR	CONTENT NO	ORMOXIA			
	THE	P-1 P	THP	-1 AraC	THP	-1 Dox		
		nmol/mg protein					pvalue	pvalue
	Mean	SD	Mean	SD	Mean	SD	(AraC vs. P)	(Dox vs. P)
			Α	mino acids				
Ala	114.12	52.86	161.29	67.69	209.29	78.88	0.398	0.168
Arg	53.92	31.04	40.27	4.05	47.58	21.28	0.53	0.79
Asn	170.84	22.21	280.70	72.31	268.20	49.39	0.109	0.058
Asp	D	D	76.47	34.09	D	D	D	D
Cit	D	D	D	D	D	D	D	D
Gln	579.07	178.26	1101.74	139.17	823.74	387.39	0.018	0.398
Glu	D	D	D	D	D	D	D	D
Gly	161.48	63.38	156.86	5.45	243.99	85.06	0.93	0.31
His	26.58	17.36	20.69	10.35	16.95	6.15	0.646	0.444
lle	55.36	18.21	86.51	23.15	57.51	24.36	0.145	0.909
Leu	71.09	24.96	95.57	17.06	78.28	46.68	0.242	0.829
Lys	16.47	12.31	11.86	7.69	7.33	3.66	0.617	0.327
Met	22.72	6.33	31.49	18.00	22.33	13.91	0.495	0.968
Orn	3.45	1.98	3.29	0.97	3.54	2.28	0.911	0.961
Phe	15.22	4.25	22.46	2.61	15.42	8.41	0.078	0.973
Pro	117.45	40.54	170.89	17.35	100.54	37.09	0.136	0.623
Ser	32.77	17.28	90.23	50.81	118.96	90.41	0.181	0.238
Thr	52.10	15.47	99.92	54.23	57.06	32.23	0.263	0.826
Trp	4.49	0.61	4.47	2.30	3.48	1.81	0.990	0.442
Tyr	29.13	5.60	42.22	10.21	30.76	5.85	0.144	0.744
Val	12.93	5.65	18.75	5.06	16.95	4.06	0.255	0.379
			P	olyamines				
Putrescine	3.07	2.24	2.59	2.18	2.03	1.79	0.805	0.568
Spermidine	0.06	0.05	0.08	0.07	0.08	0.09	0.629	0.885
Spermine	13.02	2.40	12.10	1.91	13.29	1.82	0.150	0.094

 Table 15. Intracellular content fluxes result of THP-1 cell line under normoxia. Non-detected amino acids or polyamines or amino acids and polyamines whose replicates were not reproducible are named as discarded (D).

	HL-0			CONTENT NO		50 Dox	L	1
	nL-0	00 P		g protein	HL-0		pvalue	pvalue
	Mean	SD	Mean	SD	Mean	SD	(AraC vs. P)	(Dox vs. P
	Ivicali	30		mino acids	Ivicali	30	(Arac VS. P)	UDUX VS. P
Ala	242.41	74.08	221.33	5.61	128.98	39.32	0.671	0.100
Arg	109.52	44.48	72.68	51.03	78.11	13.04	0.40	0.35
Asn	321.55	10.16	319.60	191.36	441.34	180.38	0.988	0.369
Asp	156.61	151.15	154.95	32.98	83.16	38.51	0.99	0.49
Cit	D	D	D	D	D	D	D.55	0.45 D
Gln	1082.62	561.50	631.87	281.58	832.98	292.72	0.304	0.544
Glu	D	D	D	D	D	D	D	D
Gly	470.10	206.55	260.86	66.81	854.69	572.78	0.22	0.37
His	30.98	1.65	19.31	8.51	25.03	11.30	0.136	0.459
Ile	75.42	13.80	48.03	14.98	74.25	6.51	0.081	0.903
Leu	88.97	20.96	61.89	13.39	98.84	12.18	0.145	0.528
Lys	30.23	12.85	18.59	10.30	24.00	2.02	0.291	0.491
Met	27.77	3.80	12.84	6.03	33.53	2.24	0.030	0.102
Orn	7.06	7.26	4.20	1.41	5.04	3.56	0.568	0.696
Phe	25.22	5.15	11.29	2.62	18.07	1.95	0.025	0.125
Pro	433.48	48.07	386.66	42.81	460.76	55.35	0.277	0.555
Ser	140.00	39.33	171.70	109.34	106.42	51.41	0.675	0.423
Thr	80.08	36.17	56.67	22.83	65.40	14.68	0.406	0.567
Trp	3.67	1.07	2.27	0.93	4.82	1.14	0.166	0.271
Tyr	47.12	10.87	21.51	7.56	48.09	7.35	0.034	0.905
Val	30.38	3.61	14.79	3.38	25.85	10.84	0.006	0.552
			P	olyamines				
Putrescine	13.70	9.29	9.34	3.58	18.16	11.68	0.512	0.633
permidine	23.24	3.94	17.19	0.96	25.00	7.74	0.110	0.748
Spermine	12.18	6.94	8.96	2.14	12.74	6.40	0.512	0.923

 Table 16. Intracellular content fluxes result of HL-60 cell line under normoxia. Non-detected amino acids or polyamines or amino acids and polyamines whose replicates were not reproducible are named as discarded (D).

		IN	TRACELLULA	R CONTENT H	YPOXIA			
	THP	P-1 P	THP	-1 AraC	ТНР	-1 Dox		
			nmol/m	g protein			pvalue	pvalue
	Mean	SD	Mean	SD	Mean	SD	(AraC vs. P)	(Dox vs. P)
			A	mino acids				
Ala	58.37	19.30	252.31	43.25	204.05	17.33	0.029	0.015
Arg	40.13	10.50	105.12	45.95	20.20	7.08	0.13	0.06
Asn	356.90	129.83	212.50	52.55	388.82	277.31	0.185	0.869
Asp	105.98	30.81	43.31	22.89	109.25	13.21	0.05	0.88
Cit	0.00	0.00	0.72	0.73	1.02	0.91	0.23	0.19
Gln	1587.17	414.12	1173.53	134.78	930.00	361.11	0.220	0.108
Glu	D	D	D	D	D	D	D	D
Gly	399.83	224.99	292.34	48.71	305.36	123.49	0.50	0.57
His	35.15	7.18	35.07	8.75	20.28	7.81	0.991	0.073
lle	77.21	19.25	112.58	5.15	58.54	9.32	0.077	0.231
Leu	90.23	23.01	128.29	10.77	76.73	25.01	0.085	0.530
Lys	11.80	4.88	16.42	3.51	10.82	0.67	0.261	0.762
Met	32.99	9.12	29.55	8.85	24.67	8.13	0.664	0.305
Orn	19.01	0.62	11.43	4.87	15.77	4.82	0.112	0.364
Phe	21.56	1.45	29.14	3.48	15.78	1.74	0.048	0.012
Pro	239.33	67.93	274.90	8.33	167.65	16.62	0.461	0.204
Ser	232.19	131.09	101.53	43.31	77.38	36.95	0.220	0.170
Thr	67.33	34.98	105.53	41.85	58.26	4.82	0.294	0.699
Trp	5.54	0.23	8.71	2.34	3.73	0.88	0.143	0.061
Tyr	29.89	3.98	50.98	10.06	31.97	10.02	0.053	0.763
Val	15.16	6.01	22.94	4.17	15.38	1.11	0.148	0.955
			P	olyamines				
Putrescine	2.42	0.85	1.92	0.82	2.19	1.02	0.508	0.781
Spermidine	13.55	3.69	8.56	1.11	11.81	3.30	0.134	0.574
Spermine	8.09	2.95	7.45	0.84	7.95	1.01	0.748	0.943

 Table 17. Intracellular content fluxes result of THP-1 cell line under hypoxia. Non-detected amino acids or polyamines or amino acids and polyamines whose replicates were not reproducible are named as discarded (D).

		IN	TRACELLULA	R CONTENT H	ΗΥΡΟΧΙΑ			
	HL-	60 P	HL-6	i0 AraC	HL-6	0 Dox		
			nmol/m	g protein			pvalue	pvalue
	Mean	SD	Mean	SD	Mean	SD	(AraC vs. P)	(Dox vs. P)
-			A	mino acids				
Ala	183.11	24.54	266.89	93.70	212.04	33.39	0.208	0.293
Arg	105.56	33.00	43.00	5.19	42.57	12.31	0.03	0.04
Asn	298.84	20.37	180.68	50.80	176.72	32.63	0.020	0.005
Asp	63.65	18.72	57.30	23.61	66.53	54.79	0.73	0.94
Cit	D	D	D	D	D	D	D	D
Gln	953.89	191.90	861.80	358.34	1003.52	546.63	0.715	0.889
Glu	D	D	D	D	D	D	D	D
Gly	454.91	205.52	405.82	93.39	724.33	857.76	0.78	0.62
His	25.33	8.82	17.62	9.98	19.86	8.09	0.373	0.473
lle	51.93	22.82	48.68	10.99	52.77	4.65	0.835	0.953
Leu	45.80	37.27	63.91	14.67	41.85	9.12	0.477	0.867
Lys	16.98	2.64	8.99	3.59	13.17	6.71	0.036	0.412
Met	17.84	4.43	17.21	8.52	18.25	4.58	0.916	0.916
Orn	6.50	0.86	6.25	3.26	6.06	2.21	0.905	0.765
Phe	12.89	2.44	12.83	1.99	11.92	5.12	0.974	0.782
Pro	203.83	137.10	226.32	44.91	240.79	44.61	0.801	0.680
Ser	65.62	41.34	143.96	82.57	68.39	21.64	0.216	0.923
Thr	49.75	8.47	83.74	32.97	44.96	6.82	0.159	0.488
Trp	3.23	0.20	4.32	1.10	4.04	1.41	0.165	0.379
Tyr	32.29	9.93	23.51	6.66	24.80	9.70	0.272	0.403
Val	29.89	17.64	20.14	5.66	20.81	11.54	0.414	0.497
			Р	olyamines				
Putrescine	5.42	3.47	1.49	0.64	5.97	1.94	0.185	0.826
Spermidine	13.38	3.60	7.08	2.30	12.60	2.39	0.074	0.771
Spermine	8.68	2.52	5.82	0.80	7.43	1.44	0.180	0.505

 Table 18. Intracellular content fluxes result of HL-60 cell line under hypoxia. Non-detected amino acids or polyamines or amino acids and polyamines whose replicates were not reproducible are named as discarded (D).

	THP	-1 P	THP	1 AraC	ТНР	-1 Dox		
	1117	-11		g protein	1115	-1 DUX	pvalue	pvalue
	Mean	SD	Mean	SD	Mean	SD	(AraC vs. P)	(Dox vs. P)
-		-	Acy	lcarnitines	1	-	1,,	(,
C0	3.404	1.416	4.004	1.610	4.404	2.364	0.654	0.571
C2	1.370	0.763	0.649	0.315	1.157	0.556	0.239	0.718
C3	0.618	0.264	0.500	0.221	0.610	0.238	0.585	0.970
C3-DC (C4-OH)	0.028	0.019	0.028	0.004	0.033	0.005	0.995	0.676
C3-OH	0.019	0.019	0.020	0.002	0.023	0.006	0.878	0.724
C3:1	0.014	0.013	0.012	0.001	0.016	0.004	0.851	0.816
C4	0.469	0.251	0.516	0.294	0.232	0.093	0.843	0.239
C4:1	0.016	0.012	0.017	0.001	0.020	0.002	0.919	0.596
C5	0.231	0.081	0.325	0.136	0.248	0.109	0.377	0.845
C5-DC (C6-OH)	0.023	0.021	0.024	0.002	0.028	0.005	0.930	0.718
C5-M-DC	0.017	0.016	0.016	0.004	0.018	0.004	0.928	0.953
C5-OH (C3-DC-M)	0.038	0.030	0.031	0.002	0.058	0.007	0.741	0.370
C5:1	0.028	0.024	0.032	0.004	0.037	0.007	0.816	0.616
C5:1-DC	0.016	0.013	0.019	0.002	0.019	0.005	0.733	0.691
C6 (C4:1-DC)	0.018	0.009	0.015	0.002	0.019	0.006	0.658	0.834
C6:1	0.011	0.009	0.012	0.001	0.015	0.002	0.866	0.523
C7-DC	0.012	0.014	0.012	0.001	0.013	0.002	0.917	0.934
C8	0.047	0.046	0.041	0.006	0.057	0.025	0.845	0.773
C9	0.011	0.009	0.011	0.002	0.013	0.003	0.963	0.691
C10	0.032	0.032	0.035	0.002	0.044	0.014	0.901	0.610
C10:1	0.037	0.038	0.038	0.003	0.049	0.010	0.976	0.652
C10:2	0.013	0.010	0.011	0.003	0.013	0.003	0.726	0.929
C12	0.031	0.026	0.030	0.003	0.045	0.014	0.989	0.466
C12-DC	0.043	0.039	0.044	0.007	0.051	0.012	0.953	0.749
C12:1	0.040	0.040	0.036	0.005	0.047	0.011	0.897	0.768
C14	0.047	0.013	0.024	0.002	0.028	0.008	0.091	0.106
C14:1	0.010	0.001	0.015	0.004	0.010	0.004	0.186	0.932
C14:1-OH	0.005	0.002	0.004	0.001	0.005	0.001	0.816	0.739
C14:2	0.004	0.004	0.004	0.000	0.005	0.001	0.913	0.849
C14:2-OH	0.003	0.002	0.003	0.001	0.003	0.000	0.796	0.978
C16	0.048	0.015	0.031	0.007	0.049	0.023	0.160	0.961
С16-ОН	0.005	0.003	0.004	0.001	0.006	0.002	0.925	0.550
C16:1	0.025	0.010	0.019	0.004	0.017	0.004	0.444	0.297
C16:1-OH	0.005	0.002	0.005	0.000	0.005	0.001	0.819	0.839
C16:2	0.004	0.001	0.003	0.001	0.003	0.001	0.693	0.776
C16:2-OH	0.003	0.001	0.004	0.001	0.004	0.001	0.631	0.185
C18	0.008	0.004	0.006	0.001	0.010	0.002	0.532	0.421
C18:1	0.055	0.028	0.051	0.021	0.049	0.024	0.875	0.783
C18:1-OH	0.006	0.006	0.007	0.001	0.010	0.002	0.798	0.461
C18:2	0.014	0.006	0.012	0.002	0.009	0.002	0.690	0.235

Table 19. Intracellular content of Acylcarnitines of THP-1 cell line under normoxia. Non-detected amino acidsor polyamines or amino acids and polyamines whose replicates were not reproducible are named as discarded(D).

	Ш.	60 P	HI-6	0 AraC	LI_6	0 Dox		
	пь-	DU P		g protein	HL-0	DOX	pvalue	pvalue
	Mean	SD	Mean	SD	Mean	SD	(AraC vs. P)	(Dox vs. P)
	Wiedin			lcarnitines	Mean	35	(Alac V3.1)	(DOX V3.1)
C0	2.785	0.632	0.989	0.049	4.513	0.523	0.008	0.022
C2	1.355	0.148	0.616	0.022	2.136	0.137	0.001	0.003
C3	0.229	0.038	0.034	0.006	0.557	0.179	0.001	0.036
C3-DC (C4-OH)	0.056	0.008	0.037	0.016	0.055	0.016	0.140	0.916
СЗ-ОН	0.045	0.007	0.030	0.014	0.044	0.018	0.192	0.970
C3:1	0.032	0.003	0.023	0.010	0.030	0.011	0.173	0.772
C4	2.309	0.743	0.304	0.097	2.620	0.796	0.010	0.647
C4:1	0.046	0.006	0.032	0.007	0.049	0.017	0.065	0.777
C5	0.379	0.209	0.039	0.008	0.694	0.587	0.001	0.430
C5-DC (C6-OH)	0.056	0.003	0.041	0.011	0.058	0.021	0.095	0.863
C5-M-DC	0.033	0.002	0.030	0.004	0.039	0.012	0.254	0.459
C5-OH (C3-DC-M)	0.066	0.013	0.045	0.020	0.078	0.032	0.200	0.567
C5:1	0.062	0.004	0.054	0.013	0.075	0.029	0.348	0.497
C5:1-DC	0.039	0.003	0.029	0.009	0.036	0.015	0.154	0.749
C6 (C4:1-DC)	0.037	0.005	0.028	0.011	0.043	0.012	0.274	0.481
C6:1	0.032	0.007	0.022	0.002	0.033	0.014	0.074	0.925
C7-DC	0.030	0.003	0.022	0.004	0.029	0.012	0.030	0.876
C8	0.108	0.010	0.086	0.019	0.117	0.042	0.138	0.732
C9	0.027	0.003	0.021	0.007	0.027	0.013	0.226	0.966
C10	0.076	0.003	0.066	0.012	0.087	0.036	0.205	0.629
C10:1	0.098	0.002	0.080	0.011	0.120	0.060	0.050	0.563
C10:2	0.038	0.007	0.034	0.010	0.044	0.017	0.559	0.654
C12	0.078	0.002	0.066	0.009	0.107	0.044	0.084	0.326
C12-DC	0.111	0.013	0.094	0.013	0.140	0.056	0.172	0.427
C12:1	0.106	0.005	0.088	0.014	0.140	0.067	0.101	0.424
C14	0.067	0.017	0.033	0.005	0.133	0.030	0.029	0.029
C14:1	0.065	0.008	0.026	0.030	0.039	0.013	0.094	0.038
C14:1-OH	0.010	0.001	0.008	0.002	0.016	0.002	0.352	0.021
C14:2	0.009	0.002	0.007	0.001	0.013	0.006	0.208	0.404
C14:2-OH	0.009	0.001	0.005	0.004	0.007	0.002	0.209	0.267
C16	0.087	0.020	0.103	0.041	0.177	0.057	0.579	0.061
C16-OH	0.009	0.001	0.009	0.001	0.013	0.004	0.834	0.174
C16:1	0.050	0.011	0.025	0.005	0.109	0.011	0.025	0.003
C16:1-OH	0.022	0.007	0.012	0.010	0.010	0.003	0.241	0.056
C16:2	0.010	0.001	0.006	0.003	0.015	0.006	0.057	0.195
C16:2-OH	0.008	0.002	0.007	0.002	0.010	0.001	0.443	0.368
C18	0.013	0.002	0.011	0.001	0.021	0.002	0.323	0.009
C18:1	0.070	0.019	0.026	0.009	0.119	0.022	0.022	0.043
C18:1-OH	0.013	0.005	0.013	0.002	0.019	0.009	0.983	0.410
C18:2	0.026	0.003	0.011	0.006	0.027	0.005	0.017	0.753

 Table 20. Intracellular content of Acylcarnitines of HL-60 cell line under normoxia. Non-detected amino acids or polyamines or amino acids and polyamines whose replicates were not reproducible are named as discarded (D).

	TUD	P-1 P	тир	1 AraC	тир	-1 Dox		
	Inr	-18		g protein	InP	-1 DOX	pvalue	pvalue
	Mean	SD	Mean	SD	Mean	SD	(AraC vs. P)	(Dox vs. P)
	Mean			lcarnitines	Mean	35	(Alac V3.1)	(DOX V3.1)
C0	9.376	0.704	4.869	0.506	5.026	0.380	0.001	0.001
C2	7.683	2.525	3.259	0.285	2.943	0.540	0.039	0.034
C3	0.396	0.195	0.147	0.010	0.150	0.019	0.092	0.095
C3-DC (C4-OH)	0.076	0.010	0.059	0.007	0.033	0.009	0.074	0.006
СЗ-ОН	0.021	0.009	0.011	0.004	0.014	0.011	0.171	0.470
C3:1	0.017	0.008	0.007	0.001	0.009	0.005	0.090	0.186
C4	1.054	0.270	1.565	0.054	0.633	0.022	0.033	0.055
C4:1	0.028	0.016	0.010	0.003	0.011	0.007	0.124	0.156
C5	0.741	0.276	0.135	0.021	0.084	0.016	0.002	0.001
C5-DC (C6-OH)	0.045	0.019	0.021	0.003	0.017	0.009	0.099	0.088
C5-M-DC	0.027	0.015	0.009	0.004	0.009	0.005	0.104	0.118
C5-OH (C3-DC-M)	0.053	0.009	0.018	0.003	0.029	0.010	0.003	0.036
C5:1	0.056	0.021	0.018	0.005	0.020	0.012	0.038	0.064
C5:1-DC	0.029	0.012	0.011	0.003	0.013	0.005	0.069	0.100
C6 (C4:1-DC)	0.115	0.025	0.091	0.004	0.022	0.008	0.178	0.004
C6:1	0.020	0.008	0.007	0.001	0.009	0.006	0.058	0.138
C7-DC	0.019	0.010	0.006	0.001	0.009	0.006	0.097	0.195
C8	0.086	0.039	0.028	0.007	0.036	0.027	0.066	0.142
С9	0.017	0.007	0.006	0.001	0.009	0.005	0.046	0.195
C10	0.062	0.030	0.020	0.006	0.024	0.017	0.072	0.127
C10:1	0.063	0.040	0.021	0.008	0.024	0.017	0.153	0.194
C10:2	0.022	0.010	0.007	0.002	0.010	0.008	0.054	0.168
C12	0.148	0.047	0.050	0.015	0.029	0.015	0.026	0.014
C12-DC	0.088	0.049	0.024	0.007	0.039	0.031	0.087	0.214
C12:1	0.073	0.043	0.023	0.007	0.025	0.018	0.120	0.151
C14	0.412	0.077	0.191	0.070	0.041	0.005	0.021	0.001
C14:1	0.027	0.012	0.006	0.002	0.006	0.002	0.047	0.046
C14:1-OH	0.026	0.011	0.010	0.004	0.005	0.002	0.069	0.030
C14:2	0.007	0.003	0.002	0.001	0.003	0.002	0.046	0.195
C14:2-OH	0.006	0.003	0.002	0.001	0.002	0.002	0.083	0.138
C16	0.770	0.268	0.384	0.192	0.091	0.011	0.113	0.012
C16-OH	0.019	0.006	0.008	0.003	0.006	0.002	0.050	0.027
C16:1	0.068	0.034	0.018	0.006	0.015	0.004	0.066	0.054
C16:1-OH	0.031	0.014	0.013	0.007	0.005	0.002	0.119	0.037
C16:2	0.007	0.004	0.002	0.001	0.003	0.002	0.096	0.148
C16:2-OH	0.013	0.006	0.004	0.001	0.004	0.002	0.060	0.065
C18	0.234	0.097	0.162	0.111	0.025	0.004	0.443	0.020
C18:1	0.172	0.074	0.056	0.022	0.047	0.004	0.061	0.044
C18:1-OH	0.018	0.008	0.008	0.004	0.005	0.004	0.119	0.073
C18:2	0.019	0.007	0.005	0.001	0.007	0.002	0.031	0.051

 Table 21. Intracellular content of Acylcarnitines of THP-1 cell line under hypoxia. Non-detected amino acids or polyamines or amino acids and polyamines whose replicates were not reproducible are named as discarded (D).

	ш	60 P		R CONTENT F	-	0 Dox		
	HL-I	50 P		0 AraC g protein	HL-0	U DOX	pvalue	pvalue
	Mean	SD	Mean	SD	Mean	SD	(AraC vs. P)	(Dox vs. P)
.	Wican	30		lcarnitines	Wicall		(Alac V3. P)	(DOX V3. P)
C0	2.180	0.864	0.686	0.220	2.543	0.514	0.044	0.566
C2	1.631	0.228	0.635	0.101	1.906	0.267	0.002	0.246
C3	0.105	0.005	0.017	0.006	0.286	0.058	0.000	0.006
C3-DC (C4-OH)	0.047	0.001	0.015	0.008	0.034	0.009	0.002	0.056
C3-OH	0.048	0.011	0.014	0.009	0.030	0.010	0.016	0.109
C3:1	0.029	0.005	0.008	0.006	0.018	0.005	0.011	0.066
C4	0.519	0.336	0.180	0.027	0.999	0.219	0.156	0.107
C4:1	0.043	0.008	0.012	0.007	0.026	0.011	0.006	0.085
C5	0.122	0.020	0.025	0.007	0.245	0.034	0.003	0.005
C5-DC (C6-OH)	0.067	0.013	0.018	0.013	0.044	0.016	0.009	0.117
C5-M-DC	0.043	0.008	0.011	0.007	0.026	0.011	0.006	0.091
C5-OH (C3-DC-M)	0.055	0.005	0.015	0.009	0.039	0.013	0.002	0.109
C5:1	0.072	0.013	0.019	0.014	0.041	0.013	0.008	0.047
C5:1-DC	0.040	0.004	0.010	0.008	0.030	0.012	0.004	0.250
C6 (C4:1-DC)	0.040	0.006	0.009	0.005	0.025	0.001	0.002	0.013
C6:1	0.032	0.005	0.010	0.006	0.019	0.005	0.010	0.043
C7-DC	0.029	0.006	0.008	0.006	0.019	0.007	0.010	0.091
C8	0.133	0.011	0.033	0.024	0.082	0.028	0.003	0.044
C9	0.029	0.003	0.007	0.005	0.020	0.005	0.003	0.056
C10	0.089	0.017	0.025	0.017	0.058	0.017	0.009	0.088
C10:1	0.102	0.033	0.029	0.018	0.067	0.025	0.029	0.214
C10:2	0.058	0.012	0.013	0.008	0.031	0.003	0.005	0.018
C12	0.102	0.016	0.026	0.014	0.066	0.020	0.003	0.074
C12-DC	0.152	0.016	0.038	0.028	0.096	0.031	0.004	0.050
C12:1	0.123	0.035	0.031	0.019	0.072	0.025	0.016	0.107
C14	0.070	0.009	0.019	0.006	0.117	0.027	0.001	0.046
C14:1	0.015	0.004	0.004	0.003	0.013	0.004	0.012	0.615
C14:1-OH	0.019	0.005	0.005	0.002	0.022	0.009	0.012	0.673
C14:2	0.011	0.003	0.003	0.002	0.006	0.001	0.016	0.053
C14:2-OH	0.009	0.002	0.002	0.001	0.005	0.001	0.007	0.045
C16	0.172	0.047	0.069	0.015	0.318	0.152	0.023	0.188
С16-ОН	0.013	0.003	0.004	0.002	0.010	0.002	0.010	0.126
C16:1	0.060	0.012	0.010	0.004	0.077	0.035	0.002	0.483
C16:1-OH	0.015	0.004	0.004	0.002	0.012	0.003	0.014	0.352
C16:2	0.010	0.002	0.002	0.001	0.007	0.001	0.003	0.050
C16:2-OH	0.014	0.002	0.003	0.002	0.013	0.004	0.003	0.592
C18	0.036	0.007	0.011	0.002	0.034	0.012	0.004	0.784
C18:1	0.123	0.036	0.021	0.004	0.140	0.064	0.008	0.711
C18:1-OH	0.016	0.004	0.005	0.003	0.013	0.002	0.018	0.312
C18:2	0.018	0.003	0.003	0.002	0.019	0.002	0.001	0.636

 Table 22. Intracellular content of Acylcarnitines of HL-60 cell line under hypoxia. Non-detected amino acids or polyamines or amino acids and polyamines whose replicates were not reproducible are named as discarded (D).

THP-1 AraC vs. THP-1 P cells					
Pathway	Upregulated proteins				
Wnt signaling pathway (P00057)	9				
CCKR signaling map (P06959)	6				
Inflammation mediated by chemokine and cytokine signaling pathway (P00031)	6				
p53 pathway (P00059)	6				
DNA replication (P00017)	5				
Ubiquitin proteasome pathway (P00060)	5				
Huntington disease (P00029)	4				
PDGF signaling pathway (P00047)	4				
Angiotensin II-stimulated signaling through G proteins and beta-arrestin (P05911)	3				
Apoptosis signaling pathway (P00006)	3				
De novo purine biosynthesis (P02738)	3				
Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway (P00027)	3				
Histamine H1 receptor mediated signaling pathway (P04385)	3				
Integrin signalling pathway (P00034)	3				
p38 MAPK pathway (P05918)	3				
5HT2 type receptor mediated signaling pathway (P04374)	2				
5-Hydroxytryptamine degredation (P04372)	2				
Alpha adrenergic receptor signaling pathway (P00002)	2				
Blood coagulation (P00011)	2				
Cell cycle (P00013)	2				
Cytoskeletal regulation by Rho GTPase (P00016)	2				
De novo pyrimidine deoxyribonucleotide biosynthesis (P02739)	2				
Endogenous cannabinoid signaling (P05730)	2				
Endothelin signaling pathway (P00019)	2				
Formyltetrahydroformate biosynthesis (P02743)	2				
Gonadotropin-releasing hormone receptor pathway (P06664)	2				
Insulin/IGF pathway-protein kinase B signaling cascade (P00033)	2				
Muscarinic acetylcholine receptor 1 and 3 signaling pathway (P00042)	2				
Oxytocin receptor mediated signaling pathway (P04391)	2				
Parkinson disease (P00049)	2				
Serine glycine biosynthesis (P02776)	2				
TGF-beta signaling pathway (P00052)	2				
Thyrotropin-releasing hormone receptor signaling pathway (P04394)	2				
Toll receptor signaling pathway (P00054)	2				

Table 23. Upregulated proteins involved in the pathway gene ontology PANTHER analysis in THP-1 AraCcompared to THP-1 P cells under normoxia. Proteomic profiling (SILAC) data were used. Mean±SD for n=2replicates. Pathways selected has >1 protein upregulated.

HL-60 AraC vs. HL-60 P cells					
Pathway	Upregulated proteins				
Cholesterol biosynthesis (P00014)	6				
CCKR signaling map (P06959)	5				
Apoptosis signaling pathway (P00006)	4				
Huntington disease (P00029)	4				
De novo pyrimidine deoxyribonucleotide biosynthesis (P02739)	3				
Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway (PO	3				
Inflammation mediated by chemokine and cytokine signaling pathway (P00031)	3				
p53 pathway (P00059)	3				
Ubiquitin proteasome pathway (P00060)	3				
Wnt signaling pathway (P00057)	3				
5HT1 type receptor mediated signaling pathway (P04373)	2				
Androgen/estrogene/progesterone biosynthesis (P02727)	2				
Cytoskeletal regulation by Rho GTPase (P00016)	2				
DNA replication (P00017)	2				
FAS signaling pathway (P00020)	2				
Gonadotropin-releasing hormone receptor pathway (P06664)	2				
Heme biosynthesis (P02746)	2				
Pyruvate metabolism (P02772)	2				
T cell activation (P00053)	2				

Table 24. Upregulated proteins involved in the pathway gene ontology PANTHER analysis in HL-60 AraC

compared to HL-60 P cells under normoxia. Proteomic profiling (SILAC) data were used. Mean±SD for n=2

THP-1 Dox vs. THP-1 P cells						
Pathway	Upregulated proteins					
Apoptosis signaling pathway (P00006)	4					
CCKR signaling map (P06959)	4					
TCA cycle (P00051)	3					
5-Hydroxytryptamine degredation (P04372)	2					
Angiogenesis (P00005)	2					
Asparagine and aspartate biosynthesis (P02730)	2					
ATP synthesis (P02721)	2					
Blood coagulation (P00011)	2					
De novo purine biosynthesis (P02738)	2					
De novo pyrimidine ribonucleotides biosythesis (P02740)	2					
DNA replication (P00017)	2					
Gonadotropin-releasing hormone receptor pathway (P06664)	2					
Mannose metabolism (P02752)	2					
Parkinson disease (P00049)	2					
Pentose phosphate pathway (P02762)	2					
Pyruvate metabolism (P02772)	2					
Ras Pathway (P04393)	2					
Ubiquitin proteasome pathway (P00060)	2					

replicates. Pathways selected has >1 protein upregulated.

Table 25. Upregulated proteins involved in the pathway gene ontology PANTHER analysis in THP-1 Doxcompared to THP-1 P cells under normoxia. Proteomic profiling (SILAC) data were used. Mean±SD for n=2replicates. Pathways selected has >1 protein upregulated.

HL-60 Dox vs. HL-60 P cells						
Pathway	Upregulated proteins					
Inflammation mediated by chemokine and cytokine signaling pathway (P00031)	2					
Androgen/estrogene/progesterone biosynthesis (P02727)	1					
Apoptosis signaling pathway (P00006)	1					
B cell activation (P00010)	1					
Cell cycle (P00013)	1					
Cholesterol biosynthesis (P00014)	1					
Cytoskeletal regulation by Rho GTPase (P00016)	1					
Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway (P00027)	1					
Huntington disease (P00029)	1					
Integrin signalling pathway (P00034)	1					
JAK/STAT signaling pathway (P00038)	1					
Parkinson disease (P00049)	1					
Proline biosynthesis (P02768)	1					
T cell activation (P00053)	1					

Table 26. Upregulated proteins involved in the pathway gene ontology PANTHER analysis in HL-60 Doxcompared to HL-60 P cells under normoxia. Proteomic profiling (SILAC) data were used. Mean±SD for n=2replicates. Pathways selected at least 1 protein upregulated.

APPENDIX 2

APPENDIX 2: Supplementary data of results of Chapter 2

UPREGULATED PROTEINS IN KU8	12 ImaR VS. KU81	2 P	
Protein names	Gene names	Mean Log ₂ fold change	SD Log ₂ fold change
Protein S100-A9	S100A9	8.62	0.90
Protein S100-P	S100P	7.12	0.08
NADH-cytochrome b5 reductase 2	CYB5R2	6.61	N.D.
Protein kinase C delta type	PRKCD	5.65	2.43
Protein lin-28 homolog B	LIN28B	5.51	N.D.
Cytoskeleton-associated protein 4	CKAP4	5.32	1.75
	CRIP1	5.25	0.41
Cysteine-rich protein 1			
Protein S100-A8; Protein S100-A8, N-terminally processed	S100A8	5.22	0.04
Phosphoglucomutase-1	PGM1	5.09	1.78
Apolipoprotein C-II;Proapolipoprotein C-II	APOC2	5.09	N.D.
Liver carboxylesterase 1	CES1	5.07	0.30
High affinity immunoglobulin epsilon receptor subunit gamma	FCER1G	5.06	0.51
CD166 antigen	ALCAM	5.00	N.D.
Argininosuccinate synthase	ASS1	4.96	0.16
Melanoma-associated antigen B2	MAGEB2	4.93	N.D.
Mitochondrial 10-formyltetrahydrofolate dehydrogenase	ALDH1L2	4.87	2.92
Arachidonate 5-lipoxygenase-activating protein	ALOX5AP	4.80	0.61
Peptidyl-prolyl cis-trans isomerase C	PPIC	4.79	N.D.
Bifunctional 3-phosphoadenosine 5-phosphosulfate synthase 2	PAPSS2	4.70	2.89
Aldehyde dehydrogenase, mitochondrial	ALDH2	4.70	0.89
HLA class II histocompatibility antigen gamma chain	CD74	4.65	N.D.
Myeloblastin	PRTN3	4.65	0.27
Transketolase-like protein 1	TKTL1	4.60	0.19
Cellular retinoic acid-binding protein 1	CRABP1	4.55	1.07
Cathepsin G	CTSG	4.52	0.34
Gametocyte-specific factor 1	GTSF1	4.49	N.D.
Putative hydroxypyruvate isomerase	HYI	4.45	N.D.
CAAX prenyl protease 1 homolog	ZMPSTE24	4.45	0.41
Heat shock protein beta-1	HSPB1	4.45	0.09
Cystatin-A;Cystatin-A, N-terminally processed	CSTA	4.40	0.90
Azurocidin	AZU1	4.36	N.D.
Insulin-like growth factor 2 mRNA-binding protein 1	IGF2BP1	4.35	1.43
HLA class II histocompatibility antigen, DR alpha chain	HLA-DRA	4.28	N.D.
Neutrophil cytosol factor 1;Putative neutrophil cytosol factor 1B	NCF1;NCF1B;NCF1C	4.25	N.D.
Cytochrome b-245 light chain	CYBA	4.23	N.D.
Glycogen phosphorylase, liver form	PYGL	4.15	0.29
Unconventional myosin-VI	MYO6	4.15	0.02
Pleckstrin	PLEK	4.14	0.15
Serglycin	SRGN	4.11	1.28
Ubiquitin-like modifier-activating enzyme ATG7	ATG7	3.97	0.13
Fatty acyl-CoA reductase 1	FAR1	3.94	N.D.
Sideroflexin-2	SFXN2	3.94	N.D.
Chitinase-3-like protein 1	CHI3L1	3.93	0.70
Sodium-coupled neutral amino acid transporter 1	SLC38A1/SNAT1	3.92	1.11
Major facilitator superfamily domain-containing protein 1	MFSD1	3.92	N.D.
Neutrophil elastase	ELANE	3.90	0.14
Prostaglandin reductase 1	PTGR1	3.88	0.88
CD63 antigen	CD63	3.85	N.D.
Myeloperoxidase	MPO	3.84	0.32
Sulfide:quinone oxidoreductase, mitochondrial	SQRDL	3.84	0.49
HLA class I histocompatibility antigen, A-2 alpha chain	HLA-A	3.82	0.75
Leukocyte-associated immunoglobulin-like receptor 1	LAIR1	3.82	1.17
Lymphocyte antigen 75	LY75	3.81	0.25
Myeloid cell nuclear differentiation antigen	MNDA	3.80	N.D.
Integrin beta-2	ITGB2	3.80	0.21
Mast cell-expressed membrane protein 1	MCEMP1	3.78	N.D.
Protein-methionine sulfoxide oxidase MICAL1	MICAL1	3.77	0.11
WD repeat- and FYVE domain-containing protein 4	WDFY4	3.77	0.22
Protein S100-A11; Protein S100-A11, N-terminally processed	S100A11	3.77	0.07
Solute carrier family 2, facilitated glucose transporter member 5	SLC2A5/GLUT5	3.75	N.D.
Coronin-1A	CORO1A	3.74	0.30
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform			
	PIK3CD	3.73	0.66
Engulfment and cell motility protein 2	ELMO2	3.69	0.32
Peptidase M20 domain-containing protein 2	PM20D2	3.69	N.D.
Thrombospondin type-1 domain-containing protein 7A	THSD7A	3.62	N.D.
NAD(P)H dehydrogenase [quinone] 1	NQO1	3.61	1.50
Gamma-glutamyltranspeptidase 1, 3P, 2	GGT1;GGT3P;GGT2	3.60	0.18
Nicotinate-nucleotide pyrophosphorylase [carboxylating]	QPRT	3.59	N.D.
Cullin-associated NEDD8-dissociated protein 2	CAND2	3 59	0.72
Cullin-associated NEDD8-dissociated protein 2 Dedicator of cytokinesis protein 10	CAND2 DOCK10	3.59 3.59	0.72 0.97

Decenter two twosing protein phosphotogy at	PTPRJ	2 55	0.22
Receptor-type tyrosine-protein phosphatase eta Thyroid receptor-interacting protein 6	TRIP6	3,55 3,48	0,22 N.D.
Adenylyl cyclase-associated protein 1	CAP1	3,46	0,23
Carboxypeptidase D	CPD	3,45	0,16
Dehydrogenase/reductase SDR family member 9	DHRS9	3,43	0,87
Monocarboxylate transporter 4	SLC16A3/MCT4	3,39	0,39
TYRO protein tyrosine kinase-binding protein	TYROBP	3,38	N.D.
Prolyl 3-hydroxylase 1	LEPRE1	3,37	0,04
Anoctamin-6	ANO6	3,36	0,07
C-type mannose receptor 2	MRC2	3,36	0,64
Inactive ubiquitin thioesterase FAM105A	FAM105A	3,36	N.D.
Synaptic vesicle membrane protein VAT-1 homolog-like	VAT1L	3,35	0,30
CDKN2AIP N-terminal-like protein	CDKN2AIPNL	3,34	0,57
Beta-1,4-galactosyltransferase 1	B4GALT1	3,34	N.D.
Huntingtin-interacting protein 1	HIP1	3,34	1,41
Vesicle-associated membrane protein 8	VAMP8	3,33	0,20
Tubulin beta-4A chain	TUBB4A	3,33	0,24
ER degradation-enhancing alpha-mannosidase-like protein 1	EDEM1	3,33	0,03
AT-rich interactive domain-containing protein 3A	ARID3A	3,33	0,66
Delta-1-pyrroline-5-carboxylate synthase	ALDH18A1/P5CS	3,31	0,12
Myoferlin	MYOF	3,29	0,80
Palmitoyl-protein thioesterase 1	PPT1	3,28	0,18
Fructose-2,6-bisphosphatase TIGAR	TIGAR	3,26	N.D.
PX domain-containing protein kinase-like protein	PXK	3,26	0,29
Tubulin beta-6 chain	TUBB6	3,24	0,33
Cartilage-associated protein	CRTAP	3,24	0,25
1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-2	PLCG2	3,23	0,11
Laminin subunit beta-1	LAMB1	3,21	N.D.
Interferon-induced GTP-binding protein Mx2	MX2	3,20	N.D.
Calpain-5	CAPN5	3,20	N.D.
Lipoma-preferred partner	LPP	3,19	N.D.
G1/S-specific cyclin-D3	CCND3	3,18	N.D.
Fibrillin-2	FBN2	3,18	0,25
Dynamin-1	DNM1	3,17	0,07
Integrin alpha-L	ITGAL	3,15	0,13
Ras-related protein Rab-32	RAB32	3,14	0,21
Phospholipase D4	PLD4	3,13	0,20
Phosphatidylinositol 3,4,5-trisphosphate 5-phosphatase 1	INPP5D	3,08	0,17
Golgi SNAP receptor complex member 1	GOSR1	3,06	0,20
Apoptosis-associated speck-like protein containing a CARD	PYCARD	3,04	0,11
Ubiquitin-like modifier-activating enzyme 7	UBA7	3,04	0,30
Caspase-7;Caspase-7 subunit p20;Caspase-7 subunit p11	CASP7	3,04	N.D.
Phosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit alpha	PIK3C2A	3,02	N.D.
Microtubule-associated protein 1B	MAP1B	3,02	0,08
Protein Niban	FAM129A	3,01	0,11
Annexin A4	ANXA4	3,01	0,14
Beta-1-syntrophin	SNTB1	3,00	0,92
Cell division cycle protein 20 homolog	CDC20	3,00	N.D.
Vesicular integral-membrane protein VIP36 Glutathione peroxidase 7	LMAN2 GPX7	3,00	0,11
Glutathione peroxidase 1	GPX7 GPX1	2,98 2,97	0,12 0,16
Prolyl endopeptidase-like	PREPL		
	PREX1	2,95	0,80
Phosphatidylinositol 3,4,5-trisphosphate-dependent Rac exchanger 1 protein Caspase-1	CASP1	2,95 2,95	0,94 1,38
NACHT, LRR and PYD domains-containing protein 2	NLRP2	2,95	1,58
	ACSF2	2,92	0,21
Acyl-CoA synthetase family member 2, mitochondrial Trans-Golgi network integral membrane protein 2	TGOLN2	2,92	0,50
Uncharacterized protein KIAA0930	KIAA0930	2,87	N.D.
Transmembrane protein with metallophosphoesterase domain	TMPPE	2,86	0,03
Ras GTPase-activating-like protein IQGAP3	IQGAP3	2,86	0,26
Glucocorticoid receptor	NR3C1	2,86	N.D.
Tyrosine-protein kinase HCK	НСК	2,85	2,28
Solute carrier family 35 member B1	SLC35B1	2,84	N.D.
Nuclear pore membrane glycoprotein 210	NUP210	2,84	0,04
E3 ubiquitin-protein ligase CBL	CBL	2,84	0,73
Macrophage-capping protein	CAPG	2,84	0,73
Insulin-like growth factor 2 mRNA-binding protein 3	IGF2BP3	2,83	0,28 N.D.
Proteasome subunit beta type-9	PSMB9	2,83	0,05
Ras-related protein Rab-31	RAB31	2,82	0,05
Phospholipase D3	PLD3	2,80	0,22
Sarcoplasmic reticulum histidine-rich calcium-binding protein	HRC	2,76	0,04 N.D.
Amyloid beta A4 precursor protein-binding family B member 1-interacting protein	APBB1IP	2,76	0,06
Methionine-R-sulfoxide reductase B2, mitochondrial	MSRB2	2,76	0,36
WD repeat and FYVE domain-containing protein 1	WDFY1	2,75	0,24
STE20/SPS1-related proline-alanine-rich protein kinase	STK39	2,73	0,24 N.D.
Mitochondrial peptide methionine sulfoxide reductase	MSRA	2,73	0,06
Golgi-associated plant pathogenesis-related protein 1	GLIPR2	2,71 2,71	0,06 N.D.
Galectin-3-binding protein	LGALS3BP	2,71	0,86
Transducin-like enhancer protein 3	TLE3	2,71	4,89
HLA class I histocompatibility antigen, B-58 alpha chain	HLA-B	2,67	4,85 0,17
		_,07	0,17

Peptidyl-prolyl cis-trans isomerase H	PPIH	2,66	0,05
Sn1-specific diacylglycerol lipase beta	DAGLB	2,64	0,75
CKLF-like MARVEL transmembrane domain-containing protein 6	CMTM6	2,63	0,53
Solute carrier family 12 member 9	SLC12A9	2,62	0,69
Inactive tyrosine-protein kinase 7	PTK7	2,62	N.D.
	PSMB10	2,61	0,05
Proteasome subunit beta type-10			
Insulin-like growth factor 2 mRNA-binding protein 2	IGF2BP2	2,60	0,44
2-hydroxyacyl-CoA lyase 1	HACL1	2,60	0,67
Beta-2-microglobulin;Beta-2-microglobulin form pl 5.3	B2M	2,58	0,09
DNA helicase B	HELB	2,57	N.D.
CTP synthase 1	CTPS1	2,57	0,03
Tripartite motif-containing protein 59	TRIM59	2,56	N.D.
Unconventional myosin-If	MY01F		0,04
		2,56	
Macrosialin	CD68	2,54	N.D.
Glutathione S-transferase Mu 1	GSTM1	2,53	0,26
Coiled-coil domain-containing protein 88B	CCDC88B	2,52	0,09
Glutaminefructose-6-phosphate aminotransferase [isomerizing] 1	GFPT1	2,51	0,05
Tumor necrosis factor alpha-induced protein 2	TNFAIP2	2,50	N.D.
AT-rich interactive domain-containing protein 2	ARID2	2,50	0,35
Nischarin	NISCH		
		2,49	0,59
Inositol 1,4,5-trisphosphate receptor type 1	ITPR1	2,48	0,08
Fibronectin type III domain-containing protein 3B	FNDC3B	2,48	0,64
Homologous-pairing protein 2 homolog	PSMC3IP	2,48	N.D.
Transmembrane 9 superfamily member 1	TM9SF1	2,46	N.D.
Cation-independent mannose-6-phosphate receptor	IGF2R	2,46	0,01
Fanconi anemia group D2 protein	FANCD2	2,45	0,66
	COX17		0,06
Cytochrome c oxidase copper chaperone		2,45	
Extended synaptotagmin-2	ESYT2	2,44	0,00
Liprin-beta-1	PPFIBP1	2,43	N.D.
Protein Churchill	CHURC1	2,42	N.D.
Tumor necrosis factor alpha-induced protein 8	TNFAIP8	2,42	0,64
Alpha-2-macroglobulin receptor-associated protein	LRPAP1	2,42	N.D.
Complement factor D	CFD	2,40	1,89
DNA-binding protein SATB1	SATB1	2,39	N.D.
Ephrin type-A receptor 7	EPHA7	2,39	1,90
Acyl-CoA-binding protein	DBI	2,39	0,01
Apolipoprotein B receptor	APOBR	2,39	0,33
Non-specific lipid-transfer protein	SCP2	2,39	0,06
Phosphoribosyltransferase domain-containing protein 1	PRTFDC1	2,37	0,27
AP-4 complex subunit epsilon-1	AP4E1	2,37	N.D.
Lysosomal-trafficking regulator	LYST	2,37	0,67
	DDX60L		
Probable ATP-dependent RNA helicase DDX60-like		2,36	0,70
Solute carrier family 22 member 18	SLC22A18	2,35	1,91
ATP synthase mitochondrial F1 complex assembly factor 1	ATPAF1	2,34	0,07
Insulin receptor;Insulin receptor subunit alpha;Insulin receptor subunit beta	INSR	2,33	N.D.
Interferon regulatory factor 5	IRF5	2,33	N.D.
Protein CIP2A	KIAA1524	2,33	N.D.
Microtubule-associated protein 1A	MAP1A	2,33	0,29
Sodium-coupled neutral amino acid transporter 2	SLC38A2/SNAT2	2,32	0,50
Serine dehydratase-like	SDSL	2,32	0,05
Endoplasmic reticulum aminopeptidase 1	ERAP1	2,31	0,14
Shootin-1	KIAA1598	2,31	N.D.
Glycine amidinotransferase, mitochondrial	GATM	2,31	N.D.
Protein SCAF11	SCAF11	2,30	0,01
Serine/threonine-protein phosphatase 6 regulatory ankyrin repeat subunit B	ANKRD44	2,29	0,39
DnaJ homolog subfamily B member 12	DNAJB12	2,29	N.D.
1-acyl-sn-glycerol-3-phosphate acyltransferase beta	AGPAT2		N.D.
		2,29	
Actin-related protein 2/3 complex subunit 5-like protein	ARPC5L	2,28	0,72
Alpha-1,3-mannosyl-glycoprotein 2-beta-N-acetylglucosaminyltransferase	MGAT1	2,28	N.D.
Ras-related protein Rab-27A	RAB27A	2,27	0,09
Myocyte-specific enhancer factor 2D	MEF2D	2,26	0,21
Peptidyl-prolyl cis-trans isomerase E	PPIE	2,26	0,01
Two pore calcium channel protein 1	TPCN1	2,26	N.D.
Leucine-rich repeat and calponin homology domain-containing protein 4	LRCH4	2,26	0,18
Cyclin-dependent kinase 13	CDK13	2,25	0,40
Protein canopy homolog 2	CNPY2	2,25	0,10
Insulin receptor substrate 2	IRS2	2,25	0,14
Fanconi anemia group I protein	FANCI	2,25	0,04
HLA class I histocompatibility antigen, B-46 alpha chain	HLA-B	2,25	N.D.
Kinesin-like protein KIF15	KIF15	2,24	0,01
Protein dopey-2	DOPEY2	2,24	0,34
DCC-interacting protein 13-alpha	APPL1	2,23	0,11
Arylsulfatase B	ARSB	2,23	0,04
DNA polymerase epsilon catalytic subunit A	POLE	2,22	0,18
Microsomal glutathione S-transferase 3	MGST3	2,22	0,30
N-acetylgalactosamine-6-sulfatase	GALNS	2,22	0,18
Podocalyxin	PODXL	2,22	N.D.
Apoptotic protease-activating factor 1	APAF1	2,21	0,14
Multiple epidermal growth factor-like domains protein 8	MEGF8	2,21	0,57
Scavenger receptor class B member 1	SCARB1	2,19	N.D.

	I		
Peroxisome assembly factor 2	PEX6	2,19	N.D.
Bcl-2 homologous antagonist/killer Transmembrane and coiled-coil domain-containing protein 1	BAK1 TMCO1	2,18	0,27 0,38
Peptidyl-prolyl cis-trans isomerase B	PPIB	2,18 2,17	0,09
Cell division cycle protein 123 homolog	CDC123	2,17	N.D.
TPR and ankyrin repeat-containing protein 1	TRANK1	2,16	0,02
DnaJ homolog subfamily C member 5	DNAJC5	2,16	0,25
Rho guanine nucleotide exchange factor 18	ARHGEF18	2,15	0,46
Vesicle transport protein SFT2B	SFT2D2	2,15	N.D.
Apoptosis regulator Bcl-2	BCL2	2,15	0,43
Uncharacterized protein C1orf50	C1orf50	2,14	0,31
Asparagine synthetase [glutamine-hydrolyzing]	ASNS	2,14	0,07
Transmembrane 9 superfamily member 4	TM9SF4	2,13	0,17
RNA-binding protein 33	RBM33	2,12	N.D.
Protein tyrosine phosphatase type IVA 1	PTP4A1	2,12	N.D.
Melanoma-associated antigen D2	MAGED2	2,12	0,22
Transmembrane protein 41B	TMEM41B	2,12	0,12
ATP-binding cassette sub-family D member 3	ABCD3	2,11	0,09
Phosphopantothenatecysteine ligase	PPCS	2,10	0,07
SH3 domain-binding protein 1	SH3BP1	2,10	0,02
Guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-10	GNG10	2,10	N.D.
Probable 2-oxoglutarate dehydrogenase E1 component DHKTD1, mitochondrial	DHTKD1	2,10	N.D.
Catechol O-methyltransferase	COMT	2,09	0,11
COBW domain-containing protein 1	CBWD1	2,09	0,18
Endoplasmic reticulum-Golgi intermediate compartment protein 2	ERGIC2	2,09	N.D.
Sp110 nuclear body protein	SP110	2,08	N.D.
Nesprin-3	SYNE3	2,08	N.D.
Lysophosphatidylcholine acyltransferase 1	LPCAT1	2,06	N.D.
Sodium-dependent multivitamin transporter	SLC5A6	2,06	N.D.
Gamma-parvin	PARVG	2,06	1,15
Utrophin	UTRN	2,06	0,13
Aldose 1-epimerase	GALM	2,06	N.D.
Receptor-type tyrosine-protein phosphatase F	PTPRF	2,05	0,30
Phosphoglycerate mutase 1	PGAM1	2,05	0,04
ATP-dependent 6-phosphofructokinase, muscle type	PFKM	2,04	0,02
Autophagy protein 5	ATG5	2,04	N.D.
GTP-binding protein Rheb	RHEB	2,04	0,03
Bifunctional UDP-N-acetylglucosamine 2-epimerase/N-acetylmannosamine kinase	GNE	2,04	0,54
Glucose-6-phosphate translocase	SLC37A4	2,04	N.D.
ATP-dependent 6-phosphofructokinase, platelet type	PFKP	2,03	0,12
Transport and Golgi organization protein 2 homolog	TANGO2	2,03	N.D.
Formin-binding protein 1	FNBP1	2,03	0,14
Aldose reductase	AKR1B1	2,03	0,04
Ribulose-phosphate 3-epimerase	RPE	2,03	0,07
H(+)/Cl(-) exchange transporter 7	CLCN7	2,02	N.D.
Nucleotide exchange factor SIL1	SIL1	2,02	0,15
Prolactin regulatory element-binding protein	PREB	2,02	0,28
Diacylglycerol kinase zeta	DGKZ	2,02	N.D.
Enoyl-CoA hydratase/3,2-trans-enoyl-CoA isomerase	EHHADH	2,02	0,22
Synaptojanin-1	SYNJ1	2,01	N.D.
Cob(I)yrinic acid a,c-diamide adenosyltransferase, mitochondrial	MMAB	2,01	0,56
Glycogenin-1	GYG1	2,01	0,12
Voltage-gated potassium channel subunit beta-2	KCNAB2	2,00	0,11
tRNA dimethylallyltransferase, mitochondrial	TRIT1	2,00	N.D.
Phosphoglycolate phosphatase	PGP	2,00	0,35
Maspardin ADP-dependent glucokinase	SPG21 ADPGK	2,00	0,39 0,18
Dol-P-Man:Man(5)GlcNAc(2)-PP-Dol alpha-1,3-mannosyltransferase	ALG3	1,99 1,99	0,18
Beta-galactosidase	GLB1	1,99	0,32
Pterin-4-alpha-carbinolamine dehydratase	PCBD1	1,98	0,09
Ras-related protein Rab-5B	RAB5B		
Rho-related GTP-binding protein RhoC	RHOC	1,98 1,98	0,06 0,15
Lysosome-associated membrane glycoprotein 2	LAMP2	1,98	0,15
Peroxisomal membrane protein PMP34	SLC25A17	1,98	0,06
Alkyldihydroxyacetonephosphate synthase, peroxisomal	AGPS	1,98	0,00
Protein TFG	TFG	1,97	0,15
Endoplasmic reticulum resident protein 29	ERP29	1,97	0,02
AP2-associated protein kinase 1	AAK1	1,97	N.D.
Ubiquitin carboxyl-terminal hydrolase 15	USP15	1,97	1,28
Oxidoreductase NAD-binding domain-containing protein 1	OXNAD1	1,97	N.D.
Protein disulfide-isomerase A6	PDIA6	1,96	0,02
Selenoprotein K	SELK	1,96	N.D.
Mesencephalic astrocyte-derived neurotrophic factor	MANF	1,96	0,19
Peptidyl-prolyl cis-trans isomerase F, mitochondrial	PPIF	1,96	0,10
TATA element modulatory factor	TMF1	1,96	N.D.
Zinc finger protein Rlf	RLF	1,95	0,33
IgG receptor FcRn large subunit p51	FCGRT	1,94	0,41
Calcium/calmodulin-dependent protein kinase type 1	CAMK1	1,94	2,37
Nuclear factor of activated T-cells, cytoplasmic 2	NFATC2	1,94	N.D.
Biorientation of chromosomes in cell division protein 1-like 1	BOD1L1	1,94	0,25

HAUS augmin-like complex subunit 6	HAUS6	1,93	N.D.
Endoplasmic reticulum-Golgi intermediate compartment protein 3 Cofilin-2	ERGIC3 CFL2	1,93 1,93	N.D. N.D.
Epididymis-specific alpha-mannosidase	MAN2B2	1,95	0,37
CLIP-associating protein 2	CLASP2	1,93	0,06
Persulfide dioxygenase ETHE1, mitochondrial	ETHE1	1,92	0,00
Kinetochore-associated protein 1	KNTC1	1,92	0,04
DnaJ homolog subfamily B member 11	DNAJB11	1,91	0,04
Peroxisomal membrane protein PEX16	PEX16	1,91	N.D.
Transcription elongation factor, mitochondrial	TEFM	1,90	N.D.
Protein TMED8	TMED8	1,90	N.D.
GRIP and coiled-coil domain-containing protein 2	GCC2	1,90	0,22
Nucleoside diphosphate kinase 3	NME3	1,90	0,27
Galectin-1	LGALS1	1,90	0,03
Cytoplasmic dynein 2 heavy chain 1	DYNC2H1	1,89	N.D.
Histone deacetylase 4	HDAC4	1,89	N.D.
NFU1 iron-sulfur cluster scaffold homolog, mitochondrial	NFU1	1,89	0,08
Aflatoxin B1 aldehyde reductase member 2	AKR7A2	1,89	0,00
POU domain, class 2, transcription factor 1	POU2F1;POU2F3	1,89	N.D.
Intraflagellar transport protein 25 homolog	HSPB11	1,88	0,09
Condensin-2 complex subunit G2	NCAPG2	1,88	0,64
Charged multivesicular body protein 4b	CHMP4B	1,88	0,70
Hypoxanthine-guanine phosphoribosyltransferase	HPRT1	1,87	0,04
Glycosylphosphatidylinositol anchor attachment 1 protein	GPAA1	1,87	0,26
GPI-anchor transamidase	PIGK	1,87	0,06
Brain acid soluble protein 1	BASP1	1,87	0,22
Leucine-rich repeat-containing protein 20	LRRC20	1,87	0,26
Serine/threonine-protein kinase ATR	ATR	1,87	0,07
Deoxyhypusine synthase	DHPS	1,86	0,05
Protein RFT1 homolog	RFT1	1,86	0,24
Prolyl 4-hydroxylase subunit alpha-1	P4HA1	1,86	0,20
Serine hydroxymethyltransferase, mitochondrial	SHMT2	1,86	0,01
LIM domain and actin-binding protein 1	LIMA1	1,86	N.D.
Protein disulfide-isomerase	P4HB	1,84	0,34
7,8-dihydro-8-oxoguanine triphosphatase	NUDT1	1,84	0,18
Phosphatidylinositol glycan anchor biosynthesis class U protein	PIGU	1,84	0,05
ADP-ribosylation factor-like protein 8B	ARL8B	1,83	0,01
Annexin A6	ANXA6	1,83	0,07
Phosphotriesterase-related protein	PTER	1,83	0,25
Beta-glucuronidase	GUSB	1,82	0,00
Condensin-2 complex subunit D3	NCAPD3	1,81	0,06
Tubulin alpha-4A chain	TUBA4A	1,81	0,29
Adenylate kinase isoenzyme 6	AK6	1,80	0,22
Nucleosome assembly protein 1-like 1	NAP1L1	1,80	0,09
Transmembrane protein 131	TMEM131	1,80	N.D.
Cation-dependent mannose-6-phosphate receptor	M6PR	1,80	0,67
Peroxisomal acyl-coenzyme A oxidase 1	ACOX1	1,80	0,29
Nck-associated protein 1-like	NCKAP1L	1,79	0,02
NAD-dependent malic enzyme, mitochondrial	ME2	1,79	0,13
Acetyl-CoA carboxylase 1;Biotin carboxylase	ACACA BAZ1A	1,79	0,01
Bromodomain adjacent to zinc finger domain protein 1A	SLC4A7	1,79	0,15
Sodium bicarbonate cotransporter 3	PIK3AP1	1,79	0,29
Phosphoinositide 3-kinase adapter protein 1	ARPC4	1,79	0,45
Actin-related protein 2/3 complex subunit 4	DOCK8	1,78	0,05
Dedicator of cytokinesis protein 8 Peroxisomal membrane protein 11B	PEX11B	1,78 1,78	0,06 0,01
Actin-related protein 2/3 complex subunit 3	ARPC3	1,78	0,33
Zyxin	ZYX	1,77	0,02
Actin-related protein 2/3 complex subunit 5	ARPC5	1,77	0,51
Fumarylacetoacetate hydrolase domain-containing protein 2A	FAHD2A;FAHD2B	1,77	0,20
Lysosomal alpha-glucosidase	GAA	1,77	0,01
Telomere-associated protein RIF1	RIF1	1,77	0,01
T-cell immunomodulatory protein	ITFG1	1,77	N.D.
Sulfhydryl oxidase 2	QSOX2	1,77	0,38
Transmembrane protein 128	TMEM128	1,76	N.D.
Prenylcysteine oxidase-like	PCYOX1L	1,76	0,01
Cytochrome P450 20A1	CYP20A1	1,76	0,27
Actin-related protein 2/3 complex subunit 2	ARPC2	1,75	0,14
GPI transamidase component PIG-S	PIGS	1,75	0,08
Phosphatidylinositol 3-kinase regulatory subunit alpha	PIK3R1	1,75	0,29
LEM domain-containing protein 2	LEMD2	1,74	N.D.
Pleckstrin homology domain-containing family O member 2	PLEKHO2	1,74	N.D.
Golgi apparatus protein 1	GLG1	1,74	0,14
Protein disulfide-isomerase A4	PDIA4	1,74	0,08
Transcription initiation factor TFIID subunit 4	TAF4	1,74	N.D.
Cleft lip and palate transmembrane protein 1-like protein	CLPTM1L	1,73	0,26
GPI transamidase component PIG-T	PIGT	1,73	0,45
Immediate early response 3-interacting protein 1	IER3IP1	1,73	0,05
Ras and Rab interactor 3	RIN3	1,72	N.D.
Transmembrane protein 104	TMEM104	1,72	N.D.

	1051 T	4.70	
Selenoprotein T	SELT	1,72	N.D.
UPF0690 protein C1orf52	C1orf52	1,72	0,33
Death-inducer obliterator 1	DIDO1	1,71	0,40
Secretory carrier-associated membrane protein 1	SCAMP1	1,71	0,18
Acyl-coenzyme A thioesterase 8	ACOT8	1,71	0,21
Tyrosine-protein kinase BAZ1B	BAZ1B	1,71	0,07
Torsin-1A	TOR1A	1,70	0,03
Lysosomal protective protein	CTSA	1,70	0,51
Ras-related protein Rab-13	RAB13	1,70	N.D.
Protein kish-A	TMEM167A	1,70	0,73
VIP36-like protein	LMAN2L	1,70	0,30
Polyadenylate-binding protein 4	PABPC4	1,70	0,02
4-trimethylaminobutyraldehyde dehydrogenase	ALDH9A1	1,70	0,11
Ras-related protein Rab-7a	RAB7A	1,69	0,03
EH domain-containing protein 4	EHD4	1,69	0,28
Alpha-mannosidase 2	MAN2A1	1,68	0,01
Monoacylglycerol lipase ABHD12	ABHD12	1,68	0,04
Protein OS-9	OS9		0,10
	RBL1	1,68	
Retinoblastoma-like protein 1		1,67	N.D.
PDZ and LIM domain protein 7	PDLIM7	1,67	0,02
Myc-associated zinc finger protein	MAZ	1,67	N.D.
Dolichyl-diphosphooligosaccharideprotein glycosyltransferase subunit STT3B	STT3B	1,67	0,13
Stromal cell-derived factor 2-like protein 1	SDF2L1	1,67	0,11
Transmembrane protein 41A	TMEM41A	1,67	0,10
Lysosomal alpha-mannosidase	MAN2B1	1,67	0,44
Neutral amino acid transporter A	SLC1A4	1,66	1,04
Deoxynucleoside triphosphate triphosphohydrolase SAMHD1	SAMHD1	1,65	0,25
Dolichyl-diphosphooligosaccharideprotein glycosyltransferase subunit 1	RPN1	1,65	0,21
Bridging integrator 2	BIN2	1,65	0,20
Dedicator of cytokinesis protein 2	DOCK2	1,65	0,31
Sideroflexin-3	SFXN3	1,64	0,13
Type-1 angiotensin II receptor-associated protein	AGTRAP	1,64	0,21
Sorting nexin-27	SNX27	1,63	0,28
Sigma non-opioid intracellular receptor 1	SIGMAR1	1,63	0,17
Putative helicase MOV-10	MOV10	1,63	0,33
	SFXN4		
Sideroflexin-4		1,63	N.D.
WD repeat and FYVE domain-containing protein 3	WDFY3	1,63	0,14
Spectrin alpha chain, non-erythrocytic 1	SPTAN1	1,62	0,05
DnaJ homolog subfamily C member 1	DNAJC1	1,62	1,61
Zinc finger RNA-binding protein	ZFR	1,61	0,37
Chromosome transmission fidelity protein 8 homolog isoform 2	CHTF8	1,61	N.D.
Lysosomal acid phosphatase	ACP2	1,61	0,30
Protein canopy homolog 3	CNPY3	1,61	0,33
EF-hand domain-containing protein D2	EFHD2	1,61	0,09
Lysine-specific demethylase 4A	KDM4A	1,60	N.D.
GDP-fucose protein O-fucosyltransferase 1	POFUT1	1,60	0,39
Beta-hexosaminidase subunit alpha	HEXA	1,60	0,37
Actin-related protein 3	ACTR3	1,60	0,11
Cysteine protease ATG4B	ATG4B	1,60	2,46
E3 ubiquitin-protein ligase UHRF1	UHRF1	1,60	0,12
Nuclear envelope pore membrane protein POM 121C	POM121C;POM121	1,60	1,33
Serine/threonine-protein kinase 10	STK10	1,59	0,04
Secretory carrier-associated membrane protein 2	SCAMP2	1,59	0,37
Bleomycin hydrolase	BLMH	1,59	0,06
Minor histocompatibility protein HA-1; Minor histocompatibility antigen HA-1	HMHA1	1,58	0,18
	TMA7		
Translation machinery-associated protein 7		1,57	0,05
Neurolysin, mitochondrial	NLN	1,57	0,00
Nuclear fragile X mental retardation-interacting protein 2	NUFIP2	1,57	N.D.
Stromal cell-derived factor 2	SDF2	1,56	0,08
Acetyl-coenzyme A transporter 1	SLC33A1	1,56	N.D.
Granulins;Acrogranin	GRN	1,56	0,03
Proteasome subunit beta type-8	PSMB8	1,56	0,05
LETM1 domain-containing protein 1	LETMD1	1,56	N.D.
Condensin complex subunit 2	NCAPH	1,56	0,49
Probable 18S rRNA (guanine-N(7))-methyltransferase	WBSCR22	1,55	0,14
Cathepsin S	CTSS	1,55	0,06
Myosin light polypeptide 6	MYL6	1,55	0,09
Mitotic checkpoint serine/threonine-protein kinase BUB1 beta	BUB1B	1,55	N.D.
Long-chain-fatty-acidCoA ligase 1	ACSL1	1,55	0,08
Phosphatidylinositide phosphatase SAC1	SACM1L	1,55	0,07
Niemann-Pick C1 protein	NPC1	1,54	0,06
Vesicle transport through interaction with t-SNAREs homolog 1A	VTI1A	1,54	0,16
Synaptogyrin-1	SYNGR1	1,54	0,10
Thioredoxin-dependent peroxide reductase, mitochondrial	PRDX3	1,54	0,20
C-myc promoter-binding protein	DENND4A	1,53	0,20
Bloom syndrome protein	BLM		
		1,53	N.D.
Vesicle transport protein SFT2A	SFT2D1	1,53	0,00
Aldehyde dehydrogenase X, mitochondrial	ALDH1B1	1,53	0,14
Histone H2A type 2-B	HIST2H2AB	1,53	1,05
Ribosome-releasing factor 2, mitochondrial	GFM2	1,52	0,18

Copper transport protein ATOX1	ATOX1	1,52	0,03
Ras-related protein Rab-5A	RAB5A	1,52	0,14
KIF1-binding protein	KIAA1279	1,52	0,22
Antigen peptide transporter 2	TAP2	1,52	0,60
Metalloproteinase inhibitor 1	TIMP1	1,52	N.D.
Hypoxia-inducible factor 1-alpha inhibitor	HIF1AN	1,51	N.D.
High mobility group protein B3	HMGB3	1,51	0,20
Calponin-2	CNN2		0,06
		1,51	
Peroxisomal biogenesis factor 19	PEX19	1,51	N.D.
Protein FAM3C	FAM3C	1,51	0,30
Presenilins-associated rhomboid-like protein, mitochondrial;P-beta	PARL	1,51	0,20
Small ubiquitin-related modifier 1	SUM01	1,51	0,14
Phospholipase D1	PLD1	1,50	N.D.
Osteoclast-stimulating factor 1	OSTF1	1,50	0,03
Protein timeless homolog	TIMELESS	1,50	0,14
Isoamyl acetate-hydrolyzing esterase 1 homolog	IAH1	1,50	0,41
MIP18 family protein FAM96A	FAM96A	1,50	0,19
Eukaryotic translation initiation factor 4 gamma 2	EIF4G2	1,50	0,04
GTP-binding protein SAR1a	SAR1A		
		1,49	0,11
3-ketoacyl-CoA thiolase, peroxisomal	ACAA1	1,49	0,32
Calreticulin	CALR	1,49	0,03
3-phosphoinositide-dependent protein kinase 1	PDPK1;PDPK2P	1,48	0,08
A-kinase anchor protein 1, mitochondrial	AKAP1	1,48	0,19
Protein transport protein Sec61 subunit beta	SEC61B	1,48	0,16
Protein CREG1	CREG1	1,48	0,20
Zinc transporter 5	SLC30A5	1,48	N.D.
Hematopoietic lineage cell-specific protein	HCLS1	1,47	0,61
UDP-glucose:glycoprotein glucosyltransferase 1	UGGT1	1,47	0,04
Microtubule-associated protein RP/EB family member 1	MAPRE1	1,47	0,04
Procollagen-lysine,2-oxoglutarate 5-dioxygenase 3	PLOD3	1,47	0,19
Neurogranin;NEUG(55-78)	NRGN	1,47	N.D.
U8 snoRNA-decapping enzyme	NUDT16	1,47	0,10
Gamma-aminobutyric acid receptor-associated protein	GABARAP	1,46	0,11
Immunity-related GTPase family Q protein	IRGQ	1,46	0,24
Attractin	ATRN	1,46	N.D.
Caspase recruitment domain-containing protein 16	CARD16	1,45	N.D.
Ceramide synthase 6	CERS6	1,45	N.D.
Translationally-controlled tumor protein	TPT1	1,45	0,14
	MYO18A		
Unconventional myosin-XVIIIa		1,45	0,19
Elongation factor 1-alpha 2	EEF1A2	1,45	N.D.
DnaJ homolog subfamily C member 13	DNAJC13	1,44	0,00
Volume-regulated anion channel subunit LRRC8D	LRRC8D	1,44	0,81
Histidine triad nucleotide-binding protein 2, mitochondrial	HINT2	1,44	0,03
Thioredoxin-related transmembrane protein 1	TMX1	1,44	0,05
Calnexin	CANX	1,44	0,13
CD97 antigen	CD97	1,43	0,47
HLA class I histocompatibility antigen, Cw-7 alpha chain	HLA-C	1,43	0,39
Mitochondrial import receptor subunit TOM5 homolog	томм5	1,43	0,10
UDP-glucose:glycoprotein glucosyltransferase 2	UGGT2	1,43	N.D.
Guanidinoacetate N-methyltransferase			
	GAMT	1,43	0,21
Glucose-6-phosphate 1-dehydrogenase	G6PD	1,42	0,10
PH and SEC7 domain-containing protein 4	PSD4	1,42	0,08
Rho GTPase-activating protein 4	ARHGAP4	1,42	0,08
Rapamycin-insensitive companion of mTOR	RICTOR	1,42	N.D.
Cytospin-A	SPECC1L	1,42	N.D.
Acyl-CoA dehydrogenase family member 9, mitochondrial	ACAD9	1,42	0,06
Sentrin-specific protease 3	SENP3	1,41	N.D.
Dihydrofolate reductase	DHFR	1,41	0,10
Recombining binding protein suppressor of hairless	RBPJ	1,41	0,19
Ubiquitin carboxyl-terminal hydrolase 4	USP4	1,40	0,13
PRA1 family protein 3	ARL6IP5		0,13
		1,40	
Myosin light chain 6B	MYL6B	1,40	0,41
Ataxin-10	ATXN10	1,39	0,14
Structural maintenance of chromosomes protein 4	SMC4	1,39	0,07
V-type proton ATPase subunit S1	ATP6AP1	1,39	N.D.
Pyruvate dehydrogenase phosphatase regulatory subunit, mitochondrial	PDPR	1,39	0,07
RNA-binding protein 27	RBM27	1,39	1,09
NADH-cytochrome b5 reductase 3	CYB5R3	1,39	0,01
Histone acetyltransferase type B catalytic subunit	HAT1	1,39	0,03
UDP-N-acetylhexosamine pyrophosphorylase-like protein 1	UAP1L1	1,39	N.D.
Ras-related protein Rab-33A	RAB33A	1,39	N.D.
	C9orf64		
UPF0553 protein C9orf64		1,39	N.D.
Calcium-binding mitochondrial carrier protein SCaMC-1	SLC25A24	1,38	0,05
Serine/threonine-protein kinase WNK1	WNK1	1,38	0,51
Protein VPRBP	VPRBP	1,38	0,18
Ganglioside GM2 activator; Ganglioside GM2 activator isoform short	GM2A	1,38	0,02
Glutamine-rich protein 1	QRICH1	1,38	N.D.
NAD(P)H-hydrate epimerase	APOA1BP	1,38	0,08
Zinc finger E-box-binding homeobox 2	ZEB2	1,38	N.D.
Glycerol-3-phosphate dehydrogenase, mitochondrial	GPD2	1,38	0,18
			., .

	l		
Retinoblastoma-associated protein	RB1	1,37	0,15
Nicastrin	NCSTN	1,37	0,14
DNA repair protein RAD51 homolog 3	RAD51C	1,37	N.D.
Eukaryotic translation initiation factor 4 gamma 3	EIF4G3	1,37	0,61
tRNA (guanine(10)-N2)-methyltransferase homolog	TRMT11	1,37	N.D.
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform	PIK3CB	1,36	0,18
Volume-regulated anion channel subunit LRRC8C	LRRC8C	1,36	0,31
Retinal rod rhodopsin-sensitive cGMP 3,5-cyclic phosphodiesterase subunit delta	PDE6D	1,36	N.D.
Ras-related protein Rab-8B	RAB8B	1,36	0,07
Nuclear respiratory factor 1	NRF1	1,36	N.D.
Coiled-coil domain-containing protein 58	CCDC58	1,36	0,01
N-acetylgalactosaminyltransferase 7	GALNT7	1,35	N.D.
Serine racemase	SRR	1,35	N.D.
Ras-related protein Rab-18	RAB18	1,35	0,04
Integrin-linked protein kinase	ILK		
		1,35	0,35
Syntaxin-16	STX16	1,35	N.D.
Delta(24)-sterol reductase	DHCR24	1,35	0,26
Probable C-mannosyltransferase DPY19L1	DPY19L1	1,35	N.D.
WD repeat-containing protein 62	WDR62	1,35	N.D.
Hippocalcin-like protein 1;Neuron-specific calcium-binding protein hippocalcin	HPCAL1;HPCA	1,34	0,13
Rho GTPase-activating protein 1	ARHGAP1	1,34	0,02
Monocarboxylate transporter 2	SLC16A7/MCT2	1,34	N.D.
Cleft lip and palate transmembrane protein 1	CLPTM1	1,34	0,04
Mitochondrial import inner membrane translocase subunit TIM16	PAM16	1,33	0,01
Centrosomal protein of 170 kDa	CEP170	1,33	0,09
Protein FAM136A	FAM136A	1,33	0,16
5-demethoxyubiquinone hydroxylase, mitochondrial	COQ7	1,33	N.D.
Thymidylate synthase	TYMS	1,33	N.D.
Actin-related protein 2/3 complex subunit 1B	ARPC1B	1,33	0,22
CLIP-associating protein 1	CLASP1	1,32	0,11
Thioredoxin domain-containing protein 12	TXNDC12	1,32	0,29
Thiamin pyrophosphokinase 1	TPK1	1,32	N.D.
Copine-8;Copine-9;Copine-5	CPNE8;CPNE9;CPNE5	1,32	N.D.
Mitochondrial import receptor subunit TOM22 homolog	TOMM22	1,32	0,11
Drebrin-like protein	DBNL	1,32	0,14
Lariat debranching enzyme	DBR1	1,32	0,06
Nuclease EXOG, mitochondrial	EXOG	1,32	0,19
F-box only protein 22	FBXO22	1,31	N.D.
Uncharacterized protein KIAA1143	KIAA1143	1,31	N.D.
Bifunctional epoxide hydrolase 2	EPHX2	1,31	N.D.
Neurofibromin;Neurofibromin truncated	NF1	1,31	0,20
Structural maintenance of chromosomes protein 2	SMC2	1,31	0,12
Probable dolichyl pyrophosphate Glc1Man9GlcNAc2 alpha-1,3-glucosyltransferase	ALG8	1,31	0,06
Arf-GAP with coiled-coil, ANK repeat and PH domain-containing protein 2	ACAP2	1,31	0,16
Succinyl-CoA:3-ketoacid coenzyme A transferase 1, mitochondrial	OXCT1	1,31	0,20
THUMP domain-containing protein 3	THUMPD3	1,30	0,22
78 kDa glucose-regulated protein	HSPA5	1,30	0,07
Ena/VASP-like protein	EVL	1,30	0,01
Nuclear pore complex protein Nup214	NUP214	1,30	0,21
HIV Tat-specific factor 1	HTATSF1	1,30	0,06
SUN domain-containing protein 2	SUN2	1,30	N.D.
Dihydroxyacetone phosphate acyltransferase	GNPAT	1,30	0,17
Golgin subfamily B member 1	GOLGB1	1,29	0,05
WD repeat-containing protein 70	WDR70	1,29	N.D.
GTP-binding protein SAR1b	SAR1B	1,29	0,09
Sterol O-acyltransferase 1	SOAT1	1,29	N.D.
Plexin-B2	PLXNB2	1,29	0,15
Deoxyuridine 5-triphosphate nucleotidohydrolase, mitochondrial	DUT	1,29	0,10
RNA-binding protein 26	RBM26	1,29	0,04
Phostensin	PPP1R18	1,29	0,04 N.D.
	DNAJC19		
Mitochondrial import inner membrane translocase subunit TIM14		1,28	0,02
Forkhead box protein K1	FOXK1	1,28	0,17
Adenylate kinase isoenzyme 1	AK1	1,28	0,05
Nucleoside diphosphate kinase 6	NME6	1,28	0,24
Pterin-4-alpha-carbinolamine dehydratase 2	PCBD2	1,28	0,09
Nuclear autoantigenic sperm protein	NASP	1,28	0,21
Eukaryotic translation initiation factor 2A	EIF2A	1,27	0,03
CAP-Gly domain-containing linker protein 1	CLIP1	1,27	0,24
Lysosome-associated membrane glycoprotein 1	LAMP1	1,27	0,23
Vacuolar ATPase assembly integral membrane protein VMA21	VMA21	1,27	0,07
5-formyltetrahydrofolate cyclo-ligase	MTHFS	1,27	0,30
Phospholipid hydroperoxide glutathione peroxidase, mitochondrial	GPX4		
		1,27	0,21
Erlin-1	ERLIN1	1,27	0,59
BAG family molecular chaperone regulator 1	BAG1	1,26	N.D.
Stromal membrane-associated protein 2	SMAP2	1,26	0,82
Coiled-coil domain-containing protein 51	CCDC51	1,26	N.D.
Magnesium transporter protein 1	MAGT1	1,26	0,02
Lysine-specific demethylase 3B			
	KDM3B	1,26	0,05
Growth hormone-inducible transmembrane protein	KDM3B GHITM		
Growth hormone-inducible transmembrane protein FYVE and coiled-coil domain-containing protein 1		1,26 1,25 1,25	0,05 0,24 0,48

Guanine nucleotide-binding protein subunit beta-4	GNB4	1,25	0,34
Williams-Beuren syndrome chromosomal region 16 protein	WBSCR16	1,25	N.D.
Ras-related protein Rab-22A	RAB22A	1,25	0,61
Probable serine carboxypeptidase CPVL	CPVL	1,25	0,35
Endoplasmic reticulum resident protein 44	ERP44	1,25	0,07
Chromobox protein homolog 5	CBX5	1,25	0,23
Ubiquitin-like-conjugating enzyme ATG3	ATG3	1,24	0,09
Secretory carrier-associated membrane protein 3	SCAMP3	1,24	0,03
10 kDa heat shock protein, mitochondrial	HSPE1	1,24	0,03
Enhancer of mRNA-decapping protein 4	EDC4	1,24	0,31
Phosphatidylinositol 3,4,5-trisphosphate 5-phosphatase 2	INPPL1	1,23	0,11
Motile sperm domain-containing protein 2	MOSPD2	1,23	N.D.
PAS domain-containing serine/threonine-protein kinase	PASK	1,23	N.D.
Adenosylhomocysteinase	AHCY	1,23	0,20
Signal transducer and activator of transcription 2	STAT2	1,23	0,76
Cullin-2	CUL2	1,22	0,05
G patch domain-containing protein 1	GPATCH1	1,22	0,15
Dual specificity protein phosphatase 3	DUSP3	1,22	0,32
Adenosine deaminase	ADA	1,22	0,88
TBC1 domain family member 13	TBC1D13	1,22	0,30
Mitochondrial import receptor subunit TOM20 homolog	TOMM20	1,22	N.D.
Cathepsin L1;Cathepsin L1 heavy chain;Cathepsin L1 light chain	CTSL	1,22	0,07
Protein PRRC1	PRRC1	1,21	0,41
Sulfatase-modifying factor 2	SUMF2	1,21	0,02
NAD(P) transhydrogenase, mitochondrial	NNT	1,21	0,02
PERQ amino acid-rich with GYF domain-containing protein 2	GIGYF2		
	UBAP2	1,21	0,22
Ubiquitin-associated protein 2	BRI3BP	1,21	0,54
BRI3-binding protein		1,20	0,26
Pyridoxal-dependent decarboxylase domain-containing protein 1	PDXDC1	1,20	0,23
Kinetochore protein Spc24	SPC24	1,20	0,17
ADP-ribosylation factor GTPase-activating protein 3	ARFGAP3	1,20	N.D.
Glutathione S-transferase Mu 3	GSTM3	1,20	0,07
Heat shock 70 kDa protein 14	HSPA14	1,20	0,17
GDP-fucose protein O-fucosyltransferase 2	POFUT2	1,20	N.D.
Dihydropyrimidinase-related protein 2	DPYSL2	1,20	0,21
Ras-related protein Rab-43	RAB43	1,20	N.D.
Tyrosine-protein phosphatase non-receptor type 6	PTPN6	1,20	0,01
Nucleolar MIF4G domain-containing protein 1	NOM1	1,20	0,10
Condensin complex subunit 3	NCAPG	1,19	0,16
Protein YIPF5	YIPF5	1,19	N.D.
Mitochondrial import inner membrane translocase subunit Tim17-B	TIMM17B	1,19	0,21
E3 ubiquitin-protein ligase UHRF2	UHRF2	1,19	N.D.
Transmembrane protein 33	TMEM33	1,19	0,06
Filamin-C	FLNC	1,18	N.D.
Protein PRRC2C	PRRC2C	1,18	0,06
Ovarian cancer-associated gene 2 protein	OVCA2	1,18	0,03
Zinc transporter 6	SLC30A6	1,18	N.D.
HAUS augmin-like complex subunit 2	HAUS2	1,17	0,21
Lactoylglutathione lyase	GLO1	1,17	0,01
Probable tRNA pseudouridine synthase 1	TRUB1	1,17	N.D.
F-box/LRR-repeat protein 12	FBXL12	1,17	N.D.
Sodium/potassium-transporting ATPase subunit alpha-1	ATP1A1	1,17	0,14
DNA mismatch repair protein Mlh1	MLH1	1,17	0,27
Inositol polyphosphate 1-phosphatase	INPP1	1,16	0,35
	SEC61G		
Protein transport protein Sec61 subunit gamma	OLA1	1,16	0,14
Obg-like ATPase 1 2,3-cyclic-nucleotide 3-phosphodiesterase	CNP	1,16	0,00
2,3-cyclic-nucleotide 3-phosphodiesterase		1,16	0,11
	NDC1 PTPN9	1,16	0,16
Tyrosine-protein phosphatase non-receptor type 9		1,16	0,01
NudC domain-containing protein 3	NUDCD3	1,16	0,30
3-ketoacyl-CoA thiolase, mitochondrial	ACAA2	1,16	0,17
Peptidyl-prolyl cis-trans isomerase A	PPIA	1,15	0,07
ATP-dependent DNA helicase Q4	RECQL4	1,15	N.D.
Kinetochore protein Spc25	SPC25	1,15	0,15
Cytochrome c	CYCS	1,15	0,17
SEC23-interacting protein	SEC23IP	1,15	0,02
Ribonuclease P protein subunit p14	RPP14	1,15	0,05
Annexin A11	ANXA11	1,15	0,17
Nicotinamide/nicotinic acid mononucleotide adenylyltransferase 1	NMNAT1	1,15	N.D.
Nuclear cap-binding protein subunit 2	NCBP2	1,15	0,17
ADP-ribosylation factor 4	ARF4	1,14	0,21
Calcium-binding mitochondrial carrier protein Aralar1	SLC25A12	1,14	0,00
Ganglioside-induced differentiation-associated protein 2	GDAP2	1,14	N.D.
Methionine synthase	MTR	1,14	0,04
Microtubule-associated protein 4	MAP4	1,14	0,14
[Protein ADP-ribosylarginine] hydrolase	ADPRH	1,13	0,37
Fructose-bisphosphate aldolase A	ALDOA	1,13	0,04
Ras-related protein Rab-3D	RAB3D	1,13	0,04
Vesicle transport protein GOT1B	GOLT1B	1,13	0,14
Cyclin-dependent kinase 1	CDK1	1,13	0,24
-,	00.12	1,13	0,24

Flow and the foretain Constitution detail	GFM1	1.12	0.00
Elongation factor G, mitochondrial ETS-related transcription factor Elf-1	GFM1 ELF1	1,13 1,13	0,00 0,36
DmX-like protein 2	DMXL2	1,13	0,30 N.D.
Mitochondrial chaperone BCS1	BCS1L	1,12	0,25
Actin-related protein 2	ACTR2	1,12	0,02
Proteasome activator complex subunit 2	PSME2	1,12	0,06
Renin receptor	ATP6AP2	1,12	0,01
Reactive oxygen species modulator 1	ROMO1	1,12	0,07
WD repeat domain-containing protein 83	WDR83	1,12	N.D.
Dolichyl-diphosphooligosaccharideprotein glycosyltransferase subunit DAD1	DAD1	1,12	0,02
DNA mismatch repair protein Msh6	MSH6	1,12	0,02
Prefoldin subunit 1	PFDN1	1,12	0,03
Kynureninase	KYNU	1,12	0,01
Omega-amidase NIT2	NIT2	1,12	0,17
Regulation of nuclear pre-mRNA domain-containing protein 2	RPRD2	1,12	0,11
Crk-like protein	CRKL	1,11	1,00
(3R)-hydroxyacyl-CoA dehydrogenase	HSD17B4	1,11	0,19
Ribonuclease UK114	HRSP12	1,11	0,12
Protein kinase C-binding protein 1	ZMYND8	1,11	N.D.
Spectrin beta chain, non-erythrocytic 1	SPTBN1	1,11	0,15
Plastin-2	LCP1	1,11	0,04
Ubiquitin-like modifier-activating enzyme 5	UBA5	1,10	0,14
BUB3-interacting and GLEBS motif-containing protein ZNF207	ZNF207	1,10	0,18
Torsin-1A-interacting protein 2	TOR1AIP2	1,10	N.D.
Protein transport protein Sec24D	SEC24D	1,10	0,34
Cancer-related nucleoside-triphosphatase	NTPCR	1,10	0,11
Costars family protein ABRACL	ABRACL	1,10	0,05
Protein misato homolog 1	MST01	1,09	0,01
Probable ATP-dependent RNA helicase DHX35	DHX35	1,09	0,17
BET1-like protein	BET1L	1,09	0,62
Tyrosine-protein kinase SYK	SYK	1,09	0,03
ADP-ribosylation factor 5	ARF5	1,09	0,19
Kanadaptin	SLC4A1AP	1,09	0,28
Ras-related protein Rab-21	RAB21	1,08	0,12
Toll-interacting protein	TOLLIP	1,08	2,13
Ras association domain-containing protein 2	RASSF2	1,08	N.D.
Pyridoxal kinase	PDXK	1,08	0,15
DNA replication licensing factor MCM6	MCM6	1,08	0,26
Glutaredoxin-1	GLRX	1,08	0,04
V-type proton ATPase 116 kDa subunit a isoform 1	ATP6V0A1	1,08	0,16
Phosphoserine aminotransferase	PSAT1	1,07	0,08
MAP kinase-activated protein kinase 3	МАРКАРКЗ	1,07	0,17
Pachytene checkpoint protein 2 homolog	TRIP13	1,07	0,02
Tyrosine-protein phosphatase non-receptor type 23	PTPN23	1,07	0,38
Protein transport protein Sec24A	SEC24A	1,07	0,49
Stress-70 protein, mitochondrial	HSPA9	1,07	0,02
Major facilitator superfamily domain-containing protein 10	MFSD10	1,07	N.D.
Thymosin beta-4;Hematopoietic system regulatory peptide	TMSB4X	1,07	N.D.
Minor histocompatibility antigen H13	HM13	1,07	0,03
Vesicle-fusing ATPase	NSF	1,07	0,07
Polypeptide N-acetylgalactosaminyltransferase 6	GALNT6	1,07	N.D.
Adipocyte plasma membrane-associated protein	APMAP	1,06	0,23
Coiled-coil domain-containing protein 6	CCDC6	1,06	0,07
Beta-mannosidase	MANBA	1,06	N.D.
HIG1 domain family member 1A, mitochondrial	HIGD1A	1,06	0,07
Vitamin K epoxide reductase complex subunit 1-like protein 1	VKORC1L1	1,06	0,08
Dehydrogenase/reductase SDR family member 4	DHRS4	1,06	0,10
Mitochondrial carrier homolog 1	MTCH1	1,06	0,98
Cyclin-dependent-like kinase 5	CDK5	1,06	0,08
Vesicle-associated membrane protein 7	VAMP7	1,05	0,26
Helicase ARIP4	RAD54L2	1,05	N.D.
Peptidyl-prolyl cis-trans isomerase-like 3	PPIL3	1,05	0,06
Syntaxin-binding protein 2	STXBP2	1,05	0,16
Peroxisomal biogenesis factor 3 Translocation protein SEC62	PEX3 SEC62	1,05	N.D.
Translocation protein SEC62		1,05	0,13 N D
Genetic suppressor element 1	GSE1	1,05	N.D.
DNA replication licensing factor MCM4	MCM4	1,05	0,01
Trafficking protein particle complex subunit 8	TRAPPC8	1,04	0,20
Conserved oligomeric Golgi complex subunit 3	COG3	1,04	N.D.
Amyloid beta A4 protein	APP	1,04	0,46
Receptor-type tyrosine-protein phosphatase epsilon	PTPRE	1,04	1,57
Autophagy-related protein 101	ATG101	1,04	N.D.
Tricarboxylate transport protein, mitochondrial	SLC25A1	1,04	0,07
Cytochrome b5 type B	CYB5B	1,04	0,15
SH3 domain-containing kinase-binding protein 1	SH3KBP1	1,04	0,50
Elongation of very long chain fatty acids protein 1	ELOVL1	1,04	0,06
Very-long-chain 3-oxoacyl-CoA reductase	HSD17B12	1,04	0,02
Clathrin light chain B	CLTB	1,04	N.D.
Lipase maturation factor 2 Vacualar protein sorting-associated protein 45	LMF2	1,04	0,23
Vacuolar protein sorting-associated protein 45	VPS45	1,03	0,00

Protein transport protein Sec61 subunit alpha isoform 1	SEC61A1	1,03	0,06
Target of EGR1 protein 1	TOE1	1,03	0,17
HLA class I histocompatibility antigen, Cw-3 alpha chain	HLA-C	1,03	N.D.
60 kDa heat shock protein, mitochondrial	HSPD1	1,03	0,03
Protein RER1	RER1	1,03	0,08
Probable ATP-dependent RNA helicase DDX41	DDX41	1,03	0,28
Golgin subfamily A member 4	GOLGA4	1,03	N.D.
Prefoldin subunit 4	PFDN4	1,03	0,27
Lys-63-specific deubiquitinase BRCC36	BRCC3	1,03	0,00
Protein jagunal homolog 1	JAGN1	1,03	0,03
Tonsoku-like protein	TONSL	1,02	0,02
NHL repeat-containing protein 3	NHLRC3	1,02	N.D.
Methylcrotonoyl-CoA carboxylase beta chain, mitochondrial	MCCC2	1,02	0,04
E3 SUMO-protein ligase RanBP2	RANBP2	1,02	0,21
Mitochondrial import receptor subunit TOM6 homolog	томме	1,02	N.D.
G-protein-signaling modulator 3	GPSM3	1,01	N.D.
Coiled-coil-helix-coiled-coil-helix domain-containing protein 5	CHCHD5		N.D.
		1,01	
Lactoperoxidase	LPO	1,01	N.D.
LIM and SH3 domain protein 1	LASP1	1,01	0,02
Probable cation-transporting ATPase 13A3	ATP13A3	1,01	N.D.
Endoplasmic reticulum-Golgi intermediate compartment protein 1	ERGIC1	1,01	0,03
Sepiapterin reductase	SPR	1,01	0,07
Methylated-DNAprotein-cysteine methyltransferase	MGMT	1,01	0,25
Programmed cell death 6-interacting protein	PDCD6IP	1,01	0,21
Alpha-actinin-1	ACTN1	1,01	0,04
	DPM3		
Dolichol-phosphate mannosyltransferase subunit 3		1,01	0,04
Eukaryotic initiation factor 4A-II	EIF4A2	1,01	0,09
Beta-hexosaminidase subunit beta	HEXB	1,01	0,04
Filamin-A	FLNA	1,01	0,04
Condensin complex subunit 1	NCAPD2	1,00	0,07
Protein kish-B	TMEM167B	1,00	N.D.
Protein YIF1B	YIF1B	1,00	0,34
Ataxin-2-like protein	ATXN2L	1,00	0,24
Dehydrodolichyl diphosphate syntase complex subunit NUS1	NUS1		
		1,00	N.D.
Rab3 GTPase-activating protein catalytic subunit	RAB3GAP1	1,00	0,11
Tumor necrosis factor alpha-induced protein 8-like protein 2	TNFAIP8L2	0,99	0,35
Endoplasmin	HSP90B1	0,99	0,10
AP-3 complex subunit mu-1	AP3M1	0,99	0,31
Ras GTPase-activating-like protein IQGAP1	IQGAP1	0,99	0,12
Transmembrane 9 superfamily member 3	TM9SF3	0,99	0,09
Anoctamin-10	ANO10	0,99	0,04
Uridine 5-monophosphate synthase	UMPS	0,98	0,21
	EIF3K	0,98	
Eukaryotic translation initiation factor 3 subunit K			0,15
Membrane-associated progesterone receptor component 1	PGRMC1	0,98	0,18
Single-stranded DNA-binding protein, mitochondrial	SSBP1	0,98	0,01
Protein transport protein Sec24C	SEC24C	0,98	0,06
Retinoid-inducible serine carboxypeptidase	SCPEP1	0,98	0,02
Myosin-14	MYH14	0,98	0,03
FUN14 domain-containing protein 2	FUNDC2	0,98	0,07
von Willebrand factor A domain-containing protein 8	VWA8	0,98	0,23
Calcium-binding mitochondrial carrier protein Aralar2	SLC25A13	0,98	0,04
Zinc finger CCCH-type antiviral protein 1-like	ZC3HAV1L		0,31
		0,98	
GTPase-activating protein and VPS9 domain-containing protein 1	GAPVD1	0,98	0,04
Ubiquitin-fold modifier-conjugating enzyme 1	UFC1	0,98	0,24
Importin-7	IPO7	0,97	0,02
14-3-3 protein beta/alpha	YWHAB	0,97	0,07
Kinetochore protein NDC80 homolog	NDC80	0,97	N.D.
2,5-phosphodiesterase 12	PDE12	0,97	0,15
Succinate dehydrogenase cytochrome b560 subunit, mitochondrial	SDHC	0,97	0,13
DNA replication licensing factor MCM5	MCM5	0,97	0,02
Mitochondrial import receptor subunit TOM40B	TOMM40L		N.D.
		0,97	
DNA replication licensing factor MCM2	MCM2	0,97	0,01
Ubiquitin-conjugating enzyme E2 C	UBE2C	0,97	N.D.
Protein disulfide-isomerase A5	PDIA5	0,97	0,15
Caspase recruitment domain-containing protein 8	CARD8	0,97	0,08
Syntaxin-18	STX18	0,96	0,15
Ubiquitin-conjugating enzyme E2 A	UBE2A	0,96	0,12
Alpha-1,6-mannosyl-glycoprotein 2-beta-N-acetylglucosaminyltransferase	MGAT2	0,96	N.D.
Signal recognition particle receptor subunit beta	SRPRB	0,96	0,10
Tapasin	ТАРВР	0,96	0,16
Succinate dehydrogenase [ubiquinone] cytochrome b small subunit, mitochondrial			0,10
			0,11
	SDHD	0,96	0.07
Delta(3,5)-Delta(2,4)-dienoyl-CoA isomerase, mitochondrial	SDHD ECH1	0,96	0,07
Delta(3,5)-Delta(2,4)-dienoyl-CoA isomerase, mitochondrial Probable methyltransferase TARBP1	SDHD ECH1 TARBP1	0,96 0,96	0,04
Delta(3,5)-Delta(2,4)-dienoyl-CoA isomerase, mitochondrial Probable methyltransferase TARBP1 ADP-ribosylation factor-like protein 2-binding protein	SDHD ECH1 TARBP1 ARL2BP	0,96	
Delta(3,5)-Delta(2,4)-dienoyl-CoA isomerase, mitochondrial Probable methyltransferase TARBP1	SDHD ECH1 TARBP1	0,96 0,96	0,04
Delta(3,5)-Delta(2,4)-dienoyl-CoA isomerase, mitochondrial Probable methyltransferase TARBP1 ADP-ribosylation factor-like protein 2-binding protein	SDHD ECH1 TARBP1 ARL2BP	0,96 0,96 0,96	0,04 N.D.
Delta(3,5)-Delta(2,4)-dienoyl-CoA isomerase, mitochondrial Probable methyltransferase TARBP1 ADP-ribosylation factor-like protein 2-binding protein Fucose-1-phosphate guanylyltransferase	SDHD ECH1 TARBP1 ARL2BP FPGT	0,96 0,96 0,96 0,96 0,96	0,04 N.D. N.D.
Delta(3,5)-Delta(2,4)-dienoyl-CoA isomerase, mitochondrial Probable methyltransferase TARBP1 ADP-ribosylation factor-like protein 2-binding protein Fucose-1-phosphate guanylyltransferase B-cell receptor-associated protein 31 Histone deacetylase complex subunit SAP130	SDHD ECH1 TARBP1 ARL2BP FPGT BCAP31 SAP130	0,96 0,96 0,96 0,96 0,96 0,96	0,04 N.D. 0,10 N.D.
Delta(3,5)-Delta(2,4)-dienoyl-CoA isomerase, mitochondrial Probable methyltransferase TARBP1 ADP-ribosylation factor-like protein 2-binding protein Fucose-1-phosphate guanylyltransferase B-cell receptor-associated protein 31 Histone deacetylase complex subunit SAP130 1,2-dihydroxy-3-keto-5-methylthiopentene dioxygenase	SDHD ECH1 TARBP1 ARL2BP FPGT BCAP31 SAP130 AD11	0,96 0,96 0,96 0,96 0,96 0,96 0,95	0,04 N.D. N.D. 0,10 N.D. 0,08
Delta(3,5)-Delta(2,4)-dienoyl-CoA isomerase, mitochondrial Probable methyltransferase TARBP1 ADP-ribosylation factor-like protein 2-binding protein Fucose-1-phosphate guanylyltransferase B-cell receptor-associated protein 31 Histone deacetylase complex subunit SAP130	SDHD ECH1 TARBP1 ARL2BP FPGT BCAP31 SAP130	0,96 0,96 0,96 0,96 0,96 0,96	0,04 N.D. 0,10 N.D.

Unconventional myosin-Ig;Minor histocompatibility antigen HA-2	MY01G	0,95	0,05
Ubiquitin-conjugating enzyme E2 R2 Receptor-type tyrosine-protein phosphatase beta	UBE2R2 PTPRB	0,95 0,95	N.D. N.D.
DnaJ homolog subfamily C member 10	DNAJC10	0,95	0,21
BRCA1-A complex subunit BRE	BRE	0,95	N.D.
Encyl-CoA hydratase, mitochondrial	ECHS1	0,95	0,04
AP-1 complex subunit sigma-1A	AP1S1	0,95	0,14
Protein FAM208A	FAM208A	0,95	N.D.
Zinc finger protein 598	ZNF598	0,94	N.D.
Peroxisomal acyl-coenzyme A oxidase 3	ACOX3	0,94	N.D.
mRNA-decapping enzyme 1A	DCP1A	0,94	0,37
Rho GTPase-activating protein 30	ARHGAP30	0,94	1,30
Huntingtin-interacting protein K	НҮРК	0,94	1,40
Tubulin-specific chaperone A	TBCA	0,94	0,21
Dynamin-like 120 kDa protein, mitochondrial	OPA1	0,94	0,22
Transmembrane emp24 domain-containing protein 3	TMED3	0,94	0,12
Opioid growth factor receptor	OGFR	0,93	0,10
ATP-dependent RNA helicase DDX19B	DDX19B	0,93	N.D.
Actin, cytoplasmic 2;Actin, cytoplasmic 2, N-terminally processed	ACTG1	0,93	0,00
Mesoderm-specific transcript homolog protein	MEST	0,93	0,08
Signal peptidase complex subunit 3	SPCS3	0,93	0,05
BolA-like protein 1	BOLA1	0,93	N.D.
CWF19-like protein 1	CWF19L1	0,93	0,04
Calcium/calmodulin-dependent protein kinase type II subunit delta	CAMK2D	0,93	N.D.
Adenylate kinase 2, mitochondrial	AK2	0,93	0,00
Presenilin-1	PSEN1	0,93	0,69
Nesprin-1	SYNE1	0,93	N.D.
Phosducin-like protein 3	PDCL3	0,92	0,03
Plasminogen receptor (KT)	PLGRKT	0,92	0,44
Exportin-T Nucleolar RNA helicase 2	XPOT DDX21	0,92 0,92	0,05 0,16
Disintegrin and metalloproteinase domain-containing protein 10	ADAM10	0,92	0,16
Activating transcription factor 7-interacting protein 1	ATF7IP	0,92	0,29 N.D.
Very-long-chain (3R)-3-hydroxyacyl-CoA dehydratase 2	HACD2	0,92	0,24
Thymidylate kinase	DTYMK	0,92	0,19
Lactation elevated protein 1	LACE1	0,92	N.D.
Heterogeneous nuclear ribonucleoprotein L-like	HNRNPLL	0,92	0,29
FAST kinase domain-containing protein 1	FASTKD1	0,92	0,14
Leucyl-cystinyl aminopeptidas	LNPEP	0,92	0,06
Golgi-specific brefeldin A-resistance guanine nucleotide exchange factor 1	GBF1	0,91	0,33
Clathrin interactor 1	CLINT1	0,91	0,69
Calpain-2 catalytic subunit	CAPN2	0,91	0,13
Calumenin	CALU	0,91	0,51
Rap guanine nucleotide exchange factor 6	RAPGEF6	0,91	N.D.
Serine/threonine-protein kinase TAO1	TAOK1	0,91	0,15
ADAMTS-like protein 4	ADAMTSL4	0,91	N.D.
Torsin-2A	TOR2A	0,91	N.D.
Transcription initiation factor TFIID subunit 6	TAF6	0,91	0,13
ADP-ribosylation factor-related protein 1	ARFRP1	0,90	0,54
Nuclear cap-binding protein subunit 1	NCBP1	0,90	0,02
Histone-lysine N-methyltransferase 2A	KMT2A	0,90	3,86
Signal recognition particle 19 kDa protein	SRP19	0,90	0,29
HAUS augmin-like complex subunit 8	HAUS8	0,90	0,89
Mitochondrial import inner membrane translocase subunit Tim23	TIMM23;TIMM23B	0,90	0,12
Sodium/potassium-transporting ATPase subunit beta-3	ATP1B3	0,90	0,03
Catalase	CAT	0,90	0,14
Protein zwilch homolog	ZWILCH	0,90	N.D.
U6 snRNA-associated Sm-like protein LSm8	LSM8	0,90	0,07
Emerin	EMD	0,90	0,27
V-type proton ATPase subunit E 1	ATP6V1E1	0,89	0,07
UDP-glucose 6-dehydrogenase	UGDH	0,89	0,71
Malectin	MLEC	0,89	0,03
Transforming growth factor beta-1	TGFB1	0,89	N.D.
RNA 3-terminal phosphate cyclase	RTCA MKI67	0,89	0,06
Antigen KI-67 Dolichyl-diphosphooligosaccharideprotein glycosyltransferase subunit 2	RPN2	0,89	0,02
V-type proton ATPase subunit G 1	ATP6V1G1	0,89 0,89	0,10 0,02
V-type proton ATPase subunit G 1 Exportin-2	CSE1L	0,89	0,02
Exportin-2 F-box/LRR-repeat protein 18	FBXL18	0,89	0,09 N.D.
Collagen type IV alpha-3-binding protein	COL4A3BP	0,89	0,41
Zinc transporter 7	SLC30A7	0,88	0,41
E1A-binding protein p400	EP400	0,88	0,08
Zinc finger CCHC domain-containing protein 8	ZCCHC8	0,88	0,08
Oxysterol-binding protein-related protein 1	OSBPL1A	0,88	0,39
Dolichyl-diphosphooligosaccharideprotein glycosyltransferase 48 kDa subunit	DDOST	0,88	0,11
4F2 cell-surface antigen heavy chain	SLC3A2	0,88	0,49
UPF0538 protein C2orf76	C2orf76	0,88	N.D.
Tetratricopeptide repeat protein 1	TTC1	0,88	0,46
Signal transducer and activator of transcription 1-alpha/beta	STAT1	0,88	0,25
Myeloid-derived growth factor	MYDGF	0,87	0,03

		0.07	
Actin, cytoplasmic 1 Myotubularin-related protein 14	ACTB MTMR14	0,87 0,87	N.D. 0,38
Mannose-1-phosphate guanyltransferase alpha	GMPPA	0,87	0,38
Cyclin-dependent kinase 6	CDK6	0,87	0,23
Cyclin-dependent kinase 2	CDK2	0,87	0,23
Golgi phosphoprotein 3	GOLPH3	0,87	0,05
Cytosolic 5-nucleotidase 3A	NT5C3A	0,87	N.D.
F-box-like/WD repeat-containing protein TBL1XR1	TBL1XR1	0,87	0,17
Alpha-N-acetylgalactosaminidase	NAGA	0,87	0,02
Structural maintenance of chromosomes protein 3	SMC3	0,87	0,03
Methyltransferase-like protein 5	METTL5	0,87	0,38
DNA ligase 1	LIG1	0,87	0,09
THO complex subunit 7 homolog	THOC7	0,87	0,21
Actin, alpha cardiac muscle 1	ACTC1	0,86	0,09
ADP-ribosylation factor-like protein 3	ARL3	0,86	0,16
Probable 28S rRNA (cytosine-C(5))-methyltransferase	NSUN5	0,86	0,34
DNA mismatch repair protein Msh2	MSH2	0,86	0,08
Coatomer subunit gamma-1	COPG1	0,86	0,02
Myotubularin-related protein 10	MTMR10	0,86	0,07
PDZ and LIM domain protein 1	PDLIM1	0,86	0,43
Selenocysteine lyase	SCLY	0,86	0,91
Gamma-aminobutyric acid receptor-associated protein-like 2	GABARAPL2	0,86	0,18
AlaninetRNA ligase, cytoplasmic	AARS	0,86	0,02
Serine/threonine-protein kinase Nek9	NEK9	0,85	0,00
Extended synaptotagmin-1	ESYT1	0,85	0,10
Phosphorylated adapter RNA export protein	PHAX	0,85	0,21
GH3 domain-containing protein	GHDC	0,85	0,20
TIP41-like protein	TIPRL	0,85	0,22
Malate dehydrogenase, mitochondrial	MDH2	0,85	0,06
Nuclease-sensitive element-binding protein 1	YBX1	0,85	0,02
DNA-binding protein RFX5	RFX5	0,85	N.D.
ADP-ribosylation factor GTPase-activating protein 1	ARFGAP1	0,85	N.D.
V-type proton ATPase subunit F	ATP6V1F	0,85	0,08
Chitobiosyldiphosphodolichol beta-mannosyltransferase	ALG1	0,84	1,81
Surfeit locus protein 4	SURF4	0,84	0,05
Signal peptidase complex catalytic subunit SEC11A	SEC11A	0,84	0,14
Protein-tyrosine kinase 2-beta	РТК2В	0,84	0,39
ATP synthase subunit d, mitochondrial	АТР5Н	0,84	0,21
Prefoldin subunit 5	PFDN5	0,84	0,22
Voltage-dependent anion-selective channel protein 1	VDAC1	0,84	0,09
Alpha-1,3/1,6-mannosyltransferase ALG2	ALG2	0,84	N.D.
Coatomer subunit zeta-1	COPZ1	0,84	0,11
Probable ATP-dependent RNA helicase DDX20	DDX20	0,84	0,07
Translin	TSN	0,84	0,04
Aspartyl aminopeptidase	DNPEP	0,83	0,07
ADP-ribose pyrophosphatase, mitochondrial	NUDT9	0,83	N.D.
Probable E3 ubiquitin-protein ligase HERC1	HERC1	0,83	0,10
Malate dehydrogenase, cytoplasmic	MDH1 HIST2H2BE	0,83	0,15
Histone H2B type 2-E Glycogen phosphorylase, brain form	PYGB	0,83 0,83	0,09 0,22
Interferon-induced 35 kDa protein	IFI35	0,83	0,22
	ARHGAP17		
Rho GTPase-activating protein 17	MCM3	0,83	0,05
DNA replication licensing factor MCM3 Probable ATP-dependent RNA helicase DDX56	DDX56	0,83 0,83	0,06 0,03
V-type proton ATPase subunit d 1	ATP6V0D1	0,83	0,60
WD repeat-containing protein 76	WDR76	0,82	0,00 N.D.
D-3-phosphoglycerate dehydrogenase	PHGDH	0,82	0,03
Nucleobindin-2;Nesfatin-1	NUCB2	0,82	0,22
ATP synthase-coupling factor 6, mitochondrial	ATP5J	0,82	0,03
Transmembrane emp24 domain-containing protein 7	TMED7	0,82	0,13
ATP synthase subunit e, mitochondrial	ATP5I	0,82	0,03
Annexin A5	ANXA5	0,82	0,02
Chloride intracellular channel protein 1	CLIC1	0,82	0,02
Transmembrane protein 205	TMEM205	0,82	0,26
Aladin	AAAS	0,81	0,06
Sorting nexin-6;Sorting nexin-6, N-terminally processed	SNX6	0,81	0,17
ATP synthase subunit f, mitochondrial	ATP5J2	0,81	0,19
Manganese-transporting ATPase 13A1	ATP13A1	0,81	0,14
Epoxide hydrolase 1	EPHX1	0,81	0,00
Oligosaccharyltransferase complex subunit OSTC	OSTC	0,81	0,11
DnaJ homolog subfamily C member 2	DNAJC2	0,81	0,29
Ubiquitin thioesterase otulin	OTULIN	0,81	N.D.
Procollagen galactosyltransferase 1	COLGALT1	0,80	0,09
Glyceraldehyde-3-phosphate dehydrogenase	GAPDH	0,80	0,05
NIF3-like protein 1	NIF3L1	0,80	0,09
Nucleoside diphosphate kinase B	NME2	0,80	0,06
Glutathione S-transferase P	GSTP1	0,80	0,02
Ribonuclease P protein subunit p30	RPP30	0,80	0,02
Succinate dehydrogenase [ubiquinone] iron-sulfur subunit, mitochondrial	SDHB	0,80	0,11
Mini-chromosome maintenance complex-binding protein	мсмвр	0,80	0,12

Sec1 family domain-containing protein 1	SCFD1	0,80	0,08
TBC1 domain family member 15	TBC1D15	0,80	0,01
Bifunctional methylenetetrahydrofolate dehydrogenase/cyclohydrolase, mito	MTHFD2	0,80	0,05
NF-kappa-B essential modulator	IKBKG	0,80	N.D.
Twinfilin-2	TWF2	0,79	0,26
Large neutral amino acids transporter small subunit 1	SLC7A5/LAT1	0,79	0,20
ER membrane protein complex subunit 1	EMC1	0,79	0,02
Serine/threonine-protein kinase PAK 2;PAK-2p27;PAK-2p34	PAK2	0,79	0,15
Isocitrate dehydrogenase [NAD] subunit beta, mitochondrial	IDH3B	0,79	0,81
Tumor suppressor p53-binding protein 1	TP53BP1	0,79	0,19
Protein BRICK1	BRK1	0,79	0,08
Gamma-glutamylcyclotransferase	GGCT	0,79	0,22
Cell cycle checkpoint protein RAD1	RAD1	0,79	N.D.
DnaJ homolog subfamily A member 2	DNAJA2	0,79	0,18
ATP-dependent RNA helicase DHX36	DHX36	0,79	0,07
ThreoninetRNA ligase, cytoplasmic	TARS	0,79	0,10
Rho guanine nucleotide exchange factor 2	ARHGEF2	0,78	0,19
Methylcrotonoyl-CoA carboxylase subunit alpha, mitochondrial	MCCC1	0,78	0,02
Protein SAAL1	SAAL1	0,78	N.D.
Vinculin	VCL	0,78	0,04
Signal transducing adapter molecule 2	STAM2	0,78	0,58
Xaa-Pro aminopeptidase 1	XPNPEP1	0,78	0,05
Thioredoxin domain-containing protein 9	TXNDC9	0,78	0,13
DNA replication licensing factor MCM7	MCM7	0,78	0,05
2-oxoglutarate dehydrogenase, mitochondrial	OGDH	0,78	0,02
Zinc finger protein 217	ZNF217	0,78	N.D.
Inhibitor of nuclear factor kappa-B kinase subunit alpha	СНИК	0,78	0,38
Dolichol-phosphate mannosyltransferase subunit 1	DPM1	0,78	0,02
Cytochrome c oxidase assembly factor 3 homolog, mitochondrial	COA3	0,78	0,19
Protein CDV3 homolog	CDV3	0,78	0,07
Ras-related protein Rab-24	RAB24	0,78	N.D.
Serpin H1	SERPINH1	0,78	0,31
	BZW1		
Basic leucine zipper and W2 domain-containing protein 1		0,78	0,29
Rab5 GDP/GTP exchange factor	RABGEF1	0,77	N.D.
Alpha- and gamma-adaptin-binding protein p34	AAGAB	0,77	N.D.
Myosin regulatory light chain 12A;Myosin regulatory light chain 12B	MYL12A;MYL12B	0,77	0,03
General transcription factor 3C polypeptide 2	GTF3C2	0,77	N.D.
Probable leucinetRNA ligase, mitochondrial	LARS2	0,77	0,03
ATP synthase subunit epsilon, mitochondrial	ATP5E	0,77	0,03
Vacuolar fusion protein CCZ1 homolog and homolog B	CCZ1;CCZ1B	0,77	0,18
Signal peptidase complex subunit 2	SPCS2	0,77	0,01
Ras-related protein Rab-5C	RAB5C	0,77	0,06
Ubiquitin-associated protein 2-like	UBAP2L	0,77	1,18
Ras and Rab interactor-like protein	RINL	0,77	N.D.
Multifunctional methyltransferase subunit TRM112-like protein	TRMT112	0,77	0,21
Thymidine kinase 2, mitochondrial	TK2	0,77	N.D.
Coatomer subunit epsilon	COPE	0,77	0,13
ATP synthase subunit O, mitochondrial	ATP50		0,02
		0,77	
Regulation of nuclear pre-mRNA domain-containing protein 1B	RPRD1B	0,76	0,09
ADP/ATP translocase 2; ADP/ATP translocase 2, N-terminally processed	SLC25A5	0,76	0,16
Small integral membrane protein 7	SMIM7	0,76	0,23
Eukaryotic translation initiation factor 4B	EIF4B	0,76	0,19
Transcription initiation factor TFIID subunit 1	TAF1	0,76	0,40
Ceroid-lipofuscinosis neuronal protein 6	CLN6	0,76	0,03
MAX gene-associated protein	MGA	0,76	N.D.
CMP-sialic acid transporter	SLC35A1	0,76	N.D.
ATP synthase F(0) complex subunit B1, mitochondrial	ATP5F1	0,76	0,09
PEST proteolytic signal-containing nuclear protein	PCNP	0,76	0,66
3-beta-hydroxysteroid-Delta(8),Delta(7)-isomerase	EBP	0,76	0,29
Nucleoside diphosphate kinase A	NME1	0,75	0,19
Protein AAR2 homolog	AAR2	0,75	N.D.
Cyclin-dependent kinases regulatory subunit 1	CKS1B	0,75	0,00
Up-regulated during skeletal muscle growth protein 5	USMG5	0,75	0,12
Protein sel-1 homolog 1	SEL1L	0,75	0,48
Myosin-9	MYH9	0,75	0,01
Ras-related C3 botulinum toxin substrate 1	RAC1	0,75	0,33
RUN and FYVE domain-containing protein 1	RUFY1	0,74	0,08
Phosphoinositide 3-kinase regulatory subunit 4	PIK3R4	0,74	0,10
E3 ubiquitin-protein ligase RNF31	RNF31	0,74	0,41
Vigilin	HDLBP	0,74	0,09
Rho GTPase-activating protein 27	ARHGAP27	0,74	N.D.
ADP-sugar pyrophosphatase	NUDT5	0,74	0,12
Phosphomannomutase 2	PMM2	0,74	N.D.
Protein ERGIC-53	LMAN1	0,74	0,22
COX assembly mitochondrial protein homolog	CMC1	0,74	0,18
Target of Myb protein 1	TOM1	0,74	N.D.
Non-histone chromosomal protein HMG-17 and 3	HMGN2;HMGN3	0,73	N.D.
Alpha/beta hydrolase domain-containing protein 11	ABHD11	0,73	0,30
DNA replication complex GINS protein PSF3	GINS3	0,73	0,03
Uncharacterized protein C18orf8	C18orf8	0,73	0,59
		-,	-,

Alaka askukla NCC attacka aska askain	14.54	0.72	0.05
Alpha-soluble NSF attachment protein	NAPA CC2D1B	0,73	0,05
Coiled-coil and C2 domain-containing protein 1B	CC2D1B CHMP5	0,73	0,12
Charged multivesicular body protein 5 Mismatch repair endonuclease PMS2	PMS2	0,73	0,52
		0,73	N.D.
Treacle protein	TCOF1	0,73	0,21
Mannosyl-oligosaccharide glucosidase	MOGS	0,72	0,04
1-phosphatidylinositol 3-phosphate 5-kinase	PIKFYVE	0,72	N.D.
High mobility group protein HMG-I/HMG-Y	HMGA1	0,72	N.D.
Adenosine 3-phospho 5-phosphosulfate transporter 1	SLC35B2	0,72	0,05
Cyclin-dependent kinase 4 inhibitor C	CDKN2C	0,72	0,19
Dihydropteridine reductase	QDPR	0,72	0,07
14-3-3 protein gamma	YWHAG	0,72	0,13
Prosaposin	PSAP	0,72	0,11
Protein MEMO1	MEM01	0,72	0,09
Protein DPCD	DPCD	0,72	0,06
Probable global transcription activator SNF2L2	SMARCA2	0,72	0,57
Transportin-3	TNPO3	0,72	0,22
Transcriptional activator protein Pur-beta	PURB	0,72	N.D.
BRISC complex subunit Abro1	FAM175B	0,72	N.D.
Peptidyl-prolyl cis-trans isomerase FKBP3	FKBP3	0,72	0,06
Filamin-B	FLNB	0,72	0,17
Protein YIF1A	YIF1A	0,72	0,25
Spermidine synthase	SRM	0,72	0,06
Signal recognition particle 14 kDa protein	SRP14	0,72	0,11
Transmembrane 9 superfamily member 2	TM9SF2	0,72	0,20
TBC1 domain family member 5	TBC1D5	0,71	0,24
UPF0489 protein C5orf22	C5orf22	0,71	N.D.
Ras-related protein Rap-1b	RAP1B	0,71	0,04
Mitochondrial pyruvate carrier 1	MPC1	0,71	0,16
Transmembrane emp24 domain-containing protein 5	TMED5	0,71	0,16 N.D.
Mitochondrial intermembrane space import and assembly protein 40	CHCHD4	0,71	N.D.
	CUX1		
Homeobox protein cut-like 1	KDELC2	0,71	0,28
KDEL motif-containing protein 2		0,71	N.D.
Clathrin light chain A	CLTA	0,71	0,09
ATP synthase subunit gamma, mitochondrial	ATP5C1	0,71	0,06
UTPglucose-1-phosphate uridylyltransferase	UGP2	0,71	0,03
Ribosome biogenesis protein WDR12	WDR12	0,71	0,28
Protein tyrosine phosphatase type IVA 2	PTP4A2	0,71	1,96
Integrin beta-1	ITGB1	0,71	0,04
Transmembrane protein 87A	TMEM87A	0,71	0,06
Ras GTPase-activating protein 2	RASA2	0,71	0,41
Ubiquitin-conjugating enzyme E2 L3	UBE2L3	0,70	0,15
Prefoldin subunit 3	VBP1	0,70	0,16
U6 snRNA-associated Sm-like protein LSm7	LSM7	0,70	0,19
Interleukin-1 receptor-associated kinase 3	IRAK3	0,70	0,19
Histone-lysine N-methyltransferase SETD7	SETD7	0,70	N.D.
Cystatin-C	CST3	0,70	0,64
GEM-interacting protein	GMIP	0,70	0,28
tRNA (cytosine(34)-C(5))-methyltransferase	NSUN2	0,70	0,01
CCR4-NOT transcription complex subunit 10	CNOT10	0,70	0,17
Cytochrome c oxidase protein 20 homolog	COX20	0,70	0,12
WD repeat-containing protein 55	WDR55	0,70	N.D.
PC4 and SFRS1-interacting protein	PSIP1	0,70	0,19
Rab GDP dissociation inhibitor beta	GDI2	0,70	0,05
Aconitate hydratase, mitochondrial	ACO2	0,70	0,02
Signal recognition particle 54 kDa protein	SRP54	0,70	0,08
Antigen peptide transporter 1	TAP1	0,69	0,12
Protein SON	SON	0,69	0,35
Polyribonucleotide nucleotidyltransferase 1, mitochondrial	PNPT1	0,69	0,05
ATP synthase subunit g, mitochondrial	ATP5L	0,69	0,05
Origin recognition complex subunit 2	ORC2	0,69	0,09
POTE ankyrin domain family member J	POTEJ	0,69	N.D.
Symplekin	SYMPK	0,68	0,04
ATP-dependent RNA helicase DHX8	DHX8	0,68	0,18
Calcyclin-binding protein	CACYBP	0,68	0,02
Kinesin-like protein KIF2C	KIF2C	0,68	N.D.
mRNA-decapping enzyme 1B	DCP1B	0,68	N.D.
Septin-6	SEPT6	0,68	0,56
Activated RNA polymerase II transcriptional coactivator p15	SUB1	0,68	0,05
Ras-related protein Rap-2c	RAP2C	0,68	0,31
Leucine-rich repeat flightless-interacting protein 1	LRRFIP1	0,68	0,14
Diphthineammonia ligase	DPH6	0,68	0,21
AP-4 complex subunit beta-1	AP4B1	0,68	0,04
Probable ATP-dependent RNA helicase DDX46	DDX46	0,68	0,04
Succinate dehydrogenase [ubiquinone] flavoprotein subunit, mitochondrial	SDHA	0,68	0,13
Integrin alpha-5;Integrin alpha-5 heavy chain;Integrin alpha-5 light chain	ITGA5	0,68	0,15
Histone H1.3;Histone H1.4			
	HIST1H1D;HIST1H1E	0,68	0,43
Peptidyl-prolyl cis-trans isomerase G	PPIG	0,68	N.D.
Mannose-1-phosphate guanyltransferase beta	GMPPB	0,67	0,03
Glomulin	GLMN	0,67	0,00

	4577140	0.67	0.40
Protein-lysine N-methyltransferase METTL10	METTL10	0,67	0,18
Citrate synthase, mitochondrial Mitochondrial fission process protein 1	CS MTFP1	0,67 0,67	0,23 0,24
Cell cycle control protein 50A	TMEM30A	0,67	0,24 N.D.
Leucine-rich repeat serine/threonine-protein kinase 1	LRRK1	0,67	N.D.
THO complex subunit 1	THOC1	0,67	0,04
Calcium/calmodulin-dependent protein kinase type 1D	CAMK1D	0,67	N.D.
28S ribosomal protein S36, mitochondrial	MRPS36	0,67	0,19
E3 ubiquitin-protein ligase RBX1	RBX1	0,67	0,08
Rab-like protein 3	RABL3	0,67	0,03
Rho GDP-dissociation inhibitor 2	ARHGDIB	0,67	0,07
UPF0693 protein C10orf32	C10orf32	0,67	0,06
Anaphase-promoting complex subunit 16	ANAPC16	0,67	0,30
6.8 kDa mitochondrial proteolipid	MP68	0,66	0,08
N(G),N(G)-dimethylarginine dimethylaminohydrolase 1	DDAH1	0,66	N.D.
Ras-related C3 botulinum toxin substrate 2	RAC2	0,66	0,09
Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-2	GNB2	0,66	0,22
Telomeric repeat-binding factor 2	TERF2	0,66	N.D.
5-3 exoribonuclease 1	XRN1	0,66	0,31
Gamma-soluble NSF attachment protein	NAPG	0,66	0,11
HCLS1-associated protein X-1	HAX1	0,66	N.D.
RNA-binding protein 47	RBM47	0,66	N.D.
Myotrophin	MTPN	0,66	0,08
DNA replication complex GINS protein PSF1	GINS1	0,66	N.D.
N-myc-interactor	NMI	0,66	N.D.
Ribonuclease P protein subunit p29	POP4	0,65	0,03
Enoyl-CoA delta isomerase 1, mitochondrial	ECI1	0,65	0,09
DENN domain-containing protein 4B	DENND4B	0,65	0,16
Transmembrane emp24 domain-containing protein 10	TMED10	0,65	0,13
Protein disulfide-isomerase TMX3	тмх3	0,65	0,58
V-type proton ATPase subunit D	ATP6V1D	0,65	0,10
Mitochondrial import receptor subunit TOM40 homolog	томм40	0,65	0,17
Cathepsin D	CTSD	0,65	0,25
Transketolase	ткт	0,65	0,08
Solute carrier family 35 member E1	SLC35E1	0,65	0,10
THO complex subunit 5 homolog	THOC5	0,65	0,35
6-phosphogluconolactonase	PGLS	0,65	0,09
Glutathione synthetase	GSS	0,65	0,03
Nuclear export mediator factor NEMF	NEMF	0,65	0,17
Vacuole membrane protein 1	VMP1	0,65	N.D.
Kinesin-like protein KIF2A	KIF2A	0,64	0,24
WD repeat-containing protein mio	MIOS	0,64	N.D.
Ubiquitin carboxyl-terminal hydrolase 19	USP19	0,64	0,05
Protein ELYS	AHCTF1	0,64	0,02
Uncharacterized protein KIAA2013	KIAA2013	0,64	0,11
Partner of Y14 and mago	WIBG	0,64	0,07
Activity-dependent neuroprotector homeobox protein	ADNP	0,64	0,59
ADP-ribosylation factor 1	ARF1	0,64	0,12
DNA repair protein complementing XP-G cells	ERCC5	0,64	0,12
Heat shock protein 105 kDa	HSPH1	0,63	0,06
BCL2/adenovirus E1B 19 kDa protein-interacting protein 2;Caytaxin	BNIP2;ATCAY	0,63	0,07
Ribosomal RNA small subunit methyltransferase NEP1	EMG1	0,63	0,02
AP-1 complex subunit mu-1	AP1M1	0,63	0,16
Dihydrolipoyl dehydrogenase, mitochondrial	DLD	0,63	0,03
Bcl-2-like protein 13	BCL2L13	0,63	0,03
THO complex subunit 3	тносз	0,63	0,04
Tudor domain-containing protein 7	TDRD7	0,63	N.D.
5-nucleotidase domain-containing protein 3	NT5DC3	0,63	N.D.
Dehydrogenase/reductase SDR family member 2, mitochondrial	DHRS2	0,63	N.D.
Glycogen [starch] synthase, muscle	GYS1	0,63	0,10
14 kDa phosphohistidine phosphatase	PHPT1	0,62	0,01
E3 ubiquitin-protein ligase synoviolin	SYVN1	0,62	0,07
Isopentenyl-diphosphate Delta-isomerase 1	IDI1	0,62	0,14
Iron-responsive element-binding protein 2	IREB2	0,62	0,22
CGG triplet repeat-binding protein 1	CGGBP1	0,62	0,15
SS18-like protein 2	SS18L2	0,62	0,25
Deoxyribose-phosphate aldolase	DERA	0,62	0,07
Synaptobrevin homolog YKT6	YKT6	0,62	0,08
High affinity cationic amino acid transporter 1	SLC7A1	0,62	0,01
RNA polymerase II subunit A C-terminal domain phosphatase	CTDP1	0,62	0,23
Low-density lipoprotein receptor		0,62	N.D.
Inositol monophosphatase 3	IMPAD1	0,62	0,05
ER membrane protein complex subunit 2	EMC2	0,62	N.D.
Rab GDP dissociation inhibitor alpha	GDI1	0,62	0,05
Pre-mRNA-splicing factor SYF1	XAB2	0,62	0,24
BolA-like protein 3	BOLA3 FAM195A	0,62	0,16
Protein FAM195A 2-5A-dependent ribonuclease	RNASEL	0,62	N.D.
2-5A-dependent ribonuclease Dynein light chain roadblock-type 1	DYNLRB1	0,62 0,62	N.D. 0,05
Dolichyl-diphosphooligosaccharideprotein glycosyltransferase subunit STT3A	STT3A	0,62	0,05
ponenyi-upnosphooligosacchandeprotein giycosyitransierase subufilt STT3A	SITSA	0,01	0,00

Schlafen family member 11	SLFN11	0,61	0,34
Copine-1	CPNE1	0,61	0,16
Conserved oligomeric Golgi complex subunit 1	COG1	0,61	0,08
Mitochondrial import receptor subunit TOM34	томмз4	0,61	0,22
COP9 signalosome complex subunit 8	COPS8	0,61	0,08
AP-1 complex subunit gamma-1	AP1G1	0,61	0,10
NADPHcytochrome P450 reductase	POR	0,61	0,15
Rabankyrin-5	ANKFY1	0,61	0,06
General transcription factor 3C polypeptide 1	GTF3C1	0,61	0,01
UHRF1-binding protein 1	UHRF1BP1	0,61	N.D.
Heat shock protein 75 kDa, mitochondrial	TRAP1	0,61	0,03
Proteasome subunit beta type-1	PSMB1	0,61	0,07
Double-strand-break repair protein rad21 homolog	RAD21	0,61	0,08
3-hydroxyisobutyrate dehydrogenase, mitochondrial	HIBADH	0,61	0,02
Geranylgeranyl transferase type-2 subunit beta	RABGGTB	0,61	0,09
Multiple coagulation factor deficiency protein 2	MCFD2	0,61	N.D.
DnaJ homolog subfamily C member 3	DNAJC3	0,61	0,20
60S acidic ribosomal protein P2	RPLP2	0,61	0,59
Cytoplasmic protein NCK1	NCK1	0,61	N.D.
Inverted formin-2	INF2	0,61	N.D.
Protein N-lysine methyltransferase METTL21A	METTL21A	0,61	0,67
E3 ubiquitin-protein ligase LRSAM1	LRSAM1	0,61	N.D.
Tyrosyl-DNA phosphodiesterase 1	TDP1	0,60	N.D.
Dual specificity protein phosphatase 12	DUSP12	0,60	0,14
Heat shock 70 kDa protein 4	HSPA4	0,60	0,02
Inosine-5-monophosphate dehydrogenase 1	IMPDH1	0,60	0,23
cAMP-dependent protein kinase type II-alpha regulatory subunit	PRKAR2A	0,60	0,36
Putative nucleoside diphosphate kinase	NME2P1	0,60	0,48
DNA repair endonuclease XPF	ERCC4	0,60	N.D.
Nascent polypeptide-associated complex subunit alpha, muscle-specific form	NACA	0,59	0,10
Very-long-chain enoyl-CoA reductase	TECR	0,59	0,11
THO complex subunit 6 homolog	THOC6	0,59	0,11
DNA replication complex GINS protein SLD5	GINS4	0,59	0,06
ATP synthase protein 8	MT-ATP8	0,59	0,04
Dehydrodolichyl diphosphate syntase complex subunit DHDDS	DHDDS	0,59	N.D.

Table 1 Upregulated proteins in KU812 ImaR compared to KU812 P cells under normoxia. Proteomic profiling (SILAC) data were used. Significant upregulated proteins were calculated using the fold difference threshold of 1.5 (log₂ fold change=0.58). Mean±SD for n=2 replicates. Non-detected (N.D.) means less than 2 replicates detected for one protein measured.

DOWNREGULATED PROTEINS IN	I KU812 ImaR VS. KU812 P		
Protein names	Gene names	Mean Log ₂ fold change	SD Log ₂ fold change
Cellular tumor antigen p53	TP53	-7.22	N.D.
Carboxymethylenebutenolidase homolog	CMBL	-6.31	0.19
Prolactin-inducible protein	PIP	-5.71	N.D.
Myosin-10	MYH10	-5.42	0.05
Hemoglobin subunit theta-1	HBQ1	-5.33	N.D.
Serpin B9	SERPINB9	-5.21	0.04
Tyrosine-protein kinase transmembrane receptor ROR2	ROR2	-5.08	N.D.
Protein-glutamine gamma-glutamyltransferase 2	TGM2 GRAP2	-5.05 -4.88	0.41 1.21
GRB2-related adapter protein 2 Acid ceramidase	ASAH1	-4.88	0.21
Flavin reductase (NADPH)	BLVRB	-4.80	0.01
OCIA domain-containing protein 2	OCIAD2	-4.78	0.84
CB1 cannabinoid receptor-interacting protein 1	CNRIP1	-4.78	2.37
O-acetyl-ADP-ribose deacetylase MACROD1	MACROD1	-4.73	0.51
Guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-2	GNG2	-4.71	1.10
Tropomyosin alpha-1 chain	TPM1	-4.70	N.D.
Hemoglobin subunit beta;LVV-hemorphin-7;Spinorphin	нвв	-4.60	0.67
Myosin light chain 4	MYL4	-4.53	N.D.
Apolipoprotein C-I;Truncated apolipoprotein C-I	APOC1	-4.40	N.D.
Estradiol 17-beta-dehydrogenase 8	HSD17B8	-4.35	N.D.
PDZ and LIM domain protein 5	PDLIM5	-4.26	1.46
Amine oxidase [flavin-containing] B	MAOB	-4.25	N.D.
Thiosulfate sulfurtransferase/rhodanese-like domain-containing protein 1	TSTD1	-4.23	N.D.
Dematin	DMTN	-4.20	N.D.
Latexin	LXN STAT5A	-4.18 -4.15	N.D. 0.22
Signal transducer and activator of transcription 5A	ALDH4A1/P5CDH	-4.15 -4.14	0.22
Delta-1-pyrroline-5-carboxylate dehydrogenase, mitochondrial Agmatinase, mitochondrial	AGMAT	-4.14 -4.07	1.06 N.D.
Alanine aminotransferase 1	GPT	-4.07	N.D.
Protoporphyrinogen oxidase	PPOX	-4.00	0.25
Ankyrin-1	ANK1	-4.00	0.13
Carbonic anhydrase 2	CA2	-3.97	0.12
Receptor-interacting serine/threonine-protein kinase 1	RIPK1	-3.93	0.50
Calretinin	CALB2	-3.93	N.D.
Galectin-3	LGALS3	-3.90	0.06
2-amino-3-ketobutyrate coenzyme A ligase, mitochondrial	GCAT	-3.86	N.D.
Porphobilinogen deaminase	HMBS	-3.86	0.43
von Willebrand factor A domain-containing protein 5A	VWA5A	-3.85	0.14
Hemoglobin subunit alpha	HBA1	-3.82	0.09
Transferrin receptor protein 1	TFRC	-3.82	0.03
Desmoplakin	DSP	-3.81	N.D.
Protein phosphatase 1 regulatory subunit 14A	PPP1R14A	-3.81	N.D.
NF-kappa-B inhibitor beta	NFKBIB	-3.79	N.D.
Cadherin-1	CDH1 CA8	-3.79 -3.77	0.82 1.10
Carbonic anhydrase-related protein Carbonic anhydrase 1	CA8 CA1	-3.76	0.14
RNA-binding protein 38 and 24	RBM38;RBM24	-3.75	N.D.
Junction plakoglobin	JUP	-3.75	0.48
Aldo-keto reductase family 1 member C1	AKR1C1	-3.74	0.94
Retinal dehydrogenase 1	ALDH1A1	-3.73	0.21
Annexin A1	ANXA1	-3.73	0.59
Bis(5-adenosyl)-triphosphatase	FHIT	-3.71	N.D.
Catenin alpha-2	CTNNA2	-3.71	N.D.
Pleckstrin homology domain-containing family A member 2	PLEKHA2	-3.66	N.D.
Mucin-1	MUC1	-3.64	N.D.
Ubiquitin thioesterase OTU1	YOD1	-3.60	N.D.
Hemoglobin subunit gamma-1	HBG1	-3.60	1.16
Metastasis suppressor protein 1	MTSS1	-3.56	0.02
Ferritin heavy chain;Ferritin heavy chain, N-terminally processed	FTH1	-3.55	0.09
Hemoglobin subunit gamma-2	HBG2	-3.53	0.50
Uroporphyrinogen decarboxylase	UROD	-3.49	0.09
Transmembrane protein 14C	TMEM14C	-3.48	0.14
Tyrosine-protein kinase Lyn	LYN	-3.46	0.04
Acyl-coenzyme A thioesterase 13	ACOT13	-3.45	0.01
Spectrin beta chain, non-erythrocytic 2	SPTBN2	-3.41	0.50
Spectrin alpha chain, erythrocytic 1	SPTA1 CBR4	-3.39 -3.36	0.30 0.66
Carbonyl reductase family member 4 Chloride intracellular channel protein 2	CBR4 CLIC2	-3.36	0.66
Nicotinamide/nicotinic acid mononucleotide adenylyltransferase 3	NMNAT3	-3.35	0.47 N.D.
SAM domain-containing protein SAMSN-1	SAMSN1	-3.35	N.D.
Sittle dotterning protein Shiribit 1	SHINDINE	5.55	N.D.

UDV description and the second of C	UDVALC	2.25	0.75
UBX domain-containing protein 6 Signal transducer and activator of transcription 5B	UBXN6 STAT5B	-3,35 -3,34	0,75 0,13
15-hydroxyprostaglandin dehydrogenase [NAD(+)]	HPGD	-3,34	0,29
Protein S100-A6	S100A6	-3,32	0,07
Thiopurine S-methyltransferase	TPMT	-3,31	0,38
TBC1 domain family member 4	TBC1D4	-3,31	1,05
S-methyl-5-thioadenosine phosphorylase	MTAP	-3,28	0,60
Interferon-induced guanylate-binding protein 2 and 1	GBP2;GBP1	-3,27	N.D.
55 kDa erythrocyte membrane protein	MPP1	-3,27	2,27
Mitochondrial 2-oxodicarboxylate carrier	SLC25A21 ABCC4	-3,26	1,86 0,09
Multidrug resistance-associated protein 4 Protein-glutamine gamma-glutamyltransferase K	TGM1	-3,26 -3,24	0,09 N.D.
Putative RRN3-like protein RRN3P2	RRN3P2	-3,24	N.D.
Niban-like protein 1	FAM129B	-3,22	0,40
Ectonucleotide pyrophosphatase/phosphodiesterase family member 3	ENPP3	-3,20	0,28
Bifunctional polynucleotide phosphatase/kinase	PNKP	-3,20	0,22
Nck-associated protein 1	NCKAP1	-3,20	1,01
cAMP-dependent protein kinase type I-alpha regulatory subunit	PRKAR1A	-3,19	0,78
Oxysterol-binding protein-related protein 3	OSBPL3	-3,19	N.D.
Complement receptor type 1	CR1	-3,18	N.D.
Pirin Cluterate sustaine liesee establic suburit	PIR GCLC	-3,18	N.D.
Glutamatecysteine ligase catalytic subunit Spectrin beta chain, erythrocytic	SPTB	-3,18 -3,18	0,23 0,11
ATPase WRNIP1	WRNIP1	-3,17	0,19
UPF0598 protein C8orf82	C8orf82	-3,17	0,13
Keratinocyte proline-rich protein	KPRP	-3,16	N.D.
Kynurenineoxoglutarate transaminase 3	CCBL2	-3,16	0,61
Selenium-binding protein 1	SELENBP1	-3,15	1,41
Caspase-6	CASP6	-3,13	0,89
Tight junction protein ZO-2	TJP2	-3,13	N.D.
Alpha-synuclein	SNCA	-3,12	N.D.
Flotillin-1	FLOT1 YES1	-3,12	0,50
Tyrosine-protein kinase Yes Pyruvate carboxylase, mitochondrial	PC	-3,12 -3,12	1,25 0,15
Bcl-2-like protein 1	BCL2L1	-3,12	0,04
Solute carrier family 2, facilitated glucose transporter member 3	SLC2A3/GLUT3	-3,11	0,30
Caspase-10	CASP10	-3,11	N.D.
Eukaryotic translation initiation factor 2D	EIF2D	-3,09	N.D.
Branched-chain-amino-acid aminotransferase, mitochondrial	BCAT2	-3,08	0,35
Intelectin-1	ITLN1	-3,08	0,94
Sorting nexin-9	SNX9	-3,08	0,18
Integrin alpha-IIb;Integrin alpha-IIb heavy chain	ITGA2B	-3,07	0,02
Multiple inositol polyphosphate phosphatase 1	MINPP1	-3,06	0,16
Nuclear factor 1 A-type	NFIA KIT	-3,03 -3,03	1,66 0,56
Mast/stem cell growth factor receptor Kit Mannosyl-oligosaccharide 1,2-alpha-mannosidase IA	MAN1A1	-3,03	1,40
Fatty acid desaturase 2	FADS2	-3,01	0,60
Ammonium transporter Rh type A	RHAG	-3,01	1,22
GMP reductase 1	GMPR	-3,01	0,22
Ferrochelatase, mitochondrial	FECH	-3,00	0,17
ATP-binding cassette sub-family B member 10, mitochondrial	ABCB10	-2,98	0,10
Sulfotransferase 1A4 and 1A3	SULT1A4;SULT1A3	-2,98	0,11
Stonin-2	STON2	-2,98	0,27
1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase beta-3 Oligoribonuclease, mitochondrial	PLCB3 REXO2	-2,98 -2,97	0,10 0,35
Ras-related protein Rab-6B	RAB6B	-2,97	0,33 N.D.
Solute carrier family 12 member 6	SLC12A6	-2,95	0,85
Rho GTPase-activating protein 18	ARHGAP18	-2,94	0,18
Inosine triphosphate pyrophosphatase	ITPA	-2,93	0,16
Nucleus accumbens-associated protein 1	NACC1	-2,90	N.D.
Protein PML	PML	-2,89	0,38
Valacyclovir hydrolase	BPHL	-2,88	N.D.
Heterogeneous nuclear ribonucleoprotein U-like protein 2	HNRNPUL2	-2,87	0,05
Tetratricopeptide repeat protein 7B	TTC7B GNPDA2	-2,87	N.D.
Glucosamine-6-phosphate isomerase 2 Pyruvate kinase PKLR	PKLR	-2,86 -2,86	0,11 1,44
Band 3 anion transport protein	SLC4A1	-2,80	0,86
Caspase-3;Caspase-3 subunit p17;Caspase-3 subunit p12	CASP3	-2,81	0,39
Inositol-tetrakisphosphate 1-kinase	ITPK1	-2,80	N.D.
SEC14-like protein 2	SEC14L2	-2,79	N.D.
Rap guanine nucleotide exchange factor 2	RAPGEF2	-2,78	1,23
Zinc finger Ran-binding domain-containing protein 2	ZRANB2	-2,77	N.D.
WD repeat-containing protein 74	WDR74	-2,75	0,56
HLA class I histocompatibility antigen, B-41 alpha chain	HLA-B	-2,75	N.D.
Sentrin-specific protease 6	SENP6	-2,75	N.D.
Probable asparaginetRNA ligase, mitochondrial CD2-associated protein	NARS2 CD2AP	-2,72 -2,72	0,12 0,08
Succinate-semialdehyde dehydrogenase, mitochondrial	ALDH5A1	-2,72 -2,72	0,08
Platelet glycoprotein 4	CD36	-2,71	0,38
UPF0696 protein C11orf68	C11orf68	-2,70	0,59

Chromatin complexes subunit BAP18	BAP18	-2,68	0,02
ValinetRNA ligase, mitochondrial	VARS2	-2,68	0,14
	CTNNB1	-2,67	0,69
	KSR1	-2,66	N.D.
	ANXA2;ANXA2P2	-2,66	0,08
	CDC42BPA	-2,66	0,19
Protein unc-13 homolog D	UNC13D	-2,66	0,80
Neogenin	NEO1	-2,66	0,59
Tyrosine-protein phosphatase non-receptor type 7	PTPN7	-2,64	0,27
	DDX28	-2,64	N.D.
	DOCK9	-2,63	2,43
	CTNNA1	-2,62	0,23
	AHNAK	-2,62	0,52
Serine/threonine-protein kinase 38	STK38	-2,62	N.D.
Glutamate-rich WD repeat-containing protein 1	GRWD1	-2,61	0,37
Leukocyte elastase inhibitor	SERPINB1	-2,61	0,15
	CLCC1	-2,58	N.D.
	SRXN1	-2,55	0,19
	PCYT2	-2,55	0,01
1-acyl-sn-glycerol-3-phosphate acyltransferase epsilon	AGPAT5	-2,54	0,12
Destrin	DSTN	-2,54	0,34
Ribosomal protein S6 kinase alpha-4	RPS6KA4	-2,54	0,68
	UBASH3B	-2,54	0,35
	STXBP5	-2,54	0,96
	DSG1	-2,54	
			N.D.
	THEMIS2	-2,52	0,39
	CMPK2	-2,52	1,38
Catenin delta-1	CTNND1	-2,50	0,21
	PLEKHF2	-2,49	N.D.
	TESC	-2,49	0,46
	METTL7A		
		-2,47	2,08
	TRIM16	-2,47	0,67
Apolipoprotein B-100;Apolipoprotein B-48	APOB	-2,46	N.D.
Beta-adducin	ADD2	-2,46	0,71
Focal adhesion kinase 1	PTK2	-2,45	N.D.
	POLR3G	-2,45	N.D.
	SYNE2		
		-2,45	0,42
	LDB1	-2,44	N.D.
PhenylalaninetRNA ligase, mitochondrial	FARS2	-2,44	0,08
Ubiquitin carboxyl-terminal hydrolase 25	USP25	-2,44	0,73
Lymphocyte cytosolic protein 2	LCP2	-2,44	0,78
	MAP2K3	-2,43	1,11
. ,	VRK3	-2,43	N.D.
	SH3BGRL2	-2,40	0,19
Arf-GAP with coiled-coil, ANK repeat and PH domain-containing protein 1	ACAP1	-2,40	N.D.
NF-kappa-B inhibitor epsilon	NFKBIE	-2,40	N.D.
Ribosomal protein S6 kinase beta-1	RPS6KB1	-2,39	N.D.
	MAN2A2	-2,39	0,53
	ITPR2		
and the second sec		-2,38	0,57
	CCNY	-2,38	N.D.
N-acetylgalactosamine kinase	GALK2	-2,38	0,07
Dual specificity mitogen-activated protein kinase kinase 7	MAP2K7	-2,38	N.D.
Src substrate cortactin	CTTN	-2,37	0,17
Apolipoprotein E	APOE	-2,37	1,08
	STK25	-2,36	N.D.
	HBS1L		
		-2,36	0,08
	RPS6KA3	-2,35	0,39
	DHRS11	-2,34	0,50
Stabilin-1	STAB1	-2,33	1,21
Hematopoietic prostaglandin D synthase	HPGDS	-2,33	0,50
	SCRIB	-2,33	0,19
-	ERI1	-2,32	N.D.
	ACBD6	-2,31	N.D.
	HK1	-2,31	0,11
	FBXL8	-2,30	N.D.
Amyloid-like protein 2	APLP2	-2,30	N.D.
	CHMP1B	-2,30	N.D.
	TSTA3	-2,30	0,05
	KRT6B		
		-2,28	N.D.
	BMS1	-2,28	0,62
	NDRG1	-2,27	N.D.
Alsin	ALS2	-2,26	N.D.
	HEBP1	-2,26	0,02
	FUT8	-2,26	0,30
	ECI2		
		-2,25	0,40
	TNPO2	-2,25	0,13
Oxygen-dependent coproporphyrinogen-III oxidase, mitochondrial	CPOX	-2,24	0,16
Vacuolar protein sorting-associated protein 37B	VPS37B	-2,23	N.D.
	PYCR1	-2,23	0,32
	DNAJC6	-2,23	N.D.
Putative tyrosine-protein phosphatase auxilin			

	10101	0.00	
Arf-GAP with SH3 domain, ANK repeat and PH domain-containing protein 1	ASAP1	-2,23	0,33
Ribosome production factor 2 homolog	RPF2	-2,23	0,21
Hsp70-binding protein 1	HSPBP1	-2,22	0,29
Bifunctional ATP-dependent dihydroxyacetone kinase/FAD-AMP lyase (cyclizing)	DAK	-2,22	0,36
Trafficking protein particle complex subunit 9	TRAPPC9	-2,21	N.D.
Roundabout homolog 2	ROBO2 NUDT4	-2,21	N.D.
Diphosphoinositol polyphosphate phosphohydrolase 2 Mitochondrial genome maintenance exonuclease 1		-2,21	0,14
Translation factor GUF1, mitochondrial	MGME1 GUF1	-2,21 -2,21	N.D.
Biliverdin reductase A	BLVRA		0,38
	ADD1	-2,20 -2,20	0,18
Alpha-adducin	TBPL1	-2,20	0,03 0,49
TATA box-binding protein-like protein 1 Piezo-type mechanosensitive ion channel component 1	PIEZO1	-2,20	0,49
ATP-binding cassette sub-family F member 1	ABCF1	-2,19	0,09
Bifunctional lysine-specific demethylase and histidyl-hydroxylase MINA	MINA	-2,19	0,09 N.D.
Serine/threonine-protein phosphatase 2A 65 kDa regulatory subunit A beta isoform	PPP2R1B	-2,19	0,83
60 kDa SS-A/Ro ribonucleoprotein	TROVE2	-2,13	0,03
NADPH:adrenodoxin oxidoreductase, mitochondrial	FDXR	-2,18	0,03
Eukaryotic translation initiation factor 1A, Y-chromosomal	EIF1AY	-2,18	0,08
	GMDS	-2,18	0,13
GDP-mannose 4,6 dehydratase	DIEXF		
Digestive organ expansion factor homolog	TMEM2	-2,17 -2,17	1,13 0,32
Transmembrane protein 2 Mathianing amingpoptidage 2	METAP2		
Methionine aminopeptidase 2 Coiled-coil domain-containing protein 25	CCDC25	-2,16 -2,16	0,98 0,29
Coiled-coil domain-containing protein 25	HDHD3	-2,16 -2,15	0,29 0,07
Haloacid dehalogenase-like hydrolase domain-containing protein 3	SEPT8		
Septin-8 Cyclin-dependent kinace 4	CDK4	-2,14	N.D.
Cyclin-dependent kinase 4 Threonine synthase-like 1	CDK4 THNSL1	-2,14	0,69
	SBF1	-2,13	N.D.
Myotubularin-related protein 5 Ras-related C3 botulinum toxin substrate 3	RAC3	-2,13 -2,12	N.D. 0,22
Ubiquitin carboxyl-terminal hydrolase isozyme L5	UCHL5	-2,12 -2,12	0,22
Protein kinase C theta type	PRKCQ	-2,12 -2,12	
Protein kinase C theta type Proteasome inhibitor PI31 subunit	PSMF1	-2,12 -2,12	0,74
Proteisorie Initiator Pisi subunit	FAM195B	-2,12 -2,12	0,14
			0,10
Endoplasmic reticulum aminopeptidase 2	ERAP2 NOSIP	-2,12	0,28
Nitric oxide synthase-interacting protein Cullin-5	CUL5	-2,11	0,06
	RRAS	-2,11	0,06
Ras-related protein R-Ras		-2,11	0,46
Uroporphyrinogen-III synthase	UROS	-2,11	0,10
Ribosome biogenesis regulatory protein homolog	RRS1	-2,10	0,06
Charged multivesicular body protein 7	CHMP7 PACS1	-2,10	0,30
Phosphofurin acidic cluster sorting protein 1	RDH14	-2,10 -2,09	N.D. N.D.
Retinol dehydrogenase 14	TEX2		
Testis-expressed sequence 2 protein		-2,09	N.D.
Pro-cathepsin H	CTSH PRKACB	-2,09	0,04
cAMP-dependent protein kinase catalytic subunit beta Probable ATP-dependent RNA helicase DDX10	DDX10	-2,08	0,23
Zinc finger protein 451	ZNF451	-2,08 -2,07	0,42 0,01
	RSF1	-2,07	
Remodeling and spacing factor 1 Protein MAK16 homolog	MAK16	-2,07	N.D. N.D.
Inhibitor of Bruton tyrosine kinase	IBTK	-2,00	N.D.
Atypical kinase ADCK3, mitochondrial	ADCK3	-2,05	
			0,18
Coiled-coil domain-containing protein 90B, mitochondrial Protein arginine N-methyltransferase 1	CCDC90B PRMT1	-2,05 -2,05	0,26 0,18
LIM domain-containing protein 2	LIMD2	-2,05	0,18
	UBAC1	-2,05	0,17
Ubiquitin-associated domain-containing protein 1 Kinase D-interacting substrate of 220 kDa	KIDINS220	-2,03	0,30
Interferon-induced transmembrane protein 2, 1 and 3	IFITM2;IFITM1;IFITM3	-2,04	0,12
UDP-glucose 4-epimerase Prockasint cluster region protein	GALE BCR	-2,03	0,32
Breakpoint cluster region protein Protein phosphatase 1 regulatory subunit 14B	PPP1R14B	-2,02 -2,02	0,08 0,10
Acylphosphatase-1	ACYP1		
		-2,02	0,06
MOB kinase activator 2 Thiosodovin domain containing protein 5	MOB2 TXNDC5	-2,02	0,01
Thioredoxin domain-containing protein 5		-2,01	0,38
pre-rRNA processing protein FTSJ3 Electron transfer flavoprotein subunit beta	FTSJ3 ETFB	-2,01	0,17
		-2,01	0,01
Formin-like protein 2	FMNL2	-2,01	N.D.
Interferon regulatory factor 2-binding protein-like	IRF2BPL	-2,01	N.D.
Ribosomal RNA processing protein 1 homolog B	RRP1B ZNF326	-2,00	0,33
DBIRD complex subunit ZNF326		-2,00	0,23
Copper chaperone for superoxide dismutase	CCS	-2,00	0,31
DIS3-like exonuclease 1	DIS3L	-1,99	0,58
Ran-binding protein 9 Chromatin accombly factor 1 cubupit A	RANBP9	-1,98	0,10
Chromatin assembly factor 1 subunit A	CHAF1A	-1,97	N.D.
Probable E3 ubiquitin-protein ligase HECTD4	HECTD4	-1,96	0,38
Protein Jumonji Protein phorphotoco 14	JARID2	-1,96	0,10
Protein phosphatase 1A	PPM1A	-1,96	0,33
PITH domain-containing protein 1	PITHD1	-1,95	0,03
Suppressor of cytokine signaling 2	SOCS2	-1,95	0,84
Fructosamine-3-kinase	FN3K	-1,95	N.D.

Senective bencharder protein Size Size arguing vubunit a light indermPPRIA-1.980.16Double-strader (BNA-Inder protein Size) bencharderSTAL 1-1.920.01Double-strader (BNA-Inder protein Size) bencharderSTAL 1-1.920.01DNA polymerses subunit gamm-1STAL 1STAL 10.01DNA polymerses subunit gamm-1CSBL 1STAL 10.01DNA polymerses subunit gamm-1CSBL 1STAL 10.00Unruniter-cooplation Size Size Size Size Size Size Size Size				
Exponin-79079.220.03Samaphonin-7AMMA29.320.01Samaphonin-7AMMA29.320.01Samaphonin-7APOLG9.320.01Charbonin-7APOLG9.320.01Charbonin-7APOLG9.320.01Charbonin-7APOLG9.320.01Charbonin-7APOLG9.320.01Charbonin-7APOLG9.320.02Charbonin-7APOLG9.320.02Charbonin-7APOLG9.320.02Charbonin-7APOLG9.320.02Charbonin-7APOLG9.320.02Charbonin-7APOLG9.320.02Charbonin-7APOLG9.320.02Charbonin-7APOLG9.320.02Charbonin-7APOLG9.320.02Charbonin-7APOLG9.320.02Charbonin-7APOLG9.320.02Charbonin-7APOLG9.320.02Charbonin-7APOLG9.320.02Charbonin-7APOLG9.320.02Charbonin-7APOLG9.320.32Charbonin-7APOLG9.320.32Charbonin-7APOLG9.320.32Charbonin-7APOLG9.320.32Charbonin-7APOLG9.320.32Charbonin-7APOLG9.320.32Charbonin-7APOLG9.320.32Charbonin-7APOLG	Serine/threonine-protein phosphatase 2A 55 kDa regulatory subunit B alpha isoform	PPP2R2A	-1,94	0,16
Experim?9079.920.06Semaphorin?AMMA7A9.10N.0.MAP polymers subunit germs 1.0.060.00Marchard and the product of the produc	Double-stranded RNA-binding protein Staufen homolog 1	STAU1	-1,94	N.D.
Sinal Integral nembrane protein 12MM121.9.20.1.1DNA polymersas suburit gamma-1PCUG-1.9.3N.D.DNA polymersas suburit gamma-1CTSM-1.9.00.0.0Datagator activox-terminal hydrolaes 40CTSM-1.9.0N.D.Debatis Constructure activox-terminal hydrolaes 40CTSM-1.9.0N.D.Debatis Constructure activox-terminal hydrolaes 40CTSM-1.9.0N.D.Probate Socie activo terminal hydrolaes 40CTSM-1.9.0N.D.Probate Socie activo termina hydrolaes 40CTSM-1.9.0N.D.Probate Socie activo termina hydrolaes 40CTSM-1.9.0N.D.Probate Socie activo termina hydrolaes 40CTSM-1.9.0N.D.Probate Socie activo terminal hydrolaes 40CTSM-1.9.0N.D.Consol activo terminal hydrolaes 40CTSM-1.9.0N				
sim apprintINAUTA1.9.1N.D.Chille pair and south agames 1PCIG1.9.2N.D.Chille pair B light chairs thread pair heavy chainCSB1.9.9N.D.Martin action state and south agames 1CSB1.9.9N.D.Martin action state and south agames 1CSB1.9.91.9.91.9.9Martin action state and south				
DNA polymerse subunit genome-ignoresDCG-1.92C.02Lingeuin Schurgenerse bigstrahin-Schurgen heavy daniCFS-3.980.00Lingeuin carboy-terminal hydrates 4CEEL-3.980.00Lingeuin carboy-terminal hydrates 4CEEL-3.90N.0.Lingeuin carboy-terminal hydrates for the factor fact				
Chebps BCathegoin Bight Jahn/Cathegoin Bowy JahnCTS1-300.01Margum actional functions advantables after proteinKAB4.00Margum actional functions advantables after proteinKAB4.00Margum actional functions advantables after proteinKAD4.00Margum actional functions advantables after proteinKAD4.00Margum actional functions advantables after proteinKAD4.00Margum actional functionsKAD4.00N.D.Margum actional functionsKAD4.00N.D. <t< td=""><td></td><td></td><td></td><td></td></t<>				
Usique carbox/terminal hydrolase 44USPARS-1.5000.000Kich his carbox/terminal scaleCEL-1.5000.000Kich his CPL - subclased protein 1CR11-1.5000.000Caname enderoded binding protein subunt test-like protein 1CR11-1.5000.000Protein argunate-3CR11-1.5000.0000.000Protein argunate-1CR11-1.5000.0000.000Caname enderoded binding protein subunt highp-15CR11-1.5000.0000.000Caname enderoded binding protein subunt highp-15DAVIT-1.5000.0000.000Caname enderode binding protein subunt highp-15DAVIT-1.5000.0000.000Caname enderode binding protein subunt highp-15DAVIT-1.5000.000<				
numeraCCLL1.90N.D.Kachink C-V.Saccatad proteinKAD9.06Gaarine nucleotide-binding protein subunit betalike proteinKAD9.06Kachink C-V.Saccatad proteinKAD9.00Verbain arganusciKAD9.00Verbain arganusciKAD9.00Verbain arganusciKAD9.00Scanne nucleotide-binding protein subunit alpha-15KANTATAB9.00Scanne nucleotide-binding protein subunit alpha-15KANTATAB9.00Chystophartes MUDTSCO1001.399.01Chystophartes MUDTSCO1001.399.03Chystophartes MUDTSKANTATAB7.009.03Chystophartes MUDTSCO1001.399.03Chystophartes MUDTSCO1001.399.03Chystophartes MUDTSPLS1.38N.D.Dath assoctade proteinChystophartes MUDTS1.301.30Chystophartes MUDTSPLS1.38N.D.Chystophartes MUDTSPLS <td< td=""><td>Cathepsin B;Cathepsin B light chain;Cathepsin B heavy chain</td><td>CTSB</td><td>-1,90</td><td>0,01</td></td<>	Cathepsin B;Cathepsin B light chain;Cathepsin B heavy chain	CTSB	-1,90	0,01
kich-ike Ciasociated protein 1GRAP1FLAP1FLAP0M.0.6Accolarine nucleader binding protein subunt betal-lie protein 1GRAIACO3-1.500M.0.7Arbotise B-on-Off diphosphates HUDTSNUDTS-1.500M.0.7Actable B-on-Off diphosphates HUDTSNUDTS-1.200M.0.7Actable B-on-Off diphosphates HUDTSNUDTS-	Ubiquitin carboxyl-terminal hydrolase 48	USP48	-1,90	0,00
kich-ike Ciasociated protein 1GRAP1FLAP1FLAP0M.0.6Accolarine nucleader binding protein subunt betal-lie protein 1GRAIACO3-1.500M.0.7Arbotise B-on-Off diphosphates HUDTSNUDTS-1.500M.0.7Actable B-on-Off diphosphates HUDTSNUDTS-1.200M.0.7Actable B-on-Off diphosphates HUDTSNUDTS-	Kynurenineoxoglutarate transaminase 1	CCBL1	-1.90	N.D.
Gamme nucleonide-binding protein subunit best-like protein 3CMB11-1.90N.D.Probable Sono -GFT diphopshates MUDT35NUDT35-1.90N.D.Probable Sono -GFT diphopshates MUDT35CMA12-1.90N.D.Altable stars-"Jate protein subunit Japha-135CMA13-1.90N.D.Calamen cuccotide-binding protein subunit Japha-135CMA13-1.90N.D.Calamen cuccotide-binding protein subunit Japha-135CMA13-1.90N.D.Calamen cuccotide-binding protein Subunit Japha-135CMA13-1.90N.D.Calamen cuccotide-binding protein Subunit Japha-135CMA14-1.80N.D.Calamen cuccotide-binding protein Subunit Japha-135CMA14-1.80N.D.Calamen cuccotide-binding protein Cuccotide-Dipole protein Subunit Japha-135CMA14N.D.N.D.Calamina cuccotide-binding protein Cuccotide-Dipole protein Subunit Japha-135CMA14N.D.N.D.Patch cuccotide-binding protein Cuccotide-Dipole protein Subunit Japha-135CMA14N.D.N.D.Calamina cuccotide-binding protein Cuccotide-Dipole protein Subunit Japha-135CMA14N.D.N.D.Calamina cuccotide-binding protein Subunit Japha-135CMA14N.D.N.D.N.D.Calamina cuccotide-binding protein Subunit Japha-135CMA14N.D.N.D.N.D.Calamina cuccotide-binding protein Subunit Japha-135CMA14N.D.N.D.N.D.Calamina cuccotide-binding protein Subunit Japha-135CMA14N.D.N.D.N.D.Calamina cuccotide-binding protein				
Pacter angenate-3AGO31.90N.D.Pactable Soc-Off dipolphase NUD15NOTS1.90N.D.Pactable Soc-Off dipolphase NUD15ATAYAB1.900.08Canane nucledificationing protein subunt Alpha-15GMLS1.900.021Pactable Soc-Off protein Subunt Alpha-15GMLS1.900.021Canane nucledificationing protein Subunt Alpha-15GMLS1.900.021Canane Nucledificationing Protein Subunt Alpha-15GMLS1.900.021Canane Nucledificationing Protein Subunt Alpha-15GMLS0.0210.021Canane Nucledificationing Protein Subunt Alpha-15GMLS0.0210.021Canane Nucledificationing Protein Subunt Alpha-15DAPKI-1.880.061Canane Nucledificationing Protein Subunt Alpha-15DAPKI-1.880.061Canane Nucledificationing Protein Subunt Alpha-15CANA-1.870.031Canane Nucledificationing Protein Subunt Alpha-15CANA-1.850.031Canane Nucledificationing Protein Subunt Alpha-15CANA-1.850.031Canane Nucledificationing Protein Subunt Alpha-15 <td< td=""><td></td><td></td><td></td><td></td></td<>				
pheable Baoo-diff biphophase NUDTSNUDTS1-90N.D.Atalave stars. 'Approxima Baoota Stars Sta				
junture stain J-ñie protein 30ATMV128II.000.08Calame nucleotich-biding protein staunt alph 1.5OH151.900.61T-debrig/Archiester of reductaseDHCR71.800.61Fabor only protein 7CB1091.890.07C1010 antiginCD1091.890.031ESF1 honologDEath associated protein house 10.0810.031Death-associated protein house 10.0311.880.01Death-associated protein house 10.0211.880.021Death-associated protein house 10.0211.870.023Caroline O-acch/transferaseCMAID1.870.021Death-associated protein house 1022DIO 10281.870.023Caroline O-acch/transferase, motochontralND1.830.021Caroline O-acch/transferase, motochontralND1.830.031Caroline D-acch/transferase, motochontralND1.850.031Caroline D-acch/transferase, motochontralND1.850.031Caroline D-acch/transferase, motochontralND1.850.031Caroline D-acch/transferase, motochontralND1.850.031Caroline D-acch/transferase, motochontralND1.850.031<				
Gamme nucleotide-binding protein shufund apha-15GMA15GMA15GMA15No.Flox only protein 7C109N.D.N.D.N.D.N.D.C109 antigenGD109L.B.9N.D.N.D.N.D.N.D.Flox only protein 7C109L.B.9N.D.N.D.N.D.N.D.N.D.C129 antigenGD109L.B.9N.D. <td< td=""><td></td><td></td><td></td><td></td></td<>				
2 delyncholastear ineducaseDHCR71.500.07CD020 antignCD1091.380.07CD1020 antignCD1091.381.39CD1020 antignCD1091.380.01ESF1 antignCD1091.380.01Death associated protein kinase 1DAPL11.380.01Death associated protein kinase 1DAPL11.380.08Pasta-1Transcription factor pG5PEL01.370.31Franscription factor pG5PEL01.370.32Scription antignDR0CAJP1.370.32Scription antign proteinSCRAJP1.380.06MA-dricted BMA profermase III suburit BPC2DR1531.360.00MA-dricted BMA profermase III suburit BPC2DR1531.360.02Anternet SMA inges, mitochondrialSR3521.360.04Acashy Coa scriptionanders, scription and scriptionCNADD, SNALE0.03Acashy Coa scriptionanders, scription galoCNADD, SNALE1.350.03Acashy Coa scriptionanders, scriptionanders, scriptionanders, scriptionanders, scriptionanders, scriptionande	Putative ataxin-7-like protein 3B	ATXN7L3B	-1,90	0,08
i box only protein 7It.300.07ChUBD antgemCD091.890.29Cytathionine gamma /yaseCTH1.280.01Dath stacklated protein insea 1DARCI1.28ND.Dath stacklated protein insea 1PLSI1.28ND.Dath stacklated protein insea 1PLSI1.28ND.Dath stacklated protein insea 1PLSI1.28ND.Dath stacklated protein insea 1PLSI1.28ND.Dath stacklated protein insea 1PLD1.27ND.Dath stacklated protein insea 1PLD1.27ND.Dath stacklated protein insea 1PLD1.27ND.Dath drinked fink promease III staunt RPC2PLD1.27ND.Dath drinked fink promease III staunt RPC2PLD1.28ND.Dath drink protein 3PLD1.28ND.ND.Dath drink protein 3PLD1.28ND.ND.Dath drink protein 4PLD1.28ND.ND.<	Guanine nucleotide-binding protein subunit alpha-15	GNA15	-1,90	N.D.
i box only protein 7It.300.07ChUBD antgemCD091.890.29Cytathionine gamma /yaseCTH1.280.01Dath stacklated protein insea 1DARCI1.28ND.Dath stacklated protein insea 1PLSI1.28ND.Dath stacklated protein insea 1PLSI1.28ND.Dath stacklated protein insea 1PLSI1.28ND.Dath stacklated protein insea 1PLSI1.28ND.Dath stacklated protein insea 1PLD1.27ND.Dath stacklated protein insea 1PLD1.27ND.Dath stacklated protein insea 1PLD1.27ND.Dath drinked fink promease III staunt RPC2PLD1.27ND.Dath drinked fink promease III staunt RPC2PLD1.28ND.Dath drink protein 3PLD1.28ND.ND.Dath drink protein 3PLD1.28ND.ND.Dath drink protein 4PLD1.28ND.ND.<	7-dehydrocholesterol reductase	DHCR7	-1.90	0.61
CD103 mign Cytabbonic genama-yaseCD1091.591.53SF1 honologESF1 nonlog0.331SF2 honologESF1 nonlog0.341Bath-saccitate protein kinse 10.4411.3880.01Plastin-1PLS11.2880.081Transcription factor pS5RLA1.3880.081Protein polota homologCNCNAUP1.3770.332SorcinCNCNAUP1.3770.332SorcinSR1.3770.332SorcinCNCNAUP1.3770.352SorcinSaccinter O-scatytanaferaseCNCNAUP1.3770.352SorcinSaccinter O-scatytanaferase1.3680.4910.352SorcinSaccinter O-scatytanaferase1.3680.4910.352SorcinSaccinter O-scatytanaferase1.3680.4920.332SorcinSaccinter SorcinSaccinter O-scatytanaferase0.4920.492SorcinSaccinter Sorcin1.3680.4920.492SorcinSaccinter Sorcin1.3680.4920.492SorcinSaccinter Sorcin1.3680.4920.492Sorcin Construction of Sorcing Sorcin Sorcin1.3680.4920.492Sorcin Construction of Sorcing Sorcin Sorcing Sorci				
Cystab homoigCH9.380.31Death-sacclated protein Kinse 1DARK11.380.01Death-sacclated protein Kinse 1DARK11.38N.D.Pastin-1DARK11.380.68Transcription factor p65RELA1.380.48Protein pelot homoigRELA1.370.32SorrinCDRV2A/P1.370.32Carrither D-Sacch/transfersseCRAT1.37N.D.D-Ardertedt MA polymerse II subunit RPC2POLRB1.3870.02Marter Construction regulatory factor 3SHA1.387N.D.Sorrin-ONK Ligges, matchondrialSHAS21.386N.D.Carrither D-Sacch/transfersse, matchondrialSHAS21.386N.D.Caroline J-Sacch/transfersse, matchondrialSHAS21.386N.D.Caroline Grow Ligges, matchondrialSHAS21.386N.D.Caroline Grow Ligges, matchondrialCSAUT/CSANEE1.380.03Caroline Scient MarkaInformatory matchanN.D.1.380.03Caroline Scient MarkaInformatory matchanN.D.1.380.30Caronton Registra 7MBOA171.340.300.33Caroline All All All All All All All All All Al				
SP3 homolog Deth-associated proteix kinas 1O.0.1Plastn-1PLS11.3.8ND.Plastn-1PLS11.3.80.68Practription factor pG5PLG01.3.70.32Strancription factor pG5PLG01.3.70.32Strancription Factor pG5Strancription Factor pG5ND.0.32Strancription Factor pG5Strancription Factor pG5ND.0.32Strancription Factor pG5Strancription Factor pG5ND.0.32Strancription Factor pG5Strancription Factor pG5ND.0.32Strancription Factor pG5Strancription Factor pG6ND.0.32Strancription Factor pG5Strancription Factor pG6ND.0.32Strancription Factor pG6Strancription Factor pG6ND.0.32Strancription Factor pG6Strancription Factor pG6ND.0.32Strancription Factor pG6ND.ND.1.860.00Yabox Factor pG6ND.ND.1.860.00Yabox Factor pG71.840.010.030.030.03Casen Kinase Lisoform delix/Casen Kinase Lisoform epsionCSNULD/SNNLE1.85ND.Strancription Factor pG71.840.010.030.030.03Casen Kinase Lisoform delix/Casen Kinase Lisoform epsionND.1.840.01Strancription Factor pG71.840.030.030.030.03Strancription Factor pG71.840.030.030.030.03Strancription Factor pG7	-			
bash-socalared protein Kinse 1ND.ND.Pistin-1FIS1-1.380.68Transcription factor p65FILA-1.380.68Protein p6ta homologFILO-1.370.32Chroll nobel homologCDNVAP-1.370.32Carrilne O-acetyltransferseCDNVAP-1.370.03Carrilne O-acetyltransferseCDNVAP-1.370.03Carrilne O-acetyltransferseCNAT-1.370.02DNA directed TNA polymerse II tubunt RPC2FOL38-1.570.25Interforn regulatory factor 3Saster, 1.380.480.09Sinter-UNN Ligge, nutchondrialCNAT-1.850.04Acetyl-CoA acetyltransferse, nutchondrialCNAT-1.850.03Carchine regulator 1CNAT-1.850.03Carchine regulator 1CNAT-1.850.03Carchine regulator 1CNAT-1.840.10Lysophtopilopil acyltransferse, nutchondrialCNAT-1.840.10Lysophtopilopil acyltransferse, CARM1MCR-1.840.13Stort-chai detyltransferse, CARM1CRAM1-1.840.14Lysophtopilopil acyltransferse, CARM1SPA-1.820.00Lysophtopilopil acyltransferse, CARM1SPA-1.820.00Lysophtopilopil acyltransferse, CARM1SPA-1.820.01Lysophtopilopilopilopilopilopilopilopilopilopil				
plastin-1rs1rs20.68Trancrytion factor p65FELA1.880.64Protein petota homologFELO1.870.32CNRXA-Intercating proteinCNRXA-Intercating protein0.32SortinCRAT1.870.03Carnline O-actytitransferaseN.N.0.33DNA directed RNA polymerszel II subunt RPC2FOLSFOLS0.0381.870.65Interferon regulatory factor 3RAS0.680.090.090.000	ESF1 homolog	ESF1	-1,88	0,01
Transcription factor p65RELA <td>Death-associated protein kinase 1</td> <td>DAPK1</td> <td>-1,88</td> <td>N.D.</td>	Death-associated protein kinase 1	DAPK1	-1,88	N.D.
Protein percein appectsFELOFL370.14CONVA2-interscring perceinCDNVA2-interscring percein0.32SorcinCONVA2-interscringND.DNA-directed NNA polymerses III subunit RPC2POR831.870.02Interferon regulatory factor 31.86ND.Serine-IRNA ligase, mitochondrialSAR21.860.00Chapchilina B1SH3GLB31.860.00Y-box-binding protein 3SH3GLB31.860.00V-box-binding protein 3CAR11.850.03Casen Kinase I isoform delta_Caseni knase I isoform epsilonCMKLD_SKKLE1.860.00V-box-binding protein 3CAR11.860.000.00V-box-binding aprotein 4CAR11.860.000.000.00V-box-binding aprotein 5CAR11.840.100.000.000.00V-box-binding aprotein 5MBCAT71.840.100.00	Plastin-1	PLS1	-1,88	0,68
Protein percein appectsFELOFL370.14CONVA2-interscring perceinCDNVA2-interscring percein0.32SorcinCONVA2-interscringND.DNA-directed NNA polymerses III subunit RPC2POR831.870.02Interferon regulatory factor 31.86ND.Serine-IRNA ligase, mitochondrialSAR21.860.00Chapchilina B1SH3GLB31.860.00Y-box-binding protein 3SH3GLB31.860.00V-box-binding protein 3CAR11.850.03Casen Kinase I isoform delta_Caseni knase I isoform epsilonCMKLD_SKKLE1.860.00V-box-binding protein 3CAR11.860.000.00V-box-binding aprotein 4CAR11.860.000.000.00V-box-binding aprotein 5CAR11.840.100.000.000.00V-box-binding aprotein 5MBCAT71.840.100.00				
CDNU2Arieracting proteinCDNU2Arier-1.870.03Carnitre O-acetyfransferaseCRAT-1.87NDDDNAdricced RNA polymerase III suburit RPC2POLRB-1.87NDDDNAdricced RNA polymerase III suburit RPC3IRB3-1.86NDDStrine-INAN lagse, mitochondrialSAS2-1.860.00Fore-INAN lagse, mitochondrialSAS2-1.860.00Casen linase I softer defa Casen kinase I softer defa Casen-1.850.00Acetyf-CoA acetyftransferase, mitochondrialCAC11-1.850.00Casen kinase I softer defa Casen kinase I softer defa Casen-1.850.00Soft-Chai defydragenase/ fudctase 3CSNELO,CSNKLE-1.850.00Casen kinase I softer defa Casen kinase I softer defa Casen-1.850.01Lysophospholipid acyftransferase 7MOLO-1.840.10Lysophospholipid acyftransferase CARN1CENPE-1.840.10Lysophospholipid acyftransferase CARN1MOLO-1.830.01Lysophospholipid acyftransferase CARN1MOLO-1.820.01Lysophospholipid acyftransferase CARN1MOLO-1.820.01Lysophospholipid acyftransferase CARN1MOLO-1.820.01Lysophospholipid acyftransferase CARN1MOLO-1.820.01Lysophospholipid acyftransferase CARN1MOLO-1.820.01Lysophospholipid acyftransferaseMOLO-1.820.02Single canade DNA-binding protein 1MCLO-1.820.02Lysophospholipid				
SurdinStrictStrict1.970.03Carnithe C-acytina fcraceCAT-1.97N.D.DNA-directed RNA polymerse III subunit RPC2POIR3B-1.870.25Interferon regulatory factor 31.863-1.86N.D.Serine-RNA ligate, mitochondrialSMS2-1.860.00Yoos Maing portein 3YB30-1.850.03Caser kinase I isoform delta; Zasen kinase I isoform epsilonCSNLD,CSNKIE-1.850.03Actyl CAA acetylrandfasse, mitochondrialCSNLD,CSNKIE-1.850.03Caser kinase I isoform delta; Zasen kinase I isoform epsilonCSNLD,CSNKIE-1.850.03Caser kinase I isoform epsilonCSNLD,CSNKIE-1.840.10Lycophotopilal acytransferase 7MIBOAT7-1.440.13Sort-chain delty/tagenase/reductase 3DHKS3-1.440.13Lycophotopilal acytransferase CARM1CARM1-1.430.14Lycophotopilal acytransferase CARM1CARM1-1.430.12Lycophotopilal acytransferase CARM1SB2SB20.22Strick-argine-reductase, mitochondrialSPD-1.82N.D.Lycophotopilal acytransferase CARM1SB20.00-1.82N.D.Lycophotopilal acytransferase CARM1SB20.02-1.82N.D.Lycophotopilal acytransferase CARM1SB20.02-1.820.02Spersor GNAVAL & DavologSB2-1.820.02-1.820.02Spersor GNAVAL & DavologSB2-1.820.02 <t< td=""><td></td><td></td><td></td><td></td></t<>				
Carnine O-acetyrinaderseCRAT1.97ND.DNA-directed RNA polymerse III subunit RPC2POIRB3-1.970.26Interferon regulatory factor 3BR3-1.860.00Strine-INAL Mage, mitochondrialSMS2-1.860.00Choord MarkSMS2-1.860.00Choord MarkSMS2-1.850.00Choord MarkSMS2-1.850.00Choord MarkSMS2-1.850.00Choord MarkChoord Mark-1.850.00Choord MarkChoord Mark-1.850.00Choord MarkChoord Mark-1.850.00Choord MarkChoord Mark-1.850.00Choord MarkChoord Mark-1.840.10Uxpohosholind alpritansferase 7MEMOAT-1.840.11Suppersort SW14 I homologPAN-1.830.14Unconventional myosin-10FRS-1.83ND.0Suppersort SW14 I homologPAN-1.830.22Serine-Jagnine-rich splicing factor 4SSP4-1.820.002-4-diency-CoA reductase, mitochondrialDCCR-1.820.002-4-diency-CoA reductase, mitochondrialPACIHI-1.820.002-4-diency-CoA reductase, mitochondrialSSP2SSP3-1.820.002-4-diency-CoA reductase, mitochondrialCCCC-1.83ND.0Singe-Straded DNA-binding protein 3SSP2-SSP3-1.820.002-1-activated protein Kinase-interacting protein 1SSP1-1.82<				
DNA-directed RNA polymerse III subunit RPC2POR81P187-1.670.26Interferon regulatory factor 3IRF3-1.68N.D.Serine-RNA ligase, mitochondrialSAR52-1.860.00Yobe Undring protein 3YB30-1.850.03Catery Iroba acetylicandrase, mitochondrialCACIT-1.85N.D.Acetyl-CoA acetylicandrase, mitochondrialCANT-1.85N.D.Catery Iroba is Isoform delta; Casen kinase I Isoform epsilonCSNLD, CSNKLE-1.85N.D.Mitochondrial calcum unporter regulator 1CENPT-1.840.10Sport-Chain difyringenase/iroductase 3DHRS3-1.84N.D.Sport-Chain difyringenase/iroductase 3DHRS3-1.84N.D.Sport-Chain difyringenase/iroductase 3DHRS3-1.84N.D.Sport-Chain difyringenase/iroductase 3SPS2-1.82N.D.Sport-Chain difyringenase/iroductase 3SPS2-1.82N.D.Sport-Chain difyringenase/iroductase 3SPS2-1.82N.D.Sport-Chain difyringenase/iroductase 3SSS2-SSP3-1.820.00Sport-Chain difyringenase/iroductaseN.D1.820.00Sport-Chain difyringenase/iroductaseN.D1.820.00Sport-Chain difyringenase/iroductaseSSSP2-SSP3-1.820.00Sport-Chain difyringenase/iroductaseN.D1.820.00Sport-Chain difyringenase/iroductaseN.D1.820.00Sport-Chain difyringenase/iroductaseN.D1.82 <td< td=""><td></td><td></td><td></td><td></td></td<>				
Interferon regulatory factor 3NP.Serine-TRAN Ligss, mitochondrialSAS21.860.09Ybox-binding protein 3NP.1.850.001Ybox-binding protein 3YBOX1.850.001Casen linase I isoform desilonCNNLD,CSNKIE1.850.001Kitchondrial culcum unipoter regulator 1MCURI1.850.001Casen linase I isoform desilonCNNLD,CSNKIE1.850.001Kitchondrial culcum unipoter regulator 1MCURI1.850.001Centromere protein FCRNMP1.440.101Sport-Chain dehydrogenase/reductase 3MKDAT71.440.18Sport-Chain dehydrogenase/reductase 3MKDAT71.430.14Suppension fills apytranterse 7MKDAT71.440.11Suppension redupting factor 4SportSport3.330.14Nuconventional myosin-IdMYCDI4.33ND.0.22Serine/Arginine-rich spicing factor 4SportSSF41.33ND.Sportein Synthe Budace on sincontaing protein 1Sportein 3SSF2/SSF31.820.002-4-diendy-CoA reductase, mitochondrialDCC1.820.007Plastaxed Equation transporting ATSate 4ATE24ATE240.03Sportein State Student State 10SACI1.820.03Cytosolic cup' construct Student State 10Sportein 3SSF2/SSF31.820.03Single-stranded DNA-binding protein 2CCLC1.820.030.77Plastaxed Equations Student S				
Interferor regulatory factor 3NP.31.66N.D.SerineTRAN Ligses, mitochondrialSASC.21.680.09Endophilne-B1YSG.31.680.00Aceth/CoA aceth/transfersse, mitochondrialACAT11.850.03Castin kinsse i isoform deltac/Casten kinsse i isoform pellonCSNID/CSNIEIE1.850.03Castin kinsse i isoform deltac/Casten kinsse i isoform pellonCSNID/CSNIEIE1.850.03Castin kinsse i isoform deltac/Casten kinsse i isoform pellonCSNID/CSNIEIE1.850.03Centormere protein F1.440.100.180.130.140.10Short-chail dehydrogenase/reductase 3MCDRT1.440.100.130.140.100.130.140.100.110.120.110.120.120.110.120.110.120.120.110.120.120.110.120.120.110.120.110.120.120.110.120.120.120.110.120.120.110.120.120.120.110.120.120.110.120.120.110.120.120.110.120.120.120.120.120.120.110.120.120.110.120.120.120.110.120.120.120.110.120.120.110.120.110.120.120.110.120.120.120.110.120.120.120.120.120.120.11	DNA-directed RNA polymerase III subunit RPC2	POLR3B	-1,87	0,26
Serine-RNA ligse, mitochondrialSAR521.860.09Vbob-hiding protein 3YA331.850.04Vbob-hiding protein 3YA331.850.03Acetyl-CoA acety/transferase, mitochondrialCAN111.85N.D.Mitochondrial calcium uniporter regulator 1CNND,CSNKIE1.85N.D.Mitochondrial calcium uniporter regulator 1CNNF1.840.03Centromere protein FCNNF1.840.01Lysophospholipid acytransferase 7MBOAT71.840.14Short-chai dehydrogenase/reductase 3DHR531.44N.D.Histone arginine methytransferase CARM1CARM11.840.14Unconventional myosin-IdShort-chai dehydrogenase/reductase 30.22N.D.Speresor GNV41 homologPPAN1.820.020.14Unconventional myosin-IdSKF41.820.020.172-deineov/CAA reductase, into-chondrialDECR11.820.020.122-deineov/CAA reductase, mitochondrialDCC11.820.010.020.022-deineov/CAA reductase, mitochondrialDCC11.820.010.020.020.022-deineov/CAA reductase, mitochondrialDCC11.820.010.020.020.020.022-deineov/CAA reductase, mitochondrialDCC11.820.010.020.020.020.020.020.020.020.020.020.020.020.020.020.020.020.020.02 <td< td=""><td></td><td>IRF3</td><td></td><td></td></td<>		IRF3		
EndopInite 3.StaGLE11.660.00Aceth/CoA acetyltransferase, mitochodrialACA11.850.04Aceth/CoA acetyltransferase, mitochodrialCACN11.850.03Caseh kinase itsoform detaCaseh kinase itsoform epsilonCNNLD/CSNLTE1.850.30Mitochodrial calcium uniporter regulator 1MCUR11.850.30Centrome protein FCRNPF1.840.10Lypohospholipid agvitransferase 7MBOAT71.440.13Short-Chain dehydrogenase/reductase 3DHR331.44N.D.Short-Chain dehydrogenase/reductase 3DHR331.44N.D.Suppressor of SVI4 1 homologPRNN1.330.22Serine/agninie-rich splicing factor 4SSF41.83N.D.Suppressor of SVI4 1 homologDVC1.420.002.A-diencyl-CoA reductase, mitochondrialDECR11.420.002.J-diented phase domain containing protein 1PAKIPI1.420.022.J-diented phase liguose phychosphataseN.D.T141.420.002.J-diented phase liguose phychosphataseN.D.T141.420.00Presimn-A/CLamin-A/CLMNA1.810.030.03Cell cycle ad apoptosis regulator protein 2.5CCAR21.790.18Sertin Mase Listoner hydrolaseACOT71.810.07Protein baseCCAR21.790.18Sertin Mase Listoner hydrolaseACOT71.810.07Protein baseCCAR21.790.18Sertin M		SARS2		
Yobs:YNX31.850.04Casen intase isoform deta;Casen kinase isoform epsilonCNNLD/CSNKIE1.85N.D.Mitchondial calciun inporter regulator 1CNNLD/CSNKIE1.85N.D.Mitchondial calciun inporter regulator 1CNNLD/CSNKIE1.840.00Lysophospholipid acyltransferase 7MBDAT71.440.18Stort-chai dehydrogenase/reductase 3DHRS31.44N.D.Histone arginine methytransferase CARM1CARM11.440.11Stort-chai dehydrogenase/reductase 3DHRS31.430.22Stort-chai dehydrogenase/reductase 3DHRS31.42N.D.Lisopressor G'SW14 I homologPPAN1.380.22Sterik-Arginine-reductase, into-chondrialDECR11.220.002-deinov/CAR deutaseDECR11.220.002-deinov/CAR deutase, into-chondrialDECR11.220.012-deinov/CAR deutase, into-chondrialDECR11.220.012-deinov/CAR deutase, into-chondrialDCC1.410.012-deinov/CAR deutase, into-chondrialDCC1.410.012-deinov/CAR deutase, into-chondrialDCC1.410.022-deinov/CAR deutase, into-chondrialDCC1.410.012-deinov/CAR deutase, into-chondrialDCC1.410.012-deinov/CAR deutase, into-chondrialDCC1.410.022-deinov/CAR deutase, into-chondrialDCC1.410.022-deinov/CAR deutase, into-chondrialDCC1.410.0				
Accel-CoA aceptytransferase, mitochondrialACAT1-1.850.03Casin kinase Lisoform dept.3csin kinase Lisoform epsilonCMUR1-1.85N.D.Mitochondrial calcium uniporter regulator 1MCUR1-1.850.30Centomere protein FCENPF-1.840.10Lisophospholipid av[transferase 7MBOAT7-1.840.18Short-chain dehydrogenase/reductase 3DHRS3-1.84N.D.Supportsols regulator 1CRM1-1.840.11Supportsols regulator proteinMY01D-1.830.22Serink-Arginine-rich splitoing factor 4SSP4-1.83N.D.Supported Synthase domain-containing proteinISPD-1.82N.D.2.4-disony-CoA reductase, mitochondrialDECR1-1.820.022.4-ationy-CoA reductase, mitochondrialDECR1-1.820.022.4-ationy-CoA reductase, mitochondrialDECR1-1.820.022.4-ationy-CoA reductase, mitochondrialDECR1-1.820.022.4-ationy-CoA reductase, mitochondrialSSP2/SSBP3-1.820.02Plasm a methorase cidum-transgo rotein 1SSP2N.D1.820.02Plasm a methorase cidum-transgo rotein 1SSP2-1.820.01Plasm a methorase cidum-transgo rotein 1SSP2-1.820.02Plasm amethorase cidum-transgo rotein 1SSP2-1.820.01Superoid Synthate BoataseNLD114-1.820.02Plasm amethorase cidum-transgo rotein 1SSP2-1.810.00				
Case in kinase i looform debit (ase in kinase i looform epsilonCSNLD)CSNLE-1,85N.D.Mittachondrial calcium uniporter regulator 1CENPF-1,840,00Lysophospholipid acyltransferase 7MBDA17-1,840,18Stort-chain debydrogenase/reductase 3DHR53-1,84N.D.Histon-arginine methyltransferase CARM1CARM1-1,840,11Stort-chain debydrogenase/reductase 3DHR53-1,830,14Unconventional myosin-idSK54-1,830,22Stort-chain debydrogenase/reductase 3ND-1,830,22Stort-chain debydrogenase/reductase, mitochondrialSK54-1,820,002,4-dienoyl-CoA reductase, mitochondrialDECR1-1,820,002,4-dienoyl-CoA reductase, mitochondrialDECR1-1,820,002,4-dienoyl-CoA reductase, mitochondrialDECR1-1,820,002,4-dienoyl-CoA reductase, mitochondrialDECR1-1,820,002,4-dienoyl-CoA reductase, mitochondrialSDD2-1,810,002,4-dienoyl-CoA reductase, mitochondrialSDD2-1,810,002,6-diana catoxiase (MM, mitochondrialSDD2-1,810,00Preiami-A/C_Lamin-A/CLMMA-3,810,300,33Cytosolic acyl coenzyme A thioster hydrolaseSAC5-1,80N,DSacianSAC5-1,80N,D330,30Cytosolic acyl coenzyme A thioster hydrolasePGAMS-1,770,31Serine/returnerinse-protein 2CCA2-				
Nitochordrial calcium uniporter regulator 1MCUR1-1.850.30Centromere protein FCMPF.1A40.10Lysophospholipid acyltransferase 7MBOAT7.1A40.18Short-chain dehydrogenase/reductase 3DHRS3.1,84ND.Supportspholipid acyltransferase CAML1CARM1.1,840.11Supportspholipid acyltransferase CAML1CARM1.1,840.12Supportspholipid acyltransferase CAML1CARM1.1,830.22Serine/arginine-rich spliting factor 4SSF4.1,83ND.Supportal Synthyse domain-containing proteinSSP0.1,82ND.2.4-dienoy-CoA reductase, mitochondrialDECR1.1,820.022.1-divited protein kinase-interacting proteinSSP2,SSP3.1,820.032Single-stranded DNA-binding protein 2.Single-stranded DNA-binding DNA-binding DNA-binding DNA-			-1,85	0,03
centromere protein FLB40.00Lyophopsholid acyltransferase 7MBOAT71.840.18Short-chain dehydrogenase/reductase 3DHRS31.84N.D.Histone-arginine methyltransferase CARM1CARM11.840.11Suppressor of SW14 homologPPAN1.830.22Serine/arginine-ichs picing factor 4SRSF41.830.22Serine/arginine-ichs picing factor 4SRSF41.830.22Serine/arginine-ichs picing factor 4SRSF41.820.002.4 dienovi/c.6 reductase, michondrialDECR11.820.00p21-activated protein funsse-interacting protein 1PAKIIP11.820.21Single-stranded DNA-binding protein 2 Single-stranded DNA-binding protein 3SBSP2.SSBP31.120.32Unifine diphosphate glucose prophosphateseNUDT141.820.06Superoxide distructase (Mi, mitochondrialSOD21.810.03Vortosilic avic corazyme A thioster hydrolaseCCOCBRC1.800.03Cell cycle and apotosis regulator protein 2CCM21.790.74Protein DapleSCCD21.780.210.77Seci famiy domain-containing protein 2SCFD21.790.74Epidermal growtin factor receptor substrate 15EP5151.790.74Autophagy-related protein 2 homolog 8ATG281.77N.D.NDH Addredbe-binding protein 2SCFD21.780.21NDA directed RNA point action insembly proteinPOIAL1.770.40 <td< td=""><td>Casein kinase I isoform delta;Casein kinase I isoform epsilon</td><td>CSNK1D;CSNK1E</td><td>-1,85</td><td>N.D.</td></td<>	Casein kinase I isoform delta;Casein kinase I isoform epsilon	CSNK1D;CSNK1E	-1,85	N.D.
centromere protein FLB40.00Lyophopsholid acyltransferase 7MBOAT71.840.18Short-chain dehydrogenase/reductase 3DHRS31.84N.D.Histone-arginine methyltransferase CARM1CARM11.840.11Suppressor of SW14 homologPPAN1.830.22Serine/arginine-ichs picing factor 4SRSF41.830.22Serine/arginine-ichs picing factor 4SRSF41.830.22Serine/arginine-ichs picing factor 4SRSF41.820.002.4 dienovi/c.6 reductase, michondrialDECR11.820.00p21-activated protein funsse-interacting protein 1PAKIIP11.820.21Single-stranded DNA-binding protein 2 Single-stranded DNA-binding protein 3SBSP2.SSBP31.120.32Unifine diphosphate glucose prophosphateseNUDT141.820.06Superoxide distructase (Mi, mitochondrialSOD21.810.03Vortosilic avic corazyme A thioster hydrolaseCCOCBRC1.800.03Cell cycle and apotosis regulator protein 2CCM21.790.74Protein DapleSCCD21.780.210.77Seci famiy domain-containing protein 2SCFD21.790.74Epidermal growtin factor receptor substrate 15EP5151.790.74Autophagy-related protein 2 homolog 8ATG281.77N.D.NDH Addredbe-binding protein 2SCFD21.780.21NDA directed RNA point action insembly proteinPOIAL1.770.40 <td< td=""><td>Mitochondrial calcium uniporter regulator 1</td><td>MCUR1</td><td>-1.85</td><td>0.30</td></td<>	Mitochondrial calcium uniporter regulator 1	MCUR1	-1.85	0.30
usophospholigid acytransferase 7MEDAT?1.840.18Short-chain dehydrogenase/reductase 3DHRS31.84N.D.Histone-arginine methydtransferase CARM1CARM11.840.11Suppressor of SWI4 1 homologPPAN1.830.44Unconventional mysin-IdSPD1.83N.D.Soprenoid synthase domain-containing proteinSPD1.820.0024-diencyl-CoA reductase, mitochondrialDECR11.820.0024-diencyl-CoA reductase, mitochondrialDECR11.820.01Single-stranded DNA-binding protein 3SSEP2/SSB731.820.01Plasma membrane calcium-transporting ATBase 4NDD141.820.07Plasma membrane calcium-transporting ATBase 4SDD21.810.00Prelami-A/CLainin-A/CLMNA1.810.01Prelami-A/CLainin-A/CLMNA1.810.01Prelami-A/CLainin-A/CLMNA1.810.01Prelami-A/CLainin-A/CLMNA1.810.01Prelami-A/CLainin-A/CLMNA1.810.01Prelami-A/CLainin-A/CLCCABC1.80N.D.SacsinCCC08CC1.80N.D.Cel cal apoptosis regulator protein 2CCCABC1.80N.D.Sechard Methydrogenase (ubiquinone) complex I, assembly factor 6NDUFAFG1.77N.D.NDH Hardy domain-containing protein 2SCFD21.780.21Protein IbageATG2B1.77N.D.N.D.Nobaghty domain-containing protein 2SC				
Short-chain debydrogenses/reductase 3DHRS-1.84N.D.Histone-arginine methyltransferase CARM1CARM11.940.11Suppressor of SW14 homologPPAN1.830.22Serine/arginine-richs plicing factor 4SRSF41.830.22Serine/arginine-richs plicing factor 4SRSF41.830.24toprenoid synthase domain-containing proteinISPD1.82N.D.2.4-dienoyl-CoA reductase, mitochondrialDECR11.820.002.1-ditroted protein kinase-interacting protein 1PAKIIP11.820.01Single-stranded DNA-binding protein 3SSBP2:SSBP31.820.32Uridine diphosphate glucose pyrophosphataseNUDT141.820.06Superoxide dismutase (M.I., mitochondrialSOD21.810.010Pleamin-A/C_tamin-A/CLMNA1.810.030.07Protein bagieCCCC BRC1.800.030.03Scifin cavi, coenzyme A thioester hydrolaseSACS1.600.74Protein bagieCCCC BRC1.790.180.74Sectifinarity domine-containing protein 2CCC21.790.18Sectifinarity domine-containing protein 2CCD21.790.18Sectifinarity domine-containing protein 2CCD21.77N.D.DNA-directed RNA polymerases I and III subunit RPAC1PICLM1.770.40Autophag-related protein 2 homolog BArG281.77N.D.DNA-directed RNA polymerases I and III subunit RPAC1QNGC1.760.				
Histone-arginine methyltransferase CARM1CARM11.840.11Suppressor of SW11 homologPPAN1.830.14Unconventional myosin-idMYO1D1.830.22Serine/arginine-rich splicing factor 4SRSF41.83N.D.2.4-dinoyl-CA reductase, mitochondrialDECR11.820.002.1-activated protein in 2,Single-stranded DNA-binding protein 3SSBP2;5SBP31.820.32Single-stranded DNA-binding protein 2,Single-stranded DNA-binding protein 3SSBP2;5SBP31.820.32Undine diphosphate glucose prophosphataseNUD111.820.01Plasma methrasporting ATPase 4SD2-1.810.03Superoside dismutase (Mn), mitochondrialSD2-1.810.03Prelamin-A/CLainin-A/CLMNA-1.810.350.03Cytosolic acyl coenzyme A thioester hydrolaseACOT7-1.810.07Protein DapleSACS-1.800.030.3Cell cycle and apoptosis regulator protein 2CCAR2-1.790.74Epidermal growth factor receptor substrate 15EPS15-1.790.74Epidermal growth factor receptor substrate 15SCFD2-1.780.21Protein kinase-Lind Lind Lind Lind Lind Lind Lind Lind				
SuppressorPAN1.830.14Unconventional myosin-IdMYOD-1.830.22Serine/arginne-rich splicing factor 4SRSF41.83N.D.Isoprenoid synthase domain-containing proteinISPD-1.82N.D.2.4-dienoyi-ContechnotinalDECR11.820.00p21-activated protein kinase-interacting protein 1PAKIP1-1.820.21Single-stranded DNA-binding protein 2.Single-stranded DNA-binding protein 3SSBP2/SSBP3-1.820.32Unifine diphosphate glucose prophosphataseNUDT14-1.820.017Plasma membrane calcium-transporting ATPase 4ATP244-1.820.017Superoxide disturbase [MI_nitochondrialSOD2-1.810.00Prelamin-A/C,Lamin-A/CLMNA-1.810.07Cytosolic acyl coenzyme A thioester hydrolaseACOT7-1.810.07Protein DapleCCDC88C-1.80N.D.SacsinCCAR2-1.790.19Serine/futreonine-protein phosphatase PGAMS, mitochondrialPGAMS-1.780.21Protein baptSCFD2-1.780.21Sect family domain-containing protein 2SCFD2-1.780.21Protein diprotein 2.Sect family domain-containing protein 2SCFD2-1.780.21Protein diprotein 2.Sect family domain-containing protein 2SCFD2-1.780.21Protein diprotein Phosphatase PGAMS, mitochondrialPGAMS-1.77N.D.Phosphatdyliositol-binding crotein 2SCFD2-1.780.21 <tr< td=""><td></td><td></td><td></td><td></td></tr<>				
Linconvertional myosin (d)MO ID1.830.22Serine/arginine-rich splicing factor 4SRSF4-1.83N.D.Lisoprenoid synthase domain-containing proteinISPD-1.82N.D.2.4-dienoyl-CoA reductase, mitochondrialDECR1-1.820.00D21-activated protein kinase-interacting protein 1BECR1-1.820.021Single-stranded DNA-binding protein 2,Single-stranded DNA-binding protein 3SSBP2,SSBP3-1.820.32Uridine diphosphate glucose prophosphataseNUDT14-1.820.07Plasma methrame calcium-transporting ATPase 4ATP2B4-1.820.06Superoxide dismutase [Mn], mitochondrialSDD2-1.810.07Prelamin-A/C, Lamin-A/C,	Histone-arginine methyltransferase CARM1	CARM1	-1,84	0,11
serine/rds splicing factor 4SRF41.83N.D.Isoprenoid synthase domain-containing proteinSPD1.82N.D.2.4-dienoyl-CoA reductase, mitochondrialDECR11.820.00p21-activated protein kinase-interacting protein 1PAK1PI11.820.21Single-stranded DNA-binding protein 3SSB2/SSB21.820.22Uridine diphosphate glucose pyrophosphataseNUDT141.820.06Superoxide dismutase [Mn], mitochondrialSOD21.810.10Prelamin-A/Citamin-A/CLMNA1.810.35Cytosolic activ (cenzyme A thioster hydrolaseACOT71.810.07Protein DapleCCD28C1.800.03Sactin Cale dapoptosis regulator protein 2SCAS1.800.03Serine/Hrreonine-protein phosphatase PGAMS, mitochondrialPGAM5-1.790.14Protein kinase Chaluy domain-containing protein 2CCAR2-1.780.21Serine/Hrreonine-protein phosphatase PGAMS, mitochondrialPRKDS-1.770.40Protein kinase Chaluy domain-containing protein 2SCFD2-1.780.21Protein kinase Chaluy domain-containing protein 2NDLFAG-1.770.40Autophayer-teder substrate 15PSIE5-1.770.40NDH dehydrogenase (ubiquione) complex I, assembly factor 6NDLFAG-1.770.40NDH dehydrogenase (ubiquione) complex I, assembly factor 6NDLFAG-1.770.40Nucleal transcription factor 1URIN-1.760.26Cyll-kinger prot	Suppressor of SWI4 1 homolog	PPAN	-1,83	0,14
isoprenoid synthase domain-containing proteinISPD1.82N.D.2,4-diencyl-CoA reductase, mitochondrialDECR11.820,002)4-activated protein kinase-interacting protein 1PAK1IP11.820,21Single-stranded DNA-binding protein 2, Single-stranded DNA-binding protein 3SSPS71.820,21Virdine diphosphate glucose prophosphataseNUDT141.820,06Superoxide dismutase (Mn), mitochondrialSDD21.810,07Plasma membrane calcium-transporting ATPase 4ATP2841.820,06Superoxide dismutase (Mn), mitochondrialSDD21.810,07Prelamin-A/CLamin-A/CLMMA-1.810,07Protein DapleCCDC88C1.80N.D.SacsinSACS-1.800,03Cell cycle and apoptosis regulator protein 2CCCAR2-1,790,19Epidermal growth factor receptor substrate 15EPS15-1,790,12Seci family domain-containing protein 2PFC2-1,780,21Protein kinase C beta type1, assembly factor 6NDLFAF6-1,77N.D.Nabesphatise Modiguatione locupalex I, assembly factor 6NDLFAF6-1,77N.D.Nabesphatise Modiguational dathin assembly proteinGNAQ-1,760,26Unconventional prefolin RPS interactor 1URI1-1,760,24Arginase 1NDUSCTA2-1,750,68Cytopic hall assembly protein Ago south alphaGNAQ-1,760,26Unconventional prefolin RPS interactor 1 <td>Unconventional myosin-Id</td> <td>MY01D</td> <td>-1,83</td> <td>0,22</td>	Unconventional myosin-Id	MY01D	-1,83	0,22
isoprenoid synthase domain-containing proteinISPD1.82N.D.2,4-diencyl-CoA reductase, mitochondrialDECR11.820,002)4-activated protein kinase-interacting protein 1PAK1IP11.820,21Single-stranded DNA-binding protein 2, Single-stranded DNA-binding protein 3SSPS71.820,21Virdine diphosphate glucose prophosphataseNUDT141.820,06Superoxide dismutase (Mn), mitochondrialSDD21.810,07Plasma membrane calcium-transporting ATPase 4ATP2841.820,06Superoxide dismutase (Mn), mitochondrialSDD21.810,07Prelamin-A/CLamin-A/CLMMA-1.810,07Protein DapleCCDC88C1.80N.D.SacsinSACS-1.800,03Cell cycle and apoptosis regulator protein 2CCCAR2-1,790,19Epidermal growth factor receptor substrate 15EPS15-1,790,12Seci family domain-containing protein 2PFC2-1,780,21Protein kinase C beta type1, assembly factor 6NDLFAF6-1,77N.D.Nabesphatise Modiguatione locupalex I, assembly factor 6NDLFAF6-1,77N.D.Nabesphatise Modiguational dathin assembly proteinGNAQ-1,760,26Unconventional prefolin RPS interactor 1URI1-1,760,24Arginase 1NDUSCTA2-1,750,68Cytopic hall assembly protein Ago south alphaGNAQ-1,760,26Unconventional prefolin RPS interactor 1 <td>Serine/arginine-rich splicing factor 4</td> <td>SRSF4</td> <td>-1,83</td> <td>N.D.</td>	Serine/arginine-rich splicing factor 4	SRSF4	-1,83	N.D.
2.4-dienoyi-CoA reductase, mitochondrialDECR1-1,820,00p21-activated protein kinase-interacting protein 1PAKIIP1-1,820,21Single-stranded DNA-binding protein 3SSBP2;SSBP3-1,820,22Urdine diphosphate glucose pyrophosphataseNUDT14-1,820,06Superoxide dismutase [Mn], mitochondrialSDD2-1,810,10Prelamin-A/C;Lamin-A/CLMMA-1,810,07Cytosolic acjv coenzyme A thioster hydrolaseACOT7-1,810,07Protein DapleCCDC88C-1,80N.D.SacsinSACS-1,800,03Cell cycle and apoptosis regulator protein 2CCAR2-1,790,19Serine/futreonine-protein phosphatase PGAMS, mitochondrialPGAM5-1,790,14Epidermal growth factor receptor substrate 15SSTS-1,790,14Sect family domain-containing protein 2SCFD2-1,780,21Protein kinase C beta typePRKCB-1,77N.D.NADH dehydrogenase (ubiquinone) complex I, assembly factor 6PNUFAFG-1,770,23Guanine nucleotide-binding protein G(q) subunit alphaGNAQ-1,760,26Unconventional protein 12ND-1-1,760,24Arginase-1UBF-1,770,33Guanine nucleotide-binding protein G(q) subunit alphaGNAQ-1,760,26Unconventional protein G(d) subunit alphaGNAQ-1,760,261,770,40Arginase-1UBF-1,770,33Guanine nucleotide-bindi				
p21-activated protein kinase-interacting protein 1PAIIP1-1.820.11Single-stranded DNA-binding protein 2, Single-stranded DNA-binding protein 3SSBP2;SSBP31.820.32Uridine diphosphate glucose pyrophosphataseNUDT141.820.06Plasma membrane calcium-transporting ATPase 4ATP2441.820.06Superoxide dismutase [Mn], mitochondrialSOD2-1.810.07Pretamin-A/CLamin-A/CLMNA1.810.03Cytosolic acyl coenzyme A thioester hydrolaseCCDC88C-1.800.03Cytosolic acyl coenzyme A thioester hydrolaseCCDC88C-1.800.03Cell cycle and apoptosis regulator protein 2CCCC88C-1.800.03Cell cycle and apoptosis regulator protein 2CCCR28-1.790.19Serine (threonine-protein phosphatase PGAMS, mitochondrialPGAM5-1.790.18Sect family domain-containing protein 2SCFD2-1.780.21Protein kinase C beta typePRKC8-1.77N.D.NDHFAF6-1.77N.D.Phosphatidylinositol-binding clathrin assembly factor 6NDLFAF6-1.77N.D.DNA-directed RNA polymerases 1 and III subunt RPAC1QNA-1.760.23Guanine nucleotide-binding protein 10UBT76-1.77N.D.DNA-directed RNA polymerases 1 and III subunt alphaGNAQ-1.760.24Arginase-1NGH-1.760.24NDCycl-Linger protein 706SCV2-1.750.68Erythrocyte band 7 integral membrane protein </td <td></td> <td></td> <td></td> <td></td>				
Single-stranded DNA-binding protein 3SSP2_SSP3-1.820.32Uridine diphosphate glucose pyrophosphatesNUDT4-1.820.17Plasma methymare calcium-transporting ATPase 4ATP284ATP2840.06Superoxide dismutase [Mn], mitochondrialSOD2-1.810.10Prelamin-A/CLMNA-1.810.35Cytosolic açıl coenzyme A thioester hydrolaseACOT7-1.810.07Protein DapleCCD282C-1.80N.D.SacsinCCCR2-1.900.13Cell cycle and apoptosis regulator protein 2CCAR2-1.790.14Serine/threonine-protein phosphatase PGAMS, mitochondrialEPS15-1.790.74Epidermal growth factor receptor substrate 15EPS15-1.790.18Sec1 family domain-containing protein 2SCFD2-1.780.21Protein kinase C beta typePRCBNDUFAF6-1.77N.D.NDA-directed RNA polymerases 1 and III subunit RPAC1POIR1C-1.770.23Guanine nucleotide-binding protein 2SCFD2-1.760.26Unconventional prefolin RPBS interactor 1POIR1C-1.760.26Unconventional prefolin RPBS interactor 1UBTF-1.760.24Arginase 1SCT2-1.750.68Erythrocyte bard Transporting AthieseSCT2-1.750.68Cycluster and sort for 60SUD4-1.760.24-1.760.24Arginase 1SUD4SUD4-1.760.24-1.760.26Un				
Uridine diphosphate glucose pyrophosphataseNUDT14-1,820,17Plasma membrane calcum-transporting ATPase 4ATP284-1,820,06Superoxide dismutase [Mn, nitochondrialSOD2-1,810,10Prelamin-A/C;Lamin-A/CLMNA-1,810,35Cytosolic acyl coenzyme A thioester hydrolaseACOT7-1,810,07Protein DapleCDCC88C-1,80N.D.SacsinSACS-1,800,03Cell cycle and apoptosi regulator protein 2CCCR2-1,790,74Epidermal growth factor receptor substrate 15EPS15-1,790,74Epidermal growth factor receptor substrate 15SCFD2-1,780,21Protein Kiase C beta typePRKCB-1,77N.D.NADH dehydrogenase (lubiquinone) complex I, assembly factor 6NDUFAF6-1,77N.D.Phosphatidylinositol-binding clathrin assembly proteinPCRLB-1,770,40Autophagy-related protein 2 homolog BATG2B-1,77N.D.DNA-directed RNA polymerases I and III subunit RPAC1GNAQ-1,760,26Guanine nucleotide-binding protein G(q) subuni alphaGNAQ-1,760,26Unconventional prefolia RPBs interactor 1WBIF-1,761,02SCY1-like protein 20SUD53-1,740,05CD441,740,775,08Very long-chain acyl-CoA synthetaseSUD53-1,740,05CD441,740,775,068-1,740,03Protein 706SUD53-1,				
Plasma membrane calcum-transporting ATPase 4ATP2B4-1,820,06Superoxide dismutase [Mn], mitochondrialSOD2-1,810,10Prelamin-AC_Lamin-ACLMNA-1,810,35Cytosolic acyl coenzyme A thioester hydrolaseACOT7-1,810,07Protein DapleCCDC88C-1,80N.D.SacsinSACS-1,800,03Cell cycle and apoptosis regulator protein 2CCAR2-1,790,19Serine/threonine-protein phosphatase PGAM5, mitochondrialPGAM5-1,790,18Epidermal growth factor receptor substrate 15EP515-1,770,18Sect family domain-containing protein 2SCFD2-1,781,12NDH dehydrogenase (ubiquinone) complex 1, assembly factor 6NDUFAF6-1,77N.D.Phosphatidylinositol-binding clathrin assembly proteinPICALM-1,770,23Quanine nucleotide-binding protein 18 subunit RPAC1POLR1C-1,770,23Quanine nucleotide-binding protein 198MER2-1,760,24Nucleolar transcription factor 1UBTF-1,760,24Arginase 1Zinf grag membrane proteinSUDM-1,760,02Strict protein 2SCY12-1,750,08Cyti-like protein 706ZNF706-1,761,02SCY1-like protein 706SUGM-1,740,07CD44 antigenSUDM3-1,740,07Cyti-like protein 2SUCY12-1,750,08Cyti-like protein 2SUCY2-1,740,03 <td>Single-stranded DNA-binding protein 2;Single-stranded DNA-binding protein 3</td> <td>SSBP2;SSBP3</td> <td>-1,82</td> <td>0,32</td>	Single-stranded DNA-binding protein 2;Single-stranded DNA-binding protein 3	SSBP2;SSBP3	-1,82	0,32
Superoxide dismutase [Mn], mitochondrialSOD2-1,810,10Prelamin-A/CLMMA-1,810,35Cytosolic acyt ocenzyme A thioester hydrolaseACOT7-1,810,07Protein DapleCCDC88C-1,80N.D.SacsinCCDC88C-1,800,03Cell cycle and apoptosis regulator protein 2CCAR2-1,790,19Serine/threonine-protein phosphatase PGAMS, mitochondrialPGAM5-1,790,74Epidermal growth factor receptor substrate 15EPS15-1,790,18Sect f amily domain-containing protein 2SCF02-1,780,21Protein kinase C beta typePRKCB-1,77N.D.Phosphatidynositol-binding clathrin assembly proteinPICLM-1,77N.D.Autophagy-related protein 2 homolog BATG2B-1,77N.D.DNA-directed RNA polymerases 1 and III subunit RPAC1GNAQ-1,760,28Uuconventional prefoldin RPB5 interactor 1URI1-1,760,24Arginase-1AR61-1,770,08SCY-1ike protein 2SCY12-1,750,08Very long-chain acyt-CoA synthetaseSCIM-1,740,07Sin Shistone deacetylase corepressor complex component SDS3SCIM2-1,740,07Sin Shistone deacetylase corpressor complex component SDS3SUD3-1,740,03CD44 antigenPUS7-1,740,03-1,740,03CD44 antigenPUS7-1,740,03-1,740,03CP44 antigenAK151<	Uridine diphosphate glucose pyrophosphatase	NUDT14	-1,82	0,17
Superoxide dismutase [Mn], mitochondrialSOD2-1,810,10Prelamin-A/CLMMA-1,810,35Cytosolic acyt ocenzyme A thioester hydrolaseACOT7-1,810,07Protein DapleCCDC88C-1,80N.D.SacsinCCDC88C-1,800,03Cell cycle and apoptosis regulator protein 2CCAR2-1,790,19Serine/threonine-protein phosphatase PGAMS, mitochondrialPGAM5-1,790,74Epidermal growth factor receptor substrate 15EPS15-1,790,18Sect f amily domain-containing protein 2SCF02-1,780,21Protein kinase C beta typePRKCB-1,77N.D.Phosphatidynositol-binding clathrin assembly proteinPICLM-1,77N.D.Autophagy-related protein 2 homolog BATG2B-1,77N.D.DNA-directed RNA polymerases 1 and III subunit RPAC1GNAQ-1,760,28Uuconventional prefoldin RPB5 interactor 1URI1-1,760,24Arginase-1AR61-1,770,08SCY-1ike protein 2SCY12-1,750,08Very long-chain acyt-CoA synthetaseSCIM-1,740,07Sin Shistone deacetylase corepressor complex component SDS3SCIM2-1,740,07Sin Shistone deacetylase corpressor complex component SDS3SUD3-1,740,03CD44 antigenPUS7-1,740,03-1,740,03CD44 antigenPUS7-1,740,03-1,740,03CP44 antigenAK151<	Plasma membrane calcium-transporting ATPase 4	ATP2B4	-1,82	0,06
Prelamin-A/C;Lamin-A/CLMNA-1,810,35Cytosoilc acyl coenzyme A thioester hydrolaseACOT7-1,810,07Protein DapleCCOS8C-1,80N.D.SacsinSACS-1,800,03Cell cycle and apotosis regulator protein 2CCAR2-1,790,19Serine/threonine-protein posphatase PGAMS, mitochondrialPGAM5-1,790,74Epidermal growth factor receptor substrate 15EPS15-1,790,18Sec1 family domain-containing protein 2SCFD2-1,780,21Protein kinase C beta typePRKCB-1,781,12NADH dehydrogenase (ubiquinone) complex 1, assembly factor 6NDUFAF6-1,77N.D.Phosphatidylinositol-binding clathrin assembly proteinPICALM-1,770,40Autophagy-related protein 2 homolog BATG2B-1,77N.D.DNA-directed RNA polymerases 1 and III subunit RPAC1POIR1C-1,770,23Guanine nucleotide-binding protein G(q) subunit alphaGNAQ-1,760,26Unconventional prefoldin RPB5 interactor 1UBTF-1,760,24Arginase-1ARG1-1,761,02SCY1-1/550,68Erythroyte band 7 integral membrane proteinSTOM-1,740,07CD44 attiggPUS7-1,740,03PUS7-1,740,03CY1-Like protein 2SCP12-1,750,68CY1-2-1,750,68Erythroyte band 7 integral membrane proteinSTOM-1,740,071,740,07<		SOD2	-1.81	0.10
Cytosolic acyl coenzyme A thioester hydrolaseACOT71,810,07Protein DapleCCDC88C1,80N.D.SacsinSACS1,800,03Cell cycle and apoptosis regulator protein 2CCAR21,790,19Serine/threonine-protein phosphatase PGAM5, mitochondrialPGAM51,790,74Epidermal growth factor receptor substrate 15EPS151,790,18Sec1 family domain-containing protein 2CFD21,780,21Protein kinase C beta typePRKCB1,781,12NADH dehydrogenase (ubiquinone) complex I, assembly factor 6NDUFAF61,77N.D.Phosphatidylinositol-binding clathrin assembly proteinPICALM-1,770,23Guanine nucleotide-binding protein G(q) subunit alphaGNAQ1,760,26Unconventional profolin RPB5 interactor 1URI1-1,760,24Arginase-1ARG1-1,760,28Nucleolar transcription factor 1UBTF-1,750,08CY1-like protein 2SCV12-1,750,08CY1-like protein 70SCY12-1,750,08Very long-chain acyl-CoA synthetaseSLC27A2-1,750,08Erythrocyte band 7 integral membrane proteinSTOM-1,740,07Sin3 histone deacetylase corepressor complex component SDS3SUDS3-1,740,07Sin3 histone deacetylase corepressor complex component SDS3SUDS3-1,740,03Proline-rich AKT1 substrate 1MROH1-1,740,07Voltage-depen				
Protein DapleCCDC88C1,80N.D.SacsinSACS1,800,03Cell cycle and apoptosis regulator protein 2CCAR21,790,19Serine/threonine-protein phosphatase PGAM5, mitochondrialPGAM51,790,74Epidermal growth factor receptor substrate 15EPS151,790,18Sec1 family domain-containing protein 2SCFD21,780,21Protein kinase C beta typePRKCB1,781,12NADH dehydrogenase (ubiquinone) complex I, assembly factor 6NDUFAF61,77N.D.Phosphatidylinositol-binding dathrin assembly proteinPICALM1,770,23Guanine nucleotide-binding protein G(q) subunit alphaGNAQ1,760,26Unconventional prefoldin RPB5 interactor 1URI11,760,28Vucleolar transcription factor 1URI11,760,24Arginase-1ZNF7061,750,08CY1-like protein 2SCV121,750,68CY1-like protein 2SCV121,750,68CY1-like protein 2CV141,740,77Cy1-like protein 2SCV121,750,68CY1-like protein 2SCV121,750,68CY1-like protein 2SCV121,750,68CY1-like protein 2SCV121,750,68CY1-like protein 2SCV121,750,68CY1-like protein 2SCV121,740,07Cy1-like protein 2SCV121,740,07Cy1-like protein 2SCV12 <td></td> <td></td> <td></td> <td></td>				
SacsinSACS-1,800,03Cell cycle and apoptosis regulator protein 2CCAR2-1,790,19Serine/threonine-protein phosphatase PGAM5, mitochondrialPGAM5-1,790,74Epidermal growth factor receptor substrate 15EPS15-1,790,18Sec1 family domain-containing protein 2SCFD2-1,780,21Protein kinase C beta typePRKCB-1,77N.D.Phosphatidylinositol-binding clathrin assembly factor 6NDUFAF6-1,77N.D.Phosphatidylinositol-binding clathrin assembly proteinPICALM-1,770,23Guanine nucleotide-binding protein G(q) subunit RPAC1POIR1C-1,770,26Unconventional prefoldin RPB5 interactor 1URI1-1,760,26Nucleolar transcription factor 1UBTF-1,760,24Arginase-1Zino finger protein 2SCYL2-1,750,08Cyt1-like protein 2SCYL2-1,750,08Very long-chain acyl-CoA synthetaseSLC27A2-1,750,08Cyt1-like protein 706STOM-1,740,07Sin3 histone deacetylase corepressor complex component SDS3SUDS3-1,740,07Sin3 histone deacetylase transmip rotein 3VDAC3-1,740,07Voltage-dependent anion-selective channel protein 3VDAC3-1,740,07Voltage-dependent anion-selective channel protein 3VDAC3-1,740,07Ras GTPase-activating-like protein 2VDAC3-1,740,07				
Cell cycle and apoptosis regulator protein 2CCAR2-1,790,19Serine/threonine-protein phosphatase PGAMS, mitochondrialPGAM5-1,790,74Epidermal growth factor receptor substrate 15EPS15-1,790,18Sce1 family domain-containing protein 2SCFD2-1,780,21Protein kinase C beta typePRKCB-1,77N,D.Phosphatidy/inositol-binding clathrin assembly factor 6NDUFAF6-1,77N,D.Phosphatidy/inositol-binding clathrin assembly proteinPICALM-1,770,40Autophagy-related protein 2 homolog BATG2B-1,77N,D.DNA-directed RNA polymerases 1 and III subunit RPAC1POLR1C-1,770,23Guanine nucleotide-binding protein G(q) subunit alphaGNAQ-1,760,26Nucleolar transcription factor 1UBTF-1,760,24Arginase-1ARG1-1,760,24Arginase-1SCYL2-1,750,08Very long-chain acyl-CoA synthetaseSIC27A2-1,750,08Erythrocyte band 7 integral membrane proteinSUDS3-1,740,07Sin3 histone deacetylase corepressor complex component SDS3SUDS3-1,740,03Poline-rich AKT1 substrate 1MROH1-1,740,07Volage-dependent anion-selective channel protein 3VDAC3-1,740,03Proline-rich AKT1 substrate 1AKP2-1,740,07Volage-dependent anion-selective channel protein 3VDAC3-1,740,07Akage-activating-like protein 1QGAP2 <td></td> <td></td> <td></td> <td></td>				
Serine/threonine-protein phosphatase PGAM5, mitochondrialPGAM5-1,790,74Epidermal growth factor receptor substrate 15EPS15-1,790,18Sec1 family domain-containing protein 2SCFD2-1,780,21Protein kinase C beta typePRKCB-1,77N,D.NADH dehydrogenase (ubiquinone) complex I, assembly factor 6NDUFAF6-1,77N,D.Phosphatidylinositol-binding clathrin assembly proteinPICALM-1,770,40Autophagy-related protein 2 homolog BATG2B-1,77N,D.DNA-directed RNA polymerases 1 and III subunit RPAC1POLR1C-1,770,23Guanine nucleotide-binding protein G(q) subunit alphaGNAQ-1,760,26Unconventional prefoldin RPB5 interactor 1UR11-1,760,28Nucleolar transcription factor 1ARG1-1,76N,D.Zinc finger protein 706ZNF706-1,761,02SCY1-like protein 2SCYL2-1,750,08Very long-chain acyl-CoA synthetaseSLC27A2-1,750,68Erythrocyte band 7 integral membrane proteinSTOM-1,740,07Sin3 histone deacetylase corepressor complex component SDS3SUDS3-1,74N,D.Pseudouridylate synthase 7 homologUS7-1,740,03Protein-rich AKT1 substrate 1VRCH1-1,740,07Voltage-dependent anion-selective channel protein 3VAC3-1,740,03Protine-rich AKT2 substrate 1VAC3-1,740,007Voltage-dependent anion-select	Sacsin	SACS	-1,80	0,03
Epidermal growth factor receptor substrate 15EPS15-1,790,18Sec1 family domain-containing protein 2SCFD2-1,780,21Protein kinase C beta typePRKCB-1,781,12NADH dehydrogenase (ubiquinone) complex I, assembly factor 6NDUFAF6-1,77N.D.Phosphatidylinositol-binding clathrin assembly proteinPICALM-1,770,40Autophagy-related protein 2 homolog BATG2B-1,77N.D.DNA-directed RNA polymerases I and III subunit RPAC1POLRIC-1,770,23Guanien nucleotide-binding protein G(q) subunit alphaGNAQ-1,760,26Unconventional prefoldin RPB5 interactor 1URI1-1,760,24Arginase-1UBTF-1,760,24Arginase-1ZMF706-1,761,02SCY1-like protein 2SCY12-1,750,08Very long-chain acyl-CoA synthetaseSIC27A2-1,750,68Erythrocyte band 7 integral membrane proteinSTOM-1,740,07Sin3 histone deacetylase corepressor complex component SDS3SUDS3-1,74N.D.Paedouridylate synthase 7 homologWngV-1,740,03Proline-rich AKT1 substrate 1VMC011-1,740,07Voltage-dependent anion-selective channel protein 3VMC3-1,740,03Proline-rich AKT1 substrate 1AKT2-1,740,03Poline-rich AKT1 substrate 1AKAP2-1,740,07Voltage-dependent anion-selective channel protein 3AKAP2-1,740,07 </td <td>Cell cycle and apoptosis regulator protein 2</td> <td>CCAR2</td> <td>-1,79</td> <td>0,19</td>	Cell cycle and apoptosis regulator protein 2	CCAR2	-1,79	0,19
Epidermal growth factor receptor substrate 15EPS15-1,790,18Sec1 family domain-containing protein 2SCFD2-1,780,21Protein kinase C beta typePRKCB-1,781,12NADH dehydrogenase (ubiquinone) complex I, assembly factor 6NDUFAF6-1,77N.D.Phosphatidylinositol-binding clathrin assembly proteinPICALM-1,770,40Autophagy-related protein 2 homolog BATG2B-1,77N.D.DNA-directed RNA polymerases I and III subunit RPAC1POLRIC-1,770,23Guanien nucleotide-binding protein G(q) subunit alphaGNAQ-1,760,26Unconventional prefoldin RPB5 interactor 1URI1-1,760,24Arginase-1UBTF-1,760,24Arginase-1ZMF706-1,761,02SCY1-like protein 2SCY12-1,750,08Very long-chain acyl-CoA synthetaseSIC27A2-1,750,68Erythrocyte band 7 integral membrane proteinSTOM-1,740,07Sin3 histone deacetylase corepressor complex component SDS3SUDS3-1,74N.D.Paedouridylate synthase 7 homologWngV-1,740,03Proline-rich AKT1 substrate 1VMC011-1,740,07Voltage-dependent anion-selective channel protein 3VMC3-1,740,03Proline-rich AKT1 substrate 1AKT2-1,740,03Poline-rich AKT1 substrate 1AKAP2-1,740,07Voltage-dependent anion-selective channel protein 3AKAP2-1,740,07 </td <td>Serine/threonine-protein phosphatase PGAM5, mitochondrial</td> <td>PGAM5</td> <td>-1,79</td> <td>0,74</td>	Serine/threonine-protein phosphatase PGAM5, mitochondrial	PGAM5	-1,79	0,74
Sec1 family domain-containing protein 2SCFD2-1,780,21Protein kinase C beta typePRKCB-1,781,12NADH dehydrogenase (ubiquinone) complex I, assembly factor 6NDUFAF6-1,77N.D.Phosphatidylinositol-binding clathrin assembly proteinPICALM-1,770,40Autophagy-related protein 2 homolog BATG2B-1,77N.D.DNA-directed RNA polymerases I and III subunit RPAC1POLR1C-1,770,23Guanine nucleotide-binding protein G(q) subunit alphaGNAQ-1,760,26Unconventional prefoldin RPB5 interactor 1URI1-1,760,28Nucleolar transcription factor 1UBTF-1,760,24Arginase-1ARG1-1,761,02SCY1-like protein 20SCYL2-1,750,08Very long-chain acyl-CoA synthetaseSLC27A2-1,750,08Erythrocyte band 7 integral membrane proteinSDS3-1,74N.D.Sistone deacetylase corepressor complex component SDS3SUDS3-1,740,07Sin3 histone deacetylase zontaining protein 3VDG2-1,740,03Protine-rich AKT1 substrate 1VDAC3-1,740,07Volage-dependent anion-selective channel protein 3VDAC3-1,740,07Volage-dependent anion-selective channel protein 3VDAC3-1,740,07Volage-dependent anion-selective channel protein 3VDAC3-1,740,07Ras GTPase-activating-like protein 1QGAP2IQGAP2-1,730,07		EPS15		
Protein kinase C beta typePRKCB-1,781,12NADH dehydrogenase (ubiquinone) complex I, assembly factor 6NDUFAF6-1,77N.D.Phosphatidylinositol-binding clathrin assembly proteinPICALM-1,770,40Autophagy-related protein 2 homolog BATG2B-1,77N.D.DNA-directed RNA polymerases I and III subunit RPAC1POLR1C-1,770,23Guanine nucleotide-binding protein G(q) subunit alphaGNAQ-1,760,26Unconventional prefoldin RPB5 interactor 1URI1-1,760,24Arginase-1ARG1-1,76N.D.Zinc finger protein 706ZNF706-1,761,02SCY1-like protein 2SCY12-1,750,08Very long-chain acyl-CoA synthetaseSLC27A2-1,750,68Erythrocyte band 7 integral membrane proteinSTOM-1,740,07Sin3 histone deacetylase corepressor complex component SDS3SUDS3-1,74N.D.Pseudouridylate synthase 7 homologPUS7-1,740,03Proline-rich AKT1 substrate 1MROH1-1,740,07Voltage-dependent anion-selective channel protein 3VDAC3-1,740,00Voltage-dependent anion-selective channel protein 3VDAC3-1,740,00Rais GTPase-activating-like protein 1QGAP2IQGAP2-1,730,07				
NADH dehydrogenase (ubiquinone) complex I, assembly factor 6NDUFAF6-1,77N.D.Phosphatidylinositol-binding clathrin assembly proteinPICALM-1,770,40Autophagy-related protein 2 homolog BATG2B-1,770,23Guanine nucleotide-binding protein G(q) subunit RPAC1POLR1C-1,770,23Guanine nucleotide-binding protein G(q) subunit alphaGNAQ-1,760,26Unconventional prefoldin RPB5 interactor 1UR11-1,760,28Nucleolar transcription factor 1UBTF-1,760,24Arginase-1ARG1-1,76N.D.Zinc finger protein 706ZNF706-1,761,02SCY1-like protein 2SCYL2-1,750,08Very long-chain acyl-CoA synthetaseSIC27A2-1,750,68Erythrocyte band 7 integral membrane proteinSTOM-1,740,077Sin3 histone deacetylase corepressor complex component SDS3SUDS3-1,74N.D.Pseudouridylate synthase 7 homologPUS7-1,740,03Proline-rich AKT1 substrate 1MROH1-1,740,077Endophilin-B2SH3GLB2-1,740,03Proline-rich AKT1 substrate 1AK151-1,740,07Voltage-dependent anion-selective channel protein 3AKAP2-1,74N,D.Ras GTPase-activating-like protein 1QGAP2IQGAP2-1,74N,D.	,			
Phosphatidylinositol-binding clathrin assembly proteinPICALM-1,770,40Autophagy-related protein 2 homolog BATG2B-1,77N.D.DNA-directed RNA polymerases I and III subunit RPAC1POLRIC-1,770,23Guanine nucleotide-binding protein G(q) subunit alphaGNAQ-1,760,26Unconventional prefoldin RPB5 interactor 1URI1-1,760,28Nucleolar transcription factor 1UBTF-1,760,24Arginase-1ZMF706-1,761,02SCY1-like protein 2SCYL2-1,750,08Very long-chain acyl-CoA synthetaseSIC27A2-1,750,68Erythrocyte band 7 integral membrane proteinSTOM-1,740,07Sin3 histone deacetylase corepressor complex component SDS3SUDS3-1,740,03Peduduridylate synthase 7 homologWROH1-1,740,07Endophilin-B2SH3GLB2-1,740,03Proline-rich AKT1 substrate 1VDAC3-1,740,07Voltage-dependent anion-selective channel protein 3VDAC3-1,740,07Voltage-dependent anion-selective channel protein 3VDAC3-1,740,07Voltage-dependent anion-selective channel protein 3VDAC3-1,740,07Ras GTPase-activating-like protein IQGAP2IQGAP2-1,740,07				
Autophagy-related protein 2 homolog BATG2B-1,77N.D.DNA-directed RNA polymerases 1 and III subunit RPAC1POLR1C-1,770,23Guanine nucleotide-binding protein G(q) subunit alphaGNAQ-1,760,26Unconventional prefoldin RPB5 interactor 1URI1-1,760,28Nucleolar transcription factor 1UBTF-1,760,24Arginase-1ARG1-1,761,02Zinc finger protein 706ZNF706-1,761,02SCY1-like protein 2SCYL2-1,750,08Very long-chain acyl-CoA synthetaseSLC27A2-1,750,68Erythrocyte band 7 integral membrane proteinSTOM-1,740,06CD44-1,740,077Sistone deacetylase corepressor complex component SDS3SUDS3-1,740,13Maestro heat-like repeat-containing protein family member 1MROH1-1,740,077Poline-rich AKT1 substrate 1VDAC3-1,740,07Voltage-dependent anion-selective channel protein 3VDAC3-1,740,07Voltage-dependent anion-selective channel protein 3VDAC3-1,740,07Ras GTPase-activating-like protein IQGAP2IQGAP2-1,730,07				
DNA-directed RNA polymerases I and III subunit RPAC1POLR1C-1,770,23Guanine nucleotide-binding protein G(q) subunit alphaGNAQ-1,760,26Unconventional prefoldin RPB5 interactor 1UR11-1,760,24Arginase-1UBTF-1,760,24Arginase-1ARG1-1,761,02SCY1-like protein 706ZNF706-1,761,02SCY1-like protein 2SCY12-1,750,08Very long-chain acyl-CoA synthetaseSLC27A2-1,750,68Erythrocyte band 7 integral membrane proteinSTOM-1,740,06CD44 antigenCD44-1,740,77Sin3 histone deacetylase corepressor complex component SDS3SUDS3-1,74N.D.Pseudouridylate synthase 7 homologPUS7-1,740,13Maestro heat-like repeat-containing protein family member 1MROH1-1,740,07Endophilin-B2SH3GLB2-1,740,007Voltage-dependent anion-selective channel protein 3VDAC3-1,740,01A-kinase anchor protein 2AKAP2-1,74N,D.Ras GTPase-activating-like protein IQGAP2IQGAP2-1,730,07				
Guanine nucleotide-binding protein G(q) subunit alphaGNAQ-1,760,26Unconventional prefoldin RPB5 interactor 1UR11-1,760,28Nucleolar transcription factor 1UBTF-1,760,24Arginase-1ARG1-1,76N.D.Zinc finger protein 706ZNF706-1,761,02SCY1-like protein 2SCY12-1,750,08Very long-chain acyl-CoA synthetaseSLC27A2-1,750,06Erythrocyte band 7 integral membrane proteinSTOM-1,740,07Sin Shistone deacetylase corepressor complex component SDS3SUD53-1,74N.D.Pseudouridylate synthase 7 homologPUS7-1,740,13Maestro heat-like repeat-containing protein family member 1MROH1-1,740,07Endophilin-B2SH3GLB2-1,740,007Voltage-dependent anion-selective channel protein 3VDAC3-1,740,010A-kinase anchor protein 2AKAP2-1,74N.D.Ras GTPase-activating-like protein IQGAP2IQGAP2-1,730,07	Autophagy-related protein 2 homolog B	ATG2B	-1,77	N.D.
Guanine nucleotide-binding protein G(q) subunit alphaGNAQ-1,760,26Unconventional prefoldin RPB5 interactor 1UR11-1,760,28Nucleolar transcription factor 1UBTF-1,760,24Arginase-1ARG1-1,76N.D.Zinc finger protein 706ZNF706-1,761,02SCY1-like protein 2SCY12-1,750,08Very long-chain acyl-CoA synthetaseSLC27A2-1,750,06Erythrocyte band 7 integral membrane proteinSTOM-1,740,07Sin Shistone deacetylase corepressor complex component SDS3SUD53-1,74N.D.Pseudouridylate synthase 7 homologPUS7-1,740,13Maestro heat-like repeat-containing protein family member 1MROH1-1,740,07Endophilin-B2SH3GLB2-1,740,007Voltage-dependent anion-selective channel protein 3VDAC3-1,740,010A-kinase anchor protein 2AKAP2-1,74N.D.Ras GTPase-activating-like protein IQGAP2IQGAP2-1,730,07	DNA-directed RNA polymerases I and III subunit RPAC1	POLR1C	-1,77	0,23
Unconventional prefoldin RPB5 interactor 1UR11-1,760,28Nucleolar transcription factor 1UBTF-1,760,24Arginase-1ARG1-1,76N.D.Zinf finger protein 706ZMF706-1,761,02SCY1-like protein 2SCYL2-1,750,08Very long-chain acyl-CoA synthetaseSLC27A2-1,750,68Erythrocyte band 7 integral membrane proteinSTOM-1,740,06CD44 antigenCD44-1,740,077Sin3 histone deacetylase corepressor complex component SDS3SUDS3-1,74N.D.Pseudouridylate synthase 7 homologPUS7-1,740,03Maestro heat-like repeat-containing protein family member 1MROH1-1,740,077Endophilin-B2SH3GLB2-1,740,03Proline-rich AKT1 substrate 1VDAC3-1,740,07Voltage-dependent anion-selective channel protein 3VDAC3-1,740,10A-kinase anchor protein 2AKAP2-1,740,10Ras GTPase-activating-like protein IQGAP2IQGAP2-1,730,07				
Nucleolar transcription factor 1UBTF-1,760,24Arginase-1ARG1-1,76N.D.Zinc finger protein 706ZNF706-1,761,02SCY1-like protein 2SCYL2-1,750,08Very long-chain acyl-CoA synthetaseSLC27A2-1,750,068Erythrocyte band 7 integral membrane proteinSTOM-1,740,066CD44 antigenCD44-1,740,077Sin3 histone deacetylase corepressor complex component SDS3SUDS3-1,740,131Maestro heat-like repeat-containing protein family member 1MROH1-1,740,077Endophilin-B2SH3GLB2-1,740,031Proline-rich AKT1 substrate 1AKT151-1,740,07Voltage-dependent anion-selective channel protein 3VDAC3-1,740,010A-kinase anchor protein 2AKAP2-1,740,07Ras GTPase-activating-like protein IQGAP2IQGAP2-1,730,07				
Arginase-1 ARG1 -1,76 N.D. Zinc finger protein 706 ZNF706 -1,76 1,02 SCY1-like protein 2 SCY2 -1,75 0,08 Very long-chain acyl-CoA synthetase SLC27A2 -1,75 0,68 Erythrocyte band 7 integral membrane protein STOM -1,74 0,06 CD44 antigen CD44 -1,74 0,77 Sin Shistone deacetylase corepressor complex component SDS3 SUDS3 -1,74 0,13 Maestro heat-like repeat-containing protein family member 1 MROH1 -1,74 0,07 Endophilin-B2 SH3GLB2 -1,74 0,03 Proline-rich AKT1 substrate 1 VDAC3 -1,74 0,07 Voltage-dependent anion-selective channel protein 3 VDAC3 -1,74 0,03 Arkinase anchor protein 2 AKAP2 -1,74 0,01 A-kinase anchor protein 2 AKAP2 -1,74 N.D.				
Zinc finger protein 706 CNF706 -1,76 1,02 SCY1-like protein 2 SCY12 -1,75 0,08 Very long-chain acyl-CoA synthetase SLC27A2 -1,75 0,68 Erythrocyte band 7 integral membrane protein STOM -1,74 0,06 CD44 antigen CD44 -1,74 0,77 Sin 5 histone deacetylase corepressor complex component SDS3 SUD53 -1,74 N,D. Pseudouridylate synthase 7 homolog PUS7 -1,74 0,13 Maestro heat-like repeat-containing protein family member 1 MROH1 -1,74 0,07 Endophilin-B2 SH3GLB2 -1,74 0,03 Proline-rich AKT1 substrate 1 VDAC3 -1,74 0,07 Voltage-dependent anion-selective channel protein 3 VDAC3 -1,74 0,07 Voltage-dependent anion-selective channel protein 3 VDAC3 -1,74 0,010 A-kinase anchor protein 2 AKAP2 -1,74 N,D. Ras GTPase-activating-like protein IQGAP2 -1,73 0,07				
SCY1-like SCYL2 -1,75 0,08 Very long-chain act/-CoA synthetase SLC27A2 -1,75 0,68 Erythrocyte band 7 integral membrane protein STOM -1,74 0,06 CD44 antigen CD44 -1,74 0,077 Sin3 histone deacetylase corepressor complex component SDS3 SUDS3 -1,74 0,13 Maestro heat-like repeat-containing protein family member 1 MROH1 -1,74 0,07 Indophilin-B2 SH3GLB2 -1,74 0,03 Proline-rich AKT1 substrate 1 O,07 -1,74 0,03 Voltage-dependent anion-selective channel protein 3 VDAC3 -1,74 0,07 Akinase anchor protein 2 AKAP2 -1,74 0,07 Ras GTPase-activating-like protein IQGAP2 IQGAP2 -1,74 0,07				
Very long-chain acyl-CoA synthetase SLC27A2 -1,75 0,68 Erythrocyte band 7 integral membrane protein STOM -1,74 0,06 CD44 antigen CD44 -1,74 0,77 Sin3 histone deacetylase corepressor complex component SDS3 SUDS3 -1,74 0,13 Pseudouridylate synthase 7 homolog PUS7 -1,74 0,13 Maestro heat-like repeat-containing protein family member 1 MROH1 -1,74 0,07 Endophilin-B2 SH3GLB2 -1,74 0,03 Proline-rich AKT1 substrate 1 MKT1S1 -1,74 0,07 Voltage-dependent anion-selective channel protein 3 VDAC3 -1,74 0,01 A-kinase anchor protein 2 AKAP2 -1,74 0,10 Ras GTPase-activating-like protein IQGAP2 IQGAP2 -1,74 0,07				
Erythrocyte band 7 integral membrane proteinSTOM-1,740,06CD44 antigenCD44-1,740,77Sin3 histone deacetylase corepressor complex component SDS3SUDS3-1,74N.D.Pseudouridylate synthase 7 homologPUS7-1,740,13Maestro heat-like repeat-containing protein family member 1MROH1-1,740,07Endophilin-B2SH3GLB2-1,740,03Proline-rich AKT1 substrate 1AKT151-1,740,07Voltage-dependent anion-selective channel protein 3VDAC3-1,740,10A-kinase anchor protein 2AKAP2-1,74N.D.Ras GTPase-activating-like protein IQGAP2IQGAP2-1,730,07			-1,75	0,08
Erythrocyte band 7 integral membrane protein STOM -1,74 0,06 CD44 antigen CD44 -1,74 0,77 Sin 3 histone deacetylase corepressor complex component SDS3 SUDS3 -1,74 0,13 Pseudouridylate synthase 7 homolog PUS7 -1,74 0,13 Maestro heat-like repeat-containing protein family member 1 MROH1 -1,74 0,07 Endophilin-B2 SH3GLB2 -1,74 0,03 Proline-rich AKT1 substrate 1 MROH1 -1,74 0,07 Voltage-dependent anion-selective channel protein 3 VDAC3 -1,74 0,007 Arkinase anchor protein 2 AKAP2 -1,74 0,010 Arkinase anchor protein 2 AKAP2 -1,74 0,07	Very long-chain acyl-CoA synthetase	SLC27A2	-1,75	0,68
CD44 antigen CD44 -1,74 0,77 Sin3 histone deacetylase corepressor complex component SDS3 SUDS3 -1,74 N.D. Pseudouridylate synthase 7 homolog PUS7 -1,74 0,13 Maestro heat-like repeat-containing protein family member 1 MROH1 -1,74 0,07 Endophilin-B2 SH3GLB2 -1,74 0,03 Proline-rich AKT1 substrate 1 AKTIS1 -1,74 0,07 Voltage-dependent anion-selective channel protein 3 VDAC3 -1,74 0,01 A-kinase anchor protein 2 AKAP2 -1,74 N.D. Ras GTPase-activating-like protein IQGAP2 IQGAP2 -1,73 0,07	Erythrocyte band 7 integral membrane protein	STOM		
Sin3 histone deacetylase corepressor complex component SDS3 SUDS3 -1,74 N.D. Pseudouridylate synthase 7 homolog PUS7 -1,74 0,13 Maestro heat-like repeat-containing protein family member 1 MROH1 -1,74 0,77 Endophilin-B2 SH3GLB2 -1,74 0,03 Proline-rich AKT1 substrate 1 AKT151 -1,74 0,07 Voltage-dependent anion-selective channel protein 3 VDAC3 -1,74 0,10 -kinase anchor protein 2 AKAF2 -1,74 0,07 Ras GTPase-activating-like protein IQGAP2 IQGAP2 -1,73 0,07				
Pseudouridylate synthase 7 homolog PUS7 -1,74 0,13 Maestro heat-like repeat-containing protein family member 1 MROH1 -1,74 0,77 Endophilin-B2 SH3GLB2 -1,74 0,03 Proline-rich AKT1 substrate 1 AKT1S1 -1,74 0,07 Voltage-dependent anion-selective channel protein 3 VDAC3 -1,74 0,13 A-kinase anchor protein 2 AKAP2 -1,74 0,170 Ras GTPase-activating-like protein IQGAP2 IQGAP2 -1,73 0,07				
Maestro heat-like repeat-containing protein family member 1 MROH1 -1,74 0,77 Endophilin-B2 SH3GLB2 -1,74 0,03 Proline-rich AKT1 substrate 1 AKT1S1 -1,74 0,07 Voltage-dependent anion-selective channel protein 3 VDAC3 -1,74 0,10 A-kinase anchor protein 2 AKAP2 -1,74 N.D. Ras GTPase-activating-like protein IQGAP2 IQGAP2 -1,73 0,07				
Endophilin-B2 SH3GLB2 -1,74 0,03 Proline-rich AKT1 substrate 1 AKT151 -1,74 0,07 Voltage-dependent anion-selective channel protein 3 VDAC3 -1,74 0,10 -kinase anchor protein 2 AKAP2 -1,74 N.D. Ras GTPase-activating-like protein IQGAP2 IQGAP2 -1,73 0,07				
Proline-rich AKT1 substrate 1 -1,74 0,07 Voltage-dependent anion-selective channel protein 3 VDAC3 -1,74 0,10 A-kinase anchor protein 2 AKAP2 -1,74 N.D. Ras GTPase-activating-like protein IQGAP2 IQGAP2 -1,73 0,07				
Voltage-dependent anion-selective channel protein 3 VDAC3 -1,74 0,10 A-kinase anchor protein 2 AKAP2 -1,74 N.D. Ras GTPase-activating-like protein IQGAP2 IQGAP2 -1,73 0,07	Endophilin-B2	SH3GLB2	-1,74	0,03
Voltage-dependent anion-selective channel protein 3 VDAC3 -1,74 0,10 A-kinase anchor protein 2 AKAP2 -1,74 N.D. Ras GTPase-activating-like protein IQGAP2 IQGAP2 -1,73 0,07		AKT1S1		
A-kinase anchor protein 2 AKAP2 -1,74 N.D. Ras GTPase-activating-like protein IQGAP2 IQGAP2 -1,73 0,07				
Ras GTPase-activating-like protein IQGAP2 1,73 0,07				
UPUPUPUPUPUPUPUPUPUPUPUPUPUPUPUPUPUPUP				
	Deubiquitinating protein VCIP135	VCPIP1	-1,73	0,03

		4 70	
Lamina-associated polypeptide 2, isoforms beta/gamma	TMPO POLR3E	-1,73	0,88
DNA-directed RNA polymerase III subunit RPC5	ELL	-1,73	0,07 N.D.
RNA polymerase II elongation factor ELL E3 ubiquitin-protein ligase UBR5	UBR5	-1,73 -1,73	0,04
Cytoplasmic aconitate hydratase	ACO1	-1,73	0,04
Copine-3	CPNE3	-1,73	0,02
Formin-like protein 1	FMNL1	-1,72	0,15
Something about silencing protein 10	UTP3	-1,72	N.D.
Barrier-to-autointegration factor	BANF1	-1,72	0,00
Terminal uridylyltransferase 7	ZCCHC6	-1,72	0,41
Protein NipSnap homolog 3A	NIPSNAP3A	-1,72	0,09
Serine/threonine-protein phosphatase CPPED1	CPPED1	-1,71	0,01
Guanosine-3,5-bis(diphosphate) 3-pyrophosphohydrolase MESH1	HDDC3	-1,71	0,12
5-oxoprolinase	OPLAH	-1,71	0,82
RNA-binding protein 12B	RBM12B	-1,71	0,02
Oxysterol-binding protein-related protein 6	OSBPL6	-1,70	0,37
Neuroguidin	NGDN	-1,70	N.D.
Guanylate-binding protein 4	GBP4	-1,70	N.D.
Nucleolar protein 9	NOP9	-1,70	0,49
Sarcoplasmic/endoplasmic reticulum calcium ATPase 3	ATP2A3	-1,70	0,09
O-acetyl-ADP-ribose deacetylase 1	OARD1	-1,70	0,22
Son of sevenless homolog 1	SOS1	-1,69	2,25
Calcium and integrin-binding protein 1	CIB1	-1,69	0,31
Tyrosine-protein kinase Tec	TEC	-1,69	N.D.
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	PIK3CA	-1,68	0,56
CDC42 small effector protein 2	CDC42SE2	-1,68	0,31
NudC domain-containing protein 1	NUDCD1	-1,68	0,17
Nucleoside diphosphate kinase 7	NME7	-1,68	N.D.
Cytochrome b5 reductase 4	CYB5R4	-1,68	N.D.
PHD finger protein 14	PHF14	-1,67	N.D.
Na(+)/H(+) exchange regulatory cofactor NHE-RF1	SLC9A3R1 HN1	-1,67	N.D. N.D.
Hematological and neurological expressed 1 protein	PRPF4B	-1,67 -1,67	0,14
Serine/threonine-protein kinase PRP4 homolog Protein Smaug homolog 2	SAMD4B	-1,67	N.D.
	DPAGT1		
UDP-N-acetylglucosaminedolichyl-phosphate N-acetylglucosaminephosphotransferase		-1,67	0,60
40S ribosomal protein S27-like	RPS27L	-1,66	0,02
Transcription initiation factor IIE subunit beta	GTF2E2	-1,66	0,37
N-acylneuraminate cytidylyltransferase	CMAS FHL2	-1,66	0,02
Four and a half LIM domains protein 2	ERAL1	-1,66	N.D.
GTPase Era, mitochondrial	RIOK1	-1,65	N.D. N.D.
Serine/threonine-protein kinase RIO1 NLR family member X1	NLRX1	-1,65 -1,65	0,19
Serine/threonine-protein kinase 19	STK19	-1,65	N.D.
Protein RMD5 homolog A	RMND5A	-1,65	N.D.
Receptor-type tyrosine-protein phosphatase alpha	PTPRA	-1,65	0,32
UPF0687 protein C20orf27	C20orf27	-1,64	0,32
Chromodomain-helicase-DNA-binding protein 7	CHD7	-1,64	0,56
Sorting nexin-15	SNX15	-1,64	N.D.
RNA-binding protein 4	RBM4	-1,64	0,06
52 kDa repressor of the inhibitor of the protein kinase	PRKRIR	-1,64	0,28
28S ribosomal protein S31, mitochondrial	MRPS31	-1,64	0,97
Phosducin-like protein	PDCL	-1,63	1,53
Isochorismatase domain-containing protein 1	ISOC1	-1,63	0,19
ADP/ATP translocase 1	SLC25A4	-1,63	0,18
Elongation of very long chain fatty acids protein 5	ELOVL5	-1,62	0,06
Uncharacterized protein C15orf57	C15orf57	-1,62	N.D.
Nicotinate phosphoribosyltransferase	NAPRT	-1,61	0,18
ATP-binding cassette sub-family B member 6, mitochondrial	ABCB6	-1,61	N.D.
Protein NEDD1	NEDD1	-1,61	N.D.
Synaptosomal-associated protein 23	SNAP23	-1,61	0,05
Dipeptidyl peptidase 3	DPP3	-1,61	0,06
Caspase-4	CASP4	-1,60	0,02
Spermine synthase	SMS	-1,60	0,27
Glucose 1,6-bisphosphate synthase	PGM2L1	-1,60	1,01
Small integral membrane protein 13	SMIM13	-1,60	0,67
Histone deacetylase 6	HDAC6	-1,60	0,29
Protein FAM76B	FAM76B	-1,60	N.D.
Axin interactor, dorsalization-associated protein	AIDA	-1,59	0,11
SerinetRNA ligase, cytoplasmic	SARS	-1,59	0,02
Sialate O-acetylesterase	SIAE	-1,59	0,43
Molybdopterin synthase sulfur carrier subunit	MOCS2	-1,58	0,56
Electron transfer flavoprotein subunit alpha, mitochondrial	ETFA	-1,58	0,04
Repressor of RNA polymerase III transcription MAF1 homolog	MAF1	-1,58	N.D.
Protein DDI1 homolog 2	DDI2	-1,58	0,04
Lipid phosphate phosphohydrolase 1	PPAP2A	-1,58	N.D.
Serine-protein kinase ATM	ATM	-1,58	0,05
Protein-L-isoaspartate(D-aspartate) O-methyltransferase	PCMT1	-1,57	0,04
Microtubule-actin cross-linking factor 1, isoforms 1/2/3/5	MACF1	-1,57	0,09
Grancalcin	GCA	-1,57	0,07
Zinc finger protein 30	ZNF30	-1,57	N.D.

BAG family molecular chaperone regulator 2	BAG2	-1,57	0,03
Tumor susceptibility gene 101 protein	TSG101	-1,57	N.D.
ARF GTPase-activating protein GIT1	GIT1	-1,57	0,53
TRMT1-like protein	TRMT1L	-1,57	0,47
Uncharacterized protein C1orf109	C1orf109	-1,57	N.D.
C-terminal-binding protein 2	CTBP2	-1,57	N.D.
Rho GTPase-activating protein 15	ARHGAP15	-1,56	0,09
Protein THEM6	THEM6	-1,56	0,34
Serine protease HTRA2, mitochondrial	HTRA2	-1,56	0,16
Peroxiredoxin-2	PRDX2	-1,56	0,16
Ubiquitin carboxyl-terminal hydrolase 7	USP7	-1,56	0,07
Pyrroline-5-carboxylate reductase 3	PYCRL	-1,56	N.D.
Zinc finger HIT domain-containing protein 2	ZNHIT2	-1,56	N.D.
Uncharacterized protein C7orf50	C7orf50	-1,56	0,25
Golgi integral membrane protein 4	GOLIM4	-1,55	0,50
Receptor expression-enhancing protein 4	REEP4	-1,55	N.D.
EH domain-containing protein 1	EHD1	-1,55	0,05
Hydroxymethylglutaryl-CoA lyase, mitochondrial	HMGCL	-1,55	0,04
Vacuolar protein sorting-associated protein 28 homolog	VPS28	-1,55	0,06
Choline transporter-like protein 1	SLC44A1	-1,55	N.D.
1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase beta-2	PLCB2	-1,54	0,02
Periodic tryptophan protein 1 homolog	PWP1	-1,54	0,12
Dual specificity mitogen-activated protein kinase kinase 2	MAP2K2	-1,54	0,40
Beta-catenin-like protein 1	CTNNBL1	-1,54	0,18
Protein phosphatase 1 regulatory subunit 11	PPP1R11	-1,54	0,18 N.D.
TATA-binding protein-associated factor 2N	TAF15	-1,55	0,32
	IVD	-1,53 -1,53	0,32
IsovaleryI-CoA dehydrogenase, mitochondrial Uncharacterized protein KIAA1211	KIAA1211	-1,53 -1,53	
			N.D.
TBC1 domain family member 17	TBC1D17	-1,53	N.D.
Spartin	SPG20	-1,52	0,47
Perilipin-2	PLIN2	-1,52	0,01
Brain-specific angiogenesis inhibitor 1-associated protein 2	BAIAP2	-1,52	0,16
Ankyrin repeat domain-containing protein 17	ANKRD17	-1,52	0,19
TFIIH basal transcription factor complex helicase XPB subunit	ERCC3	-1,52	0,05
Myeloid cell surface antigen CD33	CD33	-1,52	0,12
Gamma-glutamyl hydrolase	GGH	-1,52	0,01
Serine/threonine-protein kinase 26	STK26	-1,52	0,29
Eukaryotic translation initiation factor 2-alpha kinase 4	EIF2AK4	-1,52	0,66
Dynamin-3	DNM3	-1,51	N.D.
Solute carrier family 43 member 3	SLC43A3	-1,51	0,19
Dimethyladenosine transferase 1, mitochondrial	TFB1M	-1,51	0,45
RAC-alpha serine/threonine-protein kinase	AKT1	-1,51	0,46
Cystathionine beta-synthase	CBS	-1,51	0,20
Ubiquitin carboxyl-terminal hydrolase 28	USP28	-1,51	1,14
Ubiquitin/ISG15-conjugating enzyme E2 L6	UBE2L6	-1,50	0,44
tRNA (guanine(26)-N(2))-dimethyltransferase	TRMT1	-1,50	0,38
FAS-associated death domain protein	FADD	-1,49	0,25
RNA-binding protein Musashi homolog 2	MSI2	-1,49	0,60
Coronin-1C	CORO1C	-1,49	0,10
Superoxide dismutase [Cu-Zn]	SOD1	-1,48	0,27
Transmembrane protein 50A	TMEM50A	-1,48	0,34
Dedicator of cytokinesis protein 7	DOCK7	-1,48	0,57
Spermatogenesis-associated protein 5	SPATA5	-1,48	0,13
Ribosyldihydronicotinamide dehydrogenase [quinone]	NQO2 TDP2	-1,48	0,09
Tyrosyl-DNA phosphodiesterase 2		-1,48	0,66
Syntaxin-7	STX7	-1,48	0,07
Chromodomain-helicase-DNA-binding protein 2	CHD2	-1,47	0,23
Protein-glutamine gamma-glutamyltransferase E	TGM3	-1,47	N.D.
DNA polymerase beta	POLB	-1,46	N.D.
AspartatetRNA ligase, mitochondrial	DARS2	-1,46	0,05
Lamin-B receptor	LBR	-1,46	0,06
Transient receptor potential cation channel subfamily V member 2	TRPV2	-1,46	N.D.
Guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-7	GNG7	-1,46	0,27
Hepatoma-derived growth factor-related protein 2	HDGFRP2	-1,46	0,31
Werner syndrome ATP-dependent helicase	WRN	-1,46	0,31
Helicase-like transcription factor	HLTF	-1,45	0,32
Active regulator of SIRT1	RPS19BP1	-1,45	0,35
Oxidation resistance protein 1	OXR1	-1,45	N.D.
Serine/threonine-protein kinase MRCK beta	CDC42BPB	-1,45	0,82
Rab11 family-interacting protein 1	RAB11FIP1	-1,45	0,29
Golgi-associated PDZ and coiled-coil motif-containing protein	GOPC	-1,44	N.D.
RB1-inducible coiled-coil protein 1	RB1CC1	-1,44	0,31
Zinc finger protein ZPR1	ZPR1	-1,44	0,11
Echinoderm microtubule-associated protein-like 3	EML3	-1,44	0,47
Myotubularin-related protein 12	MTMR12	-1,44	0,56
Guanine nucleotide-binding protein-like 1	GNL1	-1,43	0,02
Ras-related protein R-Ras2	RRAS2	-1,43	0,02 N.D.
Rho guanine nucleotide exchange factor 12	ARHGEF12	-1,43 -1,43	N.D. 1,47
Glucosamine 6-phosphate N-acetyltransferase	GNPNAT1	-1,43 -1,43	0,19
ADP-ribosylation factor-like protein 8A	ARL8A	-1,43 -1,43	0,19
אטי אטטאומנטא ומנטראג איז	ANLOA	-1,43	0,02

Denkin IT/4 homelen	171/4	1 42	0.25
Protein LTV1 homolog N-alpha-acetyltransferase 25, NatB auxiliary subunit	LTV1 NAA25	-1,42 -1,42	0,25 0,03
Kinesin-like protein KIF13B	KIF13B	-1,42	1,03
Apoptosis-inducing factor 2	AIFM2	-1,42	N.D.
Protein SCO1 homolog, mitochondrial	SCO1	-1,42	0,07
Zinc finger CCCH domain-containing protein 18	ZC3H18	-1,42	0,85
Phosphatidylinositol 4-kinase type 2-alpha	PI4K2A	-1,42	0,31
Tropomyosin alpha-4 chain	TPM4	-1,42	0,46
Serpin B6	SERPINB6	-1,41	0,02
Acyl-coenzyme A thioesterase 9, mitochondrial	ACOT9	-1,41	1,95
Cold-inducible RNA-binding protein	CIRBP	-1,41	0,38
Unconventional myosin-Ic	MY01C	-1,41	0,16
WW domain-binding protein 2	WBP2	-1,41	0,85
NAD-dependent protein deacylase sirtuin-5, mitochondrial	SIRT5	-1,41	N.D.
Protein CBFA2T3	CBFA2T3	-1,41	N.D.
Transmembrane protein 223	TMEM223	-1,40	0,09
Transmembrane protein 109	TMEM109	-1,40	0,41
Probable ubiquitin carboxyl-terminal hydrolase FAF-X	USP9X	-1,40	0,17
Quinone oxidoreductase	CRYZ	-1,40	0,02
Nuclear pore complex protein Nup50	NUP50	-1,40	0,23
Glycerol-3-phosphate acyltransferase 4	AGPAT6	-1,39	0,52
Cytohesin-1	CYTH1	-1,39	N.D.
Probable RNA-binding protein 19	RBM19 GCLM	-1,39	0,09
Glutamatecysteine ligase regulatory subunit	ZYG11B	-1,39	0,03
Protein zyg-11 homolog B		-1,39	N.D.
Threonylcarbamoyladenosine tRNA methylthiotransferase Proline-, glutamic acid- and leucine-rich protein 1	CDKAL1 PELP1	-1,39 -1,39	N.D. 0,03
Vacuolar protein sorting-associated protein 51 homolog	VPS51	-1,39	0,03
Merlin	NF2	-1,39	N.D.
ERO1-like protein alpha	ERO1L	-1,38	0,02
Mitofusin-1	MFN1	-1,38	N.D.
Basement membrane-specific heparan sulfate proteoglycan core protein	HSPG2	-1,38	0,17
Macrophage erythroblast attacher	MAEA	-1,38	N.D.
Ras-related protein Rap-2b	RAP2B	-1,38	0,23
Vam6/Vps39-like protein	VPS39	-1,37	0,44
Dedicator of cytokinesis protein 5	DOCK5	-1,37	0,27
Coiled-coil domain-containing protein 124	CCDC124	-1,37	0,21
N-alpha-acetyltransferase 20	NAA20	-1,37	0,46
Activating signal cointegrator 1 complex subunit 2	ASCC2	-1,37	0,77
Acylpyruvase FAHD1, mitochondrial	FAHD1	-1,37	0,02
cAMP-dependent protein kinase type II-beta regulatory subunit	PRKAR2B	-1,37	N.D.
Carboxypeptidase Q	CPQ	-1,36	0,42
Methylenetetrahydrofolate reductase	MTHFR	-1,36	0,97
ATPase ASNA1	ASNA1	-1,36	0,14
Uveal autoantigen with coiled-coil domains and ankyrin repeats	UACA	-1,36	1,10
Poly [ADP-ribose] polymerase 10	PARP10	-1,36	0,69
A-kinase anchor protein 8	AKAP8	-1,36	0,14
Aminopeptidase N	ANPEP	-1,35	0,16
Ubiquinol-cytochrome-c reductase complex assembly factor 3	UQCC3	-1,35	0,07
Ubiquitin carboxyl-terminal hydrolase 11	USP11 ITGAM	-1,35	0,58
Integrin alpha-M Forritin light chain	FTL	-1,35 -1,35	0,19 0,21
Ferritin light chain Multivesicular body subunit 12A	MVB12A	-1,35	0,21 N.D.
Heterochromatin protein 1-binding protein 3	HP1BP3	-1,35 -1,34	N.D. 0,14
Galectin-9	LGALS9	-1,34	0,86
Prostaglandin G/H synthase 1	PTGS1	-1,34	N.D.
Propionyl-CoA carboxylase beta chain, mitochondrial	PCCB	-1,34	0,04
Poly [ADP-ribose] polymerase 14	PARP14	-1,34	0,17
RWD domain-containing protein 4	RWDD4	-1,33	0,18
Branched-chain-amino-acid aminotransferase, cytosolic	BCAT1	-1,33	0,30
Tetratricopeptide repeat protein 9C	TTC9C	-1,33	0,42
Oxysterol-binding protein-related protein 11 and 10	OSBPL11;OSBPL10	-1,33	0,40
Diphthine synthase	DPH5	-1,33	0,28
Phosphoacetylglucosamine mutase	PGM3	-1,33	0,09
3-mercaptopyruvate sulfurtransferase	MPST	-1,33	0,22
Mitogen-activated protein kinase kinase kinase kinase 4	MAP4K4	-1,32	0,05
Cysteine and histidine-rich domain-containing protein 1	CHORDC1	-1,32	0,08
Ribonuclease P protein subunit p25-like protein	RPP25L	-1,32	0,40
Nucleoside diphosphate-linked moiety X motif 19, mitochondrial	NUDT19	-1,32	0,74
Ester hydrolase C11orf54	C11orf54	-1,32	0,18
NADH-cytochrome b5 reductase 1	CYB5R1	-1,32	N.D.
Probable ATP-dependent RNA helicase DDX6	DDX6	-1,32	0,24
ATP-dependent RNA helicase DDX3Y	DDX3Y	-1,32	0,39
tRNA-dihydrouridine(20) synthase [NAD(P)+]-like	DUS2	-1,31	N.D.
Nuclear mitotic apparatus protein 1	NUMA1	-1,31	0,01
Microfibrillar-associated protein 1	MFAP1	-1,31	N.D.
Phosphatidylinositol 5-phosphate 4-kinase type-2 alpha	PIP4K2A MARK2	-1,30	0,57
Serine/threonine-protein kinase MARK2 RNA-binding protein 42	RBM42	-1,30 -1,30	N.D. 0,38
Plasma alpha-L-fucosidase	FUCA2	-1,30	0,38 N.D.
ו ונשווים ביוענשועמשכ	100A2	-1,50	N.D.

Membrane-associated guanylate kinase, WW and PDZ domain-containing protein 1	MAGI1	-1,29	1,53
Transmembrane protein 126A	TMEM126A	-1,29	0,24
Methylmalonate-semialdehyde dehydrogenase [acylating], mitochondrial	ALDH6A1	-1,29	N.D.
DDB1- and CUL4-associated factor 7	DCAF7	-1,29	N.D.
Tetratricopeptide repeat protein 27	TTC27 ADPRHL2	-1,29 -1,29	0,00
Poly(ADP-ribose) glycohydrolase ARH3 Calpain-1 catalytic subunit	CAPN1	-1,29	0,07 0,07
Aminopeptidase B	RNPEP	-1,29	0,07
Tripartite motif-containing protein 65	TRIM65	-1,29	0,04
Biogenesis of lysosome-related organelles complex 1 subunit 5	BLOC1S5	-1,29	0,44
Proteasomal ATPase-associated factor 1	PAAF1	-1,29	0,28
Ragulator complex protein LAMTOR1	LAMTOR1	-1,28	0,07
Glutathione reductase, mitochondrial	GSR	-1,28	0,09
FACT complex subunit SPT16	SUPT16H	-1,28	0,22
Multidrug resistance-associated protein 1	ABCC1	-1,28	0,18
Platelet-activating factor acetylhydrolase IB subunit beta	PAFAH1B2	-1,28	0,04
Beta-arrestin-1	ARRB1	-1,28	0,30
Vesicle-associated membrane protein 3	VAMP3;VAMP2	-1,28	0,29
Microtubule-associated protein 1S	MAP1S	-1,27	0,01
RNA-binding protein 14	RBM14	-1,27	0,73
PDZ domain-containing protein 8	PDZD8	-1,27	N.D.
AH receptor-interacting protein	AIP	-1,27	0,13
Crossover junction endonuclease MUS81	MUS81	-1,27	N.D.
Zinc finger protein 574	ZNF574	-1,27	0,44
Proline-rich protein PRCC	PRCC	-1,27	N.D.
Calcineurin B homologous protein 1	CHP1	-1,27	0,08
Transferrin receptor protein 2	TFR2	-1,27	N.D.
Nucleolar protein 56	NOP56	-1,26	0,23
Signal transducing adapter molecule 1	STAM	-1,26	0,47
Aldo-keto reductase family 1 member C3	AKR1C3	-1,26	N.D.
Peflin	PEF1	-1,26	0,13
ATP-dependent RNA helicase DDX55	DDX55	-1,26	0,54
Di-N-acetylchitobiase	CTBS	-1,26	N.D.
Epiplakin	EPPK1	-1,26	N.D.
Protein diaphanous homolog 1	DIAPH1	-1,25	0,13
Fermitin family homolog 3	FERMT3	-1,25	0,05
Lysosomal Pro-X carboxypeptidase	PRCP	-1,25	0,03
Testis-expressed sequence 10 protein	TEX10	-1,25	0,12
Protein SDA1 homolog	SDAD1	-1,25	0,29
YTH domain-containing family protein 3	YTHDF3	-1,25	0,60
Spermatid perinuclear RNA-binding protein	STRBP	-1,25	0,61
E3 ubiquitin-protein ligase UBR3	UBR3	-1,25	N.D.
Golgi SNAP receptor complex member 2	GOSR2	-1,24	0,09
Polypyrimidine tract-binding protein 3	РТВРЗ	-1,24	1,17
Leukosialin	SPN	-1,24	0,23
Neuropathy target esterase	PNPLA6	-1,24	0,08
Pre-mRNA-splicing factor 38A	PRPF38A	-1,24	0,28
Transmembrane emp24 domain-containing protein 1	TMED1	-1,24	0,32
NADH dehydrogenase [ubiquinone] 1 alpha subcomplex assembly factor 5	NDUFAF5	-1,24	N.D.
Peptidyl-prolyl cis-trans isomerase FKBP1A	FKBP1A	-1,23	0,06
RRP15-like protein	RRP15	-1,23	N.D.
Ragulator complex protein LAMTOR3	LAMTOR3	-1,23	0,04
rRNA/tRNA 2-O-methyltransferase fibrillarin-like protein 1	FBLL1	-1,23	N.D.
tRNA-dihydrouridine(47) synthase [NAD(P)(+)]-like	DUS3L	-1,23	0,22
Zinc finger protein 512	ZNF512	-1,23	N.D.
Lymphokine-activated killer T-cell-originated protein kinase	РВК	-1,23	0,08
Vacuolar protein sorting-associated protein 13B	VPS13B	-1,23	0,18
DNA-directed RNA polymerase III subunit RPC6	POLR3F	-1,22	N.D.
Ribonucleoprotein PTB-binding 1	RAVER1	-1,22	0,44
Transmembrane protein 68	TMEM68	-1,22	N.D.
U1 small nuclear ribonucleoprotein 70 kDa	SNRNP70	-1,22	0,38
Actin-related protein 6	ACTR6	-1,22	N.D.
Ribonucleoside-diphosphate reductase subunit M2	RRM2	-1,22	N.D.
Coiled-coil domain-containing protein 9	CCDC9	-1,22	0,79
Cytochrome c oxidase assembly protein COX19	COX19	-1,22	N.D.
SURP and G-patch domain-containing protein 1	SUGP1	-1,22	N.D.
Chromobox protein homolog 1	CBX1	-1,22	0,07
Putative pre-mRNA-splicing factor ATP-dependent RNA helicase DHX16	DHX16	-1,22	0,18
Retinol dehydrogenase 10	RDH10	-1,22	N.D.
Prostaglandin reductase 2	PTGR2	-1,21	N.D.
Intercellular adhesion molecule 1	ICAM1	-1,21	0,64
Septin-9	SEPT9	-1,21	0,13
Non-syndromic hearing impairment protein 5	DFNA5	-1,21	N.D.
Mannose-P-dolichol utilization defect 1 protein	MPDU1	-1,21	0,03
Peptidyl-prolyl cis-trans isomerase D	PPID	-1,21	0,10
Serine/threonine-protein phosphatase 6 regulatory subunit 3	PPP6R3	-1,21	0,08
RING finger protein 214	RNF214	-1,21	0,29
Protein-methionine sulfoxide oxidase MICAL3	MICAL3	-1,21	N.D.
SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily D member		-1,21	0,10
DNA-directed RNA polymerase III subunit RPC1	POLR3A	-1,21	0,13

Mitochondrial ribonuclease P protein 3	KIAA0391	-1,21	N.D.
Protein O-mannose kinase	РОМК	-1,21	N.D.
Protein-associating with the carboxyl-terminal domain of ezrin	SCYL3	-1,20	N.D.
Protein yippee-like 5	YPEL5	-1,20	0,06
U3 small nucleolar ribonucleoprotein protein MPP10	MPHOSPH10	-1,20	N.D.
Alcohol dehydrogenase class-3	ADH5	-1,20	0,05
Intermediate conductance calcium-activated potassium channel protein 4	KCNN4	-1,20	N.D.
Dedicator of cytokinesis protein 6	DOCK6	-1,20	0,44
General transcription factor IIH subunit 3	GTF2H3	-1,20	N.D.
UPF0462 protein C4orf33	C4orf33	-1,20	N.D.
Leukotriene A-4 hydrolase	LTA4H	-1,20	0,13
UPF0428 protein CXorf56	CXorf56	-1,20	N.D.
Guanine nucleotide-binding protein-like 3-like protein	GNL3L	-1,19	N.D.
DDB1- and CUL4-associated factor 8	DCAF8	-1,19	0,57
Pre-mRNA-processing factor 19	PRPF19	-1,19	0,21
PHD finger protein 6	PHF6	-1,19	0,11
WD repeat-containing protein 18	WDR18	-1,19	0,17
Lamin-B2	LMNB2	-1,18	0,04
Menin	MEN1	-1,18	0,58
		-	
Phosphoribosyl pyrophosphate synthase-associated protein 2	PRPSAP2	-1,18	0,37
Guanine nucleotide-binding protein subunit alpha-11	GNA11	-1,18	0,48
A-kinase anchor protein 8-like	AKAP8L	-1,18	0,07
Ubiquitin carboxyl-terminal hydrolase 24	USP24	-1,17	0,30
Adapter molecule crk	CRK	-1,17	0,66
Tether containing UBX domain for GLUT4	ASPSCR1	-1,17	0,26
Leucine-rich repeat-containing protein 47	LRRC47	-1,17	0,04
Peptidyl-tRNA hydrolase 2, mitochondrial	PTRH2	-1,17	0,23
Lysosomal acid lipase/cholesteryl ester hydrolase	LIPA	-1,17	N.D.
Diphthamide biosynthesis protein 1	DPH1	-1,17	0,29
Probable methyltransferase-like protein 15	METTL15	-1,17	N.D.
Trafficking protein particle complex subunit 10	TRAPPC10	-1,17	0,10
Kinesin-like protein KIFC1	KIFC1	-1,17	N.D.
Vacuolar protein sorting-associated protein 53 homolog	VPS53	-1,16	0,51
Retinoblastoma-binding protein 5	RBBP5	-1,16	0,20
FACT complex subunit SSRP1	SSRP1	-1,16	1,07
Mitochondrial import inner membrane translocase subunit Tim10 B	TIMM10B	-1,16	0,08
Lipopolysaccharide-responsive and beige-like anchor protein	LRBA	-1,16	0,19
Adaptin ear-binding coat-associated protein 2	NECAP2	-1,16	0,09
SET and MYND domain-containing protein 5	SMYD5	-1,16	0,70
AP-1 complex subunit gamma-like 2	AP1G2	-1,16	0,34
COX assembly mitochondrial protein 2 homolog	CMC2	-1,16	0,31
Enolase-phosphatase E1	ENOPH1	-1,15	0,13
	NUDT3	-1,15	0,47
Diphosphoinositol polyphosphate phosphohydrolase 1			
RNA-binding protein 10	RBM10	-1,15	0,26
General transcription factor IIE subunit 1	GTF2E1	-1,15	N.D.
LYR motif-containing protein 4	LYRM4	-1,15	0,47
[3-methyl-2-oxobutanoate dehydrogenase [lipoamide]] kinase, mitochondrial	BCKDK	-1,15	N.D.
Receptor-type tyrosine-protein phosphatase gamma	PTPRG	-1,15	N.D.
Tumor necrosis factor receptor type 1-associated DEATH domain protein	TRADD	-1,14	0,33
Heterogeneous nuclear ribonucleoprotein R	HNRNPR	-1,14	0,12
UPF0585 protein C16orf13	C16orf13	-1,14	0,15
Histone deacetylase 2	HDAC2	-1,14	0,19
Nucleoredoxin	NXN	-1,14	N.D.
Cytoplasmic tRNA 2-thiolation protein 1	CTU1	-1,14	N.D.
Nuclear RNA export factor 1	NXF1	-1,13	0,71
Transcriptional repressor CTCF	CTCF	-1,13	0,71 0,12
Dihydrolipoyllysine-residue acetyltransferase component of pyruvate dehydrogenase complex,		-1,15	0,12
mitochondrial	DLAT	-1,13	0,01
	TRIO	1.42	0.30
Triple functional domain protein	TRIO	-1,13	0,36
UV excision repair protein RAD23 homolog B	RAD23B	-1,13	0,85
General transcription factor IIH subunit 4	GTF2H4	-1,12	N.D.
Bcl-2-associated transcription factor 1	BCLAF1	-1,12	0,17
Kinectin	KTN1	-1,12	0,00
Glucose-induced degradation protein 8 homolog	GID8	-1,12	0,08
U6 snRNA-associated Sm-like protein LSm1	LSM1	-1,12	0,22
Nuclear factor NF-kappa-B p105 subunit;Nuclear factor NF-kappa-B p50 subunit	NFKB1	-1,12	0,14
Zinc finger and BTB domain-containing protein 40	ZBTB40	-1,12	0,16
Dual specificity mitogen-activated protein kinase kinase 1	MAP2K1	-1,11	N.D.
Armadillo repeat-containing protein 6	ARMC6	-1,11	0,49
Scaffold attachment factor B2	SAFB2	-1,11	0,43
Calcineurin subunit B type 1	PPP3R1	-1,11 -1,11	
			0,10
Armadillo repeat-containing protein 10	ARMC10	-1,11	0,04
Spermatogenesis-associated protein 5-like protein 1	SPATA5L1	-1,10	0,47
UBX domain-containing protein 1	UBXN1	-1,10	0,30
Craniofacial development protein 1	CFDP1	-1,10	N.D.
tRNA pseudouridine synthase A, mitochondrial	PUS1	-1,10	0,32
Nuclear protein localization protein 4 homolog	NPLOC4	-1,10	0,03
General transcription factor IIH subunit 1	GTF2H1	-1,10	N.D.
Protein phosphatase methylesterase 1	PPME1	-1,10	0,01
Cyclic AMP-dependent transcription factor ATF-1	ATF1	-1,10	N.D.
WD repeat-containing protein 89	WDR89	-1,09	N.D.
		,	

Mochonics model minical model and analysis1.001.001.00FieldFieldField1.000.02FieldFieldField1.000.02FieldFieldField1.000.02FieldFieldField1.000.02FieldFieldField1.000.02FieldFieldField1.000.02FieldFieldField1.000.02FieldFieldField1.000.02FieldFieldField1.000.02FieldFieldField1.000.02FieldFieldField1.000.02FieldFieldField1.000.02FieldFieldField1.000.02FieldFieldField1.000.02FieldFieldField1.000.02FieldFieldField1.000.02FieldFieldField1.000.02FieldFieldField1.000.02FieldFieldField1.000.02FieldFieldField1.001.000.02FieldFieldField1.001.000.02FieldFieldField1.001.000.02FieldFieldField1.001.000.02FieldFieldField1.001.000.02FieldFiel		TH 11 100	1.00	
Thyode norme neeppo-associated protein 3Protein Antibaction 4Protein Antibaction 4Protein Antibaction 4NameStafe protein Name <td< td=""><td></td><td>TIMM22</td><td>-1,09</td><td>N.D.</td></td<>		TIMM22	-1,09	N.D.
js.cinCN11.000.02Millagen-activated proteix finase finase finase finaseMM3121.000.02Millagen-activated proteix finase finase finase finase finaseDEC1.000.02Decide DZDEC1.000.030.03Series finase finase finase finase finase finase finasePRP11.000.03Decide DZPRP11.000.030.03Decide DZPRP11.000.030.03Decide DZPRP11.000.030.03Series finase finase finase finasePRP11.000.03Decide DZPRP11.000.030.03Series finase finase finase finasePRP11.000.03Decide DZPRP11.000.030.03Series finase finase finase finasePRP11.000.03Decide Series finase finase finasePRP11.000.03Series finase finase submit finasePRP11.000.03Series finase finase submit finasePRP21.000.03Series finase finase submit finasePRP21.000.03Decisione finase finase finase finasePRP21.000.03Decisione finase finase finase finasePRP21.000.0				
isiA nertyican/trans 1, microansiaMM11,00N.D.Pecien DKDK-0.00N.D.Pecien DKDK-0.00N.D.Isorberd synthesISS-0.00N.D.Pecien DKDK-0.00N.D.Pecien DKSK-0.00N.D.Pecien DKCargor Antibac Synthes-0.00N.D.Pecien DKMARCA-0.00N.D.Pecien Dirical Synthesis Antibac SynthesMARCA-0.00N.D.Transcription in Internet Synthesis Antibac SynthesN.D0.00N.D.Transcription Control Synthesis Antibac Synthesis Antibac SynthesisN.D0.00N.D.Transcription Control Synthesis Antibac Synthesynthesis Antibac Synthesis Antibac Synthesis Ant				
Mingen-schurd protein biase biase biase 5MAP3059,000,00Detein DKFCC1,00ND.Disponyt-CA. Carboylase alpha chain, mitochondrialCCA.1,000.03DSP protein biase 1CCA.1,000.03DSP protein biase 1MARCA1,070.03DSP protein biase 1MARCA1,070.03Protein frame/biase director BIGMARCA1,000.03Protein biasers 1MARCA1,000.03Protein frame/biase director BIGMARCA1,000.03Protein biasers 1MARCA1,000.03Protein biasers 2MARCA1,000.03Protein biasers 2MARCA1,000.03<				
Present DickDick1.081.0.Analter of yellsSS1.080.03Projenty CAC attronytise agine tails, mitochondrialSPCA1.080.03Thymosyte nadear protein11.080.03Thymosyte nadear protein11.080.03Thymosyte nadear protein11.080.03Thymosyte nadear protein11.080.03Thymosyte nadear protein11.080.03Thymosyte nadear protein11.070.28Thrase cinholon, mitochondrialATHY1.070.28Thrase cinholon, mitochondrialATHY1.070.28NatedexpressSMARCAA1.070.29NatedexpressMarchan1.070.29NatedexpressMarchan1.070.29NatedexpressMarchan1.070.29NatedexpressMarchan1.070.29NatedexpressMarchan1.070.29NatedexpressMarchan1.070.29NatedexpressMarchan1.050.29NatedexpressMarchan1.050.29NatedexpressMarchan1.050.29NatedexpressMarchan1.050.29NatedexpressMarchan1.050.29NatedexpressMarchan1.050.29NatedexpressMarchan1.050.29NatedexpressMarchan1.050.29NatedexpressMarchan1.050.29<				
Landard synthaseCS1-020.05Propeny C-AC Argeny C-AC Ar				
ProponyCoCA carbonylase alpa chain, mitochondrialPCCA1.080.13Thymocyte nuclear protein 1THM-1.080.03Charger multiversite body rotein 2HMMZA-1.070.38Serine/Threenine-protein phases 1 regulatory subunit 10PPP110-1.070.38Serine/Threenine-protein phases 1 regulatory subunit 10TTA-1.070.38Serine/Threenine-protein phases 1 regulatory subunit 10MARE A4-0.070.39Protein phasesMARE A4-0.070.39Protein phasesMARE A4-0.070.39Protein phasesMARE A4-0.070.39Protein phasesMARE A4-0.070.39Protein phasesMARE A4-0.07N.0.Protein aurier bronologANN-1.060.37Seruterotidase domain-constaining protein 1MARE A4-0.07N.0.Protein aurier bronologSantalHTML-1.060.38Til domain-constaing protein 1MARE A4-0.050.01Regulator complex protein 1 bronolog AMARE A4-0.050.01AP2 complex subunit alph-1AP2A1-0.050.03AP3 complex subunit alph-1AP2A1				
SNP protein lanse 11.080.03SNPL1.080.03Charged mulbreskular body protein 1211111111111.080.03Charged mulbreskular body protein 12PP12101.070.08Transcriptional regulator ATRK1.070.080.03Transcriptional regulator ATRK1.070.080.03Transcription activator BNG1MARCA41.070.03Transcription activator BNG1MARCA41.070.03Transcription activator BNG1MARCA41.070.03Transcription activator BNG1MARCA41.070.03Transcription activator BNG1MARCA41.070.02Transcription activator BNG1MARCA41.070.02Transcription activator Bordia Transcription Contained BNA-activated protein KinaseMARCA41.060.18Moless agent decempreliptic Transcription Contained BNA-activated protein KinaseMARCA41.050.03Moless agent decempreliptic Transcription Contained S and 1MARCA41.050.03Exosome Complex component RMF5MARCA41.050.030.03Relativator Complex activation Contained S and 1MARCA41.050.03AP2 complex suburit alpha 1Contained S and 1MARCA41.050.03AP3 contained Sector MarcA4MARCA41.050.030.03AP3 contained Sector MarcA4MARCA41.040.030.04AP3 contained Sector MarcA4MARCA41.040.030.06 <td< td=""><td></td><td></td><td></td><td></td></td<>				
Thymologe nuclear protein10.880.2.3Charged multivestatic body protein2.0.3N.D.Seried/Threamine-protein phosphalss 1 regulatory solumit 10PPP1B10-1.070.38Thream-phose phosphalss 1 regulatory solumit 10ATPS 1-1.070.38Thream-phose phose	Propionyl-CoA carboxylase alpha chain, mitochondrial		-1,08	0,13
Charge nulwescale body preten 7aCHMPA-1.08N.D.Transcription lengibles of transcription and preten phosphase 1 regulatory submit 10PPI10-1.070.08Transcription and transcription and subtra 100ATRK-1.070.28Transcription activator BRG1SMARCA4-1.070.28Transcription activator BRG1SMARCA4-1.070.29Nucleis preten functionation balaNULB-1.070.29Nucleis preten functionation balaNULB-1.070.29Nucleis preten functionation balaSMARCA4-1.070.29Nucleis preten functionation balaSMARCA4-0.060.17Nucleis preten functionation balaSMARCA4-0.060.018Nucleis preten function balanceNULB-0.060.03Statistic preten function balanceNULB-0.060.03Nucleis preten function balanceNULB-0.060.03Statistic preten function balanceNULB-0.060.03Reference substrating preten function balanceNULB-0.060.03Reference substration function balanceNULB-0.060.03Reference substration function balanceNULB-0.060.03Reference substration function factor function balanceNULB-0.060.03Reference substration function factor factor function factor factor function factor factor factor function factor factor factor factor factor factor factor factor factor			-1,08	0,03
Seried/Iteracine protein phosphase 1 regulary subunit 10PPE110-1.070.08ATPase inhibro, mitochondralATPS-1.070.38ATPase inhibro, mitochondralMARCA-1.070.39Protein function FRGMARCA-1.070.30Protein function FRGMARCA-1.070.30Protein function FRGMARCA-1.070.30Protein function FRGMARCA-1.07N.0.Protein function func	Thymocyte nuclear protein 1	THYN1	-1,08	0,25
Transcriptional regulator ATRXILVR0.038Transcription activator BR01SMARCA1.0770.33Transcription activator BR01FMB1.0770.35Protein fances transcription activator BR01FMB1.077N.0.Nucleohym TAA 1 isoform p40TLA11.077N.0.Snucleohym TAA 1 isoform p40TLA11.077N.0.Snucleohym TAA 1 isoform p40TLA11.076N.0.Snucleohym TAA 1 isoform p40TLA11.0660.037Mothers against decapentaping: homolog ASNA05,SMA0111.060.038Mothers against decapentaping: homolog AN.0.N.0.N.0.Mothers against decapentaping: homolog AN.0.N.0.N.0.Bagulator complex consigneres RBA2N.0.N.0.N.0.AP 2 complex submit alpha-1N.0.N.0.N.0.N.0.AP 2 complex submit alpha-1ATT1.056N.0.AD-0 dependent protein decavityse strain-2SR72N.0.N.0.Apscherint ALMOR2N.0.N.0.N.0.N.0.AD-10 dependent protein decavityse strain-2N.0.N.0.N.0.Apscherint ALMOR2N.0.N.0.N.0.N.0.Apscherint ALMOR2N.0.N.0.N.0.N.0.Apscherint ALMOR2N.0.N.0.N.0.N.0.Apscherint Almore activation of an activation of	Charged multivesicular body protein 2a	CHMP2A	-1,08	N.D.
ATPse inhibitor, "intechnodralATPse inhibitor, "intechnodral0.39Protein fanceyltransferase subunit betaFKTB1.070.39Protein fanceyltransferase subunit betaFKTB1.070.39Protein fanceyltransferase subunit betaFKTB1.070.39Protein sunder homologAJNN1.07N.D.Schuedbylta Chall Sinform p40N.D.1.060.17Interforsin-induced, double-stranded RMA-activated protein kinaseEPZAQ1.060.13Michers sgant decemptables/ homolog AProtein Sinform1.060.13Michers sgant decemptables/ homolog AProtein Sinform0.090.09Mitokina ?AMA1.050.090.09Mitokina ?MRN21.050.090.09Mitokina ?MRN21.050.030.09Mitokina ?MRN21.050.030.09Mitokina ?MRN21.050.030.09Mitokina ?MRN21.050.030.00Mitokina ?MRN21.050.030.00Mitokina ?MRN21.040.050.00Mitokina ?MRN21.040.050.00Mitokina ?MRN21.040.030.00Mitokina ?MRN21.040.030.00Mitokina ?MRN21.040.030.00Mitokina ?MRN21.040.030.00Mitokina ?MRN21.040.030.02Mitokina ?MRN2 </td <td>Serine/threonine-protein phosphatase 1 regulatory subunit 10</td> <td>PPP1R10</td> <td>-1,07</td> <td>0,08</td>	Serine/threonine-protein phosphatase 1 regulatory subunit 10	PPP1R10	-1,07	0,08
Transcription activator BR01SMARCA1.070.23Nicologin TAA Lindrom Pd0TKB1.07N.0.Nicologin TAA Lindrom Pd0TAA1.07N.0.Snucleodidase domain-containing protein 1NISOC11.062.07Interferon-induced, double-stranded RMA-activated protein kinaseETAA(2)1.060.13Micholy And Call A	Transcriptional regulator ATRX	ATRX	-1,07	0,38
product functional protectPTE1.070.23Productory TAV Storm p40TAI1.07N.D.Protein assumer homologASIN1.07N.D.Protein assumer homologASIN1.060.017Interform-induced, double-stranded RNA-activated protein kinaseET2AV21.060.037Interform-induced, double-stranded RNA-activated protein kinaseET2AV21.060.037Mothers againt decempating thomolog 5 and 1SMADSSMOD11.060.038YTH domain containing protein 1SMADSSMOD21.050.09Rissonal RNA protein stranded RNA-activated protein functionRP11.050.00Rissonal RNA protein LATMOR2LATMOR21.050.00AP2 complex subunt lapha-1AR2A11.050.00NAD-dependent protein dearbyses strain-2SIR71.050.03LiA 3 protein strat/defaCIDT731.050.00NAD-dependent protein dearbyses strain-2SIR71.050.00NAD-dependent protein dearbyses strain-2SIR71.050.02Apla-tocopies subunt lapha-1NAD0.010.040.03LiA 3 protein strat/defaNAD0.020.020.02Apla-tocopies subunt lapha-1NAD0.030.010.04Apla-tocopies subust lapha-1NAD0.020.020.02Apla-tocopies subust lapha-1NAD0.020.020.02Apla-tocopies subust lapha-1NAD0.040.040.04Protein strat/defa </td <td>ATPase inhibitor, mitochondrial</td> <td>ATPIF1</td> <td>-1,07</td> <td>0,28</td>	ATPase inhibitor, mitochondrial	ATPIF1	-1,07	0,28
Nucleopin TAA Lindform PADTAATAATAATAAND.Shurden Sudfor MonologASINND.ND.ND.Shurden Sudfor Monolog S and JNTSOC11.062.07Mother Saginst decapentapinge homolog S and JSMADDS/MADD11.060.18Mother Saginst decapentapinge homolog S and JSMADDS/MADD11.060.38Mother Saginst decapentapinge homolog S and JSMADDS/MADD11.060.39Mitrofining Protein I Anomolog ARNP11.050.39Saconne complex component RRMSCSOS91.050.09Mitrofining Protein I Anomolog ARNP11.050.03Ar2 complex subunt dipha-1ART1.050.03Ar2 complex component RRMSCLIONT21.050.03Mitrofining Protein Accerptions struing Protein Maxem Struing Protein1.040.03Ar2 complex contradit ductar proteinMCM ABAP1.040.030.03Arabitar contradit ductar proteinMCM ABAP1.040.030.04Mitcherinder accel ductar proteinMCM ABAP1.040.030.04Mitcherinder accel ductar ductar fractor M-kappa-B p2 subunitMRAS1.040.03Mitcherinder accel ductar Maxem Struing ProteinMCM ABAP1.030.04Mitcherinder accel ductar ductar fractor M-kappa-B p2 subunitMRAS1.040.04Mitcherinder accel ductar Maxem Struing ProteinMCM ABAP1.030.04 <td>Transcription activator BRG1</td> <td>SMARCA4</td> <td>-1,07</td> <td>0,19</td>	Transcription activator BRG1	SMARCA4	-1,07	0,19
NucleopantTA11.07N.D.Sourceordises domain-containing protein 1NTSDC11.062.07Interferon-induced, double-strander RNA-activated protein knasseFTAA/21.062.07Mothers against decapentaping: homolog 5 and 1SMADS;MMAD11.060.03Mothers against decapentaping: homolog 5 and 1SMADS;MMAD11.060.03Mothers against decapentaping: homolog 5 and 1SMADS;MMAD11.060.03Mothers against decapentaping: homolog 5 and 1SMADS;MMAD11.060.03Resonne complex component RPM5CSOS9-1.05N.D.Resonne complex component RPM5MRAD1.050.03Mitchinita ¹ 2AMTOR21.050.03Mutchinita ¹ 21.050.030.03Resonne complex complex situina ² 21.030.03Ja 2 strate relativatiNMAD1.040.03Activator of basit transcription 1ABT11.040.03Activator of basit transcription 1ABT11.040.03Activator of basit transcription 1NCMAD1.040.03Activator of basit transcription 1NCMAD1.040.04Mitchinghittaries devination proteinNCMAD1.040.04Aphin-terrapidNCMAD1.040.04Mitchinghittaries devination proteinNCMAD1.040.04Mitchinghittaries devination proteinNCMAD1.040.04Mitchinghittaries devination proteinNCMAD1.040.04Mitchi	Protein farnesyltransferase subunit beta	FNTB	-1,07	0,29
Protein Sunder homoligAUM1.07N.D.Protein Sunder data manual contain protein 1NTSO C11.060.07Interform induced, double-standed RNA-activated protein kinaseEFZAAZ1.060.07Nuthers spaint decempetagies fromolog 5 and 1SMADSSMAD11.060.075Stander Data Contain protein 1NTH C11.050.09Execonce complex componer RNMSEXECS1.050.09Biologian Contain protein 1NTN21.050.00AP-2 complex subunt alpha-1AP2A11.050.00AP2 complex subunt alpha-1AP2A11.050.03AP2 complex subunt alpha-1AP2A11.050.03AP3 complex subunt alpha-1AP2A11.050.03AP3 complex subunt alpha-1AP2A11.040.01AP3 complex subunt alpha-1AP30.010.01AP3 complex subunt alpha-1AP30.010.01AP3 complex subunt alpha-1AP30.010.01AP3 complex subunt alpha-1AP30.020.01AP3 complex subunt alpha-1AP30.020.02AP3 complex subunt alpha-1 <td< td=""><td>Nucleolysin TIA-1 isoform p40</td><td>TIA1</td><td></td><td></td></td<>	Nucleolysin TIA-1 isoform p40	TIA1		
S-nucleotidase domain- ontaining proteinNTSOC11.062.07Mothers against decagentaplegic homolog 5 and 1SMADS SMAD11.060.03Mothers against decagentaplegic homolog 5 and 1SMADS SMAD11.060.03Ribosoma Combes component RRPASRRP11.050.039Ribosoma Combes shortin 1 homolog ARRP11.050.09Mitofusia-2MFR21.050.00Raguitatro complex subunit alpha-1AP2A11.050.00Raguitatro complex protein LMMTOR2LAMTOR21.050.03Raduitatro complex protein decetylase situin-2SMIT21.050.03Ar2-toropics activation set/detaVINAZ1.040.02Ar2-toropics activation set/detaMTC1.040.02Ar2-toropics activation set/detaMTC1.040.02Ar2-toropics activation set/detaMTC1.040.02Ar2-toropics activation set/detaMTC1.040.01Ar2-toropics activation				
interferon-induced, double-stranded RNA-adtiveta protein inaseIFZA/2I.0.60.7.7Whethers again to decompetable for homolog & and 1YTH donal-containing protein 10.7.60.7.8Rissonal RNA processing protein 1 homolog ARP1-1.0.50.7.9Rissonal RNA processing protein 1 homolog ARP1-1.0.50.7.9Rissonal RNA processing protein 1 homolog ARP2-1.0.5N.0.AP-2 complex subunit alpha 1AP2A1-1.0.50.000Rigulator complex protein LMTOR2LMTOR2-1.0.5N.0.IA-3-2 protein sets/ates intuin - 2SIRT2-1.0.50.0.00Rigulator complex framescing nuclear protein decomplex protein advices of the complex subunit alpha 1-0.0.40.0.13IA-3-2 protein sets/defaAP21-0.0.50.0.0Advictor of basal transcripton 1AF11-0.0.40.0.13IA-3-3 protein sets/defaMCMAPA-0.0.40.0.13Advictor of basal transcripton 1RCMAPAP-0.0.40.0.13Advictor of basal transcripton 1RCMAPAP-0.0.40.0.13Advicto				
Methers again to decagent algebraSMA05 SMA011.060.18With domain containing protein 1 homolog ARPA11.060.75Ribosonal FNA processing protein 1 homolog ARPA11.050.09Mitofusin 2MFA21.050.00Are 2 complex subunit alghe 1ACMAN4P2A11.050.00Ragulator complex protein MATORAMFA21.050.01Ragulator complex protein decarbyses situin 2MITORA1.060.03Mo-dependent protein decarbyses situin 2MITORA1.040.01Arbador of basic transcription 1Clinor731.040.03Arbador of basic transcription 1MCMA3AP1.040.03Arbador of basic transcription 1MCMA3AP1.040.01Alph-ketoplutrate-dependent floxygenase FTOFTO1.040.01Alph-ketoplutrate-dependent floxygenase FTOFTO1.040.04Proline synthase co-transcripte basterial proteinMASS1.040.04Mitochondral antiviral-ignaling proteinFKR21.030.00Wireprotein 1Proles synthase sociated proteinMASS1.040.04Proles synthase co-transcripte bastase stacted proteinFKR21.030.06Shrifter from from spate stacted proteinMASS1.030.06Shrifter from from spate stacted proteinMASS1.030.04Protein flox spate stacted proteinMASS1.030.04Protein flox spate stacted protein 1PRSAP11.030.04<				
YH domain-containing proteinYTHC11.060.75Exosome complex component RRPA5EXOSOP1.050.39Exosome tRPA5EXOSOP1.050.09Mihofusin-2EXOSOP1.050.00AP-2 complex subunit alpha-1AP2A11.050.00Regulator complex protein LMMT0R2LMMT0R21.050.03NAD-dependent protein descriptuse situin-2SIRT21.050.03Yorbein HikshiCillorf731.050.03Id-3-3 protein sets/deltaYWHZ1.040.01Advattor of basal fursarciption 1AB711.040.03Garuma-center associated nuclear proteinMCMAAP1.040.03Advattor of basal fursarciption 1MCMAAP1.040.03Garuma-center associated nuclear proteinMCMAP1.040.01Aph-k-toglutran-dependent MOP(s) synthetaseMCMAP1.040.01Aph-k-toglutran-dependent Mologing proteinFMO1.040.01Parlather IchanucleaseYEEY1.030.04Parlather IchanucleaseYEEY1.030.05Sartoffactor M-Rappa-B 100 subunit/Nuclear factor NF-kappa-B 52 subunitMRAS1.040.03Nuclear factor M-Rappa-B 100 subunit/Nuclear factor NF-kappa-B 52 subunitMRAS1.030.04Parlather Ichanus Brothanase RD2YEGP1.030.050.05Sartoffactor protein 3SGEP1.030.050.05Sartoffactor Sartoffactor Sartoffactor Sartoffactor Sartoffactor Sartoffactor Sartoffac	•			
Ribosone Complex ENAPS Essone complex Essone complex Enaps Essone complex Essone complex Essoe Essone complex Essoe complex Essoe complex Essoe complex Essoe complex Essoe Essoe complex Essoe complex E				
Exosone complex component RRPASNO0.090.09AP-2 complex subunit alpha-1AP2A-0.05ND.AP-2 complex subunit alpha-1AP2A-0.050.03NAD-dependent protein dacetylase sirtuin-2Sirt2-0.050.03NAD-dependent protein dacetylase sirtuin-2Sirt2-0.050.03NAD-dependent protein dacetylase sirtuin-2Sirt2-0.050.03SirtaClinor73-0.060.03L4-35 protein attackfultaYMA/A-0.040.05Gerninal-center associated nuclear proteinMCM ABAP-0.040.03Alpha-ktoptizarte dependent tanscription 1-0.040.030.03Alpha-ktoptizarte dependent davgenase FOFO-0.040.03Protein sitkaseMVK-0.040.030.03Mitchohnital anitral is proteinPROSC-0.040.03Protein sitkaseMVK-0.040.030.03Mitchohnital anitral is proteinMVS-0.040.03Protein sitkaseMVK-0.040.030.03Mitchohnital anitral is protein 26MVK-0.040.03Nuclear factor NF-kappa-B p103 subunit,Nuclear factor NF-kappa-B p52 subunitMVS2-0.03Nuclear factor MF-kappa-B p103 subunit,Nuclear factor NF-kappa-B p52 subunitMVR2-0.03Nuclear factor NF-kappa-B p103 subunit,Nuclear factor NF-kappa-B p1030.015-0.015Simitant anitral protein 1PROSC-0.030.015Simitant anitration protein 26MVC2 <td< td=""><td></td><td></td><td></td><td></td></td<>				
MicblandMRN2M.D.Abd 2 complex synchin Labba-1AP2A1-0.050.00Ragilator complex protein (LAMTOR2LAMTOR2-0.050.03BAD dependent protein deactylase situin-2SIR7-0.050.03Abd dependent protein deactylase situin-2SIR7-0.050.03Activator of basil transcription 1ATI1.040.03Activator of basil transcription 1ATI1.040.03Activator of basil transcription 1ATI1.040.03Adjactor of basil transcription 1ATI1.040.03Adjactor of basil transcription 1ATI1.040.03Adjactor of basil transcription 1ATI1.040.03Adjack activation dependent Molygenase FTOTTO1.040.01Parlative dependent Molygenase FTOFTO1.040.03Parlative donucleasePROSC-1.040.03Parlative donucleasePROSC-1.040.03Vortine syntame contrastrote detactral homolog proteinPROSC-1.030.06Vortine detactor Netwapase BpS2 subunitMAXS-1.040.03Nuclear factor Netwapase BpS2 subunitWDR2G-1.030.06Serine/furnenine protein factor Netwapase BpS2 subunitWDR2G-1.030.06Serine/furnenine protein factor NetwapaseSANP-1.030.06Serine/furnenine-grotein fanase NO2SANP-1.030.06Serine/furnenine-grotein fanase NO2SANP-1.030.06Serine/fur				
AP-2 complex subunt alpha-1AP2A1A.050.00Ragulator complex protein AlfAbriaLAMTOR2-0.050.13NAD dependent protein deactylase sirtuin-2Sirta-0.050.33Id-3-3 protein reta/defaCL1or77-0.050.33Id-3-3 protein reta/defaWHM2-1.040.03Artivator of basil transcription 1MCMIAP-1.040.03Giutamine-dependent MAD(-) synthetaseWKK-1.040.01Apha extoglutarite-dependent MAD(-) synthetaseWROS-1.040.01Apha extoglutarite-dependent divgenase FIOPTO-1.040.01Proline synthase co-transcribed bacterial homolog proteinPROS-1.040.01Proline synthase co-transcribed bacterial homolog proteinPCMI-1.040.04Muclear factor NF-kappa P.05-1.030.000.06Sinter/Introline protein 26WROR26-1.030.00WD repate-containing protein 3PKK2-1.030.06Sinter/Introline protein 1PCR21-1.030.04Profine S-carboxylate reductase 2PKC2-1.030.04Profine S-carboxylate reductase 2ActivatorPRSA11.030.04Profine S-carboxylate reductase 2PKC2-1.030.04Profine S-carboxylate reductase 2Activator-1.030.04Profine S-carboxylate reductase 2Activator-1.030.04Profine S-carboxylate reductase 2-1.030.04-1.030.04Profine S-carboxylate reduc				
RegulatorLAMTOR2LAMTOR2L.0.50.13NAD dependent protein dacatylase situin-2SIRT2-0.65N.D.Protein filkeshiClior/73-0.650.0312-33 ordein ceta/deltaWWHAZ-0.040.01Activator of basil transcripton 1MCMAIP-1.040.03Activator of basil transcripton 1MCMAIP-1.040.03Gutamine-dependent MAD(+) synthetaseMCMAIP1.040.03Aph-ketogUlarate-dependent doxygenase FTOFTO-1.040.01Palate or darascribed bacterial homolog proteinPROSC-1.040.03Palate or darascribed bacterial homolog proteinPROSC-1.040.03Nuclear factor NF-kappa-B p52 subunitMKR2-1.030.06VD repet-containing protein 2PCDR1-1.030.06Serine/furneonine protein phosphates synthase-asociated protein 1PROSC-1.030.06Serine/furneonine protein phosphates 2A activatorPPCR4-1.030.06Serine/furneonine protein phosphates 2A activatorPPCR4-1.030.06Serine/furneonine protein phosphates 2A activatorPPCR4-1.030.06Serine/furneonine-protein functionNDL2-1.030.06Serine/furneonine-protein functionNDL2-1.030.06Serine/furneonine-protein functionNDL2-1.030.06Serine/furneonine-protein functionNDL2-1.030.06Serine/furneonine-protein functionNDL2-1.030.06Se				
NAD dependent protein descriptise sirtuin-2SNPSNPN.D.14-3Orden HileshiClinor73-1.050.3314-3Arrotein zeta/delaYMHAZ-1.040.0114-3Arrotein zeta/delaARTI1.040.05Germinal-center associated nuclear proteinMCM3AP-1.040.01Archattor of basisMCN3AP-1.040.01Alpha-ktoglutariate-dependent HAD(+) synthetaseNADS/NII-1.040.01Alpha-ktoglutariate-dependent disxgenase FTOFTO-1.040.04Proline synthase co-transcribed bacterial homolog proteinPMSC-1.040.04Preinentional material a proteinPMSC-1.040.03Muclear factor NF-kappa-B pDS bunit, Nuclear factor NF-kappa-B pDS b				
protein filleshiC.1.0.1731.0.50.331.3-3 protein red/detaYH421.040.01Activator of basal transcription 1ART11.040.55Germinal-center associated nuclear proteinMCM3AP1.04N.D.Glutamine-dependent tAO(4) synthetaseMXX1.040.01Apha-ketogitarate-dependent taO(syngenase FTOFTO1.040.01Parlative infonucleaseYEFY1.040.01Proline synthase or transcribed bacterial homolog proteinPROSC1.040.04Pericentriolar material 1 proteinMXOS1.040.03Mutchondrian fange proteinPROSA1.030.00Nuclear factor NF-kappa-B p100 subunit/Nuclear factor NF-kappa-B p52 subunitNKR21.030.00Nuclear factor NF-kappa-B p100 subunit/Nuclear factor NF-kappa-B p52 subunitNKR21.030.05PolyCri-Dinding protein 1PRPSAP11.030.060.05Serine//fivenonine-protein phosphatase 2A activatorPPCR41.030.04Pyrroline-S-carboxylate reductase 2PCR21.030.04Serine/fivenonine-protein insea RO2RIOK21.03N.D.SAP domain-containing rotein 2PCR21.03N.D.SAP domain-containing rotein 1PCB41.020.02Serine/fivenonine-protein insea RO2RIOK21.03N.D.SAP domain-containing rotein 2PCR21.03N.D.SAP domain-containing rotein 10N.D.N.D.1.020.02Anino	· · ·			
14-3 protein zeh/detaYVHAZ1.040.05Activator of base intranscription 1ART1.040.55Germinal-center associated nuclear proteinMCM3AP1.040.28Mevalonate kinaseMAX1.040.01Alpha-ktoglutante-dependent dioxygenase FIOFTO1.040.19Alpha-ktoglutante-dependent dioxygenase FIOFTO1.040.01Alpha-ktoglutante-dependent dioxygenase FIOPKDSC1.040.04Proline synthase co-transcribed bacterial homolog proteinPKDSC1.040.04Preinerviorian material 1 proteinPKDSC1.040.03Muclear factor NF-kappa-B pDS bubit(Nuclear factor NF-kappa-B pDS				
Activator of basal transcription 1AST 11.040.55Germinal-center sociated nuclear proteinMCMAPP1.040.23Mevalonate kinaseMVK1.04N.D.Glutamine-dependent NAD(+) synthetaseN.D.1.040.01Aph-actegutarate-dependent nuclear sociated nuclear proteinPCD1.040.01Pulative nonucleaseYEF1.041.07Proline synthase cortanscribe dbacterial homolog proteinPCM11.040.48Mitochondrial antivral-signaling proteinMCM21.030.00Nuclear factor NF-kappa-B p100 subunit/Nuclear factor NF-kappa-B p52 subunitNKR21.030.00Nuclear factor NF-kappa-B p100 subunit/Nuclear factor NF-kappa-B p52 subunitNKR21.030.00More protein nuclear proteinPCM11.030.060.05Poly(C)-binding protein 2.2ActivatorPP2841.030.04Proteine-Schowlater reductase 2PCG21.03N.D.0.05Serine/Intronine-protein phosphates 2.4 scituatorPP2841.030.04Proteine-Schowlater reductase 2PCG21.03N.D.N.D.SAP domain-containing ribonucleoproteinN.D.C.N.D.N.D.Anino-terminal enhancer of splitAES1.020.02Anino-terminal enhancer of splitSCHAC1.020.03Anino-terminal enhancer of splitSCHAC1.020.03Anino-terminal enhancer of splitSCHAC1.020.03Anino-terminal enhancer of split <td< td=""><td></td><td></td><td></td><td></td></td<>				
Germinal-center associated nuclear proteinNCM3AP1.040.28Mevalonate KinaseNADSYN11.040.01Alpha-ktoglutartate-dependent (loxygenase FTOFTO1.040.01Alpha-ktoglutartate-dependent dioxygenase FTOYEFY1.040.01Proline synthase co-transcribed bacterial homolog proteinPROSC1.040.04Proline synthase co-transcribed bacterial homolog proteinPROSC1.040.04Mitochodrial antiviral-signaling proteinPROSC1.040.03Nuclear factor NA-kapa-B p100 subunit, Nuclear factor NF-kapa-B p52 subunitNFR621.030.00WD repeat-containing protein 5VDR261.030.04Phosphorbosyl prophosphate synthase-associated protein 1PRPSA11.030.06Serine/Intreonine-protein jopsphatase 2A activatorPP2RA1.030.06Serine/Intreonine-protein ing insoruceproteinSRNP1.030.05Serine/Intreonine-protein ing insoruceproteinSRNP1.020.05Serine/Intreonine-protein ing insoruceproteinSRNP1.020.06Serine/Intreonine-protein ing insoruceproteinSRNP1.020.06Serine/Intreonine-protein ing insoruceproteinSRNP1.020.06Serine/Intreonine-protein ing insoruceproteinSRNP1.020.06Selenide, water diknase 2SErine/Intreonine-protein ing insoruceprotein1.020.01Autio-exernina ing insoruceproteinSRNP1.020.02Selenide/Intreonine-protein infisoruceprotein<				
Mevalonate kinaseNVK1.04N.D.Gutamine-dependent ND(4) synthetaseNTG1.040.01Alpha-ketogikarate-dependent dioxygenase FTOFTO1.040.01Putative informuleaseYBEY1.040.04Proline synthase cortranscribe bacterial homolog proteinPROC1.040.04Pericentriolar material 1 proteinPROM1.040.04Pericentriolar material 1 proteinMAVS1.040.03Nuclear factor NF-kapa-B p100 subunit, Nuclear factor NF-kapa-B p52 subunitNFR021.030.00Nuclear factor NF-kapa-B p100 subunit, Nuclear factor	Activator of basal transcription 1	ABT1	-1,04	0,55
Glutamic-dependent MO(+) synthetaseNADSYN11.040.01Alpha-ketoglutariat-dependent dioxygenase FTOFTO1.040.01Proline synthase co-transcribed bacterial homolog proteinPROSC1.040.04Proline synthase co-transcribed bacterial homolog proteinPROSC1.040.04Proline synthase co-transcribed bacterial homolog proteinPROSC1.040.04Mitochodrial antiviral-signaling proteinMAVS1.040.03Muclear factor NA-kapa-B p100 subunit, Nuclear factor NA-hapa-B p100 subunit, Nuclear factor NA-hapa-B p1	Germinal-center associated nuclear protein	MCM3AP	-1,04	0,28
Alphä-ketoglutarate-dependent dioxygenase FTOFTO-1.040.19Proline synthase co-transcribed bacterial homolog proteinPROSC-1.040.04Proline synthase co-transcribed bacterial homolog proteinPROSC-1.040.04Pericentriciar material 1 proteinPCM1-1.040.04Nucher factor NF-kappa-B p100 subunit/Nuclear factor NF-kappa-B p52 subunitNKR2-1.030.071Wor prepact-containing protein 1PRFSAP1-1.030.055Poly(C)-binding protein 1PRFSAP1-1.030.066Serine/threonine-protein hopsphatase 2A activatorPPCR2-1.030.061Serine/threonine-protein hopsphatase 2A activatorPPCR2-1.030.061Nuclear receptor 2C2-associated proteinSARNP-1.03N.D.Nuclear receptor 2C2-associated proteinSARNP-1.03N.D.Nuclear receptor 2C2-associated proteinSARNP-1.03N.D.Nuclear receptor eliniaes R02SPIN2-1.020.051Serine/threonine-protein kinaseSMC2A-1.020.052Serine/threonine-protein kinaseSMC2A-1.020.051Serine/threonine-protein kinaseSMC2A-1.020.052Serine/threonine-protein kinaseSMC2A-1.020.051Serine/threonine-protein kinaseSMC2A-1.020.021Serine/threonine-protein kinaseSMC2A-1.020.021Serine/threonine-protein kinaseSMC2A-1.020.021Serine/threonine-protein kinase-1.02 <t< td=""><td>Mevalonate kinase</td><td>MVK</td><td>-1,04</td><td>N.D.</td></t<>	Mevalonate kinase	MVK	-1,04	N.D.
platter rbonucleaseVBEY-1.041.07Porline synthase or-transcribe bactrial homolog proteinPROSC-1.040.04Pericentriolar material 1 proteinPCM11.040.04Mitochondrial antiviral-signaling proteinNAVS-1.040.13Nuclear factor NF-kappa-B pDS subunit, Nuclear	Glutamine-dependent NAD(+) synthetase	NADSYN1	-1,04	0,01
Proline synthase co-transcribed bacterial homolog proteinPROSC-1.040.044Pericentriolar material 1 proteinPCM11.040.048Mitchondrial antivria-signaling proteinMAVS1.040.013Nuclear factor NF-kappa-B p100 subunit,Nuclear factor NF-kappa-B p52 subunitNFR82-1.030.071Phosphoribosyl pyrophosphate synthase-associated protein 1PRFSAP1-1.030.051Poly(rC)-binding protein 1PCBP1-1.030.066Serine/threonine-protein fusphatase 2A activatorPPP2A4-1.030.041Pyroline-S-carboxylate reductase 2Serine/threonine-protein fusphatase R102R10K2-1.03N.D.SAP domain-containing rithonucleoproteinSARNP-1.03N.D.N.D.Nuclear receptor 2C2-associated proteinRC2AP-1.020.051Selmio-threminal enhancer of splitAES-1.020.025Selmid-threoning at thinaseSEMP52-1.02N.D.Synembryn-AGalactocerebrosidaseGALC-0.020.14Adenytate kinase 4, mitochondrialAKA-1.020.014Adenytate kinase 4, mitochondrialSARCR7L-1.020.04Adenytate kinase 4, mitochondrialSGS11-1.010.056Serine/Aroning at factor 11SGS11-1.010.056Serine/Aroning thactor creceptor substrate 15-like 1SGS11-0.01N.D.Piedermal growth factor receptor substrate 15-like 1SGS11-0.01N.D.Piedermal growth factor receptor substrate 15-like 1	Alpha-ketoglutarate-dependent dioxygenase FTO	FTO	-1,04	0,19
pericentrollar material proteinPCMPL040.48Mitochondrial antiviral-signaling proteinMAVS1.040.13Muclear factor NF-kappa-B p20 subunit, Muclear factor NF-kappa-B p52 subunitMKR21.030.00WD repeat-containing protein 26WDR26-1.030.01Phosphoribosyl pryophosphates synthase-associated protein 1PCP1-1.030.06Serine/threonine-protein phosphatase 2A activatorPPP2R4-1.030.06Serine/threonine-protein phosphatase 2A activatorPPP2R4-1.03N.D.Serine/threonine-protein kinase RIO2SIGNN.D.N.D.SAP domain-containing ribonucleoproteinSIGN-1.03N.D.Nuclear receptor 2C-associated proteinNR2CAP-1.020.06Selenide, water dikinase 2SPH52-1.020.05Selm-brieducleoproteinNR2CAP-1.020.013Synembryn-ASIGRA-1.020.013Synembryn-ASIGRA-1.020.014Addenylate kinase 4, mitochondrial-1.020.013Synembryn-ASIGRA-1.020.014Addenylate kinase 4, mitochondrial-1.020.04Serine/argining factor 11SIGRA-1.020.04Serine/argining factor 12SIGRA-1.020.04Serine/argining factor 14-1.020.03-1.020.01Signembryn-ASIGRA-1.020.01-1.020.03Signembryn-ASIGRA-1.020.01-1.020.01 <t< td=""><td>Putative ribonuclease</td><td>YBEY</td><td>-1,04</td><td>1,07</td></t<>	Putative ribonuclease	YBEY	-1,04	1,07
pericentrollar material proteinPCMPL040.48Mitochondrial antiviral-signaling proteinMAVS1.040.13Muclear factor NF-kappa-B p20 subunit, Muclear factor NF-kappa-B p52 subunitMKR21.030.00WD repeat-containing protein 26WDR26-1.030.01Phosphoribosyl pryophosphates synthase-associated protein 1PCP1-1.030.06Serine/threonine-protein phosphatase 2A activatorPPP2R4-1.030.06Serine/threonine-protein phosphatase 2A activatorPPP2R4-1.03N.D.Serine/threonine-protein kinase RIO2SIGNN.D.N.D.SAP domain-containing ribonucleoproteinSIGN-1.03N.D.Nuclear receptor 2C-associated proteinNR2CAP-1.020.06Selenide, water dikinase 2SPH52-1.020.05Selm-brieducleoproteinNR2CAP-1.020.013Synembryn-ASIGRA-1.020.013Synembryn-ASIGRA-1.020.014Addenylate kinase 4, mitochondrial-1.020.013Synembryn-ASIGRA-1.020.014Addenylate kinase 4, mitochondrial-1.020.04Serine/argining factor 11SIGRA-1.020.04Serine/argining factor 12SIGRA-1.020.04Serine/argining factor 14-1.020.03-1.020.01Signembryn-ASIGRA-1.020.01-1.020.03Signembryn-ASIGRA-1.020.01-1.020.01 <t< td=""><td>Proline synthase co-transcribed bacterial homolog protein</td><td>PROSC</td><td>-1,04</td><td>0,04</td></t<>	Proline synthase co-transcribed bacterial homolog protein	PROSC	-1,04	0,04
Nitochordrial antiviral-signaling proteinMAG1.040.13Nuclear factor NF-kappa-B p100 subunit, Nuclear factor NF-kappa-B p52 subunitNFKB2-1.030.00WD repeat-containing protein 26WDR26-1.030.01Phosphoribosyl pyrophosphate synthase-associated protein 1PPPS-PA-1.030.06Serine/threonine-protein phosphatase 2A activatorPP2R2-1.030.04Pyrroline-S-carboxylate reductase 2ND.0ND.0Serine/threonine-protein finase RIO2-1.03ND.0SAP domain-containing ribonucleoproteinSARNOP-1.020.25-1.020.60Serine/threonine-protein Kinase RIO2SEPHS2-1.020.60-0.60Selenide, water dikinase 2SEPHS2-1.020.60-0.60Selenide, water dikinase 2SEPHS2-1.020.120.13Synembryn-ARICBA-1.020.13-0.13Synembryn-AGalatcocerbrosidaseGALC-1.020.14CalactocerbrosidaseSMCR7L-1.020.43Adenylate kinase 4, mitochondrialSMCR7L-1.020.43Adenylate kinase 4, mitochondrialSMCR7L-1.020.04Serine/Aregine-ric substrate 15-like 1SSF11-1.01ND.0Ubiquitin conjugation factor F4 BSSF11-1.010.06Serine/Aregine-ric hosphatase 2A 56 KDA regulatory subunit delta isoformPP2R50-1.010.06Serine/Aregine-ric hosphatase 2A 56 KDA regulatory subunit delta isoformSSF511-1.010.06 <tr< td=""><td></td><td>PCM1</td><td>-1,04</td><td>0,48</td></tr<>		PCM1	-1,04	0,48
Nuclear factor NF-kappa-8 p100 subunit, Nuclear factor NF-kappa-8 p52 subunitNKB21.030.00WD repeat-containing protein 26WDR26-1.030.71Phosphoribosyl prophosphate synthase-associated protein 1PKPSAP1-1.030.06Poly(1C)-binding protein 1CRB1-1.030.06Serine/threonine-protein phosphatse 2A activatorPKP2A4-1.030.06Serine/threonine-protein phosphatse 2A activatorPKC2-1.03N.D.Serine/threonine-protein phosphatse 2A activatorPKC2-1.03N.D.Serine/threonine-protein hinase RIO2SARMP-1.03N.D.Nuclear receptor 2C-associated proteinNR2CAP-1.020.050Selenide, water dikinase 2SEPHS2-1.020.012Selenide, water dikinase 2RICA-1.020.12GalactoreerborsidaseRICA-1.020.12GalactoreerborsidaseGALC-1.020.13Synembryn-ARICA-1.020.01Calenytate kinase 4, mitochondrialAK4-1.020.01Cassociated protein 16TMA16-1.020.03Canstation machinery-associated protein 16MATOR5-1.020.03Calenytate kinase 4, mitochondrialAK4-1.020.00Calenytate kinase 4, mitochondrialAK4-1.020.01Calenytate kinase 4, mitochondrialSSF11-1.010.05Endophilin A2UBS41-1.010.0260.01Calenytate kinase 4, mitochondrialSSF11-1	·	MAVS		
WD repet-containing protein 26WD2661.030.71Phosphoribosyl prophosphate synthase-associated protein 1PRSAP11.030.15Poly(rC)-binding protein 1PCBP1-1.030.06Serine/futreonine-protein phosphatase 2A activatorPPCR2-1.030.06Serine/futreonine-protein kinase RO2RIOK2-1.03N.D.SAP domain-containing ribonucleoproteinNR02-1.03N.D.Nuclear receptor 2C2-associated proteinNR2C2AP-1.020.25Amino-terminal enhancer of splitSE PMS2-1.020.60Serine/futreonine-protein kinaseSEPMS2-1.020.01Synembryn-ARICSA-1.020.010.12GalactocerbrsidaseSEPMS2-1.020.010.12GalactocerbrsidaseGALC-1.020.040.12Adenylate kinase 4, mitochondrialAK4-1.020.000.06Adenylate kinase 4, mitochondrialAK4-1.010.060.5Serine/futreonine-protein LAMTOR5LIC0.01N.D.0.00CalegatocerbrsidaseUBE48-1.010.060.00Serine/futreonine-protein phosphatase 2A 56 kDa regulatory subunit delta isoformPRST9-1.010.00Serine/futreonine-protein phosphatase 2A 56 kDa regulatory subunit delta isoformPRST9-1.01N.D.Protein SST9FS1-1.010.020.070.07Protein SST9SF1-1.010.000.070.07Complement factor H <t< td=""><td></td><td></td><td></td><td></td></t<>				
Phosphoribosyl pyrophosphate synthase-associated protein 1PRPSAP1-1.030.15Poly(C)-binding protein 1PCB1-1.030.06Serine/threonine-protein phosphatase 2A activatorPPP2R4-1.030.04Pyrroline-5-carboxylate reductase 2PCR2-1.030.15SAP domain-containing ribonucleoproteinSARNP-1.03N.D.SAP domain-containing ribonucleoproteinSARNP-1.020.25Amino-terminal enhancer of splitAES-1.020.60Selenide, water dikinase 2SPP1S2-1.020.13Synembyn-ARICSA-1.020.13Synembyn-ARICSA-1.020.12GalactocerebrosidaseGALC-1.020.14Adenylate kinase 4, mitochondrialAK4-1.020.00Argulator complex protein 16MALG-1.020.04Adenylate kinase 4, mitochondrialAK4-1.020.00Bredge protein LAMTOR5LAMTOR5-1.020.43Endophilin-A2UBGR1-1.01N.D.0.66Serine/threonine-protein phosphatase 2A S6 K0a regulatory subunit deta isoformPPP2R5D-1.010.06Serine/threonine-protein S79-5.64-1.010.060.07Protein S79-1.01N.D.0.070.070.00Protein S79-1.01N.D.0.060.070.00Protein S79-1.01N.D.0.060.070.01Protein S79-1.01N.D.0.060.010.06 <td></td> <td></td> <td></td> <td></td>				
Poly(rC)-binding protein 1 PCBP1 -1.03 0.06 Serine/fibreonine-protein phosphatase 2A activator PPPRA -1.03 0.04 Serine/fibreonine-protein phosphatase R02 RIOK2 -1.03 N.D. SAP domain-containing ribonucleoprotein NADE N.D. N.D. Nuclear receptor ZC2-associated protein NR2C2AP -1.02 0.25 Amino-terminal enhancer of split AES -1.02 0.60 Selenide, water dikinase SEPHS2 -1.02 0.13 BMP-2-inducible protein kinase SEPHS2 -1.02 0.13 Synembryn-A RICBA -1.02 0.13 Galactocerebrosidase GALC -1.02 0.12 Translation machinery-associated protein 16 TMA16 -1.02 0.04 Adenylate kinase 4, mitochondrial K44 -1.02 0.04 Regulator complex protein LAMTOR5 LAMTOR5 -1.02 0.08 Endophilin-A2 UBEAB -1.01 N.D. Ubiquitin conjugation factor E4 B UBEAB -1.01 0.02				
Serine/threonine-protein phosphatase 2A activatorPP22A-1,030,04Pyrroline-5-carboxylate reductase 2PYCR21,030,16Serine/threonine-protein hanse RIO2RIOK21,03N.D.SAP domain-containing ribonucleo proteinSAR MNP-1,020,25Amino-terminal enhancer of spitAES1,020,60Selenid/theonile protein kinaseBMP2-2rinducible protein kinase1,020,01Synempyn-ABMP2-2rinducible protein kinaseBMP2-2rinducible protein kinase0,120,13Synempyn-ARICBA-1,020,120,12GalactocerebrosidaseTMA16-1,020,13Translation machinery-associated protein 16TMA16-1,020,04Adenylate kinase 4, mitochondrialSMCR7-1,020,04Langulator complex protein LAMTOR5LAMTOR51,020,08Endophiln-A2UBE48-1,020,080,06Serine/traginine-rich splicing factor 11SMCR7-1,020,36Serine/traginine-rich splicing factor 11SMCR7-1,010,26Serine/traginine-rich splicing factor 11SMCR7-1,010,26Serine/traginine-rich splicing factor 11SMCR7-1,010,26Serine/traginine-rich splicing factor 11SMCR7-1,010,00Serine/traginine-rich splicing factor 11SMCR7-1,010,00Serine/traginine-rich splicing factor 11SMCR7-1,010,00Serine/traginine-rich splicing factor 11SMCR7-1,01				
Pyrroline-5-carboxylate reductase 2PYCR21.030.16Serine/fibreonine-protein kinase RIO2RIOK21.03N.D.SAP domain-containing ribonucleoproteinSARNP1.020.25Amino-terminal enhancer of splitAES1.020.60Selenide, water dikinaseSEPH521.020.13BMP-2-inducible protein kinaseBMP2K1.020.13Synembryn-AGALC1.020.11GalactocerebrosidaseGALC1.020.14Adenylate kinase 4, mitochondrialMA161.020.43Ragulator complex protein LAMTOR5LMTOR51.020.08Endophilin-A2SH3GL1.010.66Serine/arginine-rich splitase 2A.56 kDa regulatory subunit delta isoformPP2R5D1.010.02Regulator complex protein protein protein splitase 2A.56 kDa regulatory subunit delta isoformPP2R5D1.010.06Serine/arginine-rich splitarg factor 11SR5111.010.260.07Complex protein S79ZNF5791.01N.D.0.07Pre-rRNA-processing protein TSR1 homologTSR11.010.06Serine/arginine-rich splitarg factor 11SR5111.01N.D.Putative transferaseCFH7, mitochondrialCFH1.01N.D.Pre-rRNA-processing protein TSR1 homologZNF5791.01N.D.Pre-rRNA-processing protein TSR1 homologST1.01N.D.Pre-rRNA-processing protein ZKFM21.00N.D.Pre-rRNA-protein S79<				
Serine/threonine-protein kinase RIO2RIOK2-1,03N.D.SAP domain-containing ribonucleoproteinSARWP-1,03N.D.Nuclear receptor 2C2-associated proteinNR2C2AP-1,020,25Amino-terminal enhancer of splitAES-1,020,60Selenide, water dikinase 2BMP-2-inducible protein kinaseSEPH52-1,020,13Synembryn-ARICBA-1,020,130,13GalactocerebrosidaseGALC-1,020,140,14Adenylate kinase 4, mitochondrialAK4-1,020,00Regulator complex protein LAMTOR5LAMTOR5-1,020,00Endophilin-A2UBE48-1,010,06Ubiquitin conjugation factor E4 BEpidermal growth factor receptor substrate 15-like 1EPS1511-1,010,06Serine/arginine-rich splicing factor 11Serine/arginine-rich splicing factor 11SRSF11-1,010,06Serine/arginine-rich splicing factor 11SRSF11-1,010,260,07Complement factor F4Epidermal growth factor receptor substrate 15-like 1EPS1511-1,010,06Serine/arginine-rich splicing factor 11SRSF11-1,010,060,07Complement factor HFCH02-1,010,070,07Complement factor HCFH-1,010,000,07Protein LSM14 homolog ATista-1,010,000,07Complement factor HCFH-1,01N.D.0,00Serine/threonine-protein in Sta homolog ATista<				
SAP domain-containing ribonucleoproteinSARNP-1,03N.D.Nuclear receptor 2C2 associated proteinNR2C2AP-1,020,25Amion-terminal enhancer of splitAES-1,020,60Selenide, water dikinase 2SEPH52-1,02N.D.BMP-2 -inducible protein kinaseBMP2X-1,020,13Synembryn-ARICBA-1,020,51GalactocerebrosidaseGALC-1,020,51Translation machinery-associated protein 16TMA16-1,020,04Adenylate kinase 4, mitochondrial-1,020,43-1,020,43Ragulator complex protein LAMTOR5LAMTOR5-1,020,43Endophilin-A2UBE48-1,010,06Evine/praginine-rich splicing factor 11SSCR71-1,010,06Serine/transplicing factor 13SSF11-1,010,06Serine/transplicing factor 11SSF11-1,010,06Serine/transplicing factor 11SSF11-1,010,06Serine/transplicing factor 13SAF37-1,010,10Pre-rRNA-processing protein TSR1 homologTSR1-1,010,07Complement factor 14FCH02-1,01N.D.0,07Putative transferase CAF17, mitochondrialIBA57-1,01N.D.Putative transferase CAF17, mitochondrialISA14A-1,010,007Complement factor 14FCH02-1,01N.D.N.D.Putative transferase CAF17, mitochondrialISA57-1,01N.D.Coluta cari				
Nuclear receptor 2C2-associated proteinNR2C2AP-1,020,025Amino-terminal enhancer of splitAES-1,020,60Sclenide, water dikinase 2SEPH52-1,020,13BMP-2-inducible protein kinaseBMP2K-1,020,13Synembryn-ARICBA-1,020,12GalactocerebrosidaseGALC-1,020,51Translation machinery-associated protein 16TMA16-1,020,014Adenylate kinase 4, mitochondrialAK4-1,020,00Ragulator complex protein LAMTOR5LAMTOR5-1,020,08Endophilin-A2UBE48-1,01N.D.Ubiquitin conjugation factor E4 BUBE48-1,010,26Serine/dregraginne-rich splicing factor 11SRSF11-1,010,06Serine/dregraginine-rich splicing factor 11SRSF11-1,010,06Serine/dregraging factor 13SRSF11-1,010,06Serine/dregraging factor 14IBA57-1,01N.D.Putative transferase CAF17, mitochondrialIBA57-1,01N.D.Protein ISM14 homolog ATST-1,01N.D.0,09Thiosulfate sulfurtransferaseTST-1,01N.D.Serine/threonine-protein kinase Nek7NEK7-1,01N.D.Solute carrier family 35 member F2ATSM2-1,000,014Atmain-2NEK7-1,01N.D.N.D.Serine/threonine-protein kinase Nek7NEK7-1,01N.D.Solute carrier family 35 member F2ATSM2				
Amino-terminal enhancer of splitAES-1,020,60Selenide, water diknase 2SEPH52-1,02N.D.Selenide, water diknase 2SEPH52-1,020,13ShP-2-inducible protein kinaseBMP2-X0,120,13Synembryn-ARIC8A-1,020,12GalactocerebrosidaseGALC-1,020,51Translation machinery-associated protein 16TMA16-1,020,04Adenylate kinase 4, mitochondrialAK4-1,020,04Adenylate kinase 4, mitochondrialAK4-1,020,08Endophilin-A2SH3GL1-1,01N.D.Ubiquitin conjugation factor E4 BUBE48-1,010,28Epridermal growth factor receptor substrate 15-like 1SRF11-1,010,06Serine/arginine-rich splicing factor 11SRF511-1,010,06Serine/arginine-rich splicing factor 11SRF511-1,010,26Serine/arginine-rich splicing factor 11SRF519-1,010,10Pre-rRNA-processing protein TSR1 homologTSR1-1,010,26Zinc finger protein 579-1,01N.D.N.D.Protein SM14 homolog ALSM14A-1,010,00Serine/threonine-protein ing protein 2FCHO2-1,01N.D.Protein SM14 homolog ALSM14A-1,010,00Serine/threonine-protein ing protein 1ARMC1-1,01N.D.Soluta carrier family 35 member F2SIC35F2-1,01N.D.Armadillo repeat-containing protein 1				
Selenide, water dikinase 2SEPH52-1,02N.D.BMP-2:Inducible protein kinaseBMP2 K-1,020,13Synembryn-ARIC8A-1,020,12GalactocerebrosidaseGALC-1,020,11Translation machinery-associated protein 16TMA16-1,020,14Adenylate kinase 4, mitochondrialAK41,020,00Ragulator complex protein LAMTOR5LAMTOR5-1,020,43Ragulator complex protein LAMTOR5LAMTOR5-1,020,08Endophilin-A2SH3G11-1,01N.D.Ubiquitin conjugation factor E4 BUBE48-1,010,26Epidermal growth factor receptor substrate 15-like 1SRF11-1,010,06Serine/arginine-rich splicing factor 11Strate 15-like 1-1,010,06Serine/brieronine-protein fNSt1 homologTSR1-1,010,06Zinc finger protein 5791,01N.D.0,07Pre-rRNA-processing protein TSR1 homologTSR1-1,01N.D.Putative transferase CAF17, mitochondrialIBA57-1,01N.D.Protein LSM14 homolog ALSM14A-1,010,00Thiosulate sulfurtransferaseSIC35F2-1,01N.D.Solute carrier family 35 member F2SLC35F2-1,01N.D.N.D.Atxin-2N.D.N.D.Ribonuclease inhibitorSAFB-1,000,15Scaffold attachment factor B1N.D.N.D.Atxin-2Ribonuclease inhibitorSAFB-1,000,15Scaffold attachment fac				
BMP-2-inducible protein kinaseBMP2K-1,020,13Synembryn-ARIC8A-1,020,12GalactocerebrosidaseGALC-1,020,51Translation machinery-associated protein 16TMA16-1,020,14Adenylate kinase 4, mitochondrialAK4-1,020,00Ragulator complex protein LAMTOR5LAMTOR5-1,020,43Endophilin-A2LAMTOR5-1,020,08Ubiquitin conjugation factor E4 BUBE48-1,010,26Epidermal growth factor receptor substrate 15-like 1SRSF11-1,010,56Serine/arginine-rich splicing factor 11SRSF11-1,010,06Serine/arginine-rich splicing factor 11SRSF11-1,010,26Zinc finger protein 579-1,010,100,10Pre-RNA-processing protein TSR1 homologTSR1-1,010,07Complement factor HCH02-1,01N.D.Putative transferase CAF17, mitochondrialIBA57-1,010,00Serine/arginine-protein hase Nek7SIC35F2-1,01N.D.Serine/argining protein 2CFH-1,01N.D.Putative transferase CAF17, mitochondrialSIC35F2-1,010,00Serine/threonine-protein factor HSIC35F2-1,01N.D.Serine/threonine-protein ing protein 1ARMC1-1,01N.D.Atxin-2NEk7-1,01N.D.N.D.Serine/threonine-protein factor HO00,15Saffold attachment factor B1N.D.Atxi				
Synembryn-ARIC8A-1,020,12GalactocerebrosidaseGALC-1,020,51Translation machinery-associated protein 16TMA16-1,020,01Adenylate kinase 4, mitochondrialAK4-1,020,00SMCR7L-1,020,43Ragulator complex protein LAMTOR5LAMTOR5-1,020,43Endophilin-A2UBE48-1,01N.D.Ubiquitin conjugation factor E4 BUBE48-1,010,56Serine/Arreceptor substrate 15-like 1EPS15L1-1,010,56Serine/Arreceptor substrate 15-like 1SRSF11-1,010,06Serine/Arreprotein phosphatase 2A 56 kDa regulatory subunit delta isoformPPP2RSD-1,010,10Pre-rRNA-processing protein TSR1 homologTSR1-1,010,26Zinc finger protein 579TSR1-1,010,070,07Complement factor HCFH-1,010,070,07Complement factor HCFH-1,010,070,07Complement factor HCFH-1,010,070,00Serine/Artheonine-protein kinase Nek7SIC35F2-1,01N.D.Solute carrier family 35 member F2SLC35F2-1,01N.D.Artaxin-2RXN2-1,00N,D.N.D.Ribonuclease inhibitorSAFB-1,000,03Methol-projeti ci-trans isomerase FKBP2MECP2-1,00N,D.Petidyl-prolyl (ci-trans isomerase FKBP2MECP2-1,00N,D.0,03Methol-projetiase 10,027 <td></td> <td></td> <td></td> <td></td>				
GalactocerebrosidaseGALC-1,020,51Translation machinery-associated protein 16TMA16-1,020,14Adenylate kinase 4, mitochondrialAK4-1,020,00SMCR7L-1,020,03Ragulator complex protein LAMTOR5LAMTOR5-1,020,08Endophilin-A2SH3G11-1,01N.D.Ubiquitin conjugation factor E4 BUBE4B-1,010,28Epidermal growth factor receptor substrate 15-like 1SPS11-1,010,06Serine/arginine-rich splicing factor 11SPS11-1,010,06Serine/threonine-protein phosphatase 2A 56 kDa regulatory subunit delta isoformPPP2R5D-1,010,10Pre-rRNA-processing protein TSR1 homologTSR1-1,010,26Zinc finger protein 579-1,01N.D.N.D.Putative transferase CAF17, mitochondrialBAS7-1,01N.D.Complement factor HCFH-1,01N.D.Protein LSM14 homolog AISM14A-1,010,00Thiosulfate sulfurtransferaseSIC35F2-1,01N.D.Solute carrier family 35 member F2SLC35F2-1,01N.D.Ataxin-2RNMC1-1,000,14Atixin-2Ribonuclease inhibitorSAFB-1,000,03Methoning protein 1ARL-1,000,04Atixin-2KSP2-1,00N.D.Petidyl-prolyl cis-trans isomerase FKBP2KFRP2-1,000,03Methonine aninopeptidase 1METAP1-1,000,03<				
Translation machinery-associated protein 16TMA16-1,020,14Adenylate kinase 4, mitochondrialAK4-1,020,00SMCR7L-1,020,43Ragulator complex protein LAMTOR5LAMTOR5-1,020,43Endophilin-A2LAMTOR5-1,01N.D.Ubiquitin conjugation factor E4 BUBE48-1,010,28Epidermal growth factor receptor substrate 15-like 1SRSF11-1,010,06Serine/arginine-rich splicing factor 11SRSF11-1,010,06Serine/arginine-rich splicing factor 11SRSF11-1,010,10Pre-rRNA-processing protein TSR1 homologTSR1-1,010,26Zinc finger protein 579SrN579-1,010,07Putative transferase CAF17, mitochondrialIBA57-1,010,07Complement factor HCFH-1,010,00Protein LSM14 homolog ATST-1,010,00Serine/threonine-protein kinase Nek7SIC35F2-1,01N.D.Solte carrier family 35 member F2SIC35F2-1,01N.D.Armadillo repeat-containing protein 2ATXN2-1,000,114Ribonuclease inhibitorSAFB-1,000,015Scaffold attachment factor B1SAFB-1,000,03Methonine aminopeptidase 1KFP2-1,000,03				
Adenylate kinase 4, mitochondrialAK4-1,020,00SMCR7L-1,020,43Ragulator complex protein LAMTOR5LAMTOR5-1,020,08Endophilin-A2SH3GL1-1,01N.D.Ubiquitin conjugation factor E4 BUBE48-1,010,28Epidermal growth factor receptor substrate 15-like 1EPS15L1-1,010,06Serine/Arginine-rich splicing factor 11SRSF11-1,010,06Serine/Arteonine-protein phosphatase 2A 56 kDa regulatory subunit delta isoformPPP2R5D-1,010,10Pre-RNA-processing protein TSR1 homologTSR1-1,010,26Zin Ginger protein 579ZNF579-1,01N.D.P-BAR domain only protein 2PhotomodrialIBA57-1,01N.D.Putative transferase CAF17, mitochondrialIBA57-1,010,00Complement factor HCFH-1,010,00N.D.Protein ISM14 homolog AISM14A-1,010,00Serine/Arteonine-protein kinase Nek7NEK7-1,01N.D.Solute carrier family 35 member F2SLC35F2-1,01N.D.Artaxin-2ATXN2-1,000,15Scaffold attachment factor B1SAFB-1,000,03Methonine protein 51SAFB-1,000,03Methonine aminopeptidase 1KKP2-1,000,03				
SMCR7L-1,020,43Ragulator complex protein LAMTOR5-1,020,08Endophilin-A2SH3GL1-1,01N.D.Ubiquitin conjugation factor E4 BUBE4A-1,010,28Epidermal growth factor receptor substrate 15-like 1SPS1L1-1,010,56Serine/Arginine-rich splicing factor 11SRSF11-1,010,06Serine/Arginine-rich splicing factor 11SRSF11-1,010,06Serine/Arprocessing protein TSR1 homologTSR1-1,010,26Zinc finger protein 579ZNF579-1,01N.D.F-BAR domain only protein 2CH02-1,01N.D.Putative transferase CAF17, mitochondrialIBAS7-1,010,00Complement factor HCFH-1,01N.D.Protein ISM14 homolog AISM14A-1,010,00Serine/Artheonine-protein kinase Nek7NEK7-1,01N.D.Solute carrier family 35 member F2SLC3SF2-1,01N.D.Artaxin-2RNH1-1,000,15Scaffold attachment factor B1ARNC1-1,01N.D.Artaxin-2MCP2-1,000,03Metholonig protein 58SAFB-1,000,03Metholonig protein 59SAFB-1,000,03				
Ragulator complex protein LAMTOR5LAMTOR5-1,020,08Endophilin-A2SH3GL1-1,01N.D.Ubiquitin conjugation factor E4 BUBE48-1,010,28Epidermal growth factor receptor substrate 15-like 1SR5F11-1,010,06Serine/arginine-rich splicing factor 11SRSF11-1,010,06Serine/arginine-rich splicing factor 11SRSF11-1,010,06Protein 579-1,01N.D.FGPO2-1,01N.D.Putative transferase CAF17, mitochondrialIBAS7-1,01N.D.Protein ISM14 homolog AISM14A-1,01N.D.O,007Complement factor HCFH-1,01N.D.Solute carrier family 35 member F2SC35F2-1,01N.D.Armadillo repeat-containing protein 1ARMC1-1,000,15Scaffold attachment factor B1SAFB-1,000,03Methyl-Cg6-binding protein 2FKBP2-1,000,03Methyl-Cg6-binding protein 2<	Adenylate kinase 4, mitochondrial			
Endophilin-A2SH3GL1-1,01N.D.Ubiquitin conjugation factor E4 BUBE48-1,010,28Epidermal growth factor receptor substrate 15-like 1EP515L1-1,010,06Serine/arginine-rich splicing factor 11SRSF11-1,010,06Serine/arginine-rich splicing factor 11SRSF11-1,010,06Serine/arginine-rich splicing factor 11SRSF11-1,010,10Pre-rRNA-processing protein TSR1 homologTSR1-1,010,26Zinc finger protein 579-1,01N.D.N.D.Putative transferase CAF17, mitochondrialIBA57-1,010,07Complement factor HCFH-1,01N.D.Protein LSM14 homolog AISM14A-1,010,09Thiosulffact suffurtansferaseTST-1,01N.D.Serine/threonine-protein kinase Nek7NEK7-1,01N.D.Soluce carrier family 35 member F2SLC35F2-1,01N.D.Armadillo repeat-containing protein 1ATXN2-1,000,14Ribonuclease inhibitorRNH1-1,000,15Scaffold attachment factor B1SAFB-1,000,03Methionine aminopeptidase 1KKP2-1,000,03				
Ubiquitin conjugation factor E4 BUBE4B-1,010,28Epidermal growth factor receptor substrate 15-like 1FPS15L1-1,010,56Serine/hreenine-rich splicing factor 11SRSF11-1,010,06Serine/hreenine-protein phosphatase 2A 56 kDa regulatory subunit delta isoformPPP2R5D-1,010,01Pre-rRNA-processing protein TSR1 homologTSR1-1,010,26Zinc finger protein 579ZNF579-1,01N.D.Putative transferase CAF17, mitochondrialIBAS7-1,010,07Complement factor HCFH-1,01N.D.Protein ISM14 homolog AISM14A-1,010,09Thiosulfate sulfurtransferaseTST-1,010,00Serine/threenine-protein kinase Nek7NEK7-1,01N.D.Solute carrier family 35 member F2SLC35F2-1,01N.D.Attaxin-2ATXN2-1,000,14Ribonuclease inhibitorRNH1-1,000,15Scaffold attachment factor B1SAFB-1,000,08Methionine aminopeptidase 1KKP2-1,000,03	Ragulator complex protein LAMTOR5	LAMTOR5	-1,02	0,08
Epidermal growth factor receptor substrate 15-like 1EPS15L1-1,010,56Serine/arginine-rich splicing factor 11SR5 f11-1,010,06Serine/threonine-protein phosphatase 2A 56 kDa regulatory subunit delta isoformPP2R5D-1,010,10Pre-rRNA-processing protein TSR1 homologTSR1-1,010,26Zinc finger protein 579ZNF579-1,01N.D.F-BAR domain only protein 2CHO2-1,010,07Outputster transferase CAF17, mitochondrialIBAS7-1,010,07Complement factor HCFH-1,010,00Protein LSM14 homolog AISM14A-1,010,00Serine/threonine-protein kinase Nek7NEK7-1,01N.D.Solute carrier family 35 member F2SLC35F2-1,01N.D.Ataxin-2ATXN2-1,000,15Scaffold attachment factor B1SAFB-1,000,08Methoning protein 2MECP2-1,000,08Methoning protein 57FKBP2-1,000,03			-1,01	
Serine/arginine-rich splicing factor 11SRSF11-1,010,06Serine/threonine-protein phosphatase 2A 56 kDa regulatory subunit delta isoformPP2R5D-1,010,10Pre-rRNA-processing protein TSR1 homologTSR1-1,010,26Zinc finger protein 759ZNF579-1,01N.D.F-BAR domain only protein 2FCHO2-1,01N.D.Putative transferase CAF17, mitochondrialIBAS7-1,010,07Complement factor HCFH-1,01N.D.Protein ISM14 homolog ALISM14A-1,010,09Thiosulfate sulfurtransferaseTST-1,01N.D.Serine/threonine-protein kinase Nek7NEK7-1,01N.D.Soluce carrier family 35 member F2SC35F2-1,01N.D.Armadillo repeat-containing protein 1ARMC1-1,000,15Scaffold attachment factor B1SAFB-1,000,08Methyl-CpG-binding protein 2KEP2-1,000,03Methionine aminopeptidase 1KEP2-1,000,03		UBE4B	-1,01	0,28
Serine/threonine-protein phosphatase 2A 56 kDa regulatory subunit delta isoformPPP2R5D-1,010,10Pre-rRNA-processing protein TSR1 homologTSR1-1,010,26Zinc finger protein 579ZNF579-1,01N.D.F-BAR domain only protein 2FCH02-1,01N.D.Putative transferase CAF17, mitochondrialIBA57-1,010,07Complement factor HCFH-1,01N.D.Protein LSM14 homolog ALSM14A-1,010,09Thiosulfate sulfurtransferaseTST-1,011N.D.Serine/threonine-protein kinase Nek7NEK7-1,011N.D.Solute carrier family 35 member F2SLC35F2-1,011N.D.Armadillo repeat-containing protein 1ATXN2-1,0000,14Ribonuclease inhibitorRNH1-1,0000,15Scaffold attachment factor B1SAFB-1,0000,03Methionine aminopeptidase 1KKP2-1,0000,03	Epidermal growth factor receptor substrate 15-like 1	EPS15L1	-1,01	0,56
Pre-rRNA-processing protein TSR1 homolog TSR1 -1,01 0,26 Zinc finger protein 579 ZNF579 -1,01 N.D. F-BAR domain only protein 2 FCHO2 -1,01 N.D. Putative transferase CAF17, mitochondrial IBAS7 -1,01 N.D. Putative transferase CAF17, mitochondrial IBAS7 -1,01 N.D. Complement factor H CFH -1,01 N.D. Protein ISM14 homolog A ISM14A -1,01 0,09 Thiosulfate sulfurtransferase TST -1,01 0,00 Serine/threonine-protein kinase Nek7 NEK7 -1,01 N.D. Solute carrier family 35 member F2 SLC3SF2 -1,01 N.D. Attaxin-2 Attaxin-2 -1,00 0,14 Ribonuclease inhibitor RNH1 -1,00 0,15 Scaffold attachment factor B1 SAFB -1,00 0,08 Methyl-prolyl cis-trans isomerase FKBP2 FKBP2 -1,00 0,03	Serine/arginine-rich splicing factor 11	SRSF11	-1,01	0,06
Pre-rRNA-processing protein TSR1 homolog TSR1 -1,01 0,26 Zinc finger protein 579 ZNF579 -1,01 N.D. F-BAR domain only protein 2 FCHO2 -1,01 N.D. Putative transferase CAF17, mitochondrial IBAS7 -1,01 N.D. Putative transferase CAF17, mitochondrial IBAS7 -1,01 N.D. Complement factor H CFH -1,01 N.D. Protein ISM14 homolog A ISM14A -1,01 0,09 Thiosulfate sulfurtransferase TST -1,01 0,00 Serine/threonine-protein kinase Nek7 NEK7 -1,01 N.D. Solute carrier family 35 member F2 SLC35F2 -1,01 N.D. Attaxin-2 ATX0 ATX1 N.D. Ribonuclease inhibitor RNH1 -1,00 0,15 Scaffold attachment factor B1 SAFB -1,00 0,03 Metholnine aminopeptidase 1 MECP2 -1,00 0,03	Serine/threonine-protein phosphatase 2A 56 kDa regulatory subunit delta isoform	PPP2R5D	-1,01	0,10
Zinc finger protein 379 -1,01 N.D. F-BAR domain only protein 2 FCH 02 -1,01 N.D. Putative transferase CAF17, mitochondrial IBA57 -1,01 0,07 Complement factor H CFH -1,01 N.D. Protein ISM14 homolog A ISM14A -1,01 0,09 Thiosulfate sulfurtransferase TST -1,01 0,00 Serine/threonine-protein kinase Nek7 NEK7 -1,01 N.D. Solute carrier family 35 member F2 SLC35F2 -1,01 N.D. Armadillo repeat-containing protein 1 ARMC1 -1,01 N.D. Ataxin-2 ATXN2 -1,00 0,14 Ribonuclease inhibitor SAFB -1,00 0,15 Scaffold attachment factor B1 MECP2 -1,00 0,08 Methyl-CpG-binding protein 2 FKBP2 -1,00 0,03 Methionine aminopeptidase 1 METAP1 -1,00 0,27		TSR1		
F-BAR domain only protein 2 FCHO2 -1,01 N.D. Putative transferase CAF17, mitochondrial IBAS7 -1,01 0,07 Complement factor H CFH -1,01 N.D. Protein ISM14 homolog A ISM14A -1,01 0,09 Thissulfate sulfurtransferase TST -1,01 N.D. Serine/threonine-protein kinase Nek7 NEK7 -1,01 N.D. Solute carrier family 35 member F2 SC35F2 -1,01 N.D. Armadillo repeat-containing protein 1 ARMC1 -1,01 N.D. Ataxin-2 ATXN2 -1,00 0,14 Ribonuclease inhibitor SAFB -1,00 0,15 Scaffold attachment factor B1 SAFB -1,00 0,08 Methyl-CpG-binding protein 2 MECP2 -1,00 0,03 Methonine aminopeptidase 1 METAP1 -1,00 0,027				
Putative transferase CAF17, mitochondrial IBA57 -1,01 0,07 Complement factor H CFH -1,01 N.D. Protein LSM14 homolog A LSM14A -1,01 0,09 Thiosulfate sulfurtransferase TST -1,01 0,00 Serine/threonine-protein kinase Nek7 NEK7 -1,01 0,00 Solute carrier family 35 member F2 SLC35F2 -1,01 N.D. Armadillo repeat-containing protein 1 ARMC1 -1,01 N.D. Ataxin-2 ATXN2 -1,000 0,14 Ribonuclease inhibitor RNH1 -1,000 0,015 Scaffold attachment factor B1 SAFB -1,000 0,015 Petidyl-prolyl cis-trans isomerase FKBP2 FKBP2 -1,000 N.D. Methionine aminopeptidase 1 METAP1 -1,000 0,031				
Complement factor H CFH -1,01 N.D. Protein LSM14 homolog A LSM14A -1,01 0,09 Thiosulfate sulfurtransferase TST -1,01 0,00 Serine/threonine-protein kinase Nek7 NEK7 -1,01 N.D. Solute carrier family 35 member F2 SLC35F2 -1,01 N.D. Armadillo repeat-containing protein 1 ARMC1 -1,01 N.D. Ataxin-2 ATXN2 -1,00 0,14 Ribonuclease inhibitor RNH1 -1,00 0,15 Scaffold attachment factor B1 SAFB -1,00 0,08 Methyl-CpG-binding protein 2 MECP2 -1,00 0,03 Methylonic aminopeptidase 1 METAP1 -1,00 0,27				
Protein LSM14 homolog A LSM14A -1,01 0,09 Thiosulfate sulfurtransferase TST -1,01 0,00 Serine/threonine-protein kinase Nek7 NEK7 -1,01 N.D. Solute carrier family 35 member F2 SLC35F2 -1,01 N.D. Armadillo repeat-containing protein 1 ARMC1 -1,01 N.D. Ataxin-2 ATXN2 -1,00 0,14 Ribonuclease inhibitor SNH1 -1,00 0,15 Scaffold attachment factor B1 SAFB -1,00 0,08 Methyl-CpG-binding protein 2 MECP2 -1,00 N.D. Petidyl-prolyl cis-trans isomerase FKBP2 FKBP2 -1,00 0,03 Methnoine aminopeptidase 1 METAP1 -1,00 0,27				
Thiosulfate sulfurtransferase TST -1,01 0,00 Serine/threonine-protein kinase Nek7 NEK7 -1,01 N.D. Solute carrier family 35 member F2 SLC35F2 -1,01 N.D. Armadillo repeat-containing protein 1 ARMC1 -1,01 N.D. Ataxin-2 ATXN2 -1,00 0,14 Ribonuclease inhibitor RNH1 -1,00 0,15 Scaffold attachment factor B1 SAFB -1,00 0,08 Methyl-CpG-binding protein 2 MECP2 -1,00 N.D. Petidyl-prolyl cis-trans isomerase FKBP2 FKBP2 -1,00 0,03 Methonine aminopeptidase 1 METAP1 -1,00 0,27				
Serine/threonine-protein kinase Nek7 NLK7 -1,01 N.D. Solute carrier family 35 member F2 SLC35F2 -1,01 N.D. Armadillo repeat-containing protein 1 ARMC1 -1,01 N.D. Ataxin-2 ATXN2 -1,000 0,14 Ribonuclease inhibitor RNH1 -1,000 0,15 Scaffold attachment factor B1 SAFB -1,000 0,08 Methyl-CpG-binding protein 2 MECP2 -1,000 N.D. Petidyl-prolyl cis-trans isomerase FKBP2 FKBP2 -1,000 0,03 Methoinine aminopeptidase 1 METAP1 -1,000 0,27				
Solute carrier family 35 member F2 SLC 35F2 -1,01 N.D. Armadillo repeat-containing protein 1 ARMC1 -1,01 N.D. Ataxin-2 ATXN 2 -1,00 0,14 Ribonuclease inhibitor RNH1 -1,00 0,15 Scaffold attachment factor B1 SAFB -1,00 0,08 Methyl-CpG-binding protein 2 MECP2 -1,00 N.D. Peptidyl-prolyl cis-trans isomerase FKBP2 FKBP2 -1,00 0,03 Methonine aminopeptidase 1 METAP1 -1,00 0,27				
Armadillo repeat-containing protein 1 ARMC1 -1,01 N.D. Ataxin-2 ATXN2 -1,00 0,14 Ribonuclease inhibitor RNH1 -1,00 0,15 Scaffold attachment factor B1 SAFB -1,00 0,08 Methyl-CpG-binding protein 2 MECP2 -1,00 N.D. Peptidyl-prolyl cis-trans isomerase FKBP2 FKBP2 -1,00 0,03 Methonine aminopeptidase 1 METAP1 -1,00 0,27				
Ataxin-2 ATXN2 -1,00 0,14 Ribonuclease inhibitor RNH1 -1,00 0,15 Scaffold attachment factor B1 SAFB -1,00 0,08 Methyl-CpG-binding protein 2 MECP2 -1,00 N.D. Peptidyl-prolyl cis-trans isomerase FKBP2 FKBP2 -1,00 0,03 Methylonine aminopeptidase 1 METAP1 -1,00 0,27				
Ribonuclease inhibitor RNH1 -1,00 0,15 Scaffold attachment factor B1 SAFB -1,00 0,08 Methyl-CpG-binding protein 2 MECP2 -1,00 N.D. Peptidyl-prolyl cis-trans isomerase FKBP2 FKBP2 -1,00 0,03 Methionine aminopeptidase 1 METAP1 -1,00 0,27				
Scaffold attachment factor B1 SAFB -1,00 0,08 Methyl-CpG-binding protein 2 MECP2 -1,00 N.D. Peptidyl-prolyl cis-trans isomerase FKBP2 FKBP2 -1,00 0,03 Methonine aminopeptidase 1 METAP1 -1,00 0,27				
Methyl-CpG-binding protein 2 MECP2 -1,00 N.D. Peptidyl-prolyl cis-trans isomerase FKBP2 FKBP2 -1,00 0,03 Methionine aminopeptidase 1 METAP1 -1,00 0,27				
Peptidyl-prolyl cis-trans isomerase FKBP2 -1,00 0,03 Methionine aminopeptidase 1 METAP1 -1,00 0,27				
Methionine aminopeptidase 1 METAP1 -1,00 0,27				
Small subunit processome component 20 homolog UTP20 -1,00 0,09				
	Small subunit processome component 20 homolog	UTP20	-1,00	0,09

SubsetCont1.001.001.00Juster1.001.001.001.00Tubbis Apple 10 that1.001.001.00Color angen1.001.001.00Soling Endow1.001.001.00Soling E		COLE	1.00	1 1 5
ig partnar. J. chain CregonInc.Inc.N.D.ATP-dependent problem hasse catalytic suburt sightREC0.5-1.00N.D.ATP-dependent problem hasse catalytic suburt sightREC0.5-1.00N.D.Schort problem hasse catalytic suburt sightREC0.5-0.00-0.00Reconstruct from problem has backerREC0.5-0.00-0.00Reconstruct from problem has backerREC0.5-0.00-0.00Reconstruct from problem has backerREAD.5-0.00-0.00Reconstruct from problem has backerREAD.5-0.00<	Squalene monooxygenase	SQLE	-1,00	1,15
Tabula path a ChainUDACC1.000.00AMP degender Droten kinsa catalytic subuni taphaRCCLA1.000.00CD2 angenCD21.001.01Synthe frame with 9CD21.000.01Synthe frame with 9CD21.000.01Synthe frame with 9CD21.000.01Synthe frame with 9CD20.000.01Synthe frame with 9CD20.000.01ATP depender BM heliase DD34CD240.020.02ATP depender BM heliase DD34CD240.020.02ATP depender BM heliase DD34CD240.020.02Catal deman-constraing protein 1CD4010.030.02Catal deman-constraing protein 1CD4010.030.02Catal deman-constraing protein 1CD11A0.030.02Catal deman-constraing protein 1CD11A0.030.02Catal deman-constraing protein 1CD11A0.030.02Catal deman-constraing protein 1CD11A0.030.02Catal deman-constraing protein 1CD11A0.030.02Coll-acedered Mittage LD12CD11A0.030.02Coll-aced DD22CD11A0.030.020.02Coll-aced DD22CD11A0.030.020.02Coll-aced DD22CD11A0.030.020.02Coll-aced DD22CD21A0.030.020.02Coll-aced DD22CD22A0.030.020.02Coll-aced DD2				
Altr degrammed process in kases analyses and submat alybaFCGLS in CGLS in CGL				
AdM-dependent protein kines calabirs. Suboil alphaPROCA-1.000.29Spling factor, argning/serine-1h 3SCA310.090.031Spling factor, argning/serine-1h 3SCA310.090.031Ribours and LibrariaSCA310.090.031Ribours and LibrariaSCA310.090.031Ribours and LibrariaSCA310.090.031Ribours and LibrariaSCA310.090.031Chailed grotein suboil ters 10.040710.090.031Chailed grotein suboil ters 10.040710.0310.031Chailed grotein suboil ters 10.0014710.0310.031Chailed grotein suboil ters 10.0014710.0310.031Chailed grotein suboil ters 10.0014710.0310.031Robing sector suboil ters 10.0014710.001470.031Robing sector suboil ters 10.0014710.0310.031Robing sector suboil ters 20.03140.0310.031Robing sector suboil ters 20.03140.0310.031Robing sector suboil ters 20.03140.0310.031Robing sector suboil ters 20.03140.0310				
CD22CD22-1.001.51CD23CD24-0.03Hiddening-strein-f1SUG1-0.090.01Hiddening-strein-f1SUG10-0.090.01ATP-dependent MA Incluses0.00-0.090.01ATP-dependent MA InclusesCD34-0.090.01ATP-dependent MA Incluses0.00-0.090.01ATP-dependent MA Incluses0.00-0.090.01ATP-dependent MA Incluses0.00-0.090.01Containe containing protein 1SUG10-0.090.03Collagan alpha L10(Unclusin-findstatineCOLLBA1-0.090.03Collagan alpha L20(Unclusine)COLLBA1-0.090.03Collagan alpha L20(Unclusine)COLLBA1-0.090.03Collars alpha L20(Unclusine)COLLBA1-0.090.03Collars alpha L20(Unclusine)COLLBA1-0.090.03Collars alpha L20(Unclusine)COLLBA1-0.090.02Collars alpha L20(Unclusine)COLLBA1-0.090.02Collars alpha L20(Unclusine)COLLBA1-0.090.03Collars alpha L20(Unclusine)COLLBA1-0.090.03Collars Alpha CalebanCOLLBA1-0.090.03Collars Alpha CalebanCOLLBA1-0.090.03Collars Alpha CalebanCOLLBA1-0.090.03Collars Alpha CalebanCOLLBA1-0.090.03Collars Alpha CalebanCOLLBA1-0.090.03Collars Alpha CalebanCOLLBA1				
Spleng frage, aggine/gener.ch 19SCAF10.990.03Resonal L domain-containing protein 1KBDS10.990.01Resonal L domain-containing protein 1CBDS10.990.01Resonal L domain-containing protein 1CBDS10.990.01Arti-type ander fMN helicae DDX5ACBDS10.990.01Chounding protein 1CBDS10.990.01Arti-type ander fMN helicae DDX5ACBDS10.990.03Frage Containing protein 1CBDS10.990.03Frage Containing protein 2CBDS10.990.03Frage Containing protein 3CBDS10.990.03Frage Containing Containing Containing Containing Protein 30.000.00Frage Containing Containing Containing Containing Containing Protein 30.000.00Frage Containing Co				
Bit domain containing protein 1BIOBS1-0.990071ATP-depending protein 1BLOD-0.990.001ATP-depending protein 1CAUPAI-0.990.001CA-binding protein 1CAUPAI-0.990.011CA-binding protein 1CAUPAI-0.990.011CA-binding protein 1CAUPAI-0.990.011CA-binding protein 1CAUPAI-0.990.031CA-binding protein 1CAUPAI-0.990.031CAUPAICAUPAI-0.990.031Calegan dyin-1/XVIII (ham)-findutatioCAUPAI-0.990.031Calegan dyin-1/XVIII (ham)-findutatioCAUPAI-0.990.031Calegan dyin-1/XVIII (ham)-findutatioCAUPAI-0.990.001CyClindependent Kause LIACAUPAI-0.990.021CyClindependent Kause LIACAUPAI-0.990.021CyClindependent Kause LIACAUPAI-0.990.021CyClindependent Kause LIACAUPAI-0.970.041CyClindependent Kause LIACAUPAI-0.970.041Calegan LIACAUPAI-0.970.041Calegan LIACAUPAI-0.970.041Calegan LIACAUPAI-0.970.041Calegan LIACAUPAI-0.970.041Calegan LIACAUPAI-0.970.041Calegan LIACAUPAI-0.970.041Calegan LIACAUPAI-0.970.041Calegan LIACAUPAI-0.970.041C	-			
Ribosonal Labonan-containing protein 1SLD19.990.07Att-Speein Enf Nealizas DDX5DX540.990.03Att-Speein Enf Nealizas DDX5GPATE140.990.03Charleng protein 1GPATE140.990.03G patch domain-containing protein 1GPATE1440.990.03Thrable NM4-binging protein 1RM150.030.04Tryptophan-UNN ligges. Cryptophamic 1- TryB5/T2-TryB5WAIS0.040.04ND144770.0380.0210.0380.021Strein argumaticCrySta140.0480.0010.058ND0144970.0320.0410.0580.021CryBin dependent Kinase 118/Cyclin-dependent han bioOrmPPICA0.0380.041CryBin dependent Kinase 118/Cyclin-dependent kinase 118/Cyclin-depend				
ATP-dependent NA helicse DDS40.090.01ATP-dependent NA belicse DDS40.090.01GA-binding protein subunit beta-1GAPB10.990.02Garbind Onain Containing protein 13GAPB10.990.02Patale NA bending protein 13Callant Contain Containing protein 130.090.03Chalgen garba 10-00Callant Contain Containing protein 130.090.03Chalgen garba 10-00Callant Containing protein 130.010.09Chalgen garba 10-00Callant Containing protein 130.010.09Chalgen garba 10-00Callant Containing protein 130.010.02Sender/Meenine protein protein protein protein protein fragmantCallant Containing protein 120.00Cyclin dependent Kanse 11A/Containine Containing protein 120.090.03Cyclin dependent Kanse 11A/Containine Containine Containine Containing protein 120.090.03Cyclin dependent Kanse 11A/Containine Containine Co	KH domain-containing, RNA-binding, signal transduction-associated protein 1	KHDRBS1	-0,99	0,01
Akt-bjør protein 1CPAND10.999ND.1Gahadim protein 10GaPAT Order0.999ND.1Gahadim protein 13GAPAT CH40.9990.041Gahadim protein 15RMIS0.9910.031Cingan alpha-12M (igare, cropasamic) 1-rph5/12-rph5RMIS0.9910.031Grant Mana CharlesControl 100.9980.041Protein angranue-1Control 100.9980.041Protein angranue-1Control 100.9980.021Schröder (Schröder)Protein angranue-10.9980.021Cyclin dependent kinses 118, Cyclin depen	Ribosomal L1 domain-containing protein 1	RSL1D1	-0,99	0,07
GA-binding protein subunit Berl-1GARPB19.99N.D.Grahd Gmain Containing protein 15GRAMGRAM0.990.32Putatte Mk-binding protein 15NRDS0.990.33Collgan Labsen/UVIII (bain-GotstainCOLLBA10.991.80Protein argenut-1COLLBA10.991.80NRDM Eddyrdogensac (bokunica) conject a sembly factor 7NDURA70.380.02NRDM Eddyrdogensac (bokunica) 25 conject and table informPP2C (COLLBA10.990.02Zas: (Bosonal protein 52, antical set and table informPP2C (COLLBA10.980.02Zas: (Bosonal protein 52, antical set and table informPP2C (COLLBA10.980.02Zas: (Bosonal protein 52, antical set and table informPP2C (COLLBA10.980.02Zas: (Bosonal protein 52, antical set and table informPP2C (COLLBA10.980.02Exagence (CollBA1COLBCA10.980.030.03Exagence (CollBA1COLBCA10.970.900.90Exagence (CollBA1COLBCA10.970.900.90Exagence (CollBA1COLBCA10.970.900.91Exagence (CollBA1COLBCA10.980.930.93Exagence (CollBA1COLBCA10.980.930.93Exagence (CollBA1COLBCA10.980.930.93Exagence (CollBA1COLBCA10.980.930.93Exagence (CollBA1COLBCA10.980.930.93Exagence (CollBA1COLBCA10.98 <td>ATP-dependent RNA helicase DDX54</td> <td>DDX54</td> <td>-0,99</td> <td>0,49</td>	ATP-dependent RNA helicase DDX54	DDX54	-0,99	0,49
G path domain-containing protein 1OPATCHAOPATCHAOPATCHATryptophane-RMA ligane, (rstpalsamic,T1-TrpRS,T1-TPRSWARS0.990.33Challean olpha-LVUII chain, fractostainCUILBA10.99N.D.NDMI ded yrdprogenase (lobquinon) complex I, assembly factor 7NUDHA770.08V.D.Serine (Interenine protein photphatuse 28 catuly is subunt alpha informPMPCA0.08N.D.Serine (Interenine protein photphatuse 28 catuly is subunt alpha informPMPCA0.08N.D.ZS information protein 32, mitochondrialMMPS220.030.32Decompare 14 cabulant complex Catuly is subunt alpha informPMPCA0.090.04Serine (Interenine protein size), mitochondrialMMPS220.030.02Decomphonics Information Sering Catuly is subunt 20PMS20.070.04Sering Catuly is subunt 20PMS20.070.04Sering Catuly is subunt 20PMS20.070.04Decomphonics InformationPMS20.030.04Decomphonics InformationPMS20.040.04Decomphonics InformationPMS20.040.04Decomphonics InformationPMS20.050.04Fatasin, mitchondrialTAMMA10.060.04Decomphonics InformationPMS20.060.04Fatasin, mitchondrialTAMMA10.060.04Fatasin alta Cateuri Alt	AN1-type zinc finger protein 1	ZFAND1	-0,99	0,11
PicationBMM15G.0.9G.0.33Collagen apin-1/K0111 phin: EndostatinCOLLSA1G.0.9I.8.8Protein argonautric flages corpolasmic T-PRS/T2-TPRSNGONB.0MADH dehydrogenase (ubquinone) complex 1 assembly factor 7NUVAF7G.0.820.22Sincellame T-PRS/T2-TPRSCOLLSA1G.0.98ND.0Cyclin degendent kinase 118/Cyclin-degendent kinase 11ACDX118/COLLAG.0.8ND.0Sincellame T-PRS/T2-TPRSCOX18/COLLAG.0.8ND.0Cyclin-degendent kinase 11ACDX18/COLLAG.0.8ND.0Sincellame T-PRS/T2-TPRSCOX18/COLLAG.0.9ND.0Cyclin-degendent kinase 11ACDX18/COLLAG.0.9ND.0Cyclin-degendent kinase 11ACDX18/COLLAG.0.9ND.0Cyclin-degendent kinase 11ACDX18/COLLAG.0.9ND.0Cyclin-degendent kinase 11ACDX18/COLLAG.0.9ND.0Descrypendine flagCDX18/COLLAG.0.9ND.0Descrypendine flagCDX18/COLLAG.0.9ND.0Descrypendine flagCDX18/COLLAG.0.9ND.0TAPA domain-containing protein 1TDX11G.0.9ND.0TAPA domain-containing protein 1TDX21G.0.6G.0.3TAPA domain-containing protein 1TDX21G.0.6G.0.3TAPA domain-containing protein 1TDX21G.0.6G.0.3TAPA domain-containing protein 1TDX21G.0.6G.0.3TAPA domain-containing protein 1TDX21G.0.6G.0.3TA	GA-binding protein subunit beta-1	GABPB1	-0,99	N.D.
Typopolane-HNA (pise, cytoplasmic)1-TypoS12-TypoSVARS9.090.33Protein argunate-1AGO10.99N.D.NDM dehytopense (blajunon) complex, assembly factor 7NDUA770.982.02Serine/Hreenine-protein phosphatase 28 catalylic suburt alpha latformPMPSCA0.980.00Cyclin dependent kinase 116 Xcuin dependent kinase 11ACMRSC VILLS CNILL A0.98N.D.Z8s ribosomal protein S32, mitochondrialMMPS220.980.02Samma-bubbin complex component 4DOH0.970.99Description protein factor alpha latformPMPSCA0.930.93Description phosphatase 28 catalylicsPMAG0.970.99Samma-bubbin complex component 4DOH0.970.99Description phosphatase 28 catalylicsPMAG0.970.99Description phosphatase 29, mitochondrialFAN0.970.90Description phosphatase 29, mitochondrialFAN0.970.90Parasin, matchondrialTAMM110.960.900.90Thy about 20PMAG0.910.900.90Thy about 20PMAG0.910.900.90Thy about 20PMAG0.900.900.90Thy about 20PMAG0.900.900.90Thy about 20PMAG0.900.900.90Thy about 20PMAG0.900.900.90Thy about 20PMAG0.900.900.90Thy about 20PMAG0.900.90	G patch domain-containing protein 4	GPATCH4	-0,99	0,52
Tryppophane-HNA ligaes, cytoplasmic, T-TrgBS, TrypBSWARS0.991.58Protein argonaute-3AGO10.99N.D.MADI dehytogensse (lubquinon) complex, a scenibly factor 7NDUAP770.982.022Serine, filterenine-protein phosphatuse 28 catalytic subunt alpha isoformPPECA0.980.00Cyclin dependent timas 118. Schlen demethytaseChyS1AL0.98N.D.28 sincompl protein S2, mitochondralMRPS220.980.02Sincore 13 Eabylin demethytaseChyS1AL0.98N.D.28 intochondralChyS1AL0.980.92Sincore 13 Eabylin demethytaseChyS1AL0.980.92Sincore 14 Eabylin demethytaseChyS1AL0.980.92Decagreny/dehysphates subunt 2DES0.970.01Fratasi, mitochondralPN0.970.03Protein demoti factorPN0.970.03Fratasi, mitochondralTMMS100.970.03Protein barb 30TMS100.970.01Thydosin barb 30Differenza, mitochondralTMMS110.96Protein barb 30TMS100.970.01Thydosin barb 30Differenza, mitochondralTMMS100.97Protein barb 30FAST Kinase0.960.04FAST Kinase Chaine-containing protein 1TMMS100.970.01Thydosin barb 30Differenza, mitochondralTMMS100.970.01Protein David 40FAST Kinase0.980.040.98Catase Kinase Lis	Putative RNA-binding protein 15	RBM15	-0,99	0,04
Collagen Japha - JX0011OL18A1OL18AOL18AADDADDNADD detyricopense (Japhane) complex Jasembly factor 7NUUATY0.982.02Selencit/hecoine) prostates 28 catulty (Subunt Alpha IaformPPEXA0.090.00Cyclin-degendent Kinase 115ACX113C NUTAT0.98N.D.Selencit/hecoine) prostates 28 catulty (Subunt Alpha IaformPPEXA0.98N.D.Selencit/hecoine) prostates 28 catulty (Subunt Alpha IaformPPEXA0.98N.D.Disordynaise HydrolysteCYPSIA10.98N.D.Disordynaise HydrolysteCYPSIA10.98N.D.Disordynaise HydrolystePDS20.07N.D.Disordynaise HydrolystePDS20.07N.D.Disordynaise HydrolystePDS20.07N.D.Disordynaise HydrolystesPDS20.07N.D.Disordynaise HydrolystesPDS20.07N.D.Disordynaise HydrolystesPDS30.07N.D.Disordynaise HydrolystesPDS30.060.04Disordynaise HydrolystesPDS30.060.04Disordynaise HydrolystesPDS30.050.06Disordynaise HydrolystesPDS30.060.03Disordynaise HydrolystesPDS30.060.03Disordynaise HydrolystesPDS30.060.03Disordynaise HydrolystesPDS30.060.03Disordynaise HydrolystesPDS30.060.03Disordynaise HydrolystesPDS30.060.03		WARS		0,53
Protein argenante-3AOD1Q-03N.D.MADI dehytopenase (alpational) complex) assembly factor 7NUMA77Q-38Q-202Serine/threanine-protein phosphatase 28 catalytics subunt alpha isoformPPSCAQ-38N.D.ZSS intosomal protein S2, mitochondrialMRSS2Q-38N.D.Lansterol 14-alpha feenthytaseCYSIA1Q-38N.D.ZSS intosomal protein S2, mitochondrialMRSS2Q-38N.D.FuranytectacetaseFAHQ-38Q-32DecaymythytophytaseDOHHQ-37Q-39DecaymythytophytaseDOHHQ-37Q-39DecaymythytophytaseDOHHQ-37Q-39Decaymythytophytase subunt 2RRAGCQ-37N.D.Ras-related GTN-binding protein CRRAGCQ-37N.D.Threase, mitochondrialPNNQ-39Q-39DA polymerase subunt gamase, mitochondrialTIAAH11Q-37N.D.THAP domain-containing protein 3RAMA1Q-36Q-34ATP despendent NAN helicase AD-180D-180Q-39ATP despendent NAN helicase AD-180D-180Q-34ATP despendent NAN helicase AD-180D-180Q-36ATP despendent Complexes subunt 1RAM31Q-36Q-34Ras GT Preve activating protein 3RAM3Q-36Q-34Ras GT Preve activating protein 3RAM3Q-36Q-34Ras GT Preve activating protein 3RAM3Q-36Q-34Ras GT Preve activating protein 3RAM3		COL18A1		
NOD! Agring programs (ubiquinone) complex (a ssembly factor 7NOUFAF70.000.00Cyclin dependent Kinsse 118 (Cyclin dependent Kin				
seine/fiveneme_protein prosphariase 2 data/five subunit alpha isoformPPRAPPRAPOSPOS255 indocord instase 11ACM1135/CDL14-0.38N.D.255 indocord instase 11AMMPS22-0.38-0.32255 indocord instase 11AMMPS22-0.38-0.32255 indocord instase 11AMMPS22-0.37-0.38255 indocord instase 11AUBSCP4-0.37-0.59256 informa inclusion complex component 4DOHH-0.37-0.49Decarperiv_inforphate synthase subunit 2RBAGC-0.37-0.45Decarperiv_inforphate synthase subunit 2RBAGC-0.37-0.45Disargeriv_inforphate synthase subunit 2RBAGC-0.37-0.45THAP domain-containing protein 5-0.45-0.45-0.45ATT-dependent RAN helicase ADHAG-0.45-0.45ATT-dependent RAN helicase ADHAG-0.45-0.45ATT-dependent RAN helicase ADHAG-0.45-0.46ATT-dependent RAN helicase ADHAG-0.45-0.46ATT-dependent RAN helicase ADHAG-0.45-0.46Casen tases Losoform alpha-lake subunit 1-0.45-0.46-0.46Casen tases Losoform alpha-lake sub				
Cyclin-dependent knase 11ACDX118.CDX11A0.98N.D.S25 histonal protein \$32, mitochonfraiMRP520.980.32Lanoster 14-Jehn demethylaseCYS3A10.98N.D.ImanalylacetacetseFAH0.98N.D.Gamma-Lubulin complex component 4Deckynyburin bylan for symbol0.970.59Deckynyburin bylan for symbolDOHH0.970.59Deckynyburin bylan for symbolPDS320.97N.D.Ray-related CFN-Inding protein CRRAGC0.970.09Deckynyburin bylan symbolPDS320.97N.D.Thymasin beta-10TMS100.770.01Thymasin beta-30TMS100.770.01Thymasin beta-30TMS100.770.01Thymasin beta-30TMS100.780.04FAT kinase domäin-containing protein 5MAM410.970.04Ard-dependent RAN helicase ADHS90.960.04FAT kinase i soform alpha-likeGSNLALCSNKA110.960.38Gaenie nucleatide-binding protein 5MATG20.960.33Gaenie nucleatide-binding protein 6 (k) subunt 15RAST30.960.03Gaanie nucleatide-binding protein 6 (k) subunt 14ASC10.960.03Gaenie nucleatide-binding protein 6 (k) subunt 14ASC10.960.03Gaenie nucleatide-binding protein 6 (k) subunt alphaRAST0.960.03Gaenie nucleatide-binding protein 6 (k) subunt alphaRAST0.960.03Gaenary Complex S	, , , , , , , ,			
285 ribosonal protein S2, mitochondrialMMER2MMER2MMER2MMER2MARJunarytecaacetseFAH-0.38N.D.JunarytecaacetseFAH-0.38N.D.JunarytecaacetseCMH-0.37K.S.SDecxytpuine hydroxytseDOHH-0.37K.S.SDecxytpuine hydroxytseDOHH-0.37K.S.SDecxytpuine hydroxytseDOHASSS-0.37N.D.Ras-related GTP-binding protein CRRAGC-0.37N.D.Tratan, mitochondrialPOIG2-0.37N.D.Thydromerase subunit gamma-z, mitochondrialTMAS110-0.37N.D.TAP dependent RAA helicase ADH39-0.36-0.43ATP dependent RAA helicase ADH39-0.36-0.38ATP dependent RAA helicase AMITA2-0.36-0.38ATP dependent RAA helicase AMITA2-0.36-0.34Ras GTPase activating protein 3-0.36-0.34-0.36ATP dependent RAA helicase AMITA2-0.36-0.34ATP depend				
janoster 14-informaCYPS1A10,98N.D.Gamma-blubilin complex component 4D040,340,34Gamma-blubilin complex component 4D0540,390,39Decayhynsuin hyndroxylaseD01410,370,39Decayhynsuin hyndroxylaseD01410,370,45Fratasin, mitcohondrialPN0,020,070,01Dha polymerase a bubuint gamma-2, mitcohondrialTMS8100,070,11Thyndrain bet-10TMS8100,070,111,142Phosphatidate cytidylytinasferase, mitcohondrialTAMM110,070,01Thyndrain bet-10TMS8100,070,011,142Phosphatidate cytidylytinasferase, mitcohondrialTAMM110,070,01Thyndrain bet-10TMS8100,060,040,04FAT tinsse domain-containing protein 5FAST tinsse domain-containing protein 6,000,04FAST tinsse domain-containing protein 5FAST tinsse domain-containing protein 6,000,040,04FAST tinsse domain-containing protein 5FAST tinsse domain-containing protein 6,000,04FAST tinsse domain-containing protein 5FAST tinsse domain-containing protein 6,000,04FAST tinsse domain-containing protein 6,00FAST tinsse domain-containing protein 6,000,03Gamma-bucktide-binding protein 12FAST tinsse domain <t< td=""><td></td><td></td><td></td><td></td></t<>				
junaryteckaacteseFAH0.980.14junaryteckaacteseDOHH0.970.53Beavytepuine hydroxytesDOHH0.970.43Beavytepuine hydroxytesDOHH0.970.45Beavrent-diphosphate synthas subunt 2RRAGC0.97N.D.Ras-related GTP-binding protein CRRAGC0.97N.D.Tratain, mitchondrialPUG20.97N.D.Thydromerase subunt 2 mma-2, mitchondrialTHAP10.97N.D.Thydromerase subunt 2 mma-2, mitchondrialTHAP10.960.04Thydromerase subunt 2 mma-2, mitchondrialTHAP10.960.04TAP dependent RMA helicase AOHS90.960.04ATP-dependent RMA helicase AOHS90.960.04ATP-dependent RMA helicase AMITAG20.960.04ATS finase donina constaining protein 5C.S.KIXAL,CSKIXAL0.960.04Ras GTPasa-catxiting protein 3N.D.0.72Mutple myeloma tumor-associated protein 2MITAG20.960.03Ras GTPasa-catxiting protein 3N.D.C.S.KIXAL,CSKIXAL0.960.040.96Protein LAPGRASIA0.960.030.960.03Scanne hudedite-binding protein G(k) subunit 16RASA30.960.04Scanne nucleative-binding subunit 16RASA30.960.04Scanne nucleative-binding subunit 16RASA30.960.04Scanne nucleative-binding subunit 16RASA30.960.04Scanne nucleative-bind				
Gamma-tubulin complex component 4C0.590.59Decaynpynisch hydroxylaseDOHH4.0970.49Decaynpynisch hydroxylase subunit 2PDS320.977N.D.Ras-rahet GT P-Ninding protein CRRAGC4.0970.05Fratasin, mitochondrialPNI0.0124.097N.D.MAR polymerses e subunit zamma-2, mitochondrialPOIG24.097N.D.Thymosin beta-10TMAS10-0.977N.D.Thymosin beta-10TMAS10-0.977N.D.Phosphatidate cytichyltran for ase, mitochondrialTMAM411-0.97N.D.ATP-degendent RMN helicses ADHX9-0.960.04FAT Stinsse domain-containing protein 5FAST Kinsse domain-containing protein 5N.D0.960.04RAST domain-containing protein 5MMTAG2-0.960.030.04Relator of RMA polymerses i transcription subunit 16MMTAG2-0.960.03Granne nucleolide-binding protein GIA) subunit 19haRSAS3-0.960.01Strating signal contegrator 1 complex subunit 1ASCC1-0.960.01Astiviting signal contegrator 1 complex subunit 1RSAC1-0.960.01Cornwyluutabine hydroisesESD-0.950.01Cornwyluutabine hydroisesSDO-0.960.01Cornwyluutabine hydroisesSDO-0.960.01Cornwyluutabine hydroisesSDO-0.960.01Cornwyluutabine hydroisesSDO-0.960.01Cornwyluutabine hydroisesSDO<				
Decomputation by the probate synthase submit 2DOHHO.97O.93Ras-related GTP-Ininding protein CRBAGC-9.97O.95Tratsmin, mitchondrialPOIS2-0.97N.D.Tymesin hetei.10TMSBID-0.97O.11Thy denomin containing protein 11TMAP11-0.97N.D.Thy denomin than heticase ADMS9-0.96O.01THAP domain-containing protein 11TMAP11-0.97N.D.The denomin than heticase ADMS9-0.96O.02Attable regional control and protein 21MAITAGL-0.96O.04FAST Kinase domain-containing protein 5FAST Kinase domain-containing protein 3-0.96O.03Caseen kinase i tooform alpha-likeCSKUCAL/CSNULALL-0.96O.04Relator of RMA polymeraei I transcription subunit 16MBID6-0.96O.04Ras GTRase activating protein 3RASA3-0.96O.03Guanine nucleatide-binding protein G(k) subunit alphaCRNA3-0.96O.04Guanine nucleatide-binding protein 1NCC-0.96O.04Activating signal cointegrator 1 complex subunit 1ASCC1-0.96O.04Activating signal cointegrator 1 complex subunit 2SELH-0.95O.07Protein JA2-0.96O.05O.07Protein JA2-0.96O.05Schormydigutatione hydrolase III satorSELH-0.95O.07Protein JA2-0.96O.05Schormydigutatione hydrolase III satorSELH-0.95O.07Protein JA2				
Decaperil-diphosphate synthase subunit 2PDS2PDS2PDS7N.D.Racelated GP-Molinding protein CRRAGC9.070.045Fratasin, mitochondrialPNIPOI529.090.045MA polymersze subunit gamma-2, mitochondrialPOI529.09N.D.Thymosin beta-10TMASID-0.097N.D.RAST Kinase domain-containing protein 1TMAP domain-containing protein 1POI529.060.027TAP domain-containing protein 1TAM Admit - 0.96N.D.N.D.ATP dopendent RNA helicse ADH/NS-0.960.027Multiple myeloma tumor-associated protein 2MMTAG2-0.960.33Casen kinase I isoforma ajbna-likeCSINCLALCSINCLALL-0.960.031Ros GTBsa-activity grotein 3CSINCLALCSINCLALL-0.960.031Ros GTBsa-activity grotein 3RASA3-0.960.031Ros GTBsa-activity grotein 3CSINCLALCSINCLALL-0.960.031Ros Casen kinase I isoform ajbna-likeCSINCLALCSINCLALL-0.960.031Ros Casen kinase I isoforma jbna-likeCSINCLALCSINCLALL-0.960.041Ros Casen kinase I isoformRASA3-0.960.041Ros Casen kinase I isoformSICOLA-0.960.041Replication protein A 20 Ko subunit 3SiCOLA-0.960.042Selenoprotein H 2SiCOLA-0.960.042Selenoprotein A 20 Ko subunit 3SiCOLA-0.960.042Ros Casen kinese I Subunit 3SiCOLA-0.960.031 <td></td> <td></td> <td></td> <td></td>				
Bac-deals dTP-binding protein CRBACC9.070.045Tratism, mitchondrialFNN9.070.015DNA polymeraise suburit gamma 2, mitochondrialFNN9.070.01Thymosin beta-10ThASB109.070.01Thymosin beta-10ThASB109.070.01ThAP dependent RNA helicase ADHX0-0.960.04ATP-dependent RNA helicase ADHX0-0.960.04ATP-dependent RNA helicase ADHX0-0.960.04ATST kinase domain-containing protein 5FAST Kinase i tooform alpha-likeCSKXA1LCSNXIA1L-0.960.026Muttor ASC Appimerae It transcription suburit 16MB16-0.960.040.03Readitor of RNA polymerae It transcription suburit 16MB16-0.960.04Readitor of RNA polymerae It transcription suburit 17RASC CL-0.960.09Ortetin LAZDPI-0.960.030.03Guanien nucleotide-binding protein G(k) suburit alphaGNA3-0.960.04Epiletation protein ASELH-0.950.040.04Epiletation protein ARPA2-0.960.060.04Epiletation protein A2 kDa suburit alphaSELH-0.950.04Epiletation protein A2 kDa suburit alphaNECL-0.950.07Protein S10-A10NEDLSELH-0.950.09Protein S10-A10NEDLSELH-0.950.03Epiletation protein A2 kDa suburit amma APAAH183-0.950.03Epilotati				
Fratasin, mitochondrialFNN-0.970.09DA polymersza bubuit gamma-2, mitochondrialPIGS2-0.97N.D.ThAP domain containing protein 13THAP11-0.970.11Phosphatidate cytidy/itransferase, mitochondrialTAMM411-0.970.01ATP- dependent RNA helicase ADNS-0.060.04ATP- dependent RNA helicase AFASTKD3-0.060.024ATP- dependent RNA helicase AFASTKD3-0.060.024Multiple myeloma tumor-associated protein 2MITAG2-0.060.038Scare kinase 1 isoform alpha-Zean kinase 1 isoform alpha-likeCSNL41.11-0.060.026Mediator of RNA polymerase II transcription subunt 16RASA3-0.060.014Ras GTPase-activity grotein 3GRA13-0.060.09Protein Dr1Activity in grotein 3GRA13-0.060.020Activity in griginal cointegrator 1 complex subunit 1ASCC1-0.060.04Selindor protein A32 KDa subunit 2SLH-0.950.027Protein Dr1Activity in griginal cointegrator 1 complex subunit 1ASCC1-0.050.027Protein A32 KDa subunit 2SLH-0.950.031Selindorprotein A1KDa DNA-binding subunit 2NPC2-0.050.027Protein 3100-A10SDD OAD-0.950.031-0.950.031Beplatidutionator protein A12 KDa DNA-binding subunit 3ASC-0.050.027Protein 3100-A10NPC2-0.950.027-0.950.031 <t< td=""><td></td><td></td><td></td><td></td></t<>				
DAA polymerase subunit gamma-2, mitochondrialPOLG2-0.97N.D.Thymosin beta-10TMSB10-0.97N.D.THAP domain-containing protein 11THAP11-0.97N.D.Phosphaldate cyddy/transferase, mitochondrialTAMM41-0.96N.D.ATP-dependent RNA helicase ADNSO-0.960.04FAST Kinse domain-containing protein 5FAST Kinse domain-containing protein 5-0.960.027Multiple myelome tumor-associated protein 2MMTAG2-0.960.03Gastein Kinsse I isoform alpha-(Xsein Kinsse I isoform alpha-ResCSNLA12, SNLA11-0.960.04Radiator GTRA polymerase II transcription subunit 16MED16-0.960.03Guante nucleotide-binding protein GK subunit alphaGNA13-0.960.03Guante nucleotide-binding protein GK subunit 1REA-0.960.04Replication protein A22 to 2.001CSNLA12, SNLA11-0.960.04Selinoprotein HDRI-0.960.04Selinoprotein HRA2-0.960.04Selinoprotein HDRI-0.960.04Selinoprotein HDRIA-0.960.04Selinoprotein HDRIA-0.950.04Selinoprotein HDRIA-0.950.04Selinoprotein HNPC2-0.950.04Selinoprotein HDRIA-0.950.04Selinoprotein HDRIA-0.950.04Selinoprotein HDRIA-0.950.04Replication protein 32.05 aubunit gamma			-0,97	0,45
Thymosine ben-0TMSB10-0.970.11ThAP domain-containing protein 11THAP111-0.97N.D.Phosphatidate cytchylytransferase, mitochondrialTAMM411-0.96N.D.ATP-dependent RNA helicase ADHX9-0.960.04AEX kinase domain-containing protein 5FASTKD5-0.960.27Multiple myeloma tumor-associated protein 2MMTA62-0.960.38Casen kinase 1 isoform alpha-Exen kinase 1 isoform alpha-likeCSNL4111-0.960.026Mediator of RNA polymerase II transcription subunit 15RASA3-0.960.031Ras GTPase-activating protein 3Casen kinase 1 isoform alpha-ExenERB82IP-0.960.031Protein Dr1ASCTO-Sac-activating protein 3-0.960.033-0.960.031Schaming unclosted subunit alphaGNA13-0.960.0260.04Schaming unclosted subunit alphaSCL1-0.960.031Protein Dr1ASCCT-0.950.0260.04Schaming unclostegrator 1 complex subunit 1RSCSCL1-0.950.04Epideding protein A2 kDa subunit alphaSCL1-0.950.04-0.950.04Epideding protein A2 kDa subunit alphaSCL1-0.950.04-0.950.04Epideding protein A2 kDa Subunit alphaSCL1-0.950.050.04Epideding protein A2 kDa Subunit alphaSCL1-0.950.050.05Schaming additive stransferase angly alphaRSA1-0.950.09Epideraton	Frataxin, mitochondrial	FXN	-0,97	0,09
Thymosine ben-0TMSB10-0.970.11ThAP domain-containing protein 11THAP111-0.97N.D.Phosphatidate cytchylytransferase, mitochondrialTAMM411-0.96N.D.ATP-dependent RNA helicase ADHX9-0.960.04AEX kinase domain-containing protein 5FASTKD5-0.960.27Multiple myeloma tumor-associated protein 2MMTA62-0.960.38Casen kinase 1 isoform alpha-Exen kinase 1 isoform alpha-likeCSNL4111-0.960.026Mediator of RNA polymerase II transcription subunit 15RASA3-0.960.031Ras GTPase-activating protein 3Casen kinase 1 isoform alpha-ExenERB82IP-0.960.031Protein Dr1ASCTO-Sac-activating protein 3-0.960.033-0.960.031Schaming unclosted subunit alphaGNA13-0.960.0260.04Schaming unclosted subunit alphaSCL1-0.960.031Protein Dr1ASCCT-0.950.0260.04Schaming unclostegrator 1 complex subunit 1RSCSCL1-0.950.04Epideding protein A2 kDa subunit alphaSCL1-0.950.04-0.950.04Epideding protein A2 kDa subunit alphaSCL1-0.950.04-0.950.04Epideding protein A2 kDa Subunit alphaSCL1-0.950.050.04Epideding protein A2 kDa Subunit alphaSCL1-0.950.050.05Schaming additive stransferase angly alphaRSA1-0.950.09Epideraton	DNA polymerase subunit gamma-2, mitochondrial	POLG2	-0,97	N.D.
TiAP densin-containing protein 11THAP11-0.97N.D.ATP-dependent RNA helicase ADH99-0.960.04ATP-dependent RNA helicase ADH99-0.960.04FAST kinase domain-containing protein 5PAST KD5-0.960.027Multiple myeloma tumor-associated protein 2MMTAG2-0.960.038Caser inknase i Isoform alpha-Caser inscription subunt 16MED16-0.960.04Relator of RNA polymerase II transcription subunt 16MED16-0.960.031Guante nucleotide-binding protein G(k) subunt alphaGRNA3-0.960.030Guante nucleotide-binding protein G(k) subunt alphaCRNA3-0.960.020Activating signal cointegrator 1 complex subunt 1Replacaton protein A32 K0 a subuntReplacaton protein A32 K0 a subuntReplacaton protein A32 K0 a subunt-0.960.04Epiledino protein A32 K0 a subuntRPAL-0.960.04-0.950.04Epiledino protein A32 K0 a subuntRPAL-0.950.04-0.950.04Epiledino protein A32 K0 a subuntRPAL-0.950.027-0.950.027Protein S10S100-A10-0.950.04-0.950.04Epiledino protein A32 K0 a subuntRPAL-0.950.04-0.950.04Epiledino protein A32 K0 a subunt annaPAFAH133-0.950.020Epiledino protein A32 K0 a subunt annaPAFAH133-0.950.03Replacaton protein A70 K0 DNA-bindin subunt annaPAFAH133-0.950.04R		TMSB10	-0,97	0,11
Phosphatidate cylidy/itransferase, mitchondrialTAMM410.06N.D.RAP-dependent RNA helicase AHV90.060.04FAST kinse domain-containing protein 5FAST kinse domain-containing protein 5RAST KD50.060.27Multiple myeloma tumor-associated protein 2MMTAG20.060.280.28Mediator of RNA polymerase II transcription subunt 16RASA0.060.04Ras GTPase-activating protein 3RASA30.060.031Protein IAP2GNAI3-0.060.09Guanine nucleotide-binding protein GV() subunit alphaGNAI-0.060.09Protein Dr1Activating signal contegrator 1 complex subunit 1RSCC1-0.060.04Replication protein A2 LDB subunit 1RSC1-0.060.04Selenoprotein A2 LDB subunit 1SELH-0.050.04Selenoprotein HSELH-0.050.04Epidiation protein A2 LDB subunitRPA1-0.950.04Protein D1-A2 LDB subunitRPA1-0.950.04Protein D1-A2 LDB subunitRPA1-0.950.04Replication protein A2 LDB Aubolitit gammaRPA1-0.950.04Replication protein A2 LDB Aubolitit gammaRPA1-0.950.03Replication protein 35, mitochondrialMPE35-0.050.03Gituthione Stransferase onega-1LGT4-0.950.03Replication protein 35, mitochondrialMFE35-0.050.03Gituthione Stransferase onega-1CGT1-0.950.03		THAP11		
ATP-dependent RNA helicase AOH90.060.04ATP-dependent Lnnor-associated protein 2MMTAG2-0.960.27Multiple myeloma tumor-associated protein 2MMTAG2-0.960.38Casem Inase I isoform alpha/tasen kinase I isoform alpha/likeCSNKIA1CSNKIA1L-0.960.04Mediator of RNA polymerse II transcription subunit 16MED16-0.960.03Guanie nucleotide-binding protein G(k) subunit alphaRASA3-0.960.03Guanie nucleotide-binding protein G(k) subunit 17ASCC1-0.960.00Replication protein A32 kDa subunit 1ASCC1-0.960.04Replication protein A32 kDa subunit 1ASCC1-0.960.04Selndy protein DriveSelndy protein Drive-0.960.04Selndy protein DriveSelndy protein Drive-0.960.04Selndy protein A32 kDa subunit 1ASCC1-0.960.04Selndy protein A10 kDa Subunit 18NPC2-0.950.02Selndy protein A10 kDa DNA-binding subunitSi DOA10-0.950.09Replication protein A20 kDa DNA-binding subunitRPA1-0.950.09Replication protein A20 kDa DNA-binding subunit gammaRPA1-0.950.03Zas fridopendidasePEPD-0.950.030.05Xaa-bro dipeptidasePEPD-0.950.030.03Exocyt complex component 7Exocyt complex component 7-0.950.03Exocyt complex component 7Exocyt complex component 7-0.950.03Sindothel				
FAST kinase domain-containing protein 5FASTROS-0.960.27Multiple myeloma tumor-associated protein 2MMTAG2-0.960.38Multiple myeloma tumor-associated protein 2MMTAG2-0.960.26Mediator of RNA polymerase II transcription subunit 16RASA3-0.960.031Ras GTPase-activating protein 3RASA3-0.960.031Protein LAP2ERB2JP-0.960.09Quanine nucleotide-binding protein G(k) subunit alphaGNA13-0.960.09Protein Dr1ASCC1-0.960.20Activating signal cointegrator 1 complex subunit 1RPA2-0.960.04Explication protein A 21 kDa subunitBPA2-0.960.04Epiledivan protein A 22 kDa subunitRPA2-0.950.04Epiledivanal secretory protein E1NPC2-0.950.027Protein S100-A10SID0A10SID0A100.950.09Replication protein A 70 kDa DNA-binding subunitRPA1-0.950.09Replication protein 32 mitochondrialMPE35-0.950.05Kay-Potein S10-A10SID0A10-0.950.050.03Replication protein A 70 kDa DNA-binding subunitRPA1-0.950.09Replication protein 32 mitochondrialMPE35-0.950.09Replication protein S2 mitochondrialMPE35-0.950.03Glutathione S-transferase omega-1LF3-0.950.03Glutathione S-transferase alphaKGC71-0.950.03Matter Sense S-bi				
Multiple myelom at unor-associated protein 2MMTAG20.060.38Casen kinase I isoform alpha-likeMKIALCSNKIALI0.0660.04Ras GTAse-activating protein 3MEDI6-0.9660.03Guanne nucleotide-binding protein 3(k) subunit alphaRB21P0.0660.03Granne nucleotide-binding protein 5(k) subunit alphaGNA13-0.9660.020Activating rotein 12RB21P0.9660.04Replication protein 13 2 Uba subunit 1RSC1-0.9660.04Replication protein 14 2 Uba subunit 1RSC2-0.9660.04Selpiotation protein 43 2 Uba subunit 1RSC1-0.9660.04Selpidativna iscretory protein 14NPC2-0.9550.04Selpidativna iscretory protein 151NPC2-0.9550.027Protein 510-A10NPC2-0.9550.030.95Replication protein 37 Uba DNA-binding subunitRPA1-0.9550.04Protein 510-A10NDA DNA-binding subunit gammaPAA1183-0.950.03Replication protein 37 Mba DNA-binding subunit gammaPAA1183-0.950.03Stabosmal protein 35, mitochondrialGNC1-0.950.03Stabosmal protein 35, mitochondrialMRP33-0.950.03Stabosmal protein 35, mitochondrialMRP33-0.950.03Stabosmal protein 35, mitochondrialMRP33-0.950.03Interleukin enhancer-binding factor 3ILF3-0.950.03Stabosmal protein 130HECT03-0.950.03 <td></td> <td></td> <td></td> <td></td>				
Casein kinase i lsoform alpha-likeCSNKLA1L9.060.26Mediator of RNA polymerase II transcription subunit 16MED16-0.960.04RAS GTPase-activating protein 3RASA3-0.960.031Guanine nucleotide-binding protein G(k) subunit alphaGNA13-0.960.020Activating signal cointegrator 1 complex subunit 1RPA2-0.960.016Sciontegrator 1 complex subunit 1RPA2-0.960.016Sciontegrator 1 complex subunit 1RPA2-0.960.041Selenoprotein A 2k Da subunitSciontegrator 1-0.960.041Selenoprotein HSELH-0.950.027Protein SIOA ADSioA10-0.950.014Epididymal secretory protein 1NPC2-0.950.121Protein SIOA ADNPC2-0.950.014Plotein SIOA ADNPC2-0.950.014Plotein SIOA AD-0.950.014-0.950.014Plotein SIOA ADNPC2-0.950.020Activating factor acetylhydrolase IB subunit gammaPAFAH1B3-0.950.03Interleukin enhanee-binding factor 3ND0.950.020Endothelin-converting enzyme 1-0.950.020-0.03Sorost complex component 7ECS1-0.950.020Endothelin-converting factor 3-0.950.03-0.950.03Interleukin enhanee-binding factor 3-0.950.03-0.950.03Interleukin enhanee-binding factor 3-0.950.03-0.95 <td< td=""><td></td><td></td><td></td><td></td></td<>				
Mediator of NNA polymerase II transcription subunit 16MED16MED160.04Ras GTPase-activating protein G(k) subunit alphaRASA3-0.960.031Guanien nucleotide-binding protein G(k) subunit alphaGNA13-0.960.009Protein DT1DNI-0.9660.016Activating signal cointegrator 1 complex subunit 1ASCC1-0.960.016September DT1Sector 10.000-0.9660.016Sorrnylgutathione hydrolaseESD-0.960.044Seleno protein A32 kDa subunit 200Seleno protein Silon AD0-0.950.027Protein DT1NPC2-0.950.027-0.950.027Protein S100-AD0SilonAD0-0.950.027-0.950.027Protein S100-AD1SilonAD0-0.950.031-0.950.031Phosphatidylinositol transfer protein alpha isoformRPA1-0.950.030Replication protein A70 kDa DNA-binding subunit gammaPAFAH1B3-0.950.030Ka-9ro dipeptidasePEPD-0.950.030Exocyt complex component 7EXOC7-0.950.030Exocyt complex component 7EXOC7-0.950.030Interleuxin enhance-binding factor 3LIB3-0.950.044E3 ubiquitin-protein ligase HECT03LIB3-0.950.044E3 ubiquitin-protein ligase HECT03RPA2-0.940.075Si Sportein Kinkase 20.94N.D0.950.040Si Sportein kinkase 20.94N.D0.950.040				
Res GTRss-activating protein 3RASA9.0,60.31Protein LAP2ERB82IP0.960.03Guanine nucleotide-binding protein G(k) subunit alphaGNAI3-0,960.09Protein Dr1Activating signal cointegrator 1 complex subunit 1RPA2-0,960.00Replication protein A3 kDa subunitRPA2-0,960.04Selenoprotein A1KDa subunitRPA2-0,960.04Selenoprotein HSELH-0,950.04Epididiymal secretory protein E1NPC2-0,950.04Protein S10AA0S100A10-0,950.013Phosphatidylinositol transfer protein alpha isoformPITPNA-0,950.04Platelet-activating factor acetylhydrolase IB subunit gammaPAFAH1B3-0,950.09Replication protein A7 Xba DNA-binding subunitRPA1-0,950.09Scorgst complex component 7EXOC/7-0,950.020Exocyst complex component 7EXOC/7-0,950.03Glutathione S-transferase omega-1ILB3-0,950.03Glutathione S-transferase omega-1ILB3-0,950.03Interleukin enhankaILB3-0,950.04E3 brobsomel protein S3, mitchondrialMPS35-0,950.03Interleukin enhanka-0,950.04-0,950.04E3 brobsomel protein S3, mitchondrialMPI-0,940,00Martnee-binding factor 3ILB3-0,950.04-0,95S5 protein Kinase 2MPI-0,940,00				
Protein LAP2EBB2/P-0.960.03Guanine nucleotide-binding protein G(k) subunit alphaGNA13-0.960.093Protein DT1DR1-0.960.020Activating signal cointegrator 1 complex subunit 1ASCC1-0.96N.D.Replication protein A 32 kDa subunitRPA2-0.960.044Selenoprotein HSEL-0.950.044Epidotymal secretory protein E1NPC2-0.950.077Protein S100-A10NPC2-0.950.071Prosphatidylinostol transfer protein alpha isoformRPA1-0.950.049Replication protein A7 kDa Subunit gammaRPA1-0.950.049Replication protein A70 kDa DNA-binding subunitRPA1-0.950.05Kaza-Pro dipeptidasePEPD-0.950.05Kaza-Pro dipeptidasePEPD-0.950.0290.023Exocyst complex component 7EXOC7-0.950.023Exocyst complex component 7EXOC7-0.950.033Indtrelin-converting enzyme 1EXCT1-0.950.033Indtrelin-converting enzyme 1EXCT1-0.950.033Interleukin enhancer-binding factor 3ILF3-0.950.033Interleukin enhancer-binding factor 3LIF3-0.950.040SRSF protein kinase 2SRPK2-0.940.075DNA toposomerase 3-beta-1HCT03-0.950.033Interleukin enhancer-binding factor 3ILF3-0.940.033SRSF protein kinase 2SRPK2				
Guanne nucleotide-binding protein G(k) subunit alphaGNA13-0.960.09Protein Dr1DR1-0.960.20Activating signal cointegrator 1 complex subunit 1ASCC1-0.960.016Replication protein A2 kDa subunit 5RPAZ-0.960.04Selenoprotein HSELH-0.950.04Epildidymal secretory protein E1NPC2-0.950.074Protein S100A10-0.950.013-0.950.014Phosphatdylinositol transfer protein alpha isoformPIPNA-0.950.095Replication protein A7 0k Da ONA-binding subunit gammaPAFAH1B3-0.950.095Replication protein A70 kDa ONA-binding subunit gammaPAFAH1B3-0.950.095Excoyst complex component 7Excoyst complex component 7-0.950.020Endothelin-converting enzyme 1ECE1-0.950.033Glutathione 5-transferase omega-1GST01-0.950.03Interleukin enhancer-binding factor 3ILF3-0.950.044Skr protein Nase 2SPR2-0.940.07Nanose-6-phosphate acyltransferase alphaAGPAT1-0.950.040SKS protein Kinase 2SPR2-0.940.07NA cotogenerase 3-bate 31ILF3-0.950.040SKS protein Kinase 2SPR2-0.940.07NA cotogenerase 3-bate 31GRA1-0.940.03NA cotogenerase 3-bate 31GRA1-0.940.03NA cotogenerase 3-bate 31GRA1-0.940.03 <td< td=""><td></td><td></td><td></td><td></td></td<>				
Protein Dr1 DR1 -0.96 0.20 Activating signal cointegrator 1 complex subunit 1 ASCC1 -0.96 N.D. Replication protein A 32 kba subunit RPA2 -0.96 0.044 S-formylglutathione hydrolase ESD -0.95 0.044 Epilotion protein A 32 kba subunit NPC2 -0.95 0.027 Protein S100-A10 NPC2 -0.95 0.013 Phosphatdylinostol transfer protein alpha isoform PIPTNA -0.95 0.044 Platelet-activating factor acelyhydrolase IB subunit gamma PAFAH1B3 -0.95 0.059 Exocyst complex component 7 EXOC7 -0.95 0.023 Exocyst complex component 7 EXOC7 -0.95 0.023 EX3 rhosonal protein A32, hos michondrial MRF335 -0.95 0.023 EX3 rhosonal protein S3, mitchondrial MRF335 -0.95 0.023 EX3 rhosonal protein S3, mitchondrial MRF335 -0.95 0.033 Glutathione S-transferase alpha AGPA11 -0.95 0.044 E3 ubiquitin-protein ligase HECTD3 HECTD				
Activating signal cointegrator 1 complex subunit 1ASCC1-0.96N.D.Replication protein A3 kDa subunitRPA2-0.960.16Selonoprotein HESD-0.960.04Selonoprotein HSELH-0.950.04pididymal secretory protein E1NPC2-0.950.27Protein S100-A10NDC2-0.950.03Phosphatdylinositol transfer protein alpha isoformRPA1-0.950.04Replication protein A7 Nba DNA-binding subunitRPA1-0.950.05Patelet-activating factor actylhydrolase IB subunit gammaPAFAH1B3-0.950.09Excoryt complex component 7EXOC7-0.950.03Glutathione S-transferase omega-1ECT1-0.950.03Glutathione S-transferase omega-1GST01-0.950.03Glutathione S-transferase omega-1GST01-0.950.04La vigueitario protein NSa, mitchondrialMRP53S-0.950.04Manose-6-phosphate acyltransferase alphaKGPA11-0.950.40Manose-6-phosphate acyltransferase alphaKGPA11-0.950.04Manose-6-phosphate isomeraseMPI-0.940.07MAnose-6-phosphate subunit 1TOP3B-0.940.03SKS protein kinase 2DAV-0.940.03DNA topicomerase 3-beta-1MSS10-0.940.03MottoinnetRNA ligase, cytoplasmicMARS-0.940.03MOB kinase activator 1BMOB1B-0.940.03DNA-directed RNA polym			-0,96	0,09
Replication protein A32 kDa subunit RPA2 -0.96 0.16 Sform/glutathione hydrolase ESD -0.96 0.04 Selenoprotein H SELH -0.95 0.27 Protein S100-A10 S100A10 -0.95 0.13 Phosphat/dylinoistol transfer protein alpha isoform RPIR -0.95 0.04 Replication protein A7 bba DNA-binding subunit PHTNA -0.95 0.09 Replication protein A7 bba DNA-binding subunit PAFAH1B3 -0.95 0.09 Excorst complex component 7 EXOC7 -0.95 0.023 Slobasmal protein S35, mitochondrial MRPS35 -0.95 0.03 Glutathione S-transferase omega-1 Glutathione S-transferase omega-1 -0.95 0.03 Interleukin enhancer-binding factor 3 LLF3 -0.95 0.03 Glutathione S-transferase omega-1 KLF16 -0.95 0.04 E3 ubiquitin-protein ligase HECT03 HECT03 -0.95 0.04 Chardyleike factor 16 KLF16 -0.94 N.D. Mannose-ohopsphate acyltransferase alpha KLF16 <td>Protein Dr1</td> <td>DR1</td> <td>-0,96</td> <td>0,20</td>	Protein Dr1	DR1	-0,96	0,20
S-formylglutathione hydrolaseESD-0.960.04Selenoprotein HSELH-0.950.04Selenoprotein HNPC2-0.950.27Protein S100-A10S100A10-0.950.13Phosphatidylinositol transfer protein alpa isoformPITPNA-0.950.09Replication protein A 70 Kba DNA-binding subunitRPA1-0.950.05Xaa-Pro dipeptidasePEPD-0.950.023Exocyst complex component 7EXOC7-0.950.22Exocyst complex component 7EXOC7-0.950.23Editation protein S35, mitochondrialMRP535-0.950.03Gilutathione S-transferase omega-1GST01-0.950.03Interleukin enhancer-binding factor 3IIF3-0.950.44E3 ubiquitin-protein ligase HECTD3HECTD3-0.950.04Ananose-G-posphate acyltransferase alphaAGPA11-0.950.40Krueppel-like factor 16KLF16-0.94N.D.Manose-G-posphate isomeraseMPI-0.940.75DNA topoisomerase 3-beta-1TOP3B-0.94N.D.Heterogeneous nuclear ribonucleoprotein H2HNRNPH2-0.940.03MCHonisneerase 10MAT10-0.940.330.34N-Actifransferase 10MAT1-0.940.330.34N-Actifransferase 10MAT1-0.940.330.34N-Actifransferase 10MAT1-0.940.330.34N-Actifransferase 1POLRMT-0.940.34	Activating signal cointegrator 1 complex subunit 1	ASCC1	-0,96	N.D.
Selenoprotein HSELH-0.950.044Epididymal secretory protein E1NPC2-0.950.27Protein S100-A10S100A10-0.950.03Phosphatidylinositol transfer protein alpha isoformPTPAA-0.950.09Replication protein A 70 kba DNA-binding subunitRPA1-0.950.014Phatelet-attivating factor acetylhydrolase IB subunit gammaPAFAH1B3-0.950.05Xaa-Pro dipeptidasePEPD-0.950.020Exocyst complex component 7EXOC7-0.950.033Glutathione Stars, mitochondrialMPS35-0.950.033Glutathione Stars, mitochondrialGST01-0.950.034Glutathione Stars, mitochondrialLET3-0.950.034Slutathione Stars, mitochondrialLET3-0.950.034Slutathione Stars, mitochondrialMPS35-0.950.034Slutathione Stars, mitochondrialMPS35-0.950.044E3 ubiquitin-protein ligase HCTD3-0.95N.D0.951.acyl-sn.gyterol-3-phosphate acyltransferase alphaAGPAT1-0.950.040Krueppel-like factor 16KLF16-0.94N.D.Mannose-6-phosphate isomeraseMPI-0.940.075DNA topoisomerase 3-beta-1TOP3B-0.940.075DNA topoisomerase 3-beta-1GAR1-0.940.033Nacetyltransferase 10NAT0-0.940.033Na-detyltransferase 10NAT0-0.940.033Na-detyltransferase 10N	Replication protein A 32 kDa subunit	RPA2	-0,96	0,16
Épididymal secretory protein E1NPC2-0.950.27Protein S100-A10S100A10-0.950.03Phosphatidylinositol transfer protein alpha isoformPITPNA-0.950.09Replication protein A 70 kDa DNA-binding subunitRPA1-0.950.05Naa-Pro dipeptidasePPED-0.950.09Exocyst complex component 7EXOC7-0.950.020Exocyst complex component 7EXOC7-0.950.03Glutathione S-transferase omega-1GST01-0.950.03Glutathione S-transferase omega-1GST01-0.950.04Interleukin enhancer-binding factor 3ILF3-0.950.04E Jubiquiti-protein ligase HECT03HECT03-0.950.041 acyl-sn-glycerol-3-phosphate acyltransferase alphaAGPAT1-0.950.40Kruespel-like factor 16KLF16-0.94N.D.0.40SRSF protein kinase 2SPR2-0.940.750.75DNA topiosomerase 3-beta-1HNRNPH2-0.940.070.43HActribonucleoprotein M2HNRNPH2-0.940.030.34N-acetyltransferase 10MARS-0.940.030.34N-Actribonucleoprotein complex subunit 1GAR1-0.940.03N-Actribonucleoprotein R2HNRNPH2-0.940.03N-Actribonucleoprotein R2MARS-0.940.03N-Actribonucleoprotein R2MARS-0.940.03N-Actribonucleoprotein R2MARS-0.940.03N-	S-formylglutathione hydrolase	ESD	-0,96	0,04
Protein S100-A10S100A10-0.950,13Phosphatidylinositol transfer protein alpha isoformPITPNA-0.950,09Replication protein A 70 Kba DNA-binding subunitRPA1-0.950,05Platelet-activating factor acetylhydrolase IB subunit gammaPAFAH1B3-0.950,05Xaa-Pro dipeptidasePEPD-0.950,020Excoryst complex component 7EXOC7-0.950,020Endothelin-converting enzyme 1ECE1-0.950,033Glutathione S-transferase omega-1GST01-0.950,034Interleukin enhancer-binding factor 3ILF3-0.950,040E3 Ubiquitin-protein ligase HECTD3HECTD3-0.950,400Yurueppel-like factor 16KL716-0.94N.D.Manose-6-phosphate isomeraseMPI-0.940,400SRSF protein kinase 20.940,750,034DNA topiosimerase 3-beta-1TOP38-0.940,075Hetrogeneous nuclear ribonucleoprotein H2MARS-0.940,07H/ACA ribonucleoprotein complex subunit 1-0.940,334-0.940,334Methionine-rtRNA ligase, cytoplasmicMARS-0.940,33-0.940,33DNA-doilarese ativator 18MOB18-0.940,33-0.940,33DNA-doilarese ativator 18MOB18-0.940,33-0.940,33DNA-doilarese TRNA ligase, cytoplasmicMARS-0.940,33-0.940,33DNA-dicreted RNA polymerase, mitochondrialMOB18<	Selenoprotein H	SELH	-0,95	0,04
Phosphatidylinositol transfer protein alpha isoformPITPNA-0.950.09Replication protein A 70 kDa DNA-binding subunitRPA1-0.950.05Xaa-Pro dipeptidasePAFAH183-0.950.05Xaa-Pro dipeptidasePEPD-0.950.09Exocyst complex component 7ECC1-0.950.20Endothelin-converting enzyme 1ECC1-0.950.03Glutathione 5-transferase omega-1ILF3-0.950.04E3 ubiquitin- protein S35, mitochondrialILF3-0.950.04E3 ubiquitin- protein ligase HECTD3-0.950.040.04E3 ubiquitin- protein ligase HECTD3-0.950.40N.D.1-acyl-sn-glycerol-3-phosphate acyltransferase alphaKLF16-0.94N.D.Mannose-6-phosphate isomeraseMPI-0.940.070.75DNA topolsomerase 3-beta-1MNRNPH2-0.940.750.03Heterogeneous nuclear ribonucleoprotein H2HNRNPH2-0.940.03MA-dripter Karba ferase 10MARS-0.940.030.34Methionine-tRNA ligase, cytoplasmicMARS-0.940.03DNA-dripceted RNA polymerase, mitochondrialMOB1B-0.940.03DNA-dripceted RNA polymerase 11-0.940.030.22DNA-dripcetorin RD23 homolog ARAD23A-0.940.03DNA-dripcetorin BD2MARS-0.940.030.22DNA-dripcetorin BD2MARS-0.940.030.22DNA-dripcetorin BD2MARS-0	Epididymal secretory protein E1	NPC2	-0,95	0,27
Replication protein A 70 kDa DNA-binding subunitRPA1-0.950.14Platelet-activating factor actylhydrolase IB subunit gammaPAFAH1B3-0.950.05Xaa-Pro dipeptidasePEPD-0.950.09Exocyst complex component 7EXOC7-0.950.20Endothelin-converting enzyme 1ECC1-0.950.03Glutathione S-transferase omega-1GST01-0.950.03Interleukin enhancer-binding factor 3ILF3-0.950.03Interleukin enhancer-binding factor 3ILF3-0.950.04E3 ubiquitin-protein ligase HECTD3-0.95N.D0.95N.D.1-acyl-sn glycerol-3-phosphate acyltransferase alphaAGPAT1-0.950.40Krueppel-like factor 16KLF16-0.94N.D.N.D.Mannose-6-phosphate isomeraseSRPK2-0.940.400.40SRSF protein kinase 2SRPK2-0.940.400.40NA copylaransferase alphaTOP3B-0.940.400.40NA copylaransferase 10NAT10-0.940.400.40NA copylaransferase 2SRPK2-0.940.750.44DNA topoisomerase 3-beta-1TOP3B-0.940.400.40N-actyltransferase 10NAT10-0.940.430.44MethoinetRNA ligase, cytoplasmicMARS-0.940.330.43DNA-directed RNA polymerase, mitochondrialMOB1B-0.940.030.22Thioredoxin-interacting protein AD23 homolog ASNSD1-	Protein S100-A10	S100A10	-0,95	0,13
Replication protein A 70 kDa DNA-binding subunitRPA1-0.950.14Platelet-activating factor actylhydrolase IB subunit gammaPAFAH1B3-0.950.05Xa-Pro dipeptidasePEPD-0.950.00Exocyst complex component 7EXOC7-0.950.20Endothelin-converting enzyme 1ECE1-0.950.03Glutathione S-transferase omega-1GST01-0.950.03Interleukin enhancer-binding factor 3ILF3-0.950.04E3 ubiquitin-protein ligase HECD3AGPA11-0.950.041-acyl-sn glycerol-3-phosphate acyltransferase alphaKLF16-0.940.40Krueppel-like factor 16KLF16-0.940.400.40SRSF protein kinase 2SRPK2-0.940.070.03DNA topoisomerase 3-beta-1TOP38-0.940.070.03Heterogeneous nuclear ribonucleoprotein H2HNRNPH2-0.940.03N-acetyltransferase 10NAT10-0.940.030.03N-Acetyltransferase 10MARS-0.940.030.03N-acetyltransferase 10NAT10-0.940.030.03N-acetyltransferase 10MARS-0.940.030.03N-Acetyltransferase 10MARS-0.940.030.03N-Acetyltransferase 10MARS-0.940.030.02N-Acetyltransferase 10MARS-0.940.030.02N-Acetyltransferase 10MARS-0.940.030.02N-Acetyltransferase 11<	Phosphatidylinositol transfer protein alpha isoform	PITPNA	-0,95	0,09
Platelet-activating factor acetylhydrolase IB subunit gamma PAFAH1B3 -0,95 0,05 Xaa-Pro dipeptidase PEPD -0,95 0,09 Exocyst complex component 7 EXOC7 -0,95 0,20 Endothelin-converting enzyme 1 ECE1 -0,95 0,03 285 ribosomal protein S35, mitochondrial MRPS35 -0,95 0,03 Glutathione 5-transferase omega-1 Interleukin enhancer-binding factor 3 -0,95 0,03 E1 ubiquitin-protein ligase HECTD3 HECTD3 -0,95 0,40 Krueppel-like factor 16 KLF16 -0,94 0,40 Mannose-6-phosphate acyltransferase alpha KLF16 -0,94 0,40 SRSF protein kinase 2 SRPK2 -0,94 0,75 DNA topoisomerase 3-beta-1 Hetrogeneous nuclear ribonucleoprotein H2 MRNNPH2 -0,94 0,07 Hetrogeneous nuclear ribonucleoprotein H2 MARS -0,94 0,03 -0,34 0,07 DNA-dipcetde RNA polymerase, mitochondrial MARS -0,94 0,03 0,07 DNA-directde RNA polymerase, mitochondrial M		RPA1		
Xaa-Pro dipeptidasePEPD-0,950,09Exocyt complex component 7EXOC7-0,950,20Endothelin-converting enzyme 1ECE1-0,950,23285 ribosomal protein S35, mitchondrialMRPS35-0,950,03Glutathione 5-transferase omega-1GST01-0,950,04E3 ubiquitn-protein ligase HECTD3HECTD3-0,95N.D.1-acyl-sn-glycerol-3-phosphate acyltransferase alphaAGPAT1-0,950,40Krueppel-likk factor 16KLF16-0,940,40Mannose-6-phosphate isomeraseMPI-0,940,75DNA topoisomerase 3-beta-1TOP38-0,940,07Heterogeneous nuclear ribonucleoprotein H2HNRNPH2-0,940,31N-acetyltransferase 10NATI0-0,940,33N-acetyltransferase 10NATI0-0,940,33DNA-directed RNA polymerase, mitchondrialMARS-0,940,38MOB kinase activator 18MOB18-0,940,03DNA-directed RNA polymerase, mitchondrialMARS-0,940,38MOB kinase activator 18MOB18-0,940,38UV excision repair protein RAD23 homolog ARD-0,940,32Epsin-1-0,930,22-0,940,33Diacylg/ycerol-acyltransferase 1MC-0,940,38MOB kinase activator 18-0,940,030,22Thoredoxin-interacting protein RAD23 homolog ARD-0,940,33Epsin-1-0,930,22-0,94 <td< td=""><td></td><td></td><td></td><td></td></td<>				
Exocyst complex component 7EXOC7-0.950.20Endothelin-converting enzyme 1ECE1-0.950.23285 ribosomal protein S35, mitochondrialMRPS35-0.950.03GST01-0.950.030.01Interleukin enhancer-binding factor 3ILF3-0.950.04E3 ubiquitin-protein ligase HECD3HECD3-0.950.041-acyl-sn-glyccrol-3-phosphate acyltransferase alphaKCF01-0.950.40Krueppel-like factor 16KLF16-0.940.40Manose-6-phosphate isomeraseMPI-0.940.40SRF protein kinase 2SRPK2-0.940.07DNA topoisomerase 3-beta-1TOP3B-0.940.07Heterogeneous nuclear ribonucleoprotein H2HNRNPH2-0.940.03N-acetyltransferase 10MART0-0.940.34Methionine-tRNA ligase, cytoplasmicMARS-0.940.03DNA-directed RNA polymerase, mitochondrialPOLRMT-0.940.03MOS linase activator 18MOB1B-0.940.03UV excision repair protein RAD23 homolog ARAD23A-0.940.01Epsin-1EPN1-0.930.221.02Thioredoxin-interacting proteinOmplex subunit 4OGA1-0.930.22Diacylgycerol -acyltransferase 10MCR1-0.930.221.02Drotein repair protein RAD23 homolog ARAD23A-0.940.01Epsin-1EPN1-0.930.221.021.02Thoredoxin-inter				
Endothelin-converting enzyme 1ECE 1-0.950.23285 ribosomal protein S35, mitochondrialMRPS35-0.950.03285 ribosomal protein S35, mitochondrialGST01-0.950.03interleukin enhancer-binding factor 3ILF3-0.950.04E3 ubiquitin-protein ligase HECD3HECD3-0.950.401-acyl-sn-glycerol-3-phosphate acyltransferase alphaAGPAT1-0.950.40Krueppel-like factor 160.944N.D.0.40N.D.Mannose-6-phosphate isomeraseMPI-0.940.40SRSF protein kinase 2SRPK2-0.940.75DNA topoisomerase 3-beta-1TOP3B-0.940.07Heterogeneous nuclear ribonucleoprotein H2HNRNPH2-0.940.03N-acetyltransferase 10NAT10-0.940.33N-acetyltransferase 10MARS-0.940.03DNA-directed RNA polymerase, mitochondrialPOLRMT-0.940.38DNA-directed RNA polymerase, mitochondrialMOR1B-0.940.38MOB kinase activator 18MOB1B-0.940.32UV excision repair protein RAD23 homolog ARAD23A-0.940.02Epsin-1Epsin-1-0.930.220.27Thioredoxin-interacting proteinJCAT-0.930.22Diacylglycerol -acyltransferase 1DCAC-0.930.22Diacylglycerol -acyltransferase 1CAC-0.930.13Phosphorylase b kinase regulatory subunit betaPHKB-0.930.12				
285 ribosomal protein S35, mitochondrialMRPS35-0.950.03Glutathione 5-transferase omega-1GST01-0.950.03Interleukin enhancer-binding factor 3ILF3-0.950.0428 Jubiquitin-protein ligase HECTD3HECTD3-0.950.041-acyl-sn-glycerol-3-phosphate acyltransferase alphaAGPAT1-0.950.40Krueppel-like factor 16KLF16-0.940.75Mannose-6-phosphate isomeraseMPI-0.940.75DNA topoisomerase 3-beta-1TOP38-0.940.75DNA topoisomerase 3-beta-1GAR1-0.940.03Heterogeneous nuclear ribonucleoprotein H2HNRNPH2-0.940.03M-acetyltransferase 10NATIO-0.940.03MothioninetRNA ligase, cytoplasmicNARS-0.940.03MAG1 and polymerase, mitochondrialPOLRMT-0.940.03MOS linase activator 18-0.940.030.38DV-dexision repair protein RAD23 homolog ARAD23A-0.940.03Epsin-1SNSD1-0.940.020.32Thioredoxin-interacting protein complex subunit 4DGA11-0.930.22Diacylg/yeerol 0-acyltransferase 1DGA11-0.930.22Thioredoxin-interacting protein 316ZMF316-0.930.33Phosphorylase b kinase regulatory subunit betaTXNIP-0.930.33Phosphorylase b kinase regulatory subunit betaPHKB-0.930.12Phosphorylase b kinase regulatory subunit betaTRA26				
Glutathione S-transferase omega-1GST01-0,950,03Interleukin enhancer-binding factor 3ILF3-0,950,04E3 ubiquitin-protein ligase HECTD3HECTD3-0,950,40I-acyl-sn-glycerol-3-phosphate acyltransferase alphaAGPAT10,950,40Krueppel-like factor 16KLF16-0,94N.D.Mannose-6-phosphate isomeraseMPI-0,940,40SRSF protein kinase 2SRPK2-0,940,75DNA topiosomerase 3-beta-1TOP38-0,94N.D.Heterogeneous nuclear ribonucleoprotein H2HNRNPH2-0,940,07H/ACA ribonucleoprotein complex subunit 1GAR1-0,940,33N-acetyltransferase 10NAT10-0,940,34Methionine-tRNA ligase, cytoplasmicMARS-0,940,03DNA-directed RNA polymerase, mitochondrialPOLRMT-0,940,08MOB liaase activator 18MOB18-0,940,31UV excision repair protein RAD23 homolog ARAD23A-0,940,01Epsin-1EPN1-0,930,221Thioredoxin-interacting proteinDGAT1-0,930,22Thioredoxin-interacting protein complex subunit 4DKC1-0,930,33H/ACA ribonucleoprotein complex subunit 4DKC1-0,930,37Zinc finger protein 316PHK8-0,930,12Phosphorylase b kinase regulatory subunit betaPHK8-0,930,12Phosphorylase b kinase regulatory subunit betaPHK8-0,930,12<				
Interleukin enhancer-binding factor 3ILF3-0.950.04E3 ubiquitin-protein ligase HECTD3HECTD3-0.95N.D.1-acyl-sn-glycerol-3-phosphate acyltransferase alphaAGPAT1-0.950.400Krueppel-like factor 16KLF16-0.940.05N.D.Mannose-6-phosphate isomeraseMPI-0.940.400SRSF protein kinase 2SRPK2-0.940.75DNA topoisomerase 3-beta-1TDP3B-0.940.07Heterogeneous nuclear ribonucleoprotein H2HNRNPH2-0.940.03N-acetyltransferase 10NAT10-0.940.33N-acetyltransferase 10MARS-0.940.33DA-directed RNA polymerase, mitochondrialMOR1B-0.940.38DV excision repair protein RAD23 homolog ARAD23A-0.940.01Epsin-1EPN1-0.930.220.22Thioredoxin-interacting protein complex subunit 4DGAT1-0.930.22Diacylgycerol -acyltransferase 1DGAT1-0.930.22Diacylgycerol -acyltransferase 1DGAT1-0.930.22Diacylgycerol -acyltransferase 1DGAT1-0.930.13H/ACA ribonucleoprotein complex subunit 4DGAT1-0.930.13Phosphorylase binase regulatory subunit betaPHKB-0.930.13Phosphorylase binase regulatory subunit betaPHKB-0.930.13Phosphorylase binase regulatory subunit betaPHKB-0.930.12Phorylade-binding protein 1FNA2B				
E3 ubiquitin-protein ligase HCTD3HECTD3-0.95N.D.1-acyl-sn-glycerol3-phosphate acyltransferase alphaAGPAT1-0.950.40Krueppel-like factor 16KLF16-0.940.40Mannose-6-phosphate isomeraseMPI-0.940.40SRSF protein kinase 2SRPK2-0.940.75DNA topoisomerase 3-beta-1TOP3B-0.940.07Heterogeneous nuclear ribonucleoprotein H2HNRNPH2-0.940.03Acactyltransferase 10NAT10-0.940.33N-acetyltransferase 10NAT10-0.940.33MethioninetRNA ligase, cytoplasmicMARS-0.940.03DNA-directed RNA polymerase, mitochondrialPOLRMT-0.940.38MOB kinase activator 18MOB1B-0.940.03UV excision repair protein RAD23 homolog AFPN1-0.930.22Thioredoxin-interacting protein complex subunit 4DKC1-0.930.22Diacylg/ycerol 0-acyltransferase 1DGAT1-0.930.37H/ACA ribonucleoprotein complex subunit 4ZMS16-0.930.13Phosphorylase b kinase regulatory subunit betaPHKB-0.930.13Phosphorylase b kinase regulatory subunit betaPHKB-0.930.13Phosphorylase b kinase regulatory subunit betaPHKB-0.930.12Phosphorylase b kinase regulatory subunit betaPHKB-0.930.12Phosphorylase b kinase regulatory subunit betaPHKB-0.930.12Phosphorylase b kinase regulato				
1-acylsn-glycerol-3-phosphate acyltransferase alphaAGPAT1-0.950.40Krueppel-like factor 16KLF16-0.94N.D.Mannose-6-phosphate isomeraseMPI-0.940.40SRSF protein kinase 20.940.750.40DNA topoisomerase 3-beta-1TOP3B-0.940.75DNA topoisomerase 3-beta-1TOP3B-0.940.07H/ACA ribonucleoprotein complex subunit 1GAR1-0.940.03MethioninetRNA ligase, cytoplasmicNAT10-0.940.38MOB inase activator 18MOB1B-0.940.03MV excision repair protein RAD23 homolog ARAD23A-0.940.01Epsin-1TXNIP-0.930.22Thioredoxin-interacting protein complex subunit 4DKC1-0.930.22Diacylg/ycerol 0-acyltransferase 1DGAT1-0.930.37Zinc finger protein subunit 4DKC1-0.930.37Zinc finger protein homolog betaPHKB-0.930.12Phosphorylase binase regulatory subunit betaTRA2B-0.930.12Polyadenylate-binding protein 1PABPC1-0.930.12				
Krueppel-like factor 16KLF16-0,94N.D.Mannose-6-phosphate isomeraseMPI-0,940,40SRSF protein kinase 2SRPK2-0,940,75DNA topoisomerase 3-beta-1TOP3B-0,94N.D.Heterogeneous nuclear ribonucleoprotein H2HNRNPH2-0,940,07H/ACA ribonucleoprotein complex subunit 1GAR1-0,940,33N-acetyltransferase 10NAT10-0,940,34Methionine-tRNA ligase, cytoplasmicMARS-0,940,03DNA-directed RNA polymerase, mitochondrialPOLRMT-0,940,08MOB linase activator 18MOB1B-0,940,01Epsin-1EPN1-0,930,22Thioredoxin-interacting proteinDGAT1-0,930,22Thioredoxin-interacting protein complex subunit 4DKC1-0,930,37Zinc finger protein 316ZMF316-0,930,13Phosphorylase b kinase regulatory subunit betaPHKB-0,930,12Polyadenylate-binding protein 1PABPC1-0,930,12				
Mannose-6-phosphate isomeraseMPI-0.940,40SRSF protein kinase 2SRPK2-0.940,75DNA topoisomerase 3-beta-1TOP3B-0.940,07Heterogeneous nuclear ribonucleoprotein H2HNRNPH2-0.940,07H/ACA ribonucleoprotein complex subunit 1GAR1-0.940,13N-acetyltransferase 10NAT10-0.940,03DNA-directed RNA polymerase, mitochondrialPOLRMT-0.940,03DNA-directed RNA polymerase, mitochondrialMOR1B-0.940,38MOB kinase activator 18MOB1B-0.940,31UV excision repair protein RAD23 homolog ARAD23A-0.940,01Epsin-1EPN1-0.930,22Thioredoxin-interacting proteinJOR31-0.930,22Diacylg/verol 0-acyltransferase 1DKC1-0.930,37Zinc finger protein 316ZNF316-0.930,13Phosphorylase b kinase regulatory subunit betaPHKB-0.930,12Phoyadenylate-binding protein 1TNA2-0.940,01				
SRSF protein kinase 2SRPK2-0,940,75DNA topoisomerase 3-beta-1TOP3B-0,94N.D.Heterogeneous nuclear ribonucleoprotein H2HNRNPH2-0,940,07H/ACA ribonucleoprotein complex subunit 1GAR1-0,940,13N-acetyltransferase 10NAT10-0,940,03MethioninetRNA ligase, cytoplasmicMARS-0,940,03DNA-directed RNA polymerase, mitochondrialPOLRMT-0,940,08MOB kinase activator 1BMOB1B-0,940,01Epsin-1-0,940,01Epsin-1-0,940,01Epsin-1EPN1-0,930,220,02Thioredoxin-interacting protein complex subunit 4DKC1-0,930,22Diacylg/ycerol 0-acyltransferase 1DGAT1-0,930,37Zinc finger protein 316CMS16-0,930,13Phosphorylase b kinase regulatory subunit betaPHKB-0,930,12Phosphorylase b kinase regulatory subunit betaPHKB-0,930,12Polyadenylate-binding protein 1-0,940,01-0,930,12				
DNA topoisomerase 3-beta-1TOP3B-0.94N.D.Heterogeneous nuclear ribonucleoprotein H2HNRNPH2-0.940.07H/ACA ribonucleoprotein complex subunit 1GAR1-0.940.13N-acetyltransferase 10NAT10-0.940.34MethioninetRNA ligase, cytoplasmicMARS-0.940.03DNA-directed RNA polymerase, mitochondrialPOLRNT-0.940.08MOB linase activator 18MOB1B-0.940.03DV excision repair protein RAD23 homolog ARAD23A-0.940.01Epsin-1-0.930.22Thioredoxin-interacting protein0GA71-0.930.22Thioredoxin-interacting protein complex subunit 4DKC1-0.930.372.030.37Zinc finger protein 316PHKB-0.930.13-0.940.13Phosphorylase b kinase regulatory subunit betaTRA2B-0.930.12Polyadenylate-binding protein 1PABPC1-0.930.01				
Heterogeneous nuclear ribonucleoprotein H2 HNRNP12 -0.94 0.07 H/ACA ribonucleoprotein complex subunit 1 GAR1 -0.94 0.13 N-acetyltransferase 10 NAT10 -0.94 0.03 MethioninetRNA ligase, cytoplasmic MARS -0.94 0.03 DNA-directed RNA polymerase, mitochondrial POLRMT -0.94 0.08 MOB kinase activator 1B MOB1B -0.94 0.01 UV excision repair protein RAD23 homolog A RAD23A -0.94 0.01 Epsin-1 -0.93 0.22 0.03 0.04 Thioredoxin-interacting protein DGAT1 -0.93 0.22 Diacylg/ycerol -acyltransferase 1 DGAT1 -0.93 0.22 Diacylg/ycerol -acyltransferase 1 DGAT1 -0.93 0.23 Lioc finger protein 316 ZMF316 -0.93 0.37 Phosphorylase b kinase regulatory subunit beta PHKB -0.93 0.13 Phosphorylase b kinase regulatory subunit beta PHABPC1 -0.93 0.01 Polyadenylate-binding protein 1 OABPC1				
H/ACA ribonucleoprotein complex subunit 1 GAR1 -0,94 0,13 N-acetyltransferase 10 NAT10 -0,94 0,34 MethioninetRNA ligase, cytoplasmic MARS -0,94 0,03 DNA-directed RNA polymerase, mitochondrial POLRMT -0,94 0,08 MOB kinase activator 1B MOB1B -0,94 0,01 UV excision repair protein RAD23 homolog A RAD23A -0,94 0,01 Epsin-1 EPN1 -0,93 0,22 Thioredoxin-interacting protein JOG7 -0,93 0,22 Diacylglycerol 0-acyltransferase 1 DGAT1 -0,93 0,22 Licr finger protein complex subunit 4 DKC1 -0,93 0,27 Zinc finger protein complex subunit 4 DKC1 -0,93 0,37 Zinc finger protein 316 ZNF316 -0,93 0,13 Phosphorylase b kinase regulatory subunit beta PHKB -0,93 0,12 Polyadenylate-binding protein 1 PABPC1 -0,93 0,01				
N-acetyltransferase 10NAT10-0,940,34MethioninetRNA ligase, cytoplasmicMARS-0,940,03DNA-directed RNA polymerase, mitochondrialPOLRMT-0,940,08MOB kinase activator 1BMOB RIB-0,940,38MV excision repair protein RAD23 homolog ARAD23A-0,940,01Epsin-1-0,930,220Thioredoxin-interacting proteinDKAT-0,930,22Diacylglycerol 0-acyltransferase 1DGAT1-0,930,37Zinc finger protein 316ZNF316-0,930,13Phosphorylase b kinase regulatory subunit betaPHKB-0,930,12Polyadenylate-binding protein 1PABPC1-0,930,01				0,07
MethioninetRNA ligase, cytoplasmic MARS -0,94 0,03 DNA-directed RNA polymerase, mitochondrial POLRNT -0,94 0,08 MOB kinase activator 1B MOB1B -0,94 0,38 MUV excision repair protein RAD23 homolog A RAD23A -0,94 0,01 Epsin-1 -0,93 0,22 0,01 Thioredoxin-interacting protein FN1 -0,93 0,22 Diacylg/ycerol 0-acyltransferase 1 DGAT1 -0,93 0,22 Li/ACA ribonucleoprotein complex subunit 4 DKC1 -0,93 0,37 Zinc finger protein 316 ZNF316 -0,93 0,13 Phosphorylase b kinase regulatory subunit beta PHKB -0,93 0,12 Polyadenylate-binding protein 1 PABPC1 -0,93 0,01				
DNA-directed RNA polymerase, mitochondrial POLRMT -0,94 0,08 MOB kinase activator 1B MOB1B -0,94 0,38 MOB kinase activator 1B MOB1B -0,94 0,38 UV excision repair protein RAD23 homolog A RAD23A -0,94 0,01 Epsin-1 -0,93 0,22 -0.94 0,01 Locylglycerol 0-acyltransferase 1 DGAT1 -0,93 0,22 Diacylglycerol 0-acyltransferase 1 DGAT1 -0,93 0,22 Zinc finger protein 316 ZNF316 -0,93 0,37 Phosphorylase b kinase regulatory subunit beta PHKB -0,93 0,12 Polyadenylate-binding protein 1 TRA2B -0,93 0,01	N-acetyltransferase 10	NAT10	-0,94	0,34
DNA-directed RNA polymerase, mitochondrial POLRMT -0,94 0,08 MOB kinase activator 1B MOB1B -0,94 0,38 MOD kinase activator 1B MOB1B -0,94 0,38 UV excision repair protein RAD23 homolog A RAD23A -0,94 0,01 Epsin-1 EPN1 -0,93 0,22 Thioredoxin-interacting protein DGA71 -0,93 0,22 Diacylg/ycerol 0-acyltransferase 1 DGA71 -0,93 0,22 L/ACA ribonucleoprotein complex subunit 4 DKC1 -0,93 0,37 Zinc finger protein 316 ZMF316 -0,93 0,13 Phosphorylase b kinase regulatory subunit beta PHKB -0,93 0,12 Polyadenylate-binding protein 1 PABPC1 -0,93 0,01	MethioninetRNA ligase, cytoplasmic	MARS	-0,94	0,03
MOB kinase activator 1B MOB1B -0,94 0,38 ASNSD1 -0,94 N.D. UV excision repair protein RAD23 homolog A RAD23A -0,94 0,01 Epsin-1 EPN1 -0,93 0,22 Thioredoxin-interacting protein TXNIP -0,93 0,22 Diacylglycerol O-acyltransferase 1 DGAT1 -0,93 0,37 Zinc finger protein 316 O.9,33 0,13 Phosphorylase b kinase regulatory subunit beta PKB -0,93 0,12 Polyadenylate-binding protein 1 TRA2B -0,93 0,01	DNA-directed RNA polymerase, mitochondrial	POLRMT		
ASNSD1 -0.94 N.D. UV excision repair protein RAD23 homolog A RAD23A -0.94 0.01 Epsin-1 EPN1 -0.93 0.22 Thioredoxin-interacting protein TXNIP -0.93 0.22 Diacylglycerol O-acyltransferase 1 DGAT1 -0.93 0.22 LiACA ribonucleoprotein complex subunit 4 DKC1 -0.93 0.37 Zinc finger protein 316 -0.93 0.13 Phosphorylase b kinase regulatory subunit beta PHKB -0.93 0.12 Polyadenylate-binding protein 1 OABPC1 -0.93 0.01				
UV excision repair protein RAD23 homolog A RAD23A -0,94 0,01 Epsin-1 EPN1 -0,93 0,22 Thioredoxin-interacting protein TXNIP -0,93 0,22 Diacylglycerol 0-acyltransferase 1 DGAT1 -0,93 N.D. H/ACA ribonucleoprotein complex subunit 4 DKC1 -0,93 0,37 Zinc finger protein 316 2NF316 -0,93 0,13 Phosphorylase b kinase regulatory subunit beta PHKB -0,93 0,12 Polyadenylate-binding protein 1 PABPC1 -0,93 0,01				
Epsin-1 EPN1 -0,93 0,22 Thioredoxin-interacting protein TXNIP -0,93 0,22 Diacylglycerol 0-acyltransferase 1 DGAT1 -0,93 0,22 Jack piloyeerol 0-acyltransferase 1 DGAT1 -0,93 0,037 JACA ribonucleoprotein complex subunit 4 DKC1 -0,93 0,137 Zinc finger protein 316 ZMF316 -0,93 0,13 Phosphorylase b kinase regulatory subunit beta PHKB -0,93 0,12 Transformer-2 protein homolog beta TRA2B -0,93 0,01 Polyadenylate-binding protein 1 -0,93 0,63				
Thioredoxin-interacting protein TXNIP -0,93 0,22 Diacylglycerol O-acyltransferase 1 DGAT1 -0,93 N.D. H/ACA ribonucleoprotein complex subunit 4 DKC1 -0,93 0,37 Zinc finger protein 316 -0,93 0,13 -0,93 0,13 Phosphorylase b kinase regulatory subunit beta PHK8 -0,93 0,12 Transformer-2 protein homolog beta TRA2B -0,93 0,01 Polyadenylate-binding protein 1 PABPC1 -0,93 0,63				
Diacylglycerol O-acyltransferase 1 DGAT1 -0,93 N.D. H/ACA ribonucleoprotein complex subunit 4 DKC1 -0,93 0,37 Zinc finger protein 316 ZNF316 -0,93 0,13 Phosphorylase b kinase regulatory subunit beta PHKB -0,93 0,12 Transformer-2 protein homolog beta TRA28 -0,93 0,01 Polyadenylate-binding protein 1 PABPC1 -0,93 0,63				
H/ACA ribonucleoprotein complex subunit 4 DKC1 -0,93 0,37 Zinc finger protein 316 ZNF316 -0,93 0,13 Phosphorylase b kinase regulatory subunit beta PHKB -0,93 0,12 Transformer-2 protein homolog beta TRA2B -0,93 0,01 Polyadenylate-binding protein 1 PABPC1 -0,93 0,63				
Zinc finger protein 316 ZNF316 -0,93 0,13 Phosphorylase b kinase regulatory subunit beta PHKB -0,93 0,12 Transformer-2 protein homolog beta TRA2B -0,93 0,01 Polyadenylate-binding protein 1 PABPC1 -0,93 0,63				
Phosphorylase b kinase regulatory subunit beta PHKB -0,93 0,12 Transformer-2 protein homolog beta TRA2B -0,93 0,01 Polyadenylate-binding protein 1 PABPC1 -0,93 0,63				
Transformer-2 protein homolog beta TRA2B -0,93 0,01 Polyadenylate-binding protein 1 PABPC1 -0,93 0,63				
Polyadenylate-binding protein 1 PABPC1 -0,93 0,63				
Isnurportin-1 SNUPN -0,92 0,06				
	Snurportin-1	SNUPN	-0,92	0,06

DNA directed DNA extension III entropy (2000)	001020	0.02	0.57
DNA-directed RNA polymerase III subunit RPC3	POLR3C PTPN11	-0,92	0,57
Tyrosine-protein phosphatase non-receptor type 11		-0,92	0,07
MORC family CW-type zinc finger protein 2	MORC2	-0,92	0,11
AMP deaminase 2	AMPD2	-0,92	0,68
Thimet oligopeptidase	THOP1	-0,92	0,04
Nuclear receptor coactivator 7	NCOA7	-0,91	0,19
Tubulin-specific chaperone D	TBCD	-0,91	0,06
Erlin-2	ERLIN2	-0,91	0,47
Alpha-endosulfine	ENSA	-0,91	0,77
Zinc finger FYVE domain-containing protein 1	ZFYVE1	-0,91	0,29
DNA repair protein RAD50	RAD50	-0,91	0,04
Protein KRI1 homolog	KRI1	-0,91	0,49
Heat shock factor protein 1	HSF1	-0,91	N.D.
ATP-dependent RNA helicase DDX51	DDX51	-0,91	0,21
Serine/threonine-protein phosphatase 2A 65 kDa regulatory subunit A alpha isoform	PPP2R1A	-0,91	0,18
La-related protein 7	LARP7	-0,91	0,19
Probable RNA-binding protein EIF1AD	EIF1AD	-0,91	0,08
Retinoic acid receptor RXR-beta	RXRB	-0,90	N.D.
Acyl-protein thioesterase 2	LYPLA2	-0,90	0,01
Sarcoplasmic/endoplasmic reticulum calcium ATPase 2	ATP2A2	-0,90	0,18
Sorting nexin-1	SNX1	-0,90	0,13
Cyclin-dependent kinases regulatory subunit 2	CKS2	-0,90	N.D.
Mothers against decapentaplegic homolog 3	SMAD3;SMAD2;SMAD9	-0,90	0,46
Cactin	CACTIN	-0,90	0,19
Transcription elongation factor B polypeptide 3	TCEB3	-0,90	N.D.
Serine palmitoyltransferase 2	SPTLC2	-0,89	0,05
Heterogeneous nuclear ribonucleoprotein D0	HNRNPD	-0,89	0,00
U3 small nucleolar ribonucleoprotein protein IMP3	IMP3	-0,89 -0,89	0,00
Complement component 1 Q subcomponent-binding protein, mitochondrial	C1QBP	-0,89 -0,89	0,07 0,06
Vitamin K-dependent protein S	PROS1	-0,89	0,27
General transcription factor IIH subunit 2-like protein	GTF2H2C;GTF2H2	-0,89	0,08
Transmembrane protein 261	TMEM261	-0,89	N.D.
Pre-mRNA-splicing factor SPF27	BCAS2	-0,89	0,08
Transmembrane protein 256	TMEM256	-0,88	0,04
Zinc finger CCHC domain-containing protein 3	ZCCHC3	-0,88	N.D.
Eukaryotic translation elongation factor 1 epsilon-1	EEF1E1	-0,88	0,35
Calmegin	CLGN	-0,88	0,10
Transcription initiation factor IIA subunit 2	GTF2A2	-0,88	0,24
Protein phosphatase 1 regulatory subunit 12A	PPP1R12A	-0,88	0,05
Translation initiation factor eIF-2B subunit beta	EIF2B2	-0,88	0,07
Myb-binding protein 1A	MYBBP1A	-0,88	0,04
Probable 28S rRNA (cytosine(4447)-C(5))-methyltransferase	NOP2	-0,88	0,10
Transcription and mRNA export factor ENY2	ENY2	-0,88	0,04
DNA dC->dU-editing enzyme APOBEC-3C	APOBEC3C	-0,88	0,11
Ragulator complex protein LAMTOR4	LAMTOR4	-0,87	0,05
Protein TANC1	TANC1	-0,87	0,66
Methyltransferase-like protein 17, mitochondrial	METTL17	-0,87	N.D.
DNA-binding protein SMUBP-2	IGHMBP2	-0,87	1,01
U4/U6 small nuclear ribonucleoprotein Prp31	PRPF31	-0,87	0,03
Breast cancer metastasis-suppressor 1	BRMS1	-0,87	0,16
Integrator complex subunit 8	INTS8	-0,87	0,18
Ubiquitin-like modifier-activating enzyme 1	UBA1	-0,87	0,13
Mitogen-activated protein kinase kinase kinase 7	MAP3K7	-0,87	N.D.
Ankyrin repeat domain-containing protein 27	ANKRD27	-0,87	N.D.
Armadillo repeat-containing X-linked protein 3	ARMCX3	-0,87	N.D.
Non-POU domain-containing octamer-binding protein	NONO	-0,86	N.D. 0,10
TAR DNA-binding protein 43	TARDBP	-0,86	0,10
Uncharacterized protein C12orf43	C12orf43	-0,86	N.D.
Eukaryotic translation initiation factor 5A-1	EIF5A;EIF5AL1	-0,86	0,21
Pericentrin	PCNT	-0,86	0,05
Mimitin, mitochondrial	NDUFAF2	-0,86	0,01
Nibrin	NBN	-0,86	N.D.
N-terminal Xaa-Pro-Lys N-methyltransferase 1	NTMT1	-0,86	0,25
Ribosomal protein S6 kinase alpha-5	RPS6KA5	-0,85	N.D.
Putative deoxyribonuclease TATDN1	TATDN1	-0,85	0,29
Ribosomal biogenesis protein LAS1L	LAS1L	-0,85	0,22
General transcription factor IIF subunit 1	GTF2F1	-0,85	0,10
Uncharacterized protein NCBP2-AS2	NCBP2-AS2	-0,85	N.D.
Nucleolar protein 10	NOL10	-0,85	0,70
CD59 glycoprotein	CD59	-0,85	0,89
Annexin A3	ANXA3	-0,85	0,07
Set1/Ash2 histone methyltransferase complex subunit ASH2	ASH2L	-0,85	0,46
MORC family CW-type zinc finger protein 3	MORC3	-0,85	0,17
Chromobox protein homolog 8	CBX8	-0,85	N.D.
Transmembrane protein 70, mitochondrial	TMEM70	-0,85	0,17
G protein-coupled receptor kinase 6	GRK6	-0,85	N.D.
Stress-induced-phosphoprotein 1	STIP1	-0,85	0,00
Uncharacterized protein KIAA0825	KIAA0825	-0,85	N.D.
Probable dimethyladenosine transferase	DIMT1	-0,85	0,11
Inhibitor of nuclear factor kappa-B kinase subunit beta	IKBKB	-0,84	0,32
		-,	-,

Pre-mBA/splicing regulator WTAPUTAP0.040.03Corocal amountabulantDTD0.040.03Deproval/PolicitiesDTD0.040.02Deproval/PolicitiesDTD0.040.02AdvanceDTD0.040.02AdvanceDEProval/Policities0.040.02AdvanceDEProval/Policities0.040.03AdvanceDEProval/Policities0.040.03AdvanceDEProval/Policities0.040.02Editator of Introductio dynamic protein 3DEProval/Policities0.040.02Editation of Introduction 23P, Introduction 13PDEProval/Policities0.040.02Editation of Introduction 12PDEProval/Policities0.040.02Editation of Introduction 12PDEProval/Policities0.030.030.03Editation of Introduction 12PDEProval/Policities0.030.030.03Editation 12PDEProval/PolicitiesDEProval/Policities0.030.02Editation 12PDEProval/PolicitiesDEProval/Policities0.030.02Editation 12PDEProval/PolicitiesDEProval/Policities0.030.02Editation 12PDEProval/PolicitiesDEProval/Policities0.030.02Editation 12PDEProval/PolicitiesDEProval/Policities0.030.02Editation 12PDEProval/PolicitiesDEProval/Policities0.030.02Editation 12PDEProval/PolicitiesDEProval/Policities0.020.02 </th <th></th> <th></th> <th></th> <th></th>				
Dyroge (MANIPY) descylase 1 0701 0.04 0.075 Sindessome RN-Mailess DD/SS 0.041 0.054 0.055 Assess ander preten 12/Les theck 70 Ma protein 1A AUD131 0.041 0.054 Assess ander preten 12/Les theck 70 Ma protein 1A AUD131 0.041 0.054 0.055 Assess ander preten 12/Les 1 FMAIL 4004 0.041	Pre-mRNA-splicing regulator WTAP	WTAP		N.D.
Scheeningen Hub Netlace DOX38 0.0238 0.02 Ackase and or protein 13/A stab.47 20.6 protein 1A HXALSUSFMAA 0.06 Ackase and or protein 13/A stab.47 20.6 protein 1A HXALSUSFMAA 0.04 0.03 Basi fragment stable stab.27 method on 1A HXALSUSFMAA 0.04 0.03 Basi fragment stable stab.27 HXALSUSFMAA 0.04 0.03 Basi fragment stab.10 bits 1 1 0.04 0.04 0.03 Stable stab.27 HXALSUSFMAA 0.04 0.03 1.03 Stable stab.27 HXALSUSFMAA 0.04 0.03 1.03 Stable stab.27 HXALSUSFMAA 0.04 0.03 1.03 1.03 Stable Stab.27 HXALSUSFMAA 0.03 1.03				
inst. hold MPAI BLYSALA 0.04 0.06 Akines and/or protein 13/A AAPT/A 0.04 0.05 Akines and/or protein 13/A AAPT/A 0.04 0.05 Significant Signific			-0,84	0,07
Akings andro protein 17A0.040.34Registror of incrusing extension 3000.0430.031285 ribescens ubundle braype 30.0410.021Protescens ubundle to type 30.0410.021005 ribescens ubundle to type 30.0410.041005 ribescens ubundle to type 30.0410.031005 ribescens ubundle to type 30.0410.032005 ribescens ubundle to type 30.0410.0320.042005 ribescens ubundle to type 30.0410.0320.042005 ribescens ubundle to type 30.0410.0320.042005 ribescens ubundle to type 30.0410.0220.042005 ribescens ubundle to type 30.0410.0220.042005 ribescens ubundle to type 30.0	Spliceosome RNA helicase DDX39B	DDX39B	-0,84	0,06
Regulator of microbubic dysamic protein 3MKNNMCNN0.040.38S2 histocond protein 32, microbundialPRMS0.440.27Sci hostocal protein 17-lac 1PRMS0.440.27Sci hostocal protein 17-lac 1PRMS0.440.21Terta pain 17-lac 1TSPAN140.440.21Sci hostocal protein 17-lac 11.010.440.00Exarchard protein Rab 7NAR70.430.00Exarchard protein Rab 7NAR70.430.02Probability protein Rab 7NAR70.430.02Probability protein Rab 7NAR70.430.02Probability protein Rab 7NAR70.430.02Natchore Rab 7NAR70.430.02Natchore Rab 7NAR70.430.02Natchore Rab 7NAR70.430.02Natchore Rab 7NAR70.430.03Natchore Rab 7 <td>Heat shock 70 kDa protein 1B;Heat shock 70 kDa protein 1A</td> <td>HSPA1B;HSPA1A</td> <td>-0,84</td> <td>0,06</td>	Heat shock 70 kDa protein 1B;Heat shock 70 kDa protein 1A	HSPA1B;HSPA1A	-0,84	0,06
25.5 Monotal protein 329, minorbankinal0A230.0440.017605 Monotal protein 1.7 Mile 10.0440.021605 Monotal protein 1.7 Mile 10.0440.021Fersapanin-1.81.01720.0440.019Spling factor 11.01720.0440.019Spling factor 11.01720.0440.019Spling factor 11.01720.0440.019Spling factor 11.01070.0330.032Spling factor 11.01070.0330.025Spling factor 1Nambo 10060.0330.025Nocloal protein 531.010750.0330.025Nuchelar protein 540.02580.0330.025Nuchelar protein 10.0110.0330.025Resplindering and the sequence of protein 10.0120.0330.011Monotarial asset sequence protein0.02540.02540.0254Monotarial asset sequence protein0.01140.0240.031Motor colling protein 20.02140.0240.031Motor colling protein 20.02140.0240.031Motor colling protein 20.02140.0240.021Motor colling protein 100.02140.0240.021Motor colling protein 100.02140.0240.021Motor colling protein 100.02140.0240.021Motor colling protein 100.02140.0240.021Noclear colling protein 100.02140.0240.021Noclear colling protein 10	A-kinase anchor protein 17A	AKAP17A	-0,84	0,34
protessorMMS0.0410.072CS fibusional protein LTAile 1GPL0.0420.021CS fibusional protein LTAile 1GPL0.0440.045Splitting Tactor 1STST0.0410.011La balguting protein ligase HUVE1HUVE10.0410.012Splitting Tactor 1La balguting protein ligase HUVE10.0110.0110.011La balguting protein ligase HUVE1HUME10.0240.021Decemer AT-balguting protein 1, mitochondrialHGH0.0310.021Decemer AT-balguting groups 1HLEL0.0330.032Engliment and cell monolog 1HLEL0.0330.032Engliment and cell monolog 1HLEL0.0330.032Mitochondrial Bio GTSase 2HHDTHLEL0.033Mitochondrial Bio GTSase 2HHDT0.0240.035Sintric/Incencing protein phosphates PH-gamma catalyfic subunitHHDT0.0240.032Mitochondrial Bio GTSase 2HLDT0.0240.0320.032Mitochondrial Bio GTSase 2HLDT0.0240.0320.032Mitochondrial Bio GTSase 2HLDT0.0240.0320.032Mitochondrial Bio GTSase 2HLDTHLDT0.0240.032Mitochondrial Bio GTSase 2HLDT0.0240.0320.032Mitochondrial Bio GTSase 2HLDTHLDT0.0240.032Mitochondrial Bio GTSase 2HLDTHLDT0.0240.032Mitochondrial Bio GTSase 2HLDTH	Regulator of microtubule dynamics protein 3	RMDN3	-0,84	0,38
sci fictorial protein L7-iii:9.049.02Reatin-2FLOT20.440.02Reatin-2FLOT20.440.01Reatin-2FLOT20.440.01Reatin-2FLOT20.440.02Rear-Intert protein Flab-3FLOT20.440.02Rear-Intert protein Flab-3FLOT20.340.02Probabile Flab-3FLOT20.340.02Probabile Flab-3FLOT20.340.02Protein Flab-3FLOT20.340.02Protein Flab-3FLOT20.340.02Protein Flab-3FLOT20.340.02Protein Flab-3FLOT20.340.02Protein Flab-3FLOT20.340.02Protein Flab-3FLOT20.340.02Read-flab-1FLOT20.340.35Mitch-Indrial assembly of flotacomal large submit protein 1MALL0.34Mitch-Indrial Assembly flotacomal large submit AMALL0.34Mitch-Indrial Assembly flotacomal large submit AKLIIIC0.34Mitch-Indrial Assembly flotacomal large submit AKLIIIC0.34<	28S ribosomal protein S29, mitochondrial	DAP3	-0,84	0,01
Tertaganin-1aTSPN14O.04N.D.Splitting Factor 1StatumG.040.05Splitting Factor 1StatumG.040.01Exabapatin protein ligase HUVE1HUVE1-0.440.02Ras-related protein Rab-37DRAS7-0.831.23Protein HOS1 humosHIGS0.030.03Ras-related protein Rab-37DRAS7-0.830.03Pertatricopseptide repeat-containing protein 1, mittechondrialPTCD1-0.030.03ExapIment and LinkowsHIGS-0.030.03ExapIment and LinkowsHIGS-0.030.03ExapIment and LinkowsHIGS-0.030.03ExapIment and LinkowsHIGS-0.030.03Mitchondrial Bio GTase 2Signific and Contage subunit protein 1MAD0.03Mitchondrial Bio GTase 2Signific and Contage subunit protein 1HIGS0.03Mitchondrial Bio GTase 2Signific and Contage subunit protein MDDAMAD211-0.020.03Mitchondrial Bio GTase 2Signific and Contage subunit protein MDDAMAD211-0.020.03Mitchoner 1.01 Metraming protein MDDAMAD211-0.020.031.03Linkoner 1.01 Metraming protein MDDAMAD211-0.020.03Mitchoner 1.01 Metraming protein MDDAMAD211-0.020.03Linkoner 1.01 Metraming protein MDDAMAD211-0.020.03Linkoner 1.01 Metraming protein MDDAMAD11-0.020.03Linkoner 1.01 Metraming protein MDDA	Proteasome subunit beta type-5	PSMB5	-0,84	0,07
ptmin-2LOT20.040.06Splking factor 1SF1A0.440.01Ex Jubig upper ligase HUVE1HUWE10.040.02Bar related protein Rab-37MAS70.330.32Phobable ATP-sependent RMA helicase DKX37DKX370.330.32Phobable ATP-sependent RMA helicase DKX37DKX370.330.32Phobable ATP-sependent RMA helicase DKX37DKX370.330.32Photen RMA Sependent RMA helicase DKX37DKX370.330.32Nucleidar protein SepNUE10.330.33Mutcher protein SepNUE10.330.33Mutcher protein SepMAS110.330.33Mutcher protein SepMAS110.330.34Mutcher Chara 2DKXMAS2110.320.35Serine/Threenine-protein phosphatase PH-sprimar catalytic subantMPDC10.320.34Mutcher Serinda Sering Drotein MAD2AMAD2110.320.34Mutcher Serinda Sering protein ACLIDIA0.320.34Mutcher Serinda Sering Protein ATACLIDIA0.320.34Mutcher Serinda Sering protein ACLIDIA0.320.34Mutcher Serinda Sering Protein ACLIDIA0.320.35 <td>60S ribosomal protein L7-like 1</td> <td>RPL7L1</td> <td>-0,84</td> <td>0,22</td>	60S ribosomal protein L7-like 1	RPL7L1	-0,84	0,22
Spicing factor 1CPU0-0.440.11Exhalpatin protein Bab-37KAB570.4310.32Ras-related protein Rab-37KAB570.4330.32Pentatricopetitid repeat-containing protein 1, mitochondrialFTCD 10.4310.02Nuclear protein S3NOPS30.3310.32Pentatricopetitid repeat-containing protein 1NLE0.3310.321Protein HGH1 benoingNUClear protein S30.3210.331Englimment and cell motitis protein 1MLM010.3310.312Protein HGH1 benoingPage statistic sta	Tetraspanin-14	TSPAN14	-0,84	N.D.
fl ubing/initip protein ligase HVMC1HUME10.040.02Probable ATP dependent RNA helicase DV37DH3370.830.32Probable ATP dependent RNA helicase DV37DH3370.830.32Probable ATP dependent RNA helicase DV37NCI0.830.32Probable ATP dependent RNA helicase DV37NCI0.830.32Probable ATP dependent RNA helicase DV37NCI0.830.32Probable ATP dependent RNA helicase DV37NCI0.830.32Notchess protein SNCI0.830.32Notchess protein Inomolog IRNA NEIPROEC0.830.33Mitchondral Rna Grass engulatory subunt betaNRA NEI0.830.33Mitchondral Rna Grass engulatory subunt betaNRA NEI0.830.33Mitchondral Rna Grass engulatory protein 1NRA NEI0.830.33Mitchondral Rna Grass engulatory protein ADA2ANRAD2110.820.33Visionent LJ, Niterming protein 1NRAD2ANRAD2110.820.33Visionent LJ, Niterming protein 1NRAD2ANRAD2110.820.03Visionent Contraining protein 1NRAD2ANRAD240.030.32Visionent LJ, Niterming protein 1NRAD2NRAD0.320.34Visionent Contraining protein 1NRAD2NRAD0.320.32Visionent Contraining protein 1NRAD2NRAD0.320.34Visionent Contraining protein 1NRAD2NRAD0.320.34Visionent Contraining protein 1 <td>Flotillin-2</td> <td>FLOT2</td> <td>-0,84</td> <td>0,09</td>	Flotillin-2	FLOT2	-0,84	0,09
Bas-class protein Rub-37RA37RA37RA331.02Petatricopetide great-containing protein 1, mitochondrialPTCD19.38N.032Petatricopetide repeat-containing protein 1, mitochondrialPTCD19.380.02Protein HGH InnologiNOPSE9.380.32Chrolin GHI InnologiNCH19.380.32Displatid/microscontaining protein 1NCH20.380.30Engularment and cell motify protein 1NCH20.380.31Hitochondrial innologiNCH20.380.31Seine/Hitreenine-protein protein size subunit protein 1MALSUI0.380.32Mitochondrial innologiNCH20.330.34Mitochondrial innologiNCH20.330.34Mitochondrial innologiNCH20.340.35Seine/Hitreenine-protein phosphatase PP1-gama catalytic subunitPHTCC0.380.32Victionand inno protein 1ACCD1A0.320.002Lamnoadgate-seindelewyle defriqenase-phosphatetheinyl transferaseNN0.320.02Nudera valosis-containing protein 1ACCD1A0.320.02Nudera valosis-containing protein 1A </td <td>Splicing factor 1</td> <td>SF1</td> <td>-0,84</td> <td>0,11</td>	Splicing factor 1	SF1	-0,84	0,11
probabile AIP-dependent RNA helicise DNG7DNG7DNG8N.D.Protein Infort LornologNG11NG23NG2Protein Infort LornologNG11NG23NG20Nuckolar protein SNG41NG430.30Nuckolar protein SNG41NG430.30Nuckolar protein INLE1-0.830.31Michondral RNGPINSR2-0.830.31Michondral RNG (Tasse regulatory suburit betaPINSR2-0.830.31Michondral RNG (Tasse regulatory suburit betaPINSR2-0.830.31Michondral RNG (Tasse PI) Egama catalytic suburitPIPICC-0.830.31Michondral RNG (Tasse PI) Egama catalytic suburitPIPIC-0.830.31Michondral RNG (Tasse PI) Egama catalytic suburitPIPIC-0.830.31Michon LL, Michondral RNG (Tasse PI) Egama catalytic suburitPIPIC-0.820.34Michon LL, Michondral RNG (Tasse PI) Egama catalytic suburitPIPIC-0.820.34Michon LL, Chandra RNG (Tasse PI)PIRII-0.820.34Michon LL, Michondral RNG (Tasse PI)PIRII-0.820.34Michon LL, Michondra RNG (Tasse PI)PIRII-0.820.35Michon LL, Michondra RNG (Tasse PI) <td< td=""><td>E3 ubiquitin-protein ligase HUWE1</td><td>HUWE1</td><td>-0,84</td><td>0,00</td></td<>	E3 ubiquitin-protein ligase HUWE1	HUWE1	-0,84	0,00
present containing protein 1, mitochondialPTCD1Q.33N.D.Nucloary protein SNOPSBQ.33Q.056Nucloary protein SNUE11Q.33Q.30Englifment and cell motility protein 1ELNO1Q.38Q.32Englifment and cell motility protein 1MALSUIQ.38Q.31Mochondral assembly of roboronal large subunit protein 1MALSUIQ.38Q.32Mochondral Motor Shares ergulatory subunit betaPPITCCQ.38Q.35Serine/Treonine-protein phosphatase PPI-gamma catalytic subunitPPITCCQ.38Q.35Mochondral Motor Shares ergulatory subunit betaHI10Q.32Q.33Histore H1.0, H-terminally processedHI10HI10Q.32Q.34Vipsilie-protein phosphatase non-receptor hyp 1CCDLAQ.32Q.32Vipsilie-protein phosphatase non-receptor hyp 1HI10HI10Q.32Q.32Vipsilie-protein phosphatase non-receptor hyp 1CCDLAQ.32Q.32Vipsilie-protein phosphatase non-receptor hyp 1HI10HI10Q.32Q.32Vipsilie-protein phosphatase non-receptor hyp 1CCDLAQ.32Q.32Vipsilie-protein phosphatase non-receptor hyp 2CCDLAQ.32Q.32Vipsilie-protein phosphatase non-receptor hyp 2CDLAQ.32Q.32Vipsilie-protein phosphatase non-receptor hyp 3CCDLAQ.32Q.32Vipsilie-protein Con2D3CCDLAQ.32Q.32Q.32Vipsilie-protein Con2D3CCDLAQ.32Q.33Q.	Ras-related protein Rab-37	RAB37	-0,83	1,29
Protein Right LanonkagHGH1HGH1HGH1HGH2HGB3HGD3Nutcloker protein SNELLHGB1HGB1HGB1HGB1HGB1HGB1HGB1Nutcloker protein IHLEIHGB2HGB1HGB2HGB1HGB2HGB1HGB2HGB1HGB2HGB1HGB2HGB1HGB2HGB1HGB2HGB1H	Probable ATP-dependent RNA helicase DHX37	DHX37	-0,83	0,32
Protein Right LanonkagHGH1HGH1HGH1HGH2HGB3HGD3Nutcloker protein SNELLHGB1HGB1HGB1HGB1HGB1HGB1HGB1Nutcloker protein IHLEIHGB2HGB1HGB2HGB1HGB2HGB1HGB2HGB1HGB2HGB1HGB2HGB1HGB2HGB1HGB2HGB1H	Pentatricopeptide repeat-containing protein 1, mitochondrial	PTCD1	-0,83	N.D.
Natchiesp protein homolog 1 NELI No.83 0.32 Phosphatdylinositol 3-kinase regulatory subunit protein 1 PKIMD 0.83 0.77 Mittechnordial aspes comport protein 1 MAISUI 0.83 0.34 Mittechnordial aspes comport protein NAD2A MAISUI 0.83 0.35 Mittechnordial aspentity protein MAD2A MAD21 0.82 0.35 Mittechnordial aspentity protein MAD2A MAD21 0.82 0.35 Mittechnordial sprotein Honolystephtase PP1-garma cathylic subunit PP1PC 0.82 0.34 Mittechnordial sprotein Honolystephtase PP1-garma cathylic subunit PP1PC 0.82 0.34 Mittechnordial sprotein Honolystephtase PP1-garma cathylic subunit PP1PC 0.82 0.34 Versition P10 PP1PC 0.82 0.34 0.34 Versition P10 PP1PC 0.82 0.34 0.32 0.32 Nuclear valosin-containing protein IA CC20 IA 0.82 0.32 0.32 Versition P10 CEA CAL 0.32 0.32 0.32 0.32 Ve		HGH1	-0,83	0,06
Natchiesp protein homolog 1 NELI No.83 0.32 Phosphatdylinositol 3-kinase regulatory subunit protein 1 PKIMD 0.83 0.77 Mittechnordial aspes comport protein 1 MAISUI 0.83 0.34 Mittechnordial aspes comport protein NAD2A MAISUI 0.83 0.35 Mittechnordial aspentity protein MAD2A MAD21 0.82 0.35 Mittechnordial aspentity protein MAD2A MAD21 0.82 0.35 Mittechnordial sprotein Honolystephtase PP1-garma cathylic subunit PP1PC 0.82 0.34 Mittechnordial sprotein Honolystephtase PP1-garma cathylic subunit PP1PC 0.82 0.34 Mittechnordial sprotein Honolystephtase PP1-garma cathylic subunit PP1PC 0.82 0.34 Versition P10 PP1PC 0.82 0.34 0.34 Versition P10 PP1PC 0.82 0.34 0.32 0.32 Nuclear valosin-containing protein IA CC20 IA 0.82 0.32 0.32 Versition P10 CEA CAL 0.32 0.32 0.32 0.32 Ve	Nucleolar protein 58	NOP58	-0,83	0,20
Engliment and cell motility protein 1ELMO 10.330.22Prosphatidy/inoxid 3-kinase regulatory subunit betaPHSR20.830.37Mitochondrial assembly of thosomal large subunit protein 1MLSU 10.830.35Strine/Invenine-protein phosphatase PP1 gamma catalytic subunitPFP1C0.830.35Mitochondrial MS protein MADAMAD2L10.820.33Histone H10, N-terminally processedHIFO0.820.35Yorsien-protein phosphatase 0n-receptor type 1FIPN10.820.02Colled-coll and C. domain-containing protein 1ACCD20 A0.820.02Undvaruscher Containing protein 1ACCD20 A0.820.01Undvaruscher Containing protein 1ACGD2 A0.820.01Undvaruscher Containing protein 1ACGD2 A0.820.01Undvaruscher Containing protein 1ACGD2 A0.820.02Contain gronautic 2CGD2 A0.820.02Undvaruscher Containing protein 1ACGD2 A0.820.02Undvaruscher Containing protein 1ACGD2 A0.820.02Undvaruscher Containing protein 1ACGD2 A0.820.02Contain gronautic 2CGD2 A0.820.02Contain gron		NLE1		0,30
Prosphatiquinosito 3-kinasir egulatory subunit protein 1PHSR2PHSR2PHSR2PHSR2PHSR3		FLMO1		
Mitechondrial assembly of ribosomal large subunit protein 1MAISUI0.830.34Serine//freonine-protein phosphatase PP1 gamma catalytic subunitPP1CC0.830.15Serine//freonine-protein phosphatase PP1 gamma catalytic subunitPP1CC0.820.35Histore III.0.Histone HI.0. Niterminally processedHISTO0.820.35Viposine-protein phosphatase non-receiptor type 1KHD Ca0.820.07Cielled cal and C.2 domain-containing protein ACL2D1A0.820.02Laminoadipate-semiale/byde dehydrogenase-phosphopantetheiny/transferaseANSIMPPT0.820.02Lucharactexized protein C607C03CG2D1A0.820.01Undvararctexized protein C607C03CG072030.82N.D.Histone-dysine N-methytransferase EMMT2CHMT20.820.01Undvararctexized protein C607C03CG072030.82N.D.Protein argonaute-2CG072030.820.01Undvararctexized protein C607C03CG072030.820.02Crin figer protein C607C03CG120.820.02Undvararctexized protein 1 homologUF0110.820.02Crin figer protein C607C03CG120.820.02Crin figer protein Solorian factor 1Non0.820.02Crin figer protein SolorianCT1A0.820.02Crin figer protein SolorianCT1A0.820.02Crin figer protein factor 2TFAF20.820.16Crin figer protein factor 2CCC30.810.02 <td></td> <td></td> <td></td> <td></td>				
Mitchcondral Rbs OFTBase 2NHOTZ0.830.15Serine/Hronomic protein phosphatase PP1-gamma catalytic subunitPPP1CC0.830.16Mitotic spindle assembly checkpoint protein MAD2AMAD2110.820.35Histone H1.0, Netmanial processedH1F00.820.37Kistone H1.0, Netmanial processedPTPN10.820.08Kisch domain containing protein 1AC2D1A0.820.02Colled-coll and C2 domain-containing protein 1AC2D1A0.820.02Luminoadipate-tesse, mitchcondralPTFM10.820.02Nuclear valosin-containing protein ikeNV0.820.01Uncharaterized protein C6r/203C6r/2030.82N.D.Histone-lysine Nethyltransferase EHM12EHM170.820.01Ubiquitin fusione digradation protein ikeND0.820.01Ubiquitin fusione digradation protein 1 homologUFD110.820.02Zinc Inger protein 2ZMF20.820.05Protein argonaute-2AGO20.820.15Strine fusione sociated factor 10AHRGE100.820.15Ne transfering and the sociated factor 10CPT10.620.02Ne transfering protein 2UFD10.620.05Strine fusion contains proteinCDCS10.810.02Ubiquitin fusion contains proteinCDCS10.810.02Strine fusion containsCDT20.820.15Strine fusion containsCOT20.810.02Strin				
Serind/Precome-protein phosphase PPI-gamma catabitis subunit PPICC -0.83 0.16 Nitotic spindle assembly checkjonit protein MADA MAD211 -0.82 0.33 Nitotic spindle assembly checkjonit protein MADA MAD211 -0.82 0.34 Virsinie-protein phosphase non-receptor type 1 PPFN1 -0.82 0.07 Colled-coll and C_domain-containing protein 1A CCD1A -0.82 0.02 Laminoadipate-senialing protein-ikite assembly checkjonit with and seniality of the containing protein ikite assembly checkjonit with and seniality of the containing protein ikite assembly checkjonit with and seniality of the containing protein ikite assembly checkjonity of the contassembly checkjonity of the containing protein ikite assembly ch				
Nitobic spindle assembly heckgoint protein MAD2A MAD21 0-82 0.35 Nitosne H1, 0, Netmanial processed H1F0 0-82 0.34 Tyrosine-protein phosphatse non-receptor type I PTPN I 0-82 0.08 Kich domain-containing protein JA C2D1A 0-82 0.02 Colled-coll and C2 domain-containing protein IA C2D1A 0-82 0.02 Laminoadipate-semialdehyde dehydrogenase-phosphopantetheinyl transferase NNL 0.62 0.02 Undvarar kettried ethydrogenase-phosphopantetheinyl transferase NNL 0.82 0.01 Undvarar kettried ethydrogenase-phosphopantetheinyl transferase NNL 0.82 0.01 Undvart kettried ethydrogenase-phosphopantetheinyl transferase GALNTZ 0.82 0.01 Linkarter Vijne Nmethyltransferase EHMT2 EHMT2 0.82 0.01 Dipolegite Asceptial actions protein 1 homolog ZIVF22 0.82 N.D. Polypergite Asceptial action 2 TAR2 0.82 0.63 Rin grannarte-2 RAG02 0.81 0.02 Rin grannarte-2 CEC N.D.				
Histon et 10, OHISTON et 11, OHISTON et 200.340.34Vrosine-protein phosphatsa en ne-receptor type 1PPN10.920.03Keich domain-containing protein 1CCDLA0.920.07Colled-coll and C. domain-containing protein 1.0CCDLA0.920.02Laminoadipate-senialishy dehydrogenase-phosphapantetheinyl transferaseASOHPFT0.930.02Nuckar vision-containing protein 1.0CCDLA0.920.02Presequence protesis, emtochondrialPTM10.920.02N.D.Uncharacterized protein Control (SGT/03)0.62N.D.N.D.Protein graduation protein 2Control (SGT/03)0.62N.D.Protein aground-travel (SGT/03)Control (SGT/03)0.62N.D.Protein aground-travel (SGT/03)Control (SGT/03)0.620.01Ubliquith fusion degraduation protein 1 homologUPDI 10.020.25Zinc Inger protein 22DF720.020.05Protein argonute-2Zhr Tage 20.020.05Kif receptor-associated factor 2TRAF20.020.05Net remain kinase-like proteinSCT10.020.02Serine (Phronine-protein phosphatase 6 regulatory ankyrin repeat subunit AANRD280.03Coll (Suburth-conjung in genzer E2 variant 2UEEX20.010.02Ubliquith-conjung in genzer E2 variant 2UEEX20.010.02Coll (Suburth-conjung in genzer E1 Neural Associated factor 20.020.05Nater State State Control (State State State State S				
Tyrosine-protein phosphasse non-receptor type 1PTPN1-0.820.08Keht domain-containing protein 1AC2D14-0-0.820.07Colled-coll and C2 domain-containing protein-likeNVL-0.820.02Laminoadipate-semialdehyde dehydrogenase-phosphopantetheinyl transferaseNVL-0.820.02Vactear valoait-containing protein-likeNVL-0.820.02Presequene protesse, mitochondralPTRM11-0.820.01Undnaracterized extligatacosaminyltransferase EHMT2EHMT2-0.820.01Undnaracterized extligatacosaminyltransferase 2GALVT2-0.820.01Ubiquitin fusion degradation protein 1 homologZIVF22-0.82N.D.Polypedite A-actigatacosaminyltransferase 2.GALVT2-0.820.05TNF receptor-associated factor 2TAR2-0.820.05TNF receptor-associated factor 2TAR2-0.820.04Carnither Opalintoyltransferase 1, liver isoformSCYLL-0.820.04Extender Advance 1GOSCIA-0.810.020.02Carnither Opalintoyltransferase 1, liver isoformSCYLL-0.810.02Carnither Opalintoyltransferase 1, liver isoformSCYLL-0.810.04Extension Campite 1GOSCIA-0.810.02Carnither Opalintoyltransferase 1, liver isoformSCYLL-0.810.02Carnither Opalintoyltransferase 1, liver isoformSCYLL-0.810.02Carnither Opalintoyltransferase 1, liver isoformSCYLL-0.810.02				
sicht domain-containing protein 4KLHDC40.920.074Colled-coll and C2 domain-containing protein 1ACCD1A0.920.04Laminoadipate semialdehyde dehydrogenase-phosphopantetheinyl transferaseAXSDHPFT0.920.02Nuclear volosin-containing protein-likePTTM10.920.011Uncharacterized protein Coorf203C.6orf2030.82N.D.Polypeptide N-acetylgalactosaminytransferase 2C.6orf2030.82N.D.Polypeptide N-acetylgalactosaminytransferase 2C.6orf2030.82N.D.Polypeptide N-acetylgalactosaminytransferase 2ZNF220.82N.D.Polypeptide N-acetylgalactosaminytransferase 2ZNF220.820.16Rho guanne nucleotide exchange factor 10ARHCFF100.820.25Znn finger protein 2TRAF20.820.04N+ receptora-sociated factor 2TRAF20.820.04Serline (Protein argomatic-2)CPT1A0.820.04Serline (Protein proteinCPT1A0.820.25Carnitine 0-patinitoytransferase 1, liver isoformCPT1A0.820.04Serline (Protein acetylitytoriase 1, liver isoformCPT1A0.820.04Serline (Protein acetylitytoriase 1, liver isoformCDCSL0.810.02Landstrong aphaTRA2A0.810.020.05Arasteriate acetylitytoriase 18 subunit alphaPATAH110.810.02Protein Atomolog aphaTRA2A0.810.22Ras-related protein Robel acetylitytoriase 18 subunit				
CollectionCCUDA0.920.04Laminoadipate semialdehyde dehydrogenase-phosphopantetheinyl transferaseAXSDIMPT0.820.02Presequence protenses, mitochondrialNTKM10.820.02Uncharacterized proteinSCI02030.82N.D.Histon-Lysine N-methyltransferase EHMT2EHMT20.82N.D.Dybpeptide N-extlyglactosaminyltransferase 2GAINT20.820.01Ubiquitin fusion degradation protein 1 homologUFD110.820.02Dybpeptide N-extlyglactosaminyltransferase 2ZNE220.42N.D.Protein agonaute-2RAFGETD0ARHGETD00.820.65Bho guanine nucleotide exchange factor 10RHFGETD00.820.16Neremion Rinserse 1, liver isoformCPT1A0.920.45Serine/Threonine-protein phosphatase 6 regulatory ankyrin repeat subunit AANR0280.810.02Serine/Threonine-protein Rb-1A0.810.020.300.30Transformer-2 protein Roholog alphaTRA20.810.30Transformer-2 protein Roholog alphaPATAH1110.610.02Protein Rab-1APAR1110.610.020.65Protein Rab-1APAR1110.610.020.65Protein Rab-1APAR1110.610.020.65Protein Rab-1APAR1110.610.020.65Protein Rab-1APAR1110.610.020.65Protein Rab-1APAR110.610.020.65Protein Rab-1A<				
Laminadipate-semialdehyde dehydrogensac-phosphopantetheinyl transferaseAASDHPFT0.220.02Presequence protease, mitochondrialPTRM10.820.20Presequence protease, mitochondrialPTRM10.820.20Uncharacterized protein Coorl203Coorl2030.92N.D.Polypeptide N-acetylgalactosaminyltransferase 21CANT20.820.01Unplugitul fusione kyine Netthyltransferase 23CANT20.820.01Unplugitul fusione kyine Netthyltransferase 2ZNF220.820.01Protein argonate-2AGO20.820.016Rho gaunie nucleotide exchange factor 10RhAF20.420.42Netterinal kinase-like proteinCPTIA0.420.42Serine/fhreenine-protein phosphatase 6 regulatory ankyrin repeat subunit AANRK0280.410.02Cerl division cycle 5-like proteinCDCSL0.610.080.05Exosone complex component RRM0EXOSC30.810.32Ras-related protein Rase1.1APATAH1810.810.02Protein ArgonagabaDR/SAA0.810.32Ras-related protein RAM0EXOSC30.810.32Ras-related protein RAM0PATAH1810.810.02Protein ArgonagabaDR/SAA0.810.32Ras-related protein RAM0PATAH1810.810.02Protein ManbolagabaPATAH1810.810.02Protein ManbolagabaPATAH1810.810.02Protein ArgonagabaDR/SAA0.810.32<				
Nuclear valosin-containing protein-like NVL 0.02 0.011 Presequence protease, mitochondrial PTRM 1 0.02 N.D. Histon-lysine N-methytransferase EHMT2 EHMT2 0.92 N.D. Phyperited N-activityatorsferase 2 GAINT2 0.92 N.D. Lin finger protein 2 ZNF22 0.82 N.D. Protein argonaute-2 AGO2 0.82 0.65 Rio guanine nucleositide extrage factor 10 ARHGEF10 0.82 0.45 TNF receptor-associated factor 2 TRAF2 0.82 0.12 Carnitre O-palmitoytransferase 1, liver isoform CPTIA 0.81 0.04 Serine/threconine-protein phosphatse 6 regulatory ankyrin repeat subunit A ANKR028 0.81 0.02 Carnitre O-palmitoytransferase 1, liver isoform CDCSL 0.81 0.030 Carnitre O-palmitoytransferase 2 ariant 2 UBcuith-conjugating enzyme E 2 variant				
presequence protease, microbiodrialPIRM1-0.820.11Uncharacterized protein C6orf203C6orf203-0.82N.D.Histone-lysine N-methyltransferase EHMT2EHMT2-0.82N.D.Polypeptide N-acetylgalactosaminytransferase 2GALNT2-0.820.01Ubiquith fusione lysine degradation protein 1 homologUFD11-0.820.25Zinc finger protein 2Protein argonaute-2AGO 2-0.820.16Rho guanne nucleotide exchange factor 10ARHGEF10-0.820.16N- terminal kinase-like proteinSCYL1-0.820.12Carrithine O-palmitolytransferase 1, liver isoformSCYL1-0.820.12Carrithine O-palmitolytransferase 1, liver isoformCPT1A-0.810.02Ubiquitin-conjugating enzyme E2 variant 2UBE2V2-0.810.05Exosome complex component RRP40EXOSC3-0.810.30Exosome complex component RRP40EXOSC3-0.810.32Ras-related protein Rab-11ARAB11A-0.810.92Protechenting factor acetylhydrolase Bsubunit alphaPAFAH1B1-0.810.93Ras-related protein receptor-related protein 1RP11-0.810.92Probable X7-Dependent RAb-Ablescae DV39APX11-0.810.92Probable X7-Dependent RNA helicscae DV400DV400-0.800.92Probable X7-Dependent RNA helicscae DV400DV400-0.800.92Probable X7-Dependent RNA helicscae DV400DV400-0.800.92Probable X7-Dependent				
Incharacterized protein CSort203CSort203-0.82N.D.Histone-lysine N-methyltransferase EHMT2GLNT2-0.82N.D.Dyhpeptide N-acetylgalactosaminytransferase 2GLNT2-0.820.011Ubiquitin fusion degradation protein 1 homologUPDIL-0.820.025Zinc finger protein 2ZNF22-0.82N.D.Protein argenaute-2AGO2-0.820.45Rob guanine nucleotide exchange factor 10AHGCF10-0.820.45In Fereptor-associated factor 2TRAF2-0.820.16N-terminal kinase-like proteinCPTIA-0.810.04Serine/fitneonine-protein phosphatase 6 regulatory ankyrin repeat subunit AANKRD28-0.810.02Serine/fitneonine-protein phosphatase 6 regulatory ankyrin repeat subunit AANKRD28-0.810.04Serine/fitneonine-protein phosphatase 6 regulatory ankyrin repeat subunit AANKRD28-0.810.02Ubiquitin-conjugating enzyme E2 variant 2UBEV2V-0.810.30Carratine C-palmitoy/transferase 1.liver isoformCDCSL-0.810.03Transformer-2 protein homolog alphaTRA2A-0.81N.D.Platelet-activating factor acetyltydrolase IB subunit alphaDX39A-0.810.02Arra-former-2 protein homolog alphaPATL1-0.810.02Protein PATI Inhonolog 1PATL1-0.810.02Transitional endoplasmic reticulum ATPaseVCP-0.810.02Protein PATI Inhonolog 1HEVA-0.810.05Mit	51			
Inistance-lysine A-methylinearise EMT2EMT29.02N.D.Polypeptide N-acetylysiactosaminytransferase 2GALNT2-0.820.011Ubiquitin fusion degradation protein 1 homologUPD1-0.820.025Zhn Enger protein 22AGC 2-0.82N.D.Protein argonate-2AGC 2-0.820.066Rho guanne nucleotide exchange factor 10ARHGEF10-0.820.025IN Freepton-associated factor 2TRAP2-0.820.016N-terminal kinase-like proteinCYL1-0.820.022Carnitine 0-patinitoytrinasferase 1.liver isoformCYL1-0.820.022Ubiquitin-conjugating enzyme E2 variant 2.UBE2V2-0.810.022Cell division cycle 3-like proteinCDCSL-0.810.08Exosome complex component RRP40EXOSC3-0.810.032Tarafforme-2 protein homolog alphaTRA2A-0.810.032Ras-related protein RA helicase DDX39ADDX39A-0.810.022Vacuade distribution diplation and transforme-2WPC-0.810.022Protein PAT1 homolog 1HR2A-0.810.022-0.810.022Protein PAT1 homolog 1PAT11-0.810.022-0.810.022Probable AT-Dependent RNA helicase DDX39ADDX39A-0.810.022Probable AT-Dependent RNA helicase DDX39A0.02-0.810.052Mitochondrial import inner membrane translocase subunit Tim10TIMM10-0.800.022Probable AT-Dependent RNA helicase DDX30A				
polypeptide N-acetylgalactosaminyltransferase 2CALNT2-0.820.011Ubiquitin fusion degradation protein 1 homologUFD11-0.820.25Zinc finger protein 22-0.820.02N.D.Protein argonaute-2AGO2-0.820.46Rbo guanien nucleotide exchange factor 10ARIGEF100-0.820.42Carnitine O-palmitoyltransferase 1, liver isoformTRAF2-0.820.16Serine/fibreonine-protein phosphatase 6 regulatory ankyrin repeat subunit AANIKGEF10-0.810.04Serine/fibreonine-protein phosphatase 6 regulatory ankyrin repeat subunit AANIKO28-0.810.02Ubiquith-conjugating enzyme E2 variant 2UBEZV2-0.810.05Cell division cycle 5-like proteinCDCSL-0.810.02Dataletei-activitaging enzyme E2 variant 2UBEZV2-0.810.03Zarsone complex component RRP40EXOSC3-0.810.03ATP-dependent RNA helicase DDX39A-0.810.020.32Aras-telet protein acetor related protein 1RABI1A-0.810.02Arbedreauting factor acetylhydrolase IB subunit alphaPATL1-0.810.02Arbedreauting factor acetylhydrolase IB subunit Tim10TIMM10-0.800.05Mitchondrial Import inor membrane translocase subunit Tim0TIMM10-0.800.05Mitchondrial Import inor membrane translocase subunit Tim9TIMM9-0.800.02Vacular protein 5GGG-0.800.030.03Mitchondrial Import inor membrane translocase s				
Ubiquitin fusion degradation protein 1 homologUF011-0.820.25Zinc finge protein 22ZNF22-0.82N.D.Protein argonaute-2AGO2-0.820.45Rho guante nucleotide exchange factor 10ARHGEF10-0.820.45NF receptor-associated factor 2TRAF2-0.820.12Carnitine O-palmitoyltransferase 1, liver isoformSCYL1-0.820.012Carnitine O-palmitoyltransferase 1, liver isoformCPT1A-0.810.04Serine (Threonine-protein phosphatase 6 regulatory ankyrin repeat subunit AANKR028-0.810.02Ubiquitin-conjugating enzyme E2 variant 2UBE2V2-0.810.02Cell division cycle 5-like proteinCDC51-0.810.00Exosome complex component RRP40EXOSC3-0.810.030Transformer-2 protein habnolog alphaTRA2A-0.810.01ATP-dependent RNA helicase DX39ADX39A-0.810.022Protein habnolog 1PATL1-0.810.92Protow-density lipoprotein receptor-related protein 1LRP1-0.810.92Probardensity lipoprotein receptor-related protein 1LRP1-0.810.02Transitional endoplasmic reticulum ATPaseVCP-0.810.02Probardendrik NA helicase DM40DHX40-0.800.03Probardendrik NMA elicase DM40DHX40-0.800.03Probardendrik NMA elicase SDR family member 78UHAS14-0.810.02Vacuolar protein 6HEATR6-0.800.37				
Zinc Tinger protein 22CN22CN22CN22N.D.Protein argenaute-2AGO2AGO20.4220.16Rho guanine nucleotide exchange factor 10ARIGEF10-0.8220.16TNF receptor-associated factor 2TRAF2-0.820.16N-terminal Kinase-like proteinSCV11-0.8220.16Carntine O-palmitoytransferase 1, laver isoformCPT1A-0.810.04Serine/Threonine-protein phosphatase for egulatory arkyrin repeat subunit AANKR028-0.810.02Ubiquitin-conjugating enzyme E2 variant 2UBE2V2-0.810.01Cell division cycle 5-like proteinCDCS1-0.810.008Exosome complex component RRV40EXOSC3-0.810.03Transformer-2 protein homolog alphaPAFAH1B1-0.810.01ATP-dependent RNA helicase DDX39ADX39A-0.810.02Arbein Rab-11AProtein PAT1-0.810.028Prolow-density lipoprotein receptor-related protein 1LRP1-0.810.05Mitchondral Import iner membrane translocase subunit Tim10TIMM10-0.800.07Phosbel ATP-dependent RNA helicase DHX40DHX40-0.800.03Vacubar protein sorting-associated protein 11LIP1-0.810.05Mitchondral Import iner membrane translocase subunit Tim9TIMM10-0.800.05Vacubar protein Softaed protein 11 homologRASL13-0.800.03Vacubar protein Softaed protein 11 homologRASL13-0.800.03Vacubar prote				
protein argonaute-2AG20.020.0220.045Nh guanine nucleotide extange factor 10ARHGEF10-0.6220.045N' receptor-associated factor 2TRAF2-0.620.022N-terminal kinase-like proteinSCV11-0.820.022Carritine 0-patin phosphatase 6 regulatory ankyrin repeat subunit AANKRD28-0.810.022Ubiquitin-conjugating enzyme E2 variant 2UBE2V2-0.810.021Cell division cycle 5-like proteinCDC5L-0.810.031Exosome complex component RIP40EXOSG3-0.810.031Transformer-2 protein hoosplaphaPARH181-0.810.031Platelei-activating factor acetylhydrolase IB subunit alphaPAFH181-0.810.012ATP-dependent RNA helicase DDX39ARAS11A-0.810.022Protein PAT1 homolog 1PATL1-0.610.922Protein PAT1 homolog 1LRPA-0.810.028Protein PAT1 homolog 1LRPA-0.810.028Protein dab-11ALRP1-0.810.92Protein dab-11ALRP1-0.810.92Protein PAT1 homolog 1LRP1-0.810.92Protein dab-11ALRP1-0.810.92Protein dab-11ALRP1-0.810.92Protein dab-11ALRP1-0.810.92Protein dab-11ALRP1-0.810.92Protein BAT1MIM10-0.800.02Protein BAT1LRP1-0.810.92Protein BAT1LRP1 </td <td></td> <td></td> <td></td> <td></td>				
inb guain Product State RHAF2 0.32 0.45 TNF receptor-associated factor 2 TRAF2 -0.82 0.16 Veterminal kinase-like protein SCV11 -0.82 0.12 Carnitine O-palmitoytransferase 1, liver isoform CP11A -0.81 0.04 Serine/threonine-protein phosphatase 6 regulatory ankyrin repeat subunit A ANKRD28 -0.81 0.05 Cell division cycle 5-like protein CDC5L -0.81 0.030 Transformer-2 protein homolog alpha TRAZA -0.81 0.031 Patelet-activating factor activythydrolase B subunit alpha CDC5L -0.81 0.011 ATP-dependent RNA helicase DDX39A -0.81 0.022 1.021 Protein PATI homolog 1 PATL1 -0.81 0.922 Protein PATI homolog 1 PATL1 -0.81 0.92 Protein MATI helicasee DX400 DHX4				
TNF receptor-associated factor 2 TRAF2 0.82 0.16 N-terminal kinase-like protein SCVL1 -0.82 0.12 Carnitine O-palmitolyttransferase 1, liver isoform CPT1A -0.81 0.02 Serine/Utreonine-protein phosphatase 6 regulatory ankyrin repeat subunit A ANR028 -0.81 0.02 Ubiquitin-conjugating enzyme E2 variant 2 UBE2V2 -0.81 0.02 Exosome complex component RP40 EXOSC3 -0.81 0.03 Transformer-2 protein Monolog alpha TRA2A -0.81 0.01 Arnsformer-2 protein Monolog alpha TRA2A -0.81 0.01 Ars-related protein Rb-1A RAB11A -0.81 0.02 Ras-related protein Rb-1A RAB11A -0.81 0.92 Hexokinase-2 PATL1 -0.81 0.92 Prolow-density lipoprotein receptor-related protein 1 LRP1 -0.81 0.92 Transformer-2 HZ -0.81 0.05 Mitchondrial import inner membrare translocase subunit Tim10 TIMM10 -0.80 0.07 Transformer-2 PCC <td></td> <td></td> <td></td> <td></td>				
N+terminal kinase-like proteinSCYL1-0.820.12Carnithe O-palmitolytransferase 1, liver isoformCPT1A-0.810.04Serine (threonine-protein phosphatase 6 regulatory ankyrin repeat subunit AANKRD28-0.810.02Ubiquitin-conjugating enzyme E2 variant 2UBE2V2-0.810.05Cell division cycle 5-like proteinCDCSL-0.810.030Transformer-2 protein homolog alphaTRA2A-0.810.01Datelet-activeting factor acetychlydrolase IB subunit alphaPAFAH1B1-0.810.02Ard-dependent RNA helicase DDX39APAS11-0.810.02Patelet-activeting factor acetychlydrolase IB subunit alphaPAFAH1B1-0.810.02Ard-dependent RNA helicase DDX39A-0.810.22-0.810.02Protein Rab-11APATL1-0.810.92-0.810.05Protein Rab-11APATL1-0.810.92-0.810.05Protein PAT homolog 1PATL1-0.810.92-0.810.05Mitochondrial import inner membrane translocase subunit Tim10TIMM10-0.800.09Probable ATP-dependent RNA helicase DHX40DHX40DHX400.800.02Vacuolar protein sorting associated protein 1 homologNDG9-0.800.05Mitochondrial import inner membrane translocase subunit Tim9TIMM9-0.800.02Vacuolar protein sorting associated protein 1CR57-0.800.07Phosphopantothenorytake-3RASL3-0.800.73Mitochondr	Rho guanine nucleotide exchange factor 10		-0,82	0,45
Carnitine O-palmitoyltransferase 1, liver isoformCPT1A-0,810,04Serine/threonine-protein phosphatase 6 regulatory ankyrin repeat subunit AANRD28-0,810,02Ubiquitin-conjugating enzyme 22 variant 2UBE2V2-0,810,03Cell division cycle 5-like proteinCDCSL-0,810,08Exosome complex component RP40EXOSC3-0,810,30Transformer-2 protein homolog alphaTRA2A-0,810,01Platelet-activating factor acetylhydrolase IB subunit alphaPAFAH1B1-0,810,01ATP-dependent RNA helicase DX39ARAB11A-0,810,32Ras-related protein Rab-1JAPATL1-0,810,28Protow-density lipoprotein receptor-related protein 1LRP1-0,810,28Prolow-density lipoprotein receptor-related protein 1LRP1-0,810,99Transfitional endoplasmic reticulum AlTPaseVCP-0,810,05Mitchchordinal import inner membrane translocase subunit Tim10TIMM10-0,800,02Vacuolar protein sociated protein 11 homologRASAL3-0,800,02Vacuolar protein sociated protein 11 homolo			-0,82	0,16
Serine/threonine-protein phosphatase 6 regulatory ankyrin repeat subunit AANKRD28-0.810.02Ubiquith-conjugating enzyme E2 variant 2UBE2V2-0.810.15Cell division cycle 5-like proteinCDC5L-0.810.03Transformer-2 protein homolog alphaEXOSC3-0.810.01Platelet-activiting factor accellyhydrolase IB subunit alphaPAFAH1B1-0.810.01ATP-dependent RNA helicase DDX39ADX39A-0.810.22Ras-related protein Rab-11APATL1-0.810.01Protein RA1 homolog 1PATL1-0.810.28Protein RA1 homolog 1PATL1-0.810.79Transitonal endoplasmic reticulum ATPaseVCP-0.810.79Viransitional endoplasmic reticulum ATPaseVCP-0.810.02Virauli import inner membrane translocase subunit Tim0TIMM10-0.800.01Probable ATP-dependent RNA helicase DTX40DHX40-0.800.01Viraular protein sorting-associated protein 11 homologWPS11-0.800.02Vacualar protein sorting-associated protein 11 homologWGS1-0.800.03Ras protein activator like-3RASAL3-0.800.03Ras protein activator like-3RASAL3-0.800.03Ras protein activator like-3UBE20-0.800.03Ras protein activator like-3CECKS-0.800.03Robinodrial import in 5CECKS-0.800.03Ras protein activator like-3Patter-0.800.05	N-terminal kinase-like protein		-0,82	0,12
Ubiquith-conjugating enzyme E2 variant 2UBE2V2-0.810.15Cell division cycle 5-like proteinCDCSL-0.810.08Exosome complex component RRP40EXOSC3-0.81N.D.Platelet-activating factor acetylhydrolase IB subunit alphaPAFAH1B1-0.810.01ATr-dependent RNA helicase DX39ADDX39A-0.810.021ATr-dependent RNA helicase DDX39ADDX39A-0.810.021Protein PAT1 homolog 1PATL1-0.810.022Hexokinase-2HK2-0.810.022Protein PAT1 homolog 1-0.810.0280.028Protein PAT1 homolog 1-0.810.0280.028Protein PAT1 homolog 1-0.810.0590.051Protein dipolasmic reticulum ATPaseVCP-0.810.050Mitochondrial import inner membrane translocase subunit Tim10TIMM10-0.800.021Phosphopantinner membrane translocase subunit Tim9TIMM9-0.800.021Vacuolar protein sorting-associated protein 11 homologRASA13-0.800.033RAS protein activator like-3RASA13-0.800.031Prebendent RNA polymerase II translorigons UBR2-0.800.032-0.80Mitochondrial import inner membrane translocase subunit Tim9TIMM9-0.800.033RAS protein activator like-3RASA13-0.800.033Protein SMG9UBR2-0.800.035-0.800.035RASA13DHS7B-0.800.035-0.800.035Ca	Carnitine O-palmitoyltransferase 1, liver isoform	CPT1A	-0,81	0,04
Cell division cycle 5-like proteinCDCSL-0.810.08Exosome complex component RRP40EXOSC3-0.810.30Transformer-2 protein homolog alphaTRA2A-0.810.01ATP-dependent RNA helicase DD39A-0.810.010.01ATP-dependent RNA helicase DD39A-0.810.020.22Hax cleitar protein Rab-1LARAB11A-0.810.92Hexokinase-2PATL1-0.810.79Protein PAT1 homolog 1LRP1-0.810.79Hexokinase-2VCP-0.810.79Transfitional endoplasmic reticulum ATPaseVCP-0.810.05Mitochondrial import inner membrane translocase subunit Tim10TIMM10-0.800.05Mitochondrial import inner membrane translocase subunit Tim9TIMM9-0.800.05Mitochondrial import inner membrane translocase subunit Tim9TIMM9-0.800.05Mitochondrial import inner membrane translocase subunit Tim9TIMM9-0.800.035RAS protein activator like-3RASA13-0.800.037Protein SMG9-0.800.370.35RAS protein activator like-3CECR5-0.800.17Phedytogenase/reductase SDR family member 78UH878-0.800.078Unhealthy ribosome biogenesis protein 5CECR5-0.800.17Mediator G RNA polymerase II transcription subunit 14UBE20-0.790.055LifeArt ore onlike subunit 11CPSF31-0.790.055TransdolaseTALDO1-	Serine/threonine-protein phosphatase 6 regulatory ankyrin repeat subunit A	ANKRD28	-0,81	0,02
Exosome complex component RRP40EXOSC3-0,810,30Transformer-2 protein homolog alphaTRA2A-0.81N.D.Platelet-activating factor accept/hydrolase IB subunit alphaPAFAH1B1-0.810,32Ras-related protein RAb-hilcase DDX39ADDX39A-0.810,32Ras-related protein Rab-11APATL1-0.810,92Protein PAT1 homolog 1PATL1-0.810,92Protein PAT1 homolog 1LRP1-0.810,79Transitional endoplasmic reticulum ATPaseVCP-0.810,05Mitochondrial import inner membrane translocase subunit Tim10TIMM10-0.800,09Probable ATP-dependent RNA helicase DHX40DHX40-0.800,07Phosphopantothenoylcysteine decarboxylasePPCDC-0.800,05Mitochondrial import inner membrane translocase subunit Tim9TIMM9-0.800,02Vacuolar protein sorting-associated protein 11 homologVPS11-0.800,03RAS protein attivator like-3RASAL3-0.800,137PHEAT repeat-containing protein 6HEATR6-0.800,08Dehydrogenase/reductase SDR family member 7BUHRS7B-0.800,10Cat eys syndrome critical region protein 5CECR5-0.800,117Mediator GNA pomerase II transcription subunit 14CPSF3L-0.790,05Integrator complex subunit 11CDSC47-0.790,05Integrator complex subunit 11CCDC47-0.790,05Integrator complex subunit 11CCDC47 <td< td=""><td>Ubiquitin-conjugating enzyme E2 variant 2</td><td>UBE2V2</td><td>-0,81</td><td>0,15</td></td<>	Ubiquitin-conjugating enzyme E2 variant 2	UBE2V2	-0,81	0,15
Transformer-2 protein homolog alphaTRA2A-0,81N.D.Platelet-activating factor acetylhydrolase IB subunit alphaPAFAH1B1-0,810,01ATP-dependent RNA helicase DX39A0,810,32Ras-related protein Rab-11ARAB11A-0,81N.D.Protein PAT1 homolog 1PATL1-0,810,92Protow-density lipoprotein receptor-related protein 1LRP1-0,810,79Transfitional endoplasmic reticulum ATPaseVCP-0,810,05Mitochondrial import inner membrane translocase subunit Tim10DHX40-0,800,09Probable ATP-dependent RNA helicase DHX40DHX40-0,800,017Phosphopantothenoylcysteine decarboxylasePPCC-0,800,017Phosphopantothenoylcysteine decarboxylaseVCP-0,800,035RAS protein activator like-3RNG9-0,800,335RAS protein activator like-3RASAL3-0,800,337HEAT repeat-containing protein 6HEATR6-0,800,08Dehydrogenase/reductase SDR family member 7BDHRS7B-0,800,10Cat ey syndrome critical region protein 5CECR5-0,800,17Mediator of RNA polymerase II transcription subunit 14MED14-0,790,055Integrator complex subunit 11CUPSF31-0,790,055Integrator complex subunit 11CUCC47-0,790,055Integrator complex subunit 11CUCC47-0,790,055Integrator complex subunit 11CUPSF31-0,790,055<	Cell division cycle 5-like protein	CDC5L	-0,81	0,08
Platelet-activating factor acetylhydrolase IB subunit alphaPAFAH1B1-0,810,01ATP-dependent RNA helicase DDX39A-0,810,32Bas-related protein Rab-11A-0,81N.D.Protein PAT1 homolog 1PATL1-0,810,92Hexokinase-2HK2-0,810,22Prolow-density lipoprotein receptor-related protein 1LRP1-0,810,79Transitional endoplasmic reticulum ATPaseVCP-0,810,05Mitochondrial import inner membrane translocase subunit Tim10TIMM10-0,800,09Probable ATP-dependent RNA helicase DHX40DHX40-0,800,07Phosphopantothenoylcysteine decarboxylasePPCDC-0,810,02Vacuolar protein sorting-associated protein 1 homologVPS11-0,800,02Vacuolar protein sorting-associated protein 11 homologNMS9-0,800,02Vacuolar protein sorting-associated protein 11 homologVPS11-0,800,33Protein SMG9SMG9-0,800,33Protein SMG9URB2-0,800,01Cat ey syndrome critical region protein 5CECR5-0,800,78Unhealthy ribosome biogenesis protein 1 homologURB2-0,800,17Mediator of RNA polymerase II transcription subunit 14MED14-0,790,15Cz/E3 hybrid ubiquitin-protein figase UBE2OURB2-0,800,10Cat ey syndrome critical region protein 5CECR5-0,800,17Mediator of RNA polymerase II transcription subunit 14CDS14-0,79<	Exosome complex component RRP40	EXOSC3	-0,81	0,30
ATP-dependent RNA helicase DDX39A0,810,32Ras-related protein Rab-11ARAB11A-0,81N.D.Protein PAT1 homolog 1PATL1-0,810,92Hexokinase-2HK2-0,810,28Prolow-density lipoprotein receptor-related protein 1LRP1-0,810,79Transitional endoplasmic reticulum ATPaseVCP-0,810,05Mitochondrial import inner membrane translocase subunit Tim10TIMM10-0,800,09Probable ATP-dependent RNA helicase DHX40DHX40-0,800,017Phosphopantothenoylcysteine decarboxylasePCDC-0,800,02Vacuolar protein sorting-associated protein 11 homologVPS11-0,800,33RAS protein activator like-3RASAL3-0,800,37HEAT repeat-containing protein 6HEATR6-0,800,37Dehydrogenase/reductase SDR family member 7BUR82-0,800,17Unhealthy ribosome biogenesis protein 2 homologUBE20-0,790,15Cat eye syndrome critical region protein 5CECR5-0,800,17Mediator of RNA polymerase II transcription subunit 14CD/790,15TransaldolaseLTensatodlaseTHUMPD1-0,790,05Integrator complex subunit 13CCDC47-0,790,05Colder-coil domain-containing protein 47CCDC47-0,790,05Colder-coil domain-containing protein 5CCDA1-0,790,05Colder-coil domain-containing protein 1NFS1-0,790,03Colde	Transformer-2 protein homolog alpha	TRA2A	-0,81	N.D.
Ras-related protein Rab-11APA<	Platelet-activating factor acetylhydrolase IB subunit alpha	PAFAH1B1	-0,81	0,01
Protein PAT1 homolog 1PATL1-0.810.92Hexokinase-2HK2-0.810.28Prolow-density lipoprotein receptor-related protein 1LRP 1-0.810.79Transitional endoplasmic reticulum ATPaseVCP-0.810.05Mitochondrial import inner membrane translocase subunit Tim10TIMM10-0.800.09Probable ATP-dependent RNA helicase DHX40DHX40-0.800.02Probable ATP-dependent RNA helicase DHX40DHX40-0.800.02Vacuolar protein sorting-associated protein 11 homologVPS11-0.800.35RAS protein activator like-3RASA13-0.800.37Phetar SMG9SMG9-0.800.371HEAT repeat-containing protein 6HEATR6-0.800.08Dehydrogenase/reductase SDR family member 7BDHRS7B-0.800.17Mediator of RNA polymerase II transcription subunit 14MED14-0.790.15E2/E3 hybrid ubiquitin-protein ligase UBE20UBE20-0.790.05Integrator complex subunit 11CCCC47-0.790.05THUMP domain-containing protein 7CLCC47-0.790.06Cold-coil domain-containing protein 7FHNRPF-0.790.42Cres synthome ortical protein 5CCC47-0.790.06Cold-coil domain-containing protein 1CCDC47-0.790.06Cold-coil domain-containing protein 7FHNRPF-0.790.42Cres synthase 2CCP52-0.790.42Cres synthase 2<	ATP-dependent RNA helicase DDX39A	DDX39A	-0,81	0,32
Hexokinase-2HK2-0.810.28Prolow-density lipoprotein receptor-related protein 1LRP1-0.810.79Transitional endoplasmic reticulum ATPaseVCP-0.810.05Mitochondrial import inner membrane translocase subunit Tim10TIMM10-0.800.09Probable ATP-dependent RNA helicase DHX40DHX40-0.800.17Phosphopantothenoylcysteine decarboxylasePPCDC-0.800.05Mitochondrial import inner membrane translocase subunit Tim9TIMM9-0.800.35RAS protein activator like-3RASA13-0.800.13Protein SMG9KG9-0.800.37-0.800.37HEAT repeat-containing protein 6HEATR6-0.800.080.06Dehydrogenase/reductase SDR family member 7BUHRS7B-0.800.10-0.800.10Cat ey syndrome critical region protein 5CECR5-0.800.17-0.990.15E2/E3 hybrid ubiquitin-protein ligase UBE20UBE20-0.790.05-0.790.05THMVP domain-containing protein 1THUMPD1-0.790.05-0.790.05THUMP domain-containing protein 47CCDC47-0.790.06-0.790.05Cystein desuftrase, mitochondrialNFS1-0.790.42-0.790.03-0.790.03-0.790.03-0.790.03-0.790.04-0.790.02-0.790.03-0.790.03-0.790.04-0.790.02-0.790.03-0.790	Ras-related protein Rab-11A	RAB11A	-0,81	N.D.
Hexokinase-2HK2-0.810.28Prolow-density lipoprotein receptor-related protein 1LRP1-0.810.79Transitional endoplasmic reticulum ATPaseVCP-0.810.05Mitochondrial import inner membrane translocase subunit Tim10TIMM10-0.800.09Probable ATP-dependent RNA helicase DHX40DHX40-0.800.017Phosphopantothenoylcysteine decarboxylasePPCDC-0.800.02Vacuolar protein sorting-associated protein 11 homologVPS11-0.800.35RAS protein activator like-3RASAL3-0.800.31Protein SMG9SMG9-0.800.02Unhealthy ribosome biogenesis protein 6HEATR6-0.800.08Dehydrogenase/reductase SDR family member 7BURB2-0.800.17Mediator f RNA polymerase II transcription subunit 14MED14-0.790.15E2/E3 hybrid ubiquitin-protein ligase UBE2OUBE2O-0.790.05Integrator complex subunit 11CCCC47-0.790.05TransidolaseTALDO11-0.790.06Cold-coil domain-containing protein 47CCDC47-0.790.042Cysteine desulfurase, mitochondrialHNRMFF-0.790.42Cr Psynthase 2-0.790.03-0.790.03Codarin-1Asparty/asparaginyl beta-hydroxylaseCDNN1-0.790.042TransafoldolaseTALDO1-0.790.05-0.790.42Cr Psynthase 2-0.790.790.790.790.79<		PATL1		0,92
Prolow-density lipoprotein receptor-related protein 1LRP1-0.810.79Transitional endoplasmic reticulum ATPaseVCP-0.810.05Mitochondrial import inner membrane translocase subunit Tim10TIMM10-0.800.09Probable ATP-dependent RNA helicase DHX40DHX40-0.800.017Phosphopantothenoylcysteine decarboxylasePPCDC-0.800.02Vacuolar protein sorting-associated protein 11 homologVPS11-0.800.35RAS protein activator like-3RASAL3-0.800.13Protein SMG9SMG9-0.800.37HEAT repeat-containing protein 6HEATR6-0.800.08Dehydrogenase/reductase SDR family member 7BURBS7B-0.800.101Cat eye syndrome critical region protein 5CECR5-0.800.101Cat eye syndrome critical region protein 5CECR5-0.800.171Mediator of RNA polymerase II transcription subunit 14MED14-0.790.155E2/E3 hybrid ubiquitin-protein ligase UBE20UBE20-0.790.055THUMP domain-containing protein 1CUCC47-0.790.056Colde-coil domain-containing protein FAMNNPF-0.790.042Cystein desulfura-se mitochondrialNFS1-0.79N.D.Heterogeneous nuclear ribonucleoprotein FACMSN-0.790.032Codani-1Aspartty/asparaginyl beta-hydroxylaseASPH-0.790.292Transforma Containing protein FACDN1-0.790.292Cro Synthase 2<	Hexokinase-2	нк2	-0.81	0.28
Transitional endoplasmic reticulum ATPaseVCP-0.810.05Mitochondrial import inner membrane translocase subunit Tim10TIMM10-0.800.09Probable ATP-dependent RNA helicase DHX40DHX40-0.800.05Mitochondrial import inner membrane translocase subunit Tim9TIMM9-0.800.02Vacuolar protein sorting-associated protein 11 homologVPS11-0.800.02Yacuolar protein sorting-associated protein 11 homologVPS11-0.800.35RAS protein activator like-3-0.800.37-0.800.37HEAT repeat-containing protein 6MEATR6-0.800.08Dehydrogenase/reductase SDR family member 7BDHRS7B-0.800.02Unhealthy ribosome biogenesis protein 2 homologURB2-0.800.17Mediator of RNA polymerase II transcription subunit 14MED14-0.790.15E2/E3 hybrid ubiquitin-protein figase UBE2OUBE2O-0.790.15Iterator complex subunit 11-0.790.05-0.790.05THUMP domain-containing protein 1-0.790.05-0.790.05THUMP domain-containing protein 47CDC47-0.790.06Cystein desulfurase, mitochondrialNFS1-0.790.042Cystein desulfurase, mitochondrialCTPS2-0.790.03Codationi-Asparty/asparaginyl beta-hydroxylaseASPH-0.790.29Transforming growth factor-beta receptor-associated protein 1TGFBRAP1-0.790.29				
Mitochondrial import inner membrane translocase subunit Tim10TIMM10-0.800.09Probable ATP-dependent RNA helicase DHX40DHX40-0.800,17Phosphopantothenoylcysteine decarboxylasePPCDC-0.800,05Mitochondrial import inner membrane translocase subunit Tim9TIMM9-0.800,02Vacuolar protein sorting-associated protein 11 homologVPS11-0.800,33RAS protein activator like-3RASA13-0.800,31Protein SMG9SMG9-0.800,37HEAT repeat-containing protein 6HEATR6-0.800,08Dehydrogenase/reductase SDR family member 7BDHRS7B-0.800,17Mediator of RNA polymerase II transcription subunit 14MED14-0.790,15E2/E3 hybrid ubiquitin-protein ligase UBE2OUBE2O-0.790,05Integrator complex subunit 11CPSF3L-0.790,05THMP domain-containing protein 1THUMPD1-0.790,06Cold-coil domain-containing protein 47CCDC47-0.790,06Cold-coil domain-containing protein FHNRNFF-0.790,42CTP synthase 2CDN1-0.790,03Codain-1Codarin-1Asparty/asparaginyl beta-hydroxylaseASPH-0.790,42Transforming growth factor-beta receptor-associated protein 1TGFBRAP1-0.790,29				
Probable ATP-dependent RNA helicase DHX40DHX40-0,800,17Phosphopantothenoylcysteine decarboxylasePPCDC-0,800,05Mitochondrial import inner membrane translocase subunit Tim9TIMM9-0,800,02Vacuolar protein sorting-associated protein 11 homologVPS11-0,800,35RAS protein activator like-3RASA13-0,800,13Protein SMG9SMG9-0,800,37HEAT repeat-containing protein 6HEATR6-0,800,08Dehydrogenase/reductase SDR family member 7BUHRS7B-0,800,10Cat eye syndrome critical region protein 5CECR5-0,800,17Mediator of RNA polymerase II transcription subunit 14MED14-0,790,15E2/E3 hybrid ubiquitin-protein ligase UBE20UBE20-0,790,05THUMP domain-containing protein 1THUMPD1-0,790,05Coiled-coil domain-containing protein 47CCDC47-0,790,05Cysteine desulfurase, mitochondrialNFS1-0,790,03Codanin-1CPS2-0,790,03Codanin-1Aspartyl/asparaginyl beta-hydroxylaseASPH-0,790,29Transforming growth factor-beta receptor-associated protein 1TGFBRAP1-0,790,29				
Phosphopantothenoylcysteine decarboxylasePPCDC-0.800.05Mitochondrial import inner membrane translocase subunit Tim9TIMM9-0.800.02Vacuolar protein sorting-associated protein 11 homologVPS11-0.800.35RAS protein activator like-3RASA13-0.800.13Protein SMG9SMG9-0.800.37HEAT repeat-containing protein 6HEATR6-0.800.08Dehydrogenase/reductase SDR family member 7BURBS7B-0.800.10Cat eye syndrome critical region protein 5CECR5-0.800.10Cat eye syndrome critical region protein 5CECR5-0.800.17Mediator of RNA polymerase II transcription subunit 14MED14-0.790.15E2/E3 hybrid ubiquitin-protein ligase UBE20UBE20-0.790.05TransaldolaseTALDO1-0.790.05Colled-coil domain-containing protein 47CCDC47-0.790.06Cysteine desulfurase, mitochondrialNFS1-0.790.03Codain-1Asparty/asparaginyl beta-hydroxylaseASPH-0.790.29Transformaring growth factor-beta receptor-associated protein 1TGFBRAP1-0.790.29				
Mitochondrial import inner membrane translocase subunit Tim9 TIMM9 -0.80 0.02 Vacuolar protein sorting-associated protein 11 homolog VP511 -0.80 0.35 RAS protein activator like-3 RASAL3 -0.80 0.37 Protein SMG9 SMG9 -0.80 0.37 HEAT repeat-containing protein 6 HEATR6 -0.80 0.08 Dehydrogenase/reductase SDR family member 7B DHRS7B -0.80 0.78 Unhealthy ribosome biogenesis protein 2 homolog URB2 -0.80 0.17 Mediator of RNA polymerase II transcription subunit 14 MED14 -0.79 0.15 E2/E3 hybrid ubiquitin-protein ligase UBE2O UBE2O -0.79 0.15 Integrator complex subunit 11 CPSF3L -0.79 0.05 THUMP domain-containing protein 1 TALDO1 -0.79 0.06 Cold-coil domain-containing protein F HNRNPF -0.79 0.42 Cysteine desulfurase, mitochondrial SF51 -0.79 0.42 CrP synthase 2 CrPS2 -0.79 0.03 Codain-1 As				
Vacuolar protein sorting-associated protein 11 homolog VPS11 -0.80 0.35 RAS protein activator like-3 RAS AL3 -0.80 0,13 Protein SMG9 SMG9 -0.80 0,37 Protein SMG9 HEAT repeat-containing protein 6 HEAT repeat-containing protein 2 homolog 0.80 0,78 Unhealthy ribosome biogenesis protein 2 homolog URB2 -0.80 0,17 Mediator of RNA polymerase II transcription subunit 14 KED14 -0.79 0,15 E2/E3 hybrid ubiquitin-protein ligase UBE2O UBE2O -0.79 0,05 Integrator complex subunit 11 CPSF3L -0.79 0,05 Transaldolase TALDO1 -0.79 0,05 Cold-coil domain-containing protein 47 CDCV47 -0.79 0,08 Cystein desulfurase, mitochondrial HNRNFF -0.79 0,42 CTP synthase 2 CDN1 -0.79 0,42 Codain-1 Asparty/asparaginyl beta-hydroxylase ASPH -0.79 0,42				
RAS protein activator like-3 RASAL3 -0,80 0,13 Protein SMG9 SMG9 -0,80 0,37 HEAT repeat-containing protein 6 HEATR6 -0,80 0,78 Dehydrogenase/reductase SDR family member 7B DHRS7B -0,80 0,78 Unhealthy ribosome biogenesis protein 2 homolog URB2 -0,80 0,11 Cat eye syndrome critical region protein 5 CECR5 -0,80 0,17 Mediator of RNA polymerase II transcription subunit 14 MED14 -0,79 0,15 Integrator complex subunit 11 CPSF3L -0,79 0,05 Integrator complex subunit 11 -0,79 0,05 0,07 Transaldolase TALDO1 -0,79 0,05 THUMP domain-containing protein 47 CCDC47 -0,79 0,05 Coiled-coil domain-containing protein 47 CCDC47 -0,79 0,04 Cystein desulfurase, mitochondrial NFS1 -0,79 0,42 Crys nythase 2 CDAN1 -0,79 0,42 Codanin-1 Aspartyl/asparaginyl beta-hydroxylase ASPH				
Protein SMG9 SMG9 -0,80 0,37 HEAT repeat-containing protein 6 HEAT Repeat-containing protein 6 0,080 0,080 Dehydrogenase/reductase SDR family member 7B DHRS7B -0,80 0,100 Cat eye syndrome critical region protein 2 homolog URB2 -0,80 0,101 Cat eye syndrome critical region protein 5 CECR5 -0,80 0,171 Mediator of RNA polymerase II transcription subunit 14 MED14 -0,79 0,155 E2/E3 hybrid ubiquitin-protein ligase UBE20 UBE20 -0,79 0,155 Transaldolase TALDO1 -0,79 0,056 Coiled-coil domain-containing protein 1 THUMPD1 -0,79 0,056 Coiled-coil domain-containing protein 47 CCDC47 -0,79 0,056 Coiled-coil domain-containing protein 47 CDC47 -0,79 0,042 CTP synthase 2 -0,79 0,031 Codanin-1 Asparty/asparaginyl beta-hydroxylase ASPH -0,79 0,29 Transforming growth factor-beta receptor-associated protein 1 TGFBRAP1 -0,79 0,29				
HEAT repeat-containing protein 6 HEAT Repeat-containing protein 6 0.08 0.08 Dehydrogenase/reductase SDR family member 7B DHRS7B 0.08 0,78 Unhealthy ribosome biogenesis protein 2 homolog URB2 -0.80 0,10 Cat eye syndrome critical region protein 5 CECR5 -0.80 0,17 Mediator of RNA polymerase II transcription subunit 14 MED14 -0,79 0,15 E2/E3 hybrid ubiquitin-protein ligase UBE2O UBE2O -0,79 0,15 Integrator complex subunit 11 CPSF3L -0,79 0,05 Transaldolase TALDO1 -0,79 0,06 Colde-coil domain-containing protein 47 CCDC47 -0,79 0,08 Cysteine desulfurase, mitochondrial HNRNPF -0,79 0,42 CTP synthase 2 CTPS2 -0,79 0,43 Codain-1 Asparty/asparaginyl beta-hydroxylase ASPH -0,79 0,42 Transforming growth factor-beta receptor-associated protein 1 TGFBRAP1 -0,79 0,29				
Dehydrogenase/reductase SDR family member 7B DHRS7B -0.80 0,78 Unhealthy ribosome biogenesis protein 2 homolog URB2 -0.80 0,10 Cat eye syndrome critical region protein 5 CECR5 -0.80 0,17 Mediator of RNA polymerase II transcription subunit 14 ECR5 -0.80 0,17 Mediator of RNA polymerase II transcription subunit 14 MED14 -0.79 0,15 Z/E3 hybrid ubiquitin-protein ligase UBE2O UBE2O -0.79 0,05 Integrator complex subunit 11 CPSF3L -0.79 0,05 Transaldolase TALDO1 -0.79 0,05 THUMP domain-containing protein 47 CCDC47 -0,79 0,08 Cysteine desulfurase, mitochondrial NFS1 -0,79 0,42 CTP synthase 2 CD79 0,42 CPS-2 -0,79 0,43 Codani-1 CDAN1 -0,79 0,43 Cate) -0,79 0,43 Codanin-1 CDAN1 -0,79 0,29 Transforming growth factor-beta receptor-associated protein 1 TGFBRAP1 -0,79 0,29				
Unhealthy ribosome biogenesis protein 2 homolog URB2 -0,80 0,10 Cat eye syndrome critical region protein 5 CECR5 -0,80 0,17 Mediator of RNA polymerase II transcription subunit 14 MED14 -0,79 0,05 Zy(E3 hybrid ubiquitin-protein ligase UBE2O UBE2O -0,79 0,05 Integrator complex subunit 11 CPSF3L -0,79 0,05 Transaldolase TALDO1 -0,79 0,05 Colled-coil domain-containing protein 47 CCDC47 -0,79 0,06 Cystein desulfurase, mitochondrial NFS1 -0,79 0,04 Heterogeneous nuclear ribonucleoprotein F HNRNPF -0,79 0,42 CTP synthase 2 CDAN1 -0,79 0,33 Codanin-1 Aspartyl/asparaginyl beta-hydroxylase ASPH -0,79 0,29 Transforming growth factor-beta receptor-associated protein 1 TGFBRAP1 -0,79 0,29				
Cate eye syndrome critical region protein 5 CECR5 -0.80 0,17 Mediator of RNA polymerase II transcription subunit 14 MED14 -0.79 0,15 E2/E3 hybrid ubiquitin-protein ligase UBE20 UBE20 -0.79 0,15 Integrator complex subunit 11 CPSF31 -0.79 0,15 Transaldolase TALD01 -0.79 0,06 Colled-coll domain-containing protein 1 THUMPD1 -0.79 0,06 Colled-coll domain-containing protein 47 CCDC47 -0.79 0,08 Cystein desulfurase, mitochondrial NFS1 -0.79 0,42 CTP synthase 2 CPS2 -0,79 0,33 Codanin-1 Asparty/asparaginyl beta-hydroxylase ASPH -0,79 0,42 Transforming growth factor-beta receptor-associated protein 1 TGFBRAP1 -0,79 0,29				
Mediator of RNA polymerase II transcription subunit 14 MED14 -0,79 0,15 E2/E3 hybrid ubiquitin-protein ligase UBE2O UBE2O -0,79 0,05 Integrator complex subunit 11 CPSF3L -0,79 0,15 Transaldolase TALDO1 -0,79 0,05 THUMP domain-containing protein 1 THUMPD1 -0,79 0,06 Colled-coil domain-containing protein 47 CCOC47 -0,79 0,06 Cysteine desulfurase, mitochondrial NFS1 -0,79 0,42 CTP synthase 2 CTPS2 -0,79 0,42 Colanin-1 Asparty/asparaginyl beta-hydroxylase ASPH -0,79 0,42 Transforming growth factor-beta receptor-associated protein 1 TGFBRAP1 -0,79 0,29				
E2/E3 hybrid ubiquitin-protein ligase UBE2O UBE2O -0,79 0,05 Integrator complex subunit 11 CPSF3L -0,79 0,15 Transaldolase TALDO1 -0,79 0,05 THUMP domain-containing protein 1 THUMPD1 -0,79 0,06 Coiled-coil domain-containing protein 47 CCDC47 -0,79 0,08 Cysteine desulfurase, mitochondrial NFS1 -0,79 0,42 CTP synthase 2 CTPS2 -0,79 0,03 Codani-1 CDAN1 -0,79 0,43 Aspartyl/asparaginyl beta-hydroxylase ASPH -0,79 0,29 Transforming growth factor-beta receptor-associated protein 1 TGFBRAP1 -0,79 N.D.				
Integrator complex subunit 11 CPSF3L -0,79 0,15 Transaldolase TALD01 -0,79 0,05 THUMP domain-containing protein 1 THUMPD1 -0,79 0,06 Coiled-coil domain-containing protein 47 CCDC47 -0,79 0,08 Cysteine desulfurase, mitochondrial NFS1 -0,79 0,42 CTP synthase 2 CTPS2 -0,79 0,33 Codanin-1 CDAN1 -0,79 0,43 Asparty/asparaginyl beta-hydroxylase ASPH -0,79 0,29 Transforming growth factor-beta receptor-associated protein 1 TGFBRAP1 -0,79 N.D.				
Transaldolase TALDO1 -0,79 0,05 THUMP domain-containing protein 1 THUMPD1 -0,79 0,06 Coiled-coil domain-containing protein 47 CCDC47 -0,79 0,08 Cysteine desulfurase, mitochondrial NFS1 -0,79 N.D. Heterogeneous nuclear ribonucleoprotein F HNRNPF -0,79 0,42 CTP synthase 2 CDSN1 -0,79 0,43 Codanin-1 Asparty/asparaginyl beta-hydroxylase ASPH -0,79 0,29 Transforming growth factor-beta receptor-associated protein 1 TGFBRAP1 -0,79 N.D.				
THUMP domain-containing protein 1 THUMPD1 -0,79 0,06 Coiled-coil domain-containing protein 47 CCDC47 -0,79 0,08 Cysteine desulfurase, mitochondrial NFS1 -0,79 0,42 Heterogeneous nuclear ribonucleoprotein F HNRNPF -0,79 0,42 CTP synthase 2 CTPS2 -0,79 0,43 Codanin-1 Asparty/asparaginyl beta-hydroxylase ASPH -0,79 0,29 Transforming growth factor-beta receptor-associated protein 1 TGFBRAP1 -0,79 N.D.				
Colled-coil domain-containing protein 47 CCDC47 -0,79 0,08 Cysteine desulfurase, mitochondrial NFS1 -0,79 N,D. Heterogeneous nuclear ribonucleoprotein F HNRNPF -0,79 0,42 CTP synthase 2 CTPS2 -0,79 0,03 Codanin-1 CDAN1 -0,79 0,43 Aspartyl/asparaginyl beta-hydroxylase ASPH -0,79 0,29 Transforming growth factor-beta receptor-associated protein 1 TGFBRAP1 -0,79 N.D.				
Cysteine desulfurase, mitochondrial NFS1 -0,79 N.D. Heterogeneous nuclear ribonucleoprotein F HNRNPF -0,79 0,42 CTP synthase 2 CTP S2 -0,79 0,03 Codanin-1 CDAN1 -0,79 0,43 Asparty/Jasparaginyl beta-hydroxylase ASPH -0,79 0,29 Transforming growth factor-beta receptor-associated protein 1 TGFBRAP1 -0,79 N.D.				
Heterogeneous nuclear ribonucleoprotein F HNRNPF -0,79 0,42 CTP synthase 2 CTP Synthase 2 0,09 0,03 Codanin-1 CDAN1 -0,79 0,43 Asparty/Jasparaginyl beta-hydroxylase ASPH -0,79 0,29 Transforming growth factor-beta receptor-associated protein 1 TGFBRAP1 -0,79 N.D.				
CTP synthase 2 -0,79 0,03 Codanin-1 CDAN1 -0,79 0,43 Aspartyl/asparaginyl beta-hydroxylase ASPH -0,79 0,29 Transforming growth factor-beta receptor-associated protein 1 TGFBRAP1 -0,79 N.D.				
Codanin-1 CDAN1 -0,79 0,43 Aspartyl/asparaginyl beta-hydroxylase ASPH -0,79 0,29 Transforming growth factor-beta receptor-associated protein 1 TGFBRAP1 -0,79 N.D.				
Aspartyl/asparaginyl beta-hydroxylase ASPH -0,79 0,29 Transforming growth factor-beta receptor-associated protein 1 TGFBRAP1 -0,79 N.D.				
Transforming growth factor-beta receptor-associated protein 1 TGFBRAP1 -0,79 N.D.				
Polynucleotide 5-hydroxyl-kinase NOL9 -0,79 0,15				
Ras-related protein Rab-35 RAB35 -0,79 0,22	Ras-related protein Rab-35	RAB35	-0,79	0,22

risty action integration iAMS0.780.72extransition iAMS0.780.73extransition iAMALL29-7.780.73extransition iMHT130.780.73May have brooking in the sector in th		51005	0.70	0.00
CultorCulto				
nearm unifare homolog0.4.14.290.730.33Weybase physiphysiphysiphysiphysiphysiphysiphysi				
Methyterspitzpysteris for with pass pitzpysteris for with capanies (all) methytamsferzaes cathytic subunt TRMT61AMPHT0130.720.73Sarfer Rices are used in the subunt TRMT61ATRMT61ATRMT61A0.720.73Methy Capanies (all) methytamsferzaes cathytic subunt TRMT61ATRMT61A0.770.74Methy Capanies (all) methytamsferzaes cathytic subunt TRMT61ATRMT61A0.770.74Methyt Capanies (all) methytamsferzaePMT0.770.74Methyt Capanies (all) methytamsferzaePMT0.770.74Methyte (all) methytamsferzaePMT0.770.74Methyte (all) methytamsferzaePMT0.770.74Methyte (all) methytamsferzaePMT0.750.76Methyte (all) methytamsferzaePMT0.750.76Series (Methyte parser subunt text, methonfailPMT0.760.76Methyte (all) methytamsferzaePMT0.750.73Methyte (all) methytamsferzaePMT0.750.73Methyte (all) methytamsferzaePMT0.750.73Methyte (all) methytamsferzaePMT0.750.73Methyte (all) methytamsferzaePMT0.750.73MethytamsferzaePMT0.750.73				
why has phosphoprotein isMHMCOSPNE0.780.58Sirvert locar protein laNUH0.770.18BNA (defining B)R(1)-methylans/rase catalysts subunit TRMTEAARDMTEAA0.770.18BNA (defining B)R(1)-methylans/rase catalysts subunit TRMTEAA0.770.180.770.19BNA (defining B)R(1)-methylans/rase catalysts subunitSCIP0.770.220.770.01Barneling activation hibbit 1 RMA (barneling proteinSEBP10.770.010.770.01Barneling activation hibbit 1 RMA (barneling proteinSEBP10.770.010.020.770.02Capateron Barneling protein a AraciaDarge protein and the Barneling protein a Aracia0.770.020.02Capateron Barneling protein a AraciaDarge protein and the Barneling protein a Aracia0.770.020.05Capateron Barneling protein a AraciaStar (barneling protein a Aracia0.770.020.05Capateron Barneling protein a AraciaCapateron Barneling protein a Aracia0.770.020.05Capateron Barneling protein a AraciaCapateron Barneling Barneling activation acti	-			
sprintSuff 10.720.73NSFL calcer p37NSFL calcer p470.710.31NSFL calcer p47NSFL Calcer p470.710.31NSFL calcer p47NSFL Calcer p470.710.31In audir calcer assembly enzyme ISU, mitochondrialSCL Calcer p470.710.71NSFL calcer p47NSFL Calcer p470.770.72NSFL calcer p47NSFL Calcer p470.750.77Calcer p47NSFL Calcer p470.750.75Calcer p4				
BMA (actionary 5)TPMTEAATPMTEAATPMTEAAO.770.13RSL Lockson p47SCU0.770.13Inen-adir/ cluster assembly enzyme ISCU, michondrialSCU0.770.13Mandspheshtrefulston facto complex lesses MP subuntERC210.770.03Pisminger activator inhibitor interio complex lesses MP subuntERC210.770.03Pisminger activator inhibitor facto complex lesses MP subuntERC10.770.03Amade MP subuntMASD10.770.03Amade MP subuntMASD10.770.03Amade MP subuntMASD10.770.03Amade MP subuntMASD10.770.03Amade MP subunt subunt epsilon isoformPR235E0.760.76Serine/Trevenine-protein factor complex lesses factor egaletary subunt epsilon isoformPR235E0.760.76Chubranaccateg Amade Cluster Sig AmazCLUSA0.760.750.33MA chubrand protein Sig AmazMCL0.750.330.750.33MA chubrand protein Sig AmazMCL0.750.330.750.33 </td <td></td> <td></td> <td></td> <td></td>				
NSF1 constructions of the set of the se				
International duar assemble respue GCU, mitch modulaSCU0.77N.B.Plasmingen activator inhibitor 1 RNA-binding proteinERRP10.770.14Plasmingen activator inhibitor 1 RNA-binding proteinERRP10.770.04Na-adenoise methylerandress 70 Ma subunitRCC0.770.04Na-adenoise methylerandress 70 Ma subunitMCT0.770.01Na-adenoise methylerandress 70 Ma subunitMCT0.770.01Na-adenoise methylerandress 70 Ma subunitMCC0.770.02Advertaria Marging methaMCC0.770.02Advertaria Marging methaMCC0.770.02Advertaria Marging methaMCC0.760.07Serind/Tresonine-protein photophatase 2.45 Kb ar equalatory subunit epsilon isoformPP72550.760.02Calificativa methad subfits for a gammaAdvita 30.760.650.750.02Langk-respherad 2-phaspitate agammaAdvita 30.760.850.750.02Advertaria Margin M	tRNA (adenine(58)-N(1))-methyltransferase catalytic subunit TRMT61A	TRMT61A	-0,77	0,18
AmodopshoribosyltransfersePNT0.770.14Histinging arctiny histing 1NA-bidling proteinSERP0.770.25TITH bask transcription factor complex helicas XPD subunitMCTU30.770.01Alamy-HAM eding protein 1SSP0.770.02Alamy-HAM eding protein 1.SSP0.770.02Alamy-HAM eding protein 1.SSP0.770.02D'oussicheris delivitansfersa 2 for the subunitPROSE0.770.02D'oussicheris delivitansfersa 2 for the subunit epiden isoformPROSE0.760.07Equilibritan nucleoside transporter 1SLC3AL0.760.68Langd-Straft Protein Straft S Kita Regulatory subunit epiden isoformSLC3AL0.760.68Clus missis kiteley isoform, mucleondrialClus missis0.760.68Alamy-Straft Protein Straft Straft Regulatory subunit epiden isoform0.770.030.03Protein Clus missis kiteley isoform, mucleondrialClus missis0.750.02Clus missis kiteley isoform, mucleondrialClus missis0.750.02Prophenesdynotization server and subakasClus missis0.750.02Chromodopsis transfersa Exploritory proteinClus missis0.750.02Chromodopsis transfersa Exploritory proteinClus missis0.750.02Chromodopsis transfersa Exploritory for the NA ExploritoryPPDRB0.750.02Chromodopsis transfersa Exploritory for the NA Exploritory0.750.02Chromodopsis transfersa Exploritory for the NA Explo	NSFL1 cofactor p47		-0,77	0,19
plasminger activator inhibitor 18NA-binding proteinSERBP10.770.73NS-aderosite-methyttansferzer 70.59 subunitNGC0.770.04NS-aderosite-methyttansferzer 70.59 subunitAGDC0.770.05Amy-HMM edityrgeranes vubunit best, mitochondrialCCDUB0.770.05Constructional SectorNS-Sector0.760.05Constructional SectorNS-Sector0.760.05Fructure-Selphosphats addees CNS-Sector0.760.760.76Landonal Constructional SectorCLOPSC0.760.760.76Landonal Constructional SectorCLOPSC0.760.760.76Landonal Constructional SectorCLOPSC0.760.760.76Landonal Constructional SectorCLOPSC0.760.760.750.72Landonal Constructional SectorND-TIPI0.770.780.720.760.750.72Landonal SectorCLOPSC0.75ND-DI0.750.720.760.75 <td< td=""><td>Iron-sulfur cluster assembly enzyme ISCU, mitochondrial</td><td>ISCU</td><td>-0,77</td><td>N.D.</td></td<>	Iron-sulfur cluster assembly enzyme ISCU, mitochondrial	ISCU	-0,77	N.D.
FIH bask transcription factor complex holicias 490 subunit ERC2 0.7.7 0.0.0 Alamy-ENA editing protein Arsa11 0.98P 0.7.7 0.0.8 Alamy-ENA editing protein Arsa11 0.98P 0.7.7 0.0.8 2-oxisose/enables/able adolase ALDOC 0.7.8 0.0.6 2-oxisose/enables/able adolase ALDOC 0.7.8 0.0.6 Serine/Intrasonic-protein phophatase X.36 K0 aregulatory subunit epsilon isoform PP2705E 0.7.6 0.0.6 Serine/Intrasonic-protein phophatase X.36 K0 aregulatory subunit epsilon isoform PP2705E 0.7.6 0.0.6 Serine/Intrasonic-protein SA EXED 0.7.6 0.0.6 0.0.6 Alayi-Shyferox-phosphata systardirase gamma AGPT3 0.7.6 0.0.3 0.0.6 Alayi-Shyferox-phosphatasystardirase gamma GCS 0.7.6 0.3.3 0.0.6 0.0.3 Prosphomologrounde control GCS 0.7.5 0.7.5 0.7.5 0.7.5 0.7.5 0.7.5 0.7.5 0.7.5 0.7.5 0.7.5 0.7.5 0.7.5 0.7.5 0.7.5 0.7.5 0.7.7<	Amidophosphoribosyltransferase	PPAT	-0,77	0,14
Noi-adorsin-mempuranety area 70 kbs submitMETL30.770.01Oxysterchlording proteinARSD10.770.03Oxysterchlording protein1058P0.770.08Considerating elephropenses subunt beta, mitochondrialRCNHB0.770.08Fructess highosphate aldolase CALDOC0.760.07Equilative nucleosite transporter10.770.08Equilative nucleosite transporterSIC23A10.760.47Equilative nucleosite transporter0.770.780.76Equilative nucleosite transporter0.770.780.76Equilative nucleosite transporter0.770.780.76Equilative nucleosite transporter0.770.780.78Equilative nucleosite transporter0.770.780.78Usamase kide (offer, mitochondrial0.610.760.78Exponetic offer, mitochondrial0.610.750.78Exponetic offer, mitochondrial0.750.730.78Prosten transport protein Sec23A0.720.780.73Exponetic offer, mitochondrial0.760.750.78Nochondiga protein second Sec23A0.730.780.78Exponetic offer, mitochondrial0.740.720.74Nochondiga second Seco	Plasminogen activator inhibitor 1 RNA-binding protein		-0,77	0,29
Alamy-RNA editing protein 1ARSD1-0.770.722-oxoisovalerate dehydrogenase subunt beta, mitochondrialBCKDHB-0.770.0552-oxoisovalerate dehydrogenase subunt beta, mitochondrialBCKDHB-0.770.055Serine/Thronnine-protein phophatase 2A 56 No regulatory subunt epsilon isoformPP2205E0.760.095Serine/Thronnine-protein phophatase 2A 56 No regulatory subunt epsilon isoformPP2205E0.760.095LIMOD Commin-containing protein 2C10MO10.780.650.65Line domain-containing protein 2C10MO10.780.650.65Line domain-containing protein 2C10MO10.750.760.72N-binding protein 34BEM340.760.720.750.76N-binding protein 34BEM340.760.720.750.76N-binding protein 34BEM340.760.750.760.750.75N-binding protein 34BEM340.760.75 <td>TFIIH basal transcription factor complex helicase XPD subunit</td> <td>ERCC2</td> <td>-0,77</td> <td>0,04</td>	TFIIH basal transcription factor complex helicase XPD subunit	ERCC2	-0,77	0,04
consistent of high protein0.58P-0.770.08Provisioning refer (phrogeness subunit test, mitchondral)RCNH H-0.770.05Fructose bigh opphate aldoles C0.750.750.75Equilibrative nucleoside transporter 1SLCPA10.760.75Equilibrative nucleoside transporter 1SLCPA10.760.75Equilibrative nucleoside transporter 1SLCPA10.760.75Equilibrative nucleoside transporter 1SLCPA10.760.75LongA-strategrical phosphate alcolariaSLCPA10.760.75AdvA-strategrical protein 1SLCPA10.750.750.75Deptheenolynucleus carboxylinase (SPT) mitochondralSCCPA0.750.750.75Propheenolynucleus carboxylinase (SPT) mitochondralSCCPA0.750.750.750.75Propheenolynucleus carboxylinase (SPT) mitochondralCPCA0.750.750.750.75Nackar inhibitor of poten phosphates ± Activator of NA decayPP1880.750.750.75Nuclear inhibitor of poten phosphates ± Activator of NA decayPP1880.750.750.75Nuclear inhibitor of poten phosphates ± Activator of NA decayPP1880.750.750.75Nuclear inhibitor of poten phosphates ± Activator of NA decayPP1880.740.750.75Nuclear inhibitor of poten informationPCD100.750.750.750.75Nuclear inhibitor of poten informationPCD100.750.750.750.75 <t< td=""><td>N6-adenosine-methyltransferase 70 kDa subunit</td><td>METTL3</td><td>-0,77</td><td>0,01</td></t<>	N6-adenosine-methyltransferase 70 kDa subunit	METTL3	-0,77	0,01
Doubside and set explorementsEXCNHB0.770.05Furdase bid photophatase subunit best, mitochondrialMLDOC0.760.77Serind-Furben integration biophatase 2A S6 No regulatory subunit epsilon isoformPPE2850.760.76ELMO Comain-containing protein 1SCI2A10.760.760.76Land-srind-furben itsoff-1Cloref-120.760.760.76Land-srind-grate set protein 1200752Cloref-120.760.760.76Cloresrind-Faste set primaAGPA130.760.760.76RNA binding protein 24RRM240.760.760.76Deconsulcicity furber and set protein 1RRM240.760.760.76Protein transport protein Set2ASCI2A10.750.760.76Protein transport protein Set2ACloref0.770.760.76Protein transport protein Set2ACloref0.760.760.76Protein transport protein Set2ACloref0.770.760.76Protein transport protein Set2ACloref0.770.760.76Protein transport protein Set2ACloref0.770.760.77Protein transport protein Set2ACloref0.770.760.76Protein transport protein Set2ACloref0.770.760.76Protein transport protein Set2ACloref0.770.760.76Protein transport protein Set2ACloref0.770.760.76Protein transport protein Set2ACloref	Alanyl-tRNA editing protein Aarsd1	AARSD1	-0,77	0,17
Incurso-biphophare addiss CADDC0.700.00Strick/thronine protein phophares AS 6ND regulatory subunt egsion isoformPP20550.760.00Equilative nucleoside transporter 1SLC2A10.760.760.76Equilative nucleoside transporter 1SLC2A10.760.760.76Equilative nucleoside transporter 1SLC2A10.760.760.76Long/sargerot-3phosphate suptransferase garmaACPAT30.760.760.76Al-Marindig protein 34REM340.76N.D.0.770.760.730.02Protein transport protein Sc23ASC23A0.750.060.730.040.75 <td>Oxysterol-binding protein 1</td> <td>OSBP</td> <td>-0,77</td> <td>0,08</td>	Oxysterol-binding protein 1	OSBP	-0,77	0,08
serindPP275E0.720.09EuMD Action Containing protein 1ELMO D20.760.44ELMO Contain-containing protein 2ELMO D20.760.55Lands-range protein Clorifs20.660.760.66Clummans EdMo System Clorifs20.760.760.76Lands-range protein Clorifs20.760.760.76Clummans EdMo System Clorifs20.760.760.76Clummans EdMo System Clorifs20.760.750.75EdMo System Clorifs20.770.750.75EdMo System Clorifs20.750.750.75EdMo System Clorifs20.750	2-oxoisovalerate dehydrogenase subunit beta, mitochondrial	BCKDHB	-0,77	0,05
Equilarite nucleoside transporter 1SLC2AMG.760.44LMO domain-containing protein 2C1906752-0.76N.D.Lindstraterized protein C190752C1906752-0.760.65Landstraterized protein C190752C1906752-0.760.33Landstraterized protein C190752C1906752-0.750.33MA-binding protein 34BM344-0.75N.D.Decoynucleotidytransferase terminal-interacting protein 1DNTTP1-0.750.023Protein transport protein 5c2ACC2A-0.750.044Decoynucleotidytransferase terminal-interacting protein 1EXC2-0.750.044Decoynucleotidytransferase terminal-interacting protein 1CCCA-0.750.044Decoynucleotidytransferase terminal-interacting protein 34EXC2-0.750.045Decoynucleotidytransferase terminal-interacting protein 10CCTA-0.750.021Uncharamet cill death protein 10Decoynucleotidytransferase terminal-interacting protein 11-0.75N.D.Unor Naceynicexasmine prophosphorylaseJALENT-0.740.021Unor Naceynicexasmine prophosphorylaseJALENT-0.740.021Unor Naceynicexasmine protein 10CNDE-0.740.024Unor Naceynicexasmine protein 11UNP-0.740.024Unor Naceynicexasmine protein 11CNDE-0.740.024Unor Naceynicexasmine protein 12CNDE-0.740.024Unor Naceynicexasmine protein 13CCDE17-0.740.044Unor Naceynic	Fructose-bisphosphate aldolase C	ALDOC	-0,76	0,07
LIMD domain- containing protein 2LIMD02-0.76N.D.Londraracterized protein Clargers0.650.650.65Landrash glycrol-3phosphate anytransferse grammaAGPAT3-0.760.665Glumanase Kidney isoform, intro-contral-interacting protein 1NITPI-0.75N.D.Protein transport protein 5-823ASIC23A0.750.23Protein transport protein 5-823ASIC23A0.750.01Gr75papt Adiopyravae carboxytings [GTP], mitochondrialGCHR0.750.01Gr75papt Adiopyravae carboxytings [GTP], mitochondrialGCHR0.750.02Chromodomain-heliase-DAAbinding protein 14WAL0.740.020.02Chromodomain-heliase-DAAbinding protein 14WPLA0.740.020.02Drohondomain-heliase-DAAbinding protein 14WAL0.740.020.02UPN-Nacetyffwardersen in protein MEE1AWPLA0.740.020.02UPN-Nacetyffwardersen in protein MEE1AWPLA0.740.020.02UpN-Nacetyffwardersen in protein MEE1AWPLA0.740.020.02U	Serine/threonine-protein phosphatase 2A 56 kDa regulatory subunit epsilon isoform	PPP2R5E	-0,76	0,09
Incharactrized protein CaparizeClapsrig0.65Incycl-ng/vcrofin Jack0.650.66Gluamisae kidney Loform, mittechondrial0.150.760.33Mx-binding protein Jack0.170.770.780.750.72Decsynutdecid/yfransfersse terminal-interacting protein 1DNTTP10.750.700.720.750.720.750.7	Equilibrative nucleoside transporter 1	SLC29A1	-0,76	0,44
Incharactrized protein CaparizeClapsrig0.65Incycl-ng/vcrofin Jack0.650.66Gluamisae kidney Loform, mittechondrial0.150.760.33Mx-binding protein Jack0.170.770.780.750.72Decsynutdecid/yfransfersse terminal-interacting protein 1DNTTP10.750.700.720.750.720.750.7	ELMO domain-containing protein 2	ELMOD2	-0,76	N.D.
iangisering bigs and set of the s		C19orf52		0,65
Glutamisse kidney isoform, mitochondrialGIS0.760.73RNA-binding protein 34RBM34-0,76N.D.Prosphoenolpyruxte carboxyknase (GTP, mitochondrialPCV2-0,750.23Phosphoenolpyruxte carboxyknase (GTP, mitochondrialCCVF-0,750.03Prosphoenolpyruxte carboxyknase (GTP, mitochondrialCCVF-0,750.01Prosphoenolpyruxte carboxyknase (GTP, mitochondrialCCVF-0,750.01Prosphoenolpyruxte carboxyknase (GTP, mitochondrialCCVF-0,750.01Prosphoenolpyruxte carboxyknase (GTP, mitochondrialPCDD10-0,750.00Chromodomain-lekicase-NA-hinding protein -1ikeCHO11-0,750.00Chromodomain-lekicase-NA-hinding protein -1ikeCHO1-0,750.00Non-homologuus end-joining factor 1Non0,740.06UBNA calening/SSHU1))-methyticasferase non-calykic subunit TRM6TRM76-0,740.06Ubiquitin carboxyl-terminal hydrolase 34USP34-0,740.02Ubiquitin carboxyl-terminal hydrolase 34USP34-0,740.02Ubiquitin-ike protein 70UST-0,740.04Ubiquitin-ike protein 70UST-0,740.04Ubiquitin-ike protein 70UST-0,740.04Ubiquitin-ike protein 70UST-0,740.04Ubiquitin-ike protein 70UST-0,740.04Ubiquitin-ike protein 70UST-0,740.04Ubiquitin-ike protein 70UST-0,740.04Ubiquiti		AGPAT3		0,66
RNA-binding protein 34RBM34RDA75N.D.Decaynuccied/infyransferase terminal-interacting protein 1DNTTP1-0.75N.D.Protein transport protein sec3ASEC3A-0.750.04GTP cyclohydrolase 1 fedDack regulatory proteinCLFF-0.750.06Nuclear inhibitor of protein phosphatase 1.4citoator of RNA decayPPE188-0.750.00ENuclear inhibitor of protein phosphatase 1.4citoator of RNA decayPPE188-0.750.00ENuchear inhibitor of protein phosphatase 1.4citoator of RNA decayPPE188-0.750.00ENon-homologoue end-plining factor 1Nuclear NNEEI-0.750.00ENon-homologoue end-plining factor 1Nuclear NNEEI-0.740.05EUDN-hacerylhexosine protein phosphatase 3.4citoator of RNA decayUPA1-0.740.05EUDN-hacerylhexosine protein Static subunit TRM5TRMT6-0.740.05EUDN-hacerylhexosine protein NRE11AUS34-0.740.05EUbiquitin carboxyl-termin MELIAUS34-0.740.05EUbiquitin carboxyl-termin MELIAUBI7-0.740.05EUbiquitin carboxyl-termin MELIAUBI7-0.740.05EUbiquitin carboxyl-termin MELIAUBI7-0.740.05EUbiquitin carboxyl-termin MELIAUBI7-0.740.05EUbiquitin carboxyl-termin MELIAUBI7-0.740.05EUbiquitin carboxyl-terminal hydrolase 1.4UBI7-0.740.05EUbiquitin carboxyl-terminal hydrolase 1.4UBI7-0.740.05E </td <td></td> <td>GLS</td> <td></td> <td>0.33</td>		GLS		0.33
becsynuclonicipitransferase terminal-interacting proteinDNIDNIPOTSND.Prosphoenolpyruvate carboxykinase (GTF) mitochondrialPCQ2-0.750.03Prosphoenolpyruvate carboxykinase (GTF) mitochondrialCGLFR-0.750.01DTF quodhyrifuses I feedback regulatory proteinCGLFR-0.750.02m75gppX diphosphataseDCD5-0.750.02Programmed cell death protein 10PCD10-0.750.02Chromodomain-belicase DNA-bindug protein 1-likeNHE11-0.750.02On-shemologuue edjoining frotein 1-likeNHE11-0.740.06UDPN-accyl/beasemine grophosphorylaseUPA1-0.740.06UDPN-accyl/beasemine grophosphorylaseUSP34-0.740.05Upulutin carboxy-terminal hydroise 34USP34-0.740.05Double-strand break repair protein MRE11AUBL7-0.740.05Double-strand break repair protein MRE11AUBL7-0.740.04Ubujutin-factory-terminal hydroise 34CCCC127-0.740.04Double-strand break repair protein MRE11ACCCC127-0.74ND.Returbocalibin-2RCN2-0.740.040.04Ubujutin-factory eteminal hydroise 14CCCC127-0.74ND.Regulation of nuclear preemtNA damain-containing protein 13STR8-0.740.04Vibujutin-factory eteminal hydroises 14TIMM44TIMM44-0.730.01Ubujutin-factory eteminal hydroises 14TIMM44TIMM44-0.730.01		RBM34		
rotein transport protein Sec23ASC23AO.750.75Phospheenology voite carbox/insue GTPI, mitochondrialCVL2-0.750.04Or76 pol diphosphatse 1 dealback regulatory proteinCVLF-0.750.06Nuclear inhibitor of protein phosphatse 1 Activator of RNA decayPPP IRB-0.750.00Nuclear inhibitor of protein phosphatse 1.Activator of RNA decayPPP IRB-0.750.002Chromodomain-heltase DNA-binding protein 1-likeCHO1L-0.750.002Chromodomain-heltase DNA-binding protein 1-likeCHO1L-0.740.06DUP-N-accylibeosamine prophosphorylaseUMP1-0.740.074DUP-N-accylibeosamine prophosphorylaseUMP1-0.740.06DUP-N-accylibeosamine prophosphorylaseUSP34-0.740.06Duble-stand break regair protein MRE11AME11A0.740.24Ubiquitin activacylibeosamine protein INKL2-0.740.24Ubiquitin activacylibeorderie 13KL2-0.740.24Ubiquitin activacylibeorderie 14CADB-0.740.24Ubiquitin activacylibeorderie 13ME11A0.740.24Ubiquitin activacylibeorderie 14ME11A0.740.24Ubiquitin activacylibeorderie 14ME11A0.740.24Ubiquitin activacylibeorderie 14ME11A0.740.24Ubiquitin activacylibeorderie 14ME11A0.740.24Ubiquitin activacylibeorderie 14ME1A0.730.01Ubiquitin activacylibeorderie 14ME1A0				
Phosphenolpyruvate achoxykinase [GTP], mitochondrial PK2 0.75 0.04 CTP volchydrobase 1 feetback regulatory protein GCHR 0.75 0.06 Nuclear inhibitose 1 feetback regulatory protein DCPS 0.75 0.06 Nuclear inhibitose 1 protein 1 factor 1 ND 0.75 0.02 Kundear inhibitor of protein phosphatase 1 Activator of RNA decay PPP188 0.75 0.02 Kundear inhibitor of protein phosphatase 1 Activator of RNA decay PPP181 0.75 0.02 Kundear inhibitor of protein phosphatase 1 Activator of RNA decay PP111 0.75 0.02 Kon-homologous end joining factor 1 ND ND ND ND Kon-homologous end joining factor 1 ND 0.74 0.71 0.74 0.74 Ulputtin achoxy Herminal Nytroises 34 USPN 0.74 0.74 0.74 0.74 Dioulor strand break regular protein NRE11A MRE11A 0.74 0.74 0.74 Dioulor strand break regular broaterinal factor Admain-containal strand				
GFP codbydrolass 1 feedback regulatory protein CCHR 0.75 0.19 ArGaptX diphosphatass DCPS 0.75 0.06 Nuclesr inhibitor of protein phosphatase 1.Activator of RNA decay PPP188 0.75 0.01 Programmed eif dech protein 10 PDCD10 0.75 0.02 Non-homologous end-joining factor 1 NDL 0.75 0.00 Non-homologous end-joining factor 1 NDL 0.74 0.04 VLPNA activities casual in the set result protein MRE 11A UAP1 0.74 0.024 Ubiputin carboxyl-terminal hydrolase 34 USP34 0.74 0.024 Ubiputin carboxyl-terminal hydrolase 34 UBI 27 0.74 0.24 Ubiputin carboxyl-terminal hydrolase 34 UBI 27 0.74 0.24 Ubiputin carboxyl-terminal hydrolase 34 UBI 27 0.74 0.24 Ubiputin-like protein 7 URX2 0.74 0.24 Ubiputin-like protein 7 URX2 0.74 0.24 Ubiputin-like protein 13 AAAF 0.74 0.24 Ubiputin-like protein 5 UCC127				
DCPS Q.75 Q.75 Q.75 Q.75 Widesr inhibitor of protein hosphalase 1.Activator of RNA decay PP188 Q.75 Q.021 Chromodomain-helicase DNA-binding protein 1-like Ch11 Q.75 Q.021 Chromodomain-helicase DNA-binding protein 1-like CH21 Q.74 Q.021 AcyA-protein thioesterase 1 UVPL1 Q.74 Q.05 Up-NacetyIhenessmine prophosphorylase UAP1 Q.74 Q.25 Ubiquitin crabox/terminal hytroliaes 34 USP34 Q.74 Q.25 Ubiquitin crabox/terminal hytroliaes 34 USP34 Q.74 Q.24 Double-strand break repair protein MRE11A UBIX.7 Q.74 Q.28 Roburyl-CoA dehydrogenase, mbtochondrial ACAD8 Q.74 1.24 Interconence unclear inboundeprotein 13 HIRNPH3 Q.74 N.D. Sertine/threonine-protein fision 1 protein 127 CCDC127 Q.74 N.D. Colled Coil domain-containing protein 1A HIRNPH3 Q.74 N.D. Sertine/threonine-protein and transe Araf STA8 Q.74 N.D.				
NuclearPPC180.750.01Irogrammed cilleach protein phosphatase 1.Activator of RNA decayPPC 1000.750.02Chromodomain-helicase DNA-binding protein 1.likeCHD10.750.00Non-homologous end-pining factor 1NHEI10.750.00UDP-H-acetyhexosamine pyrophosphorylaseUPL10.740.06UDP-H-acetyhexosamine pyrophosphorylaseUPL10.740.06UDP-H-acetyhexosamine pyrophosphorylaseUPL10.740.06Ubule strand below NLN (denine) SSNN)0.010.040.05Ubule strand below NLN (denine) SSNN)0.010.040.06Ubule strand below NLN (denine) SSNN0.040.060.04Ubule strand below SSNN0.010.040.04Mitochordrial fision 1 protein0.010.040.04Methytransferse neth of SSNN0.040.040.04Serine/Hreenine-protein Mase A-RafCDC1270.040.04Ubulpuit carbox/-terminal hydrolase 1AUSP40.040.06Ubulpuit carbox/-terminal hydrolase subunt TIM4TIMA40.730.01Ubulpuit carbox/-terminal hydrolase subunt TIM4TIMA40.730.01Ubulpuit carbox/-terminal hydrolase subunt TIM4TIMA40.730.01Ubulpuit carbox/-terminal hydrolase su				
Programmed cell desh proten 10POCD0-0.750.02Kromodomian-helicas-DNA-holindig protein 1-likeDH1-0.75NOAcyl-protein thiesterase 1LYPLA1-0.740.06LVPLA1-0.740.061Acyl-protein thiesterase 1LYPLA1-0.740.06UDN-Naccyl-broxine prophosphorylaseLYPLA1-0.740.25Ubiquiti carboxyl-terminal Hyrloalse 34USP34-0.740.26Double-strand break regain protein MRE11AUBIT-0.740.24Ubiquiti carboxyl-terminal Hyrloalse 34USP34-0.740.24Double-strand break regain protein MRE11AUBIT-0.740.28Ibioquitin carboxyl-terminal Hyrloalse 34UBIT-0.740.28Ibioquitin carboxyl-terminal Hyrloalse 34HNNH33-0.740.28Isoburyl-CoA delydrogenase, mitochondrialACAD8-0.741.24Isoburyl-CoA delydrogenase, mitochondrialACAD8-0.740.20Isoburyl-CoA delydrogenase, mitochondrialACAD8-0.740.20Isoburyl-CoA delydrogenase, mitochondrialACAD8-0.740.20Collect or enrenk Ad domain-containing protein 1AXRPC04-0.730.04Ubiquitin carboxyl-terminal hydrolase 14USP14-0.740.06Ubiquitin carboxyl-terminal hydrolase 14UBIN-0.730.01Ubiquitin carboxyl-terminal hydrolase 14UBIN-0.730.01Ubiquitin carboxyl-terminal hydrolase 14UBIN-0.730.02Zore fistome ma				
Chromodomain-heliase/DNA-binding protein 1-likeCH01L-0.750.00Aryl-protein thioesterase 1LYPLA1-0.740.06UDP-M-acety/hexosamine prytophosphorylaseUAPL-0.740.06UDP-M-acety/hexosamine prytophosphorylaseUAPL-0.740.05Ubiquitin carboxyl-terminal hydrolase 34USP34-0.740.02Double-strand forsk repair protein MREIIAMREIIA-0.740.24Ubiquitin carboxyl-terminal hydrolase 34USP34-0.740.29Betculocabin-2RCN-0.740.14Mitochondrial fission 1 proteinFISI-0.740.28Sobutryl-CA dehydrogenase, mitochondrialACAD8-0.740.14Methyltransferase-like protein 16MRTH116-0.740.04Serine (hreenine-protein knase ARafACAD8-0.74N.D.Coide-Coil domain-containing protein 127CDC 1137-0.74N.D.Coide-Coil domain-containing protein 127CDC 1137-0.74N.D.Regulation of nuclear pre-mRNA domain-containing protein 1ARRPOLA-0.730.07Yintan-8Ubiquitin carboxyl-terminal hydrolase 14TIMM44-0.730.04Ubiquitin carboxyl-terminal hydrolase 14TIMM44-0.730.01Tarffiching protein partice complex subunit 11M44TIMM44-0.730.01Ubiquitin Carboxyl-terminal hydrolase subunit TIM44TIMM44-0.730.01Tarffiching protein 21CTC 1137-0.74N.D.Core histone macro-HZA.1TIMAF-0				
Non-bonologous end-joining factor 1Nuc.Nuc.Ary-protein thiosestrase 1UPPA1-0,740,06UDPA-sectylhexosanine prophosphorylaseUAP1-0,740,071tNA (adenine(SS) NLI) methyltransferase non-catalytic subunit TRM6TRMT6-0,740,25Ubliquitin carboxyl-terminal hydrolase 34USP3-0,740,24Ubliquito int carboxyl-terminal hydrolase 34USP3-0,740,24Ubliquitin carboxyl-terminal hydrolase 34USP3-0,740,28Nitcoch ordin fission 1 proteinRSI-0,740,28Isoburyl-CoA dehydrogenase, mitochondrialACADE-0,740,28Isoburyl-CoA dehydrogenase, mitochondrialMETLIA-0,740,28Isoburyl-CoA dehydrogenase, mitochondrialMETLIA-0,740,28Isoburyl-CoA dehydrogenase, mitochondrialMCCDCCI217-0,74N.0.Scielled coll domain-containing protein 12CCDCI217-0,74N.0.Colled-coll domain-containing protein 1ARRPCIA-0,740,04Ubliquitin carboxyl-terminal hydrolase 14USP14-0,740,06Taffiching protein particle complex subunit TIM44USP14-0,730,07Nitchondrial import inner membrane translocase subunit TIM44NDN2-0,730,01Ubliquitin -like protein 5UBL5-0,730,01Ubliquitin -like protein 61NDL2-0,730,02Core histone macro-HazA.1MCAA-0,740,02Mitochondrial import inner membrane translocase subunit TIM44<				
Axyl-protein threaterser 1UPA1-0.740.06UDP-Nacetyl-torsamine pyrophosphorylaseUAP1-0,740.21URA (adenine(S8)-N(1))-methyltransferase non-catalytic subunit TRM6TRMT6-0,740.25Ubiquitin carboxyl-terminal hydrolase 34USF34-0,740.24Double-strand torsk repair protein MREIIAMRE1IA-0,740.24Ubiquitin like protein 7RCN2-0,740.24RetractorschildACAD8-0,740.28Sobutryl-CA dehydrogenase, mitochondrialACAD8-0,740.28Sobutryl-CA dehydrogenase, mitochondrialMRTNB-0,740.28Methyltransferase, like protein 16METTL36-0,740.20Serine/threenine-protein kinase A RafARAF-0,74N.D.Colled-coil domain-containing protein 17RCDC 127-0,74N.D.Colled-coil domain-containing protein 17RTMS6-0,740.20Syntaxin-8Ubiquitin Carboxyl-terminal hydrolase 14USP14-0,730.07Ubiquitin-18 protein 57UBIS-0,740.06-0,730.07Taffiching protein partie complex subunit 1M44USP14-0,730.07-0,730.01Metanoma-associated antigen 61NDNL2-0,730.01-0,740.02Storation fike protein 5UBIS-0,730.01-0,740.02Storation fike protein 5UBIS-0,730.01-0,730.07Mitochondrial importein 7RAPFCA-0,730.07-0,73				
UDF-N-acetylhexosamine pyrophosphorylaseUAP10.740.71tRNA (adenine(58)-N(1))-methyltransferase non-catalytic subunit TRM6TRMT6-0.740.25Ubiquitin carboxyl-terminal hydrolase 34USP34-0.740.24Doubie-strand break repair protein MRE11AMRE11A-0.740.24Ubiquitin carboxyl-terminal hydrolase 34BL17-0.740.24Ubiquitin carboxyl-terminal fission 1 proteinFIS1-0.740.28Reticulcabin-2RCN2-0.740.28Mitochondrial fission 1 proteinACAD8-0.741.24Heterogeneous nuclear ribonucleoprotein H3MRNRPH3-0.740.04Serine/Threenine-protein insase A-RafARAF-0.74N.0.Colled-coil domain-containing protein 12CDC L27-0.74N.0.Regulation of nuclear protein 127CDC L27-0.74N.0.Syntaxin-8STM8-0.740.06-0.73Ubiquitin carboxyl-terminal hydrolase 14USP1A-0.740.06Tafficking protein partice conplex subunit 4HAPPC4-0.730.07Mitochondrial import inner membrane translocase subunit TIM44TIMM44-0.730.07Mitochondrial glutamate carriesSTOM12-0.730.18Mitochondrial glutamate carriesSTOM2-0.730.12And fing domain-containing protein 1H2AFY-0.730.10Mitochondrial glutamate carriesSTOM2-0.730.12Antificking protein 5WAPA-0.730.07 <td< td=""><td></td><td></td><td></td><td></td></td<>				
RNA fadenine(S3)-KU):-nethythransferse non-catalytic subunit TRM6 RNT6 0.74 0.25 Ubiquitin carboxyl-terminal hydrolase 34 USP34 -0.74 0.06 Double-strand break repair protein MRE1JA UBI V -0.74 0.29 Retriculocation-2 RCN2 -0.74 0.24 Mitochondrial fission 1 protein FIS1 -0.74 0.28 Sobutryl-Cod dehydrogenase, mitochondrial ACAD8 -0.74 0.18 Methyltransferase.like protein 16 METTLI5 -0.74 0.04 Serine (Threonine-protein Kanse A-Raf ARAF -0.74 N.0. Collect-coil domain-containing protein 127 CCCC127 -0.74 N.0. Segulation of nuclear pre-RNA domain-containing protein 1A RPPC1A -0.73 0.00 Syntaxin-8 Ubiquitin -like protein 5 USF1A -0.74 0.06 Ubiquitin -like protein 5 USF1A -0.74 0.06 Ubiquitin -like protein 5 USF1A -0.74 0.02 Ubiquitin actoxyl-terminal hydrolase 14 USF1A -0.74 0.02 Ubiqui				
bbiputin carboxyl-terminal hydrolase 34USP34USP34UG740.06Double-strand break repair protein MRE11AMRE11AMRE11A0.740.24Double-strand break repair protein MRE11AMRE11AMRE11A0.740.24Mitchohordial fission 1 proteinRCN20.741.14Mitchohordial fission 1 proteinACADB0.741.24Isobutryl-CoA dehydrogenase, mitchohordialMRNNPH30.740.24Isobutryl-CoA dehydrogenase, mitchohordialMRNNPH30.740.48Methyldransferase-like protein 15METLIG0.740.04Serine/threonine-protein kinase-ARafMRF0.740.04Colled-coil domain-containing protein 1ARPR01A0.740.06Syntaxin-STSR0.740.060.07Mitchohordial import in protein protein protein protein protein protein science0.730.07Vittochordial import inner membrane translocase subunit TIM44USP140.730.07Uhichohordial import inner membrane translocase subunit TIM441730.030.01Vittochordial inport inner membrane translocase subunit TIM441730.070.07Vittochordial inport inner membrane translocase subunit TIM441730.070.07Vi				
Double-strand break repair protein MRE11A ME11A -0.74 0.24 Ubiquitin-like protein 7 UBL7 -0.74 0.29 Reticulocalibin-2 RCN2 -0.74 0.14 Mitochondrial fission 1 protein FIS1 -0.74 0.24 Mitochondrial fission 1 protein RCN2 -0.74 0.24 Methyltransfersa-like protein 16 RCN2 -0.74 N.D. Serine/threonine-protein kinase A-Raf ARAF -0.74 N.D. Coiled-coil domain-containing protein 127 CCCC127 -0.74 N.D. Regulation of nuclear pre-finAA domain-containing protein 1A TRRPD1A -0.74 0.04 Syntaxin-8 Ubiquitin-arboxyl-terminal hydrolase 14 -0.74 0.06 - Vindurin-like protein 5 Ubiquitin-like protein 3 -0.73 0.41 Core histome membrane translocase subunit TIM44 TIMM44 -0.73 0.01 Mitochondrial import inner membrane translocase subunit TIM44 TIMM44 -0.73 0.10 Mitochondrial import inner membrane translocase subunit 7 ND.L2 -0.73 0.10				
bblquith-like protein 7 0,74 0,29 Reticulocalbin-2 RCN2 -0,74 0,14 Nitochondrial fission 1 protein FIS1 -0,74 0,28 Isobutyrl-CoA dehydrogenase, mitochondrial ACAD8 -0,74 0,18 Heterogeneous nuclear ribonucleoprotein H3 HNRNPH3 -0,74 0,18 Methyltransferase-like protein 16 MCTL16 -0,74 N.D. Serine/threeonine-protein kinase A-Raf CCDC127 -0,74 N.D. Colled-coil domain-containing protein 127 CCDC127 -0,74 N.D. Regulation of nuclear pre-mRNA domain-containing protein 1A RPRD1A -0,74 0,04 Ubiquitin-like protein particle complex subunit 4 USP14 -0,73 0,04 Ubiquitin-like protein 3 UBI5 -0,73 0,01 In finger MW-type protein 3 ZMYM3 -0,73 0,04 Ubiquitin-like protein 3 ZMYM3 -0,73 0,01 Mitochondrial import inner membrane translocase subunit TIM44 TIMMA4 -0,73 0,01 Methorom-associated antigen G1 STOML2				
Reticucalbin-2RCN29.740.14Mitochondrial fision 1 proteinFIS1-0,740.28Sobutyyi-CoA dehydrogenase, mitochondrialHXNPMP13-0,740.28Hetterogeneous nuclear ribonucleoprotein H3HXNPMP13-0,740.04Methytransfreas-like protein 16.0740.04.0740.04Serine/threonine-protein kinase A-RafARAF-0,74N.D.Colled-coil domain-containing protein 127.CCDC127-0,74N.D.Regulation of nuclear pre-mRAM domain-containing protein 1ASTRA-0,740.04Ubiquitin carboxyi-terminal hydrolase 14USP14-0,740.06Trafficking protein particle complex subunit 4TRAPPC4-0,730.07Ubiquitin -afboxyi-terminal hydrolase 14TIMM44-0,730.09Zinc finger MVM-type protein 3ZMVM3-0,730.010Mitochondrial gutomate carrier 1NDNL2-0,73N.D.Stomatin-like protein 3STOMI2-0,730.19Core histone macro-H2A.1NDNL2-0,730.19Mitochondrial gutomate carrier 1STOMI2-0,730.07Mitochondrial gutomate carrier 1STMS-0,730.03Storatin-Rise RASSTMS-0,730.03Importin-9WAA-0,730.03Alpha-12-manosytransferase ALG9NAS-0,730.03Importin-9WAOA-0,720.13Alpha-12-mannosytransferase ALG9NACA-0,720.03Zine finger protein vati				
Mitochondrial fission 1 proteinFIS1-0,740,28isobutyryl-CoA dehydrogenase, mitochondrialACAD8-0,741,24isobutyryl-CoA dehydrogenase, mitochondrialHNRNPH3-0,740,04Methyltransferase-like protein 16METTL16-0,74N.D.Colled-coil domain-containing protein 127CCDC127-0,74N.D.Colled-coil domain-containing protein 1ARPD1A-0,740,04Ubiquitin carboxyl-terminal hydrolase 14USP14-0,740,06Trafficking protein partice complex subunit 4UB12-0,730,01Ubiquitin carboxyl-terminal hydrolase 14TRAPPCA-0,730,07Ubiquitin-like protein 5UB15-0,730,07Mitochondrial import inner membrane translocase subunit TIM44-0,730,09Zin fringer MW-type protein 3ZMYM3-0,730,10Medanoma-associated antigen 61NDNL2-0,730,10Mitochondrial glutamate carrier 1SC2SA22-0,730,19Elongation factor Tu GTP-holing domain-containing protein 1EFTUD1-0,730,03Storting nein-5SNX5-0,730,0310Ninochondrial glutamate carrier 1EFTUD1-0,730,03Icongatin factor Tu GTP-holing domain-containing protein 1EFTUD1-0,730,03Storting nein-5SNX5-0,730,0310Importin-9VM29-0,730,1311Alpha-1,2-manosyltransferase ALG9AlG9-0,730,13Zint finge				
sobutyvi-CoA debytogenase, mitochondrialACA08-0,741,24Heterogeneous nuclear ribonucleoprotein H3HNRNPH3-0,740,04Methytransferase-like protein 16METTL16-0,74N.D.Serine/threonine-protein kinase A-RafARAF-0,74N.D.Colled-coil domain-containing protein 127CCDC 127-0,74N.D.Regulation of nuclear pre-mRNA domain-containing protein 1ARPRD1A-0,740,04Syntaxin-8USP14-0,740,06Trafficking protein particle complex subunit 4TRAPPC4-0,730,01Ubiquitin-raboxyl-terminal hydrolase 14USP14-0,730,07Mitochondrial import inner membrane translocase subunit TIM44TIMM44-0,730,09Zinc finger MTM-type protein 3CCTore histone marco-H2A.1H2AFY-0,730,10Metanoma-associated antigen 61NDNL2-0,730,19Stomatin-like protein 2, mitochondrialSTOM2-0,730,07Mitochondrial glutamate carrier 1SIC2SA22-0,730,03Sorting nexin-5NDNL2-0,730,03Importin-9NDN2-0,730,0312Alpha-1,2-mannosyltransferase ALG9ALG9-0,730,12Alpha-1,2-mannosyltransferase ALG9ALG9-0,730,33Armine oxidase [flavin-containing protein 13CC2A-0,730,33Zinc finger protein ubi-d4ALG9-0,730,33Anine oxidase [flavin-containing protein 13CC3H13-0,720,33				
Heterogeneous nuclear ribonucleoprotein H3 HNRNPH3 -0.74 0.18 Methyltransferase-like protein 16 METTL16 -0.74 0.04 Serine/threonine-protein kins kase A-Raf ARAF -0.74 N.D. Colled-coll domain-containing protein 127 CCD C127 -0.74 N.D. Regulation of nuclear pre-mRNA domain-containing protein 1A RPRD1A -0.74 0.04 Ubiquitin carboxyl-terminal hydrolase 14 USP14 -0.74 0.06 Trafficking protein particle complex subunit 4 UBLS -0.73 0.07 Ubiquitin-like protein 3 UBLS -0.73 0.07 Zinc finger MVM-type protein 3 CAWHA -0.73 0.07 Mitchondrial import inner membrane translocase subunit TIM44 TIMM44 -0.73 0.04 Core histone macro-H2A.1 H2AFY -0.73 0.10 Methondrial glutamate carrier 1 Stroctastata Stromatin-like protein 2, mitchondrial Stromatin-like protein 3 -0.73 0.07 Von Willebrand factor A domain-containing protein 1 VMA9 -0.73 0.03 Trafficking protein ubi-dia -				
MethyTransferase-like protein 16METTL16-0.740.04Serine/threonine-protein kinase A.RafARAF-0.74N.D.Colled-coil domain-containing protein 127CCDC127-0.74N.D.Regulation of nuclear pre-mRNA domain-containing protein 1ARPD1A-0.740.04Syntaxin-8USP14-0.740.06Ubiquitin carboxyl-terminal hydrolase 14USP14-0.730.07Trafficking protein particle complex subunit 4UBL5-0.730.07Ubiquitin-like protein 5UBL5-0.730.09Zinc finger MYM-type protein 3CCD command20092009Zinc finger MYM-type protein 3COM-0.730.09Zinc finger MYM-type protein 3COM-0.730.07Kotondrial import inner membrane translocase subunit TIM44TIMM44-0.730.09Zinc finger MYM-type protein 3COM-0.730.10Melanoma-associated antigen G1NDNL2-0.73N.D.Stomatin-like protein 2, mitchcondrialSTOM12-0.730.10Mitchondrial glutamate carrier 1SLC25A22-0.730.19Elongation factor Tu GTP-binding domain-containing protein 1Elongation factor 1-0.730.07von Willebrand factor A domain-containing protein 1PO9-0.730.03Jumportin-9AUG9-0.730.031.21Alpha-1,2-manosyltransferase ALG9ALG9-0.730.03Trafficking protein particle complex subunit 6BTRAPPC6B-0.730.03 <td></td> <td></td> <td></td> <td></td>				
Serine/threonine-protein kinase A-RafARAF0.74N.D.Coiled-coil domain-containing protein 127C.O.CDC127-0.74N.D.Regulation of nuclear pre-mRNA domain-containing protein 1ARPRD1A-0.740.20Syntaxin-BSTX8-0.740.06Ubiquitin carboxyl-terminal hydrolase 14USP14-0.730.41Ubiquitin carboxyl-terminal import in particle complex subunit 4TRAPC4-0.730.07Witcohondrial import inner membrane translocase subunit TIM44TIMM44-0.730.09Zinc finger MYM-type protein 3ZMYM3-0.730.44Core histone macro-HZA.1HOMM44-0.730.10Melanoma-associated antigen G1NDNL2-0.730.18Stomatin-like protein 2, mitcohondrialSTOML2-0.730.19Elongation factor TA domain-containing protein 1EFTUD1-0.730.07von Willebrand factor A domain-containing protein 1EFTUD1-0.730.03Importin-9IPO9-0.730.12AlfsApha-12mannosyttransferase ALG9NDCNDC20.3333Trafficking protein and family member IPOFE-0.730.3333Amine exidase flavin-containing protein 13CGH14-0.720.11Apha-12mannosyttransferase ALG9NDC-0.730.1333Trafficking protein and family member IPOFE-0.730.3333Trafficking protein ubi-d4OP72-0.730.3333Amine exidase flavin-contai	-			
Colled-coil domain-containing protein 127CCDC127-0,74N.D.Regulation of nuclear pre-mRNA domain-containing protein 1ARPRD1A-0,740,00Syntaxin-8STK8-0,740,06Ubiquitin carboxyl-terminal hydrolase 14USP14-0,730,07Trafficking protein particle complex subunt 4UBL5-0,730,07Mitochondrial import inner membrane translocase subunit TIM44TIMM44-0,730,09Zinc finger MVM-type protein 3COre histone macro-H2A.1H2AFY-0,730,10Melanoma-associated antigen G1NDNL2-0,730,10Mitochondrial igutamate carrier 1SLC2SA22-0,730,19Elongation factor Tu GTP-binding domain-containing protein 1EFTUD1-0,730,07von Willebrand factor A domain-containing protein 1EFTUD1-0,730,03Sorting nexit-5SNKS-0,730,030,09Importin-9IPO9-0,730,030,03Intafficking protein particle complex subunit 6BTRAPC6B-0,730,12Alpha-1,2-mannos/ltransferase ALG9IRA-0,721,57POTE ankyrin domain-containing protein 1PCTE-0,730,33Amine oxidase (flavin-containing) APOF2-0,730,12Alpha-1,2-mannos/ltransferase ALG9TRAPC6B-0,730,13Zine finger protein ubi-4ALG9-0,720,13Amine oxidase (flavin-containing protein 13VCC14-0,720,30Zine finger CCCH domain-containing protein	Methyltransferase-like protein 16		-0,74	0,04
Regulation of nuclear pre-mRNA domain-containing protein 1ARPR01A-0,740,20Syntaxin-8USP14-0,740,06Ubiquitin carboxyl-terminal hydrolase 14USP14-0,740,06Trafficking protein particle complex subunit 4URAPPC4-0,730,07Ubiquitin-like protein 5UBL5-0,730,07Mtochondrial import inner membrane translocase subunit TIM44TIMM44-0,730,09Zinc finger MYM-type protein 3ZMYM3-0,730,10Melanoma-associated antigen G1NDNL2-0,730,10Melanoma-associated antigen G1NDNL2-0,730,19Stomatin-like protein 2, mitochondrialSTCML2-0,730,19Bingation factor Tu GTP-binding domain-containing protein 1EFTUD1-0,730,07von Willebrand factor A domain-containing protein 1EFTUD1-0,730,03Sorting nexin-5SNX5-0,730,030,03Importin-9IPO9-0,730,122,157Alpha-1,2-mannosyltransferase ALG9NAA-0,721,57Apha-1,2-mannosyltransferase ALG9NAA-0,720,33Zinc finger protein particle complex subunit 6BTRAPPC6B-0,730,30Zinc finger cCCH domain-containing protein 13CC3H13-0,720,11Protein particle complex subunit alpha, mitochondrialMAOA-0,720,33Amine exidase [favin-containing protein 13CC3H13-0,720,31Diff anger CCCH domain-containing protein 13CC3H13 <td>Serine/threonine-protein kinase A-Raf</td> <td>ARAF</td> <td>-0,74</td> <td>N.D.</td>	Serine/threonine-protein kinase A-Raf	ARAF	-0,74	N.D.
Syntaxin-8STX8-0,740,04Ubiquitin carboxyl-terminal hydrolase 14USP14-0,740,06Trafficking protein partice complex subunit 4TRAPPC4-0,730,07Ubiquitin-like protein 5UBL5-0,730,07Mitochondrial import inner membrane translocase subunit TIM44TIMM44-0,730,09Zinc finger WM-type protein 3ZWYM3-0,730,10Melanoma-associated antigen G1NDNL2-0,730,10Mitochondrial glutamate carrier 1SIC25A22-0,730,19Elongation factor TU GTP-binding domain-containing protein 1EFTUD1-0,730,07von Wilebrand factor A domain-containing protein 1FTUD1-0,730,03Sorting nexin-5SNX5-0,730,03Importin-9ALG9-0,730,12Alpha-1,2-mannosyltransferase ALG9ALG9-0,730,13Tafficking protein nartice complex subunit 6BTRAPPC6B-0,730,13Zinc finger Vdru domain-containing forein 13POTE1-0,720,13Zinc finger Vdru domain-containing AMOAA-0,720,13POTE ankyrin domain family member 1POTE1-0,720,13Zinc finger Vdru domain-containing protein 13C3H13-0,720,11Protein VACI4 homologVACI4-0,720,13Zinc finger CCCH domain-containing protein 13C3H13-0,720,13Zinc finger CPCH homologVACI4-0,720,13Zinc finger CPCH homologVACI4-0,7	Coiled-coil domain-containing protein 127	CCDC127	-0,74	N.D.
Ubiquitin carboxyl-terminal hydrolase 14USP14-0,740.06Trafficking protein particle complex subunit 4TRAPPC4-0,730,41Ubiquitin-like protein 5UBL5-0,730,07Mitochondrial import inner membrane translocase subunit TIM44TIMM44-0,730,09Zinc finger MYM-type protein 3ZMYM3-0,730,44Core histone macro-H2A.1NDNL2-0,730,10Melanoma-associated antigen G1NDNL2-0,730,11Stomatin-like protein 2, mitochondrialSTOML2-0,730,18Mitochondrial glutamet carrier 1EFUD1-0,730,07Von Willebrand factor A domain-containing protein 1EFUD1-0,730,03Sorting nexin-5SNS-0,730,03Importin-9IPO9-0,730,12Alpha-1,2-mannosyltransferase ALG9ALG9-0,730,13Zinc finger protein ubi-d4DPF2-0,730,33Amine oxidase [flavin-containing protein 13CC3H13-0,720,11Protein vbi-d4DPF2-0,730,33Zinc finger protein antiger protein 13CC3H13-0,720,11Protein vbi-d4DPF2-0,720,30Zinc finger protein ding protein 13CC3H13-0,720,11Protein vbi-d4DPF2-0,720,30Zinc finger protein ding protein 13CC3H13-0,720,30Zinc finger protein ding protein 13CC3H13-0,720,31Protein vbi-d4DPC2-0,72 </td <td>Regulation of nuclear pre-mRNA domain-containing protein 1A</td> <td>RPRD1A</td> <td>-0,74</td> <td>0,20</td>	Regulation of nuclear pre-mRNA domain-containing protein 1A	RPRD1A	-0,74	0,20
Trafficking protein particle complex subunit 4TRAPPC4-0,730,41Ubiquitin-like protein 5UB5-0,730,07Mitochondrial import inner membrane translocase subunit TIM44TIMM44-0,730,09Zinc finger MYM-type protein 3ZMYM3-0,730,44Core histone macro-H2A.1H2AFY-0,730,10Melanoma-associated antigen G1STOML2-0,730,18Stomatin-like protein 2, mitochondrialSTOML2-0,730,19Elongation factor Tu GTP-binding domain-containing protein 1SC25A22-0,730,07von Willebrand factor A domain- containing protein 9VWA9-0,730,63Sorting nexin-5SNX5-0,730,09Importin-9IPO9-0,730,03Alpha-1,2-mannosyltransferase ALG9RAPPC6B-0,730,18Zinc finger protein ubi-d4MAOA-0,721,57POTE ankyrin domain family member 1POTE1-0,720,13Zinc finger CCCH domain-containing protein 13PCTE1-0,720,11Protein VAC14 homologVAC14-0,720,332-oxoisovalerate dehydrogenase subunit alpha, mitochondrialBCKDHA-0,720,18Multifunctional protein ADE2DX52-0,720,18Protein VAC14 homologSUNIN-0,720,02Probable ATP-dependent RNA helicase DDX52DX52-0,720,13BolA-like protein 2Glopad domain-containing protein 4GO720,24Gloyakase domain-containing protein 4	Syntaxin-8	STX8	-0,74	0,04
Ubiquitin-like protein 5UBL5-0,730,07Mitochondrial import inner membrane translocase subunit TIM44TIMM44-0,730,09Zinc finger MYM-type protein 3ZMYM3-0,730,44Core histone macro-H2A.1H2AFY-0,73N.D.Mitochondrial gutamate carrier 1STOML2-0,730,19Elongation factor Tu GTP-binding domain-containing protein 1EFTUD1-0,730,07VW M9-0,730,070,070,07von Willebrand factor A domain-containing protein 1EFTUD1-0,730,07von Willebrand factor A domain-containing protein 9VWA9-0,730,03Sorting nexin-5INVS-0,730,030,12Importin-9IPO9-0,730,030,12Alpha-1,2-mannosyltransferase ALG9ALG9-0,730,18Zinc finger protein ubi-d4DPF2-0,730,18Zinc finger protein ubi-d4DPF2-0,730,33Amine oxidase [flavin-containing] AMAOA-0,721,57POTE ankyrin domain family member 1Zint finger CCH domain-containing protein 13C2H14-0,720,302-oxisovalerate dehydrogenase subunit alpha, mitochondrialBCKDHA-0,720,01Portein VAC14 homolog-0,720,020,11Portein 20,02Protein VAC14 homolog-0,720,220,720,22Probable ATP-dependent RNA helicase DDX52BOLA2-0,720,02BolA-like protein 2GLOA4-0,720,02	Ubiquitin carboxyl-terminal hydrolase 14	USP14	-0,74	0,06
Mitochondrial import inner membrane translocase subunit TIM44TIMM44-0,730,09Zinc finger MYM-type protein 3ZMYM3-0,730,44Core histone macro-H2A.1H2AFY-0,730,10Melanoma-associated antigen G1NDNL2-0,730,18Stomatin-like protein 2, mitochondrialSTOML2-0,730,19Elongation factor Tu GTP-binding domain-containing protein 1SLC2SA22-0,730,07von Willebrand factor A domain-containing protein 9VWA9-0,730,063Sorting nexin-5SNX5-0,730,030,12Ilpoptin-9IPO9-0,730,030,12Alpha-1,2-mannosyltransferase ALG9IRAPPCGB-0,730,03Trafficking protein particle complex subunit 6BTRAPPCGB-0,730,33Amine oxidase [flavin-containing protein 13ZC3H13-0,720,33Amine oxidase [flavin-containing protein 13ZG4H14-0,720,30Zinc finger protein ubi-d4POTE1-0,720,31Amine oxidase [flavin-containing protein 13ZG3H13-0,720,31Zinc finger CCCH domain-containing protein 13ZG4H14-0,720,302-oxoisovalerate dehydrogenase subunit alpha, mitochondrialBCKDHA-0,720,11Protein VAC14 homologVAC14-0,720,132-oxoisovalerate dehydrogenase subunit alpha, mitochondrialBCMDHA-0,720,22Probable ATP-dependent RNA helicase DDX52DDX52-0,720,13BolA-like protein 2G	Trafficking protein particle complex subunit 4	TRAPPC4	-0,73	0,41
Zinc finger MYM-type protein 3 -0,73 0,44 Core histone macro-HZA.1 H2AFY -0,73 0,10 Melanoma-associated antigen G1 NDNL2 -0,73 0,12 Stomatin-like protein 2, mitochondrial STOML2 -0,73 0,13 Mitochondrial glutamate carrier 1 SLC25A22 -0,73 0,19 Elongation factor Tu GTP-binding domain-containing protein 1 EFTUD1 -0,73 0,63 Sorting nexin-5 SNXS -0,73 0,09 Importin-9 IPO9 -0,73 0,03 Alpha-1,2-mannosyltransferase ALG9 IRAPPC6B -0,73 0,33 Zinc finger protein particle complex subunit 6B TRAPPC6B -0,73 0,33 Zinc finger protein ubi-44 DPF2 -0,73 0,33 Anime oxidase [flavin-containing protein 13 ZC3H13 -0,72 0,11 Protein ankyrin domain family member 1 ZO14 -0,72 0,30 21nc finger CCH domain-containing protein 13 ZC3H13 -0,72 0,31 PoTE ankyrin domain family member 1 ZO34 -0,72 <	Ubiquitin-like protein 5	UBL5	-0,73	0,07
Core histone macro-H2A.1H2AFY-0,730,10Melanoma-associated antigen G1NDNL2-0,73N.D.Stomatin-like protein 2, mitochondrialSTOML2-0,730,18Mitochondrial glutamate carrier 1SLC25A22-0,730,19Elongation factor Tu GTP-binding domain-containing protein 1EFTUD1-0,730,07von Willebrand factor A domain-containing protein 9VWA9-0,730,63Sorting nexin-5INPO-0,730,012Importin-9IPO9-0,730,02Alpha-1,2-mannosyltransferase ALG9ALG9-0,730,03Trafficking protein particle complex subunit 68TRAPPC6B-0,730,33Zinc finger protein ubi-d4MAOA-0,721,57POTE ankyrin domain family member 1POTEI-0,720,11Protein VAC14 homologVAC14-0,720,302-oxoisovalerate dehydrogenase subunit alpha, mitochondrialBCKDHA-0,720,12Multifunctional protein ADE2PAICS-0,720,22Probable ATP-dependent RNA helicase DDS52DDS52-0,720,02Glyoxalase domain-containing protein 4GLOD4-0,720,13BolA-like protein 2BOLA2-0,720,02Glyoxalase domain-containing protein 4GLOD4-0,720,24Heparan sulfate 2-0-sulfortansferase 1NBAS-0,720,02Glyoxalase domain-containing protein 4GLOD4-0,720,24	Mitochondrial import inner membrane translocase subunit TIM44	TIMM44	-0,73	0,09
Melanoma-associated antigen G1NDNL2-0,73N.D.Stomatin-like protein 2, mitochondrialSTOML2-0,730,18Mitochondrial glutamate carrier 1SLC25A22-0,730,19Elongation factor Tu GTP-binding domain-containing protein 1EFTUD1-0,730,07von Willebrand factor A domain-containing protein 9VWA9-0,730,63Sorting nexin-5SNX5-0,730,09Importin-9IPO9-0,730,012Alpha-1,2-mannosyltransferase ALG9ALG9-0,730,03Trafficking protein particle complex subunit 68TRAPPC6B-0,730,33Zinc finger protein ubi-d4DPF2-0,730,33Amine oxidase [flavin-containing protein 13ZC3H13-0,72N.D.Zinc finger CCCH domain-containing protein 13ZC3H13-0,720,31Protein VAC14 homologVAC14-0,720,302-oxoisovalerate dehydrogenase subunit alpha, mitochondrialBCKDHA-0,720,12Multifunctional protein ADE2DX52-0,720,22Probable ATP-dependent RNA helicase DDX52DX52-0,720,22Glyoxalase domain-containing protein 4GLOD4-0,720,24BolA-like protein 2GLOD4-0,720,24Eukaryotic transfation initiation factor 4EEIFE-0,720,24Heparan sulfate 2-0-sulfortansferase 1NBAS-0,720,24	Zinc finger MYM-type protein 3	ZMYM3	-0,73	0,44
Stomatin-like protein 2, mitochondrialSTOML2-0,730,18Mitochondrial glutamate carrier 1SLC25A22-0,730,19Elongation factor Tu GTP-binding domain-containing protein 1EFTUD1-0,730,07von Willebrand factor A domain-containing protein 9VWA9-0,730,63Sorting nexin-5SNX5-0,730,09Importin-9IPO9-0,730,12Alpha-1,2-mannosyltransferase ALG9IPO9-0,730,18Zinc finger protein particle complex subunit 6BTRAPPC6B-0,730,18Zinc finger protein ubi-d4DFF2-0,730,33Amine oxidase (flavin-containing protein 13CG3H13-0,721,57POTE anktyrin domain family member 1POTEI-0,720,31Zinc finger CCCH domain-containing protein 13ZC3H13-0,720,31Pottein VAC14 homologVAC14-0,720,322-oxoisovalerate dehydrogenase subunit alpha, mitochondrialKCMHA-0,720,42Multifunctional protein ADE2STMN1-0,720,22Probable ATP-dependent RNA helicase DDX52DDX52-0,720,02Gloyakase domain-containing protein 4GLOD4-0,720,04Retinol dehydrogenase 11GLOD4-0,720,04Retinol dehydrogenase 11RDH11-0,720,24Eukaryotic transfation initiation factor 4EEIF4E-0,720,06Heparan sulfate 2-0-sulfortansferase 1HSS-0,720,24	Core histone macro-H2A.1	H2AFY	-0,73	0,10
Mitochondrial glutamate carrier 1SLC 25A22-0,730,19Elongation factor Tu GTP-binding domain-containing protein 1ETUD1-0,730,07von Willebrand factor A domain-containing protein 9VWA9-0,730,63Sorting nexin-5INPO9-0,730,12Importin-9IPO9-0,730,12Alpha-1,2-mannosyltransferase ALG9ALG9-0,730,03Trafficking protein particle complex subunit 6BTRAPPC6B-0,730,33Amine oxidase (flavin-containing) AMAOA-0,721,57POTE ankyrin domain family member 1POTEI-0,720,11Protein VAC14 homologVAC14-0,720,132-oxoisovalerate dehydrogenase subunit alpha, mitochondrialBCKDHA-0,720,18Multifunctional protein ADE2PAICS-0,720,13Stable ATP-dependent RNA helicase DDX52DDX52-0,720,02Glyoxalase domain-containing protein 4GLOD4-0,720,13BolA-like protein 2BOLA2-0,720,02Glyoxalase domain-containing protein 4GLOD4-0,720,02Retinol dehydrogenase 11ROH11-0,720,04Retinol dehydrogenase 12NBAS-0,720,06Heparan sulfate 2-0-sulfortansferase 1HS2ST1-0,720,24	Melanoma-associated antigen G1	NDNL2	-0,73	N.D.
Elongation factor Tu GTP-binding domain-containing protein 1EFTUD1-0,730,07von Willebrand factor A domain-containing protein 9VWA9-0,730,63Sorting nexin-5SNX5-0,730,09Importin-9IPO9-0,730,12Alpha-1,2-mannosyltransferase ALG9ALG9-0,730,03Trafficking protein particle complex subunit 68TRAPPC6B-0,730,33Zinc finger protein ubi-d4MAOA-0,721,57POTE ankyrin domain family member 1POTEI-0,720,11Protein VAC14 homologVAC14-0,720,302-oxoisovalerate dehydrogenase subunit alpha, mitochondrialBCKDHA-0,720,31Multifunctional protein ADE2PAICS-0,720,30StatminSTMN1-0,720,32Probable ATP-dependent RNA helicase DDS52DDS52-0,720,02Giyoxalase domain-containing protein 4GLOD4-0,720,13BolA-like protein 2BCLA2-0,720,02Giyoxalase domain-containing protein 4StTM11-0,720,24Eukaryotic translation initation factor 4EEIFE-0,720,02Giyoxalase domain-containing protein 4GLOD4-0,720,24Eukaryotic translation ingtion factor 4EEIFE-0,720,06Heparan sulfate 2-0-sulfortansferase 1HSST1-0,720,24	Stomatin-like protein 2, mitochondrial	STOML2	-0,73	0,18
Elongation factor Tu GTP-binding domain-containing protein 1EFTUD1-0,730,07von Willebrand factor A domain-containing protein 9VMA9-0,730,63Sorting nexin-5SNX5-0,730,09Importin-9IPO9-0,730,122Alpha-1,2-mannosyltransferase ALG9ALG9-0,730,03Trafficking protein particle complex subunit 6BTRAPPC6B-0,730,33Zinc finger protein ubi-d4DPF2-0,730,33Amine oxidase [flavin-containing] AMA0A-0,721,57POTE ankyrin domain family member 1POTEI-0,720,11Protein VAC14 homologVAC14-0,720,332-oxoisovalerate dehydrogenase subunit alpha, mitochondrialBCKDHA-0,720,31Multifunctional protein ADE2PAICS-0,720,02Probable ATP-dependent RNA helicase DDS52DDS52-0,720,04BolA-like protein 2GLOD4-0,720,04Retinol dehydrogenase 11GLOD4-0,720,24Eukaryotic translation intiation factor 4EIEVE-0,720,02Heparan sulfate 2-0-sulfortansferase 1NBAS-0,720,04	Mitochondrial glutamate carrier 1	SLC25A22	-0,73	0,19
von Willebrand factor A domain-containing protein 9VWA9-0,730,63Sorting nexin-5SNX5-0,730,09Importin-9IPO9-0,730,12Alpha-1,2-mannosyltransferase ALG9ALG9-0,730,03Trafficking protein particle complex subunit 6BTRAPPC6B-0,730,13Zinc finger protein ubi-d4DFF2-0,730,33Amine oxidase [flavin-containing] AMAOA-0,721,57POTE ankyrin domain family member 1POTEI-0,720,01Zinc finger CCCH domain-containing protein 13ZC3H13-0,720,31Protein VAC14 homologVAC14-0,720,302-oxoisovalerate dehydrogenase subunit alpha, mitochondrialBCKDHA-0,720,09Stathmin-0,720,020,020,02SoloAlike protein 2DDS2-0,720,02Gloyaalase domain-containing protein 4GLOD4-0,720,02SoloAlike protein 2BOLA2-0,720,04Retinol dehydrogenase 11-0,720,040,720,04Retinol dehydrogenase 11ElfeE-0,720,01Neuroblastoma-amplified sequenceNBAS-0,720,06Heparan sulfate 2-0-sulfortansferase 1HS2ST1-0,720,24	Elongation factor Tu GTP-binding domain-containing protein 1	EFTUD1	-0,73	0,07
Sorting nexin-5 SNXS -0,73 0,09 Importin-9 IPO9 -0,73 0,12 Alpha-1,2-mannosyltransferase ALG9 ALG9 -0,73 0,03 Trafficking protein particle complex subunit 6B TRAPPC6B -0,73 0,18 Zinc finger protein ubi-d4 DPF2 -0,73 0,33 Amine oxidase (flavin-containing) A MAOA -0,72 1,57 POTE ankyrin domain family member I 2C3H13 -0,72 0,11 Zinc finger CCCH domain-containing protein 13 ZC3H13 -0,72 0,30 2-oxoisovalerate dehydrogenase subunit alpha, mitochondrial KCKDHA -0,72 0,41 Multifunctional protein ADE2 PAICS -0,72 0,12 Stathmin -0,72 0,13 BolA-like protein 2 0,02 0,13 BolA-like protein 2 GLOD4 -0,72 0,024 Clyaxalse domain-containing protein 4 -0,72 0,024 Glyaxalse domain-containing protein 4 GLOD4 -0,72 0,024 Clyaxalse domain-containing protein 4 0,72 0,024 <t< td=""><td></td><td></td><td></td><td></td></t<>				
Importin-9IPO9-0,730,12Alpha-1,2-mannosyltransferase ALG9ALG9-0,730,03Trafficking protein particle complex subunit 6BTRAPPC6B-0,730,18Zinc finger protein ubi-14DPF2-0,730,33Amine oxidase [flavin-containing] AMAOA-0,721,57POTE ankyrin domain family member IPOTEI-0,720,11Protein UAC14 homologVAC14-0,720,302-oxoisovalerate dehydrogenase subunit alpha, mitochondrialBCKDHA-0,720,18Multifunctional protein ADE2PAICS-0,720,08StatminSTMN1-0,720,13BolA-like protein 2-0,720,01Glyoxalase domain-containing protein 4BOLA2-0,720,02Glyoxalase domain-containing protein 4GLOD4-0,720,02BolA-like protein 2BOLA2-0,720,02Glyoxalase domain-containing protein 4RDH11-0,720,04Retinol dehydrogenase 11RDH11-0,720,04Eukaryotic translation indiation factor 4EIE4E-0,720,06Heparan sulfate 2-0-sulfortansferase 1NBAS-0,720,06				
Alpha-1,2-mannosyltransferase ALG9 ALG9 -0,73 0,03 Trafficking protein particle complex subunit 6B TRAPPC6B -0,73 0,18 Zinc finger protein ubi-d4 DPF2 -0,73 0,33 Amine oxidase [flavin-containing] A MAOA -0,72 1,57 POTE ankyrin domain family member I POTEI -0,72 0,11 Protein VAC14 homolog VAC14 -0,72 0,13 2-oxoisovalerate dehydrogenase subunit alpha, mitochondrial BCKDHA -0,72 0,30 Multifunctional protein ADE2 PAICS -0,72 0,31 2-oxoisovalerate dehydrogenase subunit alpha, mitochondrial BCKDHA -0,72 0,02 Statmin -0,72 0,13 -0,72 0,22 Probable ATP-dependent RNA helicase DDS52 -0,72 0,02 0,22 Glyoxalase domain-containing protein 4 GLOD4 -0,72 0,13 BolA-like protein 2 GLOD4 -0,72 0,24 Glyoxalase domain-containing protein 4 GLOD4 -0,72 0,24 Eukaryotic translation intiation factor 4E<	-			
Trafficking protein particle complex subunit 68 TRAPPC6B -0,73 0,18 Zinc finger protein ubi-d4 DPF2 -0,73 0,33 Amine oxidase [flavin-containing] A MAOA -0,72 1,57 POTE ankyrin domain family member I POTE I -0,72 N.D. Zinc finger CCCH domain-containing protein 13 ZC3H13 -0,72 0,31 Protein VAC14 homolog VAC14 -0,72 0,30 2-oxoisovalerate dehydrogenase subunit alpha, mitochondrial BCKDHA -0,72 0,30 2-oxoisovalerate dehydrogenase subunit alpha, mitochondrial BCKDHA -0,72 0,11 Multifunctional protein ADE2 PAICS -0,72 0,22 Stathmin -0,72 0,22 0,13 BolA-like protein 2 BOLA -0,72 0,12 Glyoxalase domain-containing protein 4 GLOD4 -0,72 0,24 Reinol dehydrogenase 11 -0,72 0,24 0,274 0,24 Eukaryotic translation initation factor 4E EIF4E -0,72 0,06 Heparan sulfate 2-0-sulforansferase 1				
Zinc finger protein ubi-d4 DPF2 -0,73 0,33 Amine oxidase [flavin-containing] A MAOA -0,72 1,57 POTE ankyrin domain family member I POTE I -0,72 N.D. Zinc finger CCCH domain-containing protein 13 POTE I -0,72 0,11 Protein VAC14 homolog VAC14 -0,72 0,30 2-oxoisovalerate dehydrogenase subunit alpha, mitochondrial BCKDHA -0,72 0,18 Multfunctional protein ADE2 PAICS -0,72 0,13 Stathmin -0,72 0,13 BOIA-11 -0,72 0,13 BolA-like protein 2 BOLA2 -0,72 0,13 BOIA-11 -0,72 0,02 Glyoxalase domain-containing protein 4 GLOD4 -0,72 0,02 Glyoxalase domain-containing protein 4 -0,72 0,04 Retinol dehydrogenase 11 RoH11 -0,72 0,24 Eukaryotic translation intiation factor 4E Elf4E -0,72 0,10 Neuroblastoma-amplified sequence NBAS -0,72 0,06 Heparan sulfate 2-0-sulfotransferase 1 -0,72				
Amine oxidase [flavin-containing] A MAOA -0,72 1,57 POTE ankyrin domain family member I POTEI -0,72 N.D. Zinc finger CCCH domain-containing protein 13 ZC3H13 -0,72 0,11 Protein VAC14 homolog VAC14 -0,72 0,30 2-oxoisovalerate dehydrogenase subunit alpha, mitochondrial BCKDHA -0,72 0,18 Multifunctional protein ADE2 PAICS -0,72 0,09 Statmin TMN1 -0,72 0,13 Potoble ATP-dependent RNA helicase DDX52 DDX52 -0,72 0,13 BolA-like protein 2 BOLA2 -0,72 0,13 Glyoxalase domain-containing protein 4 GLOD4 -0,72 0,02 Glyoxalase domain-containing protein 4 BOL14 -0,72 0,04 Retinol dehydrogenase 11 RoH11 -0,72 0,24 Eukaryotic translation intiation factor 4E Elf4E -0,72 0,10 Neuroblastoma-amplified sequence NBAS -0,72 0,24				
POTE ankyrin domain family member I POTE I -0,72 N.D. Zinc finger CCCH domain-containing protein 13 C3H13 -0,72 0,11 Protein VAC14 homolog VAC14 -0,72 0,30 2-oxoisovalerate dehydrogenase subunit alpha, mitochondrial BCKDHA -0,72 0,30 Stattmin BCKDHA -0,72 0,09 Stattmin STMN1 -0,72 0,22 Probable ATP-dependent RNA helicase DDX52 DDX52 -0,72 0,02 Glyoxalase domain-containing protein 4 GLOD4 -0,72 0,02 Glyoxalase domain-containing protein 4 GLOD4 -0,72 0,04 Retinol dehydrogenase 11 RDH11 -0,72 0,24 Eukaryotic translation intiation factor 4E EIF4E -0,72 0,10 Neuroblastoma-amplified sequence NBAS -0,72 0,24				
Zinc finger CCCH domain-containing protein 13 ZC3H13 -0,72 0,11 Protein VAC14 homolog VAC14 -0,72 0,30 2-oxoisovalerate dehydrogenase subunit alpha, mitochondrial BCKDHA -0,72 0,12 Multifunctional protein ADE2 PAICS -0,72 0,09 Stathmin -0,72 0,02 0,13 BolA-like protein ADE4 DDX52 -0,72 0,22 Optable ATP-dependent RNA helicase DDX52 DDX52 -0,72 0,02 Glyaxalase domain-containing protein 4 GLOD4 -0,72 0,04 Retinol dehydrogenase 11 exprotein 2 0,72 0,02 Rukaryotic translation initation factor 4E ElfeFL -0,72 0,04 Heparan sulfate 2-0-sulfortansferase 1 NBAS -0,72 0,06				
Protein VAC14 homolog VAC14 -0,72 0,30 2-oxoisovalerate dehydrogenase subunit alpha, mitochondrial BCKDHA -0,72 0,18 Multifunctional protein ADE2 PAICS -0,72 0,09 Stathmin -0,72 0,13 Probable ATP-dependent RNA helicase DDX52 -0,72 0,13 BolA-like protein 2 BOLA2 -0,72 0,02 Glyoxalase domain-containing protein 4 GLOD4 -0,72 0,04 Retinol dehydrogenase 11 RDH11 -0,72 0,24 Eukaryotic translation initiation factor 4E EIF4E -0,72 0,06 Heparan sulfate 2-0-sulfotransferase 1 HS2ST1 -0,72 0,24				
2-oxoisovalerate dehydrogenase subunit alpha, mitochondrial BCKDHA -0,72 0,18 Multifunctional protein ADE2 PAICS -0,72 0,09 Statmmin STMN1 -0,72 0,22 Probable ATP-dependent RNA helicase DDX52 DDX52 -0,72 0,13 BOIA-like protein 2 BOLA2 -0,72 0,02 Glyoxalase domain-containing protein 4 GLOD4 -0,72 0,04 Retinol dehydrogenase 11 ROH11 -0,72 0,24 Eukaryotic translation initiation factor 4E EIF4E -0,72 0,06 Heparan sulfate 2-0-sulfotransferase 1 HS2ST1 -0,72 0,24				
Multifunctional protein ADE2 -0,72 0,09 Statmin STMN1 -0,72 0,22 Probable ATP-dependent RNA helicase DDX52 DDX52 -0,72 0,13 BolA-like protein 2 BOLA2 -0,72 0,02 Glyoxalase domain-containing protein 4 GLOD4 -0,72 0,04 Retinol dehydrogenase 11 ROH11 -0,72 0,24 Eukaryotic translation initiation factor 4E EIF4E -0,72 0,06 Heparan sulfate 2-0-sulfotransferase 1 HS2ST1 -0,72 0,24				
Stathmin STMN1 -0,72 0,22 Probable ATP-dependent RNA helicase DDX52 DDX52 -0,72 0,13 BolA-like protein 2 BOLA2 -0,72 0,02 Glyoxalase domain-containing protein 4 GLODA -0,72 0,04 Retinol dehydrogenase 11 RDH11 -0,72 0,24 Eukaryotic translation initiation factor 4E EIF4E -0,72 0,06 Heparan sulfate 2-0-sulfotransferase 1 HS2ST1 -0,72 0,24				
Probable ATP-dependent RNA helicase DDX52 -0,72 0,13 BolA-like protein 2 BolA2 -0,72 0,02 Glyoxalase domain-containing protein 4 GLOD4 -0,72 0,04 Retinol dehydrogenase 11 RDH11 -0,72 0,24 Eukaryotic translation initiation factor 4E EIF4E -0,72 0,10 Neuroblastoma-amplified sequence NBAS -0,72 0,06 Heparan sulfate 2-0-sulfotransferase 1 HS2ST1 -0,72 0,24				
BolA-like protein 2 BOLA2 -0,72 0,02 Glyoxalase domain-containing protein 4 GLOD4 -0,72 0,04 Retinol dehydrogenase 11 RDH11 -0,72 0,24 Eukaryotic translation initiation factor 4E EIF4E -0,72 0,06 Neuroblastoma-amplified sequence NBAS -0,72 0,06 Heparan sulfate 2-0-sulfotransferase 1 HS2ST1 -0,72 0,24				
Glyoxalase domain-containing protein 4 GLOD4 -0,72 0,04 Retinol dehydrogenase 11 ROH11 -0,72 0,24 Eukaryotic translation initiation factor 4E EIF4E -0,72 0,10 Neuroblastoma-amplified sequence NBAS -0,72 0,06 Heparan sulfate 2-0-sulfotransferase 1 HS2ST1 -0,72 0,24				
Retinol dehydrogenase 11 -0,72 0,24 Eukaryotic translation initiation factor 4E EIF4E -0,72 0,10 Neuroblastoma-amplified sequence NBAS -0,72 0,06 Heparan sulfate 2-0-sulfotransferase 1 HS2ST1 -0,72 0,24				
Eukaryotic translation initiation factor 4E EIF4E -0,72 0,10 Neuroblastoma-amplified sequence NBAS -0,72 0,06 Heparan sulfate 2-0-sulfotransferase 1 HS2ST1 -0,72 0,24				
Neuroblastoma-amplified sequence NBAS -0,72 0,06 Heparan sulfate 2-0-sulfotransferase 1 HS2ST1 -0,72 0,24				
Heparan sulfate 2-O-sulfotransferase 1 HS2ST1 -0,72 0,24				
Galactose-1-phosphate uridylyltransferase GALT -0,72 N.D.				
	Galactose-1-phosphate uridylyltransferase	GALT	-0,72	N.D.

Biogenesis of lysosome-related organelles complex 1 subunit 1	BLOC1S1	-0,72	N.D.
p53 and DNA damage-regulated protein 1	PDRG1	-0,71	N.D.
SAP30-binding protein	SAP30BP	-0,71	N.D.
Signal transducer and activator of transcription 3	STAT3	-0,71	0,03
Sorting nexin-12	SNX12	-0,71	0,11
Transmembrane protein 161A	TMEM161A	-0,71	0,45
Cap-specific mRNA (nucleoside-2-O-)-methyltransferase 1	CMTR1	-0,71	0,85
Methylmalonyl-CoA mutase, mitochondrial	MUT	-0,71	0,11
	TRIM28	-0,71	0,07
	WDR92	-0,71	0,07
	MRPS27	-0,71	0,17
	CAPNS1	-0,71	0,10
	AP2B1	-0,71	0,17
	MAPK14	-0,71	0,04
	PSMG4	-0,70	0,14
	YARS		
		-0,70	0,02
Sector Se	MARCH5	-0,70	0,05
	HAGH	-0,70	N.D.
	ACOT1	-0,70	0,20
	L3HYPDH	-0,70	0,43
Ribosome biogenesis protein BOP1	BOP1	-0,70	0,01
Intercellular adhesion molecule 3	ICAM3	-0,70	2,22
Methylmalonic aciduria and homocystinuria type C protein	MMACHC	-0,70	N.D.
Probable histidinetRNA ligase, mitochondrial	HARS2	-0,70	N.D.
rRNA-processing protein UTP23 homolog	UTP23	-0,70	N.D.
ValinetRNA ligase	VARS	-0,69	0,02
-	ARMC8	-0,69	0,06
Cleavage and polyadenylation specificity factor subunit 6	CPSF6	-0,69	0,29
	EIF2B4	-0,69	0,14
GTPase KRas;GTPase KRas, N-terminally processed	KRAS	-0,69	N.D.
	RNGTT	-0,69	0,03
NEDD4-like E3 ubiquitin-protein ligase WWP2	WWP2	-0,69	N.D.
	NOMO1	-0,69	0,03
	SDF4	-0,69	0,05 N.D.
	ASCC3	-0,69	0,02
	PTCD3		
	MED1	-0,69	0,10
	SUGP2	-0,69	0,36
		-0,69	0,16
	YY1	-0,69	0,21
	S100A4	-0,69	0,11
	ASPM	-0,69	N.D.
	YME1L1	-0,69	0,15
	OXSR1	-0,69	0,34
10 01	PQBP1	-0,68	N.D.
Heterogeneous nuclear ribonucleoprotein U-like protein 1	HNRNPUL1	-0,68	0,18
o ,	DNAJC11	-0,68	0,14
Peptidyl-prolyl cis-trans isomerase FKBP5	FKBP5	-0,68	0,04
Isochorismatase domain-containing protein 2, mitochondrial	ISOC2	-0,68	0,17
DnaJ homolog subfamily A member 4	DNAJA4	-0,68	N.D.
Programmed cell death protein 4	PDCD4	-0,68	0,19
AP-2 complex subunit mu	AP2M1	-0,68	0,17
Eukaryotic translation initiation factor 4E-binding protein 1	EIF4EBP1	-0,68	N.D.
Cytochrome c oxidase assembly factor 6 homolog	COA6	-0,68	N.D.
	PIN1	-0,68	0,22
	AP5S1	-0,68	N.D.
	MRPS23	-0,68	0,12
	NUP54	-0,67	0,16
	SEPT2	-0,67	0,18
	DDX47	-0,67	0,18
Probable ATP-dependent RNA helicase DDX47 Chromodomain-helicase-DNA-binding protein 1	CHD1	-0,67	0,09 N.D.
Integrator complex subunit 4	INTS4		
		-0,67	0,07
	NCDN	-0,67	1,17
	EIF2B3	-0,67	0,14
	METAP1D	-0,67	N.D.
	HSPA4L	-0,67	0,12
	GNA13	-0,67	0,06
	ZFC3H1	-0,67	0,36
	VPS52	-0,67	0,01
	MTA1	-0,67	0,04
	USP36	-0,66	0,29
Nucleoplasmin-3	NPM3	-0,66	0,03
Speckle targeted PIP5K1A-regulated poly(A) polymerase	TUT1	-0,66	N.D.
	HNRNPC	-0,66	0,14
ATP-binding cassette sub-family E member 1	ABCE1	-0,66	0,03
	KIAA0101	-0,66	N.D.
	FAM98B	-0,66	0,49
Large subunit GTPase 1 homolog	LSG1	-0,66	0,23
	PPP1CA	-0,66	0,11
	OAT	-0,66	0,02
	SCARB2	-0,66	0,04
·····		2,00	2,01

Malonyl-CoA-acyl carrier protein transacylase, mitochondrial	MCAT	-0,66	0,05
Nucleoporin Nup43	NUP43	-0,66	0,07
28S ribosomal protein S26, mitochondrial	MRPS26	-0,66	0,32
28 kDa heat- and acid-stable phosphoprotein	PDAP1	-0,65	0,16
28S ribosomal protein S15, mitochondrial	MRPS15	-0,65	0,07
Eukaryotic peptide chain release factor GTP-binding subunit ERF3A	GSPT1	-0,65	0,10
Serine/threonine-protein phosphatase 4 regulatory subunit 3A	SMEK1	-0,65	0,06
Flap endonuclease 1	FEN1	-0,65	0,24
28S ribosomal protein S18b, mitochondrial	MRPS18B	-0,65	0,06
28S ribosomal protein S6, mitochondrial	MRPS6	-0,65	0,01
Vacuolar protein sorting-associated protein 26B	VPS26B	-0,65	N.D.
Chromodomain-helicase-DNA-binding protein 3	CHD3	-0,65	0,34
SAFB-like transcription modulator	SLTM	-0,65	0,02
Cytochrome c oxidase assembly factor 4 homolog, mitochondrial	COA4	-0,65	0,17
Protein phosphatase 1F	PPM1F	-0,65	0,02
	NOC2L	-0,65	0,02
ADP-ribosylation factor-like protein 2	ARL2		
		-0,64	0,18
Ribosomal protein S6 kinase alpha-1	RPS6KA1	-0,64	0,43
Septin-11	SEPT11	-0,64	0,09
	ANKRD13D	-0,64	N.D.
RNA polymerase-associated protein CTR9 homolog	CTR9	-0,64	0,05
Coiled-coil domain-containing protein 97	CCDC97	-0,64	0,28
RNA polymerase II-associated factor 1 homolog	PAF1	-0,64	0,02
Torsin-1A-interacting protein 1	TOR1AIP1	-0,64	0,02
ADP-ribosylation factor-like protein 5A	ARL5A	-0,64	N.D.
Sequestosome-1	SQSTM1	-0,64	0,20
Lysine-specific demethylase 5B	KDM5B	-0,64	N.D.
Serine/arginine-rich splicing factor 7	SRSF7	-0,64	0,02
Liprin-alpha-1	PPFIA1		
		-0,64	0,12
Ribonucleases P/MRP protein subunit POP1	POP1	-0,64	0,12
Eukaryotic translation initiation factor 1A, X-chromosomal	EIF1AX	-0,63	0,09
ATP-dependent (S)-NAD(P)H-hydrate dehydratase	CARKD	-0,63	N.D.
Heterogeneous nuclear ribonucleoprotein Q	SYNCRIP	-0,63	0,04
Histone H2A type 1-C	HIST1H2AC	-0,63	N.D.
28S ribosomal protein S7, mitochondrial	MRPS7	-0,63	0,02
TGF-beta-activated kinase 1 and MAP3K7-binding protein 1	TAB1	-0,63	0,38
Cytoskeleton-associated protein 5	СКАР5	-0,63	0,16
	HIST1H1B	-0,63	0,37
	CLPX	-0,63	0,32
ATP-dependent Clp protease ATP-binding subunit clpX-like, mitochondrial			
E3 ubiquitin-protein ligase NEDD4-like	NEDD4L	-0,63	0,45
Transmembrane protein 245	TMEM245	-0,63	0,20
rRNA 2-O-methyltransferase fibrillarin	FBL	-0,63	0,12
Glutaryl-CoA dehydrogenase, mitochondrial	GCDH	-0,63	0,30
Mitogen-activated protein kinase kinase kinase 4	MAP3K4	-0,62	0,32
THO complex subunit 4	ALYREF	-0,62	0,36
Zinc finger CCCH domain-containing protein 7B	ZC3H7B	-0,62	0,04
Down syndrome critical region protein 3	DSCR3	-0,62	0,30
	RANBP3	-0,62	0,34
Cleavage stimulation factor subunit 3	CSTF3	-0,62	0,08
	ATP5S	-0,62	0,09
	ZMIZ1	-0,62	
Zinc finger MIZ domain-containing protein 1			N.D.
PRA1 family protein 2	PRAF2	-0,62	N.D.
Etoposide-induced protein 2.4 homolog	EI24	-0,62	0,09
39S ribosomal protein L49, mitochondrial	MRPL49	-0,62	0,17
Eukaryotic peptide chain release factor GTP-binding subunit ERF3B	GSPT2	-0,62	N.D.
Girdin	CCDC88A	-0,62	0,75
Nucleolar protein 8	NOL8	-0,62	0,00
Inositol-3-phosphate synthase 1	ISYNA1	-0,62	0,13
Dual specificity protein phosphatase 23	DUSP23	-0,62	0,05
AP-3 complex subunit sigma-2	AP3S2	-0,61	N.D.
Short/branched chain specific acyl-CoA dehydrogenase, mitochondrial	ACADSB	-0,61	0,20
Dynamin-2	DNM2	-0,61	0,03
28S ribosomal protein S28, mitochondrial	MRPS28	-0,61	0,03
	ARID4B		0,01 N.D.
AT-rich interactive domain-containing protein 4B		-0,61	
	NAT1	-0,61	0,31
Polymerase delta-interacting protein 2	POLDIP2	-0,61	0,15
Uncharacterized protein C14orf119	C14orf119	-0,61	N.D.
Golgin subfamily A member 7	GOLGA7	-0,61	0,02
SHC-transforming protein 1	SHC1	-0,61	N.D.
Squamous cell carcinoma antigen recognized by T-cells 3	SART3	-0,61	0,05
CDK5 regulatory subunit-associated protein 3	CDK5RAP3	-0,61	0,19
Cytosolic non-specific dipeptidase	CNDP2	-0,60	0,03
Translation initiation factor eIF-2B subunit epsilon	EIF2B5	-0,60	0,08
Replication initiator 1	REPIN1	-0,60	0,32
Leucine-rich repeat-containing protein 40	LRRC40		
		-0,60	0,17
RNA-binding protein 5	RBM5	-0,60	N.D.
Serine/threonine-protein kinase D2	PRKD2	-0,60	N.D.
Protein FRG1	FRG1	-0,60	0,82
Hepatoma-derived growth factor	HDGF	-0,60	0,07
Atlastin-3	ATL3	-0,59	0,18

Zinc finger protein 687	ZNF687	-0,59	0,48
Cytochrome b reductase 1	CYBRD1	-0,59	N.D.
Protein UXT	UXT	-0,59	0,39
Membrane-associated progesterone receptor component 2	PGRMC2	-0,59	0,09
E3 ubiquitin-protein ligase UBR2	UBR2	-0,59	0,04
Protein AATF	AATF	-0,59	0,20
WD repeat-containing protein 81	WDR81	-0,59	0,26
Interferon regulatory factor 2-binding protein 2	IRF2BP2	-0,59	0,41

Table 2 Downregulated proteins in KU812 ImaR compared to KU812 P cells under normoxia. Proteomic profiling (SILAC) data were used. Significant downregulated proteins were calculated using the fold difference threshold of 0.7 (log₂ fold change=-0.58). Mean±SD for n=2 replicates. Non-detected (N.D.) means less than 2 replicates detected for one protein measured.

	EXTRACELLULAR FLUXES NORMOXIA					
Kpc (nmol*millioncell-1*h-1)						
	KU812 P	arental	KU812	2 ImaR		
			Amino acids	_		
	Mean	SD	Mean	SD	pvalue	
Ala	5.02	0.92	3.72	0.52	0.101	
Arg	-0.65	0.25	-3.87	4.05	0.365	
Asn	-0.26	0.02	-0.61	0.49	0.394	
Asp	0.02	0.12	-0.41	0.13	0.013	
Cit	0.01	0.00	-0.10	0.04	0.006	
Gln	-9.12	0.24	-22.44	4.79	0.034	
Glu	2.63	0.65	3.97	0.38	0.036	
Gly	0.25	0.19	0.39	0.28	0.492	
His	-0.21	0.10	-0.46	0.20	0.128	
lle	-1.43	0.09	-2.86	0.39	0.003	
Leu	-1.93	0.13	-4.13	0.68	0.005	
Lys	-1.25	0.12	-2.52	0.58	0.020	
Met	-0.32	0.01	-0.92	0.17	0.004	
Orn	0.61	0.09	1.80	0.60	0.028	
Phe	-0.45	0.04	-1.11	0.23	0.008	
Pro	0.20	0.15	2.47	0.27	0.000	
Ser	-1.79	0.11	-5.05	0.89	0.003	
Thr	-0.52	0.02	-1.91	0.68	0.025	
Тгр	-0.12	0.01	-0.25	0.09	0.062	
Tyr	-0.38	0.06	-1.01	0.09	0.001	
Val	-1.17	0.11	-2.56	0.47	0.007	
		I	Polyamines			
Putrescine	-4E-05	4E-05	-5E-04	2E-04	0.010	
Spermidine	-7E-06	2E-05	2E-05	4E-05	0.362	
Spermine	-7E-05	2E-05	-8E-04	1E-03	0.409	

 Table 3. Extracellular fluxes result of KU812 Parental and KU812 ImaR cell lines under normoxia. Amino acids and polyamines results are represented.

EXTRACELLULAR FLUXES HYPOXIA							
Kpc (nmol*millioncell-1*h-1)							
	KU812 P	Parental	KU812 ImaR				
			Amino acids				
	Mean	SD	Mean	SD	pvalue		
Ala	3.19	0.51	1.85	0.63	0.045		
Arg	-1.95	0.03	10.68	6.07	0.099		
Asn	-0.86	0.88	0.32	0.57	0.308		
Asp	-0.36	0.30	1.06	1.07	0.091		
Cit	-0.02	0.00	0.09	0.18	0.356		
Gln	-6.39	1.10	6.54	15.92	0.358		
Glu	0.90	0.71	7.01	3.50	0.041		
Gly	1.32	0.31	3.44	1.29	0.359		
His	-0.02	0.09	0.41	0.68	0.336		
lle	-0.42	0.33	-1.00	1.10	0.433		
Leu	-0.83	0.22	-1.97	1.02	0.130		
Lys	-0.24	0.64	-1.49	0.87	0.115		
Met	0.08	0.01	-0.01	0.73	0.871		
Orn	2.15	0.51	1.90	0.66	0.639		
Phe	0.09	0.25	-0.54	0.30	0.049		
Pro	0.46	0.22	1.47	0.44	0.023		
Ser	-1.58	0.26	-8.33	0.95	0.000		
Thr	-0.25	0.37	0.13	1.51	0.695		
Тгр	0.02	0.02	-0.25	0.18	0.054		
Tyr	0.13	0.29	-0.93	0.31	0.012		
Val	0.03	0.53	-1.51	0.81	0.051		
	Polyamines						
Putrescine	4E-04	2E-04	-2E-03	3E-04	0.001		
Spermidine	-1E-06	2E-05	5E-05	2E-04	0.739		
Spermine	-3E-05	3E-05	1E-04	2E-04	0.315		

 Table 4. Extracellular fluxes result of KU812 Parental and KU812 ImaR cell lines under hypoxia. Amino acids and polyamines results are represented.

	INTR	ACELLULA	R CONTENT NC	RMOXIA			
nmol/mg protein							
	KU812 P	arental	KU812 ImaR				
			Amino acids				
	Mean	SD	Mean	SD	pvalue		
Ala	271.86	130.35	448.71	198.69	0.267		
Arg	89.71	14.48	96.74	48.08	0.820		
Asn	253.43	14.36	500.37	178.44	0.075		
Asp	180.60	72.28	222.23	39.51	0.523		
Cit	D	D	D	D	D		
Gln	1162.32	500.57	2141.94	847.04	0.160		
Glu	D	D	D	D	D		
Gly	275.13	142.35	768.70	235.22	0.057		
His	26.28	3.18	47.00	28.66	0.281		
lle	67.55	13.16	138.49	32.39	0.025		
Leu	55.69	8.21	170.55	50.71	0.018		
Lys	23.24	4.06	20.24	1.44	0.295		
Met	19.15	3.70	52.75	28.28	0.111		
Orn	6.84	0.59	38.37	11.96	0.010		
Phe	18.59	1.46	34.06	6.78	0.018		
Pro	43.54	1.65	D	D	D		
Ser	39.94	14.85	81.03	69.67	0.374		
Thr	65.16	10.89	134.42	19.08	0.005		
Trp	3.42	1.48	8.04	1.58	0.021		
Tyr	30.27	3.48	60.51	21.60	0.075		
Val	22.63	5.55	21.91	10.02	0.918		
	Polyamines						
Putrescine	23.63	7.46	4.22	0.90	0.011		
Spermidine	31.66	2.06	26.32	7.98	0.324		
Spermine	15.49	0.66	9.63	2.82	0.025		

 Table 5. Intracellular content fluxes result of KU812 Parental and KU812 ImaR cells under normoxia. Non

 detected amino acids or polyamines or amino acids and polyamines whose replicates were not reproducible

 are named as discarded (D).

	INT	RACELLUL	AR CONTENT H	ΥΡΟΧΙΑ			
nmol/mg protein							
	KU812 P	arental	KU812 ImaR				
			Amino acids				
	Mean	SD	Mean	SD	pvalue		
Ala	196.81	70.77	555.71	205.39	0.267		
Arg	124.89	82.72	168.62	8.77	0.820		
Asn	374.27	155.35	584.22	159.18	0.075		
Asp	41.06	15.07	176.95	111.59	0.523		
Cit	D	D	D	D	D		
Gln	2102.55	122.34	2939.16	475.32	05.39 0.267 8.77 0.820 59.18 0.075 11.59 0.523 D D 75.32 0.160 D D 98.01 0.057 22.96 0.281 65.23 0.025 29.64 0.018 44.29 0.295 35.11 0.111 16.46 0.010 11.72 0.018 D D 8.54 0.374 98.36 0.005 5.59 0.021 32.12 0.075		
Glu	D	D	D	D	D		
Gly	341.37	25.92	1847.53	898.01	0.057		
His	50.56	17.24	85.98	22.96	0.281		
lle	124.73	37.62	306.43	65.23	0.025		
Leu	138.61	18.59	352.46	29.64	0.018		
Lys	68.98	24.70	89.94	44.29	0.295		
Met	36.54	14.07	84.08	35.11	0.111		
Orn	60.62	32.88	52.32	16.46	0.010		
Phe	33.73	3.72	75.25	11.72	0.018		
Pro	223.72	47.62	D	D	D		
Ser	99.18	67.01	107.43	8.54	0.374		
Thr	98.19	10.44	247.54	98.36	0.005		
Trp	8.06	1.54	14.28	5.59	0.021		
Tyr	55.90	13.18	113.93	32.12	0.075		
Val	66.16	32.79	104.60	37.65	0.918		
	Polyamines						
Putrescine	22.53	9.31	1.05	0.19	0.011		
Spermidine	41.91	0.44	59.18	36.97	0.324		
Spermine	19.49	6.13	25.64	13.60	0.025		

 Table 6. Intracellular content fluxes result of KU812 Parental and KU812 ImaR cells under hypoxia. Nondetected amino acids or polyamines or amino acids and polyamines whose replicates were not reproducible are named as discarded (D).






Figure 1. ¹³C Glucose label incorporation in KU812 Parental and ImaR cells under normoxia measured by NMR.

	¹³ C Gluco	se label inc	orporation				
Intensity/million cells							
	KU812 Parental KU812 ImaR						
	Amino acids						
	Mean	SD	Mean	SD	pvalue		
6-Phosphogluconate-C4	2.55E+05	5.59E+04	3.11E+05	1.06E+05	4.64E-01		
Alanine-C3	6.37E+06	1.13E+06	1.12E+07	6.99E+05	3.16E-03		
Creatine-C4	N.D.	N.D.	2.38E+05	4.95E+04	N.D.		
Glutamate-C3	1.36E+06	1.13E+05	1.09E+06	7.63E+04	2.64E-02		
Glutamate-C4	7.51E+06	6.82E+05	6.78E+06	4.32E+05	1.94E-01		
Glutamine-C2	4.95E+05	1.16E+05	2.45E+05	5.73E+04	2.85E-02		
Glutathione-C4	2.86E+06	3.69E+05	1.72E+06	2.22E+05	1.01E-02		
Glycine-C2	1.35E+06	2.66E+05	4.59E+06	3.34E+05	1.95E-04		
Isoleucine-C5	N.D.	N.D.	3.06E+05	6.72E+04	N.D.		
Lactate-C3	3.68E+07	1.24E+07	7.21E+07	1.19E+07	2.34E-02		
Leucine-C5	N.D.	N.D.	2.91E+05	1.36E+04	N.D.		
Myo-Inositol-C3	1.35E+06	7.06E+04	4.09E+05	5.11E+04	4.79E-05		
NAD-C1	6.75E+05	6.29E+04	5.16E+05	2.08E+04	1.44E-02		
Ornithine-C5	N.D.	N.D.	1.61E+05	3.97E+04	N.D.		
Proline-C5	N.D.	N.D.	2.67E+05	1.59E+04	N.D.		
Serine-C3	1.96E+05	6.33E+04	5.12E+05	5.88E+04	3.19E-03		
Threonine-C2	N.D.	N.D.	1.09E+05	9.26E+04	N.D.		

Table 6 Values of ¹³C Glucose label incorporation in KU812 Parental and ImaR cells under normoxia measured by NMR. Metabolites without ¹³C Glucose label incorporation are indicated as non -detected (N.D).





		abel incorp			
	,	/million cells			-
	KU812	ImaR			
	Maar	60	Amino acids	60	muchus
	Mean	SD 3.82E+05	Mean 2.75E+07	SD	pvalue 4.39E-06
L-Alanine-H2-C2 L-Alanine-H3a-H3b-H3c-C3	4.09E+06 7.80E+07	9.34E+06	2.75E+07 2.99E+08	1.12E+06 2.28E+07	4.39E-00 1.01E-04
L-Arginine-H5A-H5B-C5	8.32E+06	8.06E+05	3.30E+07	6.14E+05	1.89E-06
L-Asparagine-H2-C2	3.94E+06	6.25E+05	6.07E+06	1.54E+06	9.07E-02
L-Asparagine-H3A-C3	3.94E+06	6.25E+05	7.88E+06	2.99E+06	8.90E-02
L-Asparagine-H3B-C3	3.94E+06	6.25E+05	5.09E+06	6.22E+05	8.69E-02
L-Aspartic-acid-H2-C2	5.24E+06	1.15E+06	5.53E+07	6.17E+06	1.58E-04
L-Aspartic-acid-H3A-C3	6.86E+06	1.43E+06	4.82E+07	5.02E+06	1.64E-04
L-Aspartic-acid-H3B-C3	6.87E+06	9.74E+05	5.15E+07	5.93E+06	2.10E-04
Creatine-H2A-H2B-C2	3.94E+06	6.25E+05	4.79E+07	3.51E+06	2.84E-05
Creatine-H4A-H4B-H4C-C4	3.94E+06	6.25E+05	3.64E+07	1.04E+06	1.28E-06
Fumaric-acid-H2-C2	3.94E+06	6.25E+05	3.43E+06	2.37E+05	2.61E-02
L-Glutamic-acid-H2-C2	6.58E+08	6.21E+07	7.76E+08	9.09E+07	1.36E-0
L-Glutamic-acid-H3A-C3	5.50E+08	4.10E+07	8.99E+08	8.80E+07	3.40E-03
L-Glutamic-acid-H3B-C3	5.05E+08	3.70E+07	8.29E+08	7.88E+07	2.97E-03
L-Glutamic-acid-H4A-H4B-C4	8.24E+08	8.51E+07	7.48E+08	9.83E+07	3.72E-0
L-Glutamine-H4A-H4B-C4	1.73E+12	2.99E+12	2.24E+07	5.61E+06	3.74E-0
-Glutathione-(reduced)-H4A-H4B-C4	2.80E+08	2.10E+07	2.05E+08	1.93E+07	1.06E-02
L-Glycine-H2A-H2B-C2	1.27E+07	1.56E+06	9.04E+07	1.02E+07	2.03E-04
L-Histidine-H5-C5	3.94E+06	6.25E+05	3.43E+06	2.37E+05	2.61E-01
L-Histidine-H2-C2	3.94E+06	6.25E+05	3.63E+06	4.48E+05	5.24E-02
L-Lactic-acid-H2-C2	2.01E+07	1.60E+06	5.99E+07	9.49E+06	2.00E-03
L-Lactic-acid-H3A-H3B-H3C-C3	2.22E+08	1.19E+07	4.48E+08	7.20E+07	5.90E-03
L-Leucine-H5A-H5B-H5C-C5	4.09E+06	3.77E+05	2.66E+07	2.44E+06	9.36E-0
L-Leucine-H6A-H6B-H6C-C6	3.94E+06	6.25E+05	2.65E+07	2.87E+06	1.84E-04
L-Isoleucine-H2-C2	3.94E+06	6.25E+05	1.10E+07	6.21E+05	1.54E-04
L-Isoleucine-H4A-C4	3.94E+06	6.25E+05	6.30E+06	1.19E+06	3.80E-02
L-Isoleucine-H4B-C4	3.94E+00	6.25E+05	4.48E+06	5.83E+05	3.32E-02
L-Isoleucine-H5A-H5B-H5C-C5	3.94E+00	6.25E+05	2.44E+07	2.63E+05	1.96E-04
L-Isoleucine-H6A-H6B-H6C-C6	3.94E+06	6.25E+05	3.62E+07	2.65E+06	3.30E-05
L-Lysine-H6A-H6B-C6	3.94E+06	6.25E+05	4.95E+06	4.21E+05	7.97E-02
L-Malic-acid-H3a-C3	3.94E+06	6.25E+05	3.43E+06	2.37E+05	2.61E-0
L-Methionine-H4A-H4B-C4	3.94E+06	6.25E+05	5.86E+06	7.27E+05	2.53E-02
Myo-Inositol-H1-C1-H3-C3	9.02E+07	9.35E+05	4.60E+07	4.66E+06	8.70E-05
Myo-Inositol-H2-C2	6.15E+07	8.09E+05	3.17E+07	3.31E+06	1.10E-04
Myo-Inositol-H4-C4-H6-C6	1.15E+08	2.19E+06	5.57E+07	4.91E+06	4.57E-05
Myo-Inositol-H5-C5	1.19E+08	1.65E+06	5.74E+07	5.99E+06	6.67E-05
Ornithine-H5A-H5B-C5	3.94E+06	6.25E+05	5.27E+06	2.51E+06	4.22E-02
L-Proline-H3A-C3	3.94E+06	6.25E+05	1.77E+08	1.69E+07	6.02E-05
L-Proline-H4B-H4A-C4	3.94E+06	6.25E+05	1.53E+08	1.03E+07	1.52E-05
L-Proline-H5A-C5	3.94E+06	6.25E+05	1.53E+08	1.42E+07	5.38E-05
L-Proline-H5B-C5	5.89E+06	3.58E+06	1.63E+08	1.53E+07	6.51E-0
Succinic-acid-H2A-H2B-C2	4.06E+06	4.31E+05	9.73E+06	2.08E+06	9.86E-03
Succinic-acid-H3A-H3B-C3	4.06E+06	4.31E+05	9.73E+06	2.08E+06	9.86E-03
Taurine-H1A-H1B-C1	2.44E+07	6.62E+05	1.25E+07	6.73E+05	2.66E-0
Taurine-H2A-H2B-C2	2.03E+07	2.21E+06	1.17E+07	1.33E+06	4.59E-03
L-Threonine-H2-C2	3.98E+06	5.45E+05	1.70E+07	2.25E+06	6.32E-04
L-Threonine-H3-C3	3.94E+06	6.25E+05	1.20E+07	1.19E+06	4.93E-04
L-Threonine-H4A-H4B-H4C-C4	8.59E+06	7.85E+05	5.91E+07	6.66E+06	1.99E-04
L-Valine-H4A-H4B-H4C-C4	3.94E+06	6.25E+05	7.61E+06	3.90E+00	9.88E-04
L-Valine-H5A-H5B-H5C-C5	3.94E+06	6.25E+05	5.47E+06	5.71E+05	3.50E-02

Table 7. Values of ¹³C Glutamine label incorporation in KU812 Parental and ImaR cells under normoxia measured by NMR.




Figure 3. Basal and maximal mitochondrial respiration of KU812 imatinib-resistant vs. KU812 Parental cells after the normalisation with a parameter reflecting the mitochondrial content. Cells were first incubated with KHB Buffer in the presence of glucose and glutamine under normoxic incubation conditions. OCR values were measured during sequential injection of oligomycin, CCCP, and Rot+Ama in KU812 Parental (P) and imatinib-resistant (ImaR) cells under normoxia. Basal and maximal respiration were calculated as described in **section 4.12.** Data were initially normalised to protein content. Data from KU812 ImaR cells were further normalised by dividing the OCR value by the FD of the translocase of outer mitochondrial membrane 20 (TOMM20) obtained in the protein profiles. Data are provided as mean ± SD of n=3. Significance was determined by two-tailed independent sample Student's t-test. Statistically significant differences between KU812 P and ImaR cells are indicated as p<0.01(**), and p<0.001(***).